{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "3537db2c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import dependencies\n",
    "import requests\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "ccbaff78",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Base url for the api call\n",
    "url = \"https://clinicaltrials.gov/api/query/study_fields\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f5a47c77",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Headers for json call\n",
    "headers = {'Content-Type': 'application/json', \n",
    "           'Accept': 'application/json'}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "f9860ee2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# List of fields\n",
    "fields = ['OrgStudyId',\n",
    "          'BriefTitle',\n",
    "          'StudyType', \n",
    "          'StartDate',\n",
    "          'CompletionDate',\n",
    "          'OverallStatus',  \n",
    "          'ResponsiblePartyType', \n",
    "          'Gender', \n",
    "          'GenderBased', \n",
    "          'MinimumAge', \n",
    "          'MaximumAge']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "5cf1971b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a list to hold the dictionaries from the json response\n",
    "sourced_data = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ee486ebb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Set a counter to increase the ranks with each iteration\n",
    "counter = 0\n",
    "\n",
    "while True:\n",
    "    # Define the parameters of the url\n",
    "    params = {'expr': 'breast cancer AND SEARCH[Location](AREA[LocationState] California)', \n",
    "              'fields': ','.join(fields), \n",
    "              'min_rnk': 1 + 1000 * counter,  \n",
    "              'max_rnk': 1000 + 1000 * counter, \n",
    "              'fmt': 'json'}\n",
    "\n",
    "    # Make the call \n",
    "    response = requests.get(url, \n",
    "                            headers = headers, \n",
    "                            params = params)\n",
    "\n",
    "\n",
    "    \n",
    "\n",
    "    # Increment the counter\n",
    "    counter += 1\n",
    "    \n",
    "    # Check to see if more data was returned for the current response\n",
    "    if response.json()['StudyFieldsResponse']['NStudiesReturned'] == 0:\n",
    "        # If there was no new data returned, break out of the while loop\n",
    "        break\n",
    "\n",
    "    # Add the data from the api call to the sourced_data list\n",
    "    sourced_data += response.json()['StudyFieldsResponse']['StudyFields']\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "052c0dfb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'Rank': 1, 'OrgStudyId': ['CCT1043'], 'BriefTitle': ['Breast Cancer Trials Education Program'], 'StudyType': ['Interventional'], 'StartDate': ['May 2007'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 2, 'OrgStudyId': ['150B-0158'], 'BriefTitle': ['Breast Cancer Risk Reduction: A Patient Doctor Intervention'], 'StudyType': ['Interventional'], 'StartDate': ['June 2011'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 3, 'OrgStudyId': ['CHUM-CRYOABLATION'], 'BriefTitle': ['Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['April 2013'], 'CompletionDate': ['October 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 4, 'OrgStudyId': ['20107812'], 'BriefTitle': ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging'], 'StudyType': ['Observational'], 'StartDate': ['December 2010'], 'CompletionDate': ['October 2013'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 5, 'OrgStudyId': ['234870'], 'BriefTitle': ['Blood Glycan Biomarkers in Women With Stage IV Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['September 2006'], 'CompletionDate': ['January 12, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 6, 'OrgStudyId': ['FWA00010885'], 'BriefTitle': ['Breast Cancer Survivorship & Work-Related Cognitive Limitation'], 'StudyType': ['Observational'], 'StartDate': ['September 2014'], 'CompletionDate': ['February 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['69 Years']}, {'Rank': 7, 'OrgStudyId': ['CC077515'], 'BriefTitle': ['Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['March 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 8, 'OrgStudyId': ['20022306'], 'BriefTitle': ['Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2002'], 'CompletionDate': ['January 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 9, 'OrgStudyId': ['STUDY00001641'], 'BriefTitle': ['Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women'], 'StudyType': ['Interventional'], 'StartDate': ['July 16, 2022'], 'CompletionDate': ['December 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['45 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 10, 'OrgStudyId': ['00080'], 'BriefTitle': ['Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease'], 'StudyType': ['Observational'], 'StartDate': ['July 2001'], 'CompletionDate': ['September 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 11, 'OrgStudyId': ['IRB-14623 part 1'], 'BriefTitle': ['Intellectual Impairment in Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 12, 2009'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 12, 'OrgStudyId': ['IIT2015-11-Giuliano-SNBO'], 'BriefTitle': ['Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['December 2015'], 'CompletionDate': ['April 2020'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 13, 'OrgStudyId': ['13278'], 'BriefTitle': ['Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)'], 'StudyType': ['Observational'], 'StartDate': ['September 30, 2013'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 14, 'OrgStudyId': ['200715040'], 'BriefTitle': ['Molecular Imaging of Breast Cancer With Breast PET/CT'], 'StudyType': ['Interventional'], 'StartDate': ['April 2007'], 'CompletionDate': ['July 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 15, 'OrgStudyId': ['SU-10042011-8529'], 'BriefTitle': ['National Breast Cancer and Lymphedema Registry'], 'StudyType': ['Observational'], 'StartDate': ['September 12, 2011'], 'CompletionDate': ['March 2, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 16, 'OrgStudyId': ['IRB-10748'], 'BriefTitle': ['Magnetic Resonance Imaging of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1, 1995'], 'CompletionDate': ['May 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 17, 'OrgStudyId': ['IRB-12226'], 'BriefTitle': ['Development of Vitamin D as a Therapy for Breast Cancer - Phase 2'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 18, 'OrgStudyId': ['5110026'], 'BriefTitle': ['Partial Breast Proton Therapy for Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 4, 2011'], 'CompletionDate': ['May 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 19, 'OrgStudyId': ['08063'], 'BriefTitle': ['Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2, 2008'], 'CompletionDate': ['June 26, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 20, 'OrgStudyId': ['182-20-CA'], 'BriefTitle': ['18F-fluoroestradiol (FES) PET/CT for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2021'], 'CompletionDate': ['December 15, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 21, 'OrgStudyId': ['01-BR-003'], 'BriefTitle': ['Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['July 2, 2020'], 'CompletionDate': ['March 17, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 22, 'OrgStudyId': ['037519'], 'BriefTitle': ['Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 3, 2004'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 23, 'OrgStudyId': ['08103'], 'BriefTitle': ['Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2008'], 'CompletionDate': ['April 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 24, 'OrgStudyId': ['19-001004'], 'BriefTitle': ['Brain Health in Breast Cancer Survivors'], 'StudyType': ['Observational'], 'StartDate': ['March 11, 2020'], 'CompletionDate': ['March 15, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['35 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 25, 'OrgStudyId': ['14-001744'], 'BriefTitle': ['Project Connect Online: An Internet-based Intervention for Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 4, 2015'], 'CompletionDate': ['June 17, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 26, 'OrgStudyId': ['CDR0000257580'], 'BriefTitle': ['Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2002'], 'CompletionDate': ['April 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 27, 'OrgStudyId': ['99002'], 'BriefTitle': ['Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 18, 1999'], 'CompletionDate': ['June 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['59 Years']}, {'Rank': 28, 'OrgStudyId': ['12175'], 'BriefTitle': ['Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2012'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 29, 'OrgStudyId': ['UCLA-9810046'], 'BriefTitle': ['Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 1999'], 'CompletionDate': ['October 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 30, 'OrgStudyId': ['1B-15-3'], 'BriefTitle': ['Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy'], 'StudyType': ['Observational'], 'StartDate': ['August 10, 2015'], 'CompletionDate': ['November 26, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 31, 'OrgStudyId': ['BRSNSTU0009'], 'BriefTitle': ['Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2'], 'StudyType': ['Observational'], 'StartDate': ['July 2005'], 'CompletionDate': ['April 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 32, 'OrgStudyId': ['UCSF-077518'], 'BriefTitle': ['Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 33, 'OrgStudyId': ['07006'], 'BriefTitle': ['Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy'], 'StudyType': ['Observational'], 'StartDate': ['October 2007'], 'CompletionDate': ['January 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 34, 'OrgStudyId': ['10038'], 'BriefTitle': ['Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2020'], 'CompletionDate': ['January 15, 2035'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 35, 'OrgStudyId': ['IIT2015-06-Chung-SNBO'], 'BriefTitle': ['Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65'], 'StudyType': ['Interventional'], 'StartDate': ['January 22, 2016'], 'CompletionDate': ['June 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 36, 'OrgStudyId': ['SPI-POZ-101'], 'BriefTitle': ['A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 13, 2018'], 'CompletionDate': ['April 17, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 37, 'OrgStudyId': ['07213'], 'BriefTitle': ['White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['December 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 38, 'OrgStudyId': ['09147'], 'BriefTitle': ['MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['November 2009'], 'CompletionDate': ['May 20, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 39, 'OrgStudyId': ['IRB-34959'], 'BriefTitle': ['Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['August 2016'], 'CompletionDate': ['July 8, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 40, 'OrgStudyId': ['CDR0000430701'], 'BriefTitle': ['Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2005'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 41, 'OrgStudyId': ['11-003446'], 'BriefTitle': ['Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['April 2012'], 'CompletionDate': ['September 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 42, 'OrgStudyId': ['03178'], 'BriefTitle': ['IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2005'], 'CompletionDate': ['October 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 43, 'OrgStudyId': ['SC0001'], 'BriefTitle': ['Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons'], 'StudyType': ['Interventional'], 'StartDate': ['January 2003'], 'CompletionDate': ['January 2010'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 44, 'OrgStudyId': ['BRSADJ0003'], 'BriefTitle': ['Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2005'], 'CompletionDate': ['August 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 45, 'OrgStudyId': ['USI2011001'], 'BriefTitle': ['CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study'], 'StudyType': ['Observational'], 'StartDate': ['July 2011'], 'CompletionDate': ['September 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 46, 'OrgStudyId': ['IRB-48150'], 'BriefTitle': ['68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 19, 2019'], 'CompletionDate': ['June 18, 2024'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 47, 'OrgStudyId': ['CDR0000442877'], 'BriefTitle': ['Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2005'], 'CompletionDate': ['November 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 48, 'OrgStudyId': ['IIT2017-07-HO-PembroRT'], 'BriefTitle': ['Breast Cancer Study of Preoperative Pembrolizumab + Radiation'], 'StudyType': ['Interventional'], 'StartDate': ['December 22, 2017'], 'CompletionDate': ['April 21, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 49, 'OrgStudyId': ['A5481155'], 'BriefTitle': ['Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy'], 'StudyType': ['Observational'], 'StartDate': ['June 30, 2020'], 'CompletionDate': ['December 31, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 50, 'OrgStudyId': ['IIT2015-18-Mita-MK3475'], 'BriefTitle': ['Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 10, 2017'], 'CompletionDate': ['November 8, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 51, 'OrgStudyId': ['CDR0000067909'], 'BriefTitle': ['Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 1999'], 'CompletionDate': ['April 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 52, 'OrgStudyId': ['BMS-CA163-031'], 'BriefTitle': ['BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 53, 'OrgStudyId': ['CDR0000599060'], 'BriefTitle': ['Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2008'], 'CompletionDate': [], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 54, 'OrgStudyId': ['CDR0000515534'], 'BriefTitle': ['ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 55, 'OrgStudyId': ['UCI 05-38'], 'BriefTitle': ['Neoadjuvant Treatment of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2005'], 'CompletionDate': ['September 4, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 56, 'OrgStudyId': ['1B-12-6'], 'BriefTitle': ['Light-Scattering Spectroscopy for Detection of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 21, 2012'], 'CompletionDate': ['November 19, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 57, 'OrgStudyId': ['037517'], 'BriefTitle': ['Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2004'], 'CompletionDate': ['January 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 58, 'OrgStudyId': ['IRB-13807'], 'BriefTitle': ['Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': ['March 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 59, 'OrgStudyId': ['IRB-31913'], 'BriefTitle': ['Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2015'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 60, 'OrgStudyId': ['01-06-020'], 'BriefTitle': ['Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression'], 'StudyType': ['Interventional'], 'StartDate': ['August 2001'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 61, 'OrgStudyId': ['05015'], 'BriefTitle': ['Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 27, 2005'], 'CompletionDate': ['June 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 62, 'OrgStudyId': ['07170'], 'BriefTitle': ['Study of Support Groups for African-American Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['January 2008'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 63, 'OrgStudyId': ['09101'], 'BriefTitle': ['Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2011'], 'CompletionDate': ['December 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 64, 'OrgStudyId': ['1B-13-2'], 'BriefTitle': ['Core Biopsies for Establishing a Breast Tumor Tissue Repository'], 'StudyType': ['Observational'], 'StartDate': ['November 14, 2013'], 'CompletionDate': ['November 14, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 65, 'OrgStudyId': ['UCD-986545'], 'BriefTitle': ['Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1996'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 66, 'OrgStudyId': ['IRB-57723'], 'BriefTitle': ['Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 3, 2021'], 'CompletionDate': ['February 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 67, 'OrgStudyId': ['BNIT-BR-002'], 'BriefTitle': ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2007'], 'CompletionDate': ['September 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 68, 'OrgStudyId': ['960-CSP-USA_MIRA_USS2'], 'BriefTitle': ['Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2016'], 'CompletionDate': ['October 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 69, 'OrgStudyId': ['STUDY2019000317'], 'BriefTitle': ['Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 3, 2018'], 'CompletionDate': ['October 3, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 70, 'OrgStudyId': ['CDR0000271533'], 'BriefTitle': ['CP-724,714 in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2003'], 'CompletionDate': ['May 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 71, 'OrgStudyId': ['12-028 MWA - Breast Tumors'], 'BriefTitle': ['Microwave Ablation of Breast Tumors'], 'StudyType': ['Observational'], 'StartDate': ['September 2012'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 72, 'OrgStudyId': ['IRB-21034'], 'BriefTitle': ['Vitamin D and Breast Cancer: Does Weight Make a Difference?'], 'StudyType': ['Interventional'], 'StartDate': ['November 2011'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 73, 'OrgStudyId': ['IRB-21030'], 'BriefTitle': ['Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2012'], 'CompletionDate': ['March 17, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 74, 'OrgStudyId': ['F31AT003021'], 'BriefTitle': ['Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['October 2005'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 75, 'OrgStudyId': ['057519'], 'BriefTitle': ['Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 1, 2006'], 'CompletionDate': ['December 1, 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 76, 'OrgStudyId': ['1R01CA140481'], 'BriefTitle': ['Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2012'], 'CompletionDate': ['July 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 77, 'OrgStudyId': ['B27IB3856'], 'BriefTitle': ['UCLA Breast Cancer Survivor Health Promotion Research Study'], 'StudyType': ['Interventional'], 'StartDate': ['April 1, 2022'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['50 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 78, 'OrgStudyId': ['U01AT003682'], 'BriefTitle': ['A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['December 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 79, 'OrgStudyId': ['53294'], 'BriefTitle': ['Proton Therapy for Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2004'], 'CompletionDate': ['May 12, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 80, 'OrgStudyId': ['96139'], 'BriefTitle': ['Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 30, 1997'], 'CompletionDate': ['December 30, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 81, 'OrgStudyId': ['08242'], 'BriefTitle': ['Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life'], 'StudyType': ['Observational'], 'StartDate': ['June 11, 2009'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 82, 'OrgStudyId': ['08128'], 'BriefTitle': ['Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['September 4, 2008'], 'CompletionDate': ['June 20, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 83, 'OrgStudyId': ['GENBASIX-00127'], 'BriefTitle': ['Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters'], 'StudyType': ['Observational'], 'StartDate': ['January 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 84, 'OrgStudyId': ['CC# 087515'], 'BriefTitle': ['Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 10, 2008'], 'CompletionDate': ['July 29, 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 85, 'OrgStudyId': ['06102'], 'BriefTitle': ['Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': ['June 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 86, 'OrgStudyId': ['587842'], 'BriefTitle': ['Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['April 2014'], 'CompletionDate': ['April 7, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 87, 'OrgStudyId': ['UCI 03-70'], 'BriefTitle': ['Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['July 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 88, 'OrgStudyId': ['CDR0000505536'], 'BriefTitle': ['Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ'], 'StudyType': ['Interventional'], 'StartDate': ['October 2001'], 'CompletionDate': ['May 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 89, 'OrgStudyId': ['1B-03-1'], 'BriefTitle': ['Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2003'], 'CompletionDate': ['December 2006'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 90, 'OrgStudyId': ['IORT'], 'BriefTitle': ['Intraoperative Radiotherapy for Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['48 Years'], 'MaximumAge': []}, {'Rank': 91, 'OrgStudyId': ['10-001799'], 'BriefTitle': ['A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['April 2011'], 'CompletionDate': ['November 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['50 Years']}, {'Rank': 92, 'OrgStudyId': ['UCI-HS-2000-1141'], 'BriefTitle': ['Angiogenesis in Early Breast Cancer for Prognosis Prediction'], 'StudyType': ['Interventional'], 'StartDate': ['November 2000'], 'CompletionDate': ['July 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 93, 'OrgStudyId': ['160178'], 'BriefTitle': ['Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 15, 2018'], 'CompletionDate': ['January 13, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 94, 'OrgStudyId': ['BRSMTS0002'], 'BriefTitle': ['Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study'], 'StudyType': ['Observational'], 'StartDate': ['November 2000'], 'CompletionDate': ['August 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 95, 'OrgStudyId': ['IRB-03518'], 'BriefTitle': ['Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': ['March 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 96, 'OrgStudyId': ['08092'], 'BriefTitle': ['Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2008'], 'CompletionDate': ['May 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 97, 'OrgStudyId': ['25IB-0023'], 'BriefTitle': ['Exercise Study for Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['November 25, 2019'], 'CompletionDate': ['December 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 98, 'OrgStudyId': ['IRB# 06-05-104'], 'BriefTitle': ['Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2007'], 'CompletionDate': ['October 2007'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 99, 'OrgStudyId': ['CBCRP 11IB-0034'], 'BriefTitle': ['Effect of Increased Light Exposure on Fatigue in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2005'], 'CompletionDate': ['November 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 100, 'OrgStudyId': ['CDR0000465214'], 'BriefTitle': ['Radiation Therapy in Treating Women With Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['May 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 101, 'OrgStudyId': ['IRB-13429'], 'BriefTitle': ['Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['October 2000'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 102, 'OrgStudyId': ['SU-11052007-799'], 'BriefTitle': ['Molecular Analysis of Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['May 1996'], 'CompletionDate': ['May 2050'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 103, 'OrgStudyId': ['CDR0000316264'], 'BriefTitle': ['Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['May 2003'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 104, 'OrgStudyId': ['GSM'], 'BriefTitle': ['GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['November 18, 2016'], 'CompletionDate': ['July 23, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 105, 'OrgStudyId': ['UCSD-020815'], 'BriefTitle': ['Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2003'], 'CompletionDate': ['March 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 106, 'OrgStudyId': ['BNIT-BR-003'], 'BriefTitle': ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['September 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 107, 'OrgStudyId': ['IIT2018-17-McArthur-TCDRT'], 'BriefTitle': ['Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2022'], 'CompletionDate': ['July 2027'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 108, 'OrgStudyId': ['1B-05-5'], 'BriefTitle': ['Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI'], 'StudyType': ['Interventional'], 'StartDate': ['November 20, 2005'], 'CompletionDate': ['November 20, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 109, 'OrgStudyId': ['07102022_SR'], 'BriefTitle': ['Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 1, 2022'], 'CompletionDate': ['June 1, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 110, 'OrgStudyId': ['07100'], 'BriefTitle': ['Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['July 6, 2010'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 111, 'OrgStudyId': ['12383'], 'BriefTitle': ['Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['July 15, 2013'], 'CompletionDate': ['June 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 112, 'OrgStudyId': ['KCT 005'], 'BriefTitle': ['A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2021'], 'CompletionDate': ['December 31, 2021'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 113, 'OrgStudyId': ['05751'], 'BriefTitle': ['Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['February 2005'], 'CompletionDate': ['January 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 114, 'OrgStudyId': ['11115'], 'BriefTitle': ['Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2012'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 115, 'OrgStudyId': ['1B-08-7'], 'BriefTitle': ['Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2009'], 'CompletionDate': ['February 2011'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 116, 'OrgStudyId': ['07157'], 'BriefTitle': ['Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 11, 2008'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 117, 'OrgStudyId': ['UCSD#100231'], 'BriefTitle': ['Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 118, 'OrgStudyId': ['UCI-HS-2006-5162'], 'BriefTitle': ['Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis'], 'StudyType': ['Interventional'], 'StartDate': ['October 1, 2006'], 'CompletionDate': ['October 30, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 119, 'OrgStudyId': ['AVF3359s'], 'BriefTitle': ['Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study'], 'StudyType': ['Interventional'], 'StartDate': ['June 2006'], 'CompletionDate': ['October 2008'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 120, 'OrgStudyId': ['IRB-07696'], 'BriefTitle': ['Healing Touch During Chemotherapy Infusions for Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2007'], 'CompletionDate': ['August 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 121, 'OrgStudyId': ['09-09-058'], 'BriefTitle': ['Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients'], 'StudyType': ['Observational'], 'StartDate': ['May 2010'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 122, 'OrgStudyId': ['IRB-08051'], 'BriefTitle': ['Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2008'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 123, 'OrgStudyId': ['BRSADJ0013'], 'BriefTitle': ['Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival'], 'StudyType': ['Observational'], 'StartDate': ['September 2006'], 'CompletionDate': ['August 31, 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 124, 'OrgStudyId': ['IRB-13732'], 'BriefTitle': ['Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention'], 'StudyType': ['Interventional'], 'StartDate': ['November 2005'], 'CompletionDate': ['December 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 125, 'OrgStudyId': ['05042'], 'BriefTitle': ['Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2005'], 'CompletionDate': ['October 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['65 Years']}, {'Rank': 126, 'OrgStudyId': ['08166'], 'BriefTitle': ['Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 17, 2010'], 'CompletionDate': ['September 27, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 127, 'OrgStudyId': ['SPI-GCF-301-PK'], 'BriefTitle': ['Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['May 11, 2017'], 'CompletionDate': ['May 18, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 128, 'OrgStudyId': ['BRSNSTU0002'], 'BriefTitle': ['Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['November 2001'], 'CompletionDate': ['June 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 129, 'OrgStudyId': ['06136'], 'BriefTitle': ['Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers'], 'StudyType': ['Interventional'], 'StartDate': ['August 2006'], 'CompletionDate': ['November 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 130, 'OrgStudyId': ['IRB-59141'], 'BriefTitle': ['Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2023'], 'CompletionDate': ['March 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 131, 'OrgStudyId': ['5140020'], 'BriefTitle': ['Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 12, 2014'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 132, 'OrgStudyId': ['BRSADJ0009'], 'BriefTitle': ['A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['January 2009'], 'CompletionDate': ['September 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 133, 'OrgStudyId': ['1B-14-7'], 'BriefTitle': ['Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['March 5, 2015'], 'CompletionDate': ['February 7, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 134, 'OrgStudyId': ['BRSMTS0012'], 'BriefTitle': ['Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['December 2014'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 135, 'OrgStudyId': ['1B-08-1'], 'BriefTitle': ['Green Tea in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['May 7, 2008'], 'CompletionDate': ['June 6, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 136, 'OrgStudyId': ['TRIO 017'], 'BriefTitle': ['Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2009'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 137, 'OrgStudyId': ['057514'], 'BriefTitle': ['Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 20, 2007'], 'CompletionDate': ['March 24, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 138, 'OrgStudyId': ['117513'], 'BriefTitle': ['Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib'], 'StudyType': ['Interventional'], 'StartDate': ['April 27, 2012'], 'CompletionDate': ['October 2, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 139, 'OrgStudyId': ['CDR0000378088'], 'BriefTitle': ['Study of Ductal Lavage in Women at High Risk for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['August 2002'], 'CompletionDate': ['June 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 140, 'OrgStudyId': ['1098987'], 'BriefTitle': ['Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 141, 'OrgStudyId': ['TRIO 016'], 'BriefTitle': ['Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2009'], 'CompletionDate': ['March 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 142, 'OrgStudyId': ['173-18-CA'], 'BriefTitle': ['Perioperative Mindfulness Proposal'], 'StudyType': ['Interventional'], 'StartDate': ['July 31, 2019'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 143, 'OrgStudyId': ['157512'], 'BriefTitle': ['Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['August 2, 2016'], 'CompletionDate': ['December 31, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 144, 'OrgStudyId': ['16758'], 'BriefTitle': ['Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 28, 2016'], 'CompletionDate': ['February 28, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 145, 'OrgStudyId': ['11996'], 'BriefTitle': ['Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['March 27, 2012'], 'CompletionDate': ['December 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 146, 'OrgStudyId': ['VEG108843'], 'BriefTitle': ['Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 147, 'OrgStudyId': ['1B-13-8'], 'BriefTitle': ['Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['December 19, 2013'], 'CompletionDate': ['September 25, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 148, 'OrgStudyId': ['CDR0000069154'], 'BriefTitle': ['Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2001'], 'CompletionDate': ['February 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 149, 'OrgStudyId': ['QUILT-3.067'], 'BriefTitle': ['QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.'], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2018'], 'CompletionDate': ['January 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 150, 'OrgStudyId': ['197520'], 'BriefTitle': ['Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2021'], 'CompletionDate': ['March 1, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 151, 'OrgStudyId': ['UCI HS# 2015-1866'], 'BriefTitle': ['Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System'], 'StudyType': ['Observational'], 'StartDate': ['May 2015'], 'CompletionDate': ['January 25, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 152, 'OrgStudyId': ['CDR0000068369'], 'BriefTitle': ['Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 153, 'OrgStudyId': ['117527'], 'BriefTitle': ['Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2012'], 'CompletionDate': ['June 9, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 154, 'OrgStudyId': ['150860'], 'BriefTitle': ['Tracking Physical Activity Throughout Chemotherapy for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['June 1, 2015'], 'CompletionDate': ['February 8, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 155, 'OrgStudyId': ['QUILT-3.058'], 'BriefTitle': ['A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies'], 'StudyType': ['Interventional'], 'StartDate': ['September 27, 2021'], 'CompletionDate': ['January 4, 2023'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 156, 'OrgStudyId': ['IIT2022-07-YUAN-IB-TNBC'], 'BriefTitle': ['Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2023'], 'CompletionDate': ['October 2026'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 157, 'OrgStudyId': ['221183'], 'BriefTitle': ['Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis'], 'StudyType': ['Interventional'], 'StartDate': ['November 2010'], 'CompletionDate': ['March 4, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 158, 'OrgStudyId': ['CDR0000657044'], 'BriefTitle': ['Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants'], 'StudyType': ['Interventional'], 'StartDate': ['January 2016'], 'CompletionDate': [], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 159, 'OrgStudyId': ['IIT2015-12-Goodman-STOP'], 'BriefTitle': ['STOP Heart Disease in Breast Cancer Survivors Trial'], 'StudyType': ['Interventional'], 'StartDate': ['May 5, 2016'], 'CompletionDate': ['May 25, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 160, 'OrgStudyId': ['NCI-2012-02827'], 'BriefTitle': ['GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2003'], 'CompletionDate': ['March 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 161, 'OrgStudyId': ['NCI-2012-02836'], 'BriefTitle': ['Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2005'], 'CompletionDate': ['January 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 162, 'OrgStudyId': ['15BB-1300'], 'BriefTitle': ['Nuevo Amanecer: Promoting the Psychosocial Health of Latinas'], 'StudyType': ['Interventional'], 'StartDate': ['February 2011'], 'CompletionDate': ['May 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 163, 'OrgStudyId': ['017513'], 'BriefTitle': ['Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ'], 'StudyType': ['Interventional'], 'StartDate': ['February 19, 2002'], 'CompletionDate': ['June 30, 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 164, 'OrgStudyId': ['1B-12-10'], 'BriefTitle': ['Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 29, 2013'], 'CompletionDate': ['March 2, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 165, 'OrgStudyId': ['BRS0001'], 'BriefTitle': ['Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 166, 'OrgStudyId': ['22239'], 'BriefTitle': ['Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['March 15, 2023'], 'CompletionDate': ['May 15, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 167, 'OrgStudyId': ['ITL-014-TACT-MBC'], 'BriefTitle': ['Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['March 2014'], 'CompletionDate': ['March 2014'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 168, 'OrgStudyId': ['20171'], 'BriefTitle': ['Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 27, 2021'], 'CompletionDate': ['December 12, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 169, 'OrgStudyId': ['IRB-52869'], 'BriefTitle': ['Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 20, 2023'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 170, 'OrgStudyId': ['1B-21-6'], 'BriefTitle': ['Breast Cancer Survivorship Biorepository'], 'StudyType': ['Observational'], 'StartDate': ['April 11, 2022'], 'CompletionDate': ['April 11, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 171, 'OrgStudyId': ['IRB-63041'], 'BriefTitle': ['Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 16, 2022'], 'CompletionDate': ['August 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 172, 'OrgStudyId': ['U54 CA155435-01 Project 3'], 'BriefTitle': ['Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2011'], 'CompletionDate': ['December 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 173, 'OrgStudyId': ['GC-627-05'], 'BriefTitle': ['Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['April 12, 2018'], 'CompletionDate': ['March 5, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 174, 'OrgStudyId': ['CDR0000367118'], 'BriefTitle': ['GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu'], 'StudyType': ['Interventional'], 'StartDate': ['March 2004'], 'CompletionDate': ['February 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 175, 'OrgStudyId': ['UCI 19-145 [HS# 1459]'], 'BriefTitle': ['Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2022'], 'CompletionDate': ['December 31, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 176, 'OrgStudyId': ['20923'], 'BriefTitle': ['Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand'], 'StudyType': ['Observational'], 'StartDate': ['May 18, 2020'], 'CompletionDate': ['May 24, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['70 Years']}, {'Rank': 177, 'OrgStudyId': ['18496'], 'BriefTitle': ['Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 4, 2019'], 'CompletionDate': ['December 21, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 178, 'OrgStudyId': ['21094'], 'BriefTitle': ['CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 18, 2021'], 'CompletionDate': ['December 1, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 179, 'OrgStudyId': ['MMP-001'], 'BriefTitle': ['Mindful Movement for Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2015'], 'CompletionDate': ['June 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 180, 'OrgStudyId': ['1B-16-3'], 'BriefTitle': ['Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 21, 2017'], 'CompletionDate': ['July 8, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 181, 'OrgStudyId': ['QUILT-3.057'], 'BriefTitle': ['QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine'], 'StudyType': ['Interventional'], 'StartDate': ['September 2018'], 'CompletionDate': ['December 2021'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 182, 'OrgStudyId': ['21050'], 'BriefTitle': ['An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2022'], 'CompletionDate': ['February 25, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 183, 'OrgStudyId': ['10192'], 'BriefTitle': ['Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid'], 'StudyType': ['Interventional'], 'StartDate': ['September 14, 2012'], 'CompletionDate': ['February 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 184, 'OrgStudyId': ['PILOT 171548'], 'BriefTitle': ['RISE - Reduce Sitting Time Among Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['March 29, 2022'], 'CompletionDate': ['February 7, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 185, 'OrgStudyId': ['1B-12-1'], 'BriefTitle': ['Exercise Program for Early Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['May 21, 2012'], 'CompletionDate': ['October 1, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 186, 'OrgStudyId': ['16-1856'], 'BriefTitle': ['Integrative Approaches for Cancer Survivorship 2: Project 2'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['June 4, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 187, 'OrgStudyId': ['IRB-53650'], 'BriefTitle': ['Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 13, 2020'], 'CompletionDate': ['October 22, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 188, 'OrgStudyId': ['SLNPain01'], 'BriefTitle': ['Sentinel Lymph Node Mapping Post-Injection Site Pain'], 'StudyType': ['Observational'], 'StartDate': ['March 2014'], 'CompletionDate': ['February 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 189, 'OrgStudyId': ['16-18567'], 'BriefTitle': ['Integrative Approaches For Cancer Survivorship 2: Project 1'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['September 21, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 190, 'OrgStudyId': ['20107789'], 'BriefTitle': ['Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging'], 'StudyType': ['Observational'], 'StartDate': ['December 2010'], 'CompletionDate': ['December 2018'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 191, 'OrgStudyId': ['4 BB-2901'], 'BriefTitle': ['Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 192, 'OrgStudyId': ['IRB-12273'], 'BriefTitle': ['Stress, Diurnal Cortisol, and Breast Cancer Survival'], 'StudyType': ['Observational'], 'StartDate': ['September 8, 2002'], 'CompletionDate': ['December 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 193, 'OrgStudyId': ['19-001881'], 'BriefTitle': ['Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['September 29, 2021'], 'CompletionDate': ['November 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 194, 'OrgStudyId': ['IRB-57111'], 'BriefTitle': ['Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['March 15, 2021'], 'CompletionDate': ['October 31, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 195, 'OrgStudyId': ['16-185671'], 'BriefTitle': ['Integrative Approaches to Cancer Survivorship: Project 3'], 'StudyType': ['Interventional'], 'StartDate': ['April 17, 2018'], 'CompletionDate': ['January 30, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 196, 'OrgStudyId': ['IRB-58571'], 'BriefTitle': ['Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 20, 2021'], 'CompletionDate': ['October 12, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 197, 'OrgStudyId': ['20141505'], 'BriefTitle': ['Breast Tumor Oxygenation During Exercise'], 'StudyType': ['Observational'], 'StartDate': ['April 2015'], 'CompletionDate': ['January 2018'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 198, 'OrgStudyId': ['IRB-13761'], 'BriefTitle': ['Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2006'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 199, 'OrgStudyId': ['19206'], 'BriefTitle': ['Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['March 25, 2020'], 'CompletionDate': ['December 15, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['70 Years'], 'MaximumAge': []}, {'Rank': 200, 'OrgStudyId': ['17-000560'], 'BriefTitle': ['Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['July 11, 2017'], 'CompletionDate': ['December 3, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 201, 'OrgStudyId': ['18549'], 'BriefTitle': ['Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema'], 'StudyType': ['Interventional'], 'StartDate': ['April 19, 2019'], 'CompletionDate': ['March 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 202, 'OrgStudyId': ['5R03CA144751-02'], 'BriefTitle': ['Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2010'], 'CompletionDate': ['September 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 203, 'OrgStudyId': ['UCSD POISE'], 'BriefTitle': ['Predictors of Ovarian Insufficiency in Young Breast Cancer Patients'], 'StudyType': ['Observational'], 'StartDate': ['September 24, 2008'], 'CompletionDate': ['July 18, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['45 Years']}, {'Rank': 204, 'OrgStudyId': ['BRS0027'], 'BriefTitle': ['Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2013'], 'CompletionDate': ['July 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 205, 'OrgStudyId': ['16-001271'], 'BriefTitle': ['Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2, 2017'], 'CompletionDate': ['March 31, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 206, 'OrgStudyId': ['OMS-I140'], 'BriefTitle': ['Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['September 2015'], 'CompletionDate': ['July 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 207, 'OrgStudyId': [\"SIMR_onc19_IIS_D'Andre_Ashwaga\"], 'BriefTitle': ['Ashwagandha for Cognitive Dysfunction'], 'StudyType': ['Interventional'], 'StartDate': ['January 1, 2020'], 'CompletionDate': ['November 1, 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 208, 'OrgStudyId': ['04125'], 'BriefTitle': ['Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease'], 'StudyType': ['Observational'], 'StartDate': ['August 2005'], 'CompletionDate': ['June 6, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['20 Years'], 'MaximumAge': []}, {'Rank': 209, 'OrgStudyId': ['1B-16-11'], 'BriefTitle': ['Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 29, 2019'], 'CompletionDate': ['July 29, 2025'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 210, 'OrgStudyId': ['1B-11-5'], 'BriefTitle': ['Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['September 4, 2012'], 'CompletionDate': ['September 30, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 211, 'OrgStudyId': ['21152'], 'BriefTitle': ['Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 21, 2022'], 'CompletionDate': ['September 7, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 212, 'OrgStudyId': ['11174'], 'BriefTitle': ['Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2012'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 213, 'OrgStudyId': ['14135'], 'BriefTitle': ['Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['September 7, 2014'], 'CompletionDate': ['June 3, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['56 Years'], 'MaximumAge': []}, {'Rank': 214, 'OrgStudyId': ['TRIO-US B09'], 'BriefTitle': ['Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis'], 'StudyType': ['Interventional'], 'StartDate': ['June 26, 2013'], 'CompletionDate': ['May 10, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 215, 'OrgStudyId': ['20091527'], 'BriefTitle': ['The Health of Women Study'], 'StudyType': ['Observational'], 'StartDate': ['August 2009'], 'CompletionDate': ['July 18, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 216, 'OrgStudyId': ['08061'], 'BriefTitle': ['Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2008'], 'CompletionDate': ['April 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 217, 'OrgStudyId': ['CDR0000428460'], 'BriefTitle': ['Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2005'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 218, 'OrgStudyId': ['02164'], 'BriefTitle': ['Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2004'], 'CompletionDate': ['June 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['48 Years']}, {'Rank': 219, 'OrgStudyId': ['RSGPB-04-258-01-CPPB'], 'BriefTitle': ['Weight Reduction Intervention for Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['January 2005'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 220, 'OrgStudyId': ['1B-14-5'], 'BriefTitle': ['High-Intensity Interval Training for Stage I-III Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['September 29, 2015'], 'CompletionDate': ['July 15, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 221, 'OrgStudyId': ['UCLA-9908076'], 'BriefTitle': ['Cryosurgery in Treating Women With Breast Lesions'], 'StudyType': ['Interventional'], 'StartDate': ['May 2001'], 'CompletionDate': ['July 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 222, 'OrgStudyId': ['1B-09-14'], 'BriefTitle': ['Endoscopic Breast Surgery in Treating Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2010'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['15 Years'], 'MaximumAge': []}, {'Rank': 223, 'OrgStudyId': ['1B-12-4'], 'BriefTitle': ['Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 1, 2012'], 'CompletionDate': ['October 21, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 224, 'OrgStudyId': ['7BB-2400'], 'BriefTitle': ['Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?'], 'StudyType': ['Observational'], 'StartDate': ['July 1, 2000'], 'CompletionDate': ['November 30, 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['20 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 225, 'OrgStudyId': ['1R03CA168450-01'], 'BriefTitle': ['Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)'], 'StudyType': ['Interventional'], 'StartDate': ['April 2013'], 'CompletionDate': ['October 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 226, 'OrgStudyId': ['SNP-17-001'], 'BriefTitle': ['Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['September 21, 2018'], 'CompletionDate': ['November 11, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 227, 'OrgStudyId': ['16294'], 'BriefTitle': ['Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 22, 2017'], 'CompletionDate': ['November 22, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 228, 'OrgStudyId': ['SAIRB-15-0060'], 'BriefTitle': ['A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.'], 'StudyType': ['Observational'], 'StartDate': ['December 2015'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 229, 'OrgStudyId': ['P0518095'], 'BriefTitle': ['Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device'], 'StudyType': ['Interventional'], 'StartDate': ['October 31, 2017'], 'CompletionDate': ['January 31, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 230, 'OrgStudyId': ['120108'], 'BriefTitle': ['Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['March 2012'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 231, 'OrgStudyId': ['IRB-30982'], 'BriefTitle': ['Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2015'], 'CompletionDate': ['July 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 232, 'OrgStudyId': ['14253'], 'BriefTitle': ['Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 7, 2016'], 'CompletionDate': ['December 19, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 233, 'OrgStudyId': ['S07-002'], 'BriefTitle': ['Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to \"Low-risk\" Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['May 2008'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 234, 'OrgStudyId': ['17753'], 'BriefTitle': ['T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 5, 2020'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 235, 'OrgStudyId': ['167514'], 'BriefTitle': ['Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib'], 'StudyType': ['Interventional'], 'StartDate': ['October 9, 2018'], 'CompletionDate': ['October 31, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 236, 'OrgStudyId': ['R01 CA119 159'], 'BriefTitle': ['Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['July 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 237, 'OrgStudyId': ['IIT2019-21-Basho-TOPAZ'], 'BriefTitle': ['TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2022'], 'CompletionDate': ['June 1, 2024'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 238, 'OrgStudyId': ['IRB-01671'], 'BriefTitle': ['Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status'], 'StudyType': ['Interventional'], 'StartDate': ['May 2005'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 239, 'OrgStudyId': ['18-000427'], 'BriefTitle': ['Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted'], 'StudyType': ['Interventional'], 'StartDate': ['July 10, 2019'], 'CompletionDate': ['July 1, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 240, 'OrgStudyId': ['CL- Gedatolisib-001'], 'BriefTitle': ['Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2016'], 'CompletionDate': ['March 15, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 241, 'OrgStudyId': ['VINJ007'], 'BriefTitle': ['Acupuncture for CIPN in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 2015'], 'CompletionDate': ['December 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 242, 'OrgStudyId': ['21-001819'], 'BriefTitle': ['Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 7, 2022'], 'CompletionDate': ['April 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 243, 'OrgStudyId': ['AVB620-C-001'], 'BriefTitle': ['Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['April 2015'], 'CompletionDate': ['January 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 244, 'OrgStudyId': ['IRB-37299'], 'BriefTitle': ['4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 30, 2017'], 'CompletionDate': ['February 14, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 245, 'OrgStudyId': ['BRSMTS0010'], 'BriefTitle': ['Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 246, 'OrgStudyId': ['RJ-101-RCT-001'], 'BriefTitle': ['Study to Investigate the Effect of AB-101 in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['July 9, 2018'], 'CompletionDate': ['October 12, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 247, 'OrgStudyId': ['09109'], 'BriefTitle': ['Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel'], 'StudyType': ['Interventional'], 'StartDate': ['January 2010'], 'CompletionDate': ['May 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 248, 'OrgStudyId': ['13-001676'], 'BriefTitle': ['Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus'], 'StudyType': ['Interventional'], 'StartDate': ['October 8, 2014'], 'CompletionDate': ['November 30, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 249, 'OrgStudyId': ['PA18-0280'], 'BriefTitle': ['A Culturally Sensitive Social Support Intervention'], 'StudyType': ['Interventional'], 'StartDate': ['January 2015'], 'CompletionDate': ['August 2021'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 250, 'OrgStudyId': ['06-08-010'], 'BriefTitle': ['Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['October 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 251, 'OrgStudyId': ['MRSGT-10-011-01-CPPB'], 'BriefTitle': ['Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2012'], 'CompletionDate': ['March 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 252, 'OrgStudyId': ['14955'], 'BriefTitle': ['Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2015'], 'CompletionDate': ['January 8, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 253, 'OrgStudyId': ['5354-CL-1201'], 'BriefTitle': ['A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['August 10, 2022'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 254, 'OrgStudyId': ['14099'], 'BriefTitle': ['Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 7, 2015'], 'CompletionDate': ['December 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 255, 'OrgStudyId': ['CDR0000393552'], 'BriefTitle': ['Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['November 2004'], 'CompletionDate': [], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 256, 'OrgStudyId': ['BMT86'], 'BriefTitle': ['CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant'], 'StudyType': ['Interventional'], 'StartDate': ['September 1996'], 'CompletionDate': ['June 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 257, 'OrgStudyId': ['BRSNSTU0024'], 'BriefTitle': ['Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI'], 'StudyType': ['Observational'], 'StartDate': ['April 2008'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 258, 'OrgStudyId': ['CDR0000069155'], 'BriefTitle': ['Herbal Therapy in Treating Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2001'], 'CompletionDate': ['April 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 259, 'OrgStudyId': ['UCDCC#237'], 'BriefTitle': ['Oxaliplatin in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2015'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 260, 'OrgStudyId': ['KCT003'], 'BriefTitle': ['A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2021'], 'CompletionDate': ['December 31, 2021'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 261, 'OrgStudyId': ['NU 98B3'], 'BriefTitle': ['Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 1999'], 'CompletionDate': ['April 2000'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 262, 'OrgStudyId': ['CDR0000439421'], 'BriefTitle': ['Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2005'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 263, 'OrgStudyId': ['IM-T-hMN14-04'], 'BriefTitle': ['Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2000'], 'CompletionDate': ['June 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 264, 'OrgStudyId': ['16421'], 'BriefTitle': ['Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention'], 'StudyType': ['Interventional'], 'StartDate': ['August 9, 2017'], 'CompletionDate': ['December 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 265, 'OrgStudyId': ['IIT 2014-01'], 'BriefTitle': ['Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment'], 'StudyType': ['Interventional'], 'StartDate': ['July 6, 2015'], 'CompletionDate': ['May 23, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 266, 'OrgStudyId': ['140863'], 'BriefTitle': ['Reproductive Health Survivorship Care Plan'], 'StudyType': ['Interventional'], 'StartDate': ['March 25, 2015'], 'CompletionDate': ['January 24, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['45 Years']}, {'Rank': 267, 'OrgStudyId': ['Breast Pain'], 'BriefTitle': ['Symptom Management After Breast Cancer Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['September 2003'], 'CompletionDate': ['December 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 268, 'OrgStudyId': ['CRICC-BB-IND-7186'], 'BriefTitle': ['Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1997'], 'CompletionDate': ['October 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 269, 'OrgStudyId': ['20080325'], 'BriefTitle': ['A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 21, 2008'], 'CompletionDate': ['February 7, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 270, 'OrgStudyId': ['14-071'], 'BriefTitle': ['Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History'], 'StudyType': ['Observational'], 'StartDate': ['April 8, 2014'], 'CompletionDate': ['April 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 271, 'OrgStudyId': ['98096'], 'BriefTitle': ['Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 1999'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['60 Years']}, {'Rank': 272, 'OrgStudyId': ['C07-104'], 'BriefTitle': ['Safety and Efficacy Study Using Rexin-G for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 273, 'OrgStudyId': ['10-01831'], 'BriefTitle': ['Fear of Recurrence Pilot Intervention for Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2011'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 274, 'OrgStudyId': ['1B-11-9'], 'BriefTitle': ['PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 22, 2013'], 'CompletionDate': ['November 22, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 275, 'OrgStudyId': ['UCI 18-79 [HS# 2020-5660]'], 'BriefTitle': ['Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 23, 2020'], 'CompletionDate': ['February 16, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 276, 'OrgStudyId': ['IRB-29691'], 'BriefTitle': ['Molecular and Cellular Analysis of Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['September 2014'], 'CompletionDate': ['September 2024'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Minutes'], 'MaximumAge': []}, {'Rank': 277, 'OrgStudyId': ['CDR0000616135'], 'BriefTitle': ['The Impact of Lymphedema on Breast Cancer Survivors'], 'StudyType': ['Observational'], 'StartDate': ['February 2007'], 'CompletionDate': ['February 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 278, 'OrgStudyId': ['CDR0000465198'], 'BriefTitle': ['Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['August 2004'], 'CompletionDate': ['May 24, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 279, 'OrgStudyId': ['246600'], 'BriefTitle': ['Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 2008'], 'CompletionDate': ['January 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 280, 'OrgStudyId': ['5BB-1801'], 'BriefTitle': ['Alternative Support for Rural and Isolated Women in an HMO'], 'StudyType': ['Interventional'], 'StartDate': ['September 2000'], 'CompletionDate': ['May 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 281, 'OrgStudyId': ['1B-15-6'], 'BriefTitle': ['Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['March 8, 2019'], 'CompletionDate': ['July 31, 2019'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 282, 'OrgStudyId': ['UCSF-067519'], 'BriefTitle': ['Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['March 2007'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 283, 'OrgStudyId': ['16-001'], 'BriefTitle': ['Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2016'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 284, 'OrgStudyId': ['UCI 14-67 [HS# 2015-1888]'], 'BriefTitle': ['Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab'], 'StudyType': ['Interventional'], 'StartDate': ['April 2015'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 285, 'OrgStudyId': ['182113'], 'BriefTitle': ['Improving Cognition After Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 9, 2019'], 'CompletionDate': ['February 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 286, 'OrgStudyId': ['BRS0037'], 'BriefTitle': ['Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['January 2014'], 'CompletionDate': [], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 287, 'OrgStudyId': ['CDR0000674337'], 'BriefTitle': ['Monitoring and Predicting Chemotherapy Response Using DOSI'], 'StudyType': ['Interventional'], 'StartDate': ['June 2011'], 'CompletionDate': ['October 6, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 288, 'OrgStudyId': ['SU-03012010-5082'], 'BriefTitle': ['Expanding Rural Access: Distance Delivery of Support Groups (Main Study)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2008'], 'CompletionDate': ['July 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 289, 'OrgStudyId': ['IRB-17323'], 'BriefTitle': ['Management of Insomnia in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['July 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 290, 'OrgStudyId': ['HMH2015.002'], 'BriefTitle': ['Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)'], 'StudyType': ['Interventional'], 'StartDate': ['August 2013'], 'CompletionDate': ['December 30, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 291, 'OrgStudyId': ['PPHM 1401'], 'BriefTitle': ['Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2015'], 'CompletionDate': ['June 2018'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 292, 'OrgStudyId': ['BRS0039'], 'BriefTitle': [\"Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy\"], 'StudyType': ['Interventional'], 'StartDate': ['July 2014'], 'CompletionDate': ['July 7, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 293, 'OrgStudyId': ['CA025'], 'BriefTitle': ['A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2005'], 'CompletionDate': ['February 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 294, 'OrgStudyId': ['16079'], 'BriefTitle': ['Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 15, 2016'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 295, 'OrgStudyId': ['08029'], 'BriefTitle': ['Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2008'], 'CompletionDate': ['December 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 296, 'OrgStudyId': ['VI-ISRP-026'], 'BriefTitle': ['A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes'], 'StudyType': ['Interventional'], 'StartDate': ['August 1, 2018'], 'CompletionDate': ['March 1, 2020'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 297, 'OrgStudyId': ['20-30638'], 'BriefTitle': ['Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2022'], 'CompletionDate': ['September 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['64 Years']}, {'Rank': 298, 'OrgStudyId': ['TCD11487'], 'BriefTitle': ['A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2008'], 'CompletionDate': ['October 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 299, 'OrgStudyId': ['UCI-HS-2007-5519'], 'BriefTitle': ['Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2007'], 'CompletionDate': ['June 2008'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 300, 'OrgStudyId': ['JWCI OBCS WITH IORT'], 'BriefTitle': ['Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.'], 'StudyType': ['Interventional'], 'StartDate': ['December 16, 2021'], 'CompletionDate': ['February 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 301, 'OrgStudyId': ['BRS0031'], 'BriefTitle': ['Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['April 2015'], 'CompletionDate': ['August 18, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 302, 'OrgStudyId': ['STOP-BC Trial'], 'BriefTitle': ['Sulindac and Breast Density in Women at Risk of Developing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 20, 2020'], 'CompletionDate': ['February 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 303, 'OrgStudyId': ['09021-02'], 'BriefTitle': ['Health Benefits of Expressive Writing: Study One'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 304, 'OrgStudyId': ['16-18737'], 'BriefTitle': ['Nuevo Amanecer II: Translating a Stress Management Program for Latinas'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['February 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 305, 'OrgStudyId': ['CDR0000430705'], 'BriefTitle': ['Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast'], 'StudyType': ['Interventional'], 'StartDate': ['November 2004'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 306, 'OrgStudyId': ['147523'], 'BriefTitle': ['Reversing Therapy Resistance With Epigenetic-Immune Modification'], 'StudyType': ['Interventional'], 'StartDate': ['May 4, 2015'], 'CompletionDate': ['June 8, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 307, 'OrgStudyId': ['CDR0000076422'], 'BriefTitle': ['High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma'], 'StudyType': ['Interventional'], 'StartDate': ['December 1987'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 308, 'OrgStudyId': ['NCI-2013-02225'], 'BriefTitle': ['Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2002'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 309, 'OrgStudyId': ['UCDCC#185'], 'BriefTitle': ['Abraxane and Alimta in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['April 2007'], 'CompletionDate': ['October 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 310, 'OrgStudyId': ['P2100-SUR-S11'], 'BriefTitle': ['Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 10, 2021'], 'CompletionDate': ['June 1, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 311, 'OrgStudyId': ['IRB-15005'], 'BriefTitle': ['Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption'], 'StudyType': ['Interventional'], 'StartDate': ['April 2009'], 'CompletionDate': ['April 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 312, 'OrgStudyId': ['14036'], 'BriefTitle': ['Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 1, 2014'], 'CompletionDate': ['March 3, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 313, 'OrgStudyId': ['IRB-44367'], 'BriefTitle': ['Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['August 1, 2018'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 314, 'OrgStudyId': ['UCI 07-61 [HS# 2007-6084]'], 'BriefTitle': ['Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': ['July 2021'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 315, 'OrgStudyId': ['GYNOVA0033'], 'BriefTitle': ['Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2016'], 'CompletionDate': ['October 11, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 316, 'OrgStudyId': ['SCP-1'], 'BriefTitle': ['Reproductive Health Survivorship Care Plan Pilot'], 'StudyType': ['Interventional'], 'StartDate': ['March 20, 2014'], 'CompletionDate': ['December 31, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['45 Years']}, {'Rank': 317, 'OrgStudyId': ['LSB-12345'], 'BriefTitle': ['Intraoperative Use of ClearEdge Device in Breast Conserving Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['October 10, 2022'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 318, 'OrgStudyId': ['CDR0000065692 (1B-97-2)'], 'BriefTitle': ['Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1997'], 'CompletionDate': ['March 2000'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 319, 'OrgStudyId': ['12147'], 'BriefTitle': ['Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 17, 2013'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 320, 'OrgStudyId': ['12-001 Single Fraction IORT'], 'BriefTitle': ['Single Fraction Intraoperative Radiotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 2012'], 'CompletionDate': ['February 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['41 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 321, 'OrgStudyId': ['S11-00533'], 'BriefTitle': ['Fresolimumab and Radiotherapy in Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2011'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 322, 'OrgStudyId': ['NMCSD.2014.0053'], 'BriefTitle': ['A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms'], 'StudyType': ['Observational'], 'StartDate': ['May 2015'], 'CompletionDate': ['January 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 323, 'OrgStudyId': ['216529'], 'BriefTitle': ['Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms'], 'StudyType': ['Interventional'], 'StartDate': ['March 2010'], 'CompletionDate': ['March 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 324, 'OrgStudyId': ['10AB-2801'], 'BriefTitle': ['Expanding Rural Access: Distance Delivery of Support'], 'StudyType': ['Interventional'], 'StartDate': ['November 2004'], 'CompletionDate': ['June 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 325, 'OrgStudyId': ['CP-18 100'], 'BriefTitle': ['Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects'], 'StudyType': ['Interventional'], 'StartDate': ['May 2011'], 'CompletionDate': ['April 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 326, 'OrgStudyId': ['BRSADJ0020'], 'BriefTitle': ['Acupuncture for Sleep Disruption in Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['February 2011'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 327, 'OrgStudyId': ['1B-10-6'], 'BriefTitle': ['Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2010'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 328, 'OrgStudyId': ['Pro00043233'], 'BriefTitle': ['A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2016'], 'CompletionDate': ['March 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 329, 'OrgStudyId': ['214750'], 'BriefTitle': ['Evaluation of Breast CT'], 'StudyType': ['Interventional'], 'StartDate': ['November 22, 2004'], 'CompletionDate': ['March 5, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 330, 'OrgStudyId': ['LAJ 08-8001'], 'BriefTitle': ['Scripps Polster Breast Care Center Investigational GeneBank'], 'StudyType': ['Observational'], 'StartDate': ['July 2008'], 'CompletionDate': ['June 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': []}, {'Rank': 331, 'OrgStudyId': ['11130'], 'BriefTitle': ['Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2009'], 'CompletionDate': ['May 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 332, 'OrgStudyId': ['CDR0000065828'], 'BriefTitle': ['Diet and Estrogen Metabolism in Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['August 1997'], 'CompletionDate': ['June 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['69 Years']}, {'Rank': 333, 'OrgStudyId': ['LUM-BC-1.0'], 'BriefTitle': ['A Multicenter Breast Cancer Biospecimen Registry'], 'StudyType': ['Observational'], 'StartDate': ['February 2016'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 334, 'OrgStudyId': ['A112313'], 'BriefTitle': ['Integrative Approaches for Cancer Survivorship'], 'StudyType': ['Interventional'], 'StartDate': ['January 2012'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 335, 'OrgStudyId': ['CDR0000616972'], 'BriefTitle': ['Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)'], 'StudyType': ['Observational'], 'StartDate': ['October 1, 2008'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 336, 'OrgStudyId': ['L-503'], 'BriefTitle': ['The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage'], 'StudyType': ['Observational'], 'StartDate': ['July 2011'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 337, 'OrgStudyId': ['025950'], 'BriefTitle': ['Investigating the Impact of Tamoxifen Therapy on Ovarian Aging'], 'StudyType': ['Observational'], 'StartDate': ['June 2011'], 'CompletionDate': ['March 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 338, 'OrgStudyId': ['BCA-003'], 'BriefTitle': ['Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning'], 'StudyType': ['Observational'], 'StartDate': ['April 2008'], 'CompletionDate': ['April 2011'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['50 Years']}, {'Rank': 339, 'OrgStudyId': ['18-001926'], 'BriefTitle': ['Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors'], 'StudyType': ['Interventional'], 'StartDate': ['October 7, 2019'], 'CompletionDate': ['June 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 340, 'OrgStudyId': ['800646'], 'BriefTitle': [\"Intervening on Women's Health for Rural Young Breast Cancer Survivors\"], 'StudyType': ['Interventional'], 'StartDate': ['October 15, 2021'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['50 Years']}, {'Rank': 341, 'OrgStudyId': ['IIT2021-10-Giuliano-OmitRT'], 'BriefTitle': ['Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response'], 'StudyType': ['Interventional'], 'StartDate': ['May 2022'], 'CompletionDate': ['May 2028'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 342, 'OrgStudyId': ['17-001864'], 'BriefTitle': ['SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 7, 2019'], 'CompletionDate': ['December 6, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 343, 'OrgStudyId': ['20429001'], 'BriefTitle': ['Central Obesity and Cancer Prevention for Chinese American Women'], 'StudyType': ['Interventional'], 'StartDate': ['October 16, 2019'], 'CompletionDate': ['December 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 344, 'OrgStudyId': ['R01AT000486'], 'BriefTitle': ['Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health'], 'StudyType': ['Interventional'], 'StartDate': ['May 2000'], 'CompletionDate': ['January 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 345, 'OrgStudyId': ['04140'], 'BriefTitle': ['Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2005'], 'CompletionDate': ['August 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 346, 'OrgStudyId': ['CDR0000613050'], 'BriefTitle': ['Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['May 2007'], 'CompletionDate': ['June 6, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 347, 'OrgStudyId': ['CBCRP 23AB-1400'], 'BriefTitle': ['Reducing Breast Cancer Risk in Korean American Women'], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2019'], 'CompletionDate': ['December 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 348, 'OrgStudyId': ['Pro00009633'], 'BriefTitle': ['Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment'], 'StudyType': ['Observational'], 'StartDate': ['September 2014'], 'CompletionDate': ['September 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 349, 'OrgStudyId': ['1B-14-6'], 'BriefTitle': ['Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['December 16, 2014'], 'CompletionDate': ['August 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 350, 'OrgStudyId': ['CP101'], 'BriefTitle': ['Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 351, 'OrgStudyId': ['QUILT-3.013'], 'BriefTitle': ['QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2016'], 'CompletionDate': ['December 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 352, 'OrgStudyId': ['CP-CTL'], 'BriefTitle': ['Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2010'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': ['45 Years']}, {'Rank': 353, 'OrgStudyId': ['BMT42'], 'BriefTitle': ['High Dose Chemotherapy and Autologous Transplant for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': ['March 2005'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 354, 'OrgStudyId': ['CDR0000065380'], 'BriefTitle': ['Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1996'], 'CompletionDate': ['November 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 355, 'OrgStudyId': ['IRB-19595'], 'BriefTitle': ['High Resolution 3D Diffusion-weighted Breast MRI'], 'StudyType': ['Observational'], 'StartDate': ['March 2011'], 'CompletionDate': ['February 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 356, 'OrgStudyId': ['IRB-37161'], 'BriefTitle': ['Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema'], 'StudyType': ['Interventional'], 'StartDate': ['July 20, 2016'], 'CompletionDate': ['October 29, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 357, 'OrgStudyId': ['P276-00/52/10'], 'BriefTitle': ['A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin'], 'StudyType': ['Interventional'], 'StartDate': ['August 2011'], 'CompletionDate': ['March 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 358, 'OrgStudyId': ['BRSADJ0023'], 'BriefTitle': ['Phase I: At-Home Support for Rural Women Using Group Video Calling'], 'StudyType': ['Interventional'], 'StartDate': ['October 2012'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 359, 'OrgStudyId': ['STUDY00001356'], 'BriefTitle': ['IIT2020-20-SHIRAZIP-WALK: Nature Walks'], 'StudyType': ['Interventional'], 'StartDate': ['June 21, 2021'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 360, 'OrgStudyId': ['10005'], 'BriefTitle': ['Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer'], 'StudyType': ['Observational'], 'StartDate': ['November 2010'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 361, 'OrgStudyId': ['99-11-084'], 'BriefTitle': ['Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2003'], 'CompletionDate': ['November 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 362, 'OrgStudyId': ['11F.438'], 'BriefTitle': ['Quantitative Subharmonic Breast Imaging'], 'StudyType': ['Interventional'], 'StartDate': ['November 2011'], 'CompletionDate': ['April 5, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 363, 'OrgStudyId': ['18432'], 'BriefTitle': ['Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease'], 'StudyType': ['Interventional'], 'StartDate': ['March 4, 2019'], 'CompletionDate': ['July 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 364, 'OrgStudyId': ['PARW-OVCONS-0307'], 'BriefTitle': ['Examining the Long-Term Risks of Oophorectomy'], 'StudyType': ['Observational'], 'StartDate': ['January 1980'], 'CompletionDate': ['June 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 365, 'OrgStudyId': ['IIT2018-01-McArthur-IPI'], 'BriefTitle': ['Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 12, 2019'], 'CompletionDate': ['June 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 366, 'OrgStudyId': ['CD07_TNBC'], 'BriefTitle': ['Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC'], 'StudyType': ['Interventional'], 'StartDate': ['April 22, 2019'], 'CompletionDate': ['September 16, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 367, 'OrgStudyId': ['12751'], 'BriefTitle': ['Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 12, 2012'], 'CompletionDate': ['July 5, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 368, 'OrgStudyId': ['M10-265'], 'BriefTitle': ['Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2008'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 369, 'OrgStudyId': ['IIT2019-14-SHIRAZIP-SWEAT'], 'BriefTitle': ['Streaming Web-based Exercise At Home: A Pilot Study'], 'StudyType': ['Interventional'], 'StartDate': ['July 7, 2020'], 'CompletionDate': ['March 30, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 370, 'OrgStudyId': ['CDR0000617655'], 'BriefTitle': ['Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['August 11, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 371, 'OrgStudyId': ['CDR0000594671'], 'BriefTitle': ['Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 372, 'OrgStudyId': ['TALES Trial'], 'BriefTitle': ['Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial'], 'StudyType': ['Interventional'], 'StartDate': ['July 21, 2016'], 'CompletionDate': ['January 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['50 Years']}, {'Rank': 373, 'OrgStudyId': ['NBI-3001-ST-0101'], 'BriefTitle': ['Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2002'], 'CompletionDate': ['July 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 374, 'OrgStudyId': ['HMH2015.001'], 'BriefTitle': ['Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe'], 'StudyType': ['Interventional'], 'StartDate': ['March 2015'], 'CompletionDate': ['September 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 375, 'OrgStudyId': ['15754'], 'BriefTitle': ['Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial'], 'StudyType': ['Interventional'], 'StartDate': ['March 13, 2017'], 'CompletionDate': ['December 20, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['89 Years']}, {'Rank': 376, 'OrgStudyId': ['ROCHE-NP17787'], 'BriefTitle': ['Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2004'], 'CompletionDate': ['December 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 377, 'OrgStudyId': ['ACU-JOINT001'], 'BriefTitle': ['Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain'], 'StudyType': ['Interventional'], 'StartDate': ['June 2015'], 'CompletionDate': ['June 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 378, 'OrgStudyId': ['H 15430'], 'BriefTitle': ['Neoadjuvant GW572016 to Treat Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2004'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 379, 'OrgStudyId': ['IRB-55153'], 'BriefTitle': ['Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts'], 'StudyType': ['Interventional'], 'StartDate': ['April 28, 2021'], 'CompletionDate': ['April 15, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 380, 'OrgStudyId': ['EXPLLN21-01'], 'BriefTitle': ['A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG'], 'StudyType': ['Interventional'], 'StartDate': ['May 1, 2023'], 'CompletionDate': ['March 1, 2025'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 381, 'OrgStudyId': ['20152355'], 'BriefTitle': ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI'], 'StudyType': ['Interventional'], 'StartDate': ['December 2015'], 'CompletionDate': ['December 2019'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 382, 'OrgStudyId': ['228012'], 'BriefTitle': ['Impact of Topical Tranexamic Acid in Breast Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['March 30, 2023'], 'CompletionDate': ['September 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 383, 'OrgStudyId': ['UCI 03-16 [HS# 2004-3681]'], 'BriefTitle': ['Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['September 21, 2004'], 'CompletionDate': ['December 12, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 384, 'OrgStudyId': ['48134'], 'BriefTitle': ['Plant-based Diets and Risk of Cancer in the Adventist Health Study-2'], 'StudyType': ['Observational'], 'StartDate': ['February 1, 2002'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': []}, {'Rank': 385, 'OrgStudyId': ['DZ2019HE001'], 'BriefTitle': ['DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 21, 2020'], 'CompletionDate': ['May 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 386, 'OrgStudyId': ['IRB-53132'], 'BriefTitle': ['LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy'], 'StudyType': ['Interventional'], 'StartDate': ['September 10, 2021'], 'CompletionDate': ['June 1, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 387, 'OrgStudyId': ['5160378'], 'BriefTitle': ['Effect of Resveratrol on Serum IGF2 Among African American Women'], 'StudyType': ['Interventional'], 'StartDate': ['April 24, 2019'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 388, 'OrgStudyId': ['CBCRP 12BB-3900'], 'BriefTitle': ['Telephone-Based Decision Support for Rural Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 389, 'OrgStudyId': ['KCT001'], 'BriefTitle': ['Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study'], 'StudyType': ['Interventional'], 'StartDate': ['August 5, 2020'], 'CompletionDate': ['May 28, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 390, 'OrgStudyId': ['11139'], 'BriefTitle': ['Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 19, 2012'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 391, 'OrgStudyId': ['1B-03-7'], 'BriefTitle': ['A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)'], 'StudyType': ['Interventional'], 'StartDate': ['August 2006'], 'CompletionDate': ['June 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 392, 'OrgStudyId': ['16-000817'], 'BriefTitle': ['Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)'], 'StudyType': ['Interventional'], 'StartDate': ['February 20, 2017'], 'CompletionDate': ['February 1, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['49 Years']}, {'Rank': 393, 'OrgStudyId': ['EGF103892'], 'BriefTitle': ['Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2006'], 'CompletionDate': ['September 12, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 394, 'OrgStudyId': ['DCA Breast NSCLC'], 'BriefTitle': ['Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)'], 'StudyType': ['Interventional'], 'StartDate': ['December 2009'], 'CompletionDate': ['November 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 395, 'OrgStudyId': ['IRB-30470'], 'BriefTitle': ['Brief Behavioral Intervention for Insomnia During Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['January 2015'], 'CompletionDate': ['June 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 396, 'OrgStudyId': ['BIOC-046'], 'BriefTitle': ['A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide'], 'StudyType': ['Observational'], 'StartDate': ['September 7, 2022'], 'CompletionDate': ['January 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 397, 'OrgStudyId': ['eFT508-0008'], 'BriefTitle': ['A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC'], 'StudyType': ['Interventional'], 'StartDate': ['November 21, 2017'], 'CompletionDate': ['January 22, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 398, 'OrgStudyId': ['090314'], 'BriefTitle': ['Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade'], 'StudyType': ['Observational'], 'StartDate': ['July 2009'], 'CompletionDate': ['November 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 399, 'OrgStudyId': ['IRB-06037'], 'BriefTitle': ['Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['July 26, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 400, 'OrgStudyId': ['IRB-46373'], 'BriefTitle': ['Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['March 22, 2019'], 'CompletionDate': ['July 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 401, 'OrgStudyId': ['190311'], 'BriefTitle': ['Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['October 20, 2022'], 'CompletionDate': ['March 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['22 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 402, 'OrgStudyId': ['CDR0000522934'], 'BriefTitle': ['Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2006'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 403, 'OrgStudyId': ['1K07CA181323-01A1'], 'BriefTitle': ['Physical Activity and Neuropsychological Outcomes in a Cancer Population'], 'StudyType': ['Interventional'], 'StartDate': ['August 2014'], 'CompletionDate': ['July 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 404, 'OrgStudyId': ['DCIS Cryo'], 'BriefTitle': ['Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2021'], 'CompletionDate': ['November 1, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 405, 'OrgStudyId': ['1B-06-9'], 'BriefTitle': ['Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['November 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 406, 'OrgStudyId': ['18R5-002'], 'BriefTitle': ['A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2013'], 'CompletionDate': ['December 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 407, 'OrgStudyId': ['Pro00052823'], 'BriefTitle': ['Tissue Expansion in Breast Reconstruction Without Drains'], 'StudyType': ['Observational'], 'StartDate': ['February 25, 2019'], 'CompletionDate': ['October 2, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 408, 'OrgStudyId': ['2450-US-002'], 'BriefTitle': ['Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2010'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 409, 'OrgStudyId': ['5170197'], 'BriefTitle': ['Chemotherapy Induced Peripheral Neuropathy (CIPN)'], 'StudyType': ['Interventional'], 'StartDate': ['September 28, 2017'], 'CompletionDate': ['September 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 410, 'OrgStudyId': ['OSU-15222'], 'BriefTitle': ['Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 12, 2016'], 'CompletionDate': ['December 11, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 411, 'OrgStudyId': ['1B-09-12'], 'BriefTitle': ['Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.'], 'StudyType': ['Interventional'], 'StartDate': ['December 2010'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 412, 'OrgStudyId': ['MR2016-03'], 'BriefTitle': ['A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['March 1, 2017'], 'CompletionDate': ['August 30, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 413, 'OrgStudyId': ['181367'], 'BriefTitle': ['Physical Activity Intervention for Young Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['September 1, 2019'], 'CompletionDate': ['September 30, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 414, 'OrgStudyId': ['OB0012018'], 'BriefTitle': ['Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 1, 2017'], 'CompletionDate': ['May 1, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 415, 'OrgStudyId': ['NU 98B1'], 'BriefTitle': ['Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 1998'], 'CompletionDate': ['June 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 416, 'OrgStudyId': ['PEAK VP-00078'], 'BriefTitle': ['PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 417, 'OrgStudyId': ['2010-185'], 'BriefTitle': ['Breast Health in Chinese American Women'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['December 21, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['42 Years'], 'MaximumAge': []}, {'Rank': 418, 'OrgStudyId': ['CH001'], 'BriefTitle': ['Circadian Thermal Sensing to Detect Breast Disease'], 'StudyType': ['Interventional'], 'StartDate': ['June 2015'], 'CompletionDate': ['February 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 419, 'OrgStudyId': ['DAMD17-03-1-067'], 'BriefTitle': ['Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women'], 'StudyType': ['Interventional'], 'StartDate': ['September 2003'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 420, 'OrgStudyId': ['SPI-POZ-203'], 'BriefTitle': ['A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['December 23, 2019'], 'CompletionDate': ['March 29, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 421, 'OrgStudyId': ['HS-16-00483'], 'BriefTitle': ['Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)'], 'StudyType': ['Observational'], 'StartDate': ['August 16, 2016'], 'CompletionDate': ['April 29, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 422, 'OrgStudyId': ['AD-13-5635'], 'BriefTitle': ['Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers'], 'StudyType': ['Interventional'], 'StartDate': ['May 2013'], 'CompletionDate': ['December 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['85 Years']}, {'Rank': 423, 'OrgStudyId': ['KPSC IRB 11103'], 'BriefTitle': ['Implementing Systematic Distress Screening in Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 2, 2017'], 'CompletionDate': ['November 30, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 424, 'OrgStudyId': ['IRB-50877'], 'BriefTitle': ['Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution'], 'StudyType': ['Interventional'], 'StartDate': ['January 2023'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 425, 'OrgStudyId': ['2011-01-LEV'], 'BriefTitle': ['An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging'], 'StudyType': ['Interventional'], 'StartDate': ['June 2011'], 'CompletionDate': ['June 2012'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 426, 'OrgStudyId': ['21051'], 'BriefTitle': ['Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults'], 'StudyType': ['Interventional'], 'StartDate': ['August 24, 2021'], 'CompletionDate': ['June 30, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['70 Years'], 'MaximumAge': []}, {'Rank': 427, 'OrgStudyId': ['2001-2192'], 'BriefTitle': ['Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics'], 'StudyType': ['Observational'], 'StartDate': ['May 24, 2002'], 'CompletionDate': ['December 19, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 428, 'OrgStudyId': ['IIT2018-25-MITA-NEOBREADS'], 'BriefTitle': ['NEOBREADS: Neoadjuvant Breast Diet Study'], 'StudyType': ['Interventional'], 'StartDate': ['March 21, 2019'], 'CompletionDate': ['August 17, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 429, 'OrgStudyId': ['2000-1383'], 'BriefTitle': ['Following the Use of Gel Prosethetics in Breast Reconstruction'], 'StudyType': ['Observational'], 'StartDate': ['February 1, 2001'], 'CompletionDate': ['September 23, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 430, 'OrgStudyId': ['BRS0005'], 'BriefTitle': ['SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants'], 'StudyType': ['Observational'], 'StartDate': ['June 2011'], 'CompletionDate': ['September 23, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 431, 'OrgStudyId': ['08803'], 'BriefTitle': ['Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['October 2008'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 432, 'OrgStudyId': ['IIT2018-21-AMERSI-BREADS'], 'BriefTitle': ['BREADS: Breast Adjuvant Diet Study'], 'StudyType': ['Interventional'], 'StartDate': ['February 4, 2020'], 'CompletionDate': ['January 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 433, 'OrgStudyId': ['GME Study'], 'BriefTitle': ['Gene Expression, Meditative Movement, and Emotional Distress (GME)'], 'StudyType': ['Interventional'], 'StartDate': ['July 17, 2017'], 'CompletionDate': ['February 15, 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['45 Years'], 'MaximumAge': []}, {'Rank': 434, 'OrgStudyId': ['17009'], 'BriefTitle': ['Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 13, 2017'], 'CompletionDate': ['October 1, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 435, 'OrgStudyId': ['0S-20-6'], 'BriefTitle': ['Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy'], 'StudyType': ['Observational'], 'StartDate': ['December 18, 2020'], 'CompletionDate': ['June 18, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 436, 'OrgStudyId': ['31801/1'], 'BriefTitle': ['Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['March 2019'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 437, 'OrgStudyId': ['LSB-01'], 'BriefTitle': ['In Vitro Detection of Tissue Abnormality'], 'StudyType': ['Interventional'], 'StartDate': ['October 15, 2010'], 'CompletionDate': ['January 9, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['25 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 438, 'OrgStudyId': ['1B-22-2'], 'BriefTitle': ['In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 9, 2023'], 'CompletionDate': ['January 9, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 439, 'OrgStudyId': ['PROT002 - Test Plan 01 Rev A'], 'BriefTitle': ['Blue Note Therapeutics Product BNT 103 Usability and User Engagement'], 'StudyType': ['Interventional'], 'StartDate': ['September 1, 2021'], 'CompletionDate': ['December 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['35 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 440, 'OrgStudyId': ['MAP3BSS'], 'BriefTitle': ['Effects of Exemestane on Bone Strength'], 'StudyType': ['Observational'], 'StartDate': ['April 2007'], 'CompletionDate': ['June 2019'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 441, 'OrgStudyId': ['2008-0067'], 'BriefTitle': ['Lynne Cohen Consortium Project: Multi-Center Database/Registry'], 'StudyType': ['Observational'], 'StartDate': ['July 2008'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 442, 'OrgStudyId': ['UCSF-GC3-2021'], 'BriefTitle': ['Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients'], 'StudyType': ['Interventional'], 'StartDate': ['April 18, 2017'], 'CompletionDate': ['December 16, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 443, 'OrgStudyId': ['CA148791-01'], 'BriefTitle': ['Reducing Breast Cancer Recurrence With Weight Loss'], 'StudyType': ['Interventional'], 'StartDate': ['May 2010'], 'CompletionDate': ['February 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 444, 'OrgStudyId': ['ANG1005-EAP-01, EAP-02, EAP-03'], 'BriefTitle': ['Expanded Access to ANG1005 for Individual Patients'], 'StudyType': ['Expanded Access'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['No longer available'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 445, 'OrgStudyId': ['STUDY00146320'], 'BriefTitle': ['Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens'], 'StudyType': ['Interventional'], 'StartDate': ['December 14, 2021'], 'CompletionDate': ['January 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 446, 'OrgStudyId': ['NCI-2019-06461'], 'BriefTitle': ['Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 6, 2019'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 447, 'OrgStudyId': ['217510'], 'BriefTitle': ['Microbiome and Association With Implant Infections'], 'StudyType': ['Interventional'], 'StartDate': ['September 28, 2021'], 'CompletionDate': ['December 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 448, 'OrgStudyId': ['UPCC 25920'], 'BriefTitle': ['Pilot Study of an NTproBNP Guided Strategy of Cardioprotection'], 'StudyType': ['Interventional'], 'StartDate': ['March 18, 2021'], 'CompletionDate': ['June 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 449, 'OrgStudyId': ['03049'], 'BriefTitle': ['Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2004'], 'CompletionDate': ['August 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 450, 'OrgStudyId': ['HS-10-00455'], 'BriefTitle': ['Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['December 2016'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['35 Years']}, {'Rank': 451, 'OrgStudyId': ['ANG-002'], 'BriefTitle': ['Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System'], 'StudyType': ['Observational'], 'StartDate': ['March 29, 2018'], 'CompletionDate': ['December 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['22 Years'], 'MaximumAge': []}, {'Rank': 452, 'OrgStudyId': ['17-000668'], 'BriefTitle': ['Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['August 3, 2017'], 'CompletionDate': ['February 1, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 453, 'OrgStudyId': ['US-001'], 'BriefTitle': ['SentiMag® Intraoperative Comparison in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2015'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 454, 'OrgStudyId': ['GCO 15-1783'], 'BriefTitle': ['Systematic Light Exposure for Fatigue in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['January 25, 2018'], 'CompletionDate': ['April 30, 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 455, 'OrgStudyId': ['MM-121-04-01-04'], 'BriefTitle': ['A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['October 2010'], 'CompletionDate': ['July 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 456, 'OrgStudyId': ['DIG-001'], 'BriefTitle': ['Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia'], 'StudyType': ['Interventional'], 'StartDate': ['July 2013'], 'CompletionDate': ['December 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 457, 'OrgStudyId': ['TMENEO-100'], 'BriefTitle': ['TME Neoadjuvant Breast Registry'], 'StudyType': ['Observational'], 'StartDate': ['July 2015'], 'CompletionDate': ['July 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 458, 'OrgStudyId': ['15295'], 'BriefTitle': ['Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 28, 2016'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 459, 'OrgStudyId': ['18112'], 'BriefTitle': ['64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['November 3, 2021'], 'CompletionDate': ['December 1, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 460, 'OrgStudyId': ['IBCSG 25-02 / BIG 3-02'], 'BriefTitle': ['Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 3, 2003'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 461, 'OrgStudyId': ['DS8201-A-U302'], 'BriefTitle': ['DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]'], 'StudyType': ['Interventional'], 'StartDate': ['August 9, 2018'], 'CompletionDate': ['April 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 462, 'OrgStudyId': ['ACOSOG-Z1071'], 'BriefTitle': ['Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 463, 'OrgStudyId': ['20-275'], 'BriefTitle': ['Testing a New Imaging Agent to Identify Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2020'], 'CompletionDate': ['November 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 464, 'OrgStudyId': ['IIT2018-05-ASHER-IMPROV2'], 'BriefTitle': [\"LOL: It's All Improv After Cancer!™\"], 'StudyType': ['Interventional'], 'StartDate': ['August 2, 2019'], 'CompletionDate': ['July 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 465, 'OrgStudyId': ['NSABP P-2'], 'BriefTitle': ['Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['May 1999'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 466, 'OrgStudyId': ['IRB-11872'], 'BriefTitle': ['Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples'], 'StudyType': ['Observational'], 'StartDate': ['August 2001'], 'CompletionDate': ['January 2099'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 467, 'OrgStudyId': ['5150012'], 'BriefTitle': ['Liposomal Bupivacaine in Implant Based Breast Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['July 2015'], 'CompletionDate': ['July 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 468, 'OrgStudyId': ['0S-10-3'], 'BriefTitle': ['Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 29, 2013'], 'CompletionDate': ['January 29, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 469, 'OrgStudyId': ['TORI B-03'], 'BriefTitle': ['Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)'], 'StudyType': ['Interventional'], 'StartDate': ['June 2003'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 470, 'OrgStudyId': ['OUT-113-2005; 06140-01'], 'BriefTitle': ['Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': ['June 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 471, 'OrgStudyId': ['SDX-0103'], 'BriefTitle': ['Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 26, 2022'], 'CompletionDate': ['September 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 472, 'OrgStudyId': ['ACOSOG-Z11102'], 'BriefTitle': ['Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2012'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 473, 'OrgStudyId': ['PEM-06-01'], 'BriefTitle': ['Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2006'], 'CompletionDate': ['March 2009'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 474, 'OrgStudyId': ['ML18530'], 'BriefTitle': ['XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2005'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 475, 'OrgStudyId': ['TRIO030'], 'BriefTitle': ['A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide'], 'StudyType': ['Interventional'], 'StartDate': ['September 5, 2017'], 'CompletionDate': ['March 13, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 476, 'OrgStudyId': ['CDR0000069225'], 'BriefTitle': ['S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1998'], 'CompletionDate': ['November 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 477, 'OrgStudyId': ['CALGB-70806'], 'BriefTitle': ['Vitamin D and Breast Cancer Biomarkers in Female Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 2010'], 'CompletionDate': ['December 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['55 Years']}, {'Rank': 478, 'OrgStudyId': ['MA32'], 'BriefTitle': ['A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 25, 2010'], 'CompletionDate': ['July 31, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 479, 'OrgStudyId': ['A011202'], 'BriefTitle': ['Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 7, 2014'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 480, 'OrgStudyId': ['120BC201'], 'BriefTitle': ['Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding'], 'StudyType': ['Interventional'], 'StartDate': ['November 2009'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 481, 'OrgStudyId': ['BrUOG-BR-211B'], 'BriefTitle': ['Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 482, 'OrgStudyId': ['19-188'], 'BriefTitle': ['Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial'], 'StudyType': ['Interventional'], 'StartDate': ['November 18, 2021'], 'CompletionDate': ['July 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 483, 'OrgStudyId': ['NSABP B-31'], 'BriefTitle': ['Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2'], 'StudyType': ['Interventional'], 'StartDate': ['February 2000'], 'CompletionDate': ['November 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 484, 'OrgStudyId': ['NCCTG-N0434'], 'BriefTitle': ['Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole'], 'StudyType': ['Observational'], 'StartDate': ['April 2006'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 485, 'OrgStudyId': ['A5481003'], 'BriefTitle': ['Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 15, 2008'], 'CompletionDate': ['December 20, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 486, 'OrgStudyId': ['dtectDx-Breast-001'], 'BriefTitle': ['Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification'], 'StudyType': ['Observational'], 'StartDate': ['March 2013'], 'CompletionDate': ['August 2014'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['49 Years']}, {'Rank': 487, 'OrgStudyId': ['CELC-G-301'], 'BriefTitle': ['Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2022'], 'CompletionDate': ['September 30, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 488, 'OrgStudyId': ['CALGB-40101'], 'BriefTitle': ['Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2002'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 489, 'OrgStudyId': ['DS8201-A-U201'], 'BriefTitle': ['A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)'], 'StudyType': ['Interventional'], 'StartDate': ['August 25, 2017'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 490, 'OrgStudyId': ['MAP3'], 'BriefTitle': ['Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 11, 2004'], 'CompletionDate': ['January 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 491, 'OrgStudyId': ['NSABP B-32'], 'BriefTitle': ['Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 1999'], 'CompletionDate': ['February 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 492, 'OrgStudyId': ['E7389-G000-399'], 'BriefTitle': ['Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies'], 'StudyType': ['Interventional'], 'StartDate': ['August 2010'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 493, 'OrgStudyId': ['BO25126'], 'BriefTitle': ['A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 8, 2011'], 'CompletionDate': ['November 30, 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 494, 'OrgStudyId': ['CALGB-40105'], 'BriefTitle': ['Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2003'], 'CompletionDate': ['January 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 495, 'OrgStudyId': ['NSABP B-30'], 'BriefTitle': ['Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes'], 'StudyType': ['Interventional'], 'StartDate': ['March 1999'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 496, 'OrgStudyId': ['NSABP B-39/RTOG 0413'], 'BriefTitle': ['Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2005'], 'CompletionDate': ['August 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 497, 'OrgStudyId': ['A6181068'], 'BriefTitle': ['Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['June 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 498, 'OrgStudyId': ['ACE-Breast-03'], 'BriefTitle': ['ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)'], 'StudyType': ['Interventional'], 'StartDate': ['April 5, 2021'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 499, 'OrgStudyId': ['BO28407'], 'BriefTitle': ['A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 31, 2014'], 'CompletionDate': ['June 4, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 500, 'OrgStudyId': ['NSABP B-40'], 'BriefTitle': ['Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['November 2006'], 'CompletionDate': ['March 2018'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 501, 'OrgStudyId': ['16338'], 'BriefTitle': ['Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 22, 2017'], 'CompletionDate': ['June 24, 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 502, 'OrgStudyId': ['NSABP B-42'], 'BriefTitle': ['Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2006'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 503, 'OrgStudyId': ['DS8201-A-U305'], 'BriefTitle': ['A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)'], 'StudyType': ['Interventional'], 'StartDate': ['December 4, 2020'], 'CompletionDate': ['December 31, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 504, 'OrgStudyId': ['CCTG MA.39'], 'BriefTitle': ['Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 30, 2018'], 'CompletionDate': ['December 30, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 505, 'OrgStudyId': ['CDR0000504319'], 'BriefTitle': ['S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': ['July 11, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 506, 'OrgStudyId': ['E2108'], 'BriefTitle': ['Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 8, 2011'], 'CompletionDate': ['December 21, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 507, 'OrgStudyId': ['CDR0000066135'], 'BriefTitle': ['Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1997'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 508, 'OrgStudyId': ['3144A2-3004 / B1891004'], 'BriefTitle': ['Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 9, 2009'], 'CompletionDate': ['October 4, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 509, 'OrgStudyId': ['V2011201'], 'BriefTitle': ['Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 15, 2023'], 'CompletionDate': ['May 26, 2024'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 510, 'OrgStudyId': ['C3441020'], 'BriefTitle': ['Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2018'], 'CompletionDate': ['September 23, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 511, 'OrgStudyId': ['CDR0000063537'], 'BriefTitle': ['Nutrition Intervention in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1994'], 'CompletionDate': ['December 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['48 Years'], 'MaximumAge': ['78 Years']}, {'Rank': 512, 'OrgStudyId': ['CDR0000636131'], 'BriefTitle': ['S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2010'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 513, 'OrgStudyId': ['A011502'], 'BriefTitle': ['Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['December 8, 2016'], 'CompletionDate': ['February 15, 2023'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['69 Years']}, {'Rank': 514, 'OrgStudyId': ['INCB 18424-268'], 'BriefTitle': ['A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2014'], 'CompletionDate': ['January 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 515, 'OrgStudyId': ['EGF105485'], 'BriefTitle': ['Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2006'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 516, 'OrgStudyId': ['CRAD001J2101'], 'BriefTitle': ['Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['March 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 517, 'OrgStudyId': ['DS8201-A-U301'], 'BriefTitle': ['DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]'], 'StudyType': ['Interventional'], 'StartDate': ['August 1, 2018'], 'CompletionDate': ['September 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 518, 'OrgStudyId': ['06090'], 'BriefTitle': ['TAC Versus TC for Adjuvant Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 29, 2007'], 'CompletionDate': ['March 30, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 519, 'OrgStudyId': ['UCSD-980919'], 'BriefTitle': [\"Women's Healthy Eating and Living Study\"], 'StudyType': ['Observational'], 'StartDate': ['March 1995'], 'CompletionDate': ['December 31, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 520, 'OrgStudyId': ['IBCSG 24-02 / BIG 2-02'], 'BriefTitle': ['Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 17, 2003'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 521, 'OrgStudyId': ['CDR0000423180'], 'BriefTitle': ['S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2005'], 'CompletionDate': ['August 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 522, 'OrgStudyId': ['BO27938'], 'BriefTitle': ['A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)'], 'StudyType': ['Interventional'], 'StartDate': ['April 3, 2013'], 'CompletionDate': ['April 3, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 523, 'OrgStudyId': ['291'], 'BriefTitle': ['BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)'], 'StudyType': ['Interventional'], 'StartDate': ['July 24, 2014'], 'CompletionDate': ['November 30, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 524, 'OrgStudyId': ['CDR0000349337'], 'BriefTitle': ['S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['October 1, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 525, 'OrgStudyId': ['EGF30008'], 'BriefTitle': ['Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 9, 2003'], 'CompletionDate': ['March 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 526, 'OrgStudyId': ['CDR0000069440'], 'BriefTitle': ['S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 527, 'OrgStudyId': ['CLEE011O12301C'], 'BriefTitle': ['A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2018'], 'CompletionDate': ['May 29, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 528, 'OrgStudyId': ['NSABP-B-49'], 'BriefTitle': ['Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2012'], 'CompletionDate': ['November 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 529, 'OrgStudyId': ['CTKI258A2202'], 'BriefTitle': ['Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['March 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 530, 'OrgStudyId': ['NSABP B-33'], 'BriefTitle': ['Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen'], 'StudyType': ['Interventional'], 'StartDate': ['May 2001'], 'CompletionDate': ['February 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 531, 'OrgStudyId': ['CDR0000343619'], 'BriefTitle': ['Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2002'], 'CompletionDate': ['August 22, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 532, 'OrgStudyId': ['NSABP B-36'], 'BriefTitle': ['Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2004'], 'CompletionDate': ['May 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 533, 'OrgStudyId': ['LIGAND-L1069-34'], 'BriefTitle': ['Bexarotene in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 1998'], 'CompletionDate': ['March 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 534, 'OrgStudyId': ['PUMA-NER-6201'], 'BriefTitle': ['An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide'], 'StudyType': ['Interventional'], 'StartDate': ['February 2015'], 'CompletionDate': ['April 22, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 535, 'OrgStudyId': ['IBCSG 48-14 / BIG 8-13'], 'BriefTitle': ['Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 4, 2014'], 'CompletionDate': ['December 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['42 Years']}, {'Rank': 536, 'OrgStudyId': ['WO42133'], 'BriefTitle': ['A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)'], 'StudyType': ['Interventional'], 'StartDate': ['September 4, 2020'], 'CompletionDate': ['November 24, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 537, 'OrgStudyId': ['13892'], 'BriefTitle': ['Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 6, 2008'], 'CompletionDate': ['November 19, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 538, 'OrgStudyId': ['CDR0000065813'], 'BriefTitle': ['S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['November 1997'], 'CompletionDate': ['February 2001'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 539, 'OrgStudyId': ['EFC6089'], 'BriefTitle': ['Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['September 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 540, 'OrgStudyId': ['CDR0000066563'], 'BriefTitle': ['Combination Chemotherapy in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 1998'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 541, 'OrgStudyId': ['CDR0000616008'], 'BriefTitle': ['Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['April 2009'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 542, 'OrgStudyId': ['WO42633'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['May 4, 2021'], 'CompletionDate': ['October 26, 2034'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 543, 'OrgStudyId': ['CDR0000068575'], 'BriefTitle': ['S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2001'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 544, 'OrgStudyId': ['NCCTG-N093B'], 'BriefTitle': ['Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2010'], 'CompletionDate': ['September 3, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 545, 'OrgStudyId': ['EFC11486'], 'BriefTitle': ['A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 546, 'OrgStudyId': ['E3108'], 'BriefTitle': ['Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 21, 2010'], 'CompletionDate': ['May 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 547, 'OrgStudyId': ['MM-302-02-01-01'], 'BriefTitle': ['Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2011'], 'CompletionDate': ['January 2017'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 548, 'OrgStudyId': ['SPI-POZ-201'], 'BriefTitle': ['Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2016'], 'CompletionDate': ['March 11, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 549, 'OrgStudyId': ['A4061010'], 'BriefTitle': ['AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2004'], 'CompletionDate': ['November 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 550, 'OrgStudyId': ['CP-MGAH22-02'], 'BriefTitle': ['Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2013'], 'CompletionDate': ['April 14, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 551, 'OrgStudyId': ['ISB 1302-103'], 'BriefTitle': ['Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 8, 2020'], 'CompletionDate': ['July 24, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 552, 'OrgStudyId': ['E7389-A001-201'], 'BriefTitle': ['A Study of E7389 in Advanced/Metastatic Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['September 2004'], 'CompletionDate': ['November 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 553, 'OrgStudyId': ['NSABP B-27'], 'BriefTitle': ['Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed'], 'StudyType': ['Interventional'], 'StartDate': ['December 1995'], 'CompletionDate': ['February 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 554, 'OrgStudyId': ['IIT2018-04-MCARTHUR-NEOHP'], 'BriefTitle': ['Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab'], 'StudyType': ['Interventional'], 'StartDate': ['January 25, 2019'], 'CompletionDate': ['July 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 555, 'OrgStudyId': ['BO20289'], 'BriefTitle': ['BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2007'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 556, 'OrgStudyId': ['ACOSOG-Z0011'], 'BriefTitle': ['Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1999'], 'CompletionDate': ['February 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 557, 'OrgStudyId': ['CALGB-150007'], 'BriefTitle': ['Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery'], 'StudyType': ['Observational'], 'StartDate': ['February 2002'], 'CompletionDate': ['May 1, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 558, 'OrgStudyId': ['NSABP BP-58'], 'BriefTitle': ['Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1998'], 'CompletionDate': ['December 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 559, 'OrgStudyId': ['D081CC00006'], 'BriefTitle': ['Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 22, 2014'], 'CompletionDate': ['May 28, 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 560, 'OrgStudyId': ['ACOSOG-Z0010'], 'BriefTitle': ['Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1999'], 'CompletionDate': ['July 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 561, 'OrgStudyId': ['CDR0000065472'], 'BriefTitle': ['Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 1997'], 'CompletionDate': ['March 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 562, 'OrgStudyId': ['TOC4129g'], 'BriefTitle': ['A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 12, 2008'], 'CompletionDate': ['November 23, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 563, 'OrgStudyId': ['NSABP FB-13'], 'BriefTitle': ['Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 22, 2018'], 'CompletionDate': ['January 30, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 564, 'OrgStudyId': ['PVB Catheter Study'], 'BriefTitle': ['Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks'], 'StudyType': ['Interventional'], 'StartDate': ['October 2010'], 'CompletionDate': ['March 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 565, 'OrgStudyId': ['A231701CD'], 'BriefTitle': [\"Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making\"], 'StudyType': ['Interventional'], 'StartDate': ['March 1, 2019'], 'CompletionDate': ['December 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 566, 'OrgStudyId': ['D967UC00001'], 'BriefTitle': ['Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)'], 'StudyType': ['Interventional'], 'StartDate': ['April 26, 2021'], 'CompletionDate': ['December 30, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 567, 'OrgStudyId': ['D8480C00007'], 'BriefTitle': ['AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['March 2007'], 'CompletionDate': ['April 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 568, 'OrgStudyId': ['GO42784'], 'BriefTitle': [\"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)\"], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2021'], 'CompletionDate': ['November 21, 2033'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 569, 'OrgStudyId': ['BTX-BCI-016-PRT'], 'BriefTitle': ['Breast Cancer Index (BCI) Registry'], 'StudyType': ['Observational'], 'StartDate': ['April 14, 2021'], 'CompletionDate': ['December 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 570, 'OrgStudyId': ['11-PIR-11'], 'BriefTitle': ['The BEACON Study (Breast Cancer Outcomes With NKTR-102)'], 'StudyType': ['Interventional'], 'StartDate': ['December 2011'], 'CompletionDate': ['June 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 571, 'OrgStudyId': ['CALGB-49806'], 'BriefTitle': ['Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 1999'], 'CompletionDate': ['February 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 572, 'OrgStudyId': ['ORIN1001-001'], 'BriefTitle': ['ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 25, 2019'], 'CompletionDate': ['March 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 573, 'OrgStudyId': ['NSABP B-35'], 'BriefTitle': ['Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['January 2003'], 'CompletionDate': ['May 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 574, 'OrgStudyId': ['A5481008'], 'BriefTitle': ['A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2013'], 'CompletionDate': ['August 26, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 575, 'OrgStudyId': ['3475-756'], 'BriefTitle': ['Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)'], 'StudyType': ['Interventional'], 'StartDate': ['December 27, 2018'], 'CompletionDate': ['January 24, 2031'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 576, 'OrgStudyId': ['20110148'], 'BriefTitle': ['Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim'], 'StudyType': ['Interventional'], 'StartDate': ['January 17, 2013'], 'CompletionDate': ['December 15, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 577, 'OrgStudyId': ['TDM4997g'], 'BriefTitle': [\"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy\"], 'StudyType': ['Interventional'], 'StartDate': ['September 2011'], 'CompletionDate': ['August 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 578, 'OrgStudyId': ['06BR01'], 'BriefTitle': ['Phase II Study in Patients With Operable Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2006'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 579, 'OrgStudyId': ['CZOL446E2352'], 'BriefTitle': ['Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2006'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 580, 'OrgStudyId': ['CDR0000068992'], 'BriefTitle': ['Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 581, 'OrgStudyId': ['AFT-05'], 'BriefTitle': ['PALbociclib CoLlaborative Adjuvant Study'], 'StudyType': ['Interventional'], 'StartDate': ['August 2015'], 'CompletionDate': ['September 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 582, 'OrgStudyId': ['CDR0000067353'], 'BriefTitle': ['Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes'], 'StudyType': ['Interventional'], 'StartDate': ['October 1999'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 583, 'OrgStudyId': ['CO-3810-025'], 'BriefTitle': ['A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 9, 2014'], 'CompletionDate': ['January 18, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 584, 'OrgStudyId': ['9238IL/0048'], 'BriefTitle': ['The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2003'], 'CompletionDate': ['September 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['32 Years'], 'MaximumAge': ['91 Years']}, {'Rank': 585, 'OrgStudyId': ['CO40016'], 'BriefTitle': ['A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 6, 2018'], 'CompletionDate': ['January 4, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 586, 'OrgStudyId': ['TDM4652g'], 'BriefTitle': ['A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2009'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 587, 'OrgStudyId': ['GE-280-401'], 'BriefTitle': ['Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients'], 'StudyType': ['Observational'], 'StartDate': ['January 5, 2023'], 'CompletionDate': ['October 2, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 588, 'OrgStudyId': ['A011401'], 'BriefTitle': ['Breast Cancer WEight Loss Study (BWEL Study)'], 'StudyType': ['Interventional'], 'StartDate': ['August 2016'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 589, 'OrgStudyId': ['0001'], 'BriefTitle': ['SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 5, 2017'], 'CompletionDate': ['November 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 590, 'OrgStudyId': ['3144A1-202 / B1891013'], 'BriefTitle': ['A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 4, 2007'], 'CompletionDate': ['March 2, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 591, 'OrgStudyId': ['10663'], 'BriefTitle': ['A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2006'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 592, 'OrgStudyId': ['CLCL161A2201'], 'BriefTitle': ['A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2012'], 'CompletionDate': ['September 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 593, 'OrgStudyId': ['CDR0000380937'], 'BriefTitle': ['Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['December 2004'], 'CompletionDate': ['January 30, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 594, 'OrgStudyId': ['RTOG-1005'], 'BriefTitle': ['Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['May 2011'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 595, 'OrgStudyId': ['NSABP B-44-I'], 'BriefTitle': ['BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['July 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 596, 'OrgStudyId': ['NRG-BR007'], 'BriefTitle': ['De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)'], 'StudyType': ['Interventional'], 'StartDate': ['June 7, 2021'], 'CompletionDate': ['July 2041'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 597, 'OrgStudyId': ['WO39391'], 'BriefTitle': ['A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2, 2018'], 'CompletionDate': ['August 24, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 598, 'OrgStudyId': ['CALGB-49907'], 'BriefTitle': ['Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2001'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 599, 'OrgStudyId': ['7962-012'], 'BriefTitle': ['Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2009'], 'CompletionDate': ['November 18, 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 600, 'OrgStudyId': ['NCI-2009-00504'], 'BriefTitle': ['Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU'], 'StudyType': ['Interventional'], 'StartDate': ['November 2007'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 601, 'OrgStudyId': ['OAM4861g'], 'BriefTitle': ['Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2011'], 'CompletionDate': ['March 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 602, 'OrgStudyId': ['CDR0000723653'], 'BriefTitle': ['S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2012'], 'CompletionDate': ['February 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 603, 'OrgStudyId': ['NU 07B1'], 'BriefTitle': ['Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2007'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 604, 'OrgStudyId': ['V3002401'], 'BriefTitle': ['Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 12, 2021'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 605, 'OrgStudyId': ['CR004120'], 'BriefTitle': ['A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2004'], 'CompletionDate': ['December 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 606, 'OrgStudyId': ['20060359'], 'BriefTitle': ['Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)'], 'StudyType': ['Interventional'], 'StartDate': ['June 2, 2010'], 'CompletionDate': ['March 26, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 607, 'OrgStudyId': ['DS8201-A-U303'], 'BriefTitle': [\"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]\"], 'StudyType': ['Interventional'], 'StartDate': ['December 27, 2018'], 'CompletionDate': ['March 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 608, 'OrgStudyId': ['NSABP B-41'], 'BriefTitle': ['A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['March 2017'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 609, 'OrgStudyId': ['673-201'], 'BriefTitle': ['A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)'], 'StudyType': ['Interventional'], 'StartDate': ['December 13, 2013'], 'CompletionDate': ['October 31, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 610, 'OrgStudyId': ['GO28509'], 'BriefTitle': ['A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 6, 2013'], 'CompletionDate': ['December 10, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 611, 'OrgStudyId': ['E7389-G000-209'], 'BriefTitle': ['A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 31, 2009'], 'CompletionDate': ['April 30, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 612, 'OrgStudyId': ['CLEE011G2301'], 'BriefTitle': ['Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 20, 2017'], 'CompletionDate': ['March 9, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 613, 'OrgStudyId': ['S1207'], 'BriefTitle': ['S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2013'], 'CompletionDate': ['January 2030'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 614, 'OrgStudyId': ['CRAD001J2301'], 'BriefTitle': ['Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 10, 2009'], 'CompletionDate': ['October 23, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 615, 'OrgStudyId': ['A8641020'], 'BriefTitle': ['A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations'], 'StudyType': ['Interventional'], 'StartDate': ['February 3, 2015'], 'CompletionDate': ['January 14, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 616, 'OrgStudyId': ['Pro00045372'], 'BriefTitle': [\"LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2016'], 'CompletionDate': ['December 20, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 617, 'OrgStudyId': ['CDR0000068630'], 'BriefTitle': ['S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2001'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 618, 'OrgStudyId': ['A8641016'], 'BriefTitle': ['A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 4, 2013'], 'CompletionDate': ['December 24, 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 619, 'OrgStudyId': ['CALGB-79809'], 'BriefTitle': ['Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2001'], 'CompletionDate': ['February 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 620, 'OrgStudyId': ['RAD1901-308'], 'BriefTitle': ['Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 10, 2019'], 'CompletionDate': ['August 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 621, 'OrgStudyId': ['SON-8184-1075'], 'BriefTitle': ['Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2005'], 'CompletionDate': ['September 2007'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 622, 'OrgStudyId': ['CDR0000069030'], 'BriefTitle': ['Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 623, 'OrgStudyId': ['BO22589'], 'BriefTitle': ['A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)'], 'StudyType': ['Interventional'], 'StartDate': ['July 31, 2010'], 'CompletionDate': ['September 16, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 624, 'OrgStudyId': ['D9268C00001'], 'BriefTitle': [\"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)\"], 'StudyType': ['Interventional'], 'StartDate': ['October 18, 2021'], 'CompletionDate': ['August 15, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 625, 'OrgStudyId': ['CRAD001Y2301'], 'BriefTitle': ['Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole'], 'StudyType': ['Interventional'], 'StartDate': ['June 3, 2009'], 'CompletionDate': ['December 4, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 626, 'OrgStudyId': ['A6181077'], 'BriefTitle': ['Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2006'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 627, 'OrgStudyId': ['OPT-822-001'], 'BriefTitle': ['Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects'], 'StudyType': ['Interventional'], 'StartDate': ['December 2011'], 'CompletionDate': ['August 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 628, 'OrgStudyId': ['CDR0000334899'], 'BriefTitle': ['S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2003'], 'CompletionDate': ['January 2027'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 629, 'OrgStudyId': ['15804'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 23, 2016'], 'CompletionDate': ['September 20, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 630, 'OrgStudyId': ['SNDX-275-0602'], 'BriefTitle': ['Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In'], 'StudyType': ['Interventional'], 'StartDate': ['May 2016'], 'CompletionDate': ['March 10, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 631, 'OrgStudyId': ['1033-011'], 'BriefTitle': ['A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2002'], 'CompletionDate': ['May 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 632, 'OrgStudyId': ['D3615C00001'], 'BriefTitle': ['Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 16, 2020'], 'CompletionDate': ['June 7, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 633, 'OrgStudyId': ['3066A1-303'], 'BriefTitle': ['Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2004'], 'CompletionDate': ['October 2006'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 634, 'OrgStudyId': ['EA1183'], 'BriefTitle': ['Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study'], 'StudyType': ['Interventional'], 'StartDate': ['April 2, 2020'], 'CompletionDate': ['August 31, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 635, 'OrgStudyId': ['3144A2-3003 / B1891003'], 'BriefTitle': ['Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 4, 2009'], 'CompletionDate': ['June 3, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 636, 'OrgStudyId': ['3144A1-203 / B1891014'], 'BriefTitle': ['A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 11, 2007'], 'CompletionDate': ['February 7, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 637, 'OrgStudyId': ['BO21977'], 'BriefTitle': ['A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2009'], 'CompletionDate': ['September 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 638, 'OrgStudyId': ['05-055'], 'BriefTitle': ['Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2005'], 'CompletionDate': ['May 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 639, 'OrgStudyId': ['16058'], 'BriefTitle': ['Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2016'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 640, 'OrgStudyId': ['S1200'], 'BriefTitle': ['S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 16, 2012'], 'CompletionDate': ['July 1, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 641, 'OrgStudyId': ['CP14B014'], 'BriefTitle': ['Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2010'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 642, 'OrgStudyId': ['MM-121-02-02-10'], 'BriefTitle': ['Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 15, 2017'], 'CompletionDate': ['November 30, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 643, 'OrgStudyId': ['M12-914'], 'BriefTitle': ['A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 17, 2014'], 'CompletionDate': ['January 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 644, 'OrgStudyId': ['15342'], 'BriefTitle': ['Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2, 2016'], 'CompletionDate': ['September 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 645, 'OrgStudyId': ['BO41843'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)'], 'StudyType': ['Interventional'], 'StartDate': ['October 9, 2020'], 'CompletionDate': ['March 18, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 646, 'OrgStudyId': ['CDR0000520348'], 'BriefTitle': ['S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone'], 'StudyType': ['Interventional'], 'StartDate': ['March 2007'], 'CompletionDate': ['January 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 647, 'OrgStudyId': ['CBKM120F2302'], 'BriefTitle': ['Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor'], 'StudyType': ['Interventional'], 'StartDate': ['August 7, 2012'], 'CompletionDate': ['April 19, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 648, 'OrgStudyId': ['A5481023'], 'BriefTitle': ['Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)'], 'StudyType': ['Interventional'], 'StartDate': ['September 26, 2013'], 'CompletionDate': ['September 28, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 649, 'OrgStudyId': ['CBYL719X2402'], 'BriefTitle': ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments'], 'StudyType': ['Interventional'], 'StartDate': ['August 14, 2017'], 'CompletionDate': ['July 17, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 650, 'OrgStudyId': ['CDX011-03'], 'BriefTitle': ['A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 651, 'OrgStudyId': ['MM-302-02-02-03'], 'BriefTitle': [\"MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients\"], 'StudyType': ['Interventional'], 'StartDate': ['July 2014'], 'CompletionDate': ['June 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 652, 'OrgStudyId': ['GDC4950g'], 'BriefTitle': ['Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['October 2011'], 'CompletionDate': ['April 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 653, 'OrgStudyId': ['ACORN AC01B07'], 'BriefTitle': ['1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2007'], 'CompletionDate': ['November 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 654, 'OrgStudyId': ['EFC15935'], 'BriefTitle': ['Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 14, 2020'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 655, 'OrgStudyId': ['C015'], 'BriefTitle': ['CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': ['October 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 656, 'OrgStudyId': ['ML28257'], 'BriefTitle': ['An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)'], 'StudyType': ['Observational'], 'StartDate': ['June 5, 2012'], 'CompletionDate': ['November 16, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 657, 'OrgStudyId': ['15417'], 'BriefTitle': ['A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 6, 2014'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 658, 'OrgStudyId': ['NSABP B-46-I'], 'BriefTitle': ['A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2009'], 'CompletionDate': ['February 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 659, 'OrgStudyId': ['NCI-2009-00477'], 'BriefTitle': ['Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 15, 2008'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 660, 'OrgStudyId': ['17096'], 'BriefTitle': ['Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 4, 2015'], 'CompletionDate': ['October 28, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 661, 'OrgStudyId': ['9238IL/0025'], 'BriefTitle': ['A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 1998'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 662, 'OrgStudyId': ['C4891001'], 'BriefTitle': ['A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['March 3, 2023'], 'CompletionDate': ['May 15, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 663, 'OrgStudyId': ['CBYL719C2301'], 'BriefTitle': ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.'], 'StudyType': ['Interventional'], 'StartDate': ['July 23, 2015'], 'CompletionDate': ['June 8, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 664, 'OrgStudyId': ['GS-US-586-6144'], 'BriefTitle': ['Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 14, 2021'], 'CompletionDate': ['January 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 665, 'OrgStudyId': ['17395'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 16, 2019'], 'CompletionDate': ['March 23, 2023'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 666, 'OrgStudyId': ['2017'], 'BriefTitle': ['Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2000'], 'CompletionDate': ['October 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 667, 'OrgStudyId': ['108919'], 'BriefTitle': ['Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 7, 2008'], 'CompletionDate': ['July 27, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 668, 'OrgStudyId': ['20060362'], 'BriefTitle': ['QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['August 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 669, 'OrgStudyId': ['CRAD001JUS226'], 'BriefTitle': ['Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2014'], 'CompletionDate': ['March 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 670, 'OrgStudyId': ['MM-121-02-02-07 (ARD11918)'], 'BriefTitle': ['A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2011'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 671, 'OrgStudyId': ['G1T28-213'], 'BriefTitle': ['Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 22, 2021'], 'CompletionDate': ['July 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 672, 'OrgStudyId': ['MM-121-02-02-03 (ARD11588)'], 'BriefTitle': ['Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['September 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 673, 'OrgStudyId': ['POL6326-009'], 'BriefTitle': ['Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 14, 2019'], 'CompletionDate': ['March 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 674, 'OrgStudyId': ['A6181094'], 'BriefTitle': ['A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2006'], 'CompletionDate': ['August 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 675, 'OrgStudyId': ['IMMU-132-05'], 'BriefTitle': ['Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['November 7, 2017'], 'CompletionDate': ['December 8, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 676, 'OrgStudyId': ['WO29522'], 'BriefTitle': ['A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)'], 'StudyType': ['Interventional'], 'StartDate': ['June 23, 2015'], 'CompletionDate': ['August 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 677, 'OrgStudyId': ['CTMX-2009-002'], 'BriefTitle': ['Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 29, 2020'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 678, 'OrgStudyId': ['2008002'], 'BriefTitle': ['A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.'], 'StudyType': ['Observational'], 'StartDate': ['March 2009'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 679, 'OrgStudyId': ['TRIO 020'], 'BriefTitle': ['Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone'], 'StudyType': ['Interventional'], 'StartDate': ['July 2014'], 'CompletionDate': ['November 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 680, 'OrgStudyId': ['1200.67'], 'BriefTitle': ['Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['October 2011'], 'CompletionDate': ['August 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 681, 'OrgStudyId': ['EGF108916'], 'BriefTitle': ['Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2007'], 'CompletionDate': ['March 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 682, 'OrgStudyId': ['ARV-471-mBC-101'], 'BriefTitle': ['A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 5, 2019'], 'CompletionDate': ['February 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 683, 'OrgStudyId': ['NSABP B-59/GBG 96-GeparDouze'], 'BriefTitle': ['Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo'], 'StudyType': ['Interventional'], 'StartDate': ['December 19, 2017'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 684, 'OrgStudyId': ['CDR0000285698'], 'BriefTitle': ['Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2003'], 'CompletionDate': ['August 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 685, 'OrgStudyId': ['BO28408'], 'BriefTitle': ['A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 25, 2014'], 'CompletionDate': ['May 29, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 686, 'OrgStudyId': ['NeuVax™ PH3-01, BB-IND 009187'], 'BriefTitle': ['Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence'], 'StudyType': ['Interventional'], 'StartDate': ['November 2011'], 'CompletionDate': ['September 21, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 687, 'OrgStudyId': ['D931CC00001'], 'BriefTitle': ['Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 7, 2022'], 'CompletionDate': ['December 7, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 688, 'OrgStudyId': ['SPI-GCF-302'], 'BriefTitle': ['SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide'], 'StudyType': ['Interventional'], 'StartDate': ['May 10, 2017'], 'CompletionDate': ['May 6, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 689, 'OrgStudyId': ['EA1131'], 'BriefTitle': ['Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['April 29, 2015'], 'CompletionDate': ['March 29, 2031'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 690, 'OrgStudyId': ['CR004645'], 'BriefTitle': ['To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['December 2005'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 691, 'OrgStudyId': ['D926XC00001'], 'BriefTitle': [\"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)\"], 'StudyType': ['Interventional'], 'StartDate': ['November 28, 2022'], 'CompletionDate': ['March 27, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 692, 'OrgStudyId': ['NCI-2011-02572'], 'BriefTitle': ['Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 6, 2011'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 693, 'OrgStudyId': ['D9670C00001'], 'BriefTitle': [\"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['July 24, 2020'], 'CompletionDate': ['June 19, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['105 Years']}, {'Rank': 694, 'OrgStudyId': ['CDR0000065314'], 'BriefTitle': ['S9630, Medroxyprogesterone in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 1997'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 695, 'OrgStudyId': ['CBKM120F2303'], 'BriefTitle': ['A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi'], 'StudyType': ['Interventional'], 'StartDate': ['October 3, 2012'], 'CompletionDate': ['September 21, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 696, 'OrgStudyId': ['SPI-GCF-301'], 'BriefTitle': ['SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)'], 'StudyType': ['Interventional'], 'StartDate': ['January 19, 2016'], 'CompletionDate': ['October 31, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 697, 'OrgStudyId': ['CDX011-04'], 'BriefTitle': ['Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2013'], 'CompletionDate': ['August 7, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 698, 'OrgStudyId': ['CA209-7FL'], 'BriefTitle': ['Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 20, 2019'], 'CompletionDate': ['January 15, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 699, 'OrgStudyId': ['IMMU-132-09'], 'BriefTitle': [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['May 8, 2019'], 'CompletionDate': ['October 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 700, 'OrgStudyId': ['G1T28-212'], 'BriefTitle': ['Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 19, 2021'], 'CompletionDate': ['March 13, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 701, 'OrgStudyId': ['CO42867'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 20, 2021'], 'CompletionDate': ['October 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 702, 'OrgStudyId': ['D967RC00001'], 'BriefTitle': ['Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 25, 2021'], 'CompletionDate': ['June 26, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 703, 'OrgStudyId': ['213831'], 'BriefTitle': ['Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease'], 'StudyType': ['Interventional'], 'StartDate': ['June 28, 2021'], 'CompletionDate': ['August 28, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 704, 'OrgStudyId': ['M12-895'], 'BriefTitle': ['Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 23, 2012'], 'CompletionDate': ['September 2, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 705, 'OrgStudyId': ['NEO3-05'], 'BriefTitle': ['Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 706, 'OrgStudyId': ['SGNTUC-016'], 'BriefTitle': ['A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2, 2019'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 707, 'OrgStudyId': ['CBYL719G12301'], 'BriefTitle': ['Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['July 16, 2020'], 'CompletionDate': ['April 2, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 708, 'OrgStudyId': ['GO25632'], 'BriefTitle': ['Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2012'], 'CompletionDate': ['November 21, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 709, 'OrgStudyId': ['CO41101'], 'BriefTitle': ['A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['November 25, 2019'], 'CompletionDate': ['February 28, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 710, 'OrgStudyId': ['E7389-G000-301'], 'BriefTitle': ['E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes'], 'StudyType': ['Interventional'], 'StartDate': ['September 20, 2006'], 'CompletionDate': ['December 11, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 711, 'OrgStudyId': ['ONT-380-206'], 'BriefTitle': ['A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 28, 2016'], 'CompletionDate': ['August 11, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 712, 'OrgStudyId': ['CDR0000064156'], 'BriefTitle': ['Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 1995'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 713, 'OrgStudyId': ['15805'], 'BriefTitle': ['A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2015'], 'CompletionDate': ['February 12, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 714, 'OrgStudyId': ['7339-009'], 'BriefTitle': ['Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)'], 'StudyType': ['Interventional'], 'StartDate': ['December 19, 2019'], 'CompletionDate': ['January 26, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 715, 'OrgStudyId': ['ANG1005-CLN-04'], 'BriefTitle': ['ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['April 2014'], 'CompletionDate': ['September 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 716, 'OrgStudyId': ['NCI-2013-02228'], 'BriefTitle': ['Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2014'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 717, 'OrgStudyId': ['S0812'], 'BriefTitle': ['S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2011'], 'CompletionDate': ['September 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['50 Years']}, {'Rank': 718, 'OrgStudyId': ['RTOG-9517'], 'BriefTitle': ['Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 1997'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 719, 'OrgStudyId': ['CTKI258A2210'], 'BriefTitle': ['Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2012'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 720, 'OrgStudyId': ['17320'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 14, 2019'], 'CompletionDate': ['August 11, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 721, 'OrgStudyId': ['SNDX-275-0301'], 'BriefTitle': ['Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 13, 2008'], 'CompletionDate': ['November 26, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 722, 'OrgStudyId': ['A6191007'], 'BriefTitle': ['Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2006'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 723, 'OrgStudyId': ['PCS-1402-10749'], 'BriefTitle': ['Women Informed to Screen Depending on Measures of Risk (Wisdom Study)'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2016'], 'CompletionDate': ['March 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 724, 'OrgStudyId': ['SGNTUC-025'], 'BriefTitle': ['A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 1, 2020'], 'CompletionDate': ['October 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 725, 'OrgStudyId': ['1839US/0713'], 'BriefTitle': ['Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2004'], 'CompletionDate': ['May 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 726, 'OrgStudyId': ['AVENTIS-56976-TAX-311'], 'BriefTitle': ['Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 1994'], 'CompletionDate': ['June 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 727, 'OrgStudyId': ['ML18527'], 'BriefTitle': ['A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2005'], 'CompletionDate': ['December 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 728, 'OrgStudyId': ['673-301'], 'BriefTitle': ['A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)'], 'StudyType': ['Interventional'], 'StartDate': ['October 14, 2013'], 'CompletionDate': ['March 5, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 729, 'OrgStudyId': ['3160A2-201'], 'BriefTitle': ['Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2006'], 'CompletionDate': ['February 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 730, 'OrgStudyId': ['BRE09-146'], 'BriefTitle': ['PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations'], 'StudyType': ['Interventional'], 'StartDate': ['February 2010'], 'CompletionDate': ['December 15, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 731, 'OrgStudyId': ['EGF30001'], 'BriefTitle': ['Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2004'], 'CompletionDate': ['March 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 732, 'OrgStudyId': ['17384'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 10, 2021'], 'CompletionDate': ['February 9, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 733, 'OrgStudyId': ['1200.75'], 'BriefTitle': ['LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment'], 'StudyType': ['Interventional'], 'StartDate': ['June 22, 2010'], 'CompletionDate': ['July 6, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 734, 'OrgStudyId': ['NRG-BR003'], 'BriefTitle': ['Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2015'], 'CompletionDate': ['November 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 735, 'OrgStudyId': ['IPI-549-03'], 'BriefTitle': ['Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)'], 'StudyType': ['Interventional'], 'StartDate': ['December 17, 2019'], 'CompletionDate': ['August 1, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 736, 'OrgStudyId': ['ML43171'], 'BriefTitle': [\"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)\"], 'StudyType': ['Interventional'], 'StartDate': ['August 3, 2022'], 'CompletionDate': ['March 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 737, 'OrgStudyId': ['15450'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain'], 'StudyType': ['Interventional'], 'StartDate': ['April 20, 2015'], 'CompletionDate': ['November 8, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 738, 'OrgStudyId': ['GO29227'], 'BriefTitle': ['A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors'], 'StudyType': ['Interventional'], 'StartDate': ['August 19, 2014'], 'CompletionDate': ['August 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 739, 'OrgStudyId': ['CP-00-0011'], 'BriefTitle': ['Cryoablation of Small Breast Tumors in Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2013'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 740, 'OrgStudyId': ['B2151009'], 'BriefTitle': ['A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 14, 2016'], 'CompletionDate': ['January 19, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 741, 'OrgStudyId': ['C31001'], 'BriefTitle': ['Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 13, 2014'], 'CompletionDate': ['June 29, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 742, 'OrgStudyId': ['CALGB-369901'], 'BriefTitle': ['Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['August 2003'], 'CompletionDate': ['December 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 743, 'OrgStudyId': ['CZOL446EUS32'], 'BriefTitle': ['Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': ['January 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 744, 'OrgStudyId': ['CA163-115'], 'BriefTitle': ['A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2007'], 'CompletionDate': ['November 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 745, 'OrgStudyId': ['D926PC00001'], 'BriefTitle': [\"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)\"], 'StudyType': ['Interventional'], 'StartDate': ['May 16, 2022'], 'CompletionDate': ['December 3, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 746, 'OrgStudyId': ['V2000701'], 'BriefTitle': ['Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 11, 2022'], 'CompletionDate': ['January 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 747, 'OrgStudyId': ['CLEE011XUS29'], 'BriefTitle': ['Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.'], 'StudyType': ['Interventional'], 'StartDate': ['June 14, 2016'], 'CompletionDate': ['February 25, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 748, 'OrgStudyId': ['NSABP FB-5'], 'BriefTitle': ['Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2007'], 'CompletionDate': ['May 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 749, 'OrgStudyId': ['941466'], 'BriefTitle': [\"Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study\"], 'StudyType': ['Observational'], 'StartDate': ['September 2016'], 'CompletionDate': ['February 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['89 Years']}, {'Rank': 750, 'OrgStudyId': ['CAL-03'], 'BriefTitle': ['An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 751, 'OrgStudyId': ['CO39611'], 'BriefTitle': ['A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 26, 2017'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 752, 'OrgStudyId': ['A211801'], 'BriefTitle': ['Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2022'], 'CompletionDate': ['December 2033'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 753, 'OrgStudyId': ['2014-0443'], 'BriefTitle': ['Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 2014'], 'CompletionDate': ['December 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 754, 'OrgStudyId': ['A4021004'], 'BriefTitle': ['Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2007'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 755, 'OrgStudyId': ['GS-US-592-6173'], 'BriefTitle': [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['July 25, 2022'], 'CompletionDate': ['February 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 756, 'OrgStudyId': ['GS-US-592-6238'], 'BriefTitle': [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['July 20, 2022'], 'CompletionDate': ['May 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 757, 'OrgStudyId': ['NCI-2014-00746'], 'BriefTitle': ['Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic'], 'StudyType': ['Interventional'], 'StartDate': ['March 29, 2014'], 'CompletionDate': ['October 28, 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 758, 'OrgStudyId': ['LCMH-001'], 'BriefTitle': ['Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2008'], 'CompletionDate': ['October 4, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': []}, {'Rank': 759, 'OrgStudyId': ['SMX 18001'], 'BriefTitle': ['Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['September 20, 2019'], 'CompletionDate': ['February 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 760, 'OrgStudyId': ['NSABP MA.32.F'], 'BriefTitle': ['Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32'], 'StudyType': ['Observational'], 'StartDate': ['July 2011'], 'CompletionDate': ['September 2016'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 761, 'OrgStudyId': ['17471'], 'BriefTitle': ['Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 14, 2018'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['70 Years'], 'MaximumAge': []}, {'Rank': 762, 'OrgStudyId': ['18459'], 'BriefTitle': ['A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 4, 2022'], 'CompletionDate': ['March 15, 2032'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 763, 'OrgStudyId': ['CR018286'], 'BriefTitle': ['A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['August 24, 2011'], 'CompletionDate': ['August 8, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 764, 'OrgStudyId': ['CLEE011F2301'], 'BriefTitle': ['Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['June 9, 2015'], 'CompletionDate': ['January 11, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 765, 'OrgStudyId': ['SGNLVA-002'], 'BriefTitle': ['Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 27, 2018'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 766, 'OrgStudyId': ['M14-011'], 'BriefTitle': ['A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2, 2014'], 'CompletionDate': ['November 12, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 767, 'OrgStudyId': ['110264'], 'BriefTitle': ['Treatment With Pazopanib for Neoadjuvant Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['April 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 768, 'OrgStudyId': ['CDR0000068583'], 'BriefTitle': ['Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2001'], 'CompletionDate': ['March 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 769, 'OrgStudyId': ['AL42478'], 'BriefTitle': ['An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic'], 'StudyType': ['Expanded Access'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Approved for marketing'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 770, 'OrgStudyId': ['RT-016'], 'BriefTitle': ['Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2004'], 'CompletionDate': ['June 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 771, 'OrgStudyId': ['20060341'], 'BriefTitle': ['Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['May 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 772, 'OrgStudyId': ['A171601'], 'BriefTitle': ['Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 15, 2018'], 'CompletionDate': ['August 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['70 Years'], 'MaximumAge': []}, {'Rank': 773, 'OrgStudyId': ['E7389-G000-305'], 'BriefTitle': [\"E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['November 2006'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 774, 'OrgStudyId': ['A6181002'], 'BriefTitle': ['A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.'], 'StudyType': ['Interventional'], 'StartDate': ['March 2004'], 'CompletionDate': ['November 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 775, 'OrgStudyId': ['CRX100-001'], 'BriefTitle': ['Study of CRX100 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 8, 2021'], 'CompletionDate': ['March 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 776, 'OrgStudyId': ['DARE'], 'BriefTitle': ['DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 9, 2021'], 'CompletionDate': ['December 15, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 777, 'OrgStudyId': ['TP2001-202'], 'BriefTitle': ['APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['September 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 778, 'OrgStudyId': ['CO40115'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2, 2018'], 'CompletionDate': ['May 3, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 779, 'OrgStudyId': ['CDR0000442919'], 'BriefTitle': ['S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2005'], 'CompletionDate': ['January 2007'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 780, 'OrgStudyId': ['EGF 20002'], 'BriefTitle': ['Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.'], 'StudyType': ['Interventional'], 'StartDate': ['October 2002'], 'CompletionDate': ['June 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 781, 'OrgStudyId': ['NCI-2012-02305'], 'BriefTitle': ['Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2'], 'StudyType': ['Interventional'], 'StartDate': ['August 1999'], 'CompletionDate': ['March 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 782, 'OrgStudyId': ['S1202'], 'BriefTitle': ['S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['May 15, 2013'], 'CompletionDate': ['December 20, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 783, 'OrgStudyId': ['CZOL446EUS147'], 'BriefTitle': ['Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 784, 'OrgStudyId': ['CP-MGAH22-04'], 'BriefTitle': ['Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 24, 2015'], 'CompletionDate': ['June 14, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 785, 'OrgStudyId': ['NCI-2016-01595'], 'BriefTitle': ['Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 15, 2016'], 'CompletionDate': ['May 31, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 786, 'OrgStudyId': ['G1T28-04'], 'BriefTitle': ['Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['February 2, 2017'], 'CompletionDate': ['February 28, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 787, 'OrgStudyId': ['CDR0000069347'], 'BriefTitle': ['Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 788, 'OrgStudyId': ['LCCC 9727'], 'BriefTitle': ['High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 1997'], 'CompletionDate': ['January 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 789, 'OrgStudyId': ['CA180-261'], 'BriefTitle': ['Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2009'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 790, 'OrgStudyId': ['Biomed 777-CLP-30'], 'BriefTitle': ['The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2004'], 'CompletionDate': ['August 2006'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 791, 'OrgStudyId': ['NCI-2018-01519'], 'BriefTitle': ['Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 12, 2018'], 'CompletionDate': ['June 1, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 792, 'OrgStudyId': ['14392'], 'BriefTitle': ['A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2011'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 793, 'OrgStudyId': ['NCI-2009-01073'], 'BriefTitle': ['Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['December 1, 2008'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 794, 'OrgStudyId': ['NCI-2009-01172'], 'BriefTitle': ['Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['May 15, 2009'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 795, 'OrgStudyId': ['CALGB-70301'], 'BriefTitle': ['Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 2005'], 'CompletionDate': ['June 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 796, 'OrgStudyId': ['PT-304'], 'BriefTitle': ['Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['November 2009'], 'CompletionDate': ['October 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 797, 'OrgStudyId': ['08-PIR-05'], 'BriefTitle': ['Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2008'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 798, 'OrgStudyId': ['CRAD001C2222'], 'BriefTitle': ['Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['March 2005'], 'CompletionDate': ['April 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 799, 'OrgStudyId': ['NCI-2009-00341'], 'BriefTitle': ['Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['February 21, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 800, 'OrgStudyId': ['15362'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 22, 2014'], 'CompletionDate': ['January 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 801, 'OrgStudyId': ['9785-CL-1121'], 'BriefTitle': ['A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 28, 2014'], 'CompletionDate': ['March 31, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 802, 'OrgStudyId': ['NCI-2009-00561'], 'BriefTitle': ['Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2, 2007'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 803, 'OrgStudyId': ['ABI-007-MBC-001'], 'BriefTitle': ['Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)'], 'StudyType': ['Interventional'], 'StartDate': ['September 26, 2013'], 'CompletionDate': ['October 28, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 804, 'OrgStudyId': ['22339'], 'BriefTitle': ['Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['June 6, 2023'], 'CompletionDate': ['October 31, 2024'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 805, 'OrgStudyId': ['A011801'], 'BriefTitle': ['T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial'], 'StudyType': ['Interventional'], 'StartDate': ['January 6, 2021'], 'CompletionDate': ['May 2035'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 806, 'OrgStudyId': ['D0819C00003'], 'BriefTitle': ['Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.'], 'StudyType': ['Interventional'], 'StartDate': ['March 27, 2014'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 807, 'OrgStudyId': ['16131'], 'BriefTitle': ['Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2017'], 'CompletionDate': ['January 28, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 808, 'OrgStudyId': ['12444'], 'BriefTitle': ['Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 21, 2011'], 'CompletionDate': ['October 20, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 809, 'OrgStudyId': ['STn-BR-105'], 'BriefTitle': ['Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['August 2002'], 'CompletionDate': ['August 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 810, 'OrgStudyId': ['117515'], 'BriefTitle': ['Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['May 18, 2012'], 'CompletionDate': ['December 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': []}, {'Rank': 811, 'OrgStudyId': ['CDR0000068399'], 'BriefTitle': ['Digital Mammography Screening Trial (ACRIN6652)'], 'StudyType': ['Interventional'], 'StartDate': ['October 2001'], 'CompletionDate': ['June 30, 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 812, 'OrgStudyId': ['18238'], 'BriefTitle': ['Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2022'], 'CompletionDate': ['February 16, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 813, 'OrgStudyId': ['dtectDx-Breast-002'], 'BriefTitle': ['Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol'], 'StudyType': ['Observational'], 'StartDate': ['March 2014'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 814, 'OrgStudyId': ['16298'], 'BriefTitle': ['Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2, 2015'], 'CompletionDate': ['August 13, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 815, 'OrgStudyId': ['AVF3694g'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)'], 'StudyType': ['Interventional'], 'StartDate': ['December 2005'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 816, 'OrgStudyId': ['CDR0000065011'], 'BriefTitle': ['Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1997'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 817, 'OrgStudyId': ['91466'], 'BriefTitle': ['Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2006'], 'CompletionDate': ['November 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 818, 'OrgStudyId': ['A011104'], 'BriefTitle': ['MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2014'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 819, 'OrgStudyId': ['11649'], 'BriefTitle': ['Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['January 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 820, 'OrgStudyId': ['CFEM345DUS59'], 'BriefTitle': ['Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['June 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 821, 'OrgStudyId': ['CDR0000067956'], 'BriefTitle': ['Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2000'], 'CompletionDate': ['August 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 822, 'OrgStudyId': ['CALGB-70305'], 'BriefTitle': ['Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection'], 'StudyType': ['Interventional'], 'StartDate': ['June 2006'], 'CompletionDate': ['June 15, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 823, 'OrgStudyId': ['NCI-2009-00665'], 'BriefTitle': ['Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 30, 2008'], 'CompletionDate': ['October 15, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 824, 'OrgStudyId': ['09-009'], 'BriefTitle': ['Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)'], 'StudyType': ['Interventional'], 'StartDate': ['September 2011'], 'CompletionDate': ['April 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 825, 'OrgStudyId': ['CLEE011A2301'], 'BriefTitle': ['Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)'], 'StudyType': ['Interventional'], 'StartDate': ['December 17, 2013'], 'CompletionDate': ['March 26, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 826, 'OrgStudyId': ['3475-522'], 'BriefTitle': ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)'], 'StudyType': ['Interventional'], 'StartDate': ['March 7, 2017'], 'CompletionDate': ['September 30, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 827, 'OrgStudyId': ['A6181099'], 'BriefTitle': ['A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2007'], 'CompletionDate': ['June 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 828, 'OrgStudyId': ['CA163-046'], 'BriefTitle': ['Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2003'], 'CompletionDate': ['March 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 829, 'OrgStudyId': ['NCI-2009-00475'], 'BriefTitle': ['Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive'], 'StudyType': ['Interventional'], 'StartDate': ['September 15, 2006'], 'CompletionDate': ['July 2, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 830, 'OrgStudyId': ['155-CL-036'], 'BriefTitle': ['A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2009'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 831, 'OrgStudyId': ['10-008061'], 'BriefTitle': ['Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['May 2011'], 'CompletionDate': ['November 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 832, 'OrgStudyId': ['3144A2-3005 / B1891005'], 'BriefTitle': ['Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 21, 2009'], 'CompletionDate': ['June 28, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 833, 'OrgStudyId': ['20-001275'], 'BriefTitle': ['Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 9, 2020'], 'CompletionDate': ['September 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 834, 'OrgStudyId': ['GS-US-595-6184'], 'BriefTitle': [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy\"], 'StudyType': ['Interventional'], 'StartDate': ['December 12, 2022'], 'CompletionDate': ['January 2031'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 835, 'OrgStudyId': ['EGF104900'], 'BriefTitle': ['Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2005'], 'CompletionDate': ['October 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 836, 'OrgStudyId': ['SGNLVA-001'], 'BriefTitle': ['A Safety Study of SGN-LIV1A in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['October 22, 2013'], 'CompletionDate': ['February 4, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 837, 'OrgStudyId': ['NCI-2014-02409'], 'BriefTitle': ['Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 6, 2015'], 'CompletionDate': ['May 25, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 838, 'OrgStudyId': ['ARV-471-mBC-102'], 'BriefTitle': ['ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 8, 2022'], 'CompletionDate': ['February 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 839, 'OrgStudyId': ['10112'], 'BriefTitle': ['Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 20, 2011'], 'CompletionDate': ['February 22, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 840, 'OrgStudyId': ['SMX 20-001'], 'BriefTitle': ['Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['September 29, 2020'], 'CompletionDate': ['February 10, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 841, 'OrgStudyId': ['0S-17-7'], 'BriefTitle': ['Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 8, 2017'], 'CompletionDate': ['December 31, 2018'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 842, 'OrgStudyId': ['VEG20007'], 'BriefTitle': ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2006'], 'CompletionDate': ['March 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 843, 'OrgStudyId': ['C31006'], 'BriefTitle': ['Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['July 28, 2016'], 'CompletionDate': ['November 25, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 844, 'OrgStudyId': ['NCI-2011-02623'], 'BriefTitle': ['Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2011'], 'CompletionDate': ['March 7, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 845, 'OrgStudyId': ['ONC-010'], 'BriefTitle': ['EndoPredict® Extended Endocrine Trial (EXET)'], 'StudyType': ['Observational'], 'StartDate': ['July 2, 2019'], 'CompletionDate': ['March 31, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 846, 'OrgStudyId': ['CRAD001Y2201'], 'BriefTitle': ['A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['February 26, 2013'], 'CompletionDate': ['July 30, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 847, 'OrgStudyId': ['NCI-2016-01130'], 'BriefTitle': ['Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 15, 2016'], 'CompletionDate': ['August 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 848, 'OrgStudyId': ['WO40181'], 'BriefTitle': ['A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['September 6, 2018'], 'CompletionDate': ['May 6, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 849, 'OrgStudyId': ['107CS-6'], 'BriefTitle': ['Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 25, 2018'], 'CompletionDate': ['April 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 850, 'OrgStudyId': ['NCI 2013-01-03'], 'BriefTitle': ['Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['October 2015'], 'CompletionDate': ['May 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 851, 'OrgStudyId': ['PUMA-NER-1301'], 'BriefTitle': ['A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting'], 'StudyType': ['Interventional'], 'StartDate': ['March 29, 2013'], 'CompletionDate': ['December 9, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 852, 'OrgStudyId': ['NSABP-B-51'], 'BriefTitle': ['Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['August 2013'], 'CompletionDate': ['August 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 853, 'OrgStudyId': ['CLEE011A2404'], 'BriefTitle': ['Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC'], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2016'], 'CompletionDate': ['December 3, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 854, 'OrgStudyId': ['AVI-014-P02'], 'BriefTitle': ['Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 855, 'OrgStudyId': ['NCI-2009-00476'], 'BriefTitle': ['Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 13, 2008'], 'CompletionDate': ['June 15, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 856, 'OrgStudyId': ['17502'], 'BriefTitle': ['A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 10, 2019'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 857, 'OrgStudyId': ['CLEE011E2301'], 'BriefTitle': ['Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 20, 2014'], 'CompletionDate': ['March 27, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['59 Years']}, {'Rank': 858, 'OrgStudyId': ['4703'], 'BriefTitle': ['A Phase III Trial For Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2002'], 'CompletionDate': ['November 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 859, 'OrgStudyId': ['PMD-026-1-001'], 'BriefTitle': ['Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 14, 2019'], 'CompletionDate': ['March 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 860, 'OrgStudyId': ['C4391002'], 'BriefTitle': ['A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 14, 2022'], 'CompletionDate': ['December 30, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 861, 'OrgStudyId': ['NCI-2012-01849'], 'BriefTitle': ['Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 19, 2000'], 'CompletionDate': ['January 27, 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 862, 'OrgStudyId': ['SGNTUC-028'], 'BriefTitle': ['A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 7, 2022'], 'CompletionDate': ['June 30, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 863, 'OrgStudyId': ['CLEE011X2107'], 'BriefTitle': ['Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 22, 2013'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 864, 'OrgStudyId': ['NSABP FB-7'], 'BriefTitle': ['Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2010'], 'CompletionDate': ['November 25, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 865, 'OrgStudyId': ['CDR0000339812'], 'BriefTitle': ['Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 866, 'OrgStudyId': ['09-040'], 'BriefTitle': ['Study of Radiation Exposure and Bilateral Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['May 2009'], 'CompletionDate': ['May 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['54 Years']}, {'Rank': 867, 'OrgStudyId': ['S1703'], 'BriefTitle': ['S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 16, 2018'], 'CompletionDate': ['January 1, 2038'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 868, 'OrgStudyId': ['NRG-BR002'], 'BriefTitle': ['Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival'], 'StudyType': ['Interventional'], 'StartDate': ['December 24, 2014'], 'CompletionDate': ['December 20, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 869, 'OrgStudyId': ['NCCTG-N9431'], 'BriefTitle': ['Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['June 1996'], 'CompletionDate': ['October 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 870, 'OrgStudyId': ['D8532C00001'], 'BriefTitle': ['A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease'], 'StudyType': ['Interventional'], 'StartDate': ['January 28, 2021'], 'CompletionDate': ['February 1, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 871, 'OrgStudyId': ['15-102-14'], 'BriefTitle': [\"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine\"], 'StudyType': ['Interventional'], 'StartDate': ['November 2016'], 'CompletionDate': ['July 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 872, 'OrgStudyId': ['3144A1-2206 / B1891017'], 'BriefTitle': ['Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 9, 2008'], 'CompletionDate': ['June 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 873, 'OrgStudyId': ['VAR0033'], 'BriefTitle': ['Immunobiology of Cancer'], 'StudyType': ['Observational'], 'StartDate': ['October 2008'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 874, 'OrgStudyId': ['NCI-2011-02585'], 'BriefTitle': ['Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 21, 2011'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 875, 'OrgStudyId': ['ACT16105'], 'BriefTitle': [\"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['October 22, 2019'], 'CompletionDate': ['September 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 876, 'OrgStudyId': ['NCI-2012-01977'], 'BriefTitle': ['Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 26, 2012'], 'CompletionDate': ['May 20, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 877, 'OrgStudyId': ['CA023'], 'BriefTitle': ['Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2006'], 'CompletionDate': ['March 1, 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 878, 'OrgStudyId': ['090214'], 'BriefTitle': [\"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)\"], 'StudyType': ['Interventional'], 'StartDate': ['August 20, 2009'], 'CompletionDate': ['April 11, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 879, 'OrgStudyId': ['S1501'], 'BriefTitle': ['S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 15, 2017'], 'CompletionDate': ['January 1, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 880, 'OrgStudyId': ['20170770'], 'BriefTitle': ['Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 26, 2020'], 'CompletionDate': ['January 14, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 881, 'OrgStudyId': ['91743'], 'BriefTitle': ['Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI'], 'StudyType': ['Interventional'], 'StartDate': ['February 2010'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 882, 'OrgStudyId': ['EGF103659'], 'BriefTitle': ['EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer'], 'StudyType': ['Expanded Access'], 'StartDate': ['July 2006'], 'CompletionDate': ['March 2015'], 'OverallStatus': ['Approved for marketing'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 883, 'OrgStudyId': ['S2007'], 'BriefTitle': ['Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['December 15, 2020'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 884, 'OrgStudyId': ['213551'], 'BriefTitle': [\"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients\"], 'StudyType': ['Interventional'], 'StartDate': ['February 25, 2014'], 'CompletionDate': ['October 26, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 885, 'OrgStudyId': ['CDR0000617081'], 'BriefTitle': ['S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo'], 'StudyType': ['Interventional'], 'StartDate': ['September 2009'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 886, 'OrgStudyId': ['TDM4884g'], 'BriefTitle': ['A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Expanded Access'], 'StartDate': ['May 2010'], 'CompletionDate': [], 'OverallStatus': ['No longer available'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 887, 'OrgStudyId': ['368255'], 'BriefTitle': ['Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax'], 'StudyType': ['Interventional'], 'StartDate': ['May 21, 2013'], 'CompletionDate': ['September 28, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 888, 'OrgStudyId': ['18175'], 'BriefTitle': [\"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['October 4, 2021'], 'CompletionDate': ['August 31, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 889, 'OrgStudyId': ['20110147'], 'BriefTitle': ['NOLAN: Naproxen or Loratadine and Neulasta'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2012'], 'CompletionDate': ['March 18, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 890, 'OrgStudyId': ['NCI-2011-01379'], 'BriefTitle': ['Veliparib With or Without Carboplatin in Treating Patients With Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 30, 2010'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 891, 'OrgStudyId': ['111438'], 'BriefTitle': ['Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2009'], 'CompletionDate': ['March 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 892, 'OrgStudyId': ['CDR0000065237'], 'BriefTitle': ['SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial'], 'StudyType': ['Observational'], 'StartDate': ['February 1997'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 893, 'OrgStudyId': ['NCCTG-N00C9'], 'BriefTitle': ['EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2002'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 894, 'OrgStudyId': ['NCI-2015-00383'], 'BriefTitle': ['FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 2, 2016'], 'CompletionDate': ['April 4, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 895, 'OrgStudyId': ['999915030'], 'BriefTitle': ['Self-Affirmation, Emotion, and Alcohol Consumption'], 'StudyType': ['Observational'], 'StartDate': ['November 19, 2014'], 'CompletionDate': ['September 29, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 896, 'OrgStudyId': ['201209135'], 'BriefTitle': ['Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 11, 2012'], 'CompletionDate': ['March 11, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 897, 'OrgStudyId': ['A011106'], 'BriefTitle': ['Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['December 13, 2013'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 898, 'OrgStudyId': ['NCI-2015-01912'], 'BriefTitle': ['Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['July 7, 2016'], 'CompletionDate': ['October 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 899, 'OrgStudyId': ['SCUSF 0806'], 'BriefTitle': ['Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab'], 'StudyType': ['Interventional'], 'StartDate': ['March 2010'], 'CompletionDate': ['November 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 900, 'OrgStudyId': ['IRB 6110'], 'BriefTitle': ['The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels'], 'StudyType': ['Interventional'], 'StartDate': ['January 2006'], 'CompletionDate': ['March 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 901, 'OrgStudyId': ['CRAD001Y24135'], 'BriefTitle': ['Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 7, 2013'], 'CompletionDate': ['January 13, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 902, 'OrgStudyId': ['D8180C00034'], 'BriefTitle': ['Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 903, 'OrgStudyId': ['D3614C00001'], 'BriefTitle': ['Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['June 25, 2019'], 'CompletionDate': ['October 6, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 904, 'OrgStudyId': ['CDR0000069346'], 'BriefTitle': ['Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 905, 'OrgStudyId': ['CD-ON-MEDI-573-1030'], 'BriefTitle': ['Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 13, 2011'], 'CompletionDate': ['June 28, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 906, 'OrgStudyId': ['CDR0000065241'], 'BriefTitle': ['Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function'], 'StudyType': ['Interventional'], 'StartDate': ['December 1996'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 907, 'OrgStudyId': ['SPI-GCF-104'], 'BriefTitle': ['Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2020'], 'CompletionDate': ['June 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 908, 'OrgStudyId': ['NUV-422-03'], 'BriefTitle': ['Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC'], 'StudyType': ['Interventional'], 'StartDate': ['September 2022'], 'CompletionDate': ['September 2026'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 909, 'OrgStudyId': ['WO29217'], 'BriefTitle': ['A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 14, 2014'], 'CompletionDate': ['August 25, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 910, 'OrgStudyId': ['IRB-03778'], 'BriefTitle': ['Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['January 2006'], 'CompletionDate': ['March 14, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 911, 'OrgStudyId': ['NCI-2019-06088'], 'BriefTitle': ['Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones'], 'StudyType': ['Interventional'], 'StartDate': ['December 27, 2019'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 912, 'OrgStudyId': ['SCO-120-19-22'], 'BriefTitle': ['A Study in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 20, 2022'], 'CompletionDate': ['January 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 913, 'OrgStudyId': ['BO16216'], 'BriefTitle': ['A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2001'], 'CompletionDate': ['October 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 914, 'OrgStudyId': ['GEN-602-CT-101'], 'BriefTitle': ['Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 1, 2019'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 915, 'OrgStudyId': ['15419'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread'], 'StudyType': ['Interventional'], 'StartDate': ['June 10, 2014'], 'CompletionDate': ['October 22, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 916, 'OrgStudyId': ['NCI-2017-01119'], 'BriefTitle': ['Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 12, 2019'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 917, 'OrgStudyId': ['NO16853'], 'BriefTitle': ['A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2003'], 'CompletionDate': ['March 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 918, 'OrgStudyId': ['CALGB-70604'], 'BriefTitle': ['Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement'], 'StudyType': ['Interventional'], 'StartDate': ['March 2009'], 'CompletionDate': ['January 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 919, 'OrgStudyId': ['A5481082'], 'BriefTitle': ['Palbociclib in Real World Practice'], 'StudyType': ['Observational'], 'StartDate': ['January 4, 2017'], 'CompletionDate': ['October 1, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 920, 'OrgStudyId': ['CBYL719A2201'], 'BriefTitle': ['Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2014'], 'CompletionDate': ['July 8, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 921, 'OrgStudyId': ['NCI-2009-00284'], 'BriefTitle': ['Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 31, 2008'], 'CompletionDate': ['February 14, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 922, 'OrgStudyId': ['UCI 06-46'], 'BriefTitle': ['LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis'], 'StudyType': ['Interventional'], 'StartDate': ['March 2007'], 'CompletionDate': ['August 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 923, 'OrgStudyId': ['1200.11'], 'BriefTitle': ['Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['September 2006'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 924, 'OrgStudyId': ['105-08-201'], 'BriefTitle': ['Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall'], 'StudyType': ['Interventional'], 'StartDate': ['February 2013'], 'CompletionDate': ['June 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 925, 'OrgStudyId': ['SLN-USA-1'], 'BriefTitle': ['Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes'], 'StudyType': ['Interventional'], 'StartDate': ['July 2015'], 'CompletionDate': ['March 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 926, 'OrgStudyId': ['CDR0000449959'], 'BriefTitle': ['T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2005'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 927, 'OrgStudyId': ['NCI-2018-01581'], 'BriefTitle': ['Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 14, 2018'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 928, 'OrgStudyId': ['CA163-048'], 'BriefTitle': ['Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2003'], 'CompletionDate': ['March 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 929, 'OrgStudyId': ['EA1151'], 'BriefTitle': ['Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 6, 2017'], 'CompletionDate': ['December 31, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['74 Years']}, {'Rank': 930, 'OrgStudyId': ['UCI 05-46'], 'BriefTitle': ['Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab'], 'StudyType': ['Interventional'], 'StartDate': ['March 2006'], 'CompletionDate': ['June 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 931, 'OrgStudyId': ['WO43571'], 'BriefTitle': ['A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)'], 'StudyType': ['Interventional'], 'StartDate': ['July 4, 2022'], 'CompletionDate': ['September 30, 2032'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 932, 'OrgStudyId': ['CAAA504A12101'], 'BriefTitle': ['Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.'], 'StudyType': ['Interventional'], 'StartDate': ['October 14, 2021'], 'CompletionDate': ['November 10, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 933, 'OrgStudyId': ['IRB-16617'], 'BriefTitle': ['Stanford Accelerated Recovery Trial (START)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2010'], 'CompletionDate': ['July 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 934, 'OrgStudyId': ['P0339 NBRST Registry'], 'BriefTitle': ['NBRST: Prospective Neo-adjuvant REGISTRY Trial'], 'StudyType': ['Observational'], 'StartDate': ['July 2011'], 'CompletionDate': ['January 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 935, 'OrgStudyId': ['3475-B49'], 'BriefTitle': ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)'], 'StudyType': ['Interventional'], 'StartDate': ['June 18, 2021'], 'CompletionDate': ['July 21, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 936, 'OrgStudyId': ['CDR0000066242'], 'BriefTitle': ['MRI to Detect Breast Tumors in Women'], 'StudyType': ['Interventional'], 'StartDate': ['May 1998'], 'CompletionDate': ['June 30, 2000'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['79 Years']}, {'Rank': 937, 'OrgStudyId': ['EGF106708'], 'BriefTitle': ['ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D'], 'StudyType': ['Interventional'], 'StartDate': ['May 16, 2007'], 'CompletionDate': ['July 1, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 938, 'OrgStudyId': ['CTKI258A2128'], 'BriefTitle': ['Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 2011'], 'CompletionDate': ['July 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 939, 'OrgStudyId': ['NCI-2009-00707'], 'BriefTitle': ['Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)'], 'StudyType': ['Interventional'], 'StartDate': ['April 7, 2006'], 'CompletionDate': ['September 30, 2030'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 940, 'OrgStudyId': ['1839IL/0225'], 'BriefTitle': ['Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study'], 'StudyType': ['Interventional'], 'StartDate': ['October 2003'], 'CompletionDate': ['June 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 941, 'OrgStudyId': ['GYN0001'], 'BriefTitle': ['Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program'], 'StudyType': ['Observational'], 'StartDate': ['January 2010'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 942, 'OrgStudyId': ['ABI-007-ST-001'], 'BriefTitle': ['Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 12, 2015'], 'CompletionDate': ['September 12, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 943, 'OrgStudyId': ['OBI-822-011'], 'BriefTitle': ['Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['December 5, 2018'], 'CompletionDate': ['December 30, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 944, 'OrgStudyId': ['H3B-6545-A001-101'], 'BriefTitle': ['Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 17, 2017'], 'CompletionDate': ['October 1, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 945, 'OrgStudyId': ['A221803'], 'BriefTitle': ['Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['June 15, 2022'], 'CompletionDate': ['December 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 946, 'OrgStudyId': ['NEO3-09'], 'BriefTitle': ['Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['April 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 947, 'OrgStudyId': ['CLEE011XUS10T'], 'BriefTitle': ['Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2016'], 'CompletionDate': ['April 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 948, 'OrgStudyId': ['GLSI-21-01'], 'BriefTitle': ['Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects'], 'StudyType': ['Interventional'], 'StartDate': ['August 11, 2022'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 949, 'OrgStudyId': ['PrE0102'], 'BriefTitle': ['Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI'], 'StudyType': ['Interventional'], 'StartDate': ['May 31, 2013'], 'CompletionDate': ['September 12, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 950, 'OrgStudyId': ['CDR0000066165'], 'BriefTitle': ['Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 1998'], 'CompletionDate': ['January 2001'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 951, 'OrgStudyId': ['A221702'], 'BriefTitle': ['Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection'], 'StudyType': ['Interventional'], 'StartDate': ['May 31, 2019'], 'CompletionDate': ['January 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 952, 'OrgStudyId': ['S1222'], 'BriefTitle': ['S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2014'], 'CompletionDate': ['December 31, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 953, 'OrgStudyId': ['CA048-001'], 'BriefTitle': ['A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread'], 'StudyType': ['Interventional'], 'StartDate': ['September 22, 2020'], 'CompletionDate': ['August 15, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 954, 'OrgStudyId': ['213363'], 'BriefTitle': ['Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 15, 2016'], 'CompletionDate': ['September 17, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 955, 'OrgStudyId': ['0S-17-5'], 'BriefTitle': ['Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 17, 2017'], 'CompletionDate': ['July 15, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 956, 'OrgStudyId': ['1280-0022'], 'BriefTitle': ['The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread'], 'StudyType': ['Interventional'], 'StartDate': ['November 28, 2018'], 'CompletionDate': ['May 11, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 957, 'OrgStudyId': ['MC1835-ACCRU-BR-1701'], 'BriefTitle': ['TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['February 20, 2020'], 'CompletionDate': ['January 15, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 958, 'OrgStudyId': ['CDR0000069104'], 'BriefTitle': ['Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2001'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 959, 'OrgStudyId': ['ODO-TE-B301'], 'BriefTitle': ['Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2017'], 'CompletionDate': ['June 28, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 960, 'OrgStudyId': ['LPT109096'], 'BriefTitle': ['Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['August 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 961, 'OrgStudyId': ['17237'], 'BriefTitle': ['HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2018'], 'CompletionDate': ['August 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 962, 'OrgStudyId': ['209514'], 'BriefTitle': ['Pilot Study of Pancreatic Cancer Screening'], 'StudyType': ['Observational'], 'StartDate': ['January 20, 2022'], 'CompletionDate': ['January 31, 2032'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 963, 'OrgStudyId': ['E7389-M001-218'], 'BriefTitle': ['Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['August 28, 2015'], 'CompletionDate': ['April 6, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 964, 'OrgStudyId': ['CTPR-0009'], 'BriefTitle': ['Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®'], 'StudyType': ['Interventional'], 'StartDate': ['May 8, 2012'], 'CompletionDate': ['December 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 965, 'OrgStudyId': ['18-27025'], 'BriefTitle': ['SCOPE-Chinese Women Study'], 'StudyType': ['Interventional'], 'StartDate': ['July 20, 2020'], 'CompletionDate': ['December 30, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 966, 'OrgStudyId': ['SPI-GCF-12-201'], 'BriefTitle': ['Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 25, 2013'], 'CompletionDate': ['August 12, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 967, 'OrgStudyId': ['16244'], 'BriefTitle': ['Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer'], 'StudyType': ['Expanded Access'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Approved for marketing'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 968, 'OrgStudyId': ['CP-13-001'], 'BriefTitle': ['MarginProbe 2.0 Data Collection Protocol'], 'StudyType': ['Observational'], 'StartDate': ['December 15, 2021'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 969, 'OrgStudyId': ['EGF105084'], 'BriefTitle': ['Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2, 2005'], 'CompletionDate': ['March 15, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 970, 'OrgStudyId': ['A211601'], 'BriefTitle': ['Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502'], 'StudyType': ['Observational'], 'StartDate': ['August 1, 2018'], 'CompletionDate': ['July 18, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 971, 'OrgStudyId': ['DAN-22220205'], 'BriefTitle': ['A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2, 2022'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 972, 'OrgStudyId': ['CLP0008'], 'BriefTitle': ['Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['September 1, 2020'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 973, 'OrgStudyId': ['SCRI BRE 145'], 'BriefTitle': ['A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2008'], 'CompletionDate': ['November 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 974, 'OrgStudyId': ['S0927'], 'BriefTitle': [\"S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy\"], 'StudyType': ['Interventional'], 'StartDate': ['February 2012'], 'CompletionDate': ['March 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 975, 'OrgStudyId': ['NCI-2019-02752'], 'BriefTitle': ['Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 21, 2019'], 'CompletionDate': ['November 1, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 976, 'OrgStudyId': ['16-304'], 'BriefTitle': ['Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['April 1, 2018'], 'CompletionDate': ['April 1, 2030'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 977, 'OrgStudyId': ['C3621001'], 'BriefTitle': ['Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['November 27, 2018'], 'CompletionDate': ['September 27, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 978, 'OrgStudyId': ['ML29366'], 'BriefTitle': ['A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['December 16, 2015'], 'CompletionDate': ['December 29, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 979, 'OrgStudyId': ['EZN-2208-03'], 'BriefTitle': ['A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2009'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 980, 'OrgStudyId': ['VEG108838'], 'BriefTitle': ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2007'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 981, 'OrgStudyId': ['RTOG-9804'], 'BriefTitle': ['Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ'], 'StudyType': ['Interventional'], 'StartDate': ['December 1999'], 'CompletionDate': ['May 20, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['26 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 982, 'OrgStudyId': ['EA1181'], 'BriefTitle': ['CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 11, 2020'], 'CompletionDate': ['December 31, 2038'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 983, 'OrgStudyId': ['960-CSP-USA_DenseBreasts_USS1'], 'BriefTitle': ['A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts'], 'StudyType': ['Interventional'], 'StartDate': ['April 15, 2018'], 'CompletionDate': ['April 30, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 984, 'OrgStudyId': ['NEPA-17-05'], 'BriefTitle': ['A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2018'], 'CompletionDate': ['September 19, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 985, 'OrgStudyId': ['378-ONC-0030-184'], 'BriefTitle': ['Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2000'], 'CompletionDate': ['August 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 986, 'OrgStudyId': ['A191901'], 'BriefTitle': ['Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2021'], 'CompletionDate': ['October 2025'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 987, 'OrgStudyId': ['NCI-2015-00741'], 'BriefTitle': ['Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 6, 2015'], 'CompletionDate': ['February 22, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 988, 'OrgStudyId': ['G1T48-01'], 'BriefTitle': ['G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 9, 2018'], 'CompletionDate': ['September 29, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 989, 'OrgStudyId': ['CALGB-40903'], 'BriefTitle': ['Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ'], 'StudyType': ['Interventional'], 'StartDate': ['February 2012'], 'CompletionDate': ['January 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 990, 'OrgStudyId': ['ML17771'], 'BriefTitle': ['A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2004'], 'CompletionDate': ['October 2004'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 991, 'OrgStudyId': ['S1904'], 'BriefTitle': ['Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)'], 'StudyType': ['Interventional'], 'StartDate': ['September 1, 2020'], 'CompletionDate': ['June 1, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 992, 'OrgStudyId': ['MM-111-01-100'], 'BriefTitle': ['A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['June 2009'], 'CompletionDate': ['March 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 993, 'OrgStudyId': ['GS-US-350-1937'], 'BriefTitle': ['GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 10, 2017'], 'CompletionDate': ['July 19, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 994, 'OrgStudyId': ['CLEE011AUS42'], 'BriefTitle': ['A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib'], 'StudyType': ['Interventional'], 'StartDate': ['June 7, 2017'], 'CompletionDate': ['March 8, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 995, 'OrgStudyId': ['TORI B-02'], 'BriefTitle': ['Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2005'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 996, 'OrgStudyId': ['15160'], 'BriefTitle': ['Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities'], 'StudyType': ['Interventional'], 'StartDate': ['April 6, 2016'], 'CompletionDate': ['October 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 997, 'OrgStudyId': ['OSNA-BC-001'], 'BriefTitle': ['Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['February 2007'], 'CompletionDate': ['December 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 998, 'OrgStudyId': ['RTOG 0517'], 'BriefTitle': ['Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 11, 2006'], 'CompletionDate': ['February 27, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 999, 'OrgStudyId': ['114299'], 'BriefTitle': ['A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 5, 2011'], 'CompletionDate': ['June 6, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1000, 'OrgStudyId': ['ONCB-006-19F'], 'BriefTitle': ['Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 19, 2023'], 'CompletionDate': ['April 1, 2027'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1001, 'OrgStudyId': ['1505016201'], 'BriefTitle': ['Trial to Compare Radiation Fibrosis With Five Versus Three Fractions'], 'StudyType': ['Interventional'], 'StartDate': ['July 2015'], 'CompletionDate': ['July 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1002, 'OrgStudyId': ['1407426'], 'BriefTitle': ['Family History Study on Cancer Risk'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2020'], 'CompletionDate': ['August 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1003, 'OrgStudyId': ['PMT4979g'], 'BriefTitle': [\"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2011'], 'CompletionDate': ['June 25, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1004, 'OrgStudyId': ['SVMC-ONC-222'], 'BriefTitle': ['Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1991'], 'CompletionDate': ['June 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1005, 'OrgStudyId': ['104603'], 'BriefTitle': ['Excision Followed by Radiofrequency Ablation for Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['December 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 1006, 'OrgStudyId': ['NCI-2017-01921'], 'BriefTitle': ['Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['October 31, 2018'], 'CompletionDate': ['February 22, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1007, 'OrgStudyId': ['99000287'], 'BriefTitle': ['Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs'], 'StudyType': ['Observational'], 'StartDate': ['July 2008'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1008, 'OrgStudyId': ['UCSD IIT 150729'], 'BriefTitle': ['Histology-Independent Study of Palbociclib in Patients With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2018'], 'CompletionDate': ['February 1, 2024'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1009, 'OrgStudyId': ['V0407'], 'BriefTitle': ['Statins and Breast Cancer Biomarkers'], 'StudyType': ['Interventional'], 'StartDate': ['January 2005'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 1010, 'OrgStudyId': ['BioDyn-15-003'], 'BriefTitle': ['TR(ACE) Assay Clinical Specimen Study'], 'StudyType': ['Observational'], 'StartDate': ['September 2016'], 'CompletionDate': ['April 2018'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1011, 'OrgStudyId': ['07-199'], 'BriefTitle': ['Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['August 30, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1012, 'OrgStudyId': ['ICMBC-02'], 'BriefTitle': ['Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial'], 'StudyType': ['Interventional'], 'StartDate': ['October 2014'], 'CompletionDate': ['December 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 1013, 'OrgStudyId': ['KD019-204'], 'BriefTitle': ['Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2014'], 'CompletionDate': ['September 13, 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1014, 'OrgStudyId': ['LPT111111'], 'BriefTitle': ['Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC'], 'StudyType': ['Interventional'], 'StartDate': ['July 2, 2008'], 'CompletionDate': ['January 3, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1015, 'OrgStudyId': ['BRI-ROL-001'], 'BriefTitle': ['Combination Study of SV-BR-1-GM With Retifanlimab'], 'StudyType': ['Interventional'], 'StartDate': ['March 16, 2018'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1016, 'OrgStudyId': ['FLEX Registry'], 'BriefTitle': ['MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles'], 'StudyType': ['Observational'], 'StartDate': ['April 28, 2017'], 'CompletionDate': ['December 2037'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1017, 'OrgStudyId': ['D0816R00012'], 'BriefTitle': ['International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study'], 'StudyType': ['Observational'], 'StartDate': ['March 13, 2017'], 'CompletionDate': ['May 20, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1018, 'OrgStudyId': ['229510'], 'BriefTitle': ['Combination Therapy in Cancers With Mutations in DNA Repair Genes'], 'StudyType': ['Interventional'], 'StartDate': ['April 1, 2023'], 'CompletionDate': ['December 31, 2027'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1019, 'OrgStudyId': ['LYT-100-2020-01'], 'BriefTitle': ['LYT-100 in Healthy Volunteers and BCRL'], 'StudyType': ['Interventional'], 'StartDate': ['March 1, 2020'], 'CompletionDate': ['September 9, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1020, 'OrgStudyId': ['NU 10C03'], 'BriefTitle': ['Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 1, 2011'], 'CompletionDate': ['January 20, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1021, 'OrgStudyId': ['18-124'], 'BriefTitle': ['ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 22, 2018'], 'CompletionDate': ['August 30, 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 1022, 'OrgStudyId': ['PRO37771'], 'BriefTitle': ['Benefits of Exercise Training in Women With Ischemic Syndrome'], 'StudyType': ['Interventional'], 'StartDate': ['January 2016'], 'CompletionDate': ['October 2016'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 1023, 'OrgStudyId': ['CBYL719H12301'], 'BriefTitle': ['Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss'], 'StudyType': ['Interventional'], 'StartDate': ['June 8, 2020'], 'CompletionDate': ['June 19, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1024, 'OrgStudyId': ['Biomed 777-CLP-29'], 'BriefTitle': ['Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2002'], 'CompletionDate': ['January 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1025, 'OrgStudyId': ['CDR0000729174'], 'BriefTitle': ['DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2012'], 'CompletionDate': ['January 14, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1026, 'OrgStudyId': ['EAZ171'], 'BriefTitle': ['Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 27, 2019'], 'CompletionDate': ['June 1, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1027, 'OrgStudyId': ['Wellderly Immune Antibodies'], 'BriefTitle': ['Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort'], 'StudyType': ['Observational'], 'StartDate': ['June 2012'], 'CompletionDate': ['May 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['90 Years'], 'MaximumAge': []}, {'Rank': 1028, 'OrgStudyId': ['12-000493'], 'BriefTitle': ['Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2012'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1029, 'OrgStudyId': ['A4581001'], 'BriefTitle': ['MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.'], 'StudyType': ['Interventional'], 'StartDate': ['February 2004'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1030, 'OrgStudyId': ['CLEE011A2112C'], 'BriefTitle': ['Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['June 27, 2014'], 'CompletionDate': ['October 26, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1031, 'OrgStudyId': ['07-022'], 'BriefTitle': ['Bicalutamide in Treating Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 23, 2007'], 'CompletionDate': ['June 24, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1032, 'OrgStudyId': ['112515'], 'BriefTitle': ['Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone'], 'StudyType': ['Interventional'], 'StartDate': ['January 20, 2010'], 'CompletionDate': ['March 30, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1033, 'OrgStudyId': ['A211102'], 'BriefTitle': ['Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2015'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 1034, 'OrgStudyId': ['0C-07-3'], 'BriefTitle': ['Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1035, 'OrgStudyId': ['IRB00041707'], 'BriefTitle': ['Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil'], 'StudyType': ['Interventional'], 'StartDate': ['May 30, 2017'], 'CompletionDate': ['July 29, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1036, 'OrgStudyId': ['NCI-2011-01472'], 'BriefTitle': ['Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['April 20, 2009'], 'CompletionDate': ['May 19, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 1037, 'OrgStudyId': ['116911'], 'BriefTitle': ['Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans'], 'StudyType': ['Interventional'], 'StartDate': ['May 2014'], 'CompletionDate': ['February 2015'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['85 Years']}, {'Rank': 1038, 'OrgStudyId': ['1808019498'], 'BriefTitle': ['Converting HR+ Breast Cancer Into an Individualized Vaccine'], 'StudyType': ['Interventional'], 'StartDate': ['March 17, 2020'], 'CompletionDate': ['December 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1039, 'OrgStudyId': ['19-031'], 'BriefTitle': [\"'ADVANCE' (A Pilot Trial)\"], 'StudyType': ['Interventional'], 'StartDate': ['March 21, 2019'], 'CompletionDate': ['March 21, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['70 Years'], 'MaximumAge': []}, {'Rank': 1040, 'OrgStudyId': ['OMS-I141 (KEYNOTE-890)'], 'BriefTitle': ['Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['October 11, 2018'], 'CompletionDate': ['August 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1041, 'OrgStudyId': ['CDR0000066851'], 'BriefTitle': ['MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1999'], 'CompletionDate': ['June 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1042, 'OrgStudyId': ['NCI-2009-00702'], 'BriefTitle': ['Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy'], 'StudyType': ['Interventional'], 'StartDate': ['November 10, 2008'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1043, 'OrgStudyId': ['D361DC00001'], 'BriefTitle': ['Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)'], 'StudyType': ['Interventional'], 'StartDate': ['May 10, 2021'], 'CompletionDate': ['January 5, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1044, 'OrgStudyId': ['CDR0000538232'], 'BriefTitle': ['Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children'], 'StudyType': ['Observational'], 'StartDate': ['September 2006'], 'CompletionDate': ['October 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1045, 'OrgStudyId': ['097517'], 'BriefTitle': ['I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 1, 2010'], 'CompletionDate': ['December 2031'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1046, 'OrgStudyId': ['39855'], 'BriefTitle': ['Microsurgical Breast Reconstruction & VTE'], 'StudyType': ['Observational'], 'StartDate': ['January 30, 2017'], 'CompletionDate': ['December 15, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1047, 'OrgStudyId': ['SSC-311'], 'BriefTitle': ['Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System'], 'StudyType': ['Observational'], 'StartDate': ['November 2005'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['20 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1048, 'OrgStudyId': ['OIC-1UO-C001'], 'BriefTitle': ['Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome'], 'StudyType': ['Interventional'], 'StartDate': ['April 2010'], 'CompletionDate': ['September 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1049, 'OrgStudyId': ['D9673C00007'], 'BriefTitle': ['A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 22, 2021'], 'CompletionDate': ['February 9, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1050, 'OrgStudyId': ['2015-013-00US1'], 'BriefTitle': ['A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 10, 2017'], 'CompletionDate': ['March 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1051, 'OrgStudyId': ['E4112'], 'BriefTitle': ['MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ'], 'StudyType': ['Interventional'], 'StartDate': ['January 7, 2015'], 'CompletionDate': ['November 2027'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1052, 'OrgStudyId': ['BRE007-12'], 'BriefTitle': ['Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2013'], 'CompletionDate': ['January 2033'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 1053, 'OrgStudyId': ['17-455'], 'BriefTitle': ['The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 21, 2018'], 'CompletionDate': ['May 31, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1054, 'OrgStudyId': ['20-002000'], 'BriefTitle': ['Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 8, 2021'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1055, 'OrgStudyId': ['CA016'], 'BriefTitle': ['Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2004'], 'CompletionDate': ['October 1, 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1056, 'OrgStudyId': ['IRB 4260'], 'BriefTitle': ['Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women'], 'StudyType': ['Observational'], 'StartDate': ['January 1995'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 1057, 'OrgStudyId': ['CA163-100'], 'BriefTitle': ['Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1058, 'OrgStudyId': ['TARGIT Boost'], 'BriefTitle': ['A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['June 2013'], 'CompletionDate': ['April 2022'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1059, 'OrgStudyId': ['HSC 07-4789'], 'BriefTitle': ['The Healthy Elderly Longevity Cohort'], 'StudyType': ['Observational'], 'StartDate': ['August 2007'], 'CompletionDate': ['January 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['80 Years'], 'MaximumAge': []}, {'Rank': 1060, 'OrgStudyId': ['SU-09112008-1298'], 'BriefTitle': ['Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1061, 'OrgStudyId': ['ARV-471-BC-201'], 'BriefTitle': ['A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2023'], 'CompletionDate': ['June 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1062, 'OrgStudyId': ['MA21'], 'BriefTitle': ['Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 4, 2000'], 'CompletionDate': ['March 17, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['60 Years']}, {'Rank': 1063, 'OrgStudyId': ['SO-BCA-003'], 'BriefTitle': ['Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 9, 2017'], 'CompletionDate': ['June 30, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1064, 'OrgStudyId': ['D6997C00002'], 'BriefTitle': ['Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.'], 'StudyType': ['Interventional'], 'StartDate': ['February 13, 2005'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1065, 'OrgStudyId': ['13-559'], 'BriefTitle': ['Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2014'], 'CompletionDate': ['May 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1066, 'OrgStudyId': ['LCCC 0403'], 'BriefTitle': ['Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2005'], 'CompletionDate': ['August 12, 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1067, 'OrgStudyId': ['ISI dV SP - NSM-01'], 'BriefTitle': ['Robotic vs. Open NSM for Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2023'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Not yet recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1068, 'OrgStudyId': ['09-056'], 'BriefTitle': ['Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['July 2009'], 'CompletionDate': ['July 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1069, 'OrgStudyId': ['IPI-504-07'], 'BriefTitle': ['Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2009'], 'CompletionDate': ['May 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1070, 'OrgStudyId': ['CDR0000377698'], 'BriefTitle': ['S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['November 2004'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1071, 'OrgStudyId': ['147522'], 'BriefTitle': ['A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 19, 2015'], 'CompletionDate': ['January 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1072, 'OrgStudyId': ['13944'], 'BriefTitle': ['Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['March 2011'], 'CompletionDate': ['July 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1073, 'OrgStudyId': ['PN-301-21'], 'BriefTitle': ['Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 28, 2022'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1074, 'OrgStudyId': ['CDR0000069496'], 'BriefTitle': ['Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2002'], 'CompletionDate': ['March 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1075, 'OrgStudyId': ['EORTC-10085'], 'BriefTitle': ['Male Breast Cancer: Understanding the Biology for Improved Patient Care'], 'StudyType': ['Observational'], 'StartDate': ['December 2010'], 'CompletionDate': ['March 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1076, 'OrgStudyId': ['SCRI BRE 126'], 'BriefTitle': ['Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2010'], 'CompletionDate': ['September 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1077, 'OrgStudyId': ['1040-000-002'], 'BriefTitle': ['A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2002'], 'CompletionDate': ['May 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1078, 'OrgStudyId': ['CA180-059'], 'BriefTitle': [\"A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['December 2006'], 'CompletionDate': ['September 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1079, 'OrgStudyId': ['F061229006'], 'BriefTitle': ['Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 8, 2007'], 'CompletionDate': ['March 31, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 1080, 'OrgStudyId': ['3144A1-2204 / B1891015'], 'BriefTitle': ['Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 29, 2008'], 'CompletionDate': ['June 7, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1081, 'OrgStudyId': ['NOX66-005'], 'BriefTitle': ['A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 25, 2021'], 'CompletionDate': ['February 28, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1082, 'OrgStudyId': ['CC#157521+167513'], 'BriefTitle': ['Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease'], 'StudyType': ['Interventional'], 'StartDate': ['September 2, 2017'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1083, 'OrgStudyId': ['AFT-38'], 'BriefTitle': ['Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 21, 2017'], 'CompletionDate': ['March 31, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1084, 'OrgStudyId': ['CA180-088'], 'BriefTitle': ['Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2006'], 'CompletionDate': ['May 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1085, 'OrgStudyId': ['D967JC00001'], 'BriefTitle': ['A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 28, 2020'], 'CompletionDate': ['December 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1086, 'OrgStudyId': ['AVB620-C-002'], 'BriefTitle': ['Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['July 5, 2017'], 'CompletionDate': ['November 18, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1087, 'OrgStudyId': ['A5481034'], 'BriefTitle': ['Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate'], 'StudyType': ['Expanded Access'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['No longer available'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1088, 'OrgStudyId': ['ARD11439'], 'BriefTitle': ['Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen'], 'StudyType': ['Interventional'], 'StartDate': ['February 2010'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1089, 'OrgStudyId': ['08218'], 'BriefTitle': ['Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['September 2010'], 'CompletionDate': ['December 11, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 1090, 'OrgStudyId': ['0607-18 IUCRO-0154'], 'BriefTitle': ['Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1091, 'OrgStudyId': ['MAP3B'], 'BriefTitle': ['Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3'], 'StudyType': ['Observational'], 'StartDate': ['January 23, 2008'], 'CompletionDate': ['January 10, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['35 Years'], 'MaximumAge': []}, {'Rank': 1092, 'OrgStudyId': ['ARD11437'], 'BriefTitle': ['Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['April 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1093, 'OrgStudyId': ['PM1183-B-003-11'], 'BriefTitle': ['A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 13, 2012'], 'CompletionDate': ['October 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1094, 'OrgStudyId': ['STM01-102'], 'BriefTitle': ['Trial of Myocet in Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2006'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1095, 'OrgStudyId': ['11-344'], 'BriefTitle': ['HKI-272 for HER2-Positive Breast Cancer and Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['February 2012'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1096, 'OrgStudyId': ['GO28888'], 'BriefTitle': ['A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)'], 'StudyType': ['Interventional'], 'StartDate': ['November 12, 2014'], 'CompletionDate': ['March 13, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1097, 'OrgStudyId': ['NRG-BR001'], 'BriefTitle': ['Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2014'], 'CompletionDate': ['May 20, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1098, 'OrgStudyId': ['IMPACt'], 'BriefTitle': ['Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry'], 'StudyType': ['Observational'], 'StartDate': ['November 2015'], 'CompletionDate': ['August 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1099, 'OrgStudyId': ['REP0114'], 'BriefTitle': ['A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 29, 2015'], 'CompletionDate': ['March 23, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1100, 'OrgStudyId': ['21-159'], 'BriefTitle': ['ATEMPT 2.0: Adjuvant T-DM1 vs TH'], 'StudyType': ['Interventional'], 'StartDate': ['June 16, 2021'], 'CompletionDate': ['May 1, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1101, 'OrgStudyId': ['A231901CD'], 'BriefTitle': ['Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2021'], 'CompletionDate': ['January 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1102, 'OrgStudyId': ['ACOSOG-Z1072'], 'BriefTitle': ['Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2008'], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1103, 'OrgStudyId': ['A6181064'], 'BriefTitle': ['Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2007'], 'CompletionDate': ['July 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1104, 'OrgStudyId': ['NRG-BR005'], 'BriefTitle': ['Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['April 13, 2017'], 'CompletionDate': ['November 30, 2023'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1105, 'OrgStudyId': ['RTOG 1014'], 'BriefTitle': ['Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['May 20, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1106, 'OrgStudyId': ['SCRI BRE 154'], 'BriefTitle': ['Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['July 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1107, 'OrgStudyId': ['09-03'], 'BriefTitle': ['Multicenter Hologic Tomosynthesis Study'], 'StudyType': ['Interventional'], 'StartDate': ['September 2009'], 'CompletionDate': ['January 2013'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1108, 'OrgStudyId': ['CAUY922A2101'], 'BriefTitle': ['Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['July 2007'], 'CompletionDate': ['April 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1109, 'OrgStudyId': ['UCSF CC#05591'], 'BriefTitle': ['Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 2006'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1110, 'OrgStudyId': ['CLBH589C2204'], 'BriefTitle': ['A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab'], 'StudyType': ['Interventional'], 'StartDate': ['April 2008'], 'CompletionDate': ['May 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1111, 'OrgStudyId': ['3160A6-2207'], 'BriefTitle': ['Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 30, 2009'], 'CompletionDate': ['May 31, 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1112, 'OrgStudyId': ['20140299'], 'BriefTitle': ['Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['March 19, 2018'], 'CompletionDate': ['December 3, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1113, 'OrgStudyId': ['10-005'], 'BriefTitle': ['Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2010'], 'CompletionDate': ['July 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1114, 'OrgStudyId': ['D5392C00050'], 'BriefTitle': ['Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2004'], 'CompletionDate': ['October 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['55 Years'], 'MaximumAge': []}, {'Rank': 1115, 'OrgStudyId': ['HALO Dx 001'], 'BriefTitle': ['Phase I Human Analytics (HALO) Study'], 'StudyType': ['Observational'], 'StartDate': ['March 16, 2022'], 'CompletionDate': ['March 2037'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1116, 'OrgStudyId': ['NK-101'], 'BriefTitle': ['FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 18, 2018'], 'CompletionDate': ['December 15, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1117, 'OrgStudyId': ['CA209-7A8'], 'BriefTitle': ['A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 18, 2019'], 'CompletionDate': ['July 27, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1118, 'OrgStudyId': ['OCOG-2007-LISA'], 'BriefTitle': ['Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2007'], 'CompletionDate': ['June 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1119, 'OrgStudyId': ['D699BC00001'], 'BriefTitle': ['A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['October 17, 2012'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1120, 'OrgStudyId': ['BRE 354'], 'BriefTitle': ['A Study of U3-1402 in Subjects With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 3, 2021'], 'CompletionDate': ['November 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1121, 'OrgStudyId': ['NSABP FB-12'], 'BriefTitle': ['Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling'], 'StudyType': ['Interventional'], 'StartDate': ['May 14, 2018'], 'CompletionDate': ['October 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1122, 'OrgStudyId': ['B3271004'], 'BriefTitle': ['A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)'], 'StudyType': ['Interventional'], 'StartDate': ['September 23, 2014'], 'CompletionDate': ['March 9, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1123, 'OrgStudyId': ['1602017205'], 'BriefTitle': ['Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['July 2016'], 'CompletionDate': ['April 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1124, 'OrgStudyId': ['CA180-004'], 'BriefTitle': ['Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 2007'], 'CompletionDate': ['October 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1125, 'OrgStudyId': ['WO39392'], 'BriefTitle': ['A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 24, 2017'], 'CompletionDate': ['September 26, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1126, 'OrgStudyId': ['BGBC007'], 'BriefTitle': ['Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC'], 'StudyType': ['Interventional'], 'StartDate': ['July 26, 2017'], 'CompletionDate': ['August 20, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1127, 'OrgStudyId': ['LAE205INT3101'], 'BriefTitle': ['Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 18, 2022'], 'CompletionDate': ['December 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1128, 'OrgStudyId': ['IBIO-301'], 'BriefTitle': ['A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 18, 2018'], 'CompletionDate': ['September 22, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1129, 'OrgStudyId': ['CP-03-001'], 'BriefTitle': ['MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['October 2008'], 'CompletionDate': ['June 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1130, 'OrgStudyId': ['LOXO-PIK-21001'], 'BriefTitle': ['A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 11, 2022'], 'CompletionDate': ['May 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1131, 'OrgStudyId': ['UPCC 19115'], 'BriefTitle': ['Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial'], 'StudyType': ['Interventional'], 'StartDate': ['February 2016'], 'CompletionDate': ['November 2036'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1132, 'OrgStudyId': ['06-412'], 'BriefTitle': ['Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response'], 'StudyType': ['Interventional'], 'StartDate': ['June 2007'], 'CompletionDate': ['June 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1133, 'OrgStudyId': ['GO29505'], 'BriefTitle': ['A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 17, 2015'], 'CompletionDate': ['August 2, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1134, 'OrgStudyId': ['17249'], 'BriefTitle': ['A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body'], 'StudyType': ['Interventional'], 'StartDate': ['August 2, 2019'], 'CompletionDate': ['May 14, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1135, 'OrgStudyId': ['KU36-44'], 'BriefTitle': ['Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 15, 2007'], 'CompletionDate': ['December 21, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1136, 'OrgStudyId': ['C0541001'], 'BriefTitle': ['PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2017'], 'CompletionDate': ['August 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1137, 'OrgStudyId': ['D2270C00020'], 'BriefTitle': ['Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2015'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1138, 'OrgStudyId': ['MO27782'], 'BriefTitle': ['A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2012'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1139, 'OrgStudyId': ['16177'], 'BriefTitle': ['A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 14, 2016'], 'CompletionDate': ['September 20, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1140, 'OrgStudyId': ['INCB 7839-204'], 'BriefTitle': ['Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2010'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1141, 'OrgStudyId': ['CR005143'], 'BriefTitle': ['A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['March 2, 2006'], 'CompletionDate': ['January 31, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1142, 'OrgStudyId': ['CRAD001W2301'], 'BriefTitle': ['Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2009'], 'CompletionDate': ['June 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1143, 'OrgStudyId': ['REBACCCWFU-97202'], 'BriefTitle': ['Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2004'], 'CompletionDate': ['August 31, 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1144, 'OrgStudyId': ['BRSNSTU0011'], 'BriefTitle': ['Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample'], 'StudyType': ['Observational'], 'StartDate': ['October 2000'], 'CompletionDate': ['April 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1145, 'OrgStudyId': ['ZN-c5-001'], 'BriefTitle': ['A Study of ZN-c5 in Subjects With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 8, 2018'], 'CompletionDate': ['December 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1146, 'OrgStudyId': ['CO40151'], 'BriefTitle': ['A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 13, 2018'], 'CompletionDate': ['March 15, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1147, 'OrgStudyId': ['13-164 (ILC)'], 'BriefTitle': ['Endocrine Response in Women With Invasive Lobular Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2015'], 'CompletionDate': ['March 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1148, 'OrgStudyId': ['B2151002'], 'BriefTitle': ['A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['September 10, 2013'], 'CompletionDate': ['January 8, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1149, 'OrgStudyId': ['MCLA-128-CL02'], 'BriefTitle': ['MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 15, 2018'], 'CompletionDate': ['February 15, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1150, 'OrgStudyId': ['VAR0047'], 'BriefTitle': ['Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2'], 'StudyType': ['Observational'], 'StartDate': ['October 2010'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1151, 'OrgStudyId': ['CBKM120F2202'], 'BriefTitle': ['A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation'], 'StudyType': ['Interventional'], 'StartDate': ['August 2012'], 'CompletionDate': ['June 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1152, 'OrgStudyId': ['WO41554'], 'BriefTitle': ['A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 29, 2020'], 'CompletionDate': ['September 19, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1153, 'OrgStudyId': ['CDR0000374991'], 'BriefTitle': ['Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2004'], 'CompletionDate': ['May 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['44 Years']}, {'Rank': 1154, 'OrgStudyId': ['E7389-M000-219'], 'BriefTitle': ['Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)'], 'StudyType': ['Interventional'], 'StartDate': ['July 13, 2016'], 'CompletionDate': ['August 16, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1155, 'OrgStudyId': ['CL0006'], 'BriefTitle': ['Intraoperative Detection of Residual Cancer in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 6, 2018'], 'CompletionDate': ['April 10, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1156, 'OrgStudyId': ['12228'], 'BriefTitle': ['Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung'], 'StudyType': ['Interventional'], 'StartDate': ['July 2014'], 'CompletionDate': [], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1157, 'OrgStudyId': ['TOL2506A'], 'BriefTitle': ['Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2021'], 'CompletionDate': ['April 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['49 Years']}, {'Rank': 1158, 'OrgStudyId': ['CDR0000594003'], 'BriefTitle': ['Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02'], 'StudyType': ['Interventional'], 'StartDate': ['December 2007'], 'CompletionDate': ['April 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 1159, 'OrgStudyId': ['D8530C00002'], 'BriefTitle': ['A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 22, 2020'], 'CompletionDate': ['May 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1160, 'OrgStudyId': ['17-428'], 'BriefTitle': ['Olaparib In Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 1, 2018'], 'CompletionDate': ['December 30, 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1161, 'OrgStudyId': ['08007'], 'BriefTitle': ['Ixabepilone + Carboplatin Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2010'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1162, 'OrgStudyId': ['NSABP FB-11'], 'BriefTitle': ['A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2015'], 'CompletionDate': ['March 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1163, 'OrgStudyId': ['CA191-011'], 'BriefTitle': ['Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors'], 'StudyType': ['Interventional'], 'StartDate': ['December 31, 2010'], 'CompletionDate': ['November 30, 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1164, 'OrgStudyId': ['E7389-G000-211'], 'BriefTitle': ['A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine'], 'StudyType': ['Interventional'], 'StartDate': ['October 2005'], 'CompletionDate': ['September 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1165, 'OrgStudyId': ['849679'], 'BriefTitle': ['RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2022'], 'CompletionDate': ['February 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1166, 'OrgStudyId': ['11127'], 'BriefTitle': ['The Hurria Older PatiEnts (HOPE) With Breast Cancer Study'], 'StudyType': ['Observational'], 'StartDate': ['September 9, 2011'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 1167, 'OrgStudyId': ['12345'], 'BriefTitle': ['Primary Care Clinical Excellence Incentive Study'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2019'], 'CompletionDate': ['January 1, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1168, 'OrgStudyId': ['CDR0000628769'], 'BriefTitle': ['Optical Coherence Tomography in Tissue Samples From Women Undergoing Mastectomy for the Treatment or Prevention of Breast Ductal Intraepithelial Neoplasia'], 'StudyType': ['Interventional'], 'StartDate': ['November 2006'], 'CompletionDate': ['March 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1169, 'OrgStudyId': ['GO29642'], 'BriefTitle': ['A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 29, 2014'], 'CompletionDate': ['March 13, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1170, 'OrgStudyId': ['Biomed 777-CLP-32'], 'BriefTitle': ['Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 2005'], 'CompletionDate': ['June 2006'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1171, 'OrgStudyId': ['FOENIX-MBC2 TAS-120-201'], 'BriefTitle': ['A Study of TAS-120 in Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 30, 2019'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1172, 'OrgStudyId': ['1200.89'], 'BriefTitle': ['Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2011'], 'CompletionDate': ['November 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1173, 'OrgStudyId': ['Pro00019830'], 'BriefTitle': ['The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function'], 'StudyType': ['Observational'], 'StartDate': ['September 2009'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1174, 'OrgStudyId': ['CA163-081'], 'BriefTitle': ['Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)'], 'StudyType': ['Interventional'], 'StartDate': ['February 2004'], 'CompletionDate': ['December 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1175, 'OrgStudyId': ['IIT2015-07-SHIAO-HIFIDELI'], 'BriefTitle': ['Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis'], 'StudyType': ['Observational'], 'StartDate': ['August 21, 2016'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1176, 'OrgStudyId': ['CBEZ235A2101'], 'BriefTitle': ['A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2006'], 'CompletionDate': ['January 8, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1177, 'OrgStudyId': ['CA163-132'], 'BriefTitle': ['Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2008'], 'CompletionDate': ['August 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1178, 'OrgStudyId': ['15252'], 'BriefTitle': ['A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread'], 'StudyType': ['Interventional'], 'StartDate': ['March 10, 2014'], 'CompletionDate': ['September 20, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1179, 'OrgStudyId': ['C3661001'], 'BriefTitle': ['A Study of PF-06873600 in People With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 7, 2018'], 'CompletionDate': ['November 28, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1180, 'OrgStudyId': ['MCC-14662'], 'BriefTitle': ['Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2006'], 'CompletionDate': ['August 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1181, 'OrgStudyId': ['VICC BRE 1287'], 'BriefTitle': ['GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2013'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1182, 'OrgStudyId': ['201610'], 'BriefTitle': ['Predicting Chronic Pain Following Breast Surgery'], 'StudyType': ['Observational'], 'StartDate': ['July 19, 2021'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1183, 'OrgStudyId': ['MC1831'], 'BriefTitle': ['Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 28, 2019'], 'CompletionDate': ['April 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1184, 'OrgStudyId': ['MO27775'], 'BriefTitle': ['A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 17, 2012'], 'CompletionDate': ['November 14, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1185, 'OrgStudyId': ['AURORA US'], 'BriefTitle': ['Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer'], 'StudyType': ['Observational'], 'StartDate': ['September 16, 2019'], 'CompletionDate': ['November 15, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1186, 'OrgStudyId': ['13-048'], 'BriefTitle': ['T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2013'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1187, 'OrgStudyId': ['CA163-131'], 'BriefTitle': ['Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2008'], 'CompletionDate': ['March 2010'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1188, 'OrgStudyId': ['PREDAPT'], 'BriefTitle': ['A Multicenter Cancer Biospecimen Collection Study'], 'StudyType': ['Observational'], 'StartDate': ['February 5, 2020'], 'CompletionDate': ['February 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1189, 'OrgStudyId': ['CLEE011A2207'], 'BriefTitle': ['Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 11, 2019'], 'CompletionDate': ['December 30, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1190, 'OrgStudyId': ['CZOL446EUS16'], 'BriefTitle': ['Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions'], 'StudyType': ['Interventional'], 'StartDate': ['October 2001'], 'CompletionDate': ['November 2002'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1191, 'OrgStudyId': ['CDR0000460234'], 'BriefTitle': ['Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance'], 'StudyType': ['Observational'], 'StartDate': ['October 2005'], 'CompletionDate': ['March 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['78 Years']}, {'Rank': 1192, 'OrgStudyId': ['NCI-2019-00048'], 'BriefTitle': ['A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 13, 2019'], 'CompletionDate': ['February 19, 2022'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1193, 'OrgStudyId': ['29747'], 'BriefTitle': ['T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 6, 2018'], 'CompletionDate': ['December 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1194, 'OrgStudyId': ['9061'], 'BriefTitle': ['A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2003'], 'CompletionDate': ['December 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1195, 'OrgStudyId': ['TCD11608'], 'BriefTitle': ['A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['July 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1196, 'OrgStudyId': ['IRB-16-6815'], 'BriefTitle': ['Quell Opioid Reduction and Pain Relief in Patients With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2016'], 'CompletionDate': ['October 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1197, 'OrgStudyId': ['D8534C00001'], 'BriefTitle': ['Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)'], 'StudyType': ['Interventional'], 'StartDate': ['June 30, 2021'], 'CompletionDate': ['November 26, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1198, 'OrgStudyId': ['NCI-2009-00266'], 'BriefTitle': [\"Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['December 2008'], 'CompletionDate': ['October 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1199, 'OrgStudyId': ['MDX010-12'], 'BriefTitle': ['Study of MDX-010 in Stage IV Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2003'], 'CompletionDate': ['February 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1200, 'OrgStudyId': ['CL0007'], 'BriefTitle': ['Investigation of Novel Surgical Imaging for Tumor Excision'], 'StudyType': ['Interventional'], 'StartDate': ['November 4, 2019'], 'CompletionDate': ['May 4, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1201, 'OrgStudyId': ['CLEE011A2201'], 'BriefTitle': ['A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)'], 'StudyType': ['Interventional'], 'StartDate': ['October 2013'], 'CompletionDate': ['September 2014'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1202, 'OrgStudyId': ['AL-TNBC-01'], 'BriefTitle': ['A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 14, 2020'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1203, 'OrgStudyId': ['GRAIL-002'], 'BriefTitle': ['The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types'], 'StudyType': ['Observational'], 'StartDate': ['February 28, 2017'], 'CompletionDate': ['May 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1204, 'OrgStudyId': ['R01CA249419'], 'BriefTitle': ['The Engaging Primary Care in Cancer Survivorship (EPICS) Study'], 'StudyType': ['Interventional'], 'StartDate': ['September 21, 2021'], 'CompletionDate': ['May 31, 2025'], 'OverallStatus': ['Enrolling by invitation'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1205, 'OrgStudyId': ['WO30085'], 'BriefTitle': ['A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['September 26, 2016'], 'CompletionDate': ['February 6, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1206, 'OrgStudyId': ['MO42319'], 'BriefTitle': ['A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)'], 'StudyType': ['Interventional'], 'StartDate': ['June 7, 2021'], 'CompletionDate': ['December 31, 2029'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1207, 'OrgStudyId': ['ACT16106'], 'BriefTitle': ['Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 4, 2020'], 'CompletionDate': ['May 28, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1208, 'OrgStudyId': ['1280.18'], 'BriefTitle': ['This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['May 4, 2017'], 'CompletionDate': ['August 24, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1209, 'OrgStudyId': ['G1T28-208'], 'BriefTitle': ['Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['April 15, 2021'], 'CompletionDate': ['October 25, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1210, 'OrgStudyId': ['MO39196'], 'BriefTitle': ['A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)'], 'StudyType': ['Interventional'], 'StartDate': ['August 25, 2017'], 'CompletionDate': ['January 17, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1211, 'OrgStudyId': ['91782'], 'BriefTitle': ['Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2010'], 'CompletionDate': ['January 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1212, 'OrgStudyId': ['CZOL446E2105'], 'BriefTitle': ['Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year'], 'StudyType': ['Interventional'], 'StartDate': ['November 2006'], 'CompletionDate': ['November 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1213, 'OrgStudyId': ['NCI-2012-02727'], 'BriefTitle': ['Decitabine in Treating Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 2001'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1214, 'OrgStudyId': ['ELA-0121'], 'BriefTitle': ['Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2022'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1215, 'OrgStudyId': ['TPR-0186'], 'BriefTitle': ['Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2008'], 'CompletionDate': ['January 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 1216, 'OrgStudyId': ['R21AT000348-01'], 'BriefTitle': ['Massage Therapy for Cancer-Related Fatigue'], 'StudyType': ['Interventional'], 'StartDate': ['March 2001'], 'CompletionDate': ['March 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1217, 'OrgStudyId': ['16-032'], 'BriefTitle': ['Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['June 3, 2016'], 'CompletionDate': ['October 12, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1218, 'OrgStudyId': ['SYD985.002'], 'BriefTitle': [\"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2017'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1219, 'OrgStudyId': ['NCI-2012-02938'], 'BriefTitle': ['Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 25, 2010'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1220, 'OrgStudyId': ['EGF103890'], 'BriefTitle': ['Lapatinib and Bevacizumab for Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 27, 2007'], 'CompletionDate': ['June 19, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1221, 'OrgStudyId': ['187519'], 'BriefTitle': ['Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 8, 2019'], 'CompletionDate': ['July 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1222, 'OrgStudyId': ['ODO-TE-B201'], 'BriefTitle': ['Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC'], 'StudyType': ['Interventional'], 'StartDate': ['February 5, 2019'], 'CompletionDate': ['June 11, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1223, 'OrgStudyId': ['A221505'], 'BriefTitle': ['Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2018'], 'CompletionDate': ['August 2035'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1224, 'OrgStudyId': ['K5-101'], 'BriefTitle': ['Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug'], 'StudyType': ['Interventional'], 'StartDate': ['September 2009'], 'CompletionDate': ['May 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1225, 'OrgStudyId': ['BT-CL-PGG-MEL/BCA-1621/MK3475'], 'BriefTitle': ['Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2017'], 'CompletionDate': ['December 31, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1226, 'OrgStudyId': ['LPT111110'], 'BriefTitle': ['Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['May 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1227, 'OrgStudyId': ['B7501001'], 'BriefTitle': ['A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2014'], 'CompletionDate': ['July 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1228, 'OrgStudyId': ['NCI-2019-05187'], 'BriefTitle': ['Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 20, 2019'], 'CompletionDate': ['November 20, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1229, 'OrgStudyId': ['6133'], 'BriefTitle': ['A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease'], 'StudyType': ['Interventional'], 'StartDate': ['March 2002'], 'CompletionDate': ['July 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1230, 'OrgStudyId': ['ZWI-ZW25-202'], 'BriefTitle': ['A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 10, 2020'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1231, 'OrgStudyId': ['RU011501I'], 'BriefTitle': ['Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 31, 2017'], 'CompletionDate': ['July 31, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1232, 'OrgStudyId': ['URCC12048'], 'BriefTitle': ['Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['February 3, 2014'], 'CompletionDate': ['December 16, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1233, 'OrgStudyId': ['99-037'], 'BriefTitle': ['Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 1999'], 'CompletionDate': ['March 2005'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1234, 'OrgStudyId': ['201973'], 'BriefTitle': ['Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2, 2017'], 'CompletionDate': ['July 19, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1235, 'OrgStudyId': ['PCYC-1135-CA'], 'BriefTitle': ['A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 2015'], 'CompletionDate': ['August 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1236, 'OrgStudyId': ['ARC-2 (AB928CSP0002)'], 'BriefTitle': ['A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['October 15, 2018'], 'CompletionDate': ['July 2, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1237, 'OrgStudyId': ['3068A1-400'], 'BriefTitle': ['Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density'], 'StudyType': ['Observational'], 'StartDate': ['October 2006'], 'CompletionDate': ['April 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['63 Years']}, {'Rank': 1238, 'OrgStudyId': ['NCI-2016-01301'], 'BriefTitle': ['Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 17, 2017'], 'CompletionDate': ['July 1, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1239, 'OrgStudyId': ['2016-0142'], 'BriefTitle': ['Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2017'], 'CompletionDate': ['February 28, 2031'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1240, 'OrgStudyId': ['UAB 1794'], 'BriefTitle': ['Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD'], 'StudyType': ['Interventional'], 'StartDate': ['February 20, 2019'], 'CompletionDate': ['July 22, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1241, 'OrgStudyId': ['SGNTUC-019'], 'BriefTitle': ['Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations'], 'StudyType': ['Interventional'], 'StartDate': ['January 11, 2021'], 'CompletionDate': ['May 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1242, 'OrgStudyId': ['GeneSearch BLN Assay PPC Study'], 'BriefTitle': ['GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study'], 'StudyType': ['Observational'], 'StartDate': ['December 2007'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1243, 'OrgStudyId': ['LA-EP06-302'], 'BriefTitle': ['Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim'], 'StudyType': ['Interventional'], 'StartDate': ['March 2012'], 'CompletionDate': ['December 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1244, 'OrgStudyId': ['08237'], 'BriefTitle': ['Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 3, 2010'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1245, 'OrgStudyId': ['PB-2020-01'], 'BriefTitle': ['ARGONAUT: Stool and Blood Sample Bank for Cancer Patients'], 'StudyType': ['Observational'], 'StartDate': ['July 1, 2022'], 'CompletionDate': ['December 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1246, 'OrgStudyId': ['D0816C00010'], 'BriefTitle': ['Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments'], 'StudyType': ['Interventional'], 'StartDate': ['February 6, 2015'], 'CompletionDate': ['July 19, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1247, 'OrgStudyId': ['IRB-25970'], 'BriefTitle': ['18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['March 4, 2013'], 'CompletionDate': ['April 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1248, 'OrgStudyId': ['0C-09-6'], 'BriefTitle': ['Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2010'], 'CompletionDate': ['May 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1249, 'OrgStudyId': ['SHRUS 1001'], 'BriefTitle': ['Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2015'], 'CompletionDate': ['June 2021'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1250, 'OrgStudyId': ['ACORN AEJSINS0601'], 'BriefTitle': ['Treating Chronic Insomnia in Breast Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['August 2006'], 'CompletionDate': ['January 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['60 Years']}, {'Rank': 1251, 'OrgStudyId': ['TAK-676-1003'], 'BriefTitle': ['A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['September 9, 2021'], 'CompletionDate': ['February 18, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1252, 'OrgStudyId': ['1995563'], 'BriefTitle': ['Measurements of Breast Tissue Optical Properties'], 'StudyType': ['Observational'], 'StartDate': ['December 1995'], 'CompletionDate': ['July 2018'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1253, 'OrgStudyId': ['CADEX-0001'], 'BriefTitle': ['Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer'], 'StudyType': ['Observational'], 'StartDate': ['March 1, 2019'], 'CompletionDate': ['October 1, 2023'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1254, 'OrgStudyId': ['B9991025'], 'BriefTitle': ['Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 19, 2017'], 'CompletionDate': ['January 4, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1255, 'OrgStudyId': ['14988'], 'BriefTitle': ['PreView: The Preventive Video Education in Waiting Rooms Program'], 'StudyType': ['Interventional'], 'StartDate': ['July 2013'], 'CompletionDate': ['March 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1256, 'OrgStudyId': ['CA209-9GW'], 'BriefTitle': ['A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread'], 'StudyType': ['Interventional'], 'StartDate': ['June 15, 2017'], 'CompletionDate': ['July 6, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1257, 'OrgStudyId': ['DMT-2015.001 ARM 1'], 'BriefTitle': ['Delphinus SoftVue Prospective Case Collection - ARM 1'], 'StudyType': ['Observational'], 'StartDate': ['July 31, 2017'], 'CompletionDate': ['July 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1258, 'OrgStudyId': ['DMT-2015.001 ARM 2'], 'BriefTitle': ['Delphinus SoftVue Prospective Case Collection - ARM 2'], 'StudyType': ['Observational'], 'StartDate': ['December 6, 2016'], 'CompletionDate': ['July 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1259, 'OrgStudyId': ['1-04'], 'BriefTitle': ['Post Market Study Using the Xoft Axxent System'], 'StudyType': ['Interventional'], 'StartDate': ['March 26, 2007'], 'CompletionDate': ['May 7, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 1260, 'OrgStudyId': ['Pro20150001297'], 'BriefTitle': ['Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['June 2015'], 'CompletionDate': ['December 31, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': []}, {'Rank': 1261, 'OrgStudyId': ['1033IL/0039'], 'BriefTitle': ['PROACT - Pre-Operative Arimidex Compared To Tamoxifen'], 'StudyType': ['Interventional'], 'StartDate': ['August 2000'], 'CompletionDate': ['December 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': []}, {'Rank': 1262, 'OrgStudyId': ['IRB-31855'], 'BriefTitle': ['18F-FSPG PET/CT for Cancer Patients on Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['July 2015'], 'CompletionDate': ['December 14, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1263, 'OrgStudyId': ['RU221408I'], 'BriefTitle': ['Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel'], 'StudyType': ['Interventional'], 'StartDate': ['November 2014'], 'CompletionDate': ['July 8, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1264, 'OrgStudyId': ['SAN-BB-01'], 'BriefTitle': ['At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions'], 'StudyType': ['Observational'], 'StartDate': ['July 2013'], 'CompletionDate': ['December 2040'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 1265, 'OrgStudyId': ['110080'], 'BriefTitle': ['Phase II ABT-888 With Cyclophosphamide'], 'StudyType': ['Interventional'], 'StartDate': ['January 12, 2011'], 'CompletionDate': ['December 15, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1266, 'OrgStudyId': ['CBYL719X2101'], 'BriefTitle': ['A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene'], 'StudyType': ['Interventional'], 'StartDate': ['October 5, 2010'], 'CompletionDate': ['April 16, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1267, 'OrgStudyId': ['UMCC 2014.111'], 'BriefTitle': ['The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)'], 'StudyType': ['Interventional'], 'StartDate': ['March 2015'], 'CompletionDate': ['March 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': ['69 Years']}, {'Rank': 1268, 'OrgStudyId': ['20-028'], 'BriefTitle': ['Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)'], 'StudyType': ['Interventional'], 'StartDate': ['July 2, 2020'], 'CompletionDate': ['December 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1269, 'OrgStudyId': ['CUDC-907-102'], 'BriefTitle': ['Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2014'], 'CompletionDate': ['May 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['16 Years'], 'MaximumAge': []}, {'Rank': 1270, 'OrgStudyId': ['CancerDyads'], 'BriefTitle': ['Improving Survivorship Among Minority Cancer Dyads'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2021'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1271, 'OrgStudyId': ['09187'], 'BriefTitle': ['Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['August 9, 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1272, 'OrgStudyId': ['VAR0053'], 'BriefTitle': ['FNA Tumor Sampling for CD137 Modulation: A Pilot Study'], 'StudyType': ['Observational'], 'StartDate': ['March 2010'], 'CompletionDate': ['January 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1273, 'OrgStudyId': ['CTP-0003 AirXpanders'], 'BriefTitle': ['Patient Controlled Tissue Expansion for Breast Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['October 2011'], 'CompletionDate': ['August 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1274, 'OrgStudyId': ['BT5528-100'], 'BriefTitle': ['Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression'], 'StudyType': ['Interventional'], 'StartDate': ['November 7, 2019'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1275, 'OrgStudyId': ['6B-20-1'], 'BriefTitle': ['18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2021'], 'CompletionDate': ['February 15, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1276, 'OrgStudyId': ['GeneSearch BLN Timing Study'], 'BriefTitle': ['GeneSearch Breast Lymph Node (BLN) Assay Timing Study'], 'StudyType': ['Observational'], 'StartDate': ['December 2007'], 'CompletionDate': ['December 2009'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1277, 'OrgStudyId': ['02-MX-003'], 'BriefTitle': ['ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation'], 'StudyType': ['Observational'], 'StartDate': ['September 7, 2021'], 'CompletionDate': ['February 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1278, 'OrgStudyId': ['A2181002'], 'BriefTitle': ['Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)'], 'StudyType': ['Interventional'], 'StartDate': ['November 2001'], 'CompletionDate': ['December 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['60 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1279, 'OrgStudyId': ['IRB00038639'], 'BriefTitle': ['Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2014'], 'CompletionDate': ['September 24, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 1280, 'OrgStudyId': ['D6900C00001'], 'BriefTitle': ['First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['October 18, 2021'], 'CompletionDate': ['June 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1281, 'OrgStudyId': ['DS8201-A-U106'], 'BriefTitle': ['DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 10, 2020'], 'CompletionDate': ['March 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1282, 'OrgStudyId': ['DS8201-A-U105'], 'BriefTitle': ['Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 20, 2018'], 'CompletionDate': ['July 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1283, 'OrgStudyId': ['PROT001'], 'BriefTitle': ['Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment'], 'StudyType': ['Interventional'], 'StartDate': ['May 15, 2021'], 'CompletionDate': ['September 1, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1284, 'OrgStudyId': ['GS-US-296-0101'], 'BriefTitle': ['Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 29, 2013'], 'CompletionDate': ['April 23, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1285, 'OrgStudyId': ['SY-5609-101'], 'BriefTitle': ['A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 23, 2020'], 'CompletionDate': ['July 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1286, 'OrgStudyId': ['278100'], 'BriefTitle': ['Tamoxifen-MRI Study'], 'StudyType': ['Interventional'], 'StartDate': ['September 2000'], 'CompletionDate': ['July 2006'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': ['45 Years']}, {'Rank': 1287, 'OrgStudyId': ['20430'], 'BriefTitle': ['HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics'], 'StudyType': ['Interventional'], 'StartDate': ['December 30, 2021'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1288, 'OrgStudyId': ['VAR0134'], 'BriefTitle': ['Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 8, 2017'], 'CompletionDate': ['August 30, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1289, 'OrgStudyId': ['CMP-001-009'], 'BriefTitle': ['A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2021'], 'CompletionDate': ['March 7, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1290, 'OrgStudyId': ['14169'], 'BriefTitle': ['Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening'], 'StudyType': ['Interventional'], 'StartDate': ['December 8, 2014'], 'CompletionDate': ['September 6, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['55 Years'], 'MaximumAge': []}, {'Rank': 1291, 'OrgStudyId': ['CTP-0005 AirXpanders'], 'BriefTitle': ['AirXpanders AeroForm Tissue Expander System for Breast Reconstruction'], 'StudyType': ['Interventional'], 'StartDate': ['November 12, 2015'], 'CompletionDate': ['September 26, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1292, 'OrgStudyId': ['7902-005'], 'BriefTitle': ['Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)'], 'StudyType': ['Interventional'], 'StartDate': ['February 12, 2019'], 'CompletionDate': ['December 22, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1293, 'OrgStudyId': ['CLDE225X2114'], 'BriefTitle': ['Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 2012'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1294, 'OrgStudyId': ['0S-17-4'], 'BriefTitle': ['Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer'], 'StudyType': ['Observational'], 'StartDate': ['August 30, 2018'], 'CompletionDate': ['September 24, 2020'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1295, 'OrgStudyId': ['GO28289'], 'BriefTitle': ['An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)'], 'StudyType': ['Observational'], 'StartDate': ['March 2012'], 'CompletionDate': ['November 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1296, 'OrgStudyId': ['NCI-2015-01097'], 'BriefTitle': ['A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['April 26, 2016'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1297, 'OrgStudyId': ['PUMA-NER-5201'], 'BriefTitle': ['Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2013'], 'CompletionDate': ['January 2, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1298, 'OrgStudyId': ['CDR0000067052'], 'BriefTitle': ['Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone'], 'StudyType': ['Interventional'], 'StartDate': ['August 1998'], 'CompletionDate': ['January 2001'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1299, 'OrgStudyId': ['EDO-S101-1002'], 'BriefTitle': ['Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 6, 2017'], 'CompletionDate': ['May 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1300, 'OrgStudyId': ['BO40933'], 'BriefTitle': ['A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['June 11, 2019'], 'CompletionDate': ['January 4, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1301, 'OrgStudyId': ['VAR0044'], 'BriefTitle': ['Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['July 2009'], 'CompletionDate': ['December 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 1302, 'OrgStudyId': ['CYP003'], 'BriefTitle': ['A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['February 2023'], 'CompletionDate': ['February 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1303, 'OrgStudyId': ['RTOG-9714'], 'BriefTitle': ['Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 1998'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1304, 'OrgStudyId': ['CR108208'], 'BriefTitle': ['An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2016'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1305, 'OrgStudyId': ['MM-121-05-01-05 (TCD11696)'], 'BriefTitle': ['A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['October 2011'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1306, 'OrgStudyId': ['M16-573'], 'BriefTitle': ['A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 13, 2018'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1307, 'OrgStudyId': ['EMR 100070-001'], 'BriefTitle': ['Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)'], 'StudyType': ['Interventional'], 'StartDate': ['January 31, 2013'], 'CompletionDate': ['December 16, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1308, 'OrgStudyId': ['15025'], 'BriefTitle': ['PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers'], 'StudyType': ['Interventional'], 'StartDate': ['July 7, 2015'], 'CompletionDate': ['December 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1309, 'OrgStudyId': ['XL184-021'], 'BriefTitle': ['Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 5, 2017'], 'CompletionDate': ['August 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1310, 'OrgStudyId': ['SPI-POZ-501'], 'BriefTitle': ['A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib'], 'StudyType': ['Interventional'], 'StartDate': ['October 5, 2018'], 'CompletionDate': ['April 5, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1311, 'OrgStudyId': ['D4884C00001'], 'BriefTitle': ['Study of Tremelimumab in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2, 2015'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['150 Years']}, {'Rank': 1312, 'OrgStudyId': ['IMX-110-001'], 'BriefTitle': ['IMX-110 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2018'], 'CompletionDate': ['July 15, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1313, 'OrgStudyId': ['07-266'], 'BriefTitle': ['The Active After Cancer Trial (AACT)'], 'StudyType': ['Interventional'], 'StartDate': ['October 2007'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1314, 'OrgStudyId': ['94098'], 'BriefTitle': ['High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 1994'], 'CompletionDate': ['August 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['55 Years']}, {'Rank': 1315, 'OrgStudyId': ['M16-074'], 'BriefTitle': ['A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 21, 2017'], 'CompletionDate': ['April 13, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1316, 'OrgStudyId': ['AREVAMED01'], 'BriefTitle': ['Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy'], 'StudyType': ['Interventional'], 'StartDate': ['July 2011'], 'CompletionDate': ['July 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['19 Years'], 'MaximumAge': []}, {'Rank': 1317, 'OrgStudyId': ['PROMIS'], 'BriefTitle': ['PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score'], 'StudyType': ['Observational'], 'StartDate': ['May 2012'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['90 Years']}, {'Rank': 1318, 'OrgStudyId': ['CLEE011A2412B'], 'BriefTitle': ['Roll-over Study to Allow Continued Access to Ribociclib'], 'StudyType': ['Interventional'], 'StartDate': ['July 7, 2022'], 'CompletionDate': ['February 16, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1319, 'OrgStudyId': ['DS1062-A-J101'], 'BriefTitle': ['First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)'], 'StudyType': ['Interventional'], 'StartDate': ['January 31, 2018'], 'CompletionDate': ['January 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1320, 'OrgStudyId': ['2020-013-00US3'], 'BriefTitle': ['A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 9, 2021'], 'CompletionDate': ['March 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1321, 'OrgStudyId': ['970652'], 'BriefTitle': ['First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide'], 'StudyType': ['Interventional'], 'StartDate': ['November 2016'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1322, 'OrgStudyId': ['EA1141'], 'BriefTitle': ['Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts'], 'StudyType': ['Interventional'], 'StartDate': ['December 27, 2016'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1323, 'OrgStudyId': ['C4431001'], 'BriefTitle': ['A Study of PF-07260437 in Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 7, 2021'], 'CompletionDate': ['September 25, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1324, 'OrgStudyId': ['1623168'], 'BriefTitle': ['Healthy Moms: Prenatal Counseling for Postpartum Health'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2021'], 'CompletionDate': ['June 15, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['40 Years']}, {'Rank': 1325, 'OrgStudyId': ['CDR0000355116'], 'BriefTitle': ['Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation'], 'StudyType': ['Interventional'], 'StartDate': ['November 2003'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['12 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1326, 'OrgStudyId': ['mRNA-2752-P101'], 'BriefTitle': ['Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['November 27, 2018'], 'CompletionDate': ['April 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1327, 'OrgStudyId': ['TRV-003'], 'BriefTitle': ['Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance'], 'StudyType': ['Observational'], 'StartDate': ['July 15, 2022'], 'CompletionDate': ['July 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1328, 'OrgStudyId': ['11-003 Mobetron'], 'BriefTitle': ['Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 1329, 'OrgStudyId': ['19-000756'], 'BriefTitle': ['Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues'], 'StudyType': ['Interventional'], 'StartDate': ['November 5, 2019'], 'CompletionDate': ['October 17, 2031'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1330, 'OrgStudyId': ['CDR0000066283'], 'BriefTitle': ['Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer'], 'StudyType': ['Observational'], 'StartDate': ['January 1998'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1331, 'OrgStudyId': ['N0574'], 'BriefTitle': ['Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases'], 'StudyType': ['Interventional'], 'StartDate': ['July 2006'], 'CompletionDate': ['December 15, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1332, 'OrgStudyId': ['MTC-DOX-003'], 'BriefTitle': ['Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver'], 'StudyType': ['Interventional'], 'StartDate': ['July 2001'], 'CompletionDate': ['April 2003'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1333, 'OrgStudyId': ['0485-CL-0001'], 'BriefTitle': ['Assessment and Tracking of Long-term Alefacept Safety'], 'StudyType': ['Observational'], 'StartDate': ['June 2003'], 'CompletionDate': ['February 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1334, 'OrgStudyId': ['CX-839-001'], 'BriefTitle': ['Study of the Glutaminase Inhibitor CB-839 in Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 2014'], 'CompletionDate': ['March 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1335, 'OrgStudyId': ['A221102'], 'BriefTitle': ['Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment'], 'StudyType': ['Interventional'], 'StartDate': ['August 2013'], 'CompletionDate': ['September 1, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1336, 'OrgStudyId': ['ARX788-1711'], 'BriefTitle': ['A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)'], 'StudyType': ['Interventional'], 'StartDate': ['March 20, 2018'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1337, 'OrgStudyId': ['RTX-224-01'], 'BriefTitle': ['RTX-224 Monotherapy in Patients With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 12, 2022'], 'CompletionDate': ['November 30, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1338, 'OrgStudyId': ['42674'], 'BriefTitle': [\"Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study\"], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2017'], 'CompletionDate': ['December 31, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1339, 'OrgStudyId': ['2005-0328'], 'BriefTitle': ['Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2006'], 'CompletionDate': ['October 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1340, 'OrgStudyId': ['Cancer Pain Management'], 'BriefTitle': ['Improving Cancer Pain Management Through Self-Care'], 'StudyType': ['Interventional'], 'StartDate': ['December 2007'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1341, 'OrgStudyId': ['14238'], 'BriefTitle': ['Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 11, 2015'], 'CompletionDate': ['September 11, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1342, 'OrgStudyId': ['CALGB-9871'], 'BriefTitle': ['Docetaxel in Treating Patients With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 1998'], 'CompletionDate': ['January 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1343, 'OrgStudyId': ['PIONEER-01'], 'BriefTitle': ['The PIONEER-01 Study of the Imagio Breast Imaging System'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2012'], 'CompletionDate': ['September 9, 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1344, 'OrgStudyId': ['QUILT-2.025'], 'BriefTitle': ['QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.'], 'StudyType': ['Interventional'], 'StartDate': ['August 10, 2018'], 'CompletionDate': ['December 30, 2020'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1345, 'OrgStudyId': ['TO-TAS0728-101'], 'BriefTitle': ['A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities'], 'StudyType': ['Interventional'], 'StartDate': ['April 6, 2018'], 'CompletionDate': ['June 9, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1346, 'OrgStudyId': ['DCC-2036-01-004'], 'BriefTitle': ['A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 2, 2019'], 'CompletionDate': ['November 1, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1347, 'OrgStudyId': ['B7401001'], 'BriefTitle': ['A Study Of PF-06664178 In Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2014'], 'CompletionDate': ['June 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1348, 'OrgStudyId': ['TH1902-CTR-0001'], 'BriefTitle': ['TH1902 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 4, 2021'], 'CompletionDate': ['March 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1349, 'OrgStudyId': ['IIT2020-24-SHIRAZIP-BURN'], 'BriefTitle': ['The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['January 10, 2022'], 'CompletionDate': ['March 9, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['39 Years']}, {'Rank': 1350, 'OrgStudyId': ['213409'], 'BriefTitle': ['A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study'], 'StudyType': ['Interventional'], 'StartDate': ['April 16, 2021'], 'CompletionDate': ['November 13, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1351, 'OrgStudyId': ['A00152-53'], 'BriefTitle': ['Ultrasound Elastography of Breast Lesions'], 'StudyType': ['Observational'], 'StartDate': ['July 2008'], 'CompletionDate': ['June 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1352, 'OrgStudyId': ['IIT2020-13-GRESHAM-ELLY'], 'BriefTitle': ['Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients'], 'StudyType': ['Interventional'], 'StartDate': ['December 2, 2020'], 'CompletionDate': ['July 8, 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1353, 'OrgStudyId': ['20-378'], 'BriefTitle': ['Researching the Effect of Exercise on Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2, 2020'], 'CompletionDate': ['October 2, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1354, 'OrgStudyId': ['CRYO for Mastectomy (DoD)'], 'BriefTitle': ['Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy'], 'StudyType': ['Interventional'], 'StartDate': ['September 15, 2022'], 'CompletionDate': ['May 14, 2026'], 'OverallStatus': ['Enrolling by invitation'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1355, 'OrgStudyId': ['15002'], 'BriefTitle': ['Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['June 14, 2016'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1356, 'OrgStudyId': ['SY-1365-101'], 'BriefTitle': ['A Study of SY-1365 in Adult Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 12, 2017'], 'CompletionDate': ['June 24, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1357, 'OrgStudyId': ['BA3021-001'], 'BriefTitle': ['CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)'], 'StudyType': ['Interventional'], 'StartDate': ['June 27, 2018'], 'CompletionDate': ['June 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1358, 'OrgStudyId': ['U01AT001653'], 'BriefTitle': [\"Women's Isoflavone Soy Health (WISH) Trial\"], 'StudyType': ['Interventional'], 'StartDate': ['March 2004'], 'CompletionDate': ['March 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': []}, {'Rank': 1359, 'OrgStudyId': ['D8488C00001'], 'BriefTitle': ['Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 17, 2017'], 'CompletionDate': ['March 16, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1360, 'OrgStudyId': ['CPDR001X2102'], 'BriefTitle': ['A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat'], 'StudyType': ['Interventional'], 'StartDate': ['October 14, 2016'], 'CompletionDate': ['February 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1361, 'OrgStudyId': ['MAPinitial'], 'BriefTitle': ['UCLA Health Patient Health Maintenance Outreach Text Message'], 'StudyType': ['Interventional'], 'StartDate': ['March 9, 2023'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Enrolling by invitation'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1362, 'OrgStudyId': ['PEDSVAR0038'], 'BriefTitle': ['B-Receptor Signaling in Cardiomyopathy'], 'StudyType': ['Observational'], 'StartDate': ['November 2008'], 'CompletionDate': ['October 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['40 Years']}, {'Rank': 1363, 'OrgStudyId': ['213353'], 'BriefTitle': ['Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 3, 2019'], 'CompletionDate': ['January 12, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1364, 'OrgStudyId': ['IRB#13-6255'], 'BriefTitle': ['Nonmyeloablative Allogeneic Transplant'], 'StudyType': ['Interventional'], 'StartDate': ['October 2001'], 'CompletionDate': ['October 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['72 Years']}, {'Rank': 1365, 'OrgStudyId': ['TPU-TAS-120-101'], 'BriefTitle': ['A Study of TAS-120 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 2014'], 'CompletionDate': ['June 30, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1366, 'OrgStudyId': ['GS-US-382-1587'], 'BriefTitle': ['Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels'], 'StudyType': ['Interventional'], 'StartDate': ['August 19, 2022'], 'CompletionDate': ['November 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1367, 'OrgStudyId': ['GOG-8199'], 'BriefTitle': ['Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer'], 'StudyType': ['Observational'], 'StartDate': ['June 7, 2010'], 'CompletionDate': ['April 10, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['30 Years'], 'MaximumAge': []}, {'Rank': 1368, 'OrgStudyId': ['KL264-01'], 'BriefTitle': ['Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies'], 'StudyType': ['Interventional'], 'StartDate': ['February 28, 2020'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1369, 'OrgStudyId': ['SLS17-201/MK3475-770'], 'BriefTitle': ['Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['June 28, 2019'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1370, 'OrgStudyId': ['K01CA190659'], 'BriefTitle': ['Culturally Appropriate Nutrition Communication for Mexican American Women'], 'StudyType': ['Interventional'], 'StartDate': ['March 25, 2019'], 'CompletionDate': ['December 25, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['29 Years']}, {'Rank': 1371, 'OrgStudyId': ['SGN228-001'], 'BriefTitle': ['A Study of SGN-CD228A in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 3, 2019'], 'CompletionDate': ['March 9, 2023'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1372, 'OrgStudyId': ['MM-398-01-01-02'], 'BriefTitle': ['MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment'], 'StudyType': ['Interventional'], 'StartDate': ['November 2012'], 'CompletionDate': ['October 2, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1373, 'OrgStudyId': ['AMI-2008-01'], 'BriefTitle': ['F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets'], 'StudyType': ['Interventional'], 'StartDate': ['January 2009'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1374, 'OrgStudyId': ['TOS-358-001'], 'BriefTitle': ['A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2023'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1375, 'OrgStudyId': ['S1008'], 'BriefTitle': ['S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['March 2012'], 'CompletionDate': ['January 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 1376, 'OrgStudyId': ['PROT004'], 'BriefTitle': ['Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 10, 2022'], 'CompletionDate': ['December 15, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1377, 'OrgStudyId': ['ITL-002-CRYO'], 'BriefTitle': ['In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation'], 'StudyType': ['Interventional'], 'StartDate': ['August 2009'], 'CompletionDate': ['May 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1378, 'OrgStudyId': ['11-006682'], 'BriefTitle': ['Assessing the Patient Experience in Cancer Care'], 'StudyType': ['Observational'], 'StartDate': ['May 2012'], 'CompletionDate': ['September 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1379, 'OrgStudyId': ['213356'], 'BriefTitle': ['A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 21, 2013'], 'CompletionDate': ['December 26, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1380, 'OrgStudyId': ['999912039'], 'BriefTitle': ['Cancer Symptom Data From Multiple Treatment Centers'], 'StudyType': ['Observational'], 'StartDate': ['February 10, 2012'], 'CompletionDate': ['May 23, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1381, 'OrgStudyId': ['AC480IV-001'], 'BriefTitle': ['Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2010'], 'CompletionDate': ['June 2013'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1382, 'OrgStudyId': ['IIT2021-07-Atkins-CARMA'], 'BriefTitle': ['Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial'], 'StudyType': ['Interventional'], 'StartDate': ['October 7, 2022'], 'CompletionDate': ['August 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1383, 'OrgStudyId': ['PRO1184-001'], 'BriefTitle': ['PRO1184 for Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2022'], 'CompletionDate': ['September 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1384, 'OrgStudyId': ['ONC-392-001'], 'BriefTitle': ['Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC'], 'StudyType': ['Interventional'], 'StartDate': ['September 16, 2020'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1385, 'OrgStudyId': ['CTL0211'], 'BriefTitle': ['Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease'], 'StudyType': ['Interventional'], 'StartDate': ['July 2012'], 'CompletionDate': ['March 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1386, 'OrgStudyId': ['PRS-343-PCS_08_18'], 'BriefTitle': ['PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 21, 2018'], 'CompletionDate': ['July 1, 2021'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1387, 'OrgStudyId': ['CT7001_001'], 'BriefTitle': ['Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['November 14, 2017'], 'CompletionDate': ['December 15, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1388, 'OrgStudyId': ['R7075-ONC-2009'], 'BriefTitle': ['REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2020'], 'CompletionDate': ['April 1, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1389, 'OrgStudyId': ['D8410C00001'], 'BriefTitle': ['Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['June 24, 2022'], 'CompletionDate': ['December 8, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1390, 'OrgStudyId': ['CART-TnMUC1-01'], 'BriefTitle': ['A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['October 10, 2019'], 'CompletionDate': ['October 31, 2036'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1391, 'OrgStudyId': ['CA033'], 'BriefTitle': ['A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma'], 'StudyType': ['Interventional'], 'StartDate': ['April 23, 2009'], 'CompletionDate': ['February 12, 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1392, 'OrgStudyId': ['C4551001'], 'BriefTitle': ['Study of PF-07248144 in Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 16, 2020'], 'CompletionDate': ['November 8, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1393, 'OrgStudyId': ['18232'], 'BriefTitle': ['Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)'], 'StudyType': ['Observational'], 'StartDate': ['July 3, 2019'], 'CompletionDate': ['March 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1394, 'OrgStudyId': ['S0702'], 'BriefTitle': ['S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases'], 'StudyType': ['Observational'], 'StartDate': ['December 2008'], 'CompletionDate': ['June 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['120 Years']}, {'Rank': 1395, 'OrgStudyId': ['MT-5111_001'], 'BriefTitle': ['Study of MT-5111 in HER2-positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 12, 2019'], 'CompletionDate': ['May 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1396, 'OrgStudyId': ['BB-1701-101'], 'BriefTitle': ['A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 28, 2020'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1397, 'OrgStudyId': ['0S-13-1'], 'BriefTitle': ['Cancer Genetics Hereditary Cancer Panel Testing'], 'StudyType': ['Observational'], 'StartDate': ['June 12, 2014'], 'CompletionDate': ['January 5, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1398, 'OrgStudyId': ['D9720C00001'], 'BriefTitle': ['Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['November 12, 2020'], 'CompletionDate': ['January 15, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1399, 'OrgStudyId': ['FPX-01-01'], 'BriefTitle': ['A Phase 1/2 Study of [225Ac]-FPI-1434 Injection'], 'StudyType': ['Interventional'], 'StartDate': ['January 17, 2019'], 'CompletionDate': ['June 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1400, 'OrgStudyId': ['16-214-02'], 'BriefTitle': ['A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 19, 2016'], 'CompletionDate': ['April 28, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1401, 'OrgStudyId': ['1454-001'], 'BriefTitle': ['Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)'], 'StudyType': ['Interventional'], 'StartDate': ['February 3, 2017'], 'CompletionDate': ['April 21, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1402, 'OrgStudyId': ['NCI-2009-00042'], 'BriefTitle': ['Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2003'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1403, 'OrgStudyId': ['2693-CL-0304'], 'BriefTitle': ['A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause'], 'StudyType': ['Interventional'], 'StartDate': ['July 10, 2019'], 'CompletionDate': ['January 4, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 1404, 'OrgStudyId': ['ONCX-NAV-G201'], 'BriefTitle': ['A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 5, 2022'], 'CompletionDate': ['December 15, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1405, 'OrgStudyId': ['FT500-101'], 'BriefTitle': ['FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2019'], 'CompletionDate': ['November 15, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1406, 'OrgStudyId': ['2693-CL-0302'], 'BriefTitle': ['A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2'], 'StudyType': ['Interventional'], 'StartDate': ['July 10, 2019'], 'CompletionDate': ['April 23, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 1407, 'OrgStudyId': ['CUDC-101-102'], 'BriefTitle': ['A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 2010'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1408, 'OrgStudyId': ['Pro00046105'], 'BriefTitle': ['Emerging From the Haze for Gynecologic Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['January 10, 2017'], 'CompletionDate': ['November 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1409, 'OrgStudyId': ['DF1001-001'], 'BriefTitle': ['Study of DF1001 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 11, 2019'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1410, 'OrgStudyId': ['2693-CL-0301'], 'BriefTitle': ['A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause'], 'StudyType': ['Interventional'], 'StartDate': ['July 11, 2019'], 'CompletionDate': ['August 11, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['65 Years']}, {'Rank': 1411, 'OrgStudyId': ['BPX603-201A'], 'BriefTitle': ['Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2020'], 'CompletionDate': ['January 2, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1412, 'OrgStudyId': ['XL092-001'], 'BriefTitle': ['A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 20, 2019'], 'CompletionDate': ['November 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1413, 'OrgStudyId': ['INCB 123667-101'], 'BriefTitle': ['Study of INCB123667 in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 5, 2022'], 'CompletionDate': ['July 30, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1414, 'OrgStudyId': ['ADCT-502-101'], 'BriefTitle': ['Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression'], 'StudyType': ['Interventional'], 'StartDate': ['May 18, 2017'], 'CompletionDate': ['April 5, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1415, 'OrgStudyId': ['ZN-A-1041-101-US'], 'BriefTitle': ['A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 15, 2020'], 'CompletionDate': ['November 30, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1416, 'OrgStudyId': ['NEO3-06'], 'BriefTitle': ['Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['May 2009'], 'CompletionDate': ['August 2013'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1417, 'OrgStudyId': ['TAEK-VAC-HerBy-001'], 'BriefTitle': ['TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 10, 2020'], 'CompletionDate': ['June 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1418, 'OrgStudyId': ['IPI-549-01'], 'BriefTitle': ['A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549'], 'StudyType': ['Interventional'], 'StartDate': ['December 2015'], 'CompletionDate': ['December 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1419, 'OrgStudyId': ['MORAb-202-G000-201'], 'BriefTitle': ['A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types'], 'StudyType': ['Interventional'], 'StartDate': ['August 6, 2020'], 'CompletionDate': ['March 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1420, 'OrgStudyId': ['13517'], 'BriefTitle': ['A Study of LY3023414 in Participants With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 31, 2012'], 'CompletionDate': ['February 2, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1421, 'OrgStudyId': ['M19-037'], 'BriefTitle': ['A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 21, 2019'], 'CompletionDate': ['November 12, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1422, 'OrgStudyId': ['17350'], 'BriefTitle': ['Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel'], 'StudyType': ['Interventional'], 'StartDate': ['February 27, 2015'], 'CompletionDate': ['April 18, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1423, 'OrgStudyId': ['MER-XMT-2056-1'], 'BriefTitle': ['A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2'], 'StudyType': ['Interventional'], 'StartDate': ['January 24, 2023'], 'CompletionDate': ['November 2025'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1424, 'OrgStudyId': ['XmAb22841-01'], 'BriefTitle': ['A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 29, 2019'], 'CompletionDate': ['February 16, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1425, 'OrgStudyId': ['20190131'], 'BriefTitle': ['Study of AMG 650 in Adult Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 11, 2020'], 'CompletionDate': ['February 15, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1426, 'OrgStudyId': ['NUV-868-01'], 'BriefTitle': ['NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 29, 2022'], 'CompletionDate': ['February 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1427, 'OrgStudyId': ['MM-310-01-01-01'], 'BriefTitle': ['A Study Evaluating MM-310 in Patients With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2017'], 'CompletionDate': ['December 2018'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1428, 'OrgStudyId': ['16897'], 'BriefTitle': ['Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)'], 'StudyType': ['Interventional'], 'StartDate': ['March 24, 2015'], 'CompletionDate': ['July 27, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1429, 'OrgStudyId': ['CDX1127-06'], 'BriefTitle': ['A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2015'], 'CompletionDate': ['May 22, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1430, 'OrgStudyId': ['FPA150-001'], 'BriefTitle': ['FPA150 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 27, 2018'], 'CompletionDate': ['May 10, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1431, 'OrgStudyId': ['3068A1-301'], 'BriefTitle': ['Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['December 2001'], 'CompletionDate': ['September 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['55 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1432, 'OrgStudyId': ['CBKM120B2101'], 'BriefTitle': ['A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients'], 'StudyType': ['Interventional'], 'StartDate': ['April 2010'], 'CompletionDate': ['November 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1433, 'OrgStudyId': ['PY314-1-01'], 'BriefTitle': ['A Study of PY314 in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 29, 2020'], 'CompletionDate': ['October 28, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1434, 'OrgStudyId': ['CALAA-01-ST-001'], 'BriefTitle': ['Safety Study of CALAA-01 to Treat Solid Tumor Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['May 2008'], 'CompletionDate': ['September 2012'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1435, 'OrgStudyId': ['B7661001'], 'BriefTitle': ['A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 17, 2014'], 'CompletionDate': ['November 5, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1436, 'OrgStudyId': ['CPI-006-001'], 'BriefTitle': ['CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['April 25, 2018'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1437, 'OrgStudyId': ['INCAGN 2385-101'], 'BriefTitle': ['A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['June 18, 2018'], 'CompletionDate': ['October 7, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1438, 'OrgStudyId': ['INCAGN 2390-101'], 'BriefTitle': ['A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['September 24, 2018'], 'CompletionDate': ['August 18, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1439, 'OrgStudyId': ['KB-0742-1001'], 'BriefTitle': ['A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma'], 'StudyType': ['Interventional'], 'StartDate': ['February 8, 2021'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['12 Years'], 'MaximumAge': []}, {'Rank': 1440, 'OrgStudyId': ['D8532C00004'], 'BriefTitle': ['Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers'], 'StudyType': ['Interventional'], 'StartDate': ['June 13, 2022'], 'CompletionDate': ['December 13, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['50 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1441, 'OrgStudyId': ['C34003'], 'BriefTitle': ['A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 12, 2016'], 'CompletionDate': ['November 30, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1442, 'OrgStudyId': ['NP-G2-044-P1-01'], 'BriefTitle': ['Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2017'], 'CompletionDate': ['May 7, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1443, 'OrgStudyId': ['HMBD-002-V4C26-01'], 'BriefTitle': ['A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab'], 'StudyType': ['Interventional'], 'StartDate': ['January 1, 2022'], 'CompletionDate': ['January 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1444, 'OrgStudyId': ['M15-916'], 'BriefTitle': ['A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)'], 'StudyType': ['Interventional'], 'StartDate': ['July 3, 2017'], 'CompletionDate': ['November 27, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1445, 'OrgStudyId': ['BPI-2358-105 Phase 2'], 'BriefTitle': ['Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2'], 'StudyType': ['Interventional'], 'StartDate': ['April 5, 2017'], 'CompletionDate': ['April 20, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1446, 'OrgStudyId': ['GO39733'], 'BriefTitle': ['A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2017'], 'CompletionDate': ['September 29, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1447, 'OrgStudyId': ['BP29842'], 'BriefTitle': ['A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2015'], 'CompletionDate': ['November 10, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1448, 'OrgStudyId': ['NRG-CC004'], 'BriefTitle': ['Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 31, 2017'], 'CompletionDate': ['February 22, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1449, 'OrgStudyId': ['CR-TSC-001'], 'BriefTitle': ['NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)'], 'StudyType': ['Interventional'], 'StartDate': ['September 2005'], 'CompletionDate': ['December 12, 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1450, 'OrgStudyId': ['IA0132'], 'BriefTitle': ['Cognition in the Study of Tamoxifen and Raloxifene'], 'StudyType': ['Interventional'], 'StartDate': ['October 2001'], 'CompletionDate': ['March 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['65 Years'], 'MaximumAge': []}, {'Rank': 1451, 'OrgStudyId': ['S1714'], 'BriefTitle': ['Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer'], 'StudyType': ['Observational'], 'StartDate': ['March 1, 2019'], 'CompletionDate': ['February 28, 2026'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1452, 'OrgStudyId': ['INCAGN 1876-202'], 'BriefTitle': ['INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['November 21, 2017'], 'CompletionDate': ['July 1, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1453, 'OrgStudyId': ['CA-170-101'], 'BriefTitle': ['A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas'], 'StudyType': ['Interventional'], 'StartDate': ['May 2016'], 'CompletionDate': ['May 7, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1454, 'OrgStudyId': ['RXDX-101-02'], 'BriefTitle': ['Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)'], 'StudyType': ['Interventional'], 'StartDate': ['November 19, 2015'], 'CompletionDate': ['April 1, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1455, 'OrgStudyId': ['BPI-2358-105 phase 3'], 'BriefTitle': ['Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3'], 'StudyType': ['Interventional'], 'StartDate': ['May 29, 2018'], 'CompletionDate': ['February 8, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1456, 'OrgStudyId': ['XmAb20717-01'], 'BriefTitle': ['A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 10, 2018'], 'CompletionDate': ['September 6, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1457, 'OrgStudyId': ['ARRAY-818-103'], 'BriefTitle': ['Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 2, 2018'], 'CompletionDate': ['April 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1458, 'OrgStudyId': ['AFT-25'], 'BriefTitle': ['Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2017'], 'CompletionDate': ['July 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1459, 'OrgStudyId': ['PRS-343-PCS_04_16'], 'BriefTitle': ['PRS-343 in HER2-Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 28, 2017'], 'CompletionDate': ['October 7, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1460, 'OrgStudyId': ['A212102'], 'BriefTitle': ['Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection'], 'StudyType': ['Observational'], 'StartDate': ['August 1, 2022'], 'CompletionDate': ['February 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': ['75 Years']}, {'Rank': 1461, 'OrgStudyId': ['CRLX-001'], 'BriefTitle': ['Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 2006'], 'CompletionDate': ['April 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1462, 'OrgStudyId': ['C016'], 'BriefTitle': ['PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)'], 'StudyType': ['Interventional'], 'StartDate': ['September 2002'], 'CompletionDate': ['June 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1463, 'OrgStudyId': ['827486'], 'BriefTitle': ['Pulmonary Hypertension and Anastrozole Trial'], 'StudyType': ['Interventional'], 'StartDate': ['December 7, 2017'], 'CompletionDate': ['July 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1464, 'OrgStudyId': ['NCI-2020-13883'], 'BriefTitle': ['Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial'], 'StudyType': ['Interventional'], 'StartDate': ['March 5, 2021'], 'CompletionDate': ['March 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1465, 'OrgStudyId': ['INCB 18424-270'], 'BriefTitle': ['An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib'], 'StudyType': ['Interventional'], 'StartDate': ['November 30, 2016'], 'CompletionDate': ['December 31, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1466, 'OrgStudyId': ['EMR 200066-006'], 'BriefTitle': ['Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 2011'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['82 Years']}, {'Rank': 1467, 'OrgStudyId': ['FT536-101'], 'BriefTitle': ['FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 31, 2022'], 'CompletionDate': ['April 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1468, 'OrgStudyId': ['TMPS-101'], 'BriefTitle': ['Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 15, 2022'], 'CompletionDate': ['July 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1469, 'OrgStudyId': ['06-103'], 'BriefTitle': ['Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['October 23, 2006'], 'CompletionDate': ['October 26, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1470, 'OrgStudyId': ['20140318'], 'BriefTitle': ['Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611'], 'StudyType': ['Interventional'], 'StartDate': ['February 5, 2016'], 'CompletionDate': ['July 26, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1471, 'OrgStudyId': ['16447'], 'BriefTitle': ['Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients'], 'StudyType': ['Interventional'], 'StartDate': ['September 2013'], 'CompletionDate': ['December 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1472, 'OrgStudyId': ['CX-5461-04'], 'BriefTitle': ['Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['September 8, 2021'], 'CompletionDate': ['June 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1473, 'OrgStudyId': ['NRG-BN009'], 'BriefTitle': ['Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery'], 'StudyType': ['Interventional'], 'StartDate': ['December 15, 2020'], 'CompletionDate': ['January 31, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1474, 'OrgStudyId': ['J0867'], 'BriefTitle': ['Concentration and Activity of Lapatinib in Vestibular Schwannomas'], 'StudyType': ['Interventional'], 'StartDate': ['June 2009'], 'CompletionDate': ['August 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1475, 'OrgStudyId': ['HBS701'], 'BriefTitle': ['Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash'], 'StudyType': ['Interventional'], 'StartDate': ['April 3, 2008'], 'CompletionDate': ['December 30, 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1476, 'OrgStudyId': ['D0816R00006'], 'BriefTitle': ['Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer'], 'StudyType': ['Observational'], 'StartDate': ['April 21, 2015'], 'CompletionDate': ['September 30, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1477, 'OrgStudyId': ['A9001502'], 'BriefTitle': ['Treatment Resistance Following Anti-cancer Therapies'], 'StudyType': ['Interventional'], 'StartDate': ['February 13, 2019'], 'CompletionDate': ['December 14, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1478, 'OrgStudyId': ['2018-01'], 'BriefTitle': ['Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors'], 'StudyType': ['Observational'], 'StartDate': ['August 23, 2018'], 'CompletionDate': ['March 31, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1479, 'OrgStudyId': ['CP-MGC018-01'], 'BriefTitle': ['MGC018 With or Without MGA012 in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 21, 2018'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1480, 'OrgStudyId': ['ORM-5029-01-001'], 'BriefTitle': ['Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 3, 2022'], 'CompletionDate': ['October 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1481, 'OrgStudyId': ['MER-XMT-1660-1'], 'BriefTitle': ['A Study of XMT-1660 in Participants With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['August 15, 2022'], 'CompletionDate': ['January 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1482, 'OrgStudyId': ['Minnelide 101'], 'BriefTitle': ['A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 10, 2017'], 'CompletionDate': ['December 1, 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1483, 'OrgStudyId': ['INCB 24360-202/ ECHO-202'], 'BriefTitle': ['Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['July 17, 2014'], 'CompletionDate': ['November 6, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1484, 'OrgStudyId': ['CA052-002'], 'BriefTitle': ['A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 27, 2021'], 'CompletionDate': ['September 15, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1485, 'OrgStudyId': ['M15-394'], 'BriefTitle': ['ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 18, 2015'], 'CompletionDate': ['March 25, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1486, 'OrgStudyId': ['DS8201-A-J101'], 'BriefTitle': ['Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 2015'], 'CompletionDate': ['September 30, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1487, 'OrgStudyId': ['CYT-0851-01'], 'BriefTitle': ['A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 9, 2019'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1488, 'OrgStudyId': ['NCI-2012-01040'], 'BriefTitle': ['Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction'], 'StudyType': ['Interventional'], 'StartDate': ['June 12, 2012'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1489, 'OrgStudyId': ['CTAP101-CL-1017'], 'BriefTitle': ['Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid'], 'StudyType': ['Interventional'], 'StartDate': ['December 2014'], 'CompletionDate': ['March 17, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1490, 'OrgStudyId': ['DCL-10-001'], 'BriefTitle': ['Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned'], 'StudyType': ['Interventional'], 'StartDate': ['December 2011'], 'CompletionDate': ['January 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1491, 'OrgStudyId': ['TTX-080-001'], 'BriefTitle': ['TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['July 14, 2020'], 'CompletionDate': ['June 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1492, 'OrgStudyId': ['SGNSTNV-001'], 'BriefTitle': ['A Study of SGN-STNV in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 18, 2021'], 'CompletionDate': ['March 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1493, 'OrgStudyId': ['ATRC-101-A01'], 'BriefTitle': ['A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['February 11, 2020'], 'CompletionDate': ['March 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1494, 'OrgStudyId': ['D5330C00004'], 'BriefTitle': ['Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents'], 'StudyType': ['Interventional'], 'StartDate': ['October 31, 2014'], 'CompletionDate': ['November 26, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1495, 'OrgStudyId': ['CLGK974X2101'], 'BriefTitle': ['A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands'], 'StudyType': ['Interventional'], 'StartDate': ['December 1, 2011'], 'CompletionDate': ['November 23, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1496, 'OrgStudyId': ['AGS-22M6E-11-1'], 'BriefTitle': ['A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4'], 'StudyType': ['Interventional'], 'StartDate': ['June 2011'], 'CompletionDate': ['April 2015'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1497, 'OrgStudyId': ['TT420X1103'], 'BriefTitle': ['Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 14, 2021'], 'CompletionDate': ['December 1, 2022'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1498, 'OrgStudyId': ['AMC-078'], 'BriefTitle': ['Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection'], 'StudyType': ['Interventional'], 'StartDate': ['November 2013'], 'CompletionDate': ['December 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1499, 'OrgStudyId': ['CP-MGA271-01'], 'BriefTitle': ['Safety Study of MGA271 in Refractory Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2011'], 'CompletionDate': ['April 18, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1500, 'OrgStudyId': ['SGNTGT-001'], 'BriefTitle': ['A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 29, 2020'], 'CompletionDate': ['April 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1501, 'OrgStudyId': ['CP-MGD013-01'], 'BriefTitle': ['A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms'], 'StudyType': ['Interventional'], 'StartDate': ['August 18, 2017'], 'CompletionDate': ['February 8, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1502, 'OrgStudyId': ['FPI-1966-101'], 'BriefTitle': ['A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours'], 'StudyType': ['Interventional'], 'StartDate': ['April 20, 2022'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1503, 'OrgStudyId': ['SM08502-ONC-01'], 'BriefTitle': ['A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 6, 2017'], 'CompletionDate': ['December 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1504, 'OrgStudyId': ['NCI-2015-00054'], 'BriefTitle': ['Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)'], 'StudyType': ['Interventional'], 'StartDate': ['August 12, 2015'], 'CompletionDate': ['December 31, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1505, 'OrgStudyId': ['TESTW007'], 'BriefTitle': ['Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women'], 'StudyType': ['Interventional'], 'StartDate': ['January 2008'], 'CompletionDate': ['December 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['50 Years'], 'MaximumAge': []}, {'Rank': 1506, 'OrgStudyId': ['CALGB-70501'], 'BriefTitle': ['Collection of Patient-Reported Symptoms and Performance Status Via the Internet'], 'StudyType': ['Interventional'], 'StartDate': ['December 2006'], 'CompletionDate': ['June 1, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1507, 'OrgStudyId': ['BM010'], 'BriefTitle': ['ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain'], 'StudyType': ['Interventional'], 'StartDate': ['September 2009'], 'CompletionDate': ['November 14, 2016'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1508, 'OrgStudyId': ['EAQ202'], 'BriefTitle': ['Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials'], 'StudyType': ['Interventional'], 'StartDate': ['October 28, 2021'], 'CompletionDate': ['January 25, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['39 Years']}, {'Rank': 1509, 'OrgStudyId': ['TJ004309STM103'], 'BriefTitle': ['A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 2, 2021'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1510, 'OrgStudyId': ['1603.00'], 'BriefTitle': ['Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation'], 'StudyType': ['Interventional'], 'StartDate': ['April 2002'], 'CompletionDate': ['October 2004'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['12 Years'], 'MaximumAge': []}, {'Rank': 1511, 'OrgStudyId': ['7465-CL-202'], 'BriefTitle': ['A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)'], 'StudyType': ['Interventional'], 'StartDate': ['March 9, 2020'], 'CompletionDate': ['July 31, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1512, 'OrgStudyId': ['17477'], 'BriefTitle': ['A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2, 2017'], 'CompletionDate': ['September 1, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['12 Years'], 'MaximumAge': []}, {'Rank': 1513, 'OrgStudyId': ['S1415CD'], 'BriefTitle': ['S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)'], 'StudyType': ['Interventional'], 'StartDate': ['October 7, 2016'], 'CompletionDate': ['August 12, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1514, 'OrgStudyId': ['FT-003'], 'BriefTitle': ['Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy'], 'StudyType': ['Observational'], 'StartDate': ['June 11, 2019'], 'CompletionDate': ['December 2037'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1515, 'OrgStudyId': ['101'], 'BriefTitle': ['CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 2, 2021'], 'CompletionDate': ['December 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1516, 'OrgStudyId': ['PACT-0101'], 'BriefTitle': ['A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 3, 2019'], 'CompletionDate': ['August 12, 2022'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1517, 'OrgStudyId': ['15441'], 'BriefTitle': ['A Study of LY3022855 In Participants With Breast or Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['May 2015'], 'CompletionDate': ['October 4, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1518, 'OrgStudyId': ['C3881001'], 'BriefTitle': ['PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['October 4, 2018'], 'CompletionDate': ['March 30, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1519, 'OrgStudyId': ['CPG-01-001'], 'BriefTitle': ['COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.'], 'StudyType': ['Interventional'], 'StartDate': ['September 6, 2018'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1520, 'OrgStudyId': ['INCB 106385-102'], 'BriefTitle': ['INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 3, 2021'], 'CompletionDate': ['December 29, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1521, 'OrgStudyId': ['111767'], 'BriefTitle': ['Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents'], 'StudyType': ['Interventional'], 'StartDate': ['October 2008'], 'CompletionDate': ['August 19, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1522, 'OrgStudyId': ['KY1044-CT01'], 'BriefTitle': ['Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 28, 2019'], 'CompletionDate': ['November 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1523, 'OrgStudyId': ['PRP-001'], 'BriefTitle': ['Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 3, 2011'], 'CompletionDate': ['January 30, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1524, 'OrgStudyId': ['CNIR178X2201'], 'BriefTitle': ['A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma'], 'StudyType': ['Interventional'], 'StartDate': ['August 28, 2017'], 'CompletionDate': ['February 14, 2023'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1525, 'OrgStudyId': ['CPO-100-US-101'], 'BriefTitle': ['Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 24, 2021'], 'CompletionDate': ['March 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1526, 'OrgStudyId': ['213360'], 'BriefTitle': ['A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens'], 'StudyType': ['Interventional'], 'StartDate': ['March 23, 2015'], 'CompletionDate': ['August 23, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1527, 'OrgStudyId': ['D3610C00001'], 'BriefTitle': ['Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules'], 'StudyType': ['Interventional'], 'StartDate': ['December 1, 2010'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['130 Years']}, {'Rank': 1528, 'OrgStudyId': ['ST101-101'], 'BriefTitle': ['A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2020'], 'CompletionDate': ['January 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1529, 'OrgStudyId': ['ATLAS-101'], 'BriefTitle': ['A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['August 12, 2020'], 'CompletionDate': ['January 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1530, 'OrgStudyId': ['200-04'], 'BriefTitle': ['A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.'], 'StudyType': ['Observational'], 'StartDate': ['February 26, 2021'], 'CompletionDate': ['December 23, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1531, 'OrgStudyId': ['16704'], 'BriefTitle': ['Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)'], 'StudyType': ['Interventional'], 'StartDate': ['December 12, 2016'], 'CompletionDate': ['March 31, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1532, 'OrgStudyId': ['P-MUC1C-ALLO1-001'], 'BriefTitle': ['P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 15, 2022'], 'CompletionDate': ['April 2039'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1533, 'OrgStudyId': ['ONCR-177-101'], 'BriefTitle': ['Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 20, 2020'], 'CompletionDate': ['July 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1534, 'OrgStudyId': ['CDR0000415581'], 'BriefTitle': ['RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['December 2004'], 'CompletionDate': ['May 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1535, 'OrgStudyId': ['CORT125134-550'], 'BriefTitle': ['Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 23, 2016'], 'CompletionDate': ['September 12, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1536, 'OrgStudyId': ['7339-002'], 'BriefTitle': ['Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)'], 'StudyType': ['Interventional'], 'StartDate': ['December 12, 2018'], 'CompletionDate': ['December 1, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1537, 'OrgStudyId': ['NCI-2011-02500'], 'BriefTitle': ['Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction'], 'StudyType': ['Interventional'], 'StartDate': ['June 20, 2011'], 'CompletionDate': [], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1538, 'OrgStudyId': ['JZP712-201'], 'BriefTitle': ['Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 3, 2022'], 'CompletionDate': ['June 23, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1539, 'OrgStudyId': ['17493'], 'BriefTitle': ['A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 13, 2019'], 'CompletionDate': ['March 26, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['6 Months'], 'MaximumAge': ['21 Years']}, {'Rank': 1540, 'OrgStudyId': ['XmAb23104-01'], 'BriefTitle': ['A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)'], 'StudyType': ['Interventional'], 'StartDate': ['May 1, 2019'], 'CompletionDate': ['September 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1541, 'OrgStudyId': ['CTMX-M-2009-001'], 'BriefTitle': ['PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2017'], 'CompletionDate': ['September 10, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1542, 'OrgStudyId': ['1697.00'], 'BriefTitle': ['Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)'], 'StudyType': ['Interventional'], 'StartDate': ['May 2004'], 'CompletionDate': ['September 2008'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['4 Years'], 'MaximumAge': []}, {'Rank': 1543, 'OrgStudyId': ['ADCT-301-103'], 'BriefTitle': ['Study of ADCT-301 in Patients With Selected Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 9, 2018'], 'CompletionDate': ['December 8, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1544, 'OrgStudyId': ['TPST-1120-001'], 'BriefTitle': ['TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['March 20, 2019'], 'CompletionDate': ['June 23, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1545, 'OrgStudyId': ['17-262-01'], 'BriefTitle': ['REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['March 15, 2018'], 'CompletionDate': ['May 9, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1546, 'OrgStudyId': ['NCI-2020-05428'], 'BriefTitle': ['Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 1, 2021'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1547, 'OrgStudyId': ['C3651010'], 'BriefTitle': ['Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia'], 'StudyType': ['Interventional'], 'StartDate': ['May 11, 2021'], 'CompletionDate': ['August 9, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1548, 'OrgStudyId': ['IT-01'], 'BriefTitle': ['A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6'], 'StudyType': ['Interventional'], 'StartDate': ['February 9, 2017'], 'CompletionDate': ['February 22, 2023'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1549, 'OrgStudyId': ['17494'], 'BriefTitle': ['Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation'], 'StudyType': ['Expanded Access'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Available'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1550, 'OrgStudyId': ['C3441037'], 'BriefTitle': ['A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2020'], 'CompletionDate': ['July 22, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1551, 'OrgStudyId': ['EMR100018-001'], 'BriefTitle': ['First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['December 13, 2013'], 'CompletionDate': ['August 9, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1552, 'OrgStudyId': ['PY159-2-01'], 'BriefTitle': ['A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 10, 2020'], 'CompletionDate': ['April 7, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1553, 'OrgStudyId': ['ELVCAP-001-01'], 'BriefTitle': ['Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 29, 2020'], 'CompletionDate': ['June 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1554, 'OrgStudyId': ['PV-10-LC-01'], 'BriefTitle': ['A Study to Assess PV-10 Chemoablation of Cancer of the Liver'], 'StudyType': ['Interventional'], 'StartDate': ['October 2009'], 'CompletionDate': ['February 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1555, 'OrgStudyId': ['CP-MGD009-01'], 'BriefTitle': ['Safety Study of MGD009 in B7-H3-expressing Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 2015'], 'CompletionDate': ['November 25, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1556, 'OrgStudyId': ['707-IO-101'], 'BriefTitle': ['Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['June 9, 2021'], 'CompletionDate': ['July 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1557, 'OrgStudyId': ['MDNA11-01'], 'BriefTitle': ['A Beta-only IL-2 ImmunoTherapY (ABILITY) Study'], 'StudyType': ['Interventional'], 'StartDate': ['August 27, 2021'], 'CompletionDate': ['December 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1558, 'OrgStudyId': ['GB1275-1101 (KEYNOTE-A36)'], 'BriefTitle': ['GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['August 13, 2019'], 'CompletionDate': ['April 11, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1559, 'OrgStudyId': ['INCB 57643-101'], 'BriefTitle': ['Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['May 18, 2016'], 'CompletionDate': ['February 13, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1560, 'OrgStudyId': ['7684A-005'], 'BriefTitle': ['MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)'], 'StudyType': ['Interventional'], 'StartDate': ['September 16, 2021'], 'CompletionDate': ['February 22, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1561, 'OrgStudyId': ['RTOG-1008'], 'BriefTitle': ['Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['October 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1562, 'OrgStudyId': ['RTOG-0924'], 'BriefTitle': ['Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['July 2011'], 'CompletionDate': ['July 2031'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1563, 'OrgStudyId': ['M14-546'], 'BriefTitle': ['A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2015'], 'CompletionDate': ['July 5, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1564, 'OrgStudyId': ['15834'], 'BriefTitle': ['Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 26, 2017'], 'CompletionDate': ['July 26, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1565, 'OrgStudyId': ['TAK-500-1001'], 'BriefTitle': ['A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['April 26, 2022'], 'CompletionDate': ['March 20, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1566, 'OrgStudyId': ['ARC-5 (AB928CSP0005)'], 'BriefTitle': ['A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['July 24, 2018'], 'CompletionDate': ['September 3, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1567, 'OrgStudyId': ['BO41929'], 'BriefTitle': ['A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['May 24, 2021'], 'CompletionDate': ['May 16, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1568, 'OrgStudyId': ['39110-107'], 'BriefTitle': ['Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 25, 2016'], 'CompletionDate': ['November 20, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1569, 'OrgStudyId': ['17159'], 'BriefTitle': ['A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 15, 2013'], 'CompletionDate': ['November 17, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1570, 'OrgStudyId': ['BIND-014-001'], 'BriefTitle': ['A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['January 2011'], 'CompletionDate': ['February 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1571, 'OrgStudyId': ['PAL-E602-001'], 'BriefTitle': ['Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)'], 'StudyType': ['Interventional'], 'StartDate': ['February 11, 2022'], 'CompletionDate': ['June 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1572, 'OrgStudyId': ['D6015C00001'], 'BriefTitle': ['Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours'], 'StudyType': ['Interventional'], 'StartDate': ['July 1, 2015'], 'CompletionDate': ['August 22, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1573, 'OrgStudyId': ['CC-223-ST-001'], 'BriefTitle': ['Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma'], 'StudyType': ['Interventional'], 'StartDate': ['July 20, 2010'], 'CompletionDate': ['December 9, 2016'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1574, 'OrgStudyId': ['9161'], 'BriefTitle': ['Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 3, 2015'], 'CompletionDate': ['December 31, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['39 Years']}, {'Rank': 1575, 'OrgStudyId': ['XL184-203'], 'BriefTitle': ['Study of Cabozantinib (XL184) in Adults With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['August 2009'], 'CompletionDate': ['June 2014'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1576, 'OrgStudyId': ['VICCGI1523'], 'BriefTitle': ['Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study'], 'StudyType': ['Observational'], 'StartDate': ['July 2015'], 'CompletionDate': ['August 31, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1577, 'OrgStudyId': ['NRG-GU006'], 'BriefTitle': ['BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER'], 'StudyType': ['Interventional'], 'StartDate': ['April 27, 2018'], 'CompletionDate': ['October 31, 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1578, 'OrgStudyId': ['NRG-LU002'], 'BriefTitle': ['Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 7, 2017'], 'CompletionDate': ['October 2031'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1579, 'OrgStudyId': ['NRG-GU009'], 'BriefTitle': ['Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial'], 'StudyType': ['Interventional'], 'StartDate': ['December 15, 2020'], 'CompletionDate': ['December 31, 2033'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1580, 'OrgStudyId': ['AFT-28'], 'BriefTitle': ['Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 2016'], 'CompletionDate': ['January 12, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1581, 'OrgStudyId': ['NRG-GU005'], 'BriefTitle': ['Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['November 16, 2017'], 'CompletionDate': ['December 2030'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1582, 'OrgStudyId': ['CLIN-17-008'], 'BriefTitle': ['Study of the Safety and Effectiveness of Motiva Implants®'], 'StudyType': ['Interventional'], 'StartDate': ['April 6, 2018'], 'CompletionDate': ['February 28, 2033'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': ['70 Years']}, {'Rank': 1583, 'OrgStudyId': ['Adela-EDMRD-001'], 'BriefTitle': ['cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease'], 'StudyType': ['Observational'], 'StartDate': ['May 3, 2022'], 'CompletionDate': ['December 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['40 Years'], 'MaximumAge': []}, {'Rank': 1584, 'OrgStudyId': ['NC318-01'], 'BriefTitle': ['A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 28, 2018'], 'CompletionDate': ['April 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1585, 'OrgStudyId': ['16804'], 'BriefTitle': ['Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel'], 'StudyType': ['Interventional'], 'StartDate': ['May 9, 2014'], 'CompletionDate': ['October 2, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1586, 'OrgStudyId': ['1430.00'], 'BriefTitle': ['Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 1998'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1587, 'OrgStudyId': ['16712'], 'BriefTitle': ['A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 10, 2018'], 'CompletionDate': ['October 3, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1588, 'OrgStudyId': ['RXDX-101-03'], 'BriefTitle': ['Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options'], 'StudyType': ['Interventional'], 'StartDate': ['May 3, 2016'], 'CompletionDate': ['June 15, 2025'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['0 Years'], 'MaximumAge': ['18 Years']}, {'Rank': 1589, 'OrgStudyId': ['IMC-F106C-101'], 'BriefTitle': ['Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors'], 'StudyType': ['Interventional'], 'StartDate': ['February 25, 2020'], 'CompletionDate': ['February 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1590, 'OrgStudyId': ['B9991004'], 'BriefTitle': ['A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)'], 'StudyType': ['Interventional'], 'StartDate': ['November 9, 2015'], 'CompletionDate': ['February 28, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1591, 'OrgStudyId': ['20289'], 'BriefTitle': ['A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2015'], 'CompletionDate': ['October 31, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1592, 'OrgStudyId': ['LOXO-IDH-20002'], 'BriefTitle': ['Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations'], 'StudyType': ['Interventional'], 'StartDate': ['October 16, 2020'], 'CompletionDate': ['May 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1593, 'OrgStudyId': ['20210104'], 'BriefTitle': ['A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression'], 'StudyType': ['Interventional'], 'StartDate': ['September 23, 2022'], 'CompletionDate': ['July 28, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1594, 'OrgStudyId': ['0701'], 'BriefTitle': ['Cardiac Safety Assessment Study of Picoplatin in Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['July 2009'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1595, 'OrgStudyId': ['FLX475-02'], 'BriefTitle': ['Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab'], 'StudyType': ['Interventional'], 'StartDate': ['September 25, 2018'], 'CompletionDate': ['December 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1596, 'OrgStudyId': ['CO-338-100'], 'BriefTitle': ['A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes'], 'StudyType': ['Interventional'], 'StartDate': ['November 21, 2019'], 'CompletionDate': ['July 15, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1597, 'OrgStudyId': ['G200502'], 'BriefTitle': ['Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['May 2007'], 'CompletionDate': ['September 2008'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1598, 'OrgStudyId': ['BM004'], 'BriefTitle': ['ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain'], 'StudyType': ['Interventional'], 'StartDate': ['March 2008'], 'CompletionDate': ['September 2012'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['100 Years']}, {'Rank': 1599, 'OrgStudyId': ['INCB 54329-101'], 'BriefTitle': ['An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2015'], 'CompletionDate': ['January 31, 2018'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1600, 'OrgStudyId': ['ZWI-ZW25-101'], 'BriefTitle': ['Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['August 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1601, 'OrgStudyId': ['BDTX-189-01'], 'BriefTitle': ['A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.'], 'StudyType': ['Interventional'], 'StartDate': ['December 19, 2019'], 'CompletionDate': ['September 16, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1602, 'OrgStudyId': ['CBYL719X2105J'], 'BriefTitle': ['A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 27, 2012'], 'CompletionDate': ['June 1, 2017'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1603, 'OrgStudyId': ['TTI-621-02'], 'BriefTitle': ['Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides'], 'StudyType': ['Interventional'], 'StartDate': ['September 2016'], 'CompletionDate': ['March 31, 2020'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1604, 'OrgStudyId': ['CLEE011XUS03'], 'BriefTitle': ['LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)'], 'StudyType': ['Interventional'], 'StartDate': ['August 25, 2014'], 'CompletionDate': ['January 17, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1605, 'OrgStudyId': ['BR005'], 'BriefTitle': ['Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging'], 'StudyType': ['Observational'], 'StartDate': ['April 18, 2017'], 'CompletionDate': ['January 1, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1606, 'OrgStudyId': ['B1271002'], 'BriefTitle': ['Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 2011'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1607, 'OrgStudyId': ['SGN2FF-001'], 'BriefTitle': ['A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 23, 2017'], 'CompletionDate': ['June 24, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1608, 'OrgStudyId': ['TP-CA-001'], 'BriefTitle': ['Tempus Priority Study: A Pan-tumor Observational Study'], 'StudyType': ['Observational'], 'StartDate': ['October 19, 2020'], 'CompletionDate': ['October 19, 2030'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1609, 'OrgStudyId': ['CB103-C-101'], 'BriefTitle': ['Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['December 5, 2017'], 'CompletionDate': ['November 11, 2022'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1610, 'OrgStudyId': ['20070315'], 'BriefTitle': ['Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium'], 'StudyType': ['Interventional'], 'StartDate': ['November 16, 2009'], 'CompletionDate': ['August 21, 2013'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1611, 'OrgStudyId': ['1801'], 'BriefTitle': ['9-ING-41 in Patients With Advanced Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['January 4, 2019'], 'CompletionDate': ['November 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1612, 'OrgStudyId': ['63646'], 'BriefTitle': ['Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 24, 2022'], 'CompletionDate': ['October 15, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['21 Years'], 'MaximumAge': []}, {'Rank': 1613, 'OrgStudyId': ['NCI-2009-00339'], 'BriefTitle': ['Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy'], 'StudyType': ['Interventional'], 'StartDate': ['June 2008'], 'CompletionDate': ['July 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['21 Years']}, {'Rank': 1614, 'OrgStudyId': ['831-IO-101'], 'BriefTitle': ['Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 31, 2022'], 'CompletionDate': ['December 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1615, 'OrgStudyId': ['DB-1303-O-1001'], 'BriefTitle': ['A Study of DB-1303 in Advanced/Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 31, 2022'], 'CompletionDate': ['October 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1616, 'OrgStudyId': ['PMV-586-101'], 'BriefTitle': ['The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)'], 'StudyType': ['Interventional'], 'StartDate': ['October 29, 2020'], 'CompletionDate': ['July 14, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['12 Years'], 'MaximumAge': []}, {'Rank': 1617, 'OrgStudyId': ['S1201'], 'BriefTitle': ['S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 2012'], 'CompletionDate': ['September 19, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1618, 'OrgStudyId': ['ACI/2015'], 'BriefTitle': ['Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)'], 'StudyType': ['Interventional'], 'StartDate': ['July 26, 2011'], 'CompletionDate': ['December 31, 2023'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['1 Year'], 'MaximumAge': ['75 Years']}, {'Rank': 1619, 'OrgStudyId': ['INCB 54828-101'], 'BriefTitle': ['Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)'], 'StudyType': ['Interventional'], 'StartDate': ['February 27, 2015'], 'CompletionDate': ['December 17, 2021'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1620, 'OrgStudyId': ['RAIN-3202'], 'BriefTitle': ['Milademetan in Advanced/Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['November 1, 2021'], 'CompletionDate': ['August 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1621, 'OrgStudyId': ['CR100845'], 'BriefTitle': ['A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma'], 'StudyType': ['Interventional'], 'StartDate': ['June 15, 2012'], 'CompletionDate': ['July 5, 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1622, 'OrgStudyId': ['GWCA0701'], 'BriefTitle': ['A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.'], 'StudyType': ['Interventional'], 'StartDate': ['November 2007'], 'CompletionDate': ['January 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1623, 'OrgStudyId': ['MS201923_0001'], 'BriefTitle': ['M6620 First in Human Study'], 'StudyType': ['Interventional'], 'StartDate': ['December 10, 2012'], 'CompletionDate': ['March 11, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1624, 'OrgStudyId': ['TDM4529g'], 'BriefTitle': ['A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies'], 'StudyType': ['Interventional'], 'StartDate': ['October 16, 2008'], 'CompletionDate': ['September 20, 2029'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1625, 'OrgStudyId': ['CV-MMAIT-3-001'], 'BriefTitle': ['Vaccine Therapy for Patients With Stage III Melanoma'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1626, 'OrgStudyId': ['CV-MMAIT-4-001'], 'BriefTitle': ['Vaccine Therapy for Patients With Stage IV Melanoma'], 'StudyType': ['Interventional'], 'StartDate': [], 'CompletionDate': [], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1627, 'OrgStudyId': ['CDR0000067196'], 'BriefTitle': ['Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia'], 'StudyType': ['Interventional'], 'StartDate': ['July 1998'], 'CompletionDate': ['August 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1628, 'OrgStudyId': ['CDR0000069467'], 'BriefTitle': ['Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2002'], 'CompletionDate': ['June 15, 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1629, 'OrgStudyId': ['1992110-1'], 'BriefTitle': ['Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education'], 'StudyType': ['Observational'], 'StartDate': ['March 7, 2023'], 'CompletionDate': ['March 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['80 Years']}, {'Rank': 1630, 'OrgStudyId': ['18594'], 'BriefTitle': ['First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas'], 'StudyType': ['Interventional'], 'StartDate': ['July 6, 2017'], 'CompletionDate': ['April 19, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1631, 'OrgStudyId': ['ARRAY-162-311'], 'BriefTitle': [\"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer\"], 'StudyType': ['Interventional'], 'StartDate': ['June 27, 2013'], 'CompletionDate': ['August 23, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': ['Yes'], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1632, 'OrgStudyId': ['C4221015'], 'BriefTitle': ['A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['December 21, 2020'], 'CompletionDate': ['November 15, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['16 Years'], 'MaximumAge': []}, {'Rank': 1633, 'OrgStudyId': ['NO16968'], 'BriefTitle': ['A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 18, 2003'], 'CompletionDate': ['April 21, 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1634, 'OrgStudyId': ['GO42144'], 'BriefTitle': ['A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation'], 'StudyType': ['Interventional'], 'StartDate': ['July 29, 2020'], 'CompletionDate': ['November 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1635, 'OrgStudyId': ['CD-ON-MEDI4736-1108'], 'BriefTitle': ['A Phase 1/2 Study to Evaluate MEDI4736'], 'StudyType': ['Interventional'], 'StartDate': ['September 5, 2012'], 'CompletionDate': ['February 28, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1636, 'OrgStudyId': ['ML28897'], 'BriefTitle': ['My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2014'], 'CompletionDate': ['May 12, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1637, 'OrgStudyId': ['UCI 03-04'], 'BriefTitle': ['Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 2004'], 'CompletionDate': ['July 2007'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1638, 'OrgStudyId': ['9090-14'], 'BriefTitle': ['A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC'], 'StudyType': ['Interventional'], 'StartDate': ['April 2013'], 'CompletionDate': ['December 2015'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1639, 'OrgStudyId': ['ONO-4059-09'], 'BriefTitle': ['Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)'], 'StudyType': ['Interventional'], 'StartDate': ['December 29, 2021'], 'CompletionDate': ['July 1, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1640, 'OrgStudyId': ['JTX-8064-101'], 'BriefTitle': ['Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 12, 2021'], 'CompletionDate': ['January 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1641, 'OrgStudyId': ['DB-1305-O-1001'], 'BriefTitle': ['First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['July 19, 2022'], 'CompletionDate': ['June 30, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1642, 'OrgStudyId': ['BBI-20201001'], 'BriefTitle': ['A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 24, 2020'], 'CompletionDate': ['October 31, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1643, 'OrgStudyId': ['ZWI-ZW49-101'], 'BriefTitle': ['A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers'], 'StudyType': ['Interventional'], 'StartDate': ['April 15, 2019'], 'CompletionDate': ['August 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1644, 'OrgStudyId': ['HSC-SPH-15-0443'], 'BriefTitle': ['Stem Cell Injection in Cancer Survivors'], 'StudyType': ['Interventional'], 'StartDate': ['August 2016'], 'CompletionDate': ['April 20, 2020'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Principal Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['79 Years']}, {'Rank': 1645, 'OrgStudyId': ['AV-951-15-303'], 'BriefTitle': ['A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC'], 'StudyType': ['Interventional'], 'StartDate': ['April 2016'], 'CompletionDate': ['June 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1646, 'OrgStudyId': ['IDE397-001'], 'BriefTitle': ['Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion'], 'StudyType': ['Interventional'], 'StartDate': ['April 14, 2021'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1647, 'OrgStudyId': ['EORTC-08971'], 'BriefTitle': ['Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['March 1998'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1648, 'OrgStudyId': ['CDR0000271174'], 'BriefTitle': ['Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['August 2003'], 'CompletionDate': ['May 1, 2009'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}, {'Rank': 1649, 'OrgStudyId': ['213346'], 'BriefTitle': ['Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 7, 2016'], 'CompletionDate': ['October 27, 2027'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1650, 'OrgStudyId': ['NCI-2009-00258'], 'BriefTitle': ['Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 2007'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1651, 'OrgStudyId': ['Pathway Gennomics 004'], 'BriefTitle': ['Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease'], 'StudyType': ['Observational'], 'StartDate': ['November 2015'], 'CompletionDate': ['August 2017'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1652, 'OrgStudyId': ['217228'], 'BriefTitle': ['First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['March 22, 2022'], 'CompletionDate': ['December 29, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1653, 'OrgStudyId': ['UCI 04-08'], 'BriefTitle': ['Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['April 2005'], 'CompletionDate': ['October 2011'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor-Investigator'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1654, 'OrgStudyId': ['M15-891'], 'BriefTitle': ['A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 14, 2016'], 'CompletionDate': ['March 29, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1655, 'OrgStudyId': ['ARRAY-818-202'], 'BriefTitle': ['An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['June 4, 2019'], 'CompletionDate': ['June 30, 2024'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1656, 'OrgStudyId': ['YO39609'], 'BriefTitle': ['A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)'], 'StudyType': ['Interventional'], 'StartDate': ['October 13, 2017'], 'CompletionDate': ['February 8, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1657, 'OrgStudyId': ['3P-03-2'], 'BriefTitle': ['Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.'], 'StudyType': ['Interventional'], 'StartDate': ['February 2005'], 'CompletionDate': ['July 2006'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1658, 'OrgStudyId': ['INCAGN 1949-201'], 'BriefTitle': ['A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['October 9, 2017'], 'CompletionDate': ['September 17, 2019'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1659, 'OrgStudyId': ['5GYN-02-2'], 'BriefTitle': ['Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma'], 'StudyType': ['Interventional'], 'StartDate': ['November 2002'], 'CompletionDate': ['May 2010'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1660, 'OrgStudyId': ['213351'], 'BriefTitle': ['Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042'], 'StudyType': ['Interventional'], 'StartDate': ['October 12, 2017'], 'CompletionDate': ['April 20, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1661, 'OrgStudyId': ['INCAGN 1876-201'], 'BriefTitle': ['Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies'], 'StudyType': ['Interventional'], 'StartDate': ['April 25, 2017'], 'CompletionDate': ['November 9, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1662, 'OrgStudyId': ['GOG-0215'], 'BriefTitle': ['Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries'], 'StudyType': ['Interventional'], 'StartDate': ['November 28, 2005'], 'CompletionDate': [], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': []}, {'Rank': 1663, 'OrgStudyId': ['4830-001'], 'BriefTitle': ['Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)'], 'StudyType': ['Interventional'], 'StartDate': ['July 11, 2018'], 'CompletionDate': ['November 4, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1664, 'OrgStudyId': ['D081SC00001'], 'BriefTitle': ['Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['October 31, 2018'], 'CompletionDate': ['October 30, 2022'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Male'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1665, 'OrgStudyId': ['1363'], 'BriefTitle': ['Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis'], 'StudyType': ['Interventional'], 'StartDate': ['November 1994'], 'CompletionDate': ['September 1999'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': [], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': [], 'MaximumAge': ['80 Years']}, {'Rank': 1666, 'OrgStudyId': ['CAMH2_1001'], 'BriefTitle': ['A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 14, 2021'], 'CompletionDate': ['January 17, 2025'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1667, 'OrgStudyId': ['17-568'], 'BriefTitle': ['BRCA Founder OutReach (BFOR) Study'], 'StudyType': ['Observational'], 'StartDate': ['November 10, 2017'], 'CompletionDate': ['May 10, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 1668, 'OrgStudyId': ['AG0315OG/CTC0140'], 'BriefTitle': ['RegoNivo vs Standard of Care Chemotherapy in AGOC'], 'StudyType': ['Interventional'], 'StartDate': ['June 1, 2021'], 'CompletionDate': ['June 1, 2026'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1669, 'OrgStudyId': ['PBTC-042'], 'BriefTitle': ['Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['December 8, 2014'], 'CompletionDate': ['February 25, 2019'], 'OverallStatus': ['Terminated'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['4 Years'], 'MaximumAge': ['21 Years']}, {'Rank': 1670, 'OrgStudyId': ['2018-01B'], 'BriefTitle': ['Stool Collection Sub-Study of Exact Sciences Protocol 2018-01'], 'StudyType': ['Observational'], 'StartDate': ['July 21, 2020'], 'CompletionDate': ['May 25, 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1671, 'OrgStudyId': ['19741'], 'BriefTitle': ['Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2019'], 'CompletionDate': ['April 11, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1672, 'OrgStudyId': ['BO21223'], 'BriefTitle': [\"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)\"], 'StudyType': ['Interventional'], 'StartDate': ['July 6, 2011'], 'CompletionDate': ['July 30, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1673, 'OrgStudyId': ['BO29337'], 'BriefTitle': [\"A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)\"], 'StudyType': ['Interventional'], 'StartDate': ['December 1, 2014'], 'CompletionDate': ['March 16, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1674, 'OrgStudyId': ['NRG-HN010'], 'BriefTitle': ['Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['September 30, 2022'], 'CompletionDate': ['July 31, 2028'], 'OverallStatus': ['Recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1675, 'OrgStudyId': ['MS-700'], 'BriefTitle': ['MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ'], 'StudyType': ['Interventional'], 'StartDate': ['August 2003'], 'CompletionDate': ['April 2011'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['45 Years'], 'MaximumAge': []}, {'Rank': 1676, 'OrgStudyId': ['D5760C00001'], 'BriefTitle': ['A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.'], 'StudyType': ['Interventional'], 'StartDate': ['September 23, 2015'], 'CompletionDate': ['May 23, 2018'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['99 Years']}, {'Rank': 1677, 'OrgStudyId': ['20172841'], 'BriefTitle': ['The PREDICT Registry for DCIS Patients With DCISionRT Testing'], 'StudyType': ['Observational'], 'StartDate': ['February 27, 2018'], 'CompletionDate': ['November 2035'], 'OverallStatus': ['Suspended'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['Female'], 'GenderBased': [], 'MinimumAge': ['25 Years'], 'MaximumAge': []}, {'Rank': 1678, 'OrgStudyId': ['NCI-2009-00534'], 'BriefTitle': ['Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['April 24, 2006'], 'CompletionDate': ['September 1, 2021'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1679, 'OrgStudyId': ['NCI-2016-01041'], 'BriefTitle': ['Nivolumab and Ipilimumab in Treating Patients With Rare Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['January 13, 2017'], 'CompletionDate': ['October 31, 2023'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1680, 'OrgStudyId': ['NCI-2012-00723'], 'BriefTitle': ['Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery'], 'StudyType': ['Interventional'], 'StartDate': ['August 8, 2012'], 'CompletionDate': ['July 19, 2027'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1681, 'OrgStudyId': ['S1614'], 'BriefTitle': ['Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors'], 'StudyType': ['Interventional'], 'StartDate': ['February 21, 2019'], 'CompletionDate': ['February 28, 2027'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1682, 'OrgStudyId': ['NSABP MPR-1'], 'BriefTitle': ['NSABP Patient Registry and Biospecimen Profiling Repository'], 'StudyType': ['Observational'], 'StartDate': ['February 2013'], 'CompletionDate': ['March 2022'], 'OverallStatus': ['Completed'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1683, 'OrgStudyId': ['NCI-2012-00107'], 'BriefTitle': ['Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer'], 'StudyType': ['Interventional'], 'StartDate': ['February 22, 2012'], 'CompletionDate': ['August 1, 2021'], 'OverallStatus': ['Unknown status'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1684, 'OrgStudyId': ['302'], 'BriefTitle': ['177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)'], 'StudyType': ['Interventional'], 'StartDate': ['August 31, 2022'], 'CompletionDate': ['December 31, 2024'], 'OverallStatus': ['Withdrawn'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': []}, {'Rank': 1685, 'OrgStudyId': ['D967MC00001'], 'BriefTitle': ['A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations'], 'StudyType': ['Interventional'], 'StartDate': ['December 30, 2020'], 'CompletionDate': ['January 17, 2028'], 'OverallStatus': ['Active, not recruiting'], 'ResponsiblePartyType': ['Sponsor'], 'Gender': ['All'], 'GenderBased': [], 'MinimumAge': ['18 Years'], 'MaximumAge': ['120 Years']}]\n"
     ]
    }
   ],
   "source": [
    "print(sourced_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "8616d51d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[['CCT1043'],\n",
       "  ['Breast Cancer Trials Education Program'],\n",
       "  ['Interventional'],\n",
       "  ['May 2007'],\n",
       "  ['December 2015'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['150B-0158'],\n",
       "  ['Breast Cancer Risk Reduction: A Patient Doctor Intervention'],\n",
       "  ['Interventional'],\n",
       "  ['June 2011'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['74 Years']],\n",
       " [['CHUM-CRYOABLATION'],\n",
       "  ['Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers'],\n",
       "  ['Interventional'],\n",
       "  ['April 2013'],\n",
       "  ['October 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20107812'],\n",
       "  ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging'],\n",
       "  ['Observational'],\n",
       "  ['December 2010'],\n",
       "  ['October 2013'],\n",
       "  ['Withdrawn'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['234870'],\n",
       "  ['Blood Glycan Biomarkers in Women With Stage IV Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['September 2006'],\n",
       "  ['January 12, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['FWA00010885'],\n",
       "  ['Breast Cancer Survivorship & Work-Related Cognitive Limitation'],\n",
       "  ['Observational'],\n",
       "  ['September 2014'],\n",
       "  ['February 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['69 Years']],\n",
       " [['CC077515'],\n",
       "  ['Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2011'],\n",
       "  ['March 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20022306'],\n",
       "  ['Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy'],\n",
       "  ['Interventional'],\n",
       "  ['June 2002'],\n",
       "  ['January 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['75 Years']],\n",
       " [['STUDY00001641'],\n",
       "  ['Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women'],\n",
       "  ['Interventional'],\n",
       "  ['July 16, 2022'],\n",
       "  ['December 1, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['45 Years'],\n",
       "  ['80 Years']],\n",
       " [['00080'],\n",
       "  ['Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease'],\n",
       "  ['Observational'],\n",
       "  ['July 2001'],\n",
       "  ['September 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['IRB-14623 part 1'],\n",
       "  ['Intellectual Impairment in Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 12, 2009'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['65 Years']],\n",
       " [['IIT2015-11-Giuliano-SNBO'],\n",
       "  ['Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['December 2015'],\n",
       "  ['April 2020'],\n",
       "  ['Withdrawn'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['13278'],\n",
       "  ['Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)'],\n",
       "  ['Observational'],\n",
       "  ['September 30, 2013'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['200715040'],\n",
       "  ['Molecular Imaging of Breast Cancer With Breast PET/CT'],\n",
       "  ['Interventional'],\n",
       "  ['April 2007'],\n",
       "  ['July 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SU-10042011-8529'],\n",
       "  ['National Breast Cancer and Lymphedema Registry'],\n",
       "  ['Observational'],\n",
       "  ['September 12, 2011'],\n",
       "  ['March 2, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-10748'],\n",
       "  ['Magnetic Resonance Imaging of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1, 1995'],\n",
       "  ['May 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['IRB-12226'],\n",
       "  ['Development of Vitamin D as a Therapy for Breast Cancer - Phase 2'],\n",
       "  ['Interventional'],\n",
       "  ['April 2008'],\n",
       "  ['December 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['5110026'],\n",
       "  ['Partial Breast Proton Therapy for Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 4, 2011'],\n",
       "  ['May 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['80 Years']],\n",
       " [['08063'],\n",
       "  ['Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2, 2008'],\n",
       "  ['June 26, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['182-20-CA'],\n",
       "  ['18F-fluoroestradiol (FES) PET/CT for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 15, 2021'],\n",
       "  ['December 15, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['01-BR-003'],\n",
       "  ['Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['July 2, 2020'],\n",
       "  ['March 17, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['037519'],\n",
       "  ['Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 3, 2004'],\n",
       "  ['December 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08103'],\n",
       "  ['Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2008'],\n",
       "  ['April 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['19-001004'],\n",
       "  ['Brain Health in Breast Cancer Survivors'],\n",
       "  ['Observational'],\n",
       "  ['March 11, 2020'],\n",
       "  ['March 15, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['35 Years'],\n",
       "  ['65 Years']],\n",
       " [['14-001744'],\n",
       "  ['Project Connect Online: An Internet-based Intervention for Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 4, 2015'],\n",
       "  ['June 17, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000257580'],\n",
       "  ['Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2002'],\n",
       "  ['April 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['99002'],\n",
       "  ['Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 18, 1999'],\n",
       "  ['June 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['59 Years']],\n",
       " [['12175'],\n",
       "  ['Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2012'],\n",
       "  ['July 2013'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['UCLA-9810046'],\n",
       "  ['Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 1999'],\n",
       "  ['October 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['1B-15-3'],\n",
       "  ['Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy'],\n",
       "  ['Observational'],\n",
       "  ['August 10, 2015'],\n",
       "  ['November 26, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSNSTU0009'],\n",
       "  ['Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2'],\n",
       "  ['Observational'],\n",
       "  ['July 2005'],\n",
       "  ['April 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCSF-077518'],\n",
       "  ['Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2'],\n",
       "  ['Interventional'],\n",
       "  ['August 2007'],\n",
       "  ['December 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['07006'],\n",
       "  ['Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy'],\n",
       "  ['Observational'],\n",
       "  ['October 2007'],\n",
       "  ['January 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['10038'],\n",
       "  ['Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)'],\n",
       "  ['Interventional'],\n",
       "  ['January 15, 2020'],\n",
       "  ['January 15, 2035'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2015-06-Chung-SNBO'],\n",
       "  ['Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65'],\n",
       "  ['Interventional'],\n",
       "  ['January 22, 2016'],\n",
       "  ['June 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['SPI-POZ-101'],\n",
       "  ['A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 13, 2018'],\n",
       "  ['April 17, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['07213'],\n",
       "  ['White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['June 2008'],\n",
       "  ['December 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['09147'],\n",
       "  ['MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['November 2009'],\n",
       "  ['May 20, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-34959'],\n",
       "  ['Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['August 2016'],\n",
       "  ['July 8, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000430701'],\n",
       "  ['Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2005'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['11-003446'],\n",
       "  ['Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['April 2012'],\n",
       "  ['September 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['65 Years']],\n",
       " [['03178'],\n",
       "  ['IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2005'],\n",
       "  ['October 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['75 Years']],\n",
       " [['SC0001'],\n",
       "  ['Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons'],\n",
       "  ['Interventional'],\n",
       "  ['January 2003'],\n",
       "  ['January 2010'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  ['90 Years']],\n",
       " [['BRSADJ0003'],\n",
       "  ['Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2005'],\n",
       "  ['August 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['USI2011001'],\n",
       "  ['CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study'],\n",
       "  ['Observational'],\n",
       "  ['July 2011'],\n",
       "  ['September 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['IRB-48150'],\n",
       "  ['68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 19, 2019'],\n",
       "  ['June 18, 2024'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000442877'],\n",
       "  ['Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2005'],\n",
       "  ['November 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2017-07-HO-PembroRT'],\n",
       "  ['Breast Cancer Study of Preoperative Pembrolizumab + Radiation'],\n",
       "  ['Interventional'],\n",
       "  ['December 22, 2017'],\n",
       "  ['April 21, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A5481155'],\n",
       "  ['Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy'],\n",
       "  ['Observational'],\n",
       "  ['June 30, 2020'],\n",
       "  ['December 31, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2015-18-Mita-MK3475'],\n",
       "  ['Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 10, 2017'],\n",
       "  ['November 8, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000067909'],\n",
       "  ['Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 1999'],\n",
       "  ['April 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['BMS-CA163-031'],\n",
       "  ['BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2002'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['CDR0000599060'],\n",
       "  ['Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2008'],\n",
       "  [],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000515534'],\n",
       "  ['ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 05-38'],\n",
       "  ['Neoadjuvant Treatment of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2005'],\n",
       "  ['September 4, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-12-6'],\n",
       "  ['Light-Scattering Spectroscopy for Detection of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 21, 2012'],\n",
       "  ['November 19, 2020'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['037517'],\n",
       "  ['Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2004'],\n",
       "  ['January 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  ['120 Years']],\n",
       " [['IRB-13807'],\n",
       "  ['Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2002'],\n",
       "  ['March 2029'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['IRB-31913'],\n",
       "  ['Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2015'],\n",
       "  ['December 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['01-06-020'],\n",
       "  ['Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression'],\n",
       "  ['Interventional'],\n",
       "  ['August 2001'],\n",
       "  ['December 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['05015'],\n",
       "  ['Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 27, 2005'],\n",
       "  ['June 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['07170'],\n",
       "  ['Study of Support Groups for African-American Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['January 2008'],\n",
       "  ['September 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['09101'],\n",
       "  ['Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 16, 2011'],\n",
       "  ['December 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-13-2'],\n",
       "  ['Core Biopsies for Establishing a Breast Tumor Tissue Repository'],\n",
       "  ['Observational'],\n",
       "  ['November 14, 2013'],\n",
       "  ['November 14, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCD-986545'],\n",
       "  ['Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1996'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['55 Years']],\n",
       " [['IRB-57723'],\n",
       "  ['Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 3, 2021'],\n",
       "  ['February 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BNIT-BR-002'],\n",
       "  ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2007'],\n",
       "  ['September 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['960-CSP-USA_MIRA_USS2'],\n",
       "  ['Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2016'],\n",
       "  ['October 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  ['70 Years']],\n",
       " [['STUDY2019000317'],\n",
       "  ['Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 3, 2018'],\n",
       "  ['October 3, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000271533'],\n",
       "  ['CP-724,714 in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2003'],\n",
       "  ['May 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['12-028 MWA - Breast Tumors'],\n",
       "  ['Microwave Ablation of Breast Tumors'],\n",
       "  ['Observational'],\n",
       "  ['September 2012'],\n",
       "  ['December 2012'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['IRB-21034'],\n",
       "  ['Vitamin D and Breast Cancer: Does Weight Make a Difference?'],\n",
       "  ['Interventional'],\n",
       "  ['November 2011'],\n",
       "  ['October 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-21030'],\n",
       "  ['Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2012'],\n",
       "  ['March 17, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['F31AT003021'],\n",
       "  ['Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['October 2005'],\n",
       "  ['September 2009'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['057519'],\n",
       "  ['Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 1, 2006'],\n",
       "  ['December 1, 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['1R01CA140481'],\n",
       "  ['Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2012'],\n",
       "  ['July 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['B27IB3856'],\n",
       "  ['UCLA Breast Cancer Survivor Health Promotion Research Study'],\n",
       "  ['Interventional'],\n",
       "  ['April 1, 2022'],\n",
       "  ['June 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['50 Years'],\n",
       "  ['75 Years']],\n",
       " [['U01AT003682'],\n",
       "  ['A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue'],\n",
       "  ['Interventional'],\n",
       "  ['June 2008'],\n",
       "  ['December 2010'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['65 Years']],\n",
       " [['53294'],\n",
       "  ['Proton Therapy for Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2004'],\n",
       "  ['May 12, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['96139'],\n",
       "  ['Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 30, 1997'],\n",
       "  ['December 30, 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['60 Years']],\n",
       " [['08242'],\n",
       "  ['Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life'],\n",
       "  ['Observational'],\n",
       "  ['June 11, 2009'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08128'],\n",
       "  ['Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['September 4, 2008'],\n",
       "  ['June 20, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GENBASIX-00127'],\n",
       "  ['Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters'],\n",
       "  ['Observational'],\n",
       "  ['January 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CC# 087515'],\n",
       "  ['Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 10, 2008'],\n",
       "  ['July 29, 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['06102'],\n",
       "  ['Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  ['June 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['587842'],\n",
       "  ['Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['April 2014'],\n",
       "  ['April 7, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['UCI 03-70'],\n",
       "  ['Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  ['July 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000505536'],\n",
       "  ['Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ'],\n",
       "  ['Interventional'],\n",
       "  ['October 2001'],\n",
       "  ['May 2007'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-03-1'],\n",
       "  ['Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2003'],\n",
       "  ['December 2006'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IORT'],\n",
       "  ['Intraoperative Radiotherapy for Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['December 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['48 Years'],\n",
       "  []],\n",
       " [['10-001799'],\n",
       "  ['A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['April 2011'],\n",
       "  ['November 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['50 Years']],\n",
       " [['UCI-HS-2000-1141'],\n",
       "  ['Angiogenesis in Early Breast Cancer for Prognosis Prediction'],\n",
       "  ['Interventional'],\n",
       "  ['November 2000'],\n",
       "  ['July 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['160178'],\n",
       "  ['Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 15, 2018'],\n",
       "  ['January 13, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSMTS0002'],\n",
       "  ['Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study'],\n",
       "  ['Observational'],\n",
       "  ['November 2000'],\n",
       "  ['August 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['IRB-03518'],\n",
       "  ['Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  ['March 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['08092'],\n",
       "  ['Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2008'],\n",
       "  ['May 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['25IB-0023'],\n",
       "  ['Exercise Study for Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['November 25, 2019'],\n",
       "  ['December 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  [],\n",
       "  []],\n",
       " [['IRB# 06-05-104'],\n",
       "  ['Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2007'],\n",
       "  ['October 2007'],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBCRP 11IB-0034'],\n",
       "  ['Effect of Increased Light Exposure on Fatigue in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2005'],\n",
       "  ['November 2009'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000465214'],\n",
       "  ['Radiation Therapy in Treating Women With Invasive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  ['May 2004'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-13429'],\n",
       "  ['Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['October 2000'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['SU-11052007-799'],\n",
       "  ['Molecular Analysis of Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['May 1996'],\n",
       "  ['May 2050'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000316264'],\n",
       "  ['Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['May 2003'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GSM'],\n",
       "  ['GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['November 18, 2016'],\n",
       "  ['July 23, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  [],\n",
       "  []],\n",
       " [['UCSD-020815'],\n",
       "  ['Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2003'],\n",
       "  ['March 2008'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['60 Years']],\n",
       " [['BNIT-BR-003'],\n",
       "  ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['September 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2018-17-McArthur-TCDRT'],\n",
       "  ['Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2022'],\n",
       "  ['July 2027'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-05-5'],\n",
       "  ['Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI'],\n",
       "  ['Interventional'],\n",
       "  ['November 20, 2005'],\n",
       "  ['November 20, 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['07102022_SR'],\n",
       "  ['Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 1, 2022'],\n",
       "  ['June 1, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['07100'],\n",
       "  ['Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['July 6, 2010'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['12383'],\n",
       "  ['Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['July 15, 2013'],\n",
       "  ['June 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['KCT 005'],\n",
       "  ['A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2021'],\n",
       "  ['December 31, 2021'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['05751'],\n",
       "  ['Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['February 2005'],\n",
       "  ['January 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['11115'],\n",
       "  ['Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2012'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-08-7'],\n",
       "  ['Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2009'],\n",
       "  ['February 2011'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['07157'],\n",
       "  ['Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 11, 2008'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['UCSD#100231'],\n",
       "  ['Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['October 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI-HS-2006-5162'],\n",
       "  ['Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis'],\n",
       "  ['Interventional'],\n",
       "  ['October 1, 2006'],\n",
       "  ['October 30, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['90 Years']],\n",
       " [['AVF3359s'],\n",
       "  ['Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study'],\n",
       "  ['Interventional'],\n",
       "  ['June 2006'],\n",
       "  ['October 2008'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-07696'],\n",
       "  ['Healing Touch During Chemotherapy Infusions for Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2007'],\n",
       "  ['August 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['09-09-058'],\n",
       "  ['Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients'],\n",
       "  ['Observational'],\n",
       "  ['May 2010'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-08051'],\n",
       "  ['Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2008'],\n",
       "  ['December 2009'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSADJ0013'],\n",
       "  ['Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival'],\n",
       "  ['Observational'],\n",
       "  ['September 2006'],\n",
       "  ['August 31, 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  ['75 Years']],\n",
       " [['IRB-13732'],\n",
       "  ['Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention'],\n",
       "  ['Interventional'],\n",
       "  ['November 2005'],\n",
       "  ['December 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['05042'],\n",
       "  ['Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2005'],\n",
       "  ['October 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  ['65 Years']],\n",
       " [['08166'],\n",
       "  ['Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 17, 2010'],\n",
       "  ['September 27, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SPI-GCF-301-PK'],\n",
       "  ['Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['May 11, 2017'],\n",
       "  ['May 18, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSNSTU0002'],\n",
       "  ['Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['November 2001'],\n",
       "  ['June 2007'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  ['65 Years']],\n",
       " [['06136'],\n",
       "  ['Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers'],\n",
       "  ['Interventional'],\n",
       "  ['August 2006'],\n",
       "  ['November 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-59141'],\n",
       "  ['Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 23, 2023'],\n",
       "  ['March 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['5140020'],\n",
       "  ['Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 12, 2014'],\n",
       "  ['December 2023'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['BRSADJ0009'],\n",
       "  ['A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['January 2009'],\n",
       "  ['September 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-14-7'],\n",
       "  ['Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['March 5, 2015'],\n",
       "  ['February 7, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSMTS0012'],\n",
       "  ['Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers'],\n",
       "  ['Interventional'],\n",
       "  ['July 2010'],\n",
       "  ['December 2014'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-08-1'],\n",
       "  ['Green Tea in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['May 7, 2008'],\n",
       "  ['June 6, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TRIO 017'],\n",
       "  ['Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2009'],\n",
       "  ['April 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['057514'],\n",
       "  ['Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 20, 2007'],\n",
       "  ['March 24, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['117513'],\n",
       "  ['Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib'],\n",
       "  ['Interventional'],\n",
       "  ['April 27, 2012'],\n",
       "  ['October 2, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000378088'],\n",
       "  ['Study of Ductal Lavage in Women at High Risk for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['August 2002'],\n",
       "  ['June 2004'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1098987'],\n",
       "  ['Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 2007'],\n",
       "  ['December 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TRIO 016'],\n",
       "  ['Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2009'],\n",
       "  ['March 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['173-18-CA'],\n",
       "  ['Perioperative Mindfulness Proposal'],\n",
       "  ['Interventional'],\n",
       "  ['July 31, 2019'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['157512'],\n",
       "  ['Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['August 2, 2016'],\n",
       "  ['December 31, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16758'],\n",
       "  ['Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 28, 2016'],\n",
       "  ['February 28, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['85 Years']],\n",
       " [['11996'],\n",
       "  ['Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies'],\n",
       "  ['Interventional'],\n",
       "  ['March 27, 2012'],\n",
       "  ['December 31, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['VEG108843'],\n",
       "  ['Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2008'],\n",
       "  ['November 2012'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-13-8'],\n",
       "  ['Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['December 19, 2013'],\n",
       "  ['September 25, 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069154'],\n",
       "  ['Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2001'],\n",
       "  ['February 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['QUILT-3.067'],\n",
       "  ['QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.'],\n",
       "  ['Interventional'],\n",
       "  ['March 16, 2018'],\n",
       "  ['January 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['197520'],\n",
       "  ['Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 11, 2021'],\n",
       "  ['March 1, 2029'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI HS# 2015-1866'],\n",
       "  ['Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System'],\n",
       "  ['Observational'],\n",
       "  ['May 2015'],\n",
       "  ['January 25, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CDR0000068369'],\n",
       "  ['Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['117527'],\n",
       "  ['Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 1, 2012'],\n",
       "  ['June 9, 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['150860'],\n",
       "  ['Tracking Physical Activity Throughout Chemotherapy for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['June 1, 2015'],\n",
       "  ['February 8, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['85 Years']],\n",
       " [['QUILT-3.058'],\n",
       "  ['A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies'],\n",
       "  ['Interventional'],\n",
       "  ['September 27, 2021'],\n",
       "  ['January 4, 2023'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2022-07-YUAN-IB-TNBC'],\n",
       "  ['Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2023'],\n",
       "  ['October 2026'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['221183'],\n",
       "  ['Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis'],\n",
       "  ['Interventional'],\n",
       "  ['November 2010'],\n",
       "  ['March 4, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['CDR0000657044'],\n",
       "  ['Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants'],\n",
       "  ['Interventional'],\n",
       "  ['January 2016'],\n",
       "  [],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2015-12-Goodman-STOP'],\n",
       "  ['STOP Heart Disease in Breast Cancer Survivors Trial'],\n",
       "  ['Interventional'],\n",
       "  ['May 5, 2016'],\n",
       "  ['May 25, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2012-02827'],\n",
       "  ['GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2003'],\n",
       "  ['March 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2012-02836'],\n",
       "  ['Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2005'],\n",
       "  ['January 2008'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15BB-1300'],\n",
       "  ['Nuevo Amanecer: Promoting the Psychosocial Health of Latinas'],\n",
       "  ['Interventional'],\n",
       "  ['February 2011'],\n",
       "  ['May 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['017513'],\n",
       "  ['Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ'],\n",
       "  ['Interventional'],\n",
       "  ['February 19, 2002'],\n",
       "  ['June 30, 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['1B-12-10'],\n",
       "  ['Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 29, 2013'],\n",
       "  ['March 2, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRS0001'],\n",
       "  ['Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT'],\n",
       "  ['Interventional'],\n",
       "  ['February 2008'],\n",
       "  ['December 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['22239'],\n",
       "  ['Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['March 15, 2023'],\n",
       "  ['May 15, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['ITL-014-TACT-MBC'],\n",
       "  ['Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['March 2014'],\n",
       "  ['March 2014'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['20171'],\n",
       "  ['Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 27, 2021'],\n",
       "  ['December 12, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['IRB-52869'],\n",
       "  ['Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 20, 2023'],\n",
       "  ['December 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-21-6'],\n",
       "  ['Breast Cancer Survivorship Biorepository'],\n",
       "  ['Observational'],\n",
       "  ['April 11, 2022'],\n",
       "  ['April 11, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-63041'],\n",
       "  ['Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 16, 2022'],\n",
       "  ['August 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['U54 CA155435-01 Project 3'],\n",
       "  ['Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2011'],\n",
       "  ['December 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['GC-627-05'],\n",
       "  ['Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['April 12, 2018'],\n",
       "  ['March 5, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000367118'],\n",
       "  ['GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu'],\n",
       "  ['Interventional'],\n",
       "  ['March 2004'],\n",
       "  ['February 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 19-145 [HS# 1459]'],\n",
       "  ['Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 31, 2022'],\n",
       "  ['December 31, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20923'],\n",
       "  ['Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand'],\n",
       "  ['Observational'],\n",
       "  ['May 18, 2020'],\n",
       "  ['May 24, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  ['70 Years']],\n",
       " [['18496'],\n",
       "  ['Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 4, 2019'],\n",
       "  ['December 21, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['21094'],\n",
       "  ['CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 18, 2021'],\n",
       "  ['December 1, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MMP-001'],\n",
       "  ['Mindful Movement for Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['November 2015'],\n",
       "  ['June 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['1B-16-3'],\n",
       "  ['Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 21, 2017'],\n",
       "  ['July 8, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['QUILT-3.057'],\n",
       "  ['QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine'],\n",
       "  ['Interventional'],\n",
       "  ['September 2018'],\n",
       "  ['December 2021'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['21050'],\n",
       "  ['An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis'],\n",
       "  ['Interventional'],\n",
       "  ['December 21, 2022'],\n",
       "  ['February 25, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10192'],\n",
       "  ['Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid'],\n",
       "  ['Interventional'],\n",
       "  ['September 14, 2012'],\n",
       "  ['February 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['PILOT 171548'],\n",
       "  ['RISE - Reduce Sitting Time Among Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['March 29, 2022'],\n",
       "  ['February 7, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['1B-12-1'],\n",
       "  ['Exercise Program for Early Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['May 21, 2012'],\n",
       "  ['October 1, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-1856'],\n",
       "  ['Integrative Approaches for Cancer Survivorship 2: Project 2'],\n",
       "  ['Interventional'],\n",
       "  ['September 2016'],\n",
       "  ['June 4, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-53650'],\n",
       "  ['Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 13, 2020'],\n",
       "  ['October 22, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SLNPain01'],\n",
       "  ['Sentinel Lymph Node Mapping Post-Injection Site Pain'],\n",
       "  ['Observational'],\n",
       "  ['March 2014'],\n",
       "  ['February 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-18567'],\n",
       "  ['Integrative Approaches For Cancer Survivorship 2: Project 1'],\n",
       "  ['Interventional'],\n",
       "  ['September 2016'],\n",
       "  ['September 21, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20107789'],\n",
       "  ['Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging'],\n",
       "  ['Observational'],\n",
       "  ['December 2010'],\n",
       "  ['December 2018'],\n",
       "  ['Withdrawn'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['75 Years']],\n",
       " [['4 BB-2901'],\n",
       "  ['Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?'],\n",
       "  ['Interventional'],\n",
       "  [],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-12273'],\n",
       "  ['Stress, Diurnal Cortisol, and Breast Cancer Survival'],\n",
       "  ['Observational'],\n",
       "  ['September 8, 2002'],\n",
       "  ['December 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['19-001881'],\n",
       "  ['Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['September 29, 2021'],\n",
       "  ['November 1, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['74 Years']],\n",
       " [['IRB-57111'],\n",
       "  ['Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['March 15, 2021'],\n",
       "  ['October 31, 2026'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-185671'],\n",
       "  ['Integrative Approaches to Cancer Survivorship: Project 3'],\n",
       "  ['Interventional'],\n",
       "  ['April 17, 2018'],\n",
       "  ['January 30, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-58571'],\n",
       "  ['Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 20, 2021'],\n",
       "  ['October 12, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20141505'],\n",
       "  ['Breast Tumor Oxygenation During Exercise'],\n",
       "  ['Observational'],\n",
       "  ['April 2015'],\n",
       "  ['January 2018'],\n",
       "  ['Withdrawn'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['70 Years']],\n",
       " [['IRB-13761'],\n",
       "  ['Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2006'],\n",
       "  ['November 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['19206'],\n",
       "  ['Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['March 25, 2020'],\n",
       "  ['December 15, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['70 Years'],\n",
       "  []],\n",
       " [['17-000560'],\n",
       "  ['Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['July 11, 2017'],\n",
       "  ['December 3, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['18549'],\n",
       "  ['Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema'],\n",
       "  ['Interventional'],\n",
       "  ['April 19, 2019'],\n",
       "  ['March 31, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['5R03CA144751-02'],\n",
       "  ['Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2010'],\n",
       "  ['September 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['UCSD POISE'],\n",
       "  ['Predictors of Ovarian Insufficiency in Young Breast Cancer Patients'],\n",
       "  ['Observational'],\n",
       "  ['September 24, 2008'],\n",
       "  ['July 18, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['45 Years']],\n",
       " [['BRS0027'],\n",
       "  ['Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2013'],\n",
       "  ['July 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-001271'],\n",
       "  ['Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2, 2017'],\n",
       "  ['March 31, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['OMS-I140'],\n",
       "  ['Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC'],\n",
       "  ['Interventional'],\n",
       "  ['September 2015'],\n",
       "  ['July 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [[\"SIMR_onc19_IIS_D'Andre_Ashwaga\"],\n",
       "  ['Ashwagandha for Cognitive Dysfunction'],\n",
       "  ['Interventional'],\n",
       "  ['January 1, 2020'],\n",
       "  ['November 1, 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['04125'],\n",
       "  ['Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease'],\n",
       "  ['Observational'],\n",
       "  ['August 2005'],\n",
       "  ['June 6, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['20 Years'],\n",
       "  []],\n",
       " [['1B-16-11'],\n",
       "  ['Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 29, 2019'],\n",
       "  ['July 29, 2025'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-11-5'],\n",
       "  ['Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['September 4, 2012'],\n",
       "  ['September 30, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['21152'],\n",
       "  ['Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 21, 2022'],\n",
       "  ['September 7, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['11174'],\n",
       "  ['Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 15, 2012'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['14135'],\n",
       "  ['Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['September 7, 2014'],\n",
       "  ['June 3, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['56 Years'],\n",
       "  []],\n",
       " [['TRIO-US B09'],\n",
       "  ['Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis'],\n",
       "  ['Interventional'],\n",
       "  ['June 26, 2013'],\n",
       "  ['May 10, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20091527'],\n",
       "  ['The Health of Women Study'],\n",
       "  ['Observational'],\n",
       "  ['August 2009'],\n",
       "  ['July 18, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08061'],\n",
       "  ['Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2008'],\n",
       "  ['April 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['CDR0000428460'],\n",
       "  ['Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2005'],\n",
       "  ['November 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  ['65 Years']],\n",
       " [['02164'],\n",
       "  ['Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease'],\n",
       "  ['Interventional'],\n",
       "  ['March 11, 2004'],\n",
       "  ['June 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['48 Years']],\n",
       " [['RSGPB-04-258-01-CPPB'],\n",
       "  ['Weight Reduction Intervention for Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['January 2005'],\n",
       "  ['December 2009'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-14-5'],\n",
       "  ['High-Intensity Interval Training for Stage I-III Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['September 29, 2015'],\n",
       "  ['July 15, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCLA-9908076'],\n",
       "  ['Cryosurgery in Treating Women With Breast Lesions'],\n",
       "  ['Interventional'],\n",
       "  ['May 2001'],\n",
       "  ['July 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['1B-09-14'],\n",
       "  ['Endoscopic Breast Surgery in Treating Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2010'],\n",
       "  ['October 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['15 Years'],\n",
       "  []],\n",
       " [['1B-12-4'],\n",
       "  ['Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 1, 2012'],\n",
       "  ['October 21, 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['7BB-2400'],\n",
       "  ['Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?'],\n",
       "  ['Observational'],\n",
       "  ['July 1, 2000'],\n",
       "  ['November 30, 2006'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['20 Years'],\n",
       "  ['85 Years']],\n",
       " [['1R03CA168450-01'],\n",
       "  ['Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)'],\n",
       "  ['Interventional'],\n",
       "  ['April 2013'],\n",
       "  ['October 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['SNP-17-001'],\n",
       "  ['Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['September 21, 2018'],\n",
       "  ['November 11, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16294'],\n",
       "  ['Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 22, 2017'],\n",
       "  ['November 22, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['SAIRB-15-0060'],\n",
       "  ['A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.'],\n",
       "  ['Observational'],\n",
       "  ['December 2015'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['P0518095'],\n",
       "  ['Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device'],\n",
       "  ['Interventional'],\n",
       "  ['October 31, 2017'],\n",
       "  ['January 31, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['120108'],\n",
       "  ['Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['March 2012'],\n",
       "  ['December 2012'],\n",
       "  ['Withdrawn'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['85 Years']],\n",
       " [['IRB-30982'],\n",
       "  ['Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2015'],\n",
       "  ['July 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['14253'],\n",
       "  ['Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 7, 2016'],\n",
       "  ['December 19, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['S07-002'],\n",
       "  ['Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to \"Low-risk\" Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['May 2008'],\n",
       "  ['July 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['17753'],\n",
       "  ['T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 5, 2020'],\n",
       "  ['April 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['167514'],\n",
       "  ['Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib'],\n",
       "  ['Interventional'],\n",
       "  ['October 9, 2018'],\n",
       "  ['October 31, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['R01 CA119 159'],\n",
       "  ['Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms'],\n",
       "  ['Interventional'],\n",
       "  ['March 2008'],\n",
       "  ['July 31, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  ['70 Years']],\n",
       " [['IIT2019-21-Basho-TOPAZ'],\n",
       "  ['TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2022'],\n",
       "  ['June 1, 2024'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-01671'],\n",
       "  ['Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status'],\n",
       "  ['Interventional'],\n",
       "  ['May 2005'],\n",
       "  ['September 2009'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['18-000427'],\n",
       "  ['Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted'],\n",
       "  ['Interventional'],\n",
       "  ['July 10, 2019'],\n",
       "  ['July 1, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CL- Gedatolisib-001'],\n",
       "  ['Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2016'],\n",
       "  ['March 15, 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['VINJ007'],\n",
       "  ['Acupuncture for CIPN in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 2015'],\n",
       "  ['December 2018'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['21-001819'],\n",
       "  ['Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 7, 2022'],\n",
       "  ['April 1, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AVB620-C-001'],\n",
       "  ['Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['April 2015'],\n",
       "  ['January 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-37299'],\n",
       "  ['4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 30, 2017'],\n",
       "  ['February 14, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSMTS0010'],\n",
       "  ['Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast'],\n",
       "  ['Interventional'],\n",
       "  ['August 2007'],\n",
       "  ['December 2011'],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['RJ-101-RCT-001'],\n",
       "  ['Study to Investigate the Effect of AB-101 in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['July 9, 2018'],\n",
       "  ['October 12, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['09109'],\n",
       "  ['Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel'],\n",
       "  ['Interventional'],\n",
       "  ['January 2010'],\n",
       "  ['May 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['13-001676'],\n",
       "  ['Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus'],\n",
       "  ['Interventional'],\n",
       "  ['October 8, 2014'],\n",
       "  ['November 30, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PA18-0280'],\n",
       "  ['A Culturally Sensitive Social Support Intervention'],\n",
       "  ['Interventional'],\n",
       "  ['January 2015'],\n",
       "  ['August 2021'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['06-08-010'],\n",
       "  ['Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['March 2008'],\n",
       "  ['October 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['MRSGT-10-011-01-CPPB'],\n",
       "  ['Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['June 2012'],\n",
       "  ['March 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['14955'],\n",
       "  ['Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 23, 2015'],\n",
       "  ['January 8, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['5354-CL-1201'],\n",
       "  ['A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['August 10, 2022'],\n",
       "  ['September 30, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['14099'],\n",
       "  ['Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 7, 2015'],\n",
       "  ['December 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000393552'],\n",
       "  ['Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers'],\n",
       "  ['Interventional'],\n",
       "  ['November 2004'],\n",
       "  [],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['BMT86'],\n",
       "  ['CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant'],\n",
       "  ['Interventional'],\n",
       "  ['September 1996'],\n",
       "  ['June 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  ['70 Years']],\n",
       " [['BRSNSTU0024'],\n",
       "  ['Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI'],\n",
       "  ['Observational'],\n",
       "  ['April 2008'],\n",
       "  ['December 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['CDR0000069155'],\n",
       "  ['Herbal Therapy in Treating Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2001'],\n",
       "  ['April 2006'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCDCC#237'],\n",
       "  ['Oxaliplatin in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2015'],\n",
       "  ['December 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['KCT003'],\n",
       "  ['A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2021'],\n",
       "  ['December 31, 2021'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NU 98B3'],\n",
       "  ['Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 1999'],\n",
       "  ['April 2000'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000439421'],\n",
       "  ['Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2005'],\n",
       "  ['December 2009'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IM-T-hMN14-04'],\n",
       "  ['Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2000'],\n",
       "  ['June 2003'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16421'],\n",
       "  ['Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention'],\n",
       "  ['Interventional'],\n",
       "  ['August 9, 2017'],\n",
       "  ['December 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT 2014-01'],\n",
       "  ['Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment'],\n",
       "  ['Interventional'],\n",
       "  ['July 6, 2015'],\n",
       "  ['May 23, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['140863'],\n",
       "  ['Reproductive Health Survivorship Care Plan'],\n",
       "  ['Interventional'],\n",
       "  ['March 25, 2015'],\n",
       "  ['January 24, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['45 Years']],\n",
       " [['Breast Pain'],\n",
       "  ['Symptom Management After Breast Cancer Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['September 2003'],\n",
       "  ['December 2007'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRICC-BB-IND-7186'],\n",
       "  ['Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1997'],\n",
       "  ['October 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20080325'],\n",
       "  ['A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 21, 2008'],\n",
       "  ['February 7, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['14-071'],\n",
       "  ['Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History'],\n",
       "  ['Observational'],\n",
       "  ['April 8, 2014'],\n",
       "  ['April 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['60 Years'],\n",
       "  []],\n",
       " [['98096'],\n",
       "  ['Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 1999'],\n",
       "  ['December 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  ['60 Years']],\n",
       " [['C07-104'],\n",
       "  ['Safety and Efficacy Study Using Rexin-G for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2007'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10-01831'],\n",
       "  ['Fear of Recurrence Pilot Intervention for Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2011'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-11-9'],\n",
       "  ['PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 22, 2013'],\n",
       "  ['November 22, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 18-79 [HS# 2020-5660]'],\n",
       "  ['Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 23, 2020'],\n",
       "  ['February 16, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-29691'],\n",
       "  ['Molecular and Cellular Analysis of Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['September 2014'],\n",
       "  ['September 2024'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Minutes'],\n",
       "  []],\n",
       " [['CDR0000616135'],\n",
       "  ['The Impact of Lymphedema on Breast Cancer Survivors'],\n",
       "  ['Observational'],\n",
       "  ['February 2007'],\n",
       "  ['February 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CDR0000465198'],\n",
       "  ['Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['August 2004'],\n",
       "  ['May 24, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['246600'],\n",
       "  ['Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 2008'],\n",
       "  ['January 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['5BB-1801'],\n",
       "  ['Alternative Support for Rural and Isolated Women in an HMO'],\n",
       "  ['Interventional'],\n",
       "  ['September 2000'],\n",
       "  ['May 2002'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-15-6'],\n",
       "  ['Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['March 8, 2019'],\n",
       "  ['July 31, 2019'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCSF-067519'],\n",
       "  ['Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['March 2007'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['16-001'],\n",
       "  ['Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 23, 2016'],\n",
       "  ['December 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 14-67 [HS# 2015-1888]'],\n",
       "  ['Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab'],\n",
       "  ['Interventional'],\n",
       "  ['April 2015'],\n",
       "  ['December 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['182113'],\n",
       "  ['Improving Cognition After Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 9, 2019'],\n",
       "  ['February 1, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['BRS0037'],\n",
       "  ['Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['January 2014'],\n",
       "  [],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CDR0000674337'],\n",
       "  ['Monitoring and Predicting Chemotherapy Response Using DOSI'],\n",
       "  ['Interventional'],\n",
       "  ['June 2011'],\n",
       "  ['October 6, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SU-03012010-5082'],\n",
       "  ['Expanding Rural Access: Distance Delivery of Support Groups (Main Study)'],\n",
       "  ['Interventional'],\n",
       "  ['May 2008'],\n",
       "  ['July 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['IRB-17323'],\n",
       "  ['Management of Insomnia in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['January 2011'],\n",
       "  ['July 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['HMH2015.002'],\n",
       "  ['Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)'],\n",
       "  ['Interventional'],\n",
       "  ['August 2013'],\n",
       "  ['December 30, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PPHM 1401'],\n",
       "  ['Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2015'],\n",
       "  ['June 2018'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRS0039'],\n",
       "  [\"Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy\"],\n",
       "  ['Interventional'],\n",
       "  ['July 2014'],\n",
       "  ['July 7, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA025'],\n",
       "  ['A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2005'],\n",
       "  ['February 2008'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16079'],\n",
       "  ['Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 15, 2016'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08029'],\n",
       "  ['Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2008'],\n",
       "  ['December 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['VI-ISRP-026'],\n",
       "  ['A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes'],\n",
       "  ['Interventional'],\n",
       "  ['August 1, 2018'],\n",
       "  ['March 1, 2020'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20-30638'],\n",
       "  ['Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)'],\n",
       "  ['Interventional'],\n",
       "  ['February 1, 2022'],\n",
       "  ['September 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['64 Years']],\n",
       " [['TCD11487'],\n",
       "  ['A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2008'],\n",
       "  ['October 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI-HS-2007-5519'],\n",
       "  ['Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)'],\n",
       "  ['Interventional'],\n",
       "  ['May 2007'],\n",
       "  ['June 2008'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['85 Years']],\n",
       " [['JWCI OBCS WITH IORT'],\n",
       "  ['Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.'],\n",
       "  ['Interventional'],\n",
       "  ['December 16, 2021'],\n",
       "  ['February 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['BRS0031'],\n",
       "  ['Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['April 2015'],\n",
       "  ['August 18, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['STOP-BC Trial'],\n",
       "  ['Sulindac and Breast Density in Women at Risk of Developing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 20, 2020'],\n",
       "  ['February 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  ['70 Years']],\n",
       " [['09021-02'],\n",
       "  ['Health Benefits of Expressive Writing: Study One'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['October 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-18737'],\n",
       "  ['Nuevo Amanecer II: Translating a Stress Management Program for Latinas'],\n",
       "  ['Interventional'],\n",
       "  ['September 2016'],\n",
       "  ['February 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000430705'],\n",
       "  ['Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast'],\n",
       "  ['Interventional'],\n",
       "  ['November 2004'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['147523'],\n",
       "  ['Reversing Therapy Resistance With Epigenetic-Immune Modification'],\n",
       "  ['Interventional'],\n",
       "  ['May 4, 2015'],\n",
       "  ['June 8, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000076422'],\n",
       "  ['High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma'],\n",
       "  ['Interventional'],\n",
       "  ['December 1987'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2013-02225'],\n",
       "  ['Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2002'],\n",
       "  ['April 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCDCC#185'],\n",
       "  ['Abraxane and Alimta in Advanced Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['April 2007'],\n",
       "  ['October 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['P2100-SUR-S11'],\n",
       "  ['Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 10, 2021'],\n",
       "  ['June 1, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-15005'],\n",
       "  ['Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption'],\n",
       "  ['Interventional'],\n",
       "  ['April 2009'],\n",
       "  ['April 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['85 Years']],\n",
       " [['14036'],\n",
       "  ['Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 1, 2014'],\n",
       "  ['March 3, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-44367'],\n",
       "  ['Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy'],\n",
       "  ['Interventional'],\n",
       "  ['August 1, 2018'],\n",
       "  ['December 2022'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 07-61 [HS# 2007-6084]'],\n",
       "  ['Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting'],\n",
       "  ['Interventional'],\n",
       "  ['February 2008'],\n",
       "  ['July 2021'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['90 Years']],\n",
       " [['GYNOVA0033'],\n",
       "  ['Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2016'],\n",
       "  ['October 11, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SCP-1'],\n",
       "  ['Reproductive Health Survivorship Care Plan Pilot'],\n",
       "  ['Interventional'],\n",
       "  ['March 20, 2014'],\n",
       "  ['December 31, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['45 Years']],\n",
       " [['LSB-12345'],\n",
       "  ['Intraoperative Use of ClearEdge Device in Breast Conserving Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['October 10, 2022'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000065692 (1B-97-2)'],\n",
       "  ['Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1997'],\n",
       "  ['March 2000'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['12147'],\n",
       "  ['Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 17, 2013'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['12-001 Single Fraction IORT'],\n",
       "  ['Single Fraction Intraoperative Radiotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['February 2012'],\n",
       "  ['February 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['41 Years'],\n",
       "  ['90 Years']],\n",
       " [['S11-00533'],\n",
       "  ['Fresolimumab and Radiotherapy in Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2011'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NMCSD.2014.0053'],\n",
       "  ['A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms'],\n",
       "  ['Observational'],\n",
       "  ['May 2015'],\n",
       "  ['January 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['60 Years']],\n",
       " [['216529'],\n",
       "  ['Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms'],\n",
       "  ['Interventional'],\n",
       "  ['March 2010'],\n",
       "  ['March 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10AB-2801'],\n",
       "  ['Expanding Rural Access: Distance Delivery of Support'],\n",
       "  ['Interventional'],\n",
       "  ['November 2004'],\n",
       "  ['June 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CP-18 100'],\n",
       "  ['Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects'],\n",
       "  ['Interventional'],\n",
       "  ['May 2011'],\n",
       "  ['April 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['75 Years']],\n",
       " [['BRSADJ0020'],\n",
       "  ['Acupuncture for Sleep Disruption in Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['February 2011'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-10-6'],\n",
       "  ['Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 1, 2010'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  ['75 Years']],\n",
       " [['Pro00043233'],\n",
       "  ['A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2016'],\n",
       "  ['March 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['214750'],\n",
       "  ['Evaluation of Breast CT'],\n",
       "  ['Interventional'],\n",
       "  ['November 22, 2004'],\n",
       "  ['March 5, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['LAJ 08-8001'],\n",
       "  ['Scripps Polster Breast Care Center Investigational GeneBank'],\n",
       "  ['Observational'],\n",
       "  ['July 2008'],\n",
       "  ['June 2015'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  []],\n",
       " [['11130'],\n",
       "  ['Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2009'],\n",
       "  ['May 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['CDR0000065828'],\n",
       "  ['Diet and Estrogen Metabolism in Postmenopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['August 1997'],\n",
       "  ['June 2004'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  ['69 Years']],\n",
       " [['LUM-BC-1.0'],\n",
       "  ['A Multicenter Breast Cancer Biospecimen Registry'],\n",
       "  ['Observational'],\n",
       "  ['February 2016'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['A112313'],\n",
       "  ['Integrative Approaches for Cancer Survivorship'],\n",
       "  ['Interventional'],\n",
       "  ['January 2012'],\n",
       "  ['October 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000616972'],\n",
       "  ['Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)'],\n",
       "  ['Observational'],\n",
       "  ['October 1, 2008'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['L-503'],\n",
       "  ['The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage'],\n",
       "  ['Observational'],\n",
       "  ['July 2011'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['025950'],\n",
       "  ['Investigating the Impact of Tamoxifen Therapy on Ovarian Aging'],\n",
       "  ['Observational'],\n",
       "  ['June 2011'],\n",
       "  ['March 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  []],\n",
       " [['BCA-003'],\n",
       "  ['Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning'],\n",
       "  ['Observational'],\n",
       "  ['April 2008'],\n",
       "  ['April 2011'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['50 Years']],\n",
       " [['18-001926'],\n",
       "  ['Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors'],\n",
       "  ['Interventional'],\n",
       "  ['October 7, 2019'],\n",
       "  ['June 1, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['800646'],\n",
       "  [\"Intervening on Women's Health for Rural Young Breast Cancer Survivors\"],\n",
       "  ['Interventional'],\n",
       "  ['October 15, 2021'],\n",
       "  ['April 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  ['50 Years']],\n",
       " [['IIT2021-10-Giuliano-OmitRT'],\n",
       "  ['Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response'],\n",
       "  ['Interventional'],\n",
       "  ['May 2022'],\n",
       "  ['May 2028'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['17-001864'],\n",
       "  ['SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 7, 2019'],\n",
       "  ['December 6, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20429001'],\n",
       "  ['Central Obesity and Cancer Prevention for Chinese American Women'],\n",
       "  ['Interventional'],\n",
       "  ['October 16, 2019'],\n",
       "  ['December 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['R01AT000486'],\n",
       "  ['Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health'],\n",
       "  ['Interventional'],\n",
       "  ['May 2000'],\n",
       "  ['January 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['04140'],\n",
       "  ['Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2005'],\n",
       "  ['August 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000613050'],\n",
       "  ['Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['May 2007'],\n",
       "  ['June 6, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  ['80 Years']],\n",
       " [['CBCRP 23AB-1400'],\n",
       "  ['Reducing Breast Cancer Risk in Korean American Women'],\n",
       "  ['Interventional'],\n",
       "  ['March 16, 2019'],\n",
       "  ['December 31, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['Pro00009633'],\n",
       "  ['Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment'],\n",
       "  ['Observational'],\n",
       "  ['September 2014'],\n",
       "  ['September 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-14-6'],\n",
       "  ['Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['December 16, 2014'],\n",
       "  ['August 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP101'],\n",
       "  ['Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  [],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['QUILT-3.013'],\n",
       "  ['QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2016'],\n",
       "  ['December 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP-CTL'],\n",
       "  ['Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors'],\n",
       "  ['Interventional'],\n",
       "  ['November 2010'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  ['45 Years']],\n",
       " [['BMT42'],\n",
       "  ['High Dose Chemotherapy and Autologous Transplant for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  [],\n",
       "  ['March 2005'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['CDR0000065380'],\n",
       "  ['Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1996'],\n",
       "  ['November 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['IRB-19595'],\n",
       "  ['High Resolution 3D Diffusion-weighted Breast MRI'],\n",
       "  ['Observational'],\n",
       "  ['March 2011'],\n",
       "  ['February 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-37161'],\n",
       "  ['Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema'],\n",
       "  ['Interventional'],\n",
       "  ['July 20, 2016'],\n",
       "  ['October 29, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['P276-00/52/10'],\n",
       "  ['A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin'],\n",
       "  ['Interventional'],\n",
       "  ['August 2011'],\n",
       "  ['March 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRSADJ0023'],\n",
       "  ['Phase I: At-Home Support for Rural Women Using Group Video Calling'],\n",
       "  ['Interventional'],\n",
       "  ['October 2012'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['STUDY00001356'],\n",
       "  ['IIT2020-20-SHIRAZIP-WALK: Nature Walks'],\n",
       "  ['Interventional'],\n",
       "  ['June 21, 2021'],\n",
       "  ['December 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10005'],\n",
       "  ['Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer'],\n",
       "  ['Observational'],\n",
       "  ['November 2010'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['99-11-084'],\n",
       "  ['Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2003'],\n",
       "  ['November 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['11F.438'],\n",
       "  ['Quantitative Subharmonic Breast Imaging'],\n",
       "  ['Interventional'],\n",
       "  ['November 2011'],\n",
       "  ['April 5, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['18432'],\n",
       "  ['Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease'],\n",
       "  ['Interventional'],\n",
       "  ['March 4, 2019'],\n",
       "  ['July 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['PARW-OVCONS-0307'],\n",
       "  ['Examining the Long-Term Risks of Oophorectomy'],\n",
       "  ['Observational'],\n",
       "  ['January 1980'],\n",
       "  ['June 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  ['55 Years']],\n",
       " [['IIT2018-01-McArthur-IPI'],\n",
       "  ['Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 12, 2019'],\n",
       "  ['June 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CD07_TNBC'],\n",
       "  ['Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC'],\n",
       "  ['Interventional'],\n",
       "  ['April 22, 2019'],\n",
       "  ['September 16, 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['12751'],\n",
       "  ['Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 12, 2012'],\n",
       "  ['July 5, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['M10-265'],\n",
       "  ['Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2008'],\n",
       "  ['December 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2019-14-SHIRAZIP-SWEAT'],\n",
       "  ['Streaming Web-based Exercise At Home: A Pilot Study'],\n",
       "  ['Interventional'],\n",
       "  ['July 7, 2020'],\n",
       "  ['March 30, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000617655'],\n",
       "  ['Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['August 11, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['CDR0000594671'],\n",
       "  ['Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['February 2008'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TALES Trial'],\n",
       "  ['Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial'],\n",
       "  ['Interventional'],\n",
       "  ['July 21, 2016'],\n",
       "  ['January 31, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['50 Years']],\n",
       " [['NBI-3001-ST-0101'],\n",
       "  ['Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2002'],\n",
       "  ['July 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['HMH2015.001'],\n",
       "  ['Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe'],\n",
       "  ['Interventional'],\n",
       "  ['March 2015'],\n",
       "  ['September 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['15754'],\n",
       "  ['Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial'],\n",
       "  ['Interventional'],\n",
       "  ['March 13, 2017'],\n",
       "  ['December 20, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['89 Years']],\n",
       " [['ROCHE-NP17787'],\n",
       "  ['Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2004'],\n",
       "  ['December 2007'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACU-JOINT001'],\n",
       "  ['Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain'],\n",
       "  ['Interventional'],\n",
       "  ['June 2015'],\n",
       "  ['June 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['H 15430'],\n",
       "  ['Neoadjuvant GW572016 to Treat Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2004'],\n",
       "  ['February 2012'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-55153'],\n",
       "  ['Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts'],\n",
       "  ['Interventional'],\n",
       "  ['April 28, 2021'],\n",
       "  ['April 15, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['EXPLLN21-01'],\n",
       "  ['A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG'],\n",
       "  ['Interventional'],\n",
       "  ['May 1, 2023'],\n",
       "  ['March 1, 2025'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20152355'],\n",
       "  ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI'],\n",
       "  ['Interventional'],\n",
       "  ['December 2015'],\n",
       "  ['December 2019'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['80 Years']],\n",
       " [['228012'],\n",
       "  ['Impact of Topical Tranexamic Acid in Breast Reconstruction'],\n",
       "  ['Interventional'],\n",
       "  ['March 30, 2023'],\n",
       "  ['September 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 03-16 [HS# 2004-3681]'],\n",
       "  ['Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['September 21, 2004'],\n",
       "  ['December 12, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['48134'],\n",
       "  ['Plant-based Diets and Risk of Cancer in the Adventist Health Study-2'],\n",
       "  ['Observational'],\n",
       "  ['February 1, 2002'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['30 Years'],\n",
       "  []],\n",
       " [['DZ2019HE001'],\n",
       "  ['DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 21, 2020'],\n",
       "  ['May 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-53132'],\n",
       "  ['LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy'],\n",
       "  ['Interventional'],\n",
       "  ['September 10, 2021'],\n",
       "  ['June 1, 2030'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['5160378'],\n",
       "  ['Effect of Resveratrol on Serum IGF2 Among African American Women'],\n",
       "  ['Interventional'],\n",
       "  ['April 24, 2019'],\n",
       "  ['June 30, 2024'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBCRP 12BB-3900'],\n",
       "  ['Telephone-Based Decision Support for Rural Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 2007'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['KCT001'],\n",
       "  ['Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study'],\n",
       "  ['Interventional'],\n",
       "  ['August 5, 2020'],\n",
       "  ['May 28, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['11139'],\n",
       "  ['Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 19, 2012'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['1B-03-7'],\n",
       "  ['A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)'],\n",
       "  ['Interventional'],\n",
       "  ['August 2006'],\n",
       "  ['June 2008'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-000817'],\n",
       "  ['Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)'],\n",
       "  ['Interventional'],\n",
       "  ['February 20, 2017'],\n",
       "  ['February 1, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['49 Years']],\n",
       " [['EGF103892'],\n",
       "  ['Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['December 7, 2006'],\n",
       "  ['September 12, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DCA Breast NSCLC'],\n",
       "  ['Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)'],\n",
       "  ['Interventional'],\n",
       "  ['December 2009'],\n",
       "  ['November 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-30470'],\n",
       "  ['Brief Behavioral Intervention for Insomnia During Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['January 2015'],\n",
       "  ['June 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['BIOC-046'],\n",
       "  ['A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide'],\n",
       "  ['Observational'],\n",
       "  ['September 7, 2022'],\n",
       "  ['January 1, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['eFT508-0008'],\n",
       "  ['A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC'],\n",
       "  ['Interventional'],\n",
       "  ['November 21, 2017'],\n",
       "  ['January 22, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['090314'],\n",
       "  ['Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade'],\n",
       "  ['Observational'],\n",
       "  ['July 2009'],\n",
       "  ['November 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['IRB-06037'],\n",
       "  ['Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy'],\n",
       "  ['Interventional'],\n",
       "  ['June 2008'],\n",
       "  ['July 26, 2012'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-46373'],\n",
       "  ['Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma'],\n",
       "  ['Interventional'],\n",
       "  ['March 22, 2019'],\n",
       "  ['July 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['190311'],\n",
       "  ['Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction'],\n",
       "  ['Interventional'],\n",
       "  ['October 20, 2022'],\n",
       "  ['March 31, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['22 Years'],\n",
       "  ['75 Years']],\n",
       " [['CDR0000522934'],\n",
       "  ['Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2006'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['1K07CA181323-01A1'],\n",
       "  ['Physical Activity and Neuropsychological Outcomes in a Cancer Population'],\n",
       "  ['Interventional'],\n",
       "  ['August 2014'],\n",
       "  ['July 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  ['85 Years']],\n",
       " [['DCIS Cryo'],\n",
       "  ['Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ'],\n",
       "  ['Interventional'],\n",
       "  ['November 1, 2021'],\n",
       "  ['November 1, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-06-9'],\n",
       "  ['Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast'],\n",
       "  ['Interventional'],\n",
       "  ['October 2007'],\n",
       "  ['November 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['18R5-002'],\n",
       "  ['A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2013'],\n",
       "  ['December 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['Pro00052823'],\n",
       "  ['Tissue Expansion in Breast Reconstruction Without Drains'],\n",
       "  ['Observational'],\n",
       "  ['February 25, 2019'],\n",
       "  ['October 2, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['2450-US-002'],\n",
       "  ['Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2010'],\n",
       "  ['December 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['5170197'],\n",
       "  ['Chemotherapy Induced Peripheral Neuropathy (CIPN)'],\n",
       "  ['Interventional'],\n",
       "  ['September 28, 2017'],\n",
       "  ['September 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['OSU-15222'],\n",
       "  ['Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 12, 2016'],\n",
       "  ['December 11, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1B-09-12'],\n",
       "  ['Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.'],\n",
       "  ['Interventional'],\n",
       "  ['December 2010'],\n",
       "  ['October 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MR2016-03'],\n",
       "  ['A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['March 1, 2017'],\n",
       "  ['August 30, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['181367'],\n",
       "  ['Physical Activity Intervention for Young Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['September 1, 2019'],\n",
       "  ['September 30, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['55 Years']],\n",
       " [['OB0012018'],\n",
       "  ['Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 1, 2017'],\n",
       "  ['May 1, 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['80 Years']],\n",
       " [['NU 98B1'],\n",
       "  ['Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 1998'],\n",
       "  ['June 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PEAK VP-00078'],\n",
       "  ['PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['February 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['2010-185'],\n",
       "  ['Breast Health in Chinese American Women'],\n",
       "  ['Interventional'],\n",
       "  ['July 2010'],\n",
       "  ['December 21, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['42 Years'],\n",
       "  []],\n",
       " [['CH001'],\n",
       "  ['Circadian Thermal Sensing to Detect Breast Disease'],\n",
       "  ['Interventional'],\n",
       "  ['June 2015'],\n",
       "  ['February 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['DAMD17-03-1-067'],\n",
       "  ['Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women'],\n",
       "  ['Interventional'],\n",
       "  ['September 2003'],\n",
       "  ['September 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['SPI-POZ-203'],\n",
       "  ['A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies'],\n",
       "  ['Interventional'],\n",
       "  ['December 23, 2019'],\n",
       "  ['March 29, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['HS-16-00483'],\n",
       "  ['Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)'],\n",
       "  ['Observational'],\n",
       "  ['August 16, 2016'],\n",
       "  ['April 29, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['55 Years']],\n",
       " [['AD-13-5635'],\n",
       "  ['Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers'],\n",
       "  ['Interventional'],\n",
       "  ['May 2013'],\n",
       "  ['December 2017'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  ['85 Years']],\n",
       " [['KPSC IRB 11103'],\n",
       "  ['Implementing Systematic Distress Screening in Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 2, 2017'],\n",
       "  ['November 30, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-50877'],\n",
       "  ['Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution'],\n",
       "  ['Interventional'],\n",
       "  ['January 2023'],\n",
       "  ['December 2023'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['2011-01-LEV'],\n",
       "  ['An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging'],\n",
       "  ['Interventional'],\n",
       "  ['June 2011'],\n",
       "  ['June 2012'],\n",
       "  ['Unknown status'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['21051'],\n",
       "  ['Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults'],\n",
       "  ['Interventional'],\n",
       "  ['August 24, 2021'],\n",
       "  ['June 30, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['70 Years'],\n",
       "  []],\n",
       " [['2001-2192'],\n",
       "  ['Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics'],\n",
       "  ['Observational'],\n",
       "  ['May 24, 2002'],\n",
       "  ['December 19, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2018-25-MITA-NEOBREADS'],\n",
       "  ['NEOBREADS: Neoadjuvant Breast Diet Study'],\n",
       "  ['Interventional'],\n",
       "  ['March 21, 2019'],\n",
       "  ['August 17, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['2000-1383'],\n",
       "  ['Following the Use of Gel Prosethetics in Breast Reconstruction'],\n",
       "  ['Observational'],\n",
       "  ['February 1, 2001'],\n",
       "  ['September 23, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['BRS0005'],\n",
       "  ['SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants'],\n",
       "  ['Observational'],\n",
       "  ['June 2011'],\n",
       "  ['September 23, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08803'],\n",
       "  ['Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['October 2008'],\n",
       "  ['December 2009'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2018-21-AMERSI-BREADS'],\n",
       "  ['BREADS: Breast Adjuvant Diet Study'],\n",
       "  ['Interventional'],\n",
       "  ['February 4, 2020'],\n",
       "  ['January 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GME Study'],\n",
       "  ['Gene Expression, Meditative Movement, and Emotional Distress (GME)'],\n",
       "  ['Interventional'],\n",
       "  ['July 17, 2017'],\n",
       "  ['February 15, 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['45 Years'],\n",
       "  []],\n",
       " [['17009'],\n",
       "  ['Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 13, 2017'],\n",
       "  ['October 1, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['0S-20-6'],\n",
       "  ['Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy'],\n",
       "  ['Observational'],\n",
       "  ['December 18, 2020'],\n",
       "  ['June 18, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['31801/1'],\n",
       "  ['Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction'],\n",
       "  ['Interventional'],\n",
       "  ['September 2016'],\n",
       "  ['March 2019'],\n",
       "  ['Unknown status'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['85 Years']],\n",
       " [['LSB-01'],\n",
       "  ['In Vitro Detection of Tissue Abnormality'],\n",
       "  ['Interventional'],\n",
       "  ['October 15, 2010'],\n",
       "  ['January 9, 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['25 Years'],\n",
       "  ['80 Years']],\n",
       " [['1B-22-2'],\n",
       "  ['In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['January 9, 2023'],\n",
       "  ['January 9, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PROT002 - Test Plan 01 Rev A'],\n",
       "  ['Blue Note Therapeutics Product BNT 103 Usability and User Engagement'],\n",
       "  ['Interventional'],\n",
       "  ['September 1, 2021'],\n",
       "  ['December 31, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['35 Years'],\n",
       "  ['55 Years']],\n",
       " [['MAP3BSS'],\n",
       "  ['Effects of Exemestane on Bone Strength'],\n",
       "  ['Observational'],\n",
       "  ['April 2007'],\n",
       "  ['June 2019'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['2008-0067'],\n",
       "  ['Lynne Cohen Consortium Project: Multi-Center Database/Registry'],\n",
       "  ['Observational'],\n",
       "  ['July 2008'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCSF-GC3-2021'],\n",
       "  ['Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients'],\n",
       "  ['Interventional'],\n",
       "  ['April 18, 2017'],\n",
       "  ['December 16, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['CA148791-01'],\n",
       "  ['Reducing Breast Cancer Recurrence With Weight Loss'],\n",
       "  ['Interventional'],\n",
       "  ['May 2010'],\n",
       "  ['February 2015'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['ANG1005-EAP-01, EAP-02, EAP-03'],\n",
       "  ['Expanded Access to ANG1005 for Individual Patients'],\n",
       "  ['Expanded Access'],\n",
       "  [],\n",
       "  [],\n",
       "  ['No longer available'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['STUDY00146320'],\n",
       "  ['Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens'],\n",
       "  ['Interventional'],\n",
       "  ['December 14, 2021'],\n",
       "  ['January 31, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  ['60 Years']],\n",
       " [['NCI-2019-06461'],\n",
       "  ['Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 6, 2019'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['217510'],\n",
       "  ['Microbiome and Association With Implant Infections'],\n",
       "  ['Interventional'],\n",
       "  ['September 28, 2021'],\n",
       "  ['December 31, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UPCC 25920'],\n",
       "  ['Pilot Study of an NTproBNP Guided Strategy of Cardioprotection'],\n",
       "  ['Interventional'],\n",
       "  ['March 18, 2021'],\n",
       "  ['June 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['03049'],\n",
       "  ['Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2004'],\n",
       "  ['August 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['HS-10-00455'],\n",
       "  ['Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation'],\n",
       "  ['Interventional'],\n",
       "  ['January 2011'],\n",
       "  ['December 2016'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['35 Years']],\n",
       " [['ANG-002'],\n",
       "  ['Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System'],\n",
       "  ['Observational'],\n",
       "  ['March 29, 2018'],\n",
       "  ['December 31, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['22 Years'],\n",
       "  []],\n",
       " [['17-000668'],\n",
       "  ['Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['August 3, 2017'],\n",
       "  ['February 1, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['US-001'],\n",
       "  ['SentiMag® Intraoperative Comparison in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2015'],\n",
       "  ['December 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GCO 15-1783'],\n",
       "  ['Systematic Light Exposure for Fatigue in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['January 25, 2018'],\n",
       "  ['April 30, 2022'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-121-04-01-04'],\n",
       "  ['A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers'],\n",
       "  ['Interventional'],\n",
       "  ['October 2010'],\n",
       "  ['July 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DIG-001'],\n",
       "  ['Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia'],\n",
       "  ['Interventional'],\n",
       "  ['July 2013'],\n",
       "  ['December 2020'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TMENEO-100'],\n",
       "  ['TME Neoadjuvant Breast Registry'],\n",
       "  ['Observational'],\n",
       "  ['July 2015'],\n",
       "  ['July 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['15295'],\n",
       "  ['Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 28, 2016'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['18112'],\n",
       "  ['64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy'],\n",
       "  ['Interventional'],\n",
       "  ['November 3, 2021'],\n",
       "  ['December 1, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IBCSG 25-02 / BIG 3-02'],\n",
       "  ['Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 3, 2003'],\n",
       "  ['December 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['DS8201-A-U302'],\n",
       "  ['DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]'],\n",
       "  ['Interventional'],\n",
       "  ['August 9, 2018'],\n",
       "  ['April 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACOSOG-Z1071'],\n",
       "  ['Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20-275'],\n",
       "  ['Testing a New Imaging Agent to Identify Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 30, 2020'],\n",
       "  ['November 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IIT2018-05-ASHER-IMPROV2'],\n",
       "  [\"LOL: It's All Improv After Cancer!™\"],\n",
       "  ['Interventional'],\n",
       "  ['August 2, 2019'],\n",
       "  ['July 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP P-2'],\n",
       "  ['Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['May 1999'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['IRB-11872'],\n",
       "  ['Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples'],\n",
       "  ['Observational'],\n",
       "  ['August 2001'],\n",
       "  ['January 2099'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['5150012'],\n",
       "  ['Liposomal Bupivacaine in Implant Based Breast Reconstruction'],\n",
       "  ['Interventional'],\n",
       "  ['July 2015'],\n",
       "  ['July 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['0S-10-3'],\n",
       "  ['Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 29, 2013'],\n",
       "  ['January 29, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['19 Years'],\n",
       "  []],\n",
       " [['TORI B-03'],\n",
       "  ['Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)'],\n",
       "  ['Interventional'],\n",
       "  ['June 2003'],\n",
       "  ['January 2012'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['OUT-113-2005; 06140-01'],\n",
       "  ['Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  ['June 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['SDX-0103'],\n",
       "  ['Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 26, 2022'],\n",
       "  ['September 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACOSOG-Z11102'],\n",
       "  ['Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2012'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['PEM-06-01'],\n",
       "  ['Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2006'],\n",
       "  ['March 2009'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  []],\n",
       " [['ML18530'],\n",
       "  ['XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2005'],\n",
       "  ['July 2009'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TRIO030'],\n",
       "  ['A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide'],\n",
       "  ['Interventional'],\n",
       "  ['September 5, 2017'],\n",
       "  ['March 13, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069225'],\n",
       "  ['S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 1998'],\n",
       "  ['November 2003'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-70806'],\n",
       "  ['Vitamin D and Breast Cancer Biomarkers in Female Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 2010'],\n",
       "  ['December 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['55 Years']],\n",
       " [['MA32'],\n",
       "  ['A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 25, 2010'],\n",
       "  ['July 31, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['74 Years']],\n",
       " [['A011202'],\n",
       "  ['Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['February 7, 2014'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['120BC201'],\n",
       "  ['Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding'],\n",
       "  ['Interventional'],\n",
       "  ['November 2009'],\n",
       "  ['October 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BrUOG-BR-211B'],\n",
       "  ['Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2008'],\n",
       "  ['December 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['19-188'],\n",
       "  ['Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial'],\n",
       "  ['Interventional'],\n",
       "  ['November 18, 2021'],\n",
       "  ['July 31, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-31'],\n",
       "  ['Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2'],\n",
       "  ['Interventional'],\n",
       "  ['February 2000'],\n",
       "  ['November 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCCTG-N0434'],\n",
       "  ['Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole'],\n",
       "  ['Observational'],\n",
       "  ['April 2006'],\n",
       "  ['February 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A5481003'],\n",
       "  ['Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 15, 2008'],\n",
       "  ['December 20, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['dtectDx-Breast-001'],\n",
       "  ['Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification'],\n",
       "  ['Observational'],\n",
       "  ['March 2013'],\n",
       "  ['August 2014'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  ['49 Years']],\n",
       " [['CELC-G-301'],\n",
       "  ['Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)'],\n",
       "  ['Interventional'],\n",
       "  ['September 30, 2022'],\n",
       "  ['September 30, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-40101'],\n",
       "  ['Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2002'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DS8201-A-U201'],\n",
       "  ['A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)'],\n",
       "  ['Interventional'],\n",
       "  ['August 25, 2017'],\n",
       "  ['September 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MAP3'],\n",
       "  ['Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 11, 2004'],\n",
       "  ['January 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['NSABP B-32'],\n",
       "  ['Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 1999'],\n",
       "  ['February 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E7389-G000-399'],\n",
       "  ['Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies'],\n",
       "  ['Interventional'],\n",
       "  ['August 2010'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO25126'],\n",
       "  ['A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 8, 2011'],\n",
       "  ['November 30, 2028'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-40105'],\n",
       "  ['Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2003'],\n",
       "  ['January 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['NSABP B-30'],\n",
       "  ['Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes'],\n",
       "  ['Interventional'],\n",
       "  ['March 1999'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-39/RTOG 0413'],\n",
       "  ['Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2005'],\n",
       "  ['August 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6181068'],\n",
       "  ['Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2007'],\n",
       "  ['June 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACE-Breast-03'],\n",
       "  ['ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)'],\n",
       "  ['Interventional'],\n",
       "  ['April 5, 2021'],\n",
       "  ['December 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO28407'],\n",
       "  ['A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 31, 2014'],\n",
       "  ['June 4, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-40'],\n",
       "  ['Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['November 2006'],\n",
       "  ['March 2018'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['16338'],\n",
       "  ['Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 22, 2017'],\n",
       "  ['June 24, 2029'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-42'],\n",
       "  ['Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2006'],\n",
       "  ['December 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['DS8201-A-U305'],\n",
       "  ['A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)'],\n",
       "  ['Interventional'],\n",
       "  ['December 4, 2020'],\n",
       "  ['December 31, 2030'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CCTG MA.39'],\n",
       "  ['Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 30, 2018'],\n",
       "  ['December 30, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['35 Years'],\n",
       "  []],\n",
       " [['CDR0000504319'],\n",
       "  ['S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  ['July 11, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E2108'],\n",
       "  ['Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 8, 2011'],\n",
       "  ['December 21, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['CDR0000066135'],\n",
       "  ['Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 1997'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3144A2-3004 / B1891004'],\n",
       "  ['Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 9, 2009'],\n",
       "  ['October 4, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['V2011201'],\n",
       "  ['Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 15, 2023'],\n",
       "  ['May 26, 2024'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['C3441020'],\n",
       "  ['Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 27, 2018'],\n",
       "  ['September 23, 2020'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000063537'],\n",
       "  ['Nutrition Intervention in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1994'],\n",
       "  ['December 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['48 Years'],\n",
       "  ['78 Years']],\n",
       " [['CDR0000636131'],\n",
       "  ['S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2010'],\n",
       "  ['December 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A011502'],\n",
       "  ['Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['December 8, 2016'],\n",
       "  ['February 15, 2023'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['69 Years']],\n",
       " [['INCB 18424-268'],\n",
       "  ['A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2014'],\n",
       "  ['January 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF105485'],\n",
       "  ['Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2006'],\n",
       "  ['July 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001J2101'],\n",
       "  ['Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2007'],\n",
       "  ['March 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DS8201-A-U301'],\n",
       "  ['DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]'],\n",
       "  ['Interventional'],\n",
       "  ['August 1, 2018'],\n",
       "  ['September 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['06090'],\n",
       "  ['TAC Versus TC for Adjuvant Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 29, 2007'],\n",
       "  ['March 30, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['UCSD-980919'],\n",
       "  [\"Women's Healthy Eating and Living Study\"],\n",
       "  ['Observational'],\n",
       "  ['March 1995'],\n",
       "  ['December 31, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['IBCSG 24-02 / BIG 2-02'],\n",
       "  ['Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 17, 2003'],\n",
       "  ['December 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['CDR0000423180'],\n",
       "  ['S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2005'],\n",
       "  ['August 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO27938'],\n",
       "  ['A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)'],\n",
       "  ['Interventional'],\n",
       "  ['April 3, 2013'],\n",
       "  ['April 3, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['291'],\n",
       "  ['BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)'],\n",
       "  ['Interventional'],\n",
       "  ['July 24, 2014'],\n",
       "  ['November 30, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['CDR0000349337'],\n",
       "  ['S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  ['October 1, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF30008'],\n",
       "  ['Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 9, 2003'],\n",
       "  ['March 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069440'],\n",
       "  ['S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2002'],\n",
       "  ['January 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011O12301C'],\n",
       "  ['A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 7, 2018'],\n",
       "  ['May 29, 2026'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP-B-49'],\n",
       "  ['Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2012'],\n",
       "  ['November 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CTKI258A2202'],\n",
       "  ['Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['March 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-33'],\n",
       "  ['Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen'],\n",
       "  ['Interventional'],\n",
       "  ['May 2001'],\n",
       "  ['February 2011'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000343619'],\n",
       "  ['Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2002'],\n",
       "  ['August 22, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['NSABP B-36'],\n",
       "  ['Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2004'],\n",
       "  ['May 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['LIGAND-L1069-34'],\n",
       "  ['Bexarotene in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 1998'],\n",
       "  ['March 2003'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PUMA-NER-6201'],\n",
       "  ['An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide'],\n",
       "  ['Interventional'],\n",
       "  ['February 2015'],\n",
       "  ['April 22, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IBCSG 48-14 / BIG 8-13'],\n",
       "  ['Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 4, 2014'],\n",
       "  ['December 2028'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['42 Years']],\n",
       " [['WO42133'],\n",
       "  ['A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)'],\n",
       "  ['Interventional'],\n",
       "  ['September 4, 2020'],\n",
       "  ['November 24, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['13892'],\n",
       "  ['Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 6, 2008'],\n",
       "  ['November 19, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000065813'],\n",
       "  ['S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['November 1997'],\n",
       "  ['February 2001'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['EFC6089'],\n",
       "  ['Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  ['September 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000066563'],\n",
       "  ['Combination Chemotherapy in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 1998'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['CDR0000616008'],\n",
       "  ['Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['April 2009'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['WO42633'],\n",
       "  ['A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['May 4, 2021'],\n",
       "  ['October 26, 2034'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000068575'],\n",
       "  ['S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2001'],\n",
       "  ['November 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCCTG-N093B'],\n",
       "  ['Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2010'],\n",
       "  ['September 3, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EFC11486'],\n",
       "  ['A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['February 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E3108'],\n",
       "  ['Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 21, 2010'],\n",
       "  ['May 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-302-02-01-01'],\n",
       "  ['Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2011'],\n",
       "  ['January 2017'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SPI-POZ-201'],\n",
       "  ['Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 22, 2016'],\n",
       "  ['March 11, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['A4061010'],\n",
       "  ['AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2004'],\n",
       "  ['November 2008'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP-MGAH22-02'],\n",
       "  ['Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2013'],\n",
       "  ['April 14, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ISB 1302-103'],\n",
       "  ['Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 8, 2020'],\n",
       "  ['July 24, 2020'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E7389-A001-201'],\n",
       "  ['A Study of E7389 in Advanced/Metastatic Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['September 2004'],\n",
       "  ['November 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-27'],\n",
       "  ['Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed'],\n",
       "  ['Interventional'],\n",
       "  ['December 1995'],\n",
       "  ['February 2010'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['IIT2018-04-MCARTHUR-NEOHP'],\n",
       "  ['Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab'],\n",
       "  ['Interventional'],\n",
       "  ['January 25, 2019'],\n",
       "  ['July 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO20289'],\n",
       "  ['BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2007'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACOSOG-Z0011'],\n",
       "  ['Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1999'],\n",
       "  ['February 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-150007'],\n",
       "  ['Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery'],\n",
       "  ['Observational'],\n",
       "  ['February 2002'],\n",
       "  ['May 1, 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP BP-58'],\n",
       "  ['Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1998'],\n",
       "  ['December 2002'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D081CC00006'],\n",
       "  ['Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 22, 2014'],\n",
       "  ['May 28, 2029'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['ACOSOG-Z0010'],\n",
       "  ['Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 1999'],\n",
       "  ['July 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000065472'],\n",
       "  ['Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 1997'],\n",
       "  ['March 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['TOC4129g'],\n",
       "  ['A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 12, 2008'],\n",
       "  ['November 23, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP FB-13'],\n",
       "  ['Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 22, 2018'],\n",
       "  ['January 30, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PVB Catheter Study'],\n",
       "  ['Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks'],\n",
       "  ['Interventional'],\n",
       "  ['October 2010'],\n",
       "  ['March 2016'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A231701CD'],\n",
       "  [\"Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making\"],\n",
       "  ['Interventional'],\n",
       "  ['March 1, 2019'],\n",
       "  ['December 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D967UC00001'],\n",
       "  ['Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)'],\n",
       "  ['Interventional'],\n",
       "  ['April 26, 2021'],\n",
       "  ['December 30, 2029'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['D8480C00007'],\n",
       "  ['AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['March 2007'],\n",
       "  ['April 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['GO42784'],\n",
       "  [\"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)\"],\n",
       "  ['Interventional'],\n",
       "  ['August 27, 2021'],\n",
       "  ['November 21, 2033'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BTX-BCI-016-PRT'],\n",
       "  ['Breast Cancer Index (BCI) Registry'],\n",
       "  ['Observational'],\n",
       "  ['April 14, 2021'],\n",
       "  ['December 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['11-PIR-11'],\n",
       "  ['The BEACON Study (Breast Cancer Outcomes With NKTR-102)'],\n",
       "  ['Interventional'],\n",
       "  ['December 2011'],\n",
       "  ['June 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-49806'],\n",
       "  ['Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 1999'],\n",
       "  ['February 2002'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ORIN1001-001'],\n",
       "  ['ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 25, 2019'],\n",
       "  ['March 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-35'],\n",
       "  ['Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['January 2003'],\n",
       "  ['May 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['A5481008'],\n",
       "  ['A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)'],\n",
       "  ['Interventional'],\n",
       "  ['February 22, 2013'],\n",
       "  ['August 26, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3475-756'],\n",
       "  ['Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)'],\n",
       "  ['Interventional'],\n",
       "  ['December 27, 2018'],\n",
       "  ['January 24, 2031'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20110148'],\n",
       "  ['Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim'],\n",
       "  ['Interventional'],\n",
       "  ['January 17, 2013'],\n",
       "  ['December 15, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['TDM4997g'],\n",
       "  [\"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy\"],\n",
       "  ['Interventional'],\n",
       "  ['September 2011'],\n",
       "  ['August 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['06BR01'],\n",
       "  ['Phase II Study in Patients With Operable Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2006'],\n",
       "  ['September 2009'],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CZOL446E2352'],\n",
       "  ['Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2006'],\n",
       "  ['July 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000068992'],\n",
       "  ['Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AFT-05'],\n",
       "  ['PALbociclib CoLlaborative Adjuvant Study'],\n",
       "  ['Interventional'],\n",
       "  ['August 2015'],\n",
       "  ['September 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000067353'],\n",
       "  ['Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes'],\n",
       "  ['Interventional'],\n",
       "  ['October 1999'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CO-3810-025'],\n",
       "  ['A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 9, 2014'],\n",
       "  ['January 18, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['9238IL/0048'],\n",
       "  ['The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2003'],\n",
       "  ['September 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['32 Years'],\n",
       "  ['91 Years']],\n",
       " [['CO40016'],\n",
       "  ['A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 6, 2018'],\n",
       "  ['January 4, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TDM4652g'],\n",
       "  ['A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2009'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GE-280-401'],\n",
       "  ['Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients'],\n",
       "  ['Observational'],\n",
       "  ['January 5, 2023'],\n",
       "  ['October 2, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['A011401'],\n",
       "  ['Breast Cancer WEight Loss Study (BWEL Study)'],\n",
       "  ['Interventional'],\n",
       "  ['August 2016'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['0001'],\n",
       "  ['SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 5, 2017'],\n",
       "  ['November 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3144A1-202 / B1891013'],\n",
       "  ['A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 4, 2007'],\n",
       "  ['March 2, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10663'],\n",
       "  ['A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2006'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLCL161A2201'],\n",
       "  ['A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2012'],\n",
       "  ['September 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000380937'],\n",
       "  ['Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['December 2004'],\n",
       "  ['January 30, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['120 Years']],\n",
       " [['RTOG-1005'],\n",
       "  ['Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['May 2011'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-44-I'],\n",
       "  ['BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab'],\n",
       "  ['Interventional'],\n",
       "  ['April 2008'],\n",
       "  ['July 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NRG-BR007'],\n",
       "  ['De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)'],\n",
       "  ['Interventional'],\n",
       "  ['June 7, 2021'],\n",
       "  ['July 2041'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  ['70 Years']],\n",
       " [['WO39391'],\n",
       "  ['A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2, 2018'],\n",
       "  ['August 24, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-49907'],\n",
       "  ['Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2001'],\n",
       "  ['November 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['7962-012'],\n",
       "  ['Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2009'],\n",
       "  ['November 18, 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00504'],\n",
       "  ['Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU'],\n",
       "  ['Interventional'],\n",
       "  ['November 2007'],\n",
       "  ['October 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['OAM4861g'],\n",
       "  ['Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2011'],\n",
       "  ['March 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000723653'],\n",
       "  ['S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2012'],\n",
       "  ['February 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['NU 07B1'],\n",
       "  ['Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2007'],\n",
       "  ['December 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['V3002401'],\n",
       "  ['Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 12, 2021'],\n",
       "  ['April 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['CR004120'],\n",
       "  ['A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2004'],\n",
       "  ['December 2008'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20060359'],\n",
       "  ['Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)'],\n",
       "  ['Interventional'],\n",
       "  ['June 2, 2010'],\n",
       "  ['March 26, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DS8201-A-U303'],\n",
       "  [\"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]\"],\n",
       "  ['Interventional'],\n",
       "  ['December 27, 2018'],\n",
       "  ['March 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-41'],\n",
       "  ['A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2007'],\n",
       "  ['March 2017'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['673-201'],\n",
       "  ['A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)'],\n",
       "  ['Interventional'],\n",
       "  ['December 13, 2013'],\n",
       "  ['October 31, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GO28509'],\n",
       "  ['A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 6, 2013'],\n",
       "  ['December 10, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E7389-G000-209'],\n",
       "  ['A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 31, 2009'],\n",
       "  ['April 30, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011G2301'],\n",
       "  ['Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 20, 2017'],\n",
       "  ['March 9, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S1207'],\n",
       "  ['S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2013'],\n",
       "  ['January 2030'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001J2301'],\n",
       "  ['Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 10, 2009'],\n",
       "  ['October 23, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A8641020'],\n",
       "  ['A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations'],\n",
       "  ['Interventional'],\n",
       "  ['February 3, 2015'],\n",
       "  ['January 14, 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['Pro00045372'],\n",
       "  [\"LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['November 30, 2016'],\n",
       "  ['December 20, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000068630'],\n",
       "  ['S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2001'],\n",
       "  ['February 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A8641016'],\n",
       "  ['A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 4, 2013'],\n",
       "  ['December 24, 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-79809'],\n",
       "  ['Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2001'],\n",
       "  ['February 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['RAD1901-308'],\n",
       "  ['Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 10, 2019'],\n",
       "  ['August 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SON-8184-1075'],\n",
       "  ['Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2005'],\n",
       "  ['September 2007'],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069030'],\n",
       "  ['Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO22589'],\n",
       "  ['A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)'],\n",
       "  ['Interventional'],\n",
       "  ['July 31, 2010'],\n",
       "  ['September 16, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D9268C00001'],\n",
       "  [\"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)\"],\n",
       "  ['Interventional'],\n",
       "  ['October 18, 2021'],\n",
       "  ['August 15, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001Y2301'],\n",
       "  ['Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole'],\n",
       "  ['Interventional'],\n",
       "  ['June 3, 2009'],\n",
       "  ['December 4, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6181077'],\n",
       "  ['Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2006'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['OPT-822-001'],\n",
       "  ['Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects'],\n",
       "  ['Interventional'],\n",
       "  ['December 2011'],\n",
       "  ['August 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CDR0000334899'],\n",
       "  ['S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2003'],\n",
       "  ['January 2027'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15804'],\n",
       "  ['A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 23, 2016'],\n",
       "  ['September 20, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SNDX-275-0602'],\n",
       "  ['Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In'],\n",
       "  ['Interventional'],\n",
       "  ['May 2016'],\n",
       "  ['March 10, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1033-011'],\n",
       "  ['A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2002'],\n",
       "  ['May 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D3615C00001'],\n",
       "  ['Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 16, 2020'],\n",
       "  ['June 7, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['3066A1-303'],\n",
       "  ['Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2004'],\n",
       "  ['October 2006'],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EA1183'],\n",
       "  ['Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study'],\n",
       "  ['Interventional'],\n",
       "  ['April 2, 2020'],\n",
       "  ['August 31, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3144A2-3003 / B1891003'],\n",
       "  ['Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 4, 2009'],\n",
       "  ['June 3, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3144A1-203 / B1891014'],\n",
       "  ['A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 11, 2007'],\n",
       "  ['February 7, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO21977'],\n",
       "  ['A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2009'],\n",
       "  ['September 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['05-055'],\n",
       "  ['Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2005'],\n",
       "  ['May 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16058'],\n",
       "  ['Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 30, 2016'],\n",
       "  ['September 30, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S1200'],\n",
       "  ['S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 16, 2012'],\n",
       "  ['July 1, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP14B014'],\n",
       "  ['Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2010'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-121-02-02-10'],\n",
       "  ['Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 15, 2017'],\n",
       "  ['November 30, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['M12-914'],\n",
       "  ['A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 17, 2014'],\n",
       "  ['January 30, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15342'],\n",
       "  ['Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2, 2016'],\n",
       "  ['September 22, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['60 Years'],\n",
       "  []],\n",
       " [['BO41843'],\n",
       "  ['A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)'],\n",
       "  ['Interventional'],\n",
       "  ['October 9, 2020'],\n",
       "  ['March 18, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000520348'],\n",
       "  ['S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone'],\n",
       "  ['Interventional'],\n",
       "  ['March 2007'],\n",
       "  ['January 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBKM120F2302'],\n",
       "  ['Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor'],\n",
       "  ['Interventional'],\n",
       "  ['August 7, 2012'],\n",
       "  ['April 19, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A5481023'],\n",
       "  ['Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)'],\n",
       "  ['Interventional'],\n",
       "  ['September 26, 2013'],\n",
       "  ['September 28, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBYL719X2402'],\n",
       "  ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments'],\n",
       "  ['Interventional'],\n",
       "  ['August 14, 2017'],\n",
       "  ['July 17, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDX011-03'],\n",
       "  ['A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2010'],\n",
       "  ['November 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-302-02-02-03'],\n",
       "  [\"MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients\"],\n",
       "  ['Interventional'],\n",
       "  ['July 2014'],\n",
       "  ['June 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GDC4950g'],\n",
       "  ['Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['October 2011'],\n",
       "  ['April 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACORN AC01B07'],\n",
       "  ['1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['June 2007'],\n",
       "  ['November 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EFC15935'],\n",
       "  ['Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 14, 2020'],\n",
       "  ['December 29, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['C015'],\n",
       "  ['CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2002'],\n",
       "  ['October 2003'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ML28257'],\n",
       "  ['An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)'],\n",
       "  ['Observational'],\n",
       "  ['June 5, 2012'],\n",
       "  ['November 16, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15417'],\n",
       "  ['A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 6, 2014'],\n",
       "  ['September 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-46-I'],\n",
       "  ['A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2009'],\n",
       "  ['February 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['NCI-2009-00477'],\n",
       "  ['Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 15, 2008'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17096'],\n",
       "  ['Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 4, 2015'],\n",
       "  ['October 28, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['9238IL/0025'],\n",
       "  ['A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 1998'],\n",
       "  ['January 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['C4891001'],\n",
       "  ['A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['March 3, 2023'],\n",
       "  ['May 15, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBYL719C2301'],\n",
       "  ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.'],\n",
       "  ['Interventional'],\n",
       "  ['July 23, 2015'],\n",
       "  ['June 8, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GS-US-586-6144'],\n",
       "  ['Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 14, 2021'],\n",
       "  ['January 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17395'],\n",
       "  ['A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 16, 2019'],\n",
       "  ['March 23, 2023'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['2017'],\n",
       "  ['Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2000'],\n",
       "  ['October 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['108919'],\n",
       "  ['Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 7, 2008'],\n",
       "  ['July 27, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20060362'],\n",
       "  ['QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2008'],\n",
       "  ['August 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001JUS226'],\n",
       "  ['Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2014'],\n",
       "  ['March 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-121-02-02-07 (ARD11918)'],\n",
       "  ['A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2011'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['G1T28-213'],\n",
       "  ['Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 22, 2021'],\n",
       "  ['July 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MM-121-02-02-03 (ARD11588)'],\n",
       "  ['Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['September 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['POL6326-009'],\n",
       "  ['Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 14, 2019'],\n",
       "  ['March 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6181094'],\n",
       "  ['A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2006'],\n",
       "  ['August 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IMMU-132-05'],\n",
       "  ['Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)'],\n",
       "  ['Interventional'],\n",
       "  ['November 7, 2017'],\n",
       "  ['December 8, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['WO29522'],\n",
       "  ['A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)'],\n",
       "  ['Interventional'],\n",
       "  ['June 23, 2015'],\n",
       "  ['August 31, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CTMX-2009-002'],\n",
       "  ['Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 29, 2020'],\n",
       "  ['April 30, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['2008002'],\n",
       "  ['A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.'],\n",
       "  ['Observational'],\n",
       "  ['March 2009'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  []],\n",
       " [['TRIO 020'],\n",
       "  ['Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone'],\n",
       "  ['Interventional'],\n",
       "  ['July 2014'],\n",
       "  ['November 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1200.67'],\n",
       "  ['Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['October 2011'],\n",
       "  ['August 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF108916'],\n",
       "  ['Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2007'],\n",
       "  ['March 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ARV-471-mBC-101'],\n",
       "  ['A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 5, 2019'],\n",
       "  ['February 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP B-59/GBG 96-GeparDouze'],\n",
       "  ['Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo'],\n",
       "  ['Interventional'],\n",
       "  ['December 19, 2017'],\n",
       "  ['June 30, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000285698'],\n",
       "  ['Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2003'],\n",
       "  ['August 2008'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['BO28408'],\n",
       "  ['A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 25, 2014'],\n",
       "  ['May 29, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NeuVax™ PH3-01, BB-IND 009187'],\n",
       "  ['Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence'],\n",
       "  ['Interventional'],\n",
       "  ['November 2011'],\n",
       "  ['September 21, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D931CC00001'],\n",
       "  ['Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 7, 2022'],\n",
       "  ['December 7, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['SPI-GCF-302'],\n",
       "  ['SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide'],\n",
       "  ['Interventional'],\n",
       "  ['May 10, 2017'],\n",
       "  ['May 6, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EA1131'],\n",
       "  ['Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['April 29, 2015'],\n",
       "  ['March 29, 2031'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CR004645'],\n",
       "  ['To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  ['December 2005'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['60 Years'],\n",
       "  []],\n",
       " [['D926XC00001'],\n",
       "  [\"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)\"],\n",
       "  ['Interventional'],\n",
       "  ['November 28, 2022'],\n",
       "  ['March 27, 2030'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['NCI-2011-02572'],\n",
       "  ['Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 6, 2011'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D9670C00001'],\n",
       "  [\"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['July 24, 2020'],\n",
       "  ['June 19, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['105 Years']],\n",
       " [['CDR0000065314'],\n",
       "  ['S9630, Medroxyprogesterone in Treating Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 1997'],\n",
       "  ['December 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBKM120F2303'],\n",
       "  ['A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi'],\n",
       "  ['Interventional'],\n",
       "  ['October 3, 2012'],\n",
       "  ['September 21, 2017'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SPI-GCF-301'],\n",
       "  ['SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)'],\n",
       "  ['Interventional'],\n",
       "  ['January 19, 2016'],\n",
       "  ['October 31, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDX011-04'],\n",
       "  ['Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2013'],\n",
       "  ['August 7, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA209-7FL'],\n",
       "  ['Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 20, 2019'],\n",
       "  ['January 15, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IMMU-132-09'],\n",
       "  [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['May 8, 2019'],\n",
       "  ['October 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['G1T28-212'],\n",
       "  ['Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 19, 2021'],\n",
       "  ['March 13, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CO42867'],\n",
       "  ['A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 20, 2021'],\n",
       "  ['October 31, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D967RC00001'],\n",
       "  ['Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 25, 2021'],\n",
       "  ['June 26, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['213831'],\n",
       "  ['Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease'],\n",
       "  ['Interventional'],\n",
       "  ['June 28, 2021'],\n",
       "  ['August 28, 2029'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['M12-895'],\n",
       "  ['Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 23, 2012'],\n",
       "  ['September 2, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NEO3-05'],\n",
       "  ['Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma'],\n",
       "  ['Interventional'],\n",
       "  ['April 2008'],\n",
       "  ['July 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SGNTUC-016'],\n",
       "  ['A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2, 2019'],\n",
       "  ['April 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBYL719G12301'],\n",
       "  ['Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation'],\n",
       "  ['Interventional'],\n",
       "  ['July 16, 2020'],\n",
       "  ['April 2, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GO25632'],\n",
       "  ['Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 27, 2012'],\n",
       "  ['November 21, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CO41101'],\n",
       "  ['A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['November 25, 2019'],\n",
       "  ['February 28, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E7389-G000-301'],\n",
       "  ['E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes'],\n",
       "  ['Interventional'],\n",
       "  ['September 20, 2006'],\n",
       "  ['December 11, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ONT-380-206'],\n",
       "  ['A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 28, 2016'],\n",
       "  ['August 11, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000064156'],\n",
       "  ['Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 1995'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['15805'],\n",
       "  ['A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2015'],\n",
       "  ['February 12, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['7339-009'],\n",
       "  ['Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)'],\n",
       "  ['Interventional'],\n",
       "  ['December 19, 2019'],\n",
       "  ['January 26, 2026'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ANG1005-CLN-04'],\n",
       "  ['ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['April 2014'],\n",
       "  ['September 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2013-02228'],\n",
       "  ['Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 15, 2014'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S0812'],\n",
       "  ['S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 1, 2011'],\n",
       "  ['September 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['50 Years']],\n",
       " [['RTOG-9517'],\n",
       "  ['Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 1997'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['CTKI258A2210'],\n",
       "  ['Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2012'],\n",
       "  ['April 2015'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17320'],\n",
       "  ['A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 14, 2019'],\n",
       "  ['August 11, 2020'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SNDX-275-0301'],\n",
       "  ['Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 13, 2008'],\n",
       "  ['November 26, 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6191007'],\n",
       "  ['Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2006'],\n",
       "  ['July 2009'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PCS-1402-10749'],\n",
       "  ['Women Informed to Screen Depending on Measures of Risk (Wisdom Study)'],\n",
       "  ['Interventional'],\n",
       "  ['August 31, 2016'],\n",
       "  ['March 1, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['74 Years']],\n",
       " [['SGNTUC-025'],\n",
       "  ['A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 1, 2020'],\n",
       "  ['October 31, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1839US/0713'],\n",
       "  ['Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2004'],\n",
       "  ['May 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AVENTIS-56976-TAX-311'],\n",
       "  ['Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 1994'],\n",
       "  ['June 2004'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ML18527'],\n",
       "  ['A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 2005'],\n",
       "  ['December 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['673-301'],\n",
       "  ['A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)'],\n",
       "  ['Interventional'],\n",
       "  ['October 14, 2013'],\n",
       "  ['March 5, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3160A2-201'],\n",
       "  ['Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2006'],\n",
       "  ['February 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BRE09-146'],\n",
       "  ['PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations'],\n",
       "  ['Interventional'],\n",
       "  ['February 2010'],\n",
       "  ['December 15, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF30001'],\n",
       "  ['Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2004'],\n",
       "  ['March 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17384'],\n",
       "  ['A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 10, 2021'],\n",
       "  ['February 9, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1200.75'],\n",
       "  ['LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment'],\n",
       "  ['Interventional'],\n",
       "  ['June 22, 2010'],\n",
       "  ['July 6, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NRG-BR003'],\n",
       "  ['Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2015'],\n",
       "  ['November 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IPI-549-03'],\n",
       "  ['Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)'],\n",
       "  ['Interventional'],\n",
       "  ['December 17, 2019'],\n",
       "  ['August 1, 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ML43171'],\n",
       "  [\"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)\"],\n",
       "  ['Interventional'],\n",
       "  ['August 3, 2022'],\n",
       "  ['March 31, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15450'],\n",
       "  ['A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain'],\n",
       "  ['Interventional'],\n",
       "  ['April 20, 2015'],\n",
       "  ['November 8, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GO29227'],\n",
       "  ['A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors'],\n",
       "  ['Interventional'],\n",
       "  ['August 19, 2014'],\n",
       "  ['August 31, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP-00-0011'],\n",
       "  ['Cryoablation of Small Breast Tumors in Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2013'],\n",
       "  ['June 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['B2151009'],\n",
       "  ['A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 14, 2016'],\n",
       "  ['January 19, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['C31001'],\n",
       "  ['Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 13, 2014'],\n",
       "  ['June 29, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-369901'],\n",
       "  ['Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['August 2003'],\n",
       "  ['December 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['65 Years'],\n",
       "  []],\n",
       " [['CZOL446EUS32'],\n",
       "  ['Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['September 2002'],\n",
       "  ['January 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['85 Years']],\n",
       " [['CA163-115'],\n",
       "  ['A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2007'],\n",
       "  ['November 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D926PC00001'],\n",
       "  [\"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)\"],\n",
       "  ['Interventional'],\n",
       "  ['May 16, 2022'],\n",
       "  ['December 3, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['V2000701'],\n",
       "  ['Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 11, 2022'],\n",
       "  ['January 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['CLEE011XUS29'],\n",
       "  ['Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.'],\n",
       "  ['Interventional'],\n",
       "  ['June 14, 2016'],\n",
       "  ['February 25, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP FB-5'],\n",
       "  ['Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2007'],\n",
       "  ['May 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['941466'],\n",
       "  [\"Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study\"],\n",
       "  ['Observational'],\n",
       "  ['September 2016'],\n",
       "  ['February 2022'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['89 Years']],\n",
       " [['CAL-03'],\n",
       "  ['An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  [],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CO39611'],\n",
       "  ['A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 26, 2017'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A211801'],\n",
       "  ['Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation'],\n",
       "  ['Interventional'],\n",
       "  ['February 23, 2022'],\n",
       "  ['December 2033'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  ['55 Years']],\n",
       " [['2014-0443'],\n",
       "  ['Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 2014'],\n",
       "  ['December 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A4021004'],\n",
       "  ['Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2007'],\n",
       "  ['June 2014'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GS-US-592-6173'],\n",
       "  [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['July 25, 2022'],\n",
       "  ['February 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GS-US-592-6238'],\n",
       "  [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['July 20, 2022'],\n",
       "  ['May 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2014-00746'],\n",
       "  ['Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic'],\n",
       "  ['Interventional'],\n",
       "  ['March 29, 2014'],\n",
       "  ['October 28, 2028'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['LCMH-001'],\n",
       "  ['Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2008'],\n",
       "  ['October 4, 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  []],\n",
       " [['SMX 18001'],\n",
       "  ['Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'],\n",
       "  ['Interventional'],\n",
       "  ['September 20, 2019'],\n",
       "  ['February 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP MA.32.F'],\n",
       "  ['Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32'],\n",
       "  ['Observational'],\n",
       "  ['July 2011'],\n",
       "  ['September 2016'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['74 Years']],\n",
       " [['17471'],\n",
       "  ['Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 14, 2018'],\n",
       "  ['December 29, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['70 Years'],\n",
       "  []],\n",
       " [['18459'],\n",
       "  ['A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 4, 2022'],\n",
       "  ['March 15, 2032'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CR018286'],\n",
       "  ['A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['August 24, 2011'],\n",
       "  ['August 8, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011F2301'],\n",
       "  ['Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['June 9, 2015'],\n",
       "  ['January 11, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SGNLVA-002'],\n",
       "  ['Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 27, 2018'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['M14-011'],\n",
       "  ['A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2, 2014'],\n",
       "  ['November 12, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['110264'],\n",
       "  ['Treatment With Pazopanib for Neoadjuvant Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2009'],\n",
       "  ['April 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000068583'],\n",
       "  ['Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2001'],\n",
       "  ['March 2002'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AL42478'],\n",
       "  ['An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic'],\n",
       "  ['Expanded Access'],\n",
       "  [],\n",
       "  [],\n",
       "  ['Approved for marketing'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['RT-016'],\n",
       "  ['Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2004'],\n",
       "  ['June 2007'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20060341'],\n",
       "  ['Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['July 2007'],\n",
       "  ['May 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A171601'],\n",
       "  ['Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 15, 2018'],\n",
       "  ['August 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['70 Years'],\n",
       "  []],\n",
       " [['E7389-G000-305'],\n",
       "  [\"E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['November 2006'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6181002'],\n",
       "  ['A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.'],\n",
       "  ['Interventional'],\n",
       "  ['March 2004'],\n",
       "  ['November 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRX100-001'],\n",
       "  ['Study of CRX100 in Patients With Advanced Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['January 8, 2021'],\n",
       "  ['March 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['DARE'],\n",
       "  ['DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 9, 2021'],\n",
       "  ['December 15, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['TP2001-202'],\n",
       "  ['APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)'],\n",
       "  ['Interventional'],\n",
       "  ['April 2008'],\n",
       "  ['September 2009'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CO40115'],\n",
       "  ['A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2, 2018'],\n",
       "  ['May 3, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000442919'],\n",
       "  ['S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2005'],\n",
       "  ['January 2007'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['Male'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF 20002'],\n",
       "  ['Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.'],\n",
       "  ['Interventional'],\n",
       "  ['October 2002'],\n",
       "  ['June 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2012-02305'],\n",
       "  ['Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2'],\n",
       "  ['Interventional'],\n",
       "  ['August 1999'],\n",
       "  ['March 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S1202'],\n",
       "  ['S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['May 15, 2013'],\n",
       "  ['December 20, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['120 Years']],\n",
       " [['CZOL446EUS147'],\n",
       "  ['Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP-MGAH22-04'],\n",
       "  ['Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 24, 2015'],\n",
       "  ['June 14, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2016-01595'],\n",
       "  ['Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 15, 2016'],\n",
       "  ['May 31, 2026'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['G1T28-04'],\n",
       "  ['Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)'],\n",
       "  ['Interventional'],\n",
       "  ['February 2, 2017'],\n",
       "  ['February 28, 2020'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069347'],\n",
       "  ['Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['LCCC 9727'],\n",
       "  ['High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 1997'],\n",
       "  ['January 2003'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['65 Years']],\n",
       " [['CA180-261'],\n",
       "  ['Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2009'],\n",
       "  ['December 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['Biomed 777-CLP-30'],\n",
       "  ['The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2004'],\n",
       "  ['August 2006'],\n",
       "  ['Terminated'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2018-01519'],\n",
       "  ['Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 12, 2018'],\n",
       "  ['June 1, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['14392'],\n",
       "  ['A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2011'],\n",
       "  ['June 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-01073'],\n",
       "  ['Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['December 1, 2008'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-01172'],\n",
       "  ['Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['May 15, 2009'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-70301'],\n",
       "  ['Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 2005'],\n",
       "  ['June 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PT-304'],\n",
       "  ['Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['November 2009'],\n",
       "  ['October 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['08-PIR-05'],\n",
       "  ['Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2008'],\n",
       "  ['January 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001C2222'],\n",
       "  ['Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['March 2005'],\n",
       "  ['April 2007'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00341'],\n",
       "  ['Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['July 2007'],\n",
       "  ['February 21, 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15362'],\n",
       "  ['A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 22, 2014'],\n",
       "  ['January 30, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['9785-CL-1121'],\n",
       "  ['A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 28, 2014'],\n",
       "  ['March 31, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00561'],\n",
       "  ['Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2, 2007'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ABI-007-MBC-001'],\n",
       "  ['Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)'],\n",
       "  ['Interventional'],\n",
       "  ['September 26, 2013'],\n",
       "  ['October 28, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['22339'],\n",
       "  ['Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['June 6, 2023'],\n",
       "  ['October 31, 2024'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A011801'],\n",
       "  ['T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial'],\n",
       "  ['Interventional'],\n",
       "  ['January 6, 2021'],\n",
       "  ['May 2035'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D0819C00003'],\n",
       "  ['Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.'],\n",
       "  ['Interventional'],\n",
       "  ['March 27, 2014'],\n",
       "  ['December 29, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['16131'],\n",
       "  ['Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1, 2017'],\n",
       "  ['January 28, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['12444'],\n",
       "  ['Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 21, 2011'],\n",
       "  ['October 20, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['STn-BR-105'],\n",
       "  ['Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['August 2002'],\n",
       "  ['August 2005'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['117515'],\n",
       "  ['Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['May 18, 2012'],\n",
       "  ['December 31, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  []],\n",
       " [['CDR0000068399'],\n",
       "  ['Digital Mammography Screening Trial (ACRIN6652)'],\n",
       "  ['Interventional'],\n",
       "  ['October 2001'],\n",
       "  ['June 30, 2005'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  ['120 Years']],\n",
       " [['18238'],\n",
       "  ['Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 11, 2022'],\n",
       "  ['February 16, 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['dtectDx-Breast-002'],\n",
       "  ['Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol'],\n",
       "  ['Observational'],\n",
       "  ['March 2014'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  ['75 Years']],\n",
       " [['16298'],\n",
       "  ['Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2, 2015'],\n",
       "  ['August 13, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AVF3694g'],\n",
       "  ['A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)'],\n",
       "  ['Interventional'],\n",
       "  ['December 2005'],\n",
       "  ['December 2013'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000065011'],\n",
       "  ['Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 1997'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['91466'],\n",
       "  ['Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2006'],\n",
       "  ['November 2008'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A011104'],\n",
       "  ['MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2014'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['11649'],\n",
       "  ['Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2008'],\n",
       "  ['January 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CFEM345DUS59'],\n",
       "  ['Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 2008'],\n",
       "  ['June 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['50 Years'],\n",
       "  []],\n",
       " [['CDR0000067956'],\n",
       "  ['Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2000'],\n",
       "  ['August 2002'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['CALGB-70305'],\n",
       "  ['Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection'],\n",
       "  ['Interventional'],\n",
       "  ['June 2006'],\n",
       "  ['June 15, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00665'],\n",
       "  ['Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 30, 2008'],\n",
       "  ['October 15, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['09-009'],\n",
       "  ['Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)'],\n",
       "  ['Interventional'],\n",
       "  ['September 2011'],\n",
       "  ['April 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011A2301'],\n",
       "  ['Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)'],\n",
       "  ['Interventional'],\n",
       "  ['December 17, 2013'],\n",
       "  ['March 26, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3475-522'],\n",
       "  ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)'],\n",
       "  ['Interventional'],\n",
       "  ['March 7, 2017'],\n",
       "  ['September 30, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A6181099'],\n",
       "  ['A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2007'],\n",
       "  ['June 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA163-046'],\n",
       "  ['Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2003'],\n",
       "  ['March 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00475'],\n",
       "  ['Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive'],\n",
       "  ['Interventional'],\n",
       "  ['September 15, 2006'],\n",
       "  ['July 2, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['155-CL-036'],\n",
       "  ['A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2009'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10-008061'],\n",
       "  ['Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction'],\n",
       "  ['Interventional'],\n",
       "  ['May 2011'],\n",
       "  ['November 2013'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['3144A2-3005 / B1891005'],\n",
       "  ['Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 21, 2009'],\n",
       "  ['June 28, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20-001275'],\n",
       "  ['Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 9, 2020'],\n",
       "  ['September 30, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GS-US-595-6184'],\n",
       "  [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy\"],\n",
       "  ['Interventional'],\n",
       "  ['December 12, 2022'],\n",
       "  ['January 2031'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF104900'],\n",
       "  ['Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2005'],\n",
       "  ['October 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SGNLVA-001'],\n",
       "  ['A Safety Study of SGN-LIV1A in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['October 22, 2013'],\n",
       "  ['February 4, 2023'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2014-02409'],\n",
       "  ['Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 6, 2015'],\n",
       "  ['May 25, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ARV-471-mBC-102'],\n",
       "  ['ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 8, 2022'],\n",
       "  ['February 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['10112'],\n",
       "  ['Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 20, 2011'],\n",
       "  ['February 22, 2025'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['60 Years'],\n",
       "  []],\n",
       " [['SMX 20-001'],\n",
       "  ['Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'],\n",
       "  ['Interventional'],\n",
       "  ['September 29, 2020'],\n",
       "  ['February 10, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['0S-17-7'],\n",
       "  ['Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 8, 2017'],\n",
       "  ['December 31, 2018'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['VEG20007'],\n",
       "  ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2006'],\n",
       "  ['March 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['C31006'],\n",
       "  ['Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['July 28, 2016'],\n",
       "  ['November 25, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2011-02623'],\n",
       "  ['Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 15, 2011'],\n",
       "  ['March 7, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ONC-010'],\n",
       "  ['EndoPredict® Extended Endocrine Trial (EXET)'],\n",
       "  ['Observational'],\n",
       "  ['July 2, 2019'],\n",
       "  ['March 31, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CRAD001Y2201'],\n",
       "  ['A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.'],\n",
       "  ['Interventional'],\n",
       "  ['February 26, 2013'],\n",
       "  ['July 30, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2016-01130'],\n",
       "  ['Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 15, 2016'],\n",
       "  ['August 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['WO40181'],\n",
       "  ['A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['September 6, 2018'],\n",
       "  ['May 6, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['107CS-6'],\n",
       "  ['Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 25, 2018'],\n",
       "  ['April 2022'],\n",
       "  ['Unknown status'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI 2013-01-03'],\n",
       "  ['Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy'],\n",
       "  ['Interventional'],\n",
       "  ['October 2015'],\n",
       "  ['May 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PUMA-NER-1301'],\n",
       "  ['A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting'],\n",
       "  ['Interventional'],\n",
       "  ['March 29, 2013'],\n",
       "  ['December 9, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP-B-51'],\n",
       "  ['Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['August 2013'],\n",
       "  ['August 2028'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011A2404'],\n",
       "  ['Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC'],\n",
       "  ['Interventional'],\n",
       "  ['November 30, 2016'],\n",
       "  ['December 3, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['AVI-014-P02'],\n",
       "  ['Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia'],\n",
       "  ['Interventional'],\n",
       "  ['August 2007'],\n",
       "  ['July 2009'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00476'],\n",
       "  ['Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 13, 2008'],\n",
       "  ['June 15, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17502'],\n",
       "  ['A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 10, 2019'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011E2301'],\n",
       "  ['Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 20, 2014'],\n",
       "  ['March 27, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['59 Years']],\n",
       " [['4703'],\n",
       "  ['A Phase III Trial For Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2002'],\n",
       "  ['November 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['PMD-026-1-001'],\n",
       "  ['Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 14, 2019'],\n",
       "  ['March 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['C4391002'],\n",
       "  ['A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['March 14, 2022'],\n",
       "  ['December 30, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2012-01849'],\n",
       "  ['Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 19, 2000'],\n",
       "  ['January 27, 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SGNTUC-028'],\n",
       "  ['A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 7, 2022'],\n",
       "  ['June 30, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011X2107'],\n",
       "  ['Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 22, 2013'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NSABP FB-7'],\n",
       "  ['Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 2010'],\n",
       "  ['November 25, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000339812'],\n",
       "  ['Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 2004'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['25 Years'],\n",
       "  []],\n",
       " [['09-040'],\n",
       "  ['Study of Radiation Exposure and Bilateral Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['May 2009'],\n",
       "  ['May 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['54 Years']],\n",
       " [['S1703'],\n",
       "  ['S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 16, 2018'],\n",
       "  ['January 1, 2038'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NRG-BR002'],\n",
       "  ['Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival'],\n",
       "  ['Interventional'],\n",
       "  ['December 24, 2014'],\n",
       "  ['December 20, 2026'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCCTG-N9431'],\n",
       "  ['Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['June 1996'],\n",
       "  ['October 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['55 Years']],\n",
       " [['D8532C00001'],\n",
       "  ['A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease'],\n",
       "  ['Interventional'],\n",
       "  ['January 28, 2021'],\n",
       "  ['February 1, 2029'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['15-102-14'],\n",
       "  [\"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine\"],\n",
       "  ['Interventional'],\n",
       "  ['November 2016'],\n",
       "  ['July 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['3144A1-2206 / B1891017'],\n",
       "  ['Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 9, 2008'],\n",
       "  ['June 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['VAR0033'],\n",
       "  ['Immunobiology of Cancer'],\n",
       "  ['Observational'],\n",
       "  ['October 2008'],\n",
       "  ['October 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2011-02585'],\n",
       "  ['Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 21, 2011'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ACT16105'],\n",
       "  [\"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['October 22, 2019'],\n",
       "  ['September 29, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2012-01977'],\n",
       "  ['Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 26, 2012'],\n",
       "  ['May 20, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA023'],\n",
       "  ['Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 1, 2006'],\n",
       "  ['March 1, 2011'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['090214'],\n",
       "  [\"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)\"],\n",
       "  ['Interventional'],\n",
       "  ['August 20, 2009'],\n",
       "  ['April 11, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['S1501'],\n",
       "  ['S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 15, 2017'],\n",
       "  ['January 1, 2029'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20170770'],\n",
       "  ['Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 26, 2020'],\n",
       "  ['January 14, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['91743'],\n",
       "  ['Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI'],\n",
       "  ['Interventional'],\n",
       "  ['February 2010'],\n",
       "  ['January 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF103659'],\n",
       "  ['EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer'],\n",
       "  ['Expanded Access'],\n",
       "  ['July 2006'],\n",
       "  ['March 2015'],\n",
       "  ['Approved for marketing'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S2007'],\n",
       "  ['Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['December 15, 2020'],\n",
       "  ['December 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['213551'],\n",
       "  [\"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients\"],\n",
       "  ['Interventional'],\n",
       "  ['February 25, 2014'],\n",
       "  ['October 26, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000617081'],\n",
       "  ['S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo'],\n",
       "  ['Interventional'],\n",
       "  ['September 2009'],\n",
       "  ['June 2013'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['TDM4884g'],\n",
       "  ['A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Expanded Access'],\n",
       "  ['May 2010'],\n",
       "  [],\n",
       "  ['No longer available'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['368255'],\n",
       "  ['Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax'],\n",
       "  ['Interventional'],\n",
       "  ['May 21, 2013'],\n",
       "  ['September 28, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['18175'],\n",
       "  [\"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\"],\n",
       "  ['Interventional'],\n",
       "  ['October 4, 2021'],\n",
       "  ['August 31, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['20110147'],\n",
       "  ['NOLAN: Naproxen or Loratadine and Neulasta'],\n",
       "  ['Interventional'],\n",
       "  ['November 1, 2012'],\n",
       "  ['March 18, 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['NCI-2011-01379'],\n",
       "  ['Veliparib With or Without Carboplatin in Treating Patients With Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 30, 2010'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['111438'],\n",
       "  ['Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 14, 2009'],\n",
       "  ['March 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000065237'],\n",
       "  ['SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial'],\n",
       "  ['Observational'],\n",
       "  ['February 1997'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['NCCTG-N00C9'],\n",
       "  ['EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2002'],\n",
       "  ['April 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2015-00383'],\n",
       "  ['FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['February 2, 2016'],\n",
       "  ['April 4, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['999915030'],\n",
       "  ['Self-Affirmation, Emotion, and Alcohol Consumption'],\n",
       "  ['Observational'],\n",
       "  ['November 19, 2014'],\n",
       "  ['September 29, 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['201209135'],\n",
       "  ['Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 11, 2012'],\n",
       "  ['March 11, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A011106'],\n",
       "  ['Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['December 13, 2013'],\n",
       "  [],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2015-01912'],\n",
       "  ['Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['July 7, 2016'],\n",
       "  ['October 31, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SCUSF 0806'],\n",
       "  ['Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab'],\n",
       "  ['Interventional'],\n",
       "  ['March 2010'],\n",
       "  ['November 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB 6110'],\n",
       "  ['The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels'],\n",
       "  ['Interventional'],\n",
       "  ['January 2006'],\n",
       "  ['March 2007'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " [['CRAD001Y24135'],\n",
       "  ['Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 7, 2013'],\n",
       "  ['January 13, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D8180C00034'],\n",
       "  ['Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease'],\n",
       "  ['Interventional'],\n",
       "  ['February 2008'],\n",
       "  ['August 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['D3614C00001'],\n",
       "  ['Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC'],\n",
       "  ['Interventional'],\n",
       "  ['June 25, 2019'],\n",
       "  ['October 6, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['CDR0000069346'],\n",
       "  ['Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CD-ON-MEDI-573-1030'],\n",
       "  ['Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['June 13, 2011'],\n",
       "  ['June 28, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['99 Years']],\n",
       " [['CDR0000065241'],\n",
       "  ['Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function'],\n",
       "  ['Interventional'],\n",
       "  ['December 1996'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SPI-GCF-104'],\n",
       "  ['Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 11, 2020'],\n",
       "  ['June 30, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['55 Years']],\n",
       " [['NUV-422-03'],\n",
       "  ['Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC'],\n",
       "  ['Interventional'],\n",
       "  ['September 2022'],\n",
       "  ['September 2026'],\n",
       "  ['Withdrawn'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['WO29217'],\n",
       "  ['A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 14, 2014'],\n",
       "  ['August 25, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-03778'],\n",
       "  ['Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['January 2006'],\n",
       "  ['March 14, 2019'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2019-06088'],\n",
       "  ['Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones'],\n",
       "  ['Interventional'],\n",
       "  ['December 27, 2019'],\n",
       "  ['June 30, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SCO-120-19-22'],\n",
       "  ['A Study in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 20, 2022'],\n",
       "  ['January 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['BO16216'],\n",
       "  ['A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 2001'],\n",
       "  ['October 2009'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GEN-602-CT-101'],\n",
       "  ['Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 1, 2019'],\n",
       "  ['December 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15419'],\n",
       "  ['A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread'],\n",
       "  ['Interventional'],\n",
       "  ['June 10, 2014'],\n",
       "  ['October 22, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2017-01119'],\n",
       "  ['Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 12, 2019'],\n",
       "  ['April 30, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NO16853'],\n",
       "  ['A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 2003'],\n",
       "  ['March 2010'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-70604'],\n",
       "  ['Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement'],\n",
       "  ['Interventional'],\n",
       "  ['March 2009'],\n",
       "  ['January 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A5481082'],\n",
       "  ['Palbociclib in Real World Practice'],\n",
       "  ['Observational'],\n",
       "  ['January 4, 2017'],\n",
       "  ['October 1, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CBYL719A2201'],\n",
       "  ['Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women'],\n",
       "  ['Interventional'],\n",
       "  ['March 11, 2014'],\n",
       "  ['July 8, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00284'],\n",
       "  ['Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 31, 2008'],\n",
       "  ['February 14, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['UCI 06-46'],\n",
       "  ['LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis'],\n",
       "  ['Interventional'],\n",
       "  ['March 2007'],\n",
       "  ['August 2008'],\n",
       "  ['Completed'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1200.11'],\n",
       "  ['Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['September 2006'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['105-08-201'],\n",
       "  ['Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall'],\n",
       "  ['Interventional'],\n",
       "  ['February 2013'],\n",
       "  ['June 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SLN-USA-1'],\n",
       "  ['Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes'],\n",
       "  ['Interventional'],\n",
       "  ['July 2015'],\n",
       "  ['March 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['CDR0000449959'],\n",
       "  ['T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['August 2005'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['NCI-2018-01581'],\n",
       "  ['Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 14, 2018'],\n",
       "  ['December 31, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA163-048'],\n",
       "  ['Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2003'],\n",
       "  ['March 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EA1151'],\n",
       "  ['Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 6, 2017'],\n",
       "  ['December 31, 2030'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['45 Years'],\n",
       "  ['74 Years']],\n",
       " [['UCI 05-46'],\n",
       "  ['Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab'],\n",
       "  ['Interventional'],\n",
       "  ['March 2006'],\n",
       "  ['June 2010'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['WO43571'],\n",
       "  ['A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)'],\n",
       "  ['Interventional'],\n",
       "  ['July 4, 2022'],\n",
       "  ['September 30, 2032'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CAAA504A12101'],\n",
       "  ['Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.'],\n",
       "  ['Interventional'],\n",
       "  ['October 14, 2021'],\n",
       "  ['November 10, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['IRB-16617'],\n",
       "  ['Stanford Accelerated Recovery Trial (START)'],\n",
       "  ['Interventional'],\n",
       "  ['May 2010'],\n",
       "  ['July 2016'],\n",
       "  ['Terminated'],\n",
       "  ['Principal Investigator'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['P0339 NBRST Registry'],\n",
       "  ['NBRST: Prospective Neo-adjuvant REGISTRY Trial'],\n",
       "  ['Observational'],\n",
       "  ['July 2011'],\n",
       "  ['January 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['90 Years']],\n",
       " [['3475-B49'],\n",
       "  ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)'],\n",
       "  ['Interventional'],\n",
       "  ['June 18, 2021'],\n",
       "  ['July 21, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000066242'],\n",
       "  ['MRI to Detect Breast Tumors in Women'],\n",
       "  ['Interventional'],\n",
       "  ['May 1998'],\n",
       "  ['June 30, 2000'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['79 Years']],\n",
       " [['EGF106708'],\n",
       "  ['ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D'],\n",
       "  ['Interventional'],\n",
       "  ['May 16, 2007'],\n",
       "  ['July 1, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CTKI258A2128'],\n",
       "  ['Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['December 2011'],\n",
       "  ['July 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2009-00707'],\n",
       "  ['Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)'],\n",
       "  ['Interventional'],\n",
       "  ['April 7, 2006'],\n",
       "  ['September 30, 2030'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['1839IL/0225'],\n",
       "  ['Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study'],\n",
       "  ['Interventional'],\n",
       "  ['October 2003'],\n",
       "  ['June 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['130 Years']],\n",
       " [['GYN0001'],\n",
       "  ['Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program'],\n",
       "  ['Observational'],\n",
       "  ['January 2010'],\n",
       "  ['July 2013'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ABI-007-ST-001'],\n",
       "  ['Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 12, 2015'],\n",
       "  ['September 12, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['OBI-822-011'],\n",
       "  ['Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC'],\n",
       "  ['Interventional'],\n",
       "  ['December 5, 2018'],\n",
       "  ['December 30, 2027'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['H3B-6545-A001-101'],\n",
       "  ['Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['August 17, 2017'],\n",
       "  ['October 1, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A221803'],\n",
       "  ['Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy'],\n",
       "  ['Interventional'],\n",
       "  ['June 15, 2022'],\n",
       "  ['December 31, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NEO3-09'],\n",
       "  ['Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes'],\n",
       "  ['Interventional'],\n",
       "  ['June 2010'],\n",
       "  ['April 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011XUS10T'],\n",
       "  ['Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2016'],\n",
       "  ['April 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor-Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GLSI-21-01'],\n",
       "  ['Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects'],\n",
       "  ['Interventional'],\n",
       "  ['August 11, 2022'],\n",
       "  ['December 2026'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['100 Years']],\n",
       " [['PrE0102'],\n",
       "  ['Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI'],\n",
       "  ['Interventional'],\n",
       "  ['May 31, 2013'],\n",
       "  ['September 12, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000066165'],\n",
       "  ['Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors'],\n",
       "  ['Interventional'],\n",
       "  ['February 1998'],\n",
       "  ['January 2001'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['70 Years']],\n",
       " [['A221702'],\n",
       "  ['Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection'],\n",
       "  ['Interventional'],\n",
       "  ['May 31, 2019'],\n",
       "  ['January 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S1222'],\n",
       "  ['S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 2014'],\n",
       "  ['December 31, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CA048-001'],\n",
       "  ['A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread'],\n",
       "  ['Interventional'],\n",
       "  ['September 22, 2020'],\n",
       "  ['August 15, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['213363'],\n",
       "  ['Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 15, 2016'],\n",
       "  ['September 17, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['0S-17-5'],\n",
       "  ['Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors'],\n",
       "  ['Interventional'],\n",
       "  ['August 17, 2017'],\n",
       "  ['July 15, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['1280-0022'],\n",
       "  ['The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread'],\n",
       "  ['Interventional'],\n",
       "  ['November 28, 2018'],\n",
       "  ['May 11, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['MC1835-ACCRU-BR-1701'],\n",
       "  ['TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery'],\n",
       "  ['Interventional'],\n",
       "  ['February 20, 2020'],\n",
       "  ['January 15, 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CDR0000069104'],\n",
       "  ['Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2001'],\n",
       "  [],\n",
       "  ['Unknown status'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ODO-TE-B301'],\n",
       "  ['Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC'],\n",
       "  ['Interventional'],\n",
       "  ['December 21, 2017'],\n",
       "  ['June 28, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['LPT109096'],\n",
       "  ['Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.'],\n",
       "  ['Interventional'],\n",
       "  ['August 2007'],\n",
       "  ['August 2015'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['17237'],\n",
       "  ['HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases'],\n",
       "  ['Interventional'],\n",
       "  ['August 31, 2018'],\n",
       "  ['August 31, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['75 Years']],\n",
       " [['209514'],\n",
       "  ['Pilot Study of Pancreatic Cancer Screening'],\n",
       "  ['Observational'],\n",
       "  ['January 20, 2022'],\n",
       "  ['January 31, 2032'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['E7389-M001-218'],\n",
       "  ['Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)'],\n",
       "  ['Interventional'],\n",
       "  ['August 28, 2015'],\n",
       "  ['April 6, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CTPR-0009'],\n",
       "  ['Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®'],\n",
       "  ['Interventional'],\n",
       "  ['May 8, 2012'],\n",
       "  ['December 2029'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  []],\n",
       " [['18-27025'],\n",
       "  ['SCOPE-Chinese Women Study'],\n",
       "  ['Interventional'],\n",
       "  ['July 20, 2020'],\n",
       "  ['December 30, 2021'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SPI-GCF-12-201'],\n",
       "  ['Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 25, 2013'],\n",
       "  ['August 12, 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16244'],\n",
       "  ['Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer'],\n",
       "  ['Expanded Access'],\n",
       "  [],\n",
       "  [],\n",
       "  ['Approved for marketing'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CP-13-001'],\n",
       "  ['MarginProbe 2.0 Data Collection Protocol'],\n",
       "  ['Observational'],\n",
       "  ['December 15, 2021'],\n",
       "  ['December 31, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EGF105084'],\n",
       "  ['Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2, 2005'],\n",
       "  ['March 15, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A211601'],\n",
       "  ['Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502'],\n",
       "  ['Observational'],\n",
       "  ['August 1, 2018'],\n",
       "  ['July 18, 2022'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['DAN-22220205'],\n",
       "  ['A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['February 2, 2022'],\n",
       "  ['April 30, 2024'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLP0008'],\n",
       "  ['Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients'],\n",
       "  ['Interventional'],\n",
       "  ['September 1, 2020'],\n",
       "  ['December 2025'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['SCRI BRE 145'],\n",
       "  ['A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2008'],\n",
       "  ['November 2016'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S0927'],\n",
       "  [\"S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy\"],\n",
       "  ['Interventional'],\n",
       "  ['February 2012'],\n",
       "  ['March 2014'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  ['120 Years']],\n",
       " [['NCI-2019-02752'],\n",
       "  ['Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['October 21, 2019'],\n",
       "  ['November 1, 2023'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['16-304'],\n",
       "  ['Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma'],\n",
       "  ['Interventional'],\n",
       "  ['April 1, 2018'],\n",
       "  ['April 1, 2030'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Principal Investigator'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['C3621001'],\n",
       "  ['Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC'],\n",
       "  ['Interventional'],\n",
       "  ['November 27, 2018'],\n",
       "  ['September 27, 2021'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ML29366'],\n",
       "  ['A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy'],\n",
       "  ['Interventional'],\n",
       "  ['December 16, 2015'],\n",
       "  ['December 29, 2020'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['EZN-2208-03'],\n",
       "  ['A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2009'],\n",
       "  ['December 2012'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['VEG108838'],\n",
       "  ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['December 2007'],\n",
       "  ['December 2011'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['RTOG-9804'],\n",
       "  ['Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ'],\n",
       "  ['Interventional'],\n",
       "  ['December 1999'],\n",
       "  ['May 20, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['26 Years'],\n",
       "  ['120 Years']],\n",
       " [['EA1181'],\n",
       "  ['CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['February 11, 2020'],\n",
       "  ['December 31, 2038'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['960-CSP-USA_DenseBreasts_USS1'],\n",
       "  ['A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts'],\n",
       "  ['Interventional'],\n",
       "  ['April 15, 2018'],\n",
       "  ['April 30, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['40 Years'],\n",
       "  ['70 Years']],\n",
       " [['NEPA-17-05'],\n",
       "  ['A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['March 16, 2018'],\n",
       "  ['September 19, 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['378-ONC-0030-184'],\n",
       "  ['Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 2000'],\n",
       "  ['August 2006'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['A191901'],\n",
       "  ['Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy'],\n",
       "  ['Interventional'],\n",
       "  ['February 15, 2021'],\n",
       "  ['October 2025'],\n",
       "  ['Suspended'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['NCI-2015-00741'],\n",
       "  ['Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['November 6, 2015'],\n",
       "  ['February 22, 2024'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['G1T48-01'],\n",
       "  ['G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 9, 2018'],\n",
       "  ['September 29, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  ['Yes'],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CALGB-40903'],\n",
       "  ['Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ'],\n",
       "  ['Interventional'],\n",
       "  ['February 2012'],\n",
       "  ['January 2018'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ML17771'],\n",
       "  ['A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['September 2004'],\n",
       "  ['October 2004'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['S1904'],\n",
       "  ['Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)'],\n",
       "  ['Interventional'],\n",
       "  ['September 1, 2020'],\n",
       "  ['June 1, 2028'],\n",
       "  ['Recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  [],\n",
       "  []],\n",
       " [['MM-111-01-100'],\n",
       "  ['A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers'],\n",
       "  ['Interventional'],\n",
       "  ['June 2009'],\n",
       "  ['March 2012'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['GS-US-350-1937'],\n",
       "  ['GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['January 10, 2017'],\n",
       "  ['July 19, 2018'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['CLEE011AUS42'],\n",
       "  ['A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib'],\n",
       "  ['Interventional'],\n",
       "  ['June 7, 2017'],\n",
       "  ['March 8, 2019'],\n",
       "  ['Terminated'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['TORI B-02'],\n",
       "  ['Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)'],\n",
       "  ['Interventional'],\n",
       "  ['May 2005'],\n",
       "  [],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['15160'],\n",
       "  ['Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities'],\n",
       "  ['Interventional'],\n",
       "  ['April 6, 2016'],\n",
       "  ['October 15, 2023'],\n",
       "  ['Active, not recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['OSNA-BC-001'],\n",
       "  ['Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer'],\n",
       "  ['Observational'],\n",
       "  ['February 2007'],\n",
       "  ['December 2008'],\n",
       "  ['Completed'],\n",
       "  [],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['RTOG 0517'],\n",
       "  ['Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['July 11, 2006'],\n",
       "  ['February 27, 2017'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['114299'],\n",
       "  ['A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['May 5, 2011'],\n",
       "  ['June 6, 2022'],\n",
       "  ['Completed'],\n",
       "  ['Sponsor'],\n",
       "  ['Female'],\n",
       "  [],\n",
       "  ['18 Years'],\n",
       "  []],\n",
       " [['ONCB-006-19F'],\n",
       "  ['Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer'],\n",
       "  ['Interventional'],\n",
       "  ['April 19, 2023'],\n",
       "  ['April 1, 2027'],\n",
       "  ['Not yet recruiting'],\n",
       "  ['Sponsor'],\n",
       "  ['All'],\n",
       "  [],\n",
       "  ['21 Years'],\n",
       "  []],\n",
       " ...]"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "values_list = df.values.tolist()\n",
    "values_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "d3141eaa",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['CCT1043'], ['Breast Cancer Trials Education Program'], ['Interventional'], ['May 2007'], ['December 2015'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], []][['150B-0158'], ['Breast Cancer Risk Reduction: A Patient Doctor Intervention'], ['Interventional'], ['June 2011'], ['December 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['40 Years'], ['74 Years']][['CHUM-CRYOABLATION'], ['Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers'], ['Interventional'], ['April 2013'], ['October 2014'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20107812'], ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging'], ['Observational'], ['December 2010'], ['October 2013'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['234870'], ['Blood Glycan Biomarkers in Women With Stage IV Breast Cancer'], ['Observational'], ['September 2006'], ['January 12, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['FWA00010885'], ['Breast Cancer Survivorship & Work-Related Cognitive Limitation'], ['Observational'], ['September 2014'], ['February 2015'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], ['69 Years']][['CC077515'], ['Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer'], ['Interventional'], ['January 2011'], ['March 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20022306'], ['Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy'], ['Interventional'], ['June 2002'], ['January 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['75 Years']][['STUDY00001641'], ['Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women'], ['Interventional'], ['July 16, 2022'], ['December 1, 2024'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['45 Years'], ['80 Years']][['00080'], ['Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease'], ['Observational'], ['July 2001'], ['September 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['IRB-14623 part 1'], ['Intellectual Impairment in Women With Breast Cancer'], ['Interventional'], ['January 12, 2009'], ['June 2013'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['40 Years'], ['65 Years']][['IIT2015-11-Giuliano-SNBO'], ['Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy'], ['Interventional'], ['December 2015'], ['April 2020'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['13278'], ['Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)'], ['Observational'], ['September 30, 2013'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['200715040'], ['Molecular Imaging of Breast Cancer With Breast PET/CT'], ['Interventional'], ['April 2007'], ['July 2011'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['SU-10042011-8529'], ['National Breast Cancer and Lymphedema Registry'], ['Observational'], ['September 12, 2011'], ['March 2, 2018'], ['Terminated'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['IRB-10748'], ['Magnetic Resonance Imaging of Breast Cancer'], ['Interventional'], ['April 1, 1995'], ['May 2027'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['21 Years'], []][['IRB-12226'], ['Development of Vitamin D as a Therapy for Breast Cancer - Phase 2'], ['Interventional'], ['April 2008'], ['December 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['5110026'], ['Partial Breast Proton Therapy for Early Stage Breast Cancer'], ['Interventional'], ['May 4, 2011'], ['May 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], ['80 Years']][['08063'], ['Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer'], ['Interventional'], ['December 2, 2008'], ['June 26, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['182-20-CA'], ['18F-fluoroestradiol (FES) PET/CT for Breast Cancer'], ['Interventional'], ['January 15, 2021'], ['December 15, 2023'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['01-BR-003'], ['Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer'], ['Observational'], ['July 2, 2020'], ['March 17, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['037519'], ['Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer'], ['Interventional'], ['November 3, 2004'], ['December 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08103'], ['Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer'], ['Interventional'], ['November 2008'], ['April 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['19-001004'], ['Brain Health in Breast Cancer Survivors'], ['Observational'], ['March 11, 2020'], ['March 15, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['35 Years'], ['65 Years']][['14-001744'], ['Project Connect Online: An Internet-based Intervention for Women With Breast Cancer'], ['Interventional'], ['June 4, 2015'], ['June 17, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000257580'], ['Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer'], ['Interventional'], ['May 2002'], ['April 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['75 Years']][['99002'], ['Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer'], ['Interventional'], ['May 18, 1999'], ['June 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['59 Years']][['12175'], ['Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors'], ['Interventional'], ['August 2012'], ['July 2013'], ['Terminated'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['UCLA-9810046'], ['Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer'], ['Interventional'], ['January 1999'], ['October 2004'], ['Completed'], [], ['Female'], [], [], []][['1B-15-3'], ['Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy'], ['Observational'], ['August 10, 2015'], ['November 26, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRSNSTU0009'], ['Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2'], ['Observational'], ['July 2005'], ['April 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCSF-077518'], ['Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2'], ['Interventional'], ['August 2007'], ['December 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['07006'], ['Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy'], ['Observational'], ['October 2007'], ['January 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['10038'], ['Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)'], ['Interventional'], ['January 15, 2020'], ['January 15, 2035'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2015-06-Chung-SNBO'], ['Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65'], ['Interventional'], ['January 22, 2016'], ['June 2025'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['65 Years'], []][['SPI-POZ-101'], ['A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer'], ['Interventional'], ['July 13, 2018'], ['April 17, 2019'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['90 Years']][['07213'], ['White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors'], ['Interventional'], ['June 2008'], ['December 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['09147'], ['MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer'], ['Observational'], ['November 2009'], ['May 20, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-34959'], ['Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer'], ['Observational'], ['August 2016'], ['July 8, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000430701'], ['Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer'], ['Interventional'], ['April 2005'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['11-003446'], ['Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors'], ['Interventional'], ['April 2012'], ['September 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['21 Years'], ['65 Years']][['03178'], ['IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer'], ['Interventional'], ['January 2005'], ['October 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], ['75 Years']][['SC0001'], ['Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons'], ['Interventional'], ['January 2003'], ['January 2010'], ['Unknown status'], [], ['Female'], [], ['35 Years'], ['90 Years']][['BRSADJ0003'], ['Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer'], ['Interventional'], ['January 2005'], ['August 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], ['70 Years']][['USI2011001'], ['CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study'], ['Observational'], ['July 2011'], ['September 2011'], ['Completed'], ['Sponsor'], ['All'], [], [], []][['IRB-48150'], ['68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer'], ['Interventional'], ['March 19, 2019'], ['June 18, 2024'], ['Suspended'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['CDR0000442877'], ['Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer'], ['Interventional'], ['May 2005'], ['November 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IIT2017-07-HO-PembroRT'], ['Breast Cancer Study of Preoperative Pembrolizumab + Radiation'], ['Interventional'], ['December 22, 2017'], ['April 21, 2023'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['A5481155'], ['Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy'], ['Observational'], ['June 30, 2020'], ['December 31, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2015-18-Mita-MK3475'], ['Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer'], ['Interventional'], ['September 10, 2017'], ['November 8, 2024'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['CDR0000067909'], ['Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['September 1999'], ['April 2004'], ['Completed'], [], ['All'], [], [], []][['BMS-CA163-031'], ['BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['September 2002'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], ['120 Years']][['CDR0000599060'], ['Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer'], ['Interventional'], ['July 2008'], [], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000515534'], ['ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['October 2006'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['UCI 05-38'], ['Neoadjuvant Treatment of Breast Cancer'], ['Interventional'], ['October 2005'], ['September 4, 2013'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['1B-12-6'], ['Light-Scattering Spectroscopy for Detection of Breast Cancer'], ['Interventional'], ['November 21, 2012'], ['November 19, 2020'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['037517'], ['Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer'], ['Interventional'], ['May 2004'], ['January 2013'], ['Completed'], ['Sponsor'], ['All'], [], [], ['120 Years']][['IRB-13807'], ['Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer'], ['Interventional'], ['September 2002'], ['March 2029'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['IRB-31913'], ['Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors'], ['Interventional'], ['August 2015'], ['December 2022'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['01-06-020'], ['Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression'], ['Interventional'], ['August 2001'], ['December 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['05015'], ['Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer'], ['Interventional'], ['September 27, 2005'], ['June 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['07170'], ['Study of Support Groups for African-American Breast Cancer Survivors'], ['Interventional'], ['January 2008'], ['September 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['09101'], ['Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer'], ['Interventional'], ['March 16, 2011'], ['December 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1B-13-2'], ['Core Biopsies for Establishing a Breast Tumor Tissue Repository'], ['Observational'], ['November 14, 2013'], ['November 14, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCD-986545'], ['Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['April 1996'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], ['55 Years']][['IRB-57723'], ['Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer'], ['Interventional'], ['February 3, 2021'], ['February 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BNIT-BR-002'], ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer'], ['Interventional'], ['June 2007'], ['September 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['960-CSP-USA_MIRA_USS2'], ['Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer'], ['Interventional'], ['May 2016'], ['October 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['30 Years'], ['70 Years']][['STUDY2019000317'], ['Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer'], ['Observational'], ['October 3, 2018'], ['October 3, 2028'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CDR0000271533'], ['CP-724,714 in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['January 2003'], ['May 2005'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['12-028 MWA - Breast Tumors'], ['Microwave Ablation of Breast Tumors'], ['Observational'], ['September 2012'], ['December 2012'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['IRB-21034'], ['Vitamin D and Breast Cancer: Does Weight Make a Difference?'], ['Interventional'], ['November 2011'], ['October 2015'], ['Terminated'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['IRB-21030'], ['Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer'], ['Interventional'], ['July 2012'], ['March 17, 2015'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['90 Years']][['F31AT003021'], ['Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors'], ['Interventional'], ['October 2005'], ['September 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], ['70 Years']][['057519'], ['Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['March 1, 2006'], ['December 1, 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['1R01CA140481'], ['Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors'], ['Interventional'], ['August 2012'], ['July 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['B27IB3856'], ['UCLA Breast Cancer Survivor Health Promotion Research Study'], ['Interventional'], ['April 1, 2022'], ['June 2023'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['50 Years'], ['75 Years']][['U01AT003682'], ['A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue'], ['Interventional'], ['June 2008'], ['December 2010'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['40 Years'], ['65 Years']][['53294'], ['Proton Therapy for Early Stage Breast Cancer'], ['Interventional'], ['February 2004'], ['May 12, 2020'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['96139'], ['Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer'], ['Interventional'], ['May 30, 1997'], ['December 30, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['60 Years']][['08242'], ['Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life'], ['Observational'], ['June 11, 2009'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['08128'], ['Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer'], ['Observational'], ['September 4, 2008'], ['June 20, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['GENBASIX-00127'], ['Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters'], ['Observational'], ['January 2001'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], []][['CC# 087515'], ['Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer'], ['Interventional'], ['December 10, 2008'], ['July 29, 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['06102'], ['Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors'], ['Interventional'], ['October 2006'], ['June 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['587842'], ['Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer'], ['Observational'], ['April 2014'], ['April 7, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['100 Years']][['UCI 03-70'], ['Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer'], ['Interventional'], ['April 2004'], ['July 2012'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['CDR0000505536'], ['Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ'], ['Interventional'], ['October 2001'], ['May 2007'], ['Completed'], [], ['All'], [], ['18 Years'], []][['1B-03-1'], ['Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['July 2003'], ['December 2006'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IORT'], ['Intraoperative Radiotherapy for Early Stage Breast Cancer'], ['Interventional'], ['June 2010'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['48 Years'], []][['10-001799'], ['A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors'], ['Interventional'], ['April 2011'], ['November 2014'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['50 Years']][['UCI-HS-2000-1141'], ['Angiogenesis in Early Breast Cancer for Prognosis Prediction'], ['Interventional'], ['November 2000'], ['July 2010'], ['Completed'], [], ['Female'], [], ['18 Years'], ['90 Years']][['160178'], ['Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer'], ['Interventional'], ['August 15, 2018'], ['January 13, 2023'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['BRSMTS0002'], ['Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study'], ['Observational'], ['November 2000'], ['August 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], ['70 Years']][['IRB-03518'], ['Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer'], ['Interventional'], ['October 2006'], ['March 2011'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], ['70 Years']][['08092'], ['Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer'], ['Interventional'], ['November 2008'], ['May 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['50 Years'], []][['25IB-0023'], ['Exercise Study for Breast Cancer Survivors'], ['Interventional'], ['November 25, 2019'], ['December 2020'], ['Unknown status'], ['Principal Investigator'], ['Female'], ['Yes'], [], []][['IRB# 06-05-104'], ['Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer'], ['Interventional'], ['January 2007'], ['October 2007'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['CBCRP 11IB-0034'], ['Effect of Increased Light Exposure on Fatigue in Breast Cancer'], ['Interventional'], ['November 2005'], ['November 2009'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['CDR0000465214'], ['Radiation Therapy in Treating Women With Invasive Breast Cancer'], ['Interventional'], ['April 2004'], ['May 2004'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-13429'], ['Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women'], ['Interventional'], ['October 2000'], ['June 2013'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['70 Years']][['SU-11052007-799'], ['Molecular Analysis of Breast Cancer'], ['Observational'], ['May 1996'], ['May 2050'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000316264'], ['Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy'], ['Interventional'], ['May 2003'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['GSM'], ['GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors'], ['Interventional'], ['November 18, 2016'], ['July 23, 2018'], ['Terminated'], ['Principal Investigator'], ['Female'], ['Yes'], [], []][['UCSD-020815'], ['Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer'], ['Interventional'], ['July 2003'], ['March 2008'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['60 Years']][['BNIT-BR-003'], ['A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy'], ['Interventional'], ['June 2010'], ['September 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IIT2018-17-McArthur-TCDRT'], ['Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer'], ['Interventional'], ['July 2022'], ['July 2027'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1B-05-5'], ['Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI'], ['Interventional'], ['November 20, 2005'], ['November 20, 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['07102022_SR'], ['Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer'], ['Interventional'], ['September 1, 2022'], ['June 1, 2023'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['07100'], ['Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer'], ['Observational'], ['July 6, 2010'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], [], []][['12383'], ['Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors'], ['Interventional'], ['July 15, 2013'], ['June 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['KCT 005'], ['A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery'], ['Interventional'], ['June 1, 2021'], ['December 31, 2021'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['05751'], ['Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases'], ['Interventional'], ['February 2005'], ['January 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['11115'], ['Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors'], ['Interventional'], ['June 1, 2012'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1B-08-7'], ['Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer'], ['Interventional'], ['February 2009'], ['February 2011'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['07157'], ['Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer'], ['Interventional'], ['February 11, 2008'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['UCSD#100231'], ['Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer'], ['Interventional'], ['June 2010'], ['October 2015'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['UCI-HS-2006-5162'], ['Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis'], ['Interventional'], ['October 1, 2006'], ['October 30, 2017'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['90 Years']][['AVF3359s'], ['Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study'], ['Interventional'], ['June 2006'], ['October 2008'], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['IRB-07696'], ['Healing Touch During Chemotherapy Infusions for Women With Breast Cancer'], ['Interventional'], ['April 2007'], ['August 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['09-09-058'], ['Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients'], ['Observational'], ['May 2010'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-08051'], ['Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer'], ['Interventional'], ['January 2008'], ['December 2009'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['BRSADJ0013'], ['Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival'], ['Observational'], ['September 2006'], ['August 31, 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['45 Years'], ['75 Years']][['IRB-13732'], ['Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention'], ['Interventional'], ['November 2005'], ['December 2010'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['65 Years']][['05042'], ['Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer'], ['Interventional'], ['July 2005'], ['October 2014'], ['Completed'], ['Sponsor'], ['All'], [], [], ['65 Years']][['08166'], ['Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['May 17, 2010'], ['September 27, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SPI-GCF-301-PK'], ['Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy'], ['Interventional'], ['May 11, 2017'], ['May 18, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BRSNSTU0002'], ['Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer'], ['Observational'], ['November 2001'], ['June 2007'], ['Completed'], [], ['Female'], [], ['25 Years'], ['65 Years']][['06136'], ['Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers'], ['Interventional'], ['August 2006'], ['November 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-59141'], ['Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer'], ['Interventional'], ['February 23, 2023'], ['March 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['5140020'], ['Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer'], ['Interventional'], ['February 12, 2014'], ['December 2023'], ['Suspended'], ['Sponsor'], ['Female'], [], ['18 Years'], ['100 Years']][['BRSADJ0009'], ['A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer'], ['Observational'], ['January 2009'], ['September 2010'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['1B-14-7'], ['Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer'], ['Observational'], ['March 5, 2015'], ['February 7, 2017'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRSMTS0012'], ['Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers'], ['Interventional'], ['July 2010'], ['December 2014'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1B-08-1'], ['Green Tea in Breast Cancer Patients'], ['Interventional'], ['May 7, 2008'], ['June 6, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['TRIO 017'], ['Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['February 2009'], ['April 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['057514'], ['Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer'], ['Interventional'], ['August 20, 2007'], ['March 24, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], ['75 Years']][['117513'], ['Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib'], ['Interventional'], ['April 27, 2012'], ['October 2, 2019'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['CDR0000378088'], ['Study of Ductal Lavage in Women at High Risk for Breast Cancer'], ['Observational'], ['August 2002'], ['June 2004'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1098987'], ['Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients'], ['Interventional'], ['October 2007'], ['December 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['TRIO 016'], ['Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['February 2009'], ['March 2010'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['173-18-CA'], ['Perioperative Mindfulness Proposal'], ['Interventional'], ['July 31, 2019'], ['December 31, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['157512'], ['Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer'], ['Observational'], ['August 2, 2016'], ['December 31, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16758'], ['Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer'], ['Interventional'], ['December 28, 2016'], ['February 28, 2022'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], ['85 Years']][['11996'], ['Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies'], ['Interventional'], ['March 27, 2012'], ['December 31, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['80 Years']][['VEG108843'], ['Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer'], ['Interventional'], ['April 2008'], ['November 2012'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1B-13-8'], ['Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery'], ['Interventional'], ['December 19, 2013'], ['September 25, 2016'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000069154'], ['Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer'], ['Interventional'], ['February 2001'], ['February 2005'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['QUILT-3.067'], ['QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.'], ['Interventional'], ['March 16, 2018'], ['January 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['197520'], ['Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer'], ['Interventional'], ['March 11, 2021'], ['March 1, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI HS# 2015-1866'], ['Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System'], ['Observational'], ['May 2015'], ['January 25, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['CDR0000068369'], ['Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'], ['Interventional'], ['March 2001'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], []][['117527'], ['Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer'], ['Interventional'], ['November 1, 2012'], ['June 9, 2016'], ['Terminated'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['150860'], ['Tracking Physical Activity Throughout Chemotherapy for Breast Cancer'], ['Observational'], ['June 1, 2015'], ['February 8, 2018'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['85 Years']][['QUILT-3.058'], ['A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies'], ['Interventional'], ['September 27, 2021'], ['January 4, 2023'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2022-07-YUAN-IB-TNBC'], ['Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['April 2023'], ['October 2026'], ['Not yet recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['221183'], ['Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis'], ['Interventional'], ['November 2010'], ['March 4, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['CDR0000657044'], ['Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants'], ['Interventional'], ['January 2016'], [], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2015-12-Goodman-STOP'], ['STOP Heart Disease in Breast Cancer Survivors Trial'], ['Interventional'], ['May 5, 2016'], ['May 25, 2018'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['NCI-2012-02827'], ['GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['October 2003'], ['March 2010'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-02836'], ['Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer'], ['Interventional'], ['June 2005'], ['January 2008'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15BB-1300'], ['Nuevo Amanecer: Promoting the Psychosocial Health of Latinas'], ['Interventional'], ['February 2011'], ['May 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['017513'], ['Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ'], ['Interventional'], ['February 19, 2002'], ['June 30, 2011'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['1B-12-10'], ['Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer'], ['Interventional'], ['July 29, 2013'], ['March 2, 2021'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRS0001'], ['Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT'], ['Interventional'], ['February 2008'], ['December 2012'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['22239'], ['Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors'], ['Interventional'], ['March 15, 2023'], ['May 15, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['ITL-014-TACT-MBC'], ['Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients'], ['Interventional'], ['March 2014'], ['March 2014'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['20171'], ['Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer'], ['Interventional'], ['July 27, 2021'], ['December 12, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['IRB-52869'], ['Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer'], ['Interventional'], ['March 20, 2023'], ['December 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1B-21-6'], ['Breast Cancer Survivorship Biorepository'], ['Observational'], ['April 11, 2022'], ['April 11, 2028'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-63041'], ['Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer'], ['Interventional'], ['August 16, 2022'], ['August 2026'], ['Recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['U54 CA155435-01 Project 3'], ['Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors'], ['Interventional'], ['August 2011'], ['December 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], [], []][['GC-627-05'], ['Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy'], ['Interventional'], ['April 12, 2018'], ['March 5, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000367118'], ['GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu'], ['Interventional'], ['March 2004'], ['February 2005'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI 19-145 [HS# 1459]'], ['Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer'], ['Interventional'], ['August 31, 2022'], ['December 31, 2028'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['20923'], ['Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand'], ['Observational'], ['May 18, 2020'], ['May 24, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], [], ['70 Years']][['18496'], ['Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['March 4, 2019'], ['December 21, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['21094'], ['CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['October 18, 2021'], ['December 1, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MMP-001'], ['Mindful Movement for Breast Cancer Survivors'], ['Interventional'], ['November 2015'], ['June 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['1B-16-3'], ['Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer'], ['Interventional'], ['April 21, 2017'], ['July 8, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['QUILT-3.057'], ['QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine'], ['Interventional'], ['September 2018'], ['December 2021'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['21050'], ['An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis'], ['Interventional'], ['December 21, 2022'], ['February 25, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['10192'], ['Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid'], ['Interventional'], ['September 14, 2012'], ['February 2015'], ['Terminated'], ['Sponsor'], ['Female'], [], [], []][['PILOT 171548'], ['RISE - Reduce Sitting Time Among Breast Cancer Survivors'], ['Interventional'], ['March 29, 2022'], ['February 7, 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['50 Years'], []][['1B-12-1'], ['Exercise Program for Early Breast Cancer Survivors'], ['Interventional'], ['May 21, 2012'], ['October 1, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['16-1856'], ['Integrative Approaches for Cancer Survivorship 2: Project 2'], ['Interventional'], ['September 2016'], ['June 4, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-53650'], ['Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer'], ['Interventional'], ['October 13, 2020'], ['October 22, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SLNPain01'], ['Sentinel Lymph Node Mapping Post-Injection Site Pain'], ['Observational'], ['March 2014'], ['February 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['16-18567'], ['Integrative Approaches For Cancer Survivorship 2: Project 1'], ['Interventional'], ['September 2016'], ['September 21, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20107789'], ['Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging'], ['Observational'], ['December 2010'], ['December 2018'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['75 Years']][['4 BB-2901'], ['Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?'], ['Interventional'], [], [], ['Completed'], [], ['Female'], [], ['18 Years'], []][['IRB-12273'], ['Stress, Diurnal Cortisol, and Breast Cancer Survival'], ['Observational'], ['September 8, 2002'], ['December 2005'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['19-001881'], ['Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors'], ['Interventional'], ['September 29, 2021'], ['November 1, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['74 Years']][['IRB-57111'], ['Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients'], ['Interventional'], ['March 15, 2021'], ['October 31, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16-185671'], ['Integrative Approaches to Cancer Survivorship: Project 3'], ['Interventional'], ['April 17, 2018'], ['January 30, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-58571'], ['Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer'], ['Interventional'], ['January 20, 2021'], ['October 12, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20141505'], ['Breast Tumor Oxygenation During Exercise'], ['Observational'], ['April 2015'], ['January 2018'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['70 Years']][['IRB-13761'], ['Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer'], ['Interventional'], ['February 2006'], ['November 2012'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['19206'], ['Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.'], ['Interventional'], ['March 25, 2020'], ['December 15, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['70 Years'], []][['17-000560'], ['Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors'], ['Interventional'], ['July 11, 2017'], ['December 3, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['19 Years'], []][['18549'], ['Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema'], ['Interventional'], ['April 19, 2019'], ['March 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['5R03CA144751-02'], ['Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer'], ['Interventional'], ['January 2010'], ['September 2011'], ['Completed'], ['Principal Investigator'], ['All'], [], [], []][['UCSD POISE'], ['Predictors of Ovarian Insufficiency in Young Breast Cancer Patients'], ['Observational'], ['September 24, 2008'], ['July 18, 2019'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['45 Years']][['BRS0027'], ['Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer'], ['Interventional'], ['July 2013'], ['July 2015'], ['Terminated'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['16-001271'], ['Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer'], ['Interventional'], ['August 2, 2017'], ['March 31, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['19 Years'], []][['OMS-I140'], ['Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC'], ['Interventional'], ['September 2015'], ['July 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][[\"SIMR_onc19_IIS_D'Andre_Ashwaga\"], ['Ashwagandha for Cognitive Dysfunction'], ['Interventional'], ['January 1, 2020'], ['November 1, 2022'], ['Unknown status'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['04125'], ['Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease'], ['Observational'], ['August 2005'], ['June 6, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['20 Years'], []][['1B-16-11'], ['Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer'], ['Interventional'], ['July 29, 2019'], ['July 29, 2025'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1B-11-5'], ['Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy'], ['Interventional'], ['September 4, 2012'], ['September 30, 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['21152'], ['Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer'], ['Interventional'], ['June 21, 2022'], ['September 7, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['11174'], ['Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer'], ['Interventional'], ['February 15, 2012'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['19 Years'], []][['14135'], ['Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors'], ['Interventional'], ['September 7, 2014'], ['June 3, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['56 Years'], []][['TRIO-US B09'], ['Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis'], ['Interventional'], ['June 26, 2013'], ['May 10, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20091527'], ['The Health of Women Study'], ['Observational'], ['August 2009'], ['July 18, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['08061'], ['Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors'], ['Interventional'], ['August 2008'], ['April 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['CDR0000428460'], ['Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer'], ['Interventional'], ['February 2005'], ['November 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['45 Years'], ['65 Years']][['02164'], ['Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease'], ['Interventional'], ['March 11, 2004'], ['June 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['21 Years'], ['48 Years']][['RSGPB-04-258-01-CPPB'], ['Weight Reduction Intervention for Breast Cancer Survivors'], ['Interventional'], ['January 2005'], ['December 2009'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['1B-14-5'], ['High-Intensity Interval Training for Stage I-III Breast Cancer Patients'], ['Interventional'], ['September 29, 2015'], ['July 15, 2019'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCLA-9908076'], ['Cryosurgery in Treating Women With Breast Lesions'], ['Interventional'], ['May 2001'], ['July 2004'], ['Completed'], [], ['Female'], [], [], []][['1B-09-14'], ['Endoscopic Breast Surgery in Treating Patients With Breast Cancer'], ['Interventional'], ['September 2010'], ['October 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['15 Years'], []][['1B-12-4'], ['Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer'], ['Interventional'], ['October 1, 2012'], ['October 21, 2016'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['7BB-2400'], ['Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?'], ['Observational'], ['July 1, 2000'], ['November 30, 2006'], ['Completed'], ['Sponsor'], ['Female'], [], ['20 Years'], ['85 Years']][['1R03CA168450-01'], ['Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)'], ['Interventional'], ['April 2013'], ['October 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['80 Years']][['SNP-17-001'], ['Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer'], ['Observational'], ['September 21, 2018'], ['November 11, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['16294'], ['Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer'], ['Interventional'], ['March 22, 2017'], ['November 22, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], [], []][['SAIRB-15-0060'], ['A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.'], ['Observational'], ['December 2015'], [], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['P0518095'], ['Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device'], ['Interventional'], ['October 31, 2017'], ['January 31, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['120108'], ['Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy'], ['Interventional'], ['March 2012'], ['December 2012'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['85 Years']][['IRB-30982'], ['Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer'], ['Interventional'], ['August 2015'], ['July 2019'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['14253'], ['Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer'], ['Interventional'], ['January 7, 2016'], ['December 19, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['S07-002'], ['Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to \"Low-risk\" Breast Cancer Patients'], ['Interventional'], ['May 2008'], ['July 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['17753'], ['T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer'], ['Interventional'], ['February 5, 2020'], ['April 30, 2024'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['167514'], ['Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib'], ['Interventional'], ['October 9, 2018'], ['October 31, 2022'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['R01 CA119 159'], ['Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms'], ['Interventional'], ['March 2008'], ['July 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['30 Years'], ['70 Years']][['IIT2019-21-Basho-TOPAZ'], ['TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases'], ['Interventional'], ['June 1, 2022'], ['June 1, 2024'], ['Withdrawn'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['IRB-01671'], ['Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status'], ['Interventional'], ['May 2005'], ['September 2009'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['18-000427'], ['Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted'], ['Interventional'], ['July 10, 2019'], ['July 1, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CL- Gedatolisib-001'], ['Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer'], ['Interventional'], ['January 2016'], ['March 15, 2022'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['VINJ007'], ['Acupuncture for CIPN in Breast Cancer Patients'], ['Interventional'], ['October 2015'], ['December 2018'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['21-001819'], ['Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer'], ['Interventional'], ['April 7, 2022'], ['April 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AVB620-C-001'], ['Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery'], ['Interventional'], ['April 2015'], ['January 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-37299'], ['4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer'], ['Interventional'], ['October 30, 2017'], ['February 14, 2022'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['BRSMTS0010'], ['Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast'], ['Interventional'], ['August 2007'], ['December 2011'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['RJ-101-RCT-001'], ['Study to Investigate the Effect of AB-101 in Breast Cancer Survivors'], ['Interventional'], ['July 9, 2018'], ['October 12, 2019'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['70 Years']][['09109'], ['Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel'], ['Interventional'], ['January 2010'], ['May 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['13-001676'], ['Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus'], ['Interventional'], ['October 8, 2014'], ['November 30, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PA18-0280'], ['A Culturally Sensitive Social Support Intervention'], ['Interventional'], ['January 2015'], ['August 2021'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['06-08-010'], ['Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors'], ['Interventional'], ['March 2008'], ['October 2009'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['65 Years']][['MRSGT-10-011-01-CPPB'], ['Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors'], ['Interventional'], ['June 2012'], ['March 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['14955'], ['Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer'], ['Interventional'], ['February 23, 2015'], ['January 8, 2019'], ['Terminated'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['5354-CL-1201'], ['A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery'], ['Interventional'], ['August 10, 2022'], ['September 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], ['Yes'], ['18 Years'], []][['14099'], ['Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer'], ['Interventional'], ['January 7, 2015'], ['December 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000393552'], ['Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers'], ['Interventional'], ['November 2004'], [], ['Terminated'], [], ['All'], [], ['18 Years'], ['120 Years']][['BMT86'], ['CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant'], ['Interventional'], ['September 1996'], ['June 2005'], ['Completed'], [], ['All'], [], ['19 Years'], ['70 Years']][['BRSNSTU0024'], ['Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI'], ['Observational'], ['April 2008'], ['December 2011'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['80 Years']][['CDR0000069155'], ['Herbal Therapy in Treating Women With Metastatic Breast Cancer'], ['Interventional'], ['August 2001'], ['April 2006'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCDCC#237'], ['Oxaliplatin in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['May 2015'], ['December 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['KCT003'], ['A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema'], ['Interventional'], ['June 1, 2021'], ['December 31, 2021'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NU 98B3'], ['Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer'], ['Interventional'], ['October 1999'], ['April 2000'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000439421'], ['Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer'], ['Interventional'], ['April 2005'], ['December 2009'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IM-T-hMN14-04'], ['Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer'], ['Interventional'], ['February 2000'], ['June 2003'], ['Completed'], [], ['All'], [], ['18 Years'], []][['16421'], ['Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention'], ['Interventional'], ['August 9, 2017'], ['December 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IIT 2014-01'], ['Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment'], ['Interventional'], ['July 6, 2015'], ['May 23, 2018'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['140863'], ['Reproductive Health Survivorship Care Plan'], ['Interventional'], ['March 25, 2015'], ['January 24, 2019'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['45 Years']][['Breast Pain'], ['Symptom Management After Breast Cancer Surgery'], ['Interventional'], ['September 2003'], ['December 2007'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CRICC-BB-IND-7186'], ['Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['June 1997'], ['October 2004'], ['Completed'], [], ['All'], [], ['18 Years'], []][['20080325'], ['A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer'], ['Interventional'], ['October 21, 2008'], ['February 7, 2018'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['14-071'], ['Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History'], ['Observational'], ['April 8, 2014'], ['April 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['60 Years'], []][['98096'], ['Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer'], ['Interventional'], ['May 1999'], ['December 2013'], ['Completed'], ['Sponsor'], ['All'], [], [], ['60 Years']][['C07-104'], ['Safety and Efficacy Study Using Rexin-G for Breast Cancer'], ['Interventional'], ['July 2007'], ['June 2011'], ['Completed'], [], ['All'], [], ['18 Years'], []][['10-01831'], ['Fear of Recurrence Pilot Intervention for Women With Breast Cancer'], ['Interventional'], ['March 2011'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1B-11-9'], ['PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer'], ['Interventional'], ['November 22, 2013'], ['November 22, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCI 18-79 [HS# 2020-5660]'], ['Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer'], ['Interventional'], ['July 23, 2020'], ['February 16, 2022'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['IRB-29691'], ['Molecular and Cellular Analysis of Breast Cancer'], ['Observational'], ['September 2014'], ['September 2024'], ['Suspended'], ['Sponsor'], ['Female'], [], ['18 Minutes'], []][['CDR0000616135'], ['The Impact of Lymphedema on Breast Cancer Survivors'], ['Observational'], ['February 2007'], ['February 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['CDR0000465198'], ['Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery'], ['Interventional'], ['August 2004'], ['May 24, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['246600'], ['Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer'], ['Observational'], ['October 2008'], ['January 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['5BB-1801'], ['Alternative Support for Rural and Isolated Women in an HMO'], ['Interventional'], ['September 2000'], ['May 2002'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['1B-15-6'], ['Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors'], ['Interventional'], ['March 8, 2019'], ['July 31, 2019'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCSF-067519'], ['Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients'], ['Interventional'], ['March 2007'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['80 Years']][['16-001'], ['Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer'], ['Interventional'], ['February 23, 2016'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI 14-67 [HS# 2015-1888]'], ['Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab'], ['Interventional'], ['April 2015'], ['December 2022'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['182113'], ['Improving Cognition After Cancer'], ['Interventional'], ['September 9, 2019'], ['February 1, 2024'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['40 Years'], []][['BRS0037'], ['Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors'], ['Interventional'], ['January 2014'], [], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['CDR0000674337'], ['Monitoring and Predicting Chemotherapy Response Using DOSI'], ['Interventional'], ['June 2011'], ['October 6, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SU-03012010-5082'], ['Expanding Rural Access: Distance Delivery of Support Groups (Main Study)'], ['Interventional'], ['May 2008'], ['July 2010'], ['Completed'], [], ['Female'], [], ['21 Years'], []][['IRB-17323'], ['Management of Insomnia in Breast Cancer Patients'], ['Interventional'], ['January 2011'], ['July 2016'], ['Completed'], ['Principal Investigator'], ['Female'], ['Yes'], ['21 Years'], []][['HMH2015.002'], ['Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)'], ['Interventional'], ['August 2013'], ['December 30, 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['PPHM 1401'], ['Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer'], ['Interventional'], ['December 2015'], ['June 2018'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BRS0039'], [\"Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy\"], ['Interventional'], ['July 2014'], ['July 7, 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['CA025'], ['A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer'], ['Interventional'], ['August 2005'], ['February 2008'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16079'], ['Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer'], ['Interventional'], ['July 15, 2016'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08029'], ['Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer'], ['Interventional'], ['August 2008'], ['December 2010'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['VI-ISRP-026'], ['A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes'], ['Interventional'], ['August 1, 2018'], ['March 1, 2020'], ['Suspended'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['20-30638'], ['Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)'], ['Interventional'], ['February 1, 2022'], ['September 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['64 Years']][['TCD11487'], ['A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer'], ['Interventional'], ['December 2008'], ['October 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCI-HS-2007-5519'], ['Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)'], ['Interventional'], ['May 2007'], ['June 2008'], ['Withdrawn'], ['Sponsor'], ['Female'], [], ['40 Years'], ['85 Years']][['JWCI OBCS WITH IORT'], ['Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.'], ['Interventional'], ['December 16, 2021'], ['February 2026'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['50 Years'], []][['BRS0031'], ['Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer'], ['Observational'], ['April 2015'], ['August 18, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['STOP-BC Trial'], ['Sulindac and Breast Density in Women at Risk of Developing Breast Cancer'], ['Interventional'], ['November 20, 2020'], ['February 2027'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['35 Years'], ['70 Years']][['09021-02'], ['Health Benefits of Expressive Writing: Study One'], ['Interventional'], ['July 2009'], ['October 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['16-18737'], ['Nuevo Amanecer II: Translating a Stress Management Program for Latinas'], ['Interventional'], ['September 2016'], ['February 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000430705'], ['Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast'], ['Interventional'], ['November 2004'], [], ['Unknown status'], [], ['Female'], [], [], []][['147523'], ['Reversing Therapy Resistance With Epigenetic-Immune Modification'], ['Interventional'], ['May 4, 2015'], ['June 8, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000076422'], ['High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma'], ['Interventional'], ['December 1987'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['NCI-2013-02225'], ['Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer'], ['Interventional'], ['December 2002'], ['April 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCDCC#185'], ['Abraxane and Alimta in Advanced Solid Tumors'], ['Interventional'], ['April 2007'], ['October 2014'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['P2100-SUR-S11'], ['Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer'], ['Interventional'], ['September 10, 2021'], ['June 1, 2026'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['IRB-15005'], ['Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption'], ['Interventional'], ['April 2009'], ['April 2011'], ['Terminated'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], ['85 Years']][['14036'], ['Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer'], ['Interventional'], ['October 1, 2014'], ['March 3, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-44367'], ['Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy'], ['Interventional'], ['August 1, 2018'], ['December 2022'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCI 07-61 [HS# 2007-6084]'], ['Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting'], ['Interventional'], ['February 2008'], ['July 2021'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['21 Years'], ['90 Years']][['GYNOVA0033'], ['Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer'], ['Interventional'], ['August 2016'], ['October 11, 2017'], ['Terminated'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['SCP-1'], ['Reproductive Health Survivorship Care Plan Pilot'], ['Interventional'], ['March 20, 2014'], ['December 31, 2015'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['45 Years']][['LSB-12345'], ['Intraoperative Use of ClearEdge Device in Breast Conserving Surgery'], ['Interventional'], ['October 10, 2022'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000065692 (1B-97-2)'], ['Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer'], ['Interventional'], ['April 1997'], ['March 2000'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['12147'], ['Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer'], ['Interventional'], ['July 17, 2013'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['19 Years'], []][['12-001 Single Fraction IORT'], ['Single Fraction Intraoperative Radiotherapy'], ['Interventional'], ['February 2012'], ['February 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['41 Years'], ['90 Years']][['S11-00533'], ['Fresolimumab and Radiotherapy in Metastatic Breast Cancer'], ['Interventional'], ['July 2011'], ['June 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NMCSD.2014.0053'], ['A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms'], ['Observational'], ['May 2015'], ['January 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['60 Years']][['216529'], ['Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms'], ['Interventional'], ['March 2010'], ['March 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['10AB-2801'], ['Expanding Rural Access: Distance Delivery of Support'], ['Interventional'], ['November 2004'], ['June 2006'], ['Completed'], [], ['Female'], [], ['21 Years'], []][['CP-18 100'], ['Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects'], ['Interventional'], ['May 2011'], ['April 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['21 Years'], ['75 Years']][['BRSADJ0020'], ['Acupuncture for Sleep Disruption in Cancer Survivors'], ['Interventional'], ['February 2011'], ['August 2012'], ['Completed'], ['Principal Investigator'], ['Female'], ['Yes'], ['18 Years'], []][['1B-10-6'], ['Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer'], ['Interventional'], ['July 1, 2010'], ['December 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['30 Years'], ['75 Years']][['Pro00043233'], ['A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer'], ['Interventional'], ['October 2016'], ['March 2020'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['214750'], ['Evaluation of Breast CT'], ['Interventional'], ['November 22, 2004'], ['March 5, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['LAJ 08-8001'], ['Scripps Polster Breast Care Center Investigational GeneBank'], ['Observational'], ['July 2008'], ['June 2015'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['30 Years'], []][['11130'], ['Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer'], ['Interventional'], ['June 2009'], ['May 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], [], []][['CDR0000065828'], ['Diet and Estrogen Metabolism in Postmenopausal Women'], ['Interventional'], ['August 1997'], ['June 2004'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], ['69 Years']][['LUM-BC-1.0'], ['A Multicenter Breast Cancer Biospecimen Registry'], ['Observational'], ['February 2016'], [], ['Unknown status'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['A112313'], ['Integrative Approaches for Cancer Survivorship'], ['Interventional'], ['January 2012'], ['October 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000616972'], ['Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)'], ['Observational'], ['October 1, 2008'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['L-503'], ['The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage'], ['Observational'], ['July 2011'], ['August 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['025950'], ['Investigating the Impact of Tamoxifen Therapy on Ovarian Aging'], ['Observational'], ['June 2011'], ['March 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['25 Years'], []][['BCA-003'], ['Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning'], ['Observational'], ['April 2008'], ['April 2011'], ['Unknown status'], [], ['Female'], [], ['21 Years'], ['50 Years']][['18-001926'], ['Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors'], ['Interventional'], ['October 7, 2019'], ['June 1, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], [], []][['800646'], [\"Intervening on Women's Health for Rural Young Breast Cancer Survivors\"], ['Interventional'], ['October 15, 2021'], ['April 30, 2024'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['18 Years'], ['50 Years']][['IIT2021-10-Giuliano-OmitRT'], ['Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response'], ['Interventional'], ['May 2022'], ['May 2028'], ['Not yet recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['40 Years'], []][['17-001864'], ['SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer'], ['Interventional'], ['April 7, 2019'], ['December 6, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20429001'], ['Central Obesity and Cancer Prevention for Chinese American Women'], ['Interventional'], ['October 16, 2019'], ['December 2020'], ['Unknown status'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['R01AT000486'], ['Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health'], ['Interventional'], ['May 2000'], ['January 2005'], ['Completed'], [], ['All'], [], [], []][['04140'], ['Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer'], ['Interventional'], ['June 2005'], ['August 2010'], ['Completed'], [], ['All'], [], ['18 Years'], []][['CDR0000613050'], ['Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer'], ['Observational'], ['May 2007'], ['June 6, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], ['80 Years']][['CBCRP 23AB-1400'], ['Reducing Breast Cancer Risk in Korean American Women'], ['Interventional'], ['March 16, 2019'], ['December 31, 2019'], ['Completed'], ['Sponsor'], ['All'], ['Yes'], ['18 Years'], []][['Pro00009633'], ['Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment'], ['Observational'], ['September 2014'], ['September 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1B-14-6'], ['Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer'], ['Observational'], ['December 16, 2014'], ['August 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP101'], ['Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer'], ['Interventional'], [], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['QUILT-3.013'], ['QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer'], ['Interventional'], ['December 2016'], ['December 2020'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-CTL'], ['Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors'], ['Interventional'], ['November 2010'], ['June 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['30 Years'], ['45 Years']][['BMT42'], ['High Dose Chemotherapy and Autologous Transplant for Breast Cancer'], ['Interventional'], [], ['March 2005'], ['Unknown status'], [], ['All'], [], ['18 Years'], ['65 Years']][['CDR0000065380'], ['Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['June 1996'], ['November 2005'], ['Completed'], [], ['All'], [], [], []][['IRB-19595'], ['High Resolution 3D Diffusion-weighted Breast MRI'], ['Observational'], ['March 2011'], ['February 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB-37161'], ['Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema'], ['Interventional'], ['July 20, 2016'], ['October 29, 2020'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['75 Years']][['P276-00/52/10'], ['A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin'], ['Interventional'], ['August 2011'], ['March 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRSADJ0023'], ['Phase I: At-Home Support for Rural Women Using Group Video Calling'], ['Interventional'], ['October 2012'], ['June 2014'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], []][['STUDY00001356'], ['IIT2020-20-SHIRAZIP-WALK: Nature Walks'], ['Interventional'], ['June 21, 2021'], ['December 2023'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['10005'], ['Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer'], ['Observational'], ['November 2010'], ['December 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['99-11-084'], ['Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer'], ['Interventional'], ['July 2003'], ['November 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['80 Years']][['11F.438'], ['Quantitative Subharmonic Breast Imaging'], ['Interventional'], ['November 2011'], ['April 5, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['18432'], ['Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease'], ['Interventional'], ['March 4, 2019'], ['July 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], [], []][['PARW-OVCONS-0307'], ['Examining the Long-Term Risks of Oophorectomy'], ['Observational'], ['January 1980'], ['June 2004'], ['Completed'], [], ['Female'], [], ['30 Years'], ['55 Years']][['IIT2018-01-McArthur-IPI'], ['Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer'], ['Interventional'], ['November 12, 2019'], ['June 2026'], ['Recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['CD07_TNBC'], ['Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC'], ['Interventional'], ['April 22, 2019'], ['September 16, 2022'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['12751'], ['Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer'], ['Interventional'], ['July 12, 2012'], ['July 5, 2019'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['M10-265'], ['Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer'], ['Interventional'], ['July 2008'], ['December 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IIT2019-14-SHIRAZIP-SWEAT'], ['Streaming Web-based Exercise At Home: A Pilot Study'], ['Interventional'], ['July 7, 2020'], ['March 30, 2023'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['CDR0000617655'], ['Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast'], ['Interventional'], ['July 2009'], ['August 11, 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['CDR0000594671'], ['Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery'], ['Interventional'], ['February 2008'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['TALES Trial'], ['Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial'], ['Interventional'], ['July 21, 2016'], ['January 31, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['50 Years']][['NBI-3001-ST-0101'], ['Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer'], ['Interventional'], ['January 2002'], ['July 2008'], ['Completed'], [], ['All'], [], ['18 Years'], []][['HMH2015.001'], ['Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe'], ['Interventional'], ['March 2015'], ['September 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], [], []][['15754'], ['Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial'], ['Interventional'], ['March 13, 2017'], ['December 20, 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['89 Years']][['ROCHE-NP17787'], ['Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['May 2004'], ['December 2007'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['ACU-JOINT001'], ['Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain'], ['Interventional'], ['June 2015'], ['June 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['H 15430'], ['Neoadjuvant GW572016 to Treat Breast Cancer'], ['Interventional'], ['August 2004'], ['February 2012'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['IRB-55153'], ['Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts'], ['Interventional'], ['April 28, 2021'], ['April 15, 2023'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['65 Years']][['EXPLLN21-01'], ['A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG'], ['Interventional'], ['May 1, 2023'], ['March 1, 2025'], ['Not yet recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20152355'], ['Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI'], ['Interventional'], ['December 2015'], ['December 2019'], ['Withdrawn'], ['Sponsor-Investigator'], ['Female'], [], ['21 Years'], ['80 Years']][['228012'], ['Impact of Topical Tranexamic Acid in Breast Reconstruction'], ['Interventional'], ['March 30, 2023'], ['September 30, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCI 03-16 [HS# 2004-3681]'], ['Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women'], ['Interventional'], ['September 21, 2004'], ['December 12, 2018'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['48134'], ['Plant-based Diets and Risk of Cancer in the Adventist Health Study-2'], ['Observational'], ['February 1, 2002'], ['December 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['30 Years'], []][['DZ2019HE001'], ['DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer'], ['Interventional'], ['September 21, 2020'], ['May 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-53132'], ['LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy'], ['Interventional'], ['September 10, 2021'], ['June 1, 2030'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['75 Years']][['5160378'], ['Effect of Resveratrol on Serum IGF2 Among African American Women'], ['Interventional'], ['April 24, 2019'], ['June 30, 2024'], ['Suspended'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CBCRP 12BB-3900'], ['Telephone-Based Decision Support for Rural Patients'], ['Interventional'], ['October 2007'], ['June 2011'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['KCT001'], ['Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study'], ['Interventional'], ['August 5, 2020'], ['May 28, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['11139'], ['Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['June 19, 2012'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['65 Years'], []][['1B-03-7'], ['A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)'], ['Interventional'], ['August 2006'], ['June 2008'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['16-000817'], ['Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)'], ['Interventional'], ['February 20, 2017'], ['February 1, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], [], ['49 Years']][['EGF103892'], ['Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.'], ['Interventional'], ['December 7, 2006'], ['September 12, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DCA Breast NSCLC'], ['Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)'], ['Interventional'], ['December 2009'], ['November 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-30470'], ['Brief Behavioral Intervention for Insomnia During Chemotherapy'], ['Interventional'], ['January 2015'], ['June 2020'], ['Completed'], ['Principal Investigator'], ['Female'], ['Yes'], ['21 Years'], []][['BIOC-046'], ['A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide'], ['Observational'], ['September 7, 2022'], ['January 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], [], []][['eFT508-0008'], ['A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC'], ['Interventional'], ['November 21, 2017'], ['January 22, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['090314'], ['Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade'], ['Observational'], ['July 2009'], ['November 2010'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], [], []][['IRB-06037'], ['Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy'], ['Interventional'], ['June 2008'], ['July 26, 2012'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['IRB-46373'], ['Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma'], ['Interventional'], ['March 22, 2019'], ['July 2025'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['190311'], ['Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction'], ['Interventional'], ['October 20, 2022'], ['March 31, 2025'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['22 Years'], ['75 Years']][['CDR0000522934'], ['Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer'], ['Interventional'], ['July 2006'], ['June 2011'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['1K07CA181323-01A1'], ['Physical Activity and Neuropsychological Outcomes in a Cancer Population'], ['Interventional'], ['August 2014'], ['July 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], ['85 Years']][['DCIS Cryo'], ['Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ'], ['Interventional'], ['November 1, 2021'], ['November 1, 2026'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['1B-06-9'], ['Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast'], ['Interventional'], ['October 2007'], ['November 2016'], ['Terminated'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['18R5-002'], ['A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['September 2013'], ['December 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['Pro00052823'], ['Tissue Expansion in Breast Reconstruction Without Drains'], ['Observational'], ['February 25, 2019'], ['October 2, 2020'], ['Completed'], ['Principal Investigator'], ['Female'], ['Yes'], ['21 Years'], []][['2450-US-002'], ['Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer'], ['Interventional'], ['December 2010'], ['December 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['5170197'], ['Chemotherapy Induced Peripheral Neuropathy (CIPN)'], ['Interventional'], ['September 28, 2017'], ['September 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['OSU-15222'], ['Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer'], ['Interventional'], ['October 12, 2016'], ['December 11, 2021'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['1B-09-12'], ['Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.'], ['Interventional'], ['December 2010'], ['October 2011'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['MR2016-03'], ['A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer'], ['Observational'], ['March 1, 2017'], ['August 30, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['181367'], ['Physical Activity Intervention for Young Cancer Survivors'], ['Interventional'], ['September 1, 2019'], ['September 30, 2020'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['55 Years']][['OB0012018'], ['Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer'], ['Observational'], ['October 1, 2017'], ['May 1, 2022'], ['Active, not recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['80 Years']][['NU 98B1'], ['Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer'], ['Interventional'], ['November 1998'], ['June 2005'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PEAK VP-00078'], ['PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy'], ['Interventional'], ['July 2009'], ['February 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['2010-185'], ['Breast Health in Chinese American Women'], ['Interventional'], ['July 2010'], ['December 21, 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['42 Years'], []][['CH001'], ['Circadian Thermal Sensing to Detect Breast Disease'], ['Interventional'], ['June 2015'], ['February 2020'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['DAMD17-03-1-067'], ['Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women'], ['Interventional'], ['September 2003'], ['September 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['SPI-POZ-203'], ['A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies'], ['Interventional'], ['December 23, 2019'], ['March 29, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['HS-16-00483'], ['Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)'], ['Observational'], ['August 16, 2016'], ['April 29, 2018'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['55 Years']][['AD-13-5635'], ['Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers'], ['Interventional'], ['May 2013'], ['December 2017'], ['Completed'], ['Principal Investigator'], ['All'], [], [], ['85 Years']][['KPSC IRB 11103'], ['Implementing Systematic Distress Screening in Breast Cancer'], ['Observational'], ['October 2, 2017'], ['November 30, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-50877'], ['Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution'], ['Interventional'], ['January 2023'], ['December 2023'], ['Not yet recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2011-01-LEV'], ['An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging'], ['Interventional'], ['June 2011'], ['June 2012'], ['Unknown status'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['21051'], ['Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults'], ['Interventional'], ['August 24, 2021'], ['June 30, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['70 Years'], []][['2001-2192'], ['Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics'], ['Observational'], ['May 24, 2002'], ['December 19, 2013'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['IIT2018-25-MITA-NEOBREADS'], ['NEOBREADS: Neoadjuvant Breast Diet Study'], ['Interventional'], ['March 21, 2019'], ['August 17, 2021'], ['Terminated'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['2000-1383'], ['Following the Use of Gel Prosethetics in Breast Reconstruction'], ['Observational'], ['February 1, 2001'], ['September 23, 2013'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['BRS0005'], ['SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants'], ['Observational'], ['June 2011'], ['September 23, 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08803'], ['Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy'], ['Interventional'], ['October 2008'], ['December 2009'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['IIT2018-21-AMERSI-BREADS'], ['BREADS: Breast Adjuvant Diet Study'], ['Interventional'], ['February 4, 2020'], ['January 2024'], ['Recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['GME Study'], ['Gene Expression, Meditative Movement, and Emotional Distress (GME)'], ['Interventional'], ['July 17, 2017'], ['February 15, 2020'], ['Unknown status'], ['Sponsor'], ['Female'], ['Yes'], ['45 Years'], []][['17009'], ['Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients'], ['Interventional'], ['October 13, 2017'], ['October 1, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['0S-20-6'], ['Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy'], ['Observational'], ['December 18, 2020'], ['June 18, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['31801/1'], ['Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction'], ['Interventional'], ['September 2016'], ['March 2019'], ['Unknown status'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['85 Years']][['LSB-01'], ['In Vitro Detection of Tissue Abnormality'], ['Interventional'], ['October 15, 2010'], ['January 9, 2012'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['25 Years'], ['80 Years']][['1B-22-2'], ['In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors'], ['Interventional'], ['January 9, 2023'], ['January 9, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PROT002 - Test Plan 01 Rev A'], ['Blue Note Therapeutics Product BNT 103 Usability and User Engagement'], ['Interventional'], ['September 1, 2021'], ['December 31, 2021'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['35 Years'], ['55 Years']][['MAP3BSS'], ['Effects of Exemestane on Bone Strength'], ['Observational'], ['April 2007'], ['June 2019'], ['Unknown status'], ['Sponsor'], ['Female'], [], [], []][['2008-0067'], ['Lynne Cohen Consortium Project: Multi-Center Database/Registry'], ['Observational'], ['July 2008'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UCSF-GC3-2021'], ['Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients'], ['Interventional'], ['April 18, 2017'], ['December 16, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['70 Years']][['CA148791-01'], ['Reducing Breast Cancer Recurrence With Weight Loss'], ['Interventional'], ['May 2010'], ['February 2015'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], []][['ANG1005-EAP-01, EAP-02, EAP-03'], ['Expanded Access to ANG1005 for Individual Patients'], ['Expanded Access'], [], [], ['No longer available'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['STUDY00146320'], ['Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens'], ['Interventional'], ['December 14, 2021'], ['January 31, 2026'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['45 Years'], ['60 Years']][['NCI-2019-06461'], ['Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer'], ['Interventional'], ['December 6, 2019'], ['June 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['217510'], ['Microbiome and Association With Implant Infections'], ['Interventional'], ['September 28, 2021'], ['December 31, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UPCC 25920'], ['Pilot Study of an NTproBNP Guided Strategy of Cardioprotection'], ['Interventional'], ['March 18, 2021'], ['June 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['03049'], ['Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['January 2004'], ['August 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['HS-10-00455'], ['Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation'], ['Interventional'], ['January 2011'], ['December 2016'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], ['35 Years']][['ANG-002'], ['Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System'], ['Observational'], ['March 29, 2018'], ['December 31, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['22 Years'], []][['17-000668'], ['Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery'], ['Interventional'], ['August 3, 2017'], ['February 1, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['19 Years'], []][['US-001'], ['SentiMag® Intraoperative Comparison in Breast Cancer'], ['Interventional'], ['January 2015'], ['December 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GCO 15-1783'], ['Systematic Light Exposure for Fatigue in Breast Cancer Patients'], ['Interventional'], ['January 25, 2018'], ['April 30, 2022'], ['Recruiting'], ['Principal Investigator'], ['Female'], ['Yes'], ['18 Years'], []][['MM-121-04-01-04'], ['A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers'], ['Interventional'], ['October 2010'], ['July 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DIG-001'], ['Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia'], ['Interventional'], ['July 2013'], ['December 2020'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['TMENEO-100'], ['TME Neoadjuvant Breast Registry'], ['Observational'], ['July 2015'], ['July 2022'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], ['90 Years']][['15295'], ['Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer'], ['Interventional'], ['March 28, 2016'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['18112'], ['64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy'], ['Interventional'], ['November 3, 2021'], ['December 1, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IBCSG 25-02 / BIG 3-02'], ['Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'], ['Interventional'], ['November 3, 2003'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['65 Years']][['DS8201-A-U302'], ['DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]'], ['Interventional'], ['August 9, 2018'], ['April 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACOSOG-Z1071'], ['Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer'], ['Interventional'], ['July 2009'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20-275'], ['Testing a New Imaging Agent to Identify Cancer'], ['Interventional'], ['November 30, 2020'], ['November 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2018-05-ASHER-IMPROV2'], [\"LOL: It's All Improv After Cancer!™\"], ['Interventional'], ['August 2, 2019'], ['July 2025'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['NSABP P-2'], ['Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women'], ['Interventional'], ['May 1999'], ['August 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['IRB-11872'], ['Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples'], ['Observational'], ['August 2001'], ['January 2099'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['5150012'], ['Liposomal Bupivacaine in Implant Based Breast Reconstruction'], ['Interventional'], ['July 2015'], ['July 2017'], ['Terminated'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['99 Years']][['0S-10-3'], ['Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer'], ['Interventional'], ['January 29, 2013'], ['January 29, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['19 Years'], []][['TORI B-03'], ['Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)'], ['Interventional'], ['June 2003'], ['January 2012'], ['Completed'], [], ['Female'], [], ['18 Years'], ['75 Years']][['OUT-113-2005; 06140-01'], ['Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment'], ['Interventional'], ['October 2006'], ['June 2008'], ['Completed'], [], ['All'], [], ['21 Years'], []][['SDX-0103'], ['Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer'], ['Interventional'], ['August 26, 2022'], ['September 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACOSOG-Z11102'], ['Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer'], ['Interventional'], ['July 2012'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['PEM-06-01'], ['Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer'], ['Interventional'], ['September 2006'], ['March 2009'], ['Unknown status'], [], ['Female'], [], ['25 Years'], []][['ML18530'], ['XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer'], ['Interventional'], ['August 2005'], ['July 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['TRIO030'], ['A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide'], ['Interventional'], ['September 5, 2017'], ['March 13, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000069225'], ['S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer'], ['Interventional'], ['July 1998'], ['November 2003'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CALGB-70806'], ['Vitamin D and Breast Cancer Biomarkers in Female Patients'], ['Interventional'], ['October 2010'], ['December 2014'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['55 Years']][['MA32'], ['A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer'], ['Interventional'], ['June 25, 2010'], ['July 31, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['74 Years']][['A011202'], ['Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy'], ['Interventional'], ['February 7, 2014'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['120BC201'], ['Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding'], ['Interventional'], ['November 2009'], ['October 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BrUOG-BR-211B'], ['Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer'], ['Interventional'], ['February 2008'], ['December 2015'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['19-188'], ['Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial'], ['Interventional'], ['November 18, 2021'], ['July 31, 2024'], ['Recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['NSABP B-31'], ['Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2'], ['Interventional'], ['February 2000'], ['November 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCCTG-N0434'], ['Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole'], ['Observational'], ['April 2006'], ['February 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A5481003'], ['Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer'], ['Interventional'], ['September 15, 2008'], ['December 20, 2017'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['dtectDx-Breast-001'], ['Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification'], ['Observational'], ['March 2013'], ['August 2014'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['25 Years'], ['49 Years']][['CELC-G-301'], ['Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)'], ['Interventional'], ['September 30, 2022'], ['September 30, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALGB-40101'], ['Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer'], ['Interventional'], ['May 2002'], ['June 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['DS8201-A-U201'], ['A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)'], ['Interventional'], ['August 25, 2017'], ['September 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MAP3'], ['Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer'], ['Interventional'], ['February 11, 2004'], ['January 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['NSABP B-32'], ['Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer'], ['Interventional'], ['May 1999'], ['February 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['E7389-G000-399'], ['Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies'], ['Interventional'], ['August 2010'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BO25126'], ['A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer'], ['Interventional'], ['November 8, 2011'], ['November 30, 2028'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALGB-40105'], ['Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer'], ['Interventional'], ['February 2003'], ['January 2010'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['NSABP B-30'], ['Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes'], ['Interventional'], ['March 1999'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP B-39/RTOG 0413'], ['Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer'], ['Interventional'], ['March 2005'], ['August 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A6181068'], ['Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer'], ['Interventional'], ['August 2007'], ['June 2010'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['ACE-Breast-03'], ['ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)'], ['Interventional'], ['April 5, 2021'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO28407'], ['A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer'], ['Interventional'], ['January 31, 2014'], ['June 4, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP B-40'], ['Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery'], ['Interventional'], ['November 2006'], ['March 2018'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['16338'], ['Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer'], ['Interventional'], ['August 22, 2017'], ['June 24, 2029'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP B-42'], ['Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer'], ['Interventional'], ['August 2006'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['DS8201-A-U305'], ['A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)'], ['Interventional'], ['December 4, 2020'], ['December 31, 2030'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CCTG MA.39'], ['Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer'], ['Interventional'], ['May 30, 2018'], ['December 30, 2027'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['35 Years'], []][['CDR0000504319'], ['S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo'], ['Interventional'], ['October 2006'], ['July 11, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['E2108'], ['Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer'], ['Interventional'], ['February 8, 2011'], ['December 21, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['CDR0000066135'], ['Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer'], ['Interventional'], ['July 1997'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], []][['3144A2-3004 / B1891004'], ['Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer'], ['Interventional'], ['July 9, 2009'], ['October 4, 2019'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['V2011201'], ['Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer'], ['Interventional'], ['March 15, 2023'], ['May 26, 2024'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['C3441020'], ['Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer'], ['Interventional'], ['August 27, 2018'], ['September 23, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000063537'], ['Nutrition Intervention in Treating Women With Breast Cancer'], ['Interventional'], ['April 1994'], ['December 2006'], ['Completed'], [], ['Female'], [], ['48 Years'], ['78 Years']][['CDR0000636131'], ['S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer'], ['Interventional'], ['April 2010'], ['December 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A011502'], ['Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy'], ['Interventional'], ['December 8, 2016'], ['February 15, 2023'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], ['69 Years']][['INCB 18424-268'], ['A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer'], ['Interventional'], ['May 2014'], ['January 2017'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EGF105485'], ['Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer'], ['Interventional'], ['August 2006'], ['July 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CRAD001J2101'], ['Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer'], ['Interventional'], ['July 2007'], ['March 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['DS8201-A-U301'], ['DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]'], ['Interventional'], ['August 1, 2018'], ['September 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['06090'], ['TAC Versus TC for Adjuvant Breast Cancer'], ['Interventional'], ['May 29, 2007'], ['March 30, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['UCSD-980919'], [\"Women's Healthy Eating and Living Study\"], ['Observational'], ['March 1995'], ['December 31, 2018'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['70 Years']][['IBCSG 24-02 / BIG 2-02'], ['Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer'], ['Interventional'], ['December 17, 2003'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['65 Years']][['CDR0000423180'], ['S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer'], ['Interventional'], ['August 2005'], ['August 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BO27938'], ['A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)'], ['Interventional'], ['April 3, 2013'], ['April 3, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['291'], ['BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)'], ['Interventional'], ['July 24, 2014'], ['November 30, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['CDR0000349337'], ['S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer'], ['Interventional'], ['April 2004'], ['October 1, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EGF30008'], ['Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer'], ['Interventional'], ['December 9, 2003'], ['March 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000069440'], ['S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'], ['Interventional'], ['September 2002'], ['January 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011O12301C'], ['A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer'], ['Interventional'], ['December 7, 2018'], ['May 29, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP-B-49'], ['Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer'], ['Interventional'], ['April 2012'], ['November 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CTKI258A2202'], ['Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer'], ['Interventional'], ['July 2009'], ['March 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP B-33'], ['Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen'], ['Interventional'], ['May 2001'], ['February 2011'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['CDR0000343619'], ['Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer'], ['Interventional'], ['July 2002'], ['August 22, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['NSABP B-36'], ['Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer'], ['Interventional'], ['May 2004'], ['May 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['LIGAND-L1069-34'], ['Bexarotene in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['October 1998'], ['March 2003'], ['Completed'], [], ['All'], [], ['18 Years'], []][['PUMA-NER-6201'], ['An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide'], ['Interventional'], ['February 2015'], ['April 22, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IBCSG 48-14 / BIG 8-13'], ['Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer'], ['Interventional'], ['December 4, 2014'], ['December 2028'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['42 Years']][['WO42133'], ['A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)'], ['Interventional'], ['September 4, 2020'], ['November 24, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['13892'], ['Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer'], ['Interventional'], ['August 6, 2008'], ['November 19, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000065813'], ['S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer'], ['Observational'], ['November 1997'], ['February 2001'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['EFC6089'], ['Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer'], ['Interventional'], ['April 2004'], ['September 2006'], ['Completed'], [], ['All'], [], ['18 Years'], []][['CDR0000066563'], ['Combination Chemotherapy in Treating Women With Breast Cancer'], ['Interventional'], ['August 1998'], [], ['Completed'], [], ['Female'], [], ['18 Years'], ['120 Years']][['CDR0000616008'], ['Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery'], ['Interventional'], ['April 2009'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['WO42633'], ['A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy'], ['Interventional'], ['May 4, 2021'], ['October 26, 2034'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000068575'], ['S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer'], ['Interventional'], ['May 2001'], ['November 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCCTG-N093B'], ['Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['September 2010'], ['September 3, 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EFC11486'], ['A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer'], ['Interventional'], ['July 2009'], ['February 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['E3108'], ['Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer'], ['Interventional'], ['September 21, 2010'], ['May 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-302-02-01-01'], ['Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer'], ['Interventional'], ['March 2011'], ['January 2017'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SPI-POZ-201'], ['Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer'], ['Interventional'], ['February 22, 2016'], ['March 11, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['90 Years']][['A4061010'], ['AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer'], ['Interventional'], ['February 2004'], ['November 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP-MGAH22-02'], ['Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer'], ['Interventional'], ['March 2013'], ['April 14, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ISB 1302-103'], ['Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer'], ['Interventional'], ['April 8, 2020'], ['July 24, 2020'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['E7389-A001-201'], ['A Study of E7389 in Advanced/Metastatic Breast Cancer Patients'], ['Interventional'], ['September 2004'], ['November 2006'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['NSABP B-27'], ['Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed'], ['Interventional'], ['December 1995'], ['February 2010'], ['Completed'], [], ['Female'], [], [], []][['IIT2018-04-MCARTHUR-NEOHP'], ['Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab'], ['Interventional'], ['January 25, 2019'], ['July 2025'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['BO20289'], ['BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer'], ['Interventional'], ['December 2007'], ['June 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACOSOG-Z0011'], ['Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer'], ['Interventional'], ['April 1999'], ['February 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CALGB-150007'], ['Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery'], ['Observational'], ['February 2002'], ['May 1, 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP BP-58'], ['Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer'], ['Interventional'], ['June 1998'], ['December 2002'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D081CC00006'], ['Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer'], ['Interventional'], ['April 22, 2014'], ['May 28, 2029'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['ACOSOG-Z0010'], ['Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer'], ['Interventional'], ['April 1999'], ['July 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000065472'], ['Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer'], ['Interventional'], ['May 1997'], ['March 2006'], ['Completed'], [], ['Female'], [], [], []][['TOC4129g'], ['A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer'], ['Interventional'], ['February 12, 2008'], ['November 23, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP FB-13'], ['Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer'], ['Interventional'], ['October 22, 2018'], ['January 30, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PVB Catheter Study'], ['Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks'], ['Interventional'], ['October 2010'], ['March 2016'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['A231701CD'], [\"Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making\"], ['Interventional'], ['March 1, 2019'], ['December 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D967UC00001'], ['Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)'], ['Interventional'], ['April 26, 2021'], ['December 30, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['D8480C00007'], ['AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.'], ['Interventional'], ['March 2007'], ['April 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['130 Years']][['GO42784'], [\"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)\"], ['Interventional'], ['August 27, 2021'], ['November 21, 2033'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BTX-BCI-016-PRT'], ['Breast Cancer Index (BCI) Registry'], ['Observational'], ['April 14, 2021'], ['December 2028'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['11-PIR-11'], ['The BEACON Study (Breast Cancer Outcomes With NKTR-102)'], ['Interventional'], ['December 2011'], ['June 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CALGB-49806'], ['Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer'], ['Interventional'], ['December 1999'], ['February 2002'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ORIN1001-001'], ['ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer'], ['Interventional'], ['May 25, 2019'], ['March 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP B-35'], ['Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy'], ['Interventional'], ['January 2003'], ['May 2016'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['A5481008'], ['A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)'], ['Interventional'], ['February 22, 2013'], ['August 26, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['3475-756'], ['Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)'], ['Interventional'], ['December 27, 2018'], ['January 24, 2031'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20110148'], ['Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim'], ['Interventional'], ['January 17, 2013'], ['December 15, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['99 Years']][['TDM4997g'], [\"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy\"], ['Interventional'], ['September 2011'], ['August 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['06BR01'], ['Phase II Study in Patients With Operable Breast Cancer'], ['Interventional'], ['October 2006'], ['September 2009'], ['Unknown status'], [], ['Female'], [], ['21 Years'], []][['CZOL446E2352'], ['Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer'], ['Interventional'], ['February 2006'], ['July 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000068992'], ['Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer'], ['Interventional'], ['January 2001'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['AFT-05'], ['PALbociclib CoLlaborative Adjuvant Study'], ['Interventional'], ['August 2015'], ['September 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000067353'], ['Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes'], ['Interventional'], ['October 1999'], [], ['Completed'], [], ['Female'], [], ['18 Years'], []][['CO-3810-025'], ['A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer'], ['Interventional'], ['September 9, 2014'], ['January 18, 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['9238IL/0048'], ['The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer'], ['Interventional'], ['August 2003'], ['September 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['32 Years'], ['91 Years']][['CO40016'], ['A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer'], ['Interventional'], ['January 6, 2018'], ['January 4, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TDM4652g'], ['A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['August 2009'], ['June 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GE-280-401'], ['Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients'], ['Observational'], ['January 5, 2023'], ['October 2, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['99 Years']][['A011401'], ['Breast Cancer WEight Loss Study (BWEL Study)'], ['Interventional'], ['August 2016'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['0001'], ['SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer'], ['Interventional'], ['May 5, 2017'], ['November 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['3144A1-202 / B1891013'], ['A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer'], ['Interventional'], ['April 4, 2007'], ['March 2, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['10663'], ['A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer'], ['Interventional'], ['May 2006'], ['August 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLCL161A2201'], ['A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer'], ['Interventional'], ['August 2012'], ['September 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000380937'], ['Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer'], ['Observational'], ['December 2004'], ['January 30, 2013'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['120 Years']][['RTOG-1005'], ['Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery'], ['Interventional'], ['May 2011'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP B-44-I'], ['BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab'], ['Interventional'], ['April 2008'], ['July 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NRG-BR007'], ['De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)'], ['Interventional'], ['June 7, 2021'], ['July 2041'], ['Recruiting'], ['Sponsor'], ['All'], [], ['50 Years'], ['70 Years']][['WO39391'], ['A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer'], ['Interventional'], ['August 2, 2018'], ['August 24, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALGB-49907'], ['Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer'], ['Interventional'], ['September 2001'], ['November 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['7962-012'], ['Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer'], ['Interventional'], ['June 1, 2009'], ['November 18, 2010'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-00504'], ['Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU'], ['Interventional'], ['November 2007'], ['October 2015'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['OAM4861g'], ['Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer'], ['Interventional'], ['March 2011'], ['March 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000723653'], ['S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer'], ['Interventional'], ['May 2012'], ['February 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['NU 07B1'], ['Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer'], ['Interventional'], ['June 2007'], ['December 2022'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['V3002401'], ['Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer'], ['Interventional'], ['October 12, 2021'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['CR004120'], ['A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer'], ['Interventional'], ['September 2004'], ['December 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20060359'], ['Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)'], ['Interventional'], ['June 2, 2010'], ['March 26, 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['DS8201-A-U303'], [\"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]\"], ['Interventional'], ['December 27, 2018'], ['March 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP B-41'], ['A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer'], ['Interventional'], ['July 2007'], ['March 2017'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['673-201'], ['A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)'], ['Interventional'], ['December 13, 2013'], ['October 31, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO28509'], ['A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['February 6, 2013'], ['December 10, 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['E7389-G000-209'], ['A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer'], ['Interventional'], ['March 31, 2009'], ['April 30, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011G2301'], ['Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer'], ['Interventional'], ['June 20, 2017'], ['March 9, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['S1207'], ['S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer'], ['Interventional'], ['April 2013'], ['January 2030'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CRAD001J2301'], ['Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['September 10, 2009'], ['October 23, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A8641020'], ['A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations'], ['Interventional'], ['February 3, 2015'], ['January 14, 2016'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['Pro00045372'], [\"LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer\"], ['Interventional'], ['November 30, 2016'], ['December 20, 2017'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['CDR0000068630'], ['S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer'], ['Interventional'], ['May 2001'], ['February 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A8641016'], ['A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer'], ['Interventional'], ['November 4, 2013'], ['December 24, 2015'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CALGB-79809'], ['Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer'], ['Interventional'], ['December 2001'], ['February 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['RAD1901-308'], ['Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer'], ['Interventional'], ['May 10, 2019'], ['August 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SON-8184-1075'], ['Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer'], ['Interventional'], ['September 2005'], ['September 2007'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['CDR0000069030'], ['Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer'], ['Interventional'], ['November 2001'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['BO22589'], ['A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)'], ['Interventional'], ['July 31, 2010'], ['September 16, 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D9268C00001'], [\"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)\"], ['Interventional'], ['October 18, 2021'], ['August 15, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CRAD001Y2301'], ['Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole'], ['Interventional'], ['June 3, 2009'], ['December 4, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A6181077'], ['Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer'], ['Interventional'], ['January 2006'], ['June 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['OPT-822-001'], ['Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects'], ['Interventional'], ['December 2011'], ['August 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['CDR0000334899'], ['S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer'], ['Interventional'], ['November 2003'], ['January 2027'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15804'], ['A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['May 23, 2016'], ['September 20, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SNDX-275-0602'], ['Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In'], ['Interventional'], ['May 2016'], ['March 10, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1033-011'], ['A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer'], ['Interventional'], ['December 2002'], ['May 2005'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['D3615C00001'], ['Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer'], ['Interventional'], ['April 16, 2020'], ['June 7, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['3066A1-303'], ['Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer'], ['Interventional'], ['May 2004'], ['October 2006'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['EA1183'], ['Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study'], ['Interventional'], ['April 2, 2020'], ['August 31, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['3144A2-3003 / B1891003'], ['Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer'], ['Interventional'], ['February 4, 2009'], ['June 3, 2018'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['3144A1-203 / B1891014'], ['A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer'], ['Interventional'], ['September 11, 2007'], ['February 7, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO21977'], ['A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['February 2009'], ['September 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['05-055'], ['Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer'], ['Interventional'], ['June 2005'], ['May 2011'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['16058'], ['Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer'], ['Interventional'], ['September 30, 2016'], ['September 30, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S1200'], ['S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer'], ['Interventional'], ['May 16, 2012'], ['July 1, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP14B014'], ['Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['November 2010'], ['December 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-121-02-02-10'], ['Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer'], ['Interventional'], ['August 15, 2017'], ['November 30, 2018'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['M12-914'], ['A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer'], ['Interventional'], ['July 17, 2014'], ['January 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15342'], ['Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer'], ['Interventional'], ['December 2, 2016'], ['September 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['60 Years'], []][['BO41843'], ['A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)'], ['Interventional'], ['October 9, 2020'], ['March 18, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000520348'], ['S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone'], ['Interventional'], ['March 2007'], ['January 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CBKM120F2302'], ['Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor'], ['Interventional'], ['August 7, 2012'], ['April 19, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A5481023'], ['Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)'], ['Interventional'], ['September 26, 2013'], ['September 28, 2022'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CBYL719X2402'], ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments'], ['Interventional'], ['August 14, 2017'], ['July 17, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDX011-03'], ['A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer'], ['Interventional'], ['July 2010'], ['November 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-302-02-02-03'], [\"MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients\"], ['Interventional'], ['July 2014'], ['June 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GDC4950g'], ['Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy'], ['Interventional'], ['October 2011'], ['April 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ACORN AC01B07'], ['1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy'], ['Interventional'], ['June 2007'], ['November 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EFC15935'], ['Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer'], ['Interventional'], ['October 14, 2020'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C015'], ['CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer'], ['Interventional'], ['September 2002'], ['October 2003'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['ML28257'], ['An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)'], ['Observational'], ['June 5, 2012'], ['November 16, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15417'], ['A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer'], ['Interventional'], ['November 6, 2014'], ['September 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP B-46-I'], ['A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer'], ['Interventional'], ['May 2009'], ['February 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['NCI-2009-00477'], ['Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer'], ['Interventional'], ['May 15, 2008'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['17096'], ['Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer'], ['Interventional'], ['June 4, 2015'], ['October 28, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['9238IL/0025'], ['A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer'], ['Interventional'], ['November 1998'], ['January 2012'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['C4891001'], ['A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.'], ['Interventional'], ['March 3, 2023'], ['May 15, 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CBYL719C2301'], ['Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.'], ['Interventional'], ['July 23, 2015'], ['June 8, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GS-US-586-6144'], ['Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer'], ['Interventional'], ['December 14, 2021'], ['January 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17395'], ['A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer'], ['Interventional'], ['September 16, 2019'], ['March 23, 2023'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2017'], ['Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer'], ['Interventional'], ['July 2000'], ['October 2005'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['108919'], ['Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer'], ['Interventional'], ['October 7, 2008'], ['July 27, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['20060362'], ['QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['March 2008'], ['August 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CRAD001JUS226'], ['Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer'], ['Interventional'], ['May 2014'], ['March 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['MM-121-02-02-07 (ARD11918)'], ['A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer'], ['Interventional'], ['August 2011'], ['June 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['G1T28-213'], ['Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer'], ['Interventional'], ['November 22, 2021'], ['July 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-121-02-02-03 (ARD11588)'], ['Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer'], ['Interventional'], ['June 2010'], ['September 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['POL6326-009'], ['Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['June 14, 2019'], ['March 2022'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A6181094'], ['A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer'], ['Interventional'], ['November 2006'], ['August 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IMMU-132-05'], ['Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)'], ['Interventional'], ['November 7, 2017'], ['December 8, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['WO29522'], ['A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)'], ['Interventional'], ['June 23, 2015'], ['August 31, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTMX-2009-002'], ['Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer'], ['Interventional'], ['December 29, 2020'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2008002'], ['A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.'], ['Observational'], ['March 2009'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['25 Years'], []][['TRIO 020'], ['Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone'], ['Interventional'], ['July 2014'], ['November 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1200.67'], ['Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases'], ['Interventional'], ['October 2011'], ['August 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EGF108916'], ['Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer'], ['Interventional'], ['November 2007'], ['March 2010'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ARV-471-mBC-101'], ['A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['August 5, 2019'], ['February 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP B-59/GBG 96-GeparDouze'], ['Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo'], ['Interventional'], ['December 19, 2017'], ['June 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000285698'], ['Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer'], ['Interventional'], ['February 2003'], ['August 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['BO28408'], ['A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer'], ['Interventional'], ['June 25, 2014'], ['May 29, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NeuVax™ PH3-01, BB-IND 009187'], ['Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence'], ['Interventional'], ['November 2011'], ['September 21, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D931CC00001'], ['Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer'], ['Interventional'], ['November 7, 2022'], ['December 7, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['SPI-GCF-302'], ['SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide'], ['Interventional'], ['May 10, 2017'], ['May 6, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EA1131'], ['Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy'], ['Interventional'], ['April 29, 2015'], ['March 29, 2031'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CR004645'], ['To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older'], ['Interventional'], ['April 2004'], ['December 2005'], ['Terminated'], ['Sponsor'], ['Female'], [], ['60 Years'], []][['D926XC00001'], [\"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)\"], ['Interventional'], ['November 28, 2022'], ['March 27, 2030'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['NCI-2011-02572'], ['Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer'], ['Interventional'], ['January 6, 2011'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D9670C00001'], [\"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer\"], ['Interventional'], ['July 24, 2020'], ['June 19, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['105 Years']][['CDR0000065314'], ['S9630, Medroxyprogesterone in Treating Women With Breast Cancer'], ['Interventional'], ['March 1997'], ['December 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CBKM120F2303'], ['A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi'], ['Interventional'], ['October 3, 2012'], ['September 21, 2017'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SPI-GCF-301'], ['SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)'], ['Interventional'], ['January 19, 2016'], ['October 31, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDX011-04'], ['Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer'], ['Interventional'], ['November 2013'], ['August 7, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA209-7FL'], ['Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer'], ['Interventional'], ['November 20, 2019'], ['January 15, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IMMU-132-09'], [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer\"], ['Interventional'], ['May 8, 2019'], ['October 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['G1T28-212'], ['Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer'], ['Interventional'], ['November 19, 2021'], ['March 13, 2023'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CO42867'], ['A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer'], ['Interventional'], ['June 20, 2021'], ['October 31, 2026'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D967RC00001'], ['Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer'], ['Interventional'], ['October 25, 2021'], ['June 26, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['213831'], ['Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease'], ['Interventional'], ['June 28, 2021'], ['August 28, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M12-895'], ['Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer'], ['Interventional'], ['January 23, 2012'], ['September 2, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NEO3-05'], ['Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma'], ['Interventional'], ['April 2008'], ['July 2009'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SGNTUC-016'], ['A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer'], ['Interventional'], ['October 2, 2019'], ['April 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CBYL719G12301'], ['Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation'], ['Interventional'], ['July 16, 2020'], ['April 2, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO25632'], ['Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer'], ['Interventional'], ['August 27, 2012'], ['November 21, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CO41101'], ['A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.'], ['Interventional'], ['November 25, 2019'], ['February 28, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['E7389-G000-301'], ['E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes'], ['Interventional'], ['September 20, 2006'], ['December 11, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ONT-380-206'], ['A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer'], ['Interventional'], ['January 28, 2016'], ['August 11, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000064156'], ['Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer'], ['Interventional'], ['October 1995'], [], ['Completed'], [], ['Female'], [], [], []][['15805'], ['A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer'], ['Interventional'], ['August 2015'], ['February 12, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['7339-009'], ['Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)'], ['Interventional'], ['December 19, 2019'], ['January 26, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ANG1005-CLN-04'], ['ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases'], ['Interventional'], ['April 2014'], ['September 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2013-02228'], ['Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer'], ['Interventional'], ['January 15, 2014'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S0812'], ['S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer'], ['Interventional'], ['November 1, 2011'], ['September 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['50 Years']][['RTOG-9517'], ['Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer'], ['Interventional'], ['May 1997'], [], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['CTKI258A2210'], ['Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer'], ['Interventional'], ['April 2012'], ['April 2015'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['17320'], ['A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer'], ['Interventional'], ['August 14, 2019'], ['August 11, 2020'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SNDX-275-0301'], ['Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer'], ['Interventional'], ['June 13, 2008'], ['November 26, 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A6191007'], ['Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer'], ['Interventional'], ['April 2006'], ['July 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['PCS-1402-10749'], ['Women Informed to Screen Depending on Measures of Risk (Wisdom Study)'], ['Interventional'], ['August 31, 2016'], ['March 1, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], ['74 Years']][['SGNTUC-025'], ['A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer'], ['Interventional'], ['December 1, 2020'], ['October 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1839US/0713'], ['Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer'], ['Interventional'], ['January 2004'], ['May 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['AVENTIS-56976-TAX-311'], ['Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer'], ['Interventional'], ['August 1994'], ['June 2004'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['ML18527'], ['A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer'], ['Interventional'], ['June 2005'], ['December 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['673-301'], ['A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)'], ['Interventional'], ['October 14, 2013'], ['March 5, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['3160A2-201'], ['Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer'], ['Interventional'], ['May 2006'], ['February 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRE09-146'], ['PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations'], ['Interventional'], ['February 2010'], ['December 15, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EGF30001'], ['Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer'], ['Interventional'], ['January 2004'], ['March 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['17384'], ['A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer'], ['Interventional'], ['May 10, 2021'], ['February 9, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1200.75'], ['LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment'], ['Interventional'], ['June 22, 2010'], ['July 6, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NRG-BR003'], ['Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer'], ['Interventional'], ['July 2015'], ['November 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IPI-549-03'], ['Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)'], ['Interventional'], ['December 17, 2019'], ['August 1, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ML43171'], [\"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)\"], ['Interventional'], ['August 3, 2022'], ['March 31, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15450'], ['A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain'], ['Interventional'], ['April 20, 2015'], ['November 8, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO29227'], ['A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors'], ['Interventional'], ['August 19, 2014'], ['August 31, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP-00-0011'], ['Cryoablation of Small Breast Tumors in Early Stage Breast Cancer'], ['Interventional'], ['November 2013'], ['June 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['B2151009'], ['A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer'], ['Interventional'], ['June 14, 2016'], ['January 19, 2022'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['C31001'], ['Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer'], ['Interventional'], ['February 13, 2014'], ['June 29, 2018'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CALGB-369901'], ['Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer'], ['Observational'], ['August 2003'], ['December 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['CZOL446EUS32'], ['Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy'], ['Interventional'], ['September 2002'], ['January 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['85 Years']][['CA163-115'], ['A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer'], ['Interventional'], ['March 2007'], ['November 2009'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D926PC00001'], [\"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)\"], ['Interventional'], ['May 16, 2022'], ['December 3, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['V2000701'], ['Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer'], ['Interventional'], ['April 11, 2022'], ['January 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['CLEE011XUS29'], ['Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.'], ['Interventional'], ['June 14, 2016'], ['February 25, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP FB-5'], ['Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer'], ['Interventional'], ['May 2007'], ['May 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['941466'], [\"Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study\"], ['Observational'], ['September 2016'], ['February 2022'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['89 Years']][['CAL-03'], ['An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer'], ['Interventional'], [], [], ['Completed'], [], ['Female'], [], ['18 Years'], []][['CO39611'], ['A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer'], ['Interventional'], ['December 26, 2017'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A211801'], ['Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation'], ['Interventional'], ['February 23, 2022'], ['December 2033'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['25 Years'], ['55 Years']][['2014-0443'], ['Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients'], ['Interventional'], ['October 2014'], ['December 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A4021004'], ['Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer'], ['Interventional'], ['February 2007'], ['June 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['GS-US-592-6173'], [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\"], ['Interventional'], ['July 25, 2022'], ['February 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GS-US-592-6238'], [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer\"], ['Interventional'], ['July 20, 2022'], ['May 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2014-00746'], ['Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic'], ['Interventional'], ['March 29, 2014'], ['October 28, 2028'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LCMH-001'], ['Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer'], ['Interventional'], ['September 2008'], ['October 4, 2016'], ['Terminated'], ['Sponsor'], ['Female'], [], ['45 Years'], []][['SMX 18001'], ['Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'], ['Interventional'], ['September 20, 2019'], ['February 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['NSABP MA.32.F'], ['Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32'], ['Observational'], ['July 2011'], ['September 2016'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], ['74 Years']][['17471'], ['Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer'], ['Interventional'], ['June 14, 2018'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['70 Years'], []][['18459'], ['A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer'], ['Interventional'], ['October 4, 2022'], ['March 15, 2032'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CR018286'], ['A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy'], ['Interventional'], ['August 24, 2011'], ['August 8, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011F2301'], ['Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.'], ['Interventional'], ['June 9, 2015'], ['January 11, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SGNLVA-002'], ['Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer'], ['Interventional'], ['February 27, 2018'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M14-011'], ['A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer'], ['Interventional'], ['April 2, 2014'], ['November 12, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['99 Years']][['110264'], ['Treatment With Pazopanib for Neoadjuvant Breast Cancer'], ['Interventional'], ['July 2009'], ['April 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000068583'], ['Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer'], ['Interventional'], ['January 2001'], ['March 2002'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['AL42478'], ['An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic'], ['Expanded Access'], [], [], ['Approved for marketing'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RT-016'], ['Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer'], ['Interventional'], ['February 2004'], ['June 2007'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['20060341'], ['Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients'], ['Interventional'], ['July 2007'], ['May 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A171601'], ['Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer'], ['Interventional'], ['August 15, 2018'], ['August 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['70 Years'], []][['E7389-G000-305'], [\"E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer\"], ['Interventional'], ['November 2006'], ['June 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A6181002'], ['A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.'], ['Interventional'], ['March 2004'], ['November 2005'], ['Completed'], [], ['All'], [], ['18 Years'], []][['CRX100-001'], ['Study of CRX100 in Patients With Advanced Solid Tumors'], ['Interventional'], ['January 8, 2021'], ['March 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DARE'], ['DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer'], ['Interventional'], ['February 9, 2021'], ['December 15, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], [], []][['TP2001-202'], ['APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)'], ['Interventional'], ['April 2008'], ['September 2009'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CO40115'], ['A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer'], ['Interventional'], ['April 2, 2018'], ['May 3, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000442919'], ['S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['September 2005'], ['January 2007'], ['Withdrawn'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['EGF 20002'], ['Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.'], ['Interventional'], ['October 2002'], ['June 2005'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2012-02305'], ['Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2'], ['Interventional'], ['August 1999'], ['March 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S1202'], ['S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy'], ['Interventional'], ['May 15, 2013'], ['December 20, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['120 Years']][['CZOL446EUS147'], ['Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients'], ['Interventional'], ['June 2010'], ['August 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP-MGAH22-04'], ['Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer'], ['Interventional'], ['August 24, 2015'], ['June 14, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2016-01595'], ['Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer'], ['Interventional'], ['November 15, 2016'], ['May 31, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['G1T28-04'], ['Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)'], ['Interventional'], ['February 2, 2017'], ['February 28, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000069347'], ['Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer'], ['Interventional'], ['August 2001'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['LCCC 9727'], ['High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer'], ['Interventional'], ['September 1997'], ['January 2003'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['65 Years']][['CA180-261'], ['Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer'], ['Interventional'], ['February 2009'], ['December 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Biomed 777-CLP-30'], ['The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer'], ['Interventional'], ['December 2004'], ['August 2006'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['NCI-2018-01519'], ['Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer'], ['Interventional'], ['September 12, 2018'], ['June 1, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['14392'], ['A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer'], ['Interventional'], ['November 2011'], ['June 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-01073'], ['Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery'], ['Interventional'], ['December 1, 2008'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2009-01172'], ['Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery'], ['Interventional'], ['May 15, 2009'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALGB-70301'], ['Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer'], ['Observational'], ['October 2005'], ['June 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PT-304'], ['Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer'], ['Observational'], ['November 2009'], ['October 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08-PIR-05'], ['Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer'], ['Interventional'], ['October 2008'], ['January 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CRAD001C2222'], ['Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women'], ['Interventional'], ['March 2005'], ['April 2007'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-00341'], ['Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery'], ['Interventional'], ['July 2007'], ['February 21, 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['15362'], ['A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer'], ['Interventional'], ['July 22, 2014'], ['January 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['9785-CL-1121'], ['A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer'], ['Interventional'], ['August 28, 2014'], ['March 31, 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-00561'], ['Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer'], ['Interventional'], ['November 2, 2007'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ABI-007-MBC-001'], ['Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)'], ['Interventional'], ['September 26, 2013'], ['October 28, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['22339'], ['Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors'], ['Interventional'], ['June 6, 2023'], ['October 31, 2024'], ['Not yet recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A011801'], ['T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial'], ['Interventional'], ['January 6, 2021'], ['May 2035'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D0819C00003'], ['Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.'], ['Interventional'], ['March 27, 2014'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['16131'], ['Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['June 1, 2017'], ['January 28, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['12444'], ['Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer'], ['Interventional'], ['February 21, 2011'], ['October 20, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['STn-BR-105'], ['Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients'], ['Interventional'], ['August 2002'], ['August 2005'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['117515'], ['Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery'], ['Interventional'], ['May 18, 2012'], ['December 31, 2026'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['45 Years'], []][['CDR0000068399'], ['Digital Mammography Screening Trial (ACRIN6652)'], ['Interventional'], ['October 2001'], ['June 30, 2005'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['120 Years']][['18238'], ['Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer'], ['Interventional'], ['March 11, 2022'], ['February 16, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['dtectDx-Breast-002'], ['Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol'], ['Observational'], ['March 2014'], [], ['Unknown status'], ['Sponsor'], ['Female'], [], ['25 Years'], ['75 Years']][['16298'], ['Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer'], ['Interventional'], ['March 2, 2015'], ['August 13, 2019'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['AVF3694g'], ['A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)'], ['Interventional'], ['December 2005'], ['December 2013'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000065011'], ['Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['June 1997'], [], ['Completed'], [], ['Female'], [], ['18 Years'], []][['91466'], ['Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer'], ['Interventional'], ['April 2006'], ['November 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A011104'], ['MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer'], ['Interventional'], ['February 2014'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['11649'], ['Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['March 2008'], ['January 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CFEM345DUS59'], ['Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer'], ['Interventional'], ['March 2008'], ['June 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['CDR0000067956'], ['Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer'], ['Interventional'], ['July 2000'], ['August 2002'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['CALGB-70305'], ['Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection'], ['Interventional'], ['June 2006'], ['June 15, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-00665'], ['Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer'], ['Interventional'], ['July 30, 2008'], ['October 15, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['09-009'], ['Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)'], ['Interventional'], ['September 2011'], ['April 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011A2301'], ['Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)'], ['Interventional'], ['December 17, 2013'], ['March 26, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['3475-522'], ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)'], ['Interventional'], ['March 7, 2017'], ['September 30, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A6181099'], ['A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer'], ['Interventional'], ['February 2007'], ['June 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA163-046'], ['Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'], ['Interventional'], ['September 2003'], ['March 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['NCI-2009-00475'], ['Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive'], ['Interventional'], ['September 15, 2006'], ['July 2, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['155-CL-036'], ['A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer'], ['Interventional'], ['December 2009'], ['June 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['10-008061'], ['Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction'], ['Interventional'], ['May 2011'], ['November 2013'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['90 Years']][['3144A2-3005 / B1891005'], ['Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer'], ['Interventional'], ['August 21, 2009'], ['June 28, 2018'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['20-001275'], ['Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer'], ['Interventional'], ['October 9, 2020'], ['September 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GS-US-595-6184'], [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy\"], ['Interventional'], ['December 12, 2022'], ['January 2031'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EGF104900'], ['Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer'], ['Interventional'], ['November 2005'], ['October 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SGNLVA-001'], ['A Safety Study of SGN-LIV1A in Breast Cancer Patients'], ['Interventional'], ['October 22, 2013'], ['February 4, 2023'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2014-02409'], ['Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer'], ['Interventional'], ['March 6, 2015'], ['May 25, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ARV-471-mBC-102'], ['ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer'], ['Interventional'], ['September 8, 2022'], ['February 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['10112'], ['Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['April 20, 2011'], ['February 22, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['60 Years'], []][['SMX 20-001'], ['Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation'], ['Interventional'], ['September 29, 2020'], ['February 10, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['0S-17-7'], ['Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer'], ['Interventional'], ['November 8, 2017'], ['December 31, 2018'], ['Withdrawn'], ['Sponsor'], ['All'], [], [], []][['VEG20007'], ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer'], ['Interventional'], ['July 2006'], ['March 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['C31006'], ['Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy'], ['Interventional'], ['July 28, 2016'], ['November 25, 2019'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['NCI-2011-02623'], ['Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer'], ['Interventional'], ['January 15, 2011'], ['March 7, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ONC-010'], ['EndoPredict® Extended Endocrine Trial (EXET)'], ['Observational'], ['July 2, 2019'], ['March 31, 2022'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CRAD001Y2201'], ['A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.'], ['Interventional'], ['February 26, 2013'], ['July 30, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2016-01130'], ['Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer'], ['Interventional'], ['November 15, 2016'], ['August 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['WO40181'], ['A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy'], ['Interventional'], ['September 6, 2018'], ['May 6, 2021'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['107CS-6'], ['Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer'], ['Interventional'], ['July 25, 2018'], ['April 2022'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI 2013-01-03'], ['Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy'], ['Interventional'], ['October 2015'], ['May 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PUMA-NER-1301'], ['A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting'], ['Interventional'], ['March 29, 2013'], ['December 9, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP-B-51'], ['Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery'], ['Interventional'], ['August 2013'], ['August 2028'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011A2404'], ['Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC'], ['Interventional'], ['November 30, 2016'], ['December 3, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AVI-014-P02'], ['Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia'], ['Interventional'], ['August 2007'], ['July 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['NCI-2009-00476'], ['Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer'], ['Interventional'], ['October 13, 2008'], ['June 15, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17502'], ['A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer'], ['Interventional'], ['December 10, 2019'], ['December 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011E2301'], ['Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer'], ['Interventional'], ['November 20, 2014'], ['March 27, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['59 Years']][['4703'], ['A Phase III Trial For Patients With Metastatic Breast Cancer'], ['Interventional'], ['February 2002'], ['November 2008'], ['Completed'], [], ['All'], [], ['18 Years'], []][['PMD-026-1-001'], ['Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['November 14, 2019'], ['March 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C4391002'], ['A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors'], ['Interventional'], ['March 14, 2022'], ['December 30, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-01849'], ['Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer'], ['Interventional'], ['May 19, 2000'], ['January 27, 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SGNTUC-028'], ['A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer'], ['Interventional'], ['March 7, 2022'], ['June 30, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011X2107'], ['Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer'], ['Interventional'], ['October 22, 2013'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NSABP FB-7'], ['Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer'], ['Interventional'], ['October 2010'], ['November 25, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000339812'], ['Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer'], ['Interventional'], ['April 2004'], [], ['Completed'], [], ['Female'], [], ['25 Years'], []][['09-040'], ['Study of Radiation Exposure and Bilateral Breast Cancer'], ['Observational'], ['May 2009'], ['May 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['54 Years']][['S1703'], ['S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer'], ['Interventional'], ['July 16, 2018'], ['January 1, 2038'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-BR002'], ['Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival'], ['Interventional'], ['December 24, 2014'], ['December 20, 2026'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCCTG-N9431'], ['Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer'], ['Observational'], ['June 1996'], ['October 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['55 Years']][['D8532C00001'], ['A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease'], ['Interventional'], ['January 28, 2021'], ['February 1, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['15-102-14'], [\"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine\"], ['Interventional'], ['November 2016'], ['July 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['3144A1-2206 / B1891017'], ['Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer'], ['Interventional'], ['December 9, 2008'], ['June 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VAR0033'], ['Immunobiology of Cancer'], ['Observational'], ['October 2008'], ['October 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2011-02585'], ['Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer'], ['Interventional'], ['April 21, 2011'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACT16105'], [\"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer\"], ['Interventional'], ['October 22, 2019'], ['September 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-01977'], ['Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer'], ['Interventional'], ['July 26, 2012'], ['May 20, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA023'], ['Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer'], ['Interventional'], ['February 1, 2006'], ['March 1, 2011'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['090214'], [\"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)\"], ['Interventional'], ['August 20, 2009'], ['April 11, 2019'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['120 Years']][['S1501'], ['S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer'], ['Interventional'], ['September 15, 2017'], ['January 1, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20170770'], ['Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer'], ['Interventional'], ['February 26, 2020'], ['January 14, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['91743'], ['Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI'], ['Interventional'], ['February 2010'], ['January 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EGF103659'], ['EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer'], ['Expanded Access'], ['July 2006'], ['March 2015'], ['Approved for marketing'], ['Sponsor'], ['All'], [], ['18 Years'], []][['S2007'], ['Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases'], ['Interventional'], ['December 15, 2020'], ['December 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['213551'], [\"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients\"], ['Interventional'], ['February 25, 2014'], ['October 26, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000617081'], ['S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo'], ['Interventional'], ['September 2009'], ['June 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['TDM4884g'], ['A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer'], ['Expanded Access'], ['May 2010'], [], ['No longer available'], ['Sponsor'], ['All'], [], ['18 Years'], []][['368255'], ['Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax'], ['Interventional'], ['May 21, 2013'], ['September 28, 2018'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['18175'], [\"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\"], ['Interventional'], ['October 4, 2021'], ['August 31, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20110147'], ['NOLAN: Naproxen or Loratadine and Neulasta'], ['Interventional'], ['November 1, 2012'], ['March 18, 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['100 Years']][['NCI-2011-01379'], ['Veliparib With or Without Carboplatin in Treating Patients With Stage IV Breast Cancer'], ['Interventional'], ['June 30, 2010'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['111438'], ['Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer'], ['Interventional'], ['April 14, 2009'], ['March 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000065237'], ['SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial'], ['Observational'], ['February 1997'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['NCCTG-N00C9'], ['EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer'], ['Interventional'], ['December 2002'], ['April 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2015-00383'], ['FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy'], ['Interventional'], ['February 2, 2016'], ['April 4, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['999915030'], ['Self-Affirmation, Emotion, and Alcohol Consumption'], ['Observational'], ['November 19, 2014'], ['September 29, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['201209135'], ['Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer'], ['Interventional'], ['December 11, 2012'], ['March 11, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A011106'], ['Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery'], ['Interventional'], ['December 13, 2013'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2015-01912'], ['Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases'], ['Interventional'], ['July 7, 2016'], ['October 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SCUSF 0806'], ['Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab'], ['Interventional'], ['March 2010'], ['November 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB 6110'], ['The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels'], ['Interventional'], ['January 2006'], ['March 2007'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['21 Years'], []][['CRAD001Y24135'], ['Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer'], ['Interventional'], ['March 7, 2013'], ['January 13, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D8180C00034'], ['Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease'], ['Interventional'], ['February 2008'], ['August 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D3614C00001'], ['Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC'], ['Interventional'], ['June 25, 2019'], ['October 6, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['CDR0000069346'], ['Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer'], ['Interventional'], ['August 2001'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['CD-ON-MEDI-573-1030'], ['Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer'], ['Interventional'], ['June 13, 2011'], ['June 28, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['99 Years']][['CDR0000065241'], ['Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function'], ['Interventional'], ['December 1996'], [], ['Completed'], [], ['All'], [], ['18 Years'], []][['SPI-GCF-104'], ['Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer'], ['Interventional'], ['March 11, 2020'], ['June 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['55 Years']][['NUV-422-03'], ['Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC'], ['Interventional'], ['September 2022'], ['September 2026'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['WO29217'], ['A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer'], ['Interventional'], ['July 14, 2014'], ['August 25, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-03778'], ['Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases'], ['Interventional'], ['January 2006'], ['March 14, 2019'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['NCI-2019-06088'], ['Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones'], ['Interventional'], ['December 27, 2019'], ['June 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SCO-120-19-22'], ['A Study in Patients With Advanced Breast Cancer'], ['Interventional'], ['May 20, 2022'], ['January 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO16216'], ['A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer'], ['Interventional'], ['January 2001'], ['October 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['GEN-602-CT-101'], ['Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer'], ['Interventional'], ['March 1, 2019'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15419'], ['A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread'], ['Interventional'], ['June 10, 2014'], ['October 22, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2017-01119'], ['Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer'], ['Interventional'], ['March 12, 2019'], ['April 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NO16853'], ['A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['July 2003'], ['March 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CALGB-70604'], ['Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement'], ['Interventional'], ['March 2009'], ['January 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A5481082'], ['Palbociclib in Real World Practice'], ['Observational'], ['January 4, 2017'], ['October 1, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CBYL719A2201'], ['Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women'], ['Interventional'], ['March 11, 2014'], ['July 8, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2009-00284'], ['Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer'], ['Interventional'], ['October 31, 2008'], ['February 14, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI 06-46'], ['LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis'], ['Interventional'], ['March 2007'], ['August 2008'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['1200.11'], ['Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy'], ['Interventional'], ['September 2006'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['105-08-201'], ['Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall'], ['Interventional'], ['February 2013'], ['June 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SLN-USA-1'], ['Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes'], ['Interventional'], ['July 2015'], ['March 2017'], ['Completed'], ['Sponsor'], ['All'], [], [], []][['CDR0000449959'], ['T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors'], ['Interventional'], ['August 2005'], [], ['Completed'], ['Sponsor'], ['All'], [], [], []][['NCI-2018-01581'], ['Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer'], ['Interventional'], ['December 14, 2018'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA163-048'], ['Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer'], ['Interventional'], ['November 2003'], ['March 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['EA1151'], ['Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer'], ['Interventional'], ['July 6, 2017'], ['December 31, 2030'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['45 Years'], ['74 Years']][['UCI 05-46'], ['Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab'], ['Interventional'], ['March 2006'], ['June 2010'], ['Terminated'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['WO43571'], ['A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)'], ['Interventional'], ['July 4, 2022'], ['September 30, 2032'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CAAA504A12101'], ['Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.'], ['Interventional'], ['October 14, 2021'], ['November 10, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB-16617'], ['Stanford Accelerated Recovery Trial (START)'], ['Interventional'], ['May 2010'], ['July 2016'], ['Terminated'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['75 Years']][['P0339 NBRST Registry'], ['NBRST: Prospective Neo-adjuvant REGISTRY Trial'], ['Observational'], ['July 2011'], ['January 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['3475-B49'], ['Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)'], ['Interventional'], ['June 18, 2021'], ['July 21, 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000066242'], ['MRI to Detect Breast Tumors in Women'], ['Interventional'], ['May 1998'], ['June 30, 2000'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['79 Years']][['EGF106708'], ['ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D'], ['Interventional'], ['May 16, 2007'], ['July 1, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTKI258A2128'], ['Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors'], ['Interventional'], ['December 2011'], ['July 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2009-00707'], ['Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)'], ['Interventional'], ['April 7, 2006'], ['September 30, 2030'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['75 Years']][['1839IL/0225'], ['Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study'], ['Interventional'], ['October 2003'], ['June 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['130 Years']][['GYN0001'], ['Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program'], ['Observational'], ['January 2010'], ['July 2013'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ABI-007-ST-001'], ['Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer'], ['Interventional'], ['January 12, 2015'], ['September 12, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['OBI-822-011'], ['Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC'], ['Interventional'], ['December 5, 2018'], ['December 30, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['H3B-6545-A001-101'], ['Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer'], ['Interventional'], ['August 17, 2017'], ['October 1, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A221803'], ['Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy'], ['Interventional'], ['June 15, 2022'], ['December 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NEO3-09'], ['Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes'], ['Interventional'], ['June 2010'], ['April 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011XUS10T'], ['Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer'], ['Interventional'], ['February 2016'], ['April 2023'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['GLSI-21-01'], ['Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects'], ['Interventional'], ['August 11, 2022'], ['December 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['PrE0102'], ['Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI'], ['Interventional'], ['May 31, 2013'], ['September 12, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000066165'], ['Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors'], ['Interventional'], ['February 1998'], ['January 2001'], ['Completed'], [], ['All'], [], ['18 Years'], ['70 Years']][['A221702'], ['Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection'], ['Interventional'], ['May 31, 2019'], ['January 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S1222'], ['S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer'], ['Interventional'], ['May 2014'], ['December 31, 2019'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CA048-001'], ['A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread'], ['Interventional'], ['September 22, 2020'], ['August 15, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['213363'], ['Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer'], ['Interventional'], ['April 15, 2016'], ['September 17, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['0S-17-5'], ['Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors'], ['Interventional'], ['August 17, 2017'], ['July 15, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1280-0022'], ['The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread'], ['Interventional'], ['November 28, 2018'], ['May 11, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['MC1835-ACCRU-BR-1701'], ['TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery'], ['Interventional'], ['February 20, 2020'], ['January 15, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000069104'], ['Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer'], ['Interventional'], ['December 2001'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['ODO-TE-B301'], ['Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC'], ['Interventional'], ['December 21, 2017'], ['June 28, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LPT109096'], ['Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.'], ['Interventional'], ['August 2007'], ['August 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['17237'], ['HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases'], ['Interventional'], ['August 31, 2018'], ['August 31, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['75 Years']][['209514'], ['Pilot Study of Pancreatic Cancer Screening'], ['Observational'], ['January 20, 2022'], ['January 31, 2032'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['E7389-M001-218'], ['Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)'], ['Interventional'], ['August 28, 2015'], ['April 6, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTPR-0009'], ['Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®'], ['Interventional'], ['May 8, 2012'], ['December 2029'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], []][['18-27025'], ['SCOPE-Chinese Women Study'], ['Interventional'], ['July 20, 2020'], ['December 30, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SPI-GCF-12-201'], ['Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer'], ['Interventional'], ['March 25, 2013'], ['August 12, 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16244'], ['Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer'], ['Expanded Access'], [], [], ['Approved for marketing'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-13-001'], ['MarginProbe 2.0 Data Collection Protocol'], ['Observational'], ['December 15, 2021'], ['December 31, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EGF105084'], ['Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer'], ['Interventional'], ['December 2, 2005'], ['March 15, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A211601'], ['Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502'], ['Observational'], ['August 1, 2018'], ['July 18, 2022'], ['Terminated'], ['Sponsor'], ['Female'], [], [], []][['DAN-22220205'], ['A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer'], ['Interventional'], ['February 2, 2022'], ['April 30, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLP0008'], ['Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients'], ['Interventional'], ['September 1, 2020'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SCRI BRE 145'], ['A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer'], ['Interventional'], ['December 2008'], ['November 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S0927'], [\"S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy\"], ['Interventional'], ['February 2012'], ['March 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['NCI-2019-02752'], ['Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer'], ['Interventional'], ['October 21, 2019'], ['November 1, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16-304'], ['Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma'], ['Interventional'], ['April 1, 2018'], ['April 1, 2030'], ['Active, not recruiting'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['C3621001'], ['Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC'], ['Interventional'], ['November 27, 2018'], ['September 27, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ML29366'], ['A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy'], ['Interventional'], ['December 16, 2015'], ['December 29, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EZN-2208-03'], ['A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer'], ['Interventional'], ['November 2009'], ['December 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['VEG108838'], ['Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer'], ['Interventional'], ['December 2007'], ['December 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['RTOG-9804'], ['Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ'], ['Interventional'], ['December 1999'], ['May 20, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['26 Years'], ['120 Years']][['EA1181'], ['CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy'], ['Interventional'], ['February 11, 2020'], ['December 31, 2038'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['960-CSP-USA_DenseBreasts_USS1'], ['A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts'], ['Interventional'], ['April 15, 2018'], ['April 30, 2019'], ['Terminated'], ['Sponsor'], ['Female'], [], ['40 Years'], ['70 Years']][['NEPA-17-05'], ['A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer'], ['Interventional'], ['March 16, 2018'], ['September 19, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['378-ONC-0030-184'], ['Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer'], ['Interventional'], ['November 2000'], ['August 2006'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['A191901'], ['Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy'], ['Interventional'], ['February 15, 2021'], ['October 2025'], ['Suspended'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2015-00741'], ['Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer'], ['Interventional'], ['November 6, 2015'], ['February 22, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['G1T48-01'], ['G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer'], ['Interventional'], ['May 9, 2018'], ['September 29, 2022'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['CALGB-40903'], ['Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ'], ['Interventional'], ['February 2012'], ['January 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ML17771'], ['A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer'], ['Interventional'], ['September 2004'], ['October 2004'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['S1904'], ['Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)'], ['Interventional'], ['September 1, 2020'], ['June 1, 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], [], []][['MM-111-01-100'], ['A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers'], ['Interventional'], ['June 2009'], ['March 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GS-US-350-1937'], ['GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer'], ['Interventional'], ['January 10, 2017'], ['July 19, 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011AUS42'], ['A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib'], ['Interventional'], ['June 7, 2017'], ['March 8, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TORI B-02'], ['Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)'], ['Interventional'], ['May 2005'], [], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['15160'], ['Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities'], ['Interventional'], ['April 6, 2016'], ['October 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['OSNA-BC-001'], ['Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer'], ['Observational'], ['February 2007'], ['December 2008'], ['Completed'], [], ['All'], [], ['18 Years'], []][['RTOG 0517'], ['Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer'], ['Interventional'], ['July 11, 2006'], ['February 27, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['114299'], ['A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer'], ['Interventional'], ['May 5, 2011'], ['June 6, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ONCB-006-19F'], ['Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer'], ['Interventional'], ['April 19, 2023'], ['April 1, 2027'], ['Not yet recruiting'], ['Sponsor'], ['All'], [], ['21 Years'], []][['1505016201'], ['Trial to Compare Radiation Fibrosis With Five Versus Three Fractions'], ['Interventional'], ['July 2015'], ['July 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], ['90 Years']][['1407426'], ['Family History Study on Cancer Risk'], ['Interventional'], ['July 1, 2020'], ['August 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['25 Years'], ['75 Years']][['PMT4979g'], [\"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer\"], ['Interventional'], ['March 16, 2011'], ['June 25, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SVMC-ONC-222'], ['Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer'], ['Interventional'], ['April 1991'], ['June 2009'], ['Completed'], [], ['All'], [], ['18 Years'], []][['104603'], ['Excision Followed by Radiofrequency Ablation for Breast Cancer'], ['Interventional'], ['June 2010'], ['December 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], ['100 Years']][['NCI-2017-01921'], ['Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery'], ['Interventional'], ['October 31, 2018'], ['February 22, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['99000287'], ['Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs'], ['Observational'], ['July 2008'], [], ['Unknown status'], [], ['All'], [], ['18 Years'], ['80 Years']][['UCSD IIT 150729'], ['Histology-Independent Study of Palbociclib in Patients With Advanced Cancer'], ['Interventional'], ['July 1, 2018'], ['February 1, 2024'], ['Withdrawn'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['V0407'], ['Statins and Breast Cancer Biomarkers'], ['Interventional'], ['January 2005'], [], ['Unknown status'], [], ['Female'], [], ['35 Years'], ['55 Years']][['BioDyn-15-003'], ['TR(ACE) Assay Clinical Specimen Study'], ['Observational'], ['September 2016'], ['April 2018'], ['Unknown status'], ['Sponsor'], ['All'], [], ['21 Years'], []][['07-199'], ['Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer'], ['Interventional'], ['October 2007'], ['August 30, 2022'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['ICMBC-02'], ['Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial'], ['Interventional'], ['October 2014'], ['December 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['KD019-204'], ['Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer'], ['Interventional'], ['May 2014'], ['September 13, 2015'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['LPT111111'], ['Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC'], ['Interventional'], ['July 2, 2008'], ['January 3, 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRI-ROL-001'], ['Combination Study of SV-BR-1-GM With Retifanlimab'], ['Interventional'], ['March 16, 2018'], ['June 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['FLEX Registry'], ['MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles'], ['Observational'], ['April 28, 2017'], ['December 2037'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D0816R00012'], ['International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study'], ['Observational'], ['March 13, 2017'], ['May 20, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['229510'], ['Combination Therapy in Cancers With Mutations in DNA Repair Genes'], ['Interventional'], ['April 1, 2023'], ['December 31, 2027'], ['Not yet recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['LYT-100-2020-01'], ['LYT-100 in Healthy Volunteers and BCRL'], ['Interventional'], ['March 1, 2020'], ['September 9, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['80 Years']][['NU 10C03'], ['Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer'], ['Interventional'], ['August 1, 2011'], ['January 20, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['18-124'], ['ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer'], ['Interventional'], ['August 22, 2018'], ['August 30, 2029'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['60 Years'], []][['PRO37771'], ['Benefits of Exercise Training in Women With Ischemic Syndrome'], ['Interventional'], ['January 2016'], ['October 2016'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['60 Years']][['CBYL719H12301'], ['Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss'], ['Interventional'], ['June 8, 2020'], ['June 19, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Biomed 777-CLP-29'], ['Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer'], ['Interventional'], ['June 2002'], ['January 2006'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CDR0000729174'], ['DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy'], ['Interventional'], ['August 27, 2012'], ['January 14, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EAZ171'], ['Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer'], ['Interventional'], ['June 27, 2019'], ['June 1, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['Wellderly Immune Antibodies'], ['Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort'], ['Observational'], ['June 2012'], ['May 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['90 Years'], []][['12-000493'], ['Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme'], ['Interventional'], ['December 7, 2012'], ['June 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A4581001'], ['MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.'], ['Interventional'], ['February 2004'], ['July 2013'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011A2112C'], ['Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.'], ['Interventional'], ['June 27, 2014'], ['October 26, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['07-022'], ['Bicalutamide in Treating Patients With Metastatic Breast Cancer'], ['Interventional'], ['March 23, 2007'], ['June 24, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['112515'], ['Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone'], ['Interventional'], ['January 20, 2010'], ['March 30, 2018'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['A211102'], ['Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer'], ['Interventional'], ['February 1, 2015'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['25 Years'], ['55 Years']][['0C-07-3'], ['Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib'], ['Interventional'], ['March 2008'], ['June 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IRB00041707'], ['Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil'], ['Interventional'], ['May 30, 2017'], ['July 29, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['75 Years']][['NCI-2011-01472'], ['Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy'], ['Interventional'], ['April 20, 2009'], ['May 19, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['19 Years'], []][['116911'], ['Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans'], ['Interventional'], ['May 2014'], ['February 2015'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], ['85 Years']][['1808019498'], ['Converting HR+ Breast Cancer Into an Individualized Vaccine'], ['Interventional'], ['March 17, 2020'], ['December 30, 2025'], ['Recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['90 Years']][['19-031'], [\"'ADVANCE' (A Pilot Trial)\"], ['Interventional'], ['March 21, 2019'], ['March 21, 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['70 Years'], []][['OMS-I141 (KEYNOTE-890)'], ['Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC'], ['Interventional'], ['October 11, 2018'], ['August 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000066851'], ['MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer'], ['Interventional'], ['June 1999'], ['June 2002'], ['Completed'], [], ['Female'], [], ['25 Years'], ['120 Years']][['NCI-2009-00702'], ['Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy'], ['Interventional'], ['November 10, 2008'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D361DC00001'], ['Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)'], ['Interventional'], ['May 10, 2021'], ['January 5, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['CDR0000538232'], ['Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children'], ['Observational'], ['September 2006'], ['October 2013'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['097517'], ['I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer'], ['Interventional'], ['March 1, 2010'], ['December 2031'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['39855'], ['Microsurgical Breast Reconstruction & VTE'], ['Observational'], ['January 30, 2017'], ['December 15, 2017'], ['Completed'], ['Principal Investigator'], ['Female'], ['Yes'], ['18 Years'], ['90 Years']][['SSC-311'], ['Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System'], ['Observational'], ['November 2005'], [], ['Unknown status'], [], ['Female'], [], ['20 Years'], ['80 Years']][['OIC-1UO-C001'], ['Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome'], ['Interventional'], ['April 2010'], ['September 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D9673C00007'], ['A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer'], ['Interventional'], ['June 22, 2021'], ['February 9, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['2015-013-00US1'], ['A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer'], ['Interventional'], ['November 10, 2017'], ['March 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['E4112'], ['MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ'], ['Interventional'], ['January 7, 2015'], ['November 2027'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRE007-12'], ['Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer'], ['Interventional'], ['February 2013'], ['January 2033'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['17-455'], ['The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer'], ['Interventional'], ['June 21, 2018'], ['May 31, 2025'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['20-002000'], ['Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer'], ['Interventional'], ['April 8, 2021'], ['December 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA016'], ['Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer'], ['Interventional'], ['June 1, 2004'], ['October 1, 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB 4260'], ['Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women'], ['Observational'], ['January 1995'], ['December 2009'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['40 Years'], ['60 Years']][['CA163-100'], ['Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer'], ['Interventional'], ['October 2007'], ['December 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['TARGIT Boost'], ['A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.'], ['Interventional'], ['June 2013'], ['April 2022'], ['Unknown status'], ['Sponsor'], ['Female'], [], [], []][['HSC 07-4789'], ['The Healthy Elderly Longevity Cohort'], ['Observational'], ['August 2007'], ['January 2030'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['80 Years'], []][['SU-09112008-1298'], ['Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer'], ['Interventional'], [], [], ['Withdrawn'], [], ['All'], [], ['18 Years'], []][['ARV-471-BC-201'], ['A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery'], ['Interventional'], ['February 15, 2023'], ['June 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['MA21'], ['Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer'], ['Interventional'], ['December 4, 2000'], ['March 17, 2014'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['60 Years']][['SO-BCA-003'], ['Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer'], ['Interventional'], ['March 9, 2017'], ['June 30, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D6997C00002'], ['Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.'], ['Interventional'], ['February 13, 2005'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['45 Years'], ['130 Years']][['13-559'], ['Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer'], ['Interventional'], ['January 2014'], ['May 2020'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['LCCC 0403'], ['Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer'], ['Interventional'], ['November 2005'], ['August 12, 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['ISI dV SP - NSM-01'], ['Robotic vs. Open NSM for Early Stage Breast Cancer'], ['Interventional'], ['April 2023'], ['December 2026'], ['Not yet recruiting'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['09-056'], ['Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer'], ['Observational'], ['July 2009'], ['July 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IPI-504-07'], ['Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer'], ['Interventional'], ['March 2009'], ['May 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000377698'], ['S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women'], ['Interventional'], ['November 2004'], ['July 2009'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['147522'], ['A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer'], ['Interventional'], ['October 19, 2015'], ['January 31, 2021'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['13944'], ['Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients'], ['Interventional'], ['March 2011'], ['July 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PN-301-21'], ['Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer'], ['Interventional'], ['February 28, 2022'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000069496'], ['Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer'], ['Interventional'], ['May 2002'], ['March 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EORTC-10085'], ['Male Breast Cancer: Understanding the Biology for Improved Patient Care'], ['Observational'], ['December 2010'], ['March 2023'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['SCRI BRE 126'], ['Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer'], ['Interventional'], ['February 2010'], ['September 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1040-000-002'], ['A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer'], ['Interventional'], ['January 2002'], ['May 2003'], ['Completed'], [], ['All'], [], ['18 Years'], []][['CA180-059'], [\"A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer\"], ['Interventional'], ['December 2006'], ['September 2008'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['F061229006'], ['Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer'], ['Interventional'], ['October 8, 2007'], ['March 31, 2022'], ['Completed'], ['Principal Investigator'], ['All'], [], ['19 Years'], []][['3144A1-2204 / B1891015'], ['Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer'], ['Interventional'], ['April 29, 2008'], ['June 7, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NOX66-005'], ['A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors'], ['Interventional'], ['October 25, 2021'], ['February 28, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CC#157521+167513'], ['Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease'], ['Interventional'], ['September 2, 2017'], ['September 30, 2023'], ['Recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['AFT-38'], ['Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer'], ['Interventional'], ['June 21, 2017'], ['March 31, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA180-088'], ['Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer'], ['Interventional'], ['December 2006'], ['May 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['D967JC00001'], ['A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer'], ['Interventional'], ['December 28, 2020'], ['December 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AVB620-C-002'], ['Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery'], ['Interventional'], ['July 5, 2017'], ['November 18, 2020'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['A5481034'], ['Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate'], ['Expanded Access'], [], [], ['No longer available'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['ARD11439'], ['Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen'], ['Interventional'], ['February 2010'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08218'], ['Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors'], ['Interventional'], ['September 2010'], ['December 11, 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['Female'], [], ['25 Years'], []][['0607-18 IUCRO-0154'], ['Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer'], ['Interventional'], ['July 2007'], ['December 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MAP3B'], ['Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3'], ['Observational'], ['January 23, 2008'], ['January 10, 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['35 Years'], []][['ARD11437'], ['Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer'], ['Interventional'], ['June 2010'], ['April 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PM1183-B-003-11'], ['A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer'], ['Interventional'], ['June 13, 2012'], ['October 2018'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['75 Years']][['STM01-102'], ['Trial of Myocet in Metastatic Breast Cancer'], ['Interventional'], ['January 2006'], [], ['Unknown status'], [], ['Female'], [], ['18 Years'], []][['11-344'], ['HKI-272 for HER2-Positive Breast Cancer and Brain Metastases'], ['Interventional'], ['February 2012'], ['December 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['GO28888'], ['A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)'], ['Interventional'], ['November 12, 2014'], ['March 13, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NRG-BR001'], ['Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer'], ['Interventional'], ['August 2014'], ['May 20, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IMPACt'], ['Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry'], ['Observational'], ['November 2015'], ['August 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['REP0114'], ['A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer'], ['Interventional'], ['July 29, 2015'], ['March 23, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['21-159'], ['ATEMPT 2.0: Adjuvant T-DM1 vs TH'], ['Interventional'], ['June 16, 2021'], ['May 1, 2028'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['A231901CD'], ['Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions'], ['Interventional'], ['January 15, 2021'], ['January 2027'], ['Recruiting'], ['Sponsor'], ['Female'], [], [], []][['ACOSOG-Z1072'], ['Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer'], ['Interventional'], ['September 2008'], [], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A6181064'], ['Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer'], ['Interventional'], ['February 2007'], ['July 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NRG-BR005'], ['Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery'], ['Interventional'], ['April 13, 2017'], ['November 30, 2023'], ['Suspended'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RTOG 1014'], ['Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery'], ['Interventional'], ['June 2010'], ['May 20, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['SCRI BRE 154'], ['Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer'], ['Interventional'], ['July 2009'], ['July 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['09-03'], ['Multicenter Hologic Tomosynthesis Study'], ['Interventional'], ['September 2009'], ['January 2013'], ['Unknown status'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CAUY922A2101'], ['Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients'], ['Interventional'], ['July 2007'], ['April 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCSF CC#05591'], ['Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors'], ['Interventional'], ['February 2006'], ['December 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLBH589C2204'], ['A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab'], ['Interventional'], ['April 2008'], ['May 2011'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['3160A6-2207'], ['Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer'], ['Interventional'], ['July 30, 2009'], ['May 31, 2010'], ['Terminated'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['20140299'], ['Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases'], ['Interventional'], ['March 19, 2018'], ['December 3, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['10-005'], ['Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer'], ['Interventional'], ['April 2010'], ['July 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D5392C00050'], ['Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer'], ['Interventional'], ['April 2004'], ['October 2007'], ['Completed'], [], ['Female'], [], ['55 Years'], []][['HALO Dx 001'], ['Phase I Human Analytics (HALO) Study'], ['Observational'], ['March 16, 2022'], ['March 2037'], ['Recruiting'], ['Sponsor'], ['Male'], [], ['45 Years'], ['90 Years']][['NK-101'], ['FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors'], ['Interventional'], ['January 18, 2018'], ['December 15, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA209-7A8'], ['A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer'], ['Interventional'], ['October 18, 2019'], ['July 27, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['OCOG-2007-LISA'], ['Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer'], ['Interventional'], ['August 2007'], ['June 2018'], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['D699BC00001'], ['A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.'], ['Interventional'], ['October 17, 2012'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], ['130 Years']][['BRE 354'], ['A Study of U3-1402 in Subjects With Metastatic Breast Cancer'], ['Interventional'], ['May 3, 2021'], ['November 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP FB-12'], ['Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling'], ['Interventional'], ['May 14, 2018'], ['October 30, 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['B3271004'], ['A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)'], ['Interventional'], ['September 23, 2014'], ['March 9, 2016'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['1602017205'], ['Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients'], ['Interventional'], ['July 2016'], ['April 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CA180-004'], ['Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer'], ['Interventional'], ['June 2007'], ['October 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['WO39392'], ['A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer'], ['Interventional'], ['July 24, 2017'], ['September 26, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BGBC007'], ['Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC'], ['Interventional'], ['July 26, 2017'], ['August 20, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LAE205INT3101'], ['Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer'], ['Interventional'], ['February 18, 2022'], ['December 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IBIO-301'], ['A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer'], ['Interventional'], ['March 18, 2018'], ['September 22, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CP-03-001'], ['MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery'], ['Interventional'], ['October 2008'], ['June 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['LOXO-PIK-21001'], ['A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors'], ['Interventional'], ['May 11, 2022'], ['May 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UPCC 19115'], ['Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial'], ['Interventional'], ['February 2016'], ['November 2036'], ['Recruiting'], ['Sponsor'], ['All'], [], ['21 Years'], []][['06-412'], ['Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response'], ['Interventional'], ['June 2007'], ['June 2017'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['GO29505'], ['A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer'], ['Interventional'], ['February 17, 2015'], ['August 2, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['17249'], ['A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body'], ['Interventional'], ['August 2, 2019'], ['May 14, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['KU36-44'], ['Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer'], ['Interventional'], ['June 15, 2007'], ['December 21, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['130 Years']][['C0541001'], ['PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors'], ['Interventional'], ['November 1, 2017'], ['August 31, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D2270C00020'], ['Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer'], ['Interventional'], ['December 7, 2015'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['130 Years']][['MO27782'], ['A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer'], ['Interventional'], ['April 2012'], ['October 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16177'], ['A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer'], ['Interventional'], ['November 14, 2016'], ['September 20, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 7839-204'], ['Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer'], ['Interventional'], ['October 2010'], ['October 2011'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CR005143'], ['A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy'], ['Interventional'], ['March 2, 2006'], ['January 31, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['99 Years']][['CRAD001W2301'], ['Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['October 2009'], ['June 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['REBACCCWFU-97202'], ['Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer'], ['Interventional'], ['August 27, 2004'], ['August 31, 2009'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['BRSNSTU0011'], ['Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample'], ['Observational'], ['October 2000'], ['April 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ZN-c5-001'], ['A Study of ZN-c5 in Subjects With Breast Cancer'], ['Interventional'], ['December 8, 2018'], ['December 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CO40151'], ['A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer'], ['Interventional'], ['February 13, 2018'], ['March 15, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['13-164 (ILC)'], ['Endocrine Response in Women With Invasive Lobular Breast Cancer'], ['Interventional'], ['September 30, 2015'], ['March 2023'], ['Recruiting'], ['Sponsor-Investigator'], ['Female'], [], [], []][['B2151002'], ['A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)'], ['Interventional'], ['September 10, 2013'], ['January 8, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MCLA-128-CL02'], ['MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer'], ['Interventional'], ['January 15, 2018'], ['February 15, 2024'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['VAR0047'], ['Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2'], ['Observational'], ['October 2010'], ['December 2015'], ['Suspended'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['CBKM120F2202'], ['A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation'], ['Interventional'], ['August 2012'], ['June 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['WO41554'], ['A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['January 29, 2020'], ['September 19, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000374991'], ['Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer'], ['Interventional'], ['July 2004'], ['May 2008'], ['Terminated'], ['Sponsor'], ['Female'], [], [], ['44 Years']][['E7389-M000-219'], ['Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)'], ['Interventional'], ['July 13, 2016'], ['August 16, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CL0006'], ['Intraoperative Detection of Residual Cancer in Breast Cancer'], ['Interventional'], ['February 6, 2018'], ['April 10, 2020'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['12228'], ['Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung'], ['Interventional'], ['July 2014'], [], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TOL2506A'], ['Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer'], ['Interventional'], ['July 1, 2021'], ['April 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['49 Years']][['CDR0000594003'], ['Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02'], ['Interventional'], ['December 2007'], ['April 2016'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['120 Years']][['D8530C00002'], ['A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer'], ['Interventional'], ['April 22, 2020'], ['May 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['130 Years']][['17-428'], ['Olaparib In Metastatic Breast Cancer'], ['Interventional'], ['April 1, 2018'], ['December 30, 2022'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['08007'], ['Ixabepilone + Carboplatin Metastatic Breast Cancer'], ['Interventional'], ['January 2010'], ['June 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP FB-11'], ['A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer'], ['Interventional'], ['January 2015'], ['March 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CA191-011'], ['Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors'], ['Interventional'], ['December 31, 2010'], ['November 30, 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['E7389-G000-211'], ['A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine'], ['Interventional'], ['October 2005'], ['September 2007'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['849679'], ['RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)'], ['Interventional'], ['April 14, 2022'], ['February 1, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['11127'], ['The Hurria Older PatiEnts (HOPE) With Breast Cancer Study'], ['Observational'], ['September 9, 2011'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['65 Years'], []][['12345'], ['Primary Care Clinical Excellence Incentive Study'], ['Interventional'], ['November 1, 2019'], ['January 1, 2021'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CDR0000628769'], ['Optical Coherence Tomography in Tissue Samples From Women Undergoing Mastectomy for the Treatment or Prevention of Breast Ductal Intraepithelial Neoplasia'], ['Interventional'], ['November 2006'], ['March 2009'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['GO29642'], ['A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer'], ['Interventional'], ['December 29, 2014'], ['March 13, 2020'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['Biomed 777-CLP-32'], ['Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer'], ['Interventional'], ['November 2005'], ['June 2006'], ['Terminated'], [], ['Female'], [], ['18 Years'], []][['FOENIX-MBC2 TAS-120-201'], ['A Study of TAS-120 in Patients With Metastatic Breast Cancer'], ['Interventional'], ['August 30, 2019'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1200.89'], ['Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer'], ['Interventional'], ['August 2011'], ['November 2014'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['Pro00019830'], ['The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function'], ['Observational'], ['September 2009'], ['January 2012'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CA163-081'], ['Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)'], ['Interventional'], ['February 2004'], ['December 2006'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['IIT2015-07-SHIAO-HIFIDELI'], ['Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis'], ['Observational'], ['August 21, 2016'], ['December 2023'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CBEZ235A2101'], ['A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer'], ['Interventional'], ['December 21, 2006'], ['January 8, 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA163-132'], ['Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer'], ['Interventional'], ['May 2008'], ['August 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['15252'], ['A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread'], ['Interventional'], ['March 10, 2014'], ['September 20, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['C3661001'], ['A Study of PF-06873600 in People With Cancer'], ['Interventional'], ['March 7, 2018'], ['November 28, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MCC-14662'], ['Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer'], ['Interventional'], ['February 2006'], ['August 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VICC BRE 1287'], ['GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer'], ['Interventional'], ['September 2013'], ['April 2015'], ['Terminated'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['201610'], ['Predicting Chronic Pain Following Breast Surgery'], ['Observational'], ['July 19, 2021'], ['December 31, 2023'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['MC1831'], ['Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer'], ['Interventional'], ['August 28, 2019'], ['April 30, 2024'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['MO27775'], ['A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer'], ['Interventional'], ['February 17, 2012'], ['November 14, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['AURORA US'], ['Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer'], ['Observational'], ['September 16, 2019'], ['November 15, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['13-048'], ['T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)'], ['Interventional'], ['May 2013'], ['December 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CA163-131'], ['Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer'], ['Interventional'], ['February 2008'], ['March 2010'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PREDAPT'], ['A Multicenter Cancer Biospecimen Collection Study'], ['Observational'], ['February 5, 2020'], ['February 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011A2207'], ['Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer'], ['Interventional'], ['June 11, 2019'], ['December 30, 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CZOL446EUS16'], ['Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions'], ['Interventional'], ['October 2001'], ['November 2002'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000460234'], ['Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance'], ['Observational'], ['October 2005'], ['March 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['78 Years']][['NCI-2019-00048'], ['A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer'], ['Interventional'], ['February 13, 2019'], ['February 19, 2022'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['29747'], ['T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer'], ['Interventional'], ['December 6, 2018'], ['December 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['9061'], ['A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy'], ['Interventional'], ['June 2003'], ['December 2005'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['TCD11608'], ['A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis'], ['Interventional'], ['July 2010'], ['July 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['21 Years'], []][['IRB-16-6815'], ['Quell Opioid Reduction and Pain Relief in Patients With Cancer'], ['Interventional'], ['July 2016'], ['October 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D8534C00001'], ['Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)'], ['Interventional'], ['June 30, 2021'], ['November 26, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['NCI-2009-00266'], [\"Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer\"], ['Interventional'], ['December 2008'], ['October 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MDX010-12'], ['Study of MDX-010 in Stage IV Breast Cancer'], ['Interventional'], ['May 2003'], ['February 2006'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['CL0007'], ['Investigation of Novel Surgical Imaging for Tumor Excision'], ['Interventional'], ['November 4, 2019'], ['May 4, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CLEE011A2201'], ['A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)'], ['Interventional'], ['October 2013'], ['September 2014'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['AL-TNBC-01'], ['A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer'], ['Interventional'], ['August 14, 2020'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GRAIL-002'], ['The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types'], ['Observational'], ['February 28, 2017'], ['May 2025'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['R01CA249419'], ['The Engaging Primary Care in Cancer Survivorship (EPICS) Study'], ['Interventional'], ['September 21, 2021'], ['May 31, 2025'], ['Enrolling by invitation'], ['Principal Investigator'], ['All'], [], ['21 Years'], []][['WO30085'], ['A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy'], ['Interventional'], ['September 26, 2016'], ['February 6, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MO42319'], ['A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)'], ['Interventional'], ['June 7, 2021'], ['December 31, 2029'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACT16106'], ['Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer'], ['Interventional'], ['February 4, 2020'], ['May 28, 2021'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1280.18'], ['This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.'], ['Interventional'], ['May 4, 2017'], ['August 24, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['G1T28-208'], ['Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)'], ['Interventional'], ['April 15, 2021'], ['October 25, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MO39196'], ['A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)'], ['Interventional'], ['August 25, 2017'], ['January 17, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['91782'], ['Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)'], ['Interventional'], ['May 2010'], ['January 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CZOL446E2105'], ['Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year'], ['Interventional'], ['November 2006'], ['November 2009'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['75 Years']][['NCI-2012-02727'], ['Decitabine in Treating Patients With Advanced Solid Tumors'], ['Interventional'], ['December 2001'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ELA-0121'], ['Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer'], ['Interventional'], ['August 31, 2022'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TPR-0186'], ['Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer'], ['Interventional'], ['May 2008'], ['January 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['R21AT000348-01'], ['Massage Therapy for Cancer-Related Fatigue'], ['Interventional'], ['March 2001'], ['March 2004'], ['Completed'], [], ['All'], [], ['18 Years'], []][['16-032'], ['Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients'], ['Interventional'], ['June 3, 2016'], ['October 12, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['SYD985.002'], [\"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer\"], ['Interventional'], ['November 30, 2017'], ['December 2022'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['NCI-2012-02938'], ['Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer'], ['Interventional'], ['March 25, 2010'], [], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['EGF103890'], ['Lapatinib and Bevacizumab for Metastatic Breast Cancer'], ['Interventional'], ['February 27, 2007'], ['June 19, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['187519'], ['Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer'], ['Interventional'], ['July 8, 2019'], ['July 30, 2023'], ['Recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['ODO-TE-B201'], ['Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC'], ['Interventional'], ['February 5, 2019'], ['June 11, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A221505'], ['Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer'], ['Interventional'], ['February 1, 2018'], ['August 2035'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['K5-101'], ['Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug'], ['Interventional'], ['September 2009'], ['May 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BT-CL-PGG-MEL/BCA-1621/MK3475'], ['Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer'], ['Interventional'], ['February 22, 2017'], ['December 31, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LPT111110'], ['Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects'], ['Interventional'], ['June 2008'], ['May 2012'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['B7501001'], ['A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors'], ['Interventional'], ['June 2014'], ['July 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2019-05187'], ['Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer'], ['Interventional'], ['November 20, 2019'], ['November 20, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['6133'], ['A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease'], ['Interventional'], ['March 2002'], ['July 2007'], ['Completed'], [], ['Female'], [], ['18 Years'], []][['ZWI-ZW25-202'], ['A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer'], ['Interventional'], ['June 10, 2020'], ['June 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RU011501I'], ['Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer'], ['Interventional'], ['March 31, 2017'], ['July 31, 2026'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['URCC12048'], ['Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy'], ['Interventional'], ['February 3, 2014'], ['December 16, 2016'], ['Completed'], ['Sponsor-Investigator'], ['Female'], [], ['21 Years'], []][['99-037'], ['Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer'], ['Interventional'], ['July 1999'], ['March 2005'], ['Completed'], [], ['All'], [], ['18 Years'], []][['201973'], ['Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer'], ['Interventional'], ['February 2, 2017'], ['July 19, 2021'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['PCYC-1135-CA'], ['A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors'], ['Interventional'], ['March 2015'], ['August 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ARC-2 (AB928CSP0002)'], ['A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies'], ['Interventional'], ['October 15, 2018'], ['July 2, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['3068A1-400'], ['Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density'], ['Observational'], ['October 2006'], ['April 2010'], ['Completed'], [], ['Female'], [], ['18 Years'], ['63 Years']][['NCI-2016-01301'], ['Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer'], ['Interventional'], ['May 17, 2017'], ['July 1, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['2016-0142'], ['Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer'], ['Interventional'], ['February 23, 2017'], ['February 28, 2031'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['UAB 1794'], ['Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD'], ['Interventional'], ['February 20, 2019'], ['July 22, 2024'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['SGNTUC-019'], ['Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations'], ['Interventional'], ['January 11, 2021'], ['May 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GeneSearch BLN Assay PPC Study'], ['GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study'], ['Observational'], ['December 2007'], ['December 2009'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LA-EP06-302'], ['Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim'], ['Interventional'], ['March 2012'], ['December 2013'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['08237'], ['Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer'], ['Interventional'], ['September 3, 2010'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['PB-2020-01'], ['ARGONAUT: Stool and Blood Sample Bank for Cancer Patients'], ['Observational'], ['July 1, 2022'], ['December 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D0816C00010'], ['Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments'], ['Interventional'], ['February 6, 2015'], ['July 19, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['130 Years']][['IRB-25970'], ['18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy'], ['Interventional'], ['March 4, 2013'], ['April 2019'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['0C-09-6'], ['Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors'], ['Interventional'], ['June 2010'], ['May 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SHRUS 1001'], ['Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors'], ['Interventional'], ['June 2015'], ['June 2021'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ACORN AEJSINS0601'], ['Treating Chronic Insomnia in Breast Cancer Patients'], ['Interventional'], ['August 2006'], ['January 2009'], ['Terminated'], ['Sponsor'], ['Female'], [], ['21 Years'], ['60 Years']][['TAK-676-1003'], ['A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers'], ['Interventional'], ['September 9, 2021'], ['February 18, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1995563'], ['Measurements of Breast Tissue Optical Properties'], ['Observational'], ['December 1995'], ['July 2018'], ['Withdrawn'], ['Principal Investigator'], ['Female'], [], ['18 Years'], ['75 Years']][['CADEX-0001'], ['Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer'], ['Observational'], ['March 1, 2019'], ['October 1, 2023'], ['Suspended'], ['Sponsor'], ['All'], [], ['18 Years'], []][['B9991025'], ['Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors'], ['Interventional'], ['October 19, 2017'], ['January 4, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['14988'], ['PreView: The Preventive Video Education in Waiting Rooms Program'], ['Interventional'], ['July 2013'], ['March 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['50 Years'], ['70 Years']][['CA209-9GW'], ['A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread'], ['Interventional'], ['June 15, 2017'], ['July 6, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DMT-2015.001 ARM 1'], ['Delphinus SoftVue Prospective Case Collection - ARM 1'], ['Observational'], ['July 31, 2017'], ['July 31, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['DMT-2015.001 ARM 2'], ['Delphinus SoftVue Prospective Case Collection - ARM 2'], ['Observational'], ['December 6, 2016'], ['July 31, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['1-04'], ['Post Market Study Using the Xoft Axxent System'], ['Interventional'], ['March 26, 2007'], ['May 7, 2016'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['Pro20150001297'], ['Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery'], ['Interventional'], ['June 2015'], ['December 31, 2022'], ['Active, not recruiting'], ['Principal Investigator'], ['Female'], [], ['45 Years'], []][['1033IL/0039'], ['PROACT - Pre-Operative Arimidex Compared To Tamoxifen'], ['Interventional'], ['August 2000'], ['December 2007'], ['Completed'], [], ['Female'], [], ['60 Years'], []][['IRB-31855'], ['18F-FSPG PET/CT for Cancer Patients on Therapy'], ['Interventional'], ['July 2015'], ['December 14, 2016'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['RU221408I'], ['Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel'], ['Interventional'], ['November 2014'], ['July 8, 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SAN-BB-01'], ['At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions'], ['Observational'], ['July 2013'], ['December 2040'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['110080'], ['Phase II ABT-888 With Cyclophosphamide'], ['Interventional'], ['January 12, 2011'], ['December 15, 2016'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CBYL719X2101'], ['A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene'], ['Interventional'], ['October 5, 2010'], ['April 16, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UMCC 2014.111'], ['The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)'], ['Interventional'], ['March 2015'], ['March 2026'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['50 Years'], ['69 Years']][['20-028'], ['Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)'], ['Interventional'], ['July 2, 2020'], ['December 30, 2025'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CUDC-907-102'], ['Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors'], ['Interventional'], ['November 2014'], ['May 31, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['16 Years'], []][['CancerDyads'], ['Improving Survivorship Among Minority Cancer Dyads'], ['Interventional'], ['July 1, 2021'], ['December 31, 2024'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['09187'], ['Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload'], ['Interventional'], ['July 2010'], ['August 9, 2011'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VAR0053'], ['FNA Tumor Sampling for CD137 Modulation: A Pilot Study'], ['Observational'], ['March 2010'], ['January 2016'], ['Terminated'], ['Sponsor'], ['All'], [], ['21 Years'], []][['CTP-0003 AirXpanders'], ['Patient Controlled Tissue Expansion for Breast Reconstruction'], ['Interventional'], ['October 2011'], ['August 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['BT5528-100'], ['Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression'], ['Interventional'], ['November 7, 2019'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['6B-20-1'], ['18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases'], ['Interventional'], ['February 15, 2021'], ['February 15, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GeneSearch BLN Timing Study'], ['GeneSearch Breast Lymph Node (BLN) Assay Timing Study'], ['Observational'], ['December 2007'], ['December 2009'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['02-MX-003'], ['ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation'], ['Observational'], ['September 7, 2021'], ['February 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A2181002'], ['Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)'], ['Interventional'], ['November 2001'], ['December 2007'], ['Completed'], [], ['Female'], [], ['60 Years'], ['80 Years']][['IRB00038639'], ['Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)'], ['Interventional'], ['February 1, 2014'], ['September 24, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['21 Years'], ['100 Years']][['D6900C00001'], ['First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies'], ['Interventional'], ['October 18, 2021'], ['June 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DS8201-A-U106'], ['DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer'], ['Interventional'], ['February 10, 2020'], ['March 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DS8201-A-U105'], ['Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer'], ['Interventional'], ['June 20, 2018'], ['July 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PROT001'], ['Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment'], ['Interventional'], ['May 15, 2021'], ['September 1, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], ['75 Years']][['GS-US-296-0101'], ['Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors'], ['Interventional'], ['March 29, 2013'], ['April 23, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SY-5609-101'], ['A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors'], ['Interventional'], ['January 23, 2020'], ['July 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['278100'], ['Tamoxifen-MRI Study'], ['Interventional'], ['September 2000'], ['July 2006'], ['Completed'], [], ['Female'], [], ['25 Years'], ['45 Years']][['20430'], ['HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics'], ['Interventional'], ['December 30, 2021'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VAR0134'], ['Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer'], ['Interventional'], ['August 8, 2017'], ['August 30, 2022'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['CMP-001-009'], ['A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer'], ['Interventional'], ['November 30, 2021'], ['March 7, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['14169'], ['Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening'], ['Interventional'], ['December 8, 2014'], ['September 6, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['55 Years'], []][['CTP-0005 AirXpanders'], ['AirXpanders AeroForm Tissue Expander System for Breast Reconstruction'], ['Interventional'], ['November 12, 2015'], ['September 26, 2017'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['70 Years']][['7902-005'], ['Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)'], ['Interventional'], ['February 12, 2019'], ['December 22, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLDE225X2114'], ['Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors'], ['Interventional'], ['July 2012'], ['April 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['0S-17-4'], ['Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer'], ['Observational'], ['August 30, 2018'], ['September 24, 2020'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO28289'], ['An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)'], ['Observational'], ['March 2012'], ['November 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2015-01097'], ['A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors'], ['Interventional'], ['April 26, 2016'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PUMA-NER-5201'], ['Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations'], ['Interventional'], ['September 30, 2013'], ['January 2, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000067052'], ['Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone'], ['Interventional'], ['August 1998'], ['January 2001'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EDO-S101-1002'], ['Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors'], ['Interventional'], ['October 6, 2017'], ['May 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO40933'], ['A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.'], ['Interventional'], ['June 11, 2019'], ['January 4, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VAR0044'], ['Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors'], ['Interventional'], ['July 2009'], ['December 2011'], ['Completed'], ['Principal Investigator'], ['All'], [], ['19 Years'], []][['CYP003'], ['A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers'], ['Interventional'], ['February 2023'], ['February 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RTOG-9714'], ['Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer'], ['Interventional'], ['February 1998'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CR108208'], ['An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies'], ['Interventional'], ['August 31, 2016'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['MM-121-05-01-05 (TCD11696)'], ['A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers'], ['Interventional'], ['October 2011'], ['June 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M16-573'], ['A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors'], ['Interventional'], ['July 13, 2018'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EMR 100070-001'], ['Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)'], ['Interventional'], ['January 31, 2013'], ['December 16, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15025'], ['PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers'], ['Interventional'], ['July 7, 2015'], ['December 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['21 Years'], []][['XL184-021'], ['Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors'], ['Interventional'], ['September 5, 2017'], ['August 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SPI-POZ-501'], ['A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib'], ['Interventional'], ['October 5, 2018'], ['April 5, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D4884C00001'], ['Study of Tremelimumab in Patients With Advanced Solid Tumors'], ['Interventional'], ['November 2, 2015'], ['December 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['150 Years']][['IMX-110-001'], ['IMX-110 in Patients With Advanced Solid Tumors'], ['Interventional'], ['February 15, 2018'], ['July 15, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['07-266'], ['The Active After Cancer Trial (AACT)'], ['Interventional'], ['October 2007'], ['December 2023'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['94098'], ['High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer'], ['Interventional'], ['December 1994'], ['August 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['55 Years']][['M16-074'], ['A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'], ['Interventional'], ['March 21, 2017'], ['April 13, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AREVAMED01'], ['Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy'], ['Interventional'], ['July 2011'], ['July 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['19 Years'], []][['PROMIS'], ['PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score'], ['Observational'], ['May 2012'], ['December 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['90 Years']][['CLEE011A2412B'], ['Roll-over Study to Allow Continued Access to Ribociclib'], ['Interventional'], ['July 7, 2022'], ['February 16, 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DS1062-A-J101'], ['First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)'], ['Interventional'], ['January 31, 2018'], ['January 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2020-013-00US3'], ['A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors'], ['Interventional'], ['August 9, 2021'], ['March 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['970652'], ['First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide'], ['Interventional'], ['November 2016'], ['December 2023'], ['Active, not recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['EA1141'], ['Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts'], ['Interventional'], ['December 27, 2016'], ['June 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], ['75 Years']][['C4431001'], ['A Study of PF-07260437 in Advanced or Metastatic Solid Tumors'], ['Interventional'], ['October 7, 2021'], ['September 25, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1623168'], ['Healthy Moms: Prenatal Counseling for Postpartum Health'], ['Interventional'], ['February 1, 2021'], ['June 15, 2023'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['40 Years']][['CDR0000355116'], ['Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation'], ['Interventional'], ['November 2003'], [], ['Completed'], [], ['All'], [], ['12 Years'], ['120 Years']][['mRNA-2752-P101'], ['Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies'], ['Interventional'], ['November 27, 2018'], ['April 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TRV-003'], ['Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance'], ['Observational'], ['July 15, 2022'], ['July 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['11-003 Mobetron'], ['Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)'], ['Interventional'], ['January 2011'], ['December 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['40 Years'], []][['19-000756'], ['Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues'], ['Interventional'], ['November 5, 2019'], ['October 17, 2031'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000066283'], ['Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer'], ['Observational'], ['January 1998'], [], ['Completed'], ['Sponsor'], ['All'], [], [], []][['N0574'], ['Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases'], ['Interventional'], ['July 2006'], ['December 15, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MTC-DOX-003'], ['Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver'], ['Interventional'], ['July 2001'], ['April 2003'], ['Completed'], [], ['All'], [], ['18 Years'], ['80 Years']][['0485-CL-0001'], ['Assessment and Tracking of Long-term Alefacept Safety'], ['Observational'], ['June 2003'], ['February 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CX-839-001'], ['Study of the Glutaminase Inhibitor CB-839 in Solid Tumors'], ['Interventional'], ['February 2014'], ['March 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A221102'], ['Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment'], ['Interventional'], ['August 2013'], ['September 1, 2019'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['ARX788-1711'], ['A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)'], ['Interventional'], ['March 20, 2018'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RTX-224-01'], ['RTX-224 Monotherapy in Patients With Solid Tumors'], ['Interventional'], ['January 12, 2022'], ['November 30, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['42674'], [\"Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study\"], ['Interventional'], ['February 15, 2017'], ['December 31, 2018'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['2005-0328'], ['Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer'], ['Interventional'], ['February 2006'], ['October 2008'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Cancer Pain Management'], ['Improving Cancer Pain Management Through Self-Care'], ['Interventional'], ['December 2007'], ['June 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['14238'], ['Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer'], ['Interventional'], ['November 11, 2015'], ['September 11, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALGB-9871'], ['Docetaxel in Treating Patients With Solid Tumors'], ['Interventional'], ['September 1998'], ['January 2008'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PIONEER-01'], ['The PIONEER-01 Study of the Imagio Breast Imaging System'], ['Interventional'], ['December 21, 2012'], ['September 9, 2015'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['QUILT-2.025'], ['QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.'], ['Interventional'], ['August 10, 2018'], ['December 30, 2020'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TO-TAS0728-101'], ['A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities'], ['Interventional'], ['April 6, 2018'], ['June 9, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DCC-2036-01-004'], ['A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors'], ['Interventional'], ['January 2, 2019'], ['November 1, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['B7401001'], ['A Study Of PF-06664178 In Patients With Advanced Solid Tumors'], ['Interventional'], ['August 2014'], ['June 2016'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TH1902-CTR-0001'], ['TH1902 in Patients With Advanced Solid Tumors'], ['Interventional'], ['March 4, 2021'], ['March 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2020-24-SHIRAZIP-BURN'], ['The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors'], ['Interventional'], ['January 10, 2022'], ['March 9, 2024'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['39 Years']][['213409'], ['A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study'], ['Interventional'], ['April 16, 2021'], ['November 13, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A00152-53'], ['Ultrasound Elastography of Breast Lesions'], ['Observational'], ['July 2008'], ['June 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['21 Years'], []][['IIT2020-13-GRESHAM-ELLY'], ['Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients'], ['Interventional'], ['December 2, 2020'], ['July 8, 2022'], ['Recruiting'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['20-378'], ['Researching the Effect of Exercise on Cancer'], ['Interventional'], ['October 2, 2020'], ['October 2, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CRYO for Mastectomy (DoD)'], ['Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy'], ['Interventional'], ['September 15, 2022'], ['May 14, 2026'], ['Enrolling by invitation'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['15002'], ['Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy'], ['Interventional'], ['June 14, 2016'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SY-1365-101'], ['A Study of SY-1365 in Adult Patients With Advanced Solid Tumors'], ['Interventional'], ['May 12, 2017'], ['June 24, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BA3021-001'], ['CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)'], ['Interventional'], ['June 27, 2018'], ['June 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['U01AT001653'], [\"Women's Isoflavone Soy Health (WISH) Trial\"], ['Interventional'], ['March 2004'], ['March 2009'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['30 Years'], []][['D8488C00001'], ['Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer'], ['Interventional'], ['January 17, 2017'], ['March 16, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], ['120 Years']][['CPDR001X2102'], ['A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat'], ['Interventional'], ['October 14, 2016'], ['February 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MAPinitial'], ['UCLA Health Patient Health Maintenance Outreach Text Message'], ['Interventional'], ['March 9, 2023'], ['June 30, 2024'], ['Enrolling by invitation'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['PEDSVAR0038'], ['B-Receptor Signaling in Cardiomyopathy'], ['Observational'], ['November 2008'], ['October 2010'], ['Completed'], ['Sponsor-Investigator'], ['All'], [], [], ['40 Years']][['213353'], ['Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer'], ['Interventional'], ['October 3, 2019'], ['January 12, 2022'], ['Terminated'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['IRB#13-6255'], ['Nonmyeloablative Allogeneic Transplant'], ['Interventional'], ['October 2001'], ['October 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['72 Years']][['TPU-TAS-120-101'], ['A Study of TAS-120 in Patients With Advanced Solid Tumors'], ['Interventional'], ['July 2014'], ['June 30, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GS-US-382-1587'], ['Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels'], ['Interventional'], ['August 19, 2022'], ['November 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GOG-8199'], ['Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer'], ['Observational'], ['June 7, 2010'], ['April 10, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['30 Years'], []][['KL264-01'], ['Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies'], ['Interventional'], ['February 28, 2020'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['75 Years']][['SLS17-201/MK3475-770'], ['Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers'], ['Interventional'], ['June 28, 2019'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['K01CA190659'], ['Culturally Appropriate Nutrition Communication for Mexican American Women'], ['Interventional'], ['March 25, 2019'], ['December 25, 2022'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], ['Yes'], ['18 Years'], ['29 Years']][['SGN228-001'], ['A Study of SGN-CD228A in Advanced Solid Tumors'], ['Interventional'], ['September 3, 2019'], ['March 9, 2023'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-398-01-01-02'], ['MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment'], ['Interventional'], ['November 2012'], ['October 2, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AMI-2008-01'], ['F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets'], ['Interventional'], ['January 2009'], ['June 2013'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TOS-358-001'], ['A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors'], ['Interventional'], ['February 15, 2023'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['S1008'], ['S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors'], ['Interventional'], ['March 2012'], ['January 2017'], ['Completed'], ['Sponsor'], ['Female'], [], [], ['120 Years']][['PROT004'], ['Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer'], ['Interventional'], ['March 10, 2022'], ['December 15, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ITL-002-CRYO'], ['In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation'], ['Interventional'], ['August 2009'], ['May 2011'], ['Completed'], [], ['All'], [], ['18 Years'], []][['11-006682'], ['Assessing the Patient Experience in Cancer Care'], ['Observational'], ['May 2012'], ['September 2015'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['213356'], ['A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer'], ['Interventional'], ['June 21, 2013'], ['December 26, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['999912039'], ['Cancer Symptom Data From Multiple Treatment Centers'], ['Observational'], ['February 10, 2012'], ['May 23, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['AC480IV-001'], ['Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors'], ['Interventional'], ['November 2010'], ['June 2013'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IIT2021-07-Atkins-CARMA'], ['Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial'], ['Interventional'], ['October 7, 2022'], ['August 31, 2024'], ['Active, not recruiting'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['PRO1184-001'], ['PRO1184 for Advanced Solid Tumors'], ['Interventional'], ['December 7, 2022'], ['September 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ONC-392-001'], ['Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC'], ['Interventional'], ['September 16, 2020'], ['December 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTL0211'], ['Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease'], ['Interventional'], ['July 2012'], ['March 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PRS-343-PCS_08_18'], ['PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors'], ['Interventional'], ['August 21, 2018'], ['July 1, 2021'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CT7001_001'], ['Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies'], ['Interventional'], ['November 14, 2017'], ['December 15, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['R7075-ONC-2009'], ['REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors'], ['Interventional'], ['December 21, 2020'], ['April 1, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D8410C00001'], ['Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies'], ['Interventional'], ['June 24, 2022'], ['December 8, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['CART-TnMUC1-01'], ['A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers'], ['Interventional'], ['October 10, 2019'], ['October 31, 2036'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA033'], ['A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma'], ['Interventional'], ['April 23, 2009'], ['February 12, 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C4551001'], ['Study of PF-07248144 in Advanced or Metastatic Solid Tumors'], ['Interventional'], ['November 16, 2020'], ['November 8, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['18232'], ['Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)'], ['Observational'], ['July 3, 2019'], ['March 31, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['S0702'], ['S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases'], ['Observational'], ['December 2008'], ['June 2019'], ['Completed'], ['Sponsor'], ['All'], [], [], ['120 Years']][['MT-5111_001'], ['Study of MT-5111 in HER2-positive Solid Tumors'], ['Interventional'], ['November 12, 2019'], ['May 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BB-1701-101'], ['A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors'], ['Interventional'], ['July 28, 2020'], ['December 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['0S-13-1'], ['Cancer Genetics Hereditary Cancer Panel Testing'], ['Observational'], ['June 12, 2014'], ['January 5, 2017'], ['Completed'], ['Sponsor'], ['All'], [], [], []][['D9720C00001'], ['Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies'], ['Interventional'], ['November 12, 2020'], ['January 15, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['FPX-01-01'], ['A Phase 1/2 Study of [225Ac]-FPI-1434 Injection'], ['Interventional'], ['January 17, 2019'], ['June 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16-214-02'], ['A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors'], ['Interventional'], ['December 19, 2016'], ['April 28, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1454-001'], ['Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)'], ['Interventional'], ['February 3, 2017'], ['April 21, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2009-00042'], ['Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer'], ['Interventional'], ['April 2003'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2693-CL-0304'], ['A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause'], ['Interventional'], ['July 10, 2019'], ['January 4, 2022'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], ['65 Years']][['ONCX-NAV-G201'], ['A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors'], ['Interventional'], ['August 5, 2022'], ['December 15, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['FT500-101'], ['FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors'], ['Interventional'], ['February 15, 2019'], ['November 15, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2693-CL-0302'], ['A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2'], ['Interventional'], ['July 10, 2019'], ['April 23, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], ['65 Years']][['CUDC-101-102'], ['A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors'], ['Interventional'], ['July 2010'], ['October 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Pro00046105'], ['Emerging From the Haze for Gynecologic Cancer Survivors'], ['Interventional'], ['January 10, 2017'], ['November 2017'], ['Completed'], ['Principal Investigator'], ['Female'], [], ['18 Years'], []][['DF1001-001'], ['Study of DF1001 in Patients With Advanced Solid Tumors'], ['Interventional'], ['November 11, 2019'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2693-CL-0301'], ['A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause'], ['Interventional'], ['July 11, 2019'], ['August 11, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['40 Years'], ['65 Years']][['BPX603-201A'], ['Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors'], ['Interventional'], ['December 7, 2020'], ['January 2, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['XL092-001'], ['A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors'], ['Interventional'], ['March 20, 2019'], ['November 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 123667-101'], ['Study of INCB123667 in Subjects With Advanced Solid Tumors'], ['Interventional'], ['July 5, 2022'], ['July 30, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['ADCT-502-101'], ['Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression'], ['Interventional'], ['May 18, 2017'], ['April 5, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ZN-A-1041-101-US'], ['A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors'], ['Interventional'], ['October 15, 2020'], ['November 30, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NEO3-06'], ['Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma'], ['Interventional'], ['May 2009'], ['August 2013'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TAEK-VAC-HerBy-001'], ['TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer'], ['Interventional'], ['August 10, 2020'], ['June 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IPI-549-01'], ['A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549'], ['Interventional'], ['December 2015'], ['December 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MORAb-202-G000-201'], ['A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types'], ['Interventional'], ['August 6, 2020'], ['March 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['13517'], ['A Study of LY3023414 in Participants With Advanced Cancer'], ['Interventional'], ['July 31, 2012'], ['February 2, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M19-037'], ['A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors'], ['Interventional'], ['May 21, 2019'], ['November 12, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17350'], ['Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel'], ['Interventional'], ['February 27, 2015'], ['April 18, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MER-XMT-2056-1'], ['A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2'], ['Interventional'], ['January 24, 2023'], ['November 2025'], ['Suspended'], ['Sponsor'], ['All'], [], ['18 Years'], []][['XmAb22841-01'], ['A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors'], ['Interventional'], ['May 29, 2019'], ['February 16, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20190131'], ['Study of AMG 650 in Adult Participants With Advanced Solid Tumors'], ['Interventional'], ['March 11, 2020'], ['February 15, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['NUV-868-01'], ['NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors'], ['Interventional'], ['March 29, 2022'], ['February 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MM-310-01-01-01'], ['A Study Evaluating MM-310 in Patients With Solid Tumors'], ['Interventional'], ['February 22, 2017'], ['December 2018'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16897'], ['Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)'], ['Interventional'], ['March 24, 2015'], ['July 27, 2016'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDX1127-06'], ['A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer'], ['Interventional'], ['October 2015'], ['May 22, 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['FPA150-001'], ['FPA150 in Patients With Advanced Solid Tumors'], ['Interventional'], ['March 27, 2018'], ['May 10, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['3068A1-301'], ['Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women'], ['Interventional'], ['December 2001'], ['September 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['55 Years'], ['80 Years']][['CBKM120B2101'], ['A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients'], ['Interventional'], ['April 2010'], ['November 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PY314-1-01'], ['A Study of PY314 in Subjects With Advanced Solid Tumors'], ['Interventional'], ['October 29, 2020'], ['October 28, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CALAA-01-ST-001'], ['Safety Study of CALAA-01 to Treat Solid Tumor Cancers'], ['Interventional'], ['May 2008'], ['September 2012'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['B7661001'], ['A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors'], ['Interventional'], ['October 17, 2014'], ['November 5, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CPI-006-001'], ['CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers'], ['Interventional'], ['April 25, 2018'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCAGN 2385-101'], ['A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies'], ['Interventional'], ['June 18, 2018'], ['October 7, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCAGN 2390-101'], ['A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies'], ['Interventional'], ['September 24, 2018'], ['August 18, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['KB-0742-1001'], ['A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma'], ['Interventional'], ['February 8, 2021'], ['December 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['12 Years'], []][['D8532C00004'], ['Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers'], ['Interventional'], ['June 13, 2022'], ['December 13, 2022'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['50 Years'], ['70 Years']][['C34003'], ['A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors'], ['Interventional'], ['August 12, 2016'], ['November 30, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NP-G2-044-P1-01'], ['Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies'], ['Interventional'], ['December 21, 2017'], ['May 7, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['HMBD-002-V4C26-01'], ['A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab'], ['Interventional'], ['January 1, 2022'], ['January 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M15-916'], ['A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)'], ['Interventional'], ['July 3, 2017'], ['November 27, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BPI-2358-105 Phase 2'], ['Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2'], ['Interventional'], ['April 5, 2017'], ['April 20, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO39733'], ['A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors'], ['Interventional'], ['December 21, 2017'], ['September 29, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BP29842'], ['A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)'], ['Interventional'], ['December 7, 2015'], ['November 10, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-CC004'], ['Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer'], ['Interventional'], ['May 31, 2017'], ['February 22, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['CR-TSC-001'], ['NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)'], ['Interventional'], ['September 2005'], ['December 12, 2007'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IA0132'], ['Cognition in the Study of Tamoxifen and Raloxifene'], ['Interventional'], ['October 2001'], ['March 2008'], ['Completed'], ['Sponsor'], ['Female'], [], ['65 Years'], []][['S1714'], ['Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer'], ['Observational'], ['March 1, 2019'], ['February 28, 2026'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCAGN 1876-202'], ['INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies'], ['Interventional'], ['November 21, 2017'], ['July 1, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA-170-101'], ['A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas'], ['Interventional'], ['May 2016'], ['May 7, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RXDX-101-02'], ['Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)'], ['Interventional'], ['November 19, 2015'], ['April 1, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BPI-2358-105 phase 3'], ['Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3'], ['Interventional'], ['May 29, 2018'], ['February 8, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['XmAb20717-01'], ['A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors'], ['Interventional'], ['July 10, 2018'], ['September 6, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ARRAY-818-103'], ['Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors'], ['Interventional'], ['January 2, 2018'], ['April 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AFT-25'], ['Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS'], ['Interventional'], ['February 22, 2017'], ['July 2023'], ['Recruiting'], ['Sponsor'], ['Female'], [], ['40 Years'], ['99 Years']][['PRS-343-PCS_04_16'], ['PRS-343 in HER2-Positive Solid Tumors'], ['Interventional'], ['September 28, 2017'], ['October 7, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['A212102'], ['Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection'], ['Observational'], ['August 1, 2022'], ['February 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['40 Years'], ['75 Years']][['CRLX-001'], ['Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors'], ['Interventional'], ['May 2006'], ['April 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C016'], ['PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)'], ['Interventional'], ['September 2002'], ['June 2007'], ['Completed'], [], ['All'], [], ['18 Years'], []][['827486'], ['Pulmonary Hypertension and Anastrozole Trial'], ['Interventional'], ['December 7, 2017'], ['July 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2020-13883'], ['Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial'], ['Interventional'], ['March 5, 2021'], ['March 31, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 18424-270'], ['An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib'], ['Interventional'], ['November 30, 2016'], ['December 31, 2022'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EMR 200066-006'], ['Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors'], ['Interventional'], ['May 2011'], ['April 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['82 Years']][['FT536-101'], ['FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors'], ['Interventional'], ['May 31, 2022'], ['April 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TMPS-101'], ['Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors'], ['Interventional'], ['March 15, 2022'], ['July 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['06-103'], ['Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma'], ['Interventional'], ['October 23, 2006'], ['October 26, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20140318'], ['Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611'], ['Interventional'], ['February 5, 2016'], ['July 26, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16447'], ['Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients'], ['Interventional'], ['September 2013'], ['December 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CX-5461-04'], ['Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation'], ['Interventional'], ['September 8, 2021'], ['June 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-BN009'], ['Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery'], ['Interventional'], ['December 15, 2020'], ['January 31, 2030'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['J0867'], ['Concentration and Activity of Lapatinib in Vestibular Schwannomas'], ['Interventional'], ['June 2009'], ['August 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['HBS701'], ['Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash'], ['Interventional'], ['April 3, 2008'], ['December 30, 2009'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D0816R00006'], ['Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer'], ['Observational'], ['April 21, 2015'], ['September 30, 2016'], ['Completed'], ['Sponsor'], ['All'], [], [], []][['A9001502'], ['Treatment Resistance Following Anti-cancer Therapies'], ['Interventional'], ['February 13, 2019'], ['December 14, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['2018-01'], ['Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors'], ['Observational'], ['August 23, 2018'], ['March 31, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-MGC018-01'], ['MGC018 With or Without MGA012 in Advanced Solid Tumors'], ['Interventional'], ['November 21, 2018'], ['June 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ORM-5029-01-001'], ['Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors'], ['Interventional'], ['October 3, 2022'], ['October 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MER-XMT-1660-1'], ['A Study of XMT-1660 in Participants With Solid Tumors'], ['Interventional'], ['August 15, 2022'], ['January 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Minnelide 101'], ['A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors'], ['Interventional'], ['October 10, 2017'], ['December 1, 2022'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 24360-202/ ECHO-202'], ['Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers'], ['Interventional'], ['July 17, 2014'], ['November 6, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CA052-002'], ['A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors'], ['Interventional'], ['May 27, 2021'], ['September 15, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['M15-394'], ['ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors'], ['Interventional'], ['September 18, 2015'], ['March 25, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DS8201-A-J101'], ['Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors'], ['Interventional'], ['September 2015'], ['September 30, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CYT-0851-01'], ['A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors'], ['Interventional'], ['October 9, 2019'], ['December 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-01040'], ['Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction'], ['Interventional'], ['June 12, 2012'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTAP101-CL-1017'], ['Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid'], ['Interventional'], ['December 2014'], ['March 17, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DCL-10-001'], ['Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned'], ['Interventional'], ['December 2011'], ['January 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TTX-080-001'], ['TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers'], ['Interventional'], ['July 14, 2020'], ['June 1, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SGNSTNV-001'], ['A Study of SGN-STNV in Advanced Solid Tumors'], ['Interventional'], ['January 18, 2021'], ['March 31, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ATRC-101-A01'], ['A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies'], ['Interventional'], ['February 11, 2020'], ['March 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D5330C00004'], ['Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents'], ['Interventional'], ['October 31, 2014'], ['November 26, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['CLGK974X2101'], ['A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands'], ['Interventional'], ['December 1, 2011'], ['November 23, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AGS-22M6E-11-1'], ['A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4'], ['Interventional'], ['June 2011'], ['April 2015'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TT420X1103'], ['Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors'], ['Interventional'], ['July 14, 2021'], ['December 1, 2022'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['AMC-078'], ['Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection'], ['Interventional'], ['November 2013'], ['December 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-MGA271-01'], ['Safety Study of MGA271 in Refractory Cancer'], ['Interventional'], ['July 2011'], ['April 18, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SGNTGT-001'], ['A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer'], ['Interventional'], ['May 29, 2020'], ['April 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-MGD013-01'], ['A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms'], ['Interventional'], ['August 18, 2017'], ['February 8, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['FPI-1966-101'], ['A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours'], ['Interventional'], ['April 20, 2022'], ['December 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SM08502-ONC-01'], ['A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors'], ['Interventional'], ['November 6, 2017'], ['December 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2015-00054'], ['Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)'], ['Interventional'], ['August 12, 2015'], ['December 31, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TESTW007'], ['Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women'], ['Interventional'], ['January 2008'], ['December 2012'], ['Completed'], ['Sponsor'], ['Female'], [], ['50 Years'], []][['CALGB-70501'], ['Collection of Patient-Reported Symptoms and Performance Status Via the Internet'], ['Interventional'], ['December 2006'], ['June 1, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BM010'], ['ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain'], ['Interventional'], ['September 2009'], ['November 14, 2016'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EAQ202'], ['Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials'], ['Interventional'], ['October 28, 2021'], ['January 25, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['39 Years']][['TJ004309STM103'], ['A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors'], ['Interventional'], ['November 2, 2021'], ['June 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1603.00'], ['Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation'], ['Interventional'], ['April 2002'], ['October 2004'], ['Completed'], [], ['All'], [], ['12 Years'], []][['7465-CL-202'], ['A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)'], ['Interventional'], ['March 9, 2020'], ['July 31, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17477'], ['A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)'], ['Interventional'], ['May 2, 2017'], ['September 1, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['12 Years'], []][['S1415CD'], ['S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)'], ['Interventional'], ['October 7, 2016'], ['August 12, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['FT-003'], ['Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy'], ['Observational'], ['June 11, 2019'], ['December 2037'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['101'], ['CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors'], ['Interventional'], ['February 2, 2021'], ['December 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PACT-0101'], ['A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors'], ['Interventional'], ['July 3, 2019'], ['August 12, 2022'], ['Suspended'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15441'], ['A Study of LY3022855 In Participants With Breast or Prostate Cancer'], ['Interventional'], ['May 2015'], ['October 4, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C3881001'], ['PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors'], ['Interventional'], ['October 4, 2018'], ['March 30, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CPG-01-001'], ['COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.'], ['Interventional'], ['September 6, 2018'], ['December 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 106385-102'], ['INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors'], ['Interventional'], ['February 3, 2021'], ['December 29, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['111767'], ['Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents'], ['Interventional'], ['October 2008'], ['August 19, 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['KY1044-CT01'], ['Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer'], ['Interventional'], ['January 28, 2019'], ['November 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PRP-001'], ['Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors'], ['Interventional'], ['January 3, 2011'], ['January 30, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CNIR178X2201'], ['A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma'], ['Interventional'], ['August 28, 2017'], ['February 14, 2023'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CPO-100-US-101'], ['Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors'], ['Interventional'], ['March 24, 2021'], ['March 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['213360'], ['A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens'], ['Interventional'], ['March 23, 2015'], ['August 23, 2021'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['D3610C00001'], ['Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules'], ['Interventional'], ['December 1, 2010'], ['December 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['130 Years']][['ST101-101'], ['A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors'], ['Interventional'], ['July 1, 2020'], ['January 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ATLAS-101'], ['A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies'], ['Interventional'], ['August 12, 2020'], ['January 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['200-04'], ['A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.'], ['Observational'], ['February 26, 2021'], ['December 23, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16704'], ['Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)'], ['Interventional'], ['December 12, 2016'], ['March 31, 2024'], ['Recruiting'], ['Sponsor-Investigator'], ['Female'], [], ['18 Years'], []][['P-MUC1C-ALLO1-001'], ['P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors'], ['Interventional'], ['February 15, 2022'], ['April 2039'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ONCR-177-101'], ['Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors'], ['Interventional'], ['May 20, 2020'], ['July 2028'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000415581'], ['RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma'], ['Interventional'], ['December 2004'], ['May 2008'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CORT125134-550'], ['Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors'], ['Interventional'], ['May 23, 2016'], ['September 12, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['7339-002'], ['Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)'], ['Interventional'], ['December 12, 2018'], ['December 1, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2011-02500'], ['Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction'], ['Interventional'], ['June 20, 2011'], [], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['JZP712-201'], ['Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors'], ['Interventional'], ['March 3, 2022'], ['June 23, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17493'], ['A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors'], ['Interventional'], ['June 13, 2019'], ['March 26, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['6 Months'], ['21 Years']][['XmAb23104-01'], ['A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)'], ['Interventional'], ['May 1, 2019'], ['September 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CTMX-M-2009-001'], ['PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors'], ['Interventional'], ['June 1, 2017'], ['September 10, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1697.00'], ['Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)'], ['Interventional'], ['May 2004'], ['September 2008'], ['Terminated'], ['Sponsor-Investigator'], ['All'], [], ['4 Years'], []][['ADCT-301-103'], ['Study of ADCT-301 in Patients With Selected Advanced Solid Tumors'], ['Interventional'], ['November 9, 2018'], ['December 8, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TPST-1120-001'], ['TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers'], ['Interventional'], ['March 20, 2019'], ['June 23, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17-262-01'], ['REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies'], ['Interventional'], ['March 15, 2018'], ['May 9, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2020-05428'], ['Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer'], ['Interventional'], ['February 1, 2021'], ['December 31, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C3651010'], ['Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia'], ['Interventional'], ['May 11, 2021'], ['August 9, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IT-01'], ['A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6'], ['Interventional'], ['February 9, 2017'], ['February 22, 2023'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17494'], ['Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation'], ['Expanded Access'], [], [], ['Available'], ['Sponsor'], ['All'], [], ['18 Years'], []][['C3441037'], ['A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors'], ['Interventional'], ['December 21, 2020'], ['July 22, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['70 Years']][['EMR100018-001'], ['First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies'], ['Interventional'], ['December 13, 2013'], ['August 9, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PY159-2-01'], ['A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors'], ['Interventional'], ['November 10, 2020'], ['April 7, 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ELVCAP-001-01'], ['Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors'], ['Interventional'], ['September 29, 2020'], ['June 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PV-10-LC-01'], ['A Study to Assess PV-10 Chemoablation of Cancer of the Liver'], ['Interventional'], ['October 2009'], ['February 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CP-MGD009-01'], ['Safety Study of MGD009 in B7-H3-expressing Tumors'], ['Interventional'], ['September 2015'], ['November 25, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['707-IO-101'], ['Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies'], ['Interventional'], ['June 9, 2021'], ['July 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MDNA11-01'], ['A Beta-only IL-2 ImmunoTherapY (ABILITY) Study'], ['Interventional'], ['August 27, 2021'], ['December 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], ['Yes'], ['18 Years'], []][['GB1275-1101 (KEYNOTE-A36)'], ['GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma'], ['Interventional'], ['August 13, 2019'], ['April 11, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCB 57643-101'], ['Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies'], ['Interventional'], ['May 18, 2016'], ['February 13, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['7684A-005'], ['MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)'], ['Interventional'], ['September 16, 2021'], ['February 22, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RTOG-1008'], ['Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery'], ['Interventional'], ['January 2011'], ['October 2028'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RTOG-0924'], ['Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer'], ['Interventional'], ['July 2011'], ['July 2031'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['M14-546'], ['A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer'], ['Interventional'], ['April 14, 2015'], ['July 5, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['15834'], ['Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors'], ['Interventional'], ['May 26, 2017'], ['July 26, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TAK-500-1001'], ['A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors'], ['Interventional'], ['April 26, 2022'], ['March 20, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ARC-5 (AB928CSP0005)'], ['A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies'], ['Interventional'], ['July 24, 2018'], ['September 3, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO41929'], ['A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors'], ['Interventional'], ['May 24, 2021'], ['May 16, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['39110-107'], ['Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors'], ['Interventional'], ['January 25, 2016'], ['November 20, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17159'], ['A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors'], ['Interventional'], ['November 15, 2013'], ['November 17, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BIND-014-001'], ['A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer'], ['Interventional'], ['January 2011'], ['February 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PAL-E602-001'], ['Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)'], ['Interventional'], ['February 11, 2022'], ['June 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D6015C00001'], ['Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours'], ['Interventional'], ['July 1, 2015'], ['August 22, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['CC-223-ST-001'], ['Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma'], ['Interventional'], ['July 20, 2010'], ['December 9, 2016'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['9161'], ['Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors'], ['Interventional'], ['August 3, 2015'], ['December 31, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['39 Years']][['XL184-203'], ['Study of Cabozantinib (XL184) in Adults With Advanced Malignancies'], ['Interventional'], ['August 2009'], ['June 2014'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['VICCGI1523'], ['Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study'], ['Observational'], ['July 2015'], ['August 31, 2021'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], []][['NRG-GU006'], ['BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER'], ['Interventional'], ['April 27, 2018'], ['October 31, 2028'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['NRG-LU002'], ['Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer'], ['Interventional'], ['April 7, 2017'], ['October 2031'], ['Suspended'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-GU009'], ['Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial'], ['Interventional'], ['December 15, 2020'], ['December 31, 2033'], ['Recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['AFT-28'], ['Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer'], ['Interventional'], ['December 2016'], ['January 12, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-GU005'], ['Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer'], ['Interventional'], ['November 16, 2017'], ['December 2030'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], []][['CLIN-17-008'], ['Study of the Safety and Effectiveness of Motiva Implants®'], ['Interventional'], ['April 6, 2018'], ['February 28, 2033'], ['Active, not recruiting'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], ['70 Years']][['Adela-EDMRD-001'], ['cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease'], ['Observational'], ['May 3, 2022'], ['December 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['40 Years'], []][['NC318-01'], ['A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors'], ['Interventional'], ['September 28, 2018'], ['April 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['16804'], ['Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel'], ['Interventional'], ['May 9, 2014'], ['October 2, 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1430.00'], ['Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer'], ['Interventional'], ['August 1998'], [], ['Completed'], [], ['All'], [], ['18 Years'], []][['16712'], ['A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer'], ['Interventional'], ['April 10, 2018'], ['October 3, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['RXDX-101-03'], ['Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options'], ['Interventional'], ['May 3, 2016'], ['June 15, 2025'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['0 Years'], ['18 Years']][['IMC-F106C-101'], ['Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors'], ['Interventional'], ['February 25, 2020'], ['February 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['B9991004'], ['A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)'], ['Interventional'], ['November 9, 2015'], ['February 28, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20289'], ['A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors'], ['Interventional'], ['September 30, 2015'], ['October 31, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['LOXO-IDH-20002'], ['Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations'], ['Interventional'], ['October 16, 2020'], ['May 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20210104'], ['A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression'], ['Interventional'], ['September 23, 2022'], ['July 28, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['0701'], ['Cardiac Safety Assessment Study of Picoplatin in Solid Tumors'], ['Interventional'], ['June 2008'], ['July 2009'], ['Unknown status'], [], ['All'], [], ['18 Years'], []][['FLX475-02'], ['Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab'], ['Interventional'], ['September 25, 2018'], ['December 2023'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CO-338-100'], ['A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes'], ['Interventional'], ['November 21, 2019'], ['July 15, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['G200502'], ['Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.'], ['Interventional'], ['May 2007'], ['September 2008'], ['Completed'], ['Sponsor'], ['All'], [], [], []][['BM004'], ['ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain'], ['Interventional'], ['March 2008'], ['September 2012'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['100 Years']][['INCB 54329-101'], ['An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies'], ['Interventional'], ['April 14, 2015'], ['January 31, 2018'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ZWI-ZW25-101'], ['Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers'], ['Interventional'], ['September 2016'], ['August 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BDTX-189-01'], ['A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.'], ['Interventional'], ['December 19, 2019'], ['September 16, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CBYL719X2105J'], ['A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors'], ['Interventional'], ['November 27, 2012'], ['June 1, 2017'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TTI-621-02'], ['Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides'], ['Interventional'], ['September 2016'], ['March 31, 2020'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CLEE011XUS03'], ['LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)'], ['Interventional'], ['August 25, 2014'], ['January 17, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BR005'], ['Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging'], ['Observational'], ['April 18, 2017'], ['January 1, 2020'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['B1271002'], ['Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer'], ['Interventional'], ['October 2011'], ['December 2015'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['SGN2FF-001'], ['A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors'], ['Interventional'], ['February 23, 2017'], ['June 24, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TP-CA-001'], ['Tempus Priority Study: A Pan-tumor Observational Study'], ['Observational'], ['October 19, 2020'], ['October 19, 2030'], ['Recruiting'], ['Sponsor'], ['All'], [], [], []][['CB103-C-101'], ['Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies'], ['Interventional'], ['December 5, 2017'], ['November 11, 2022'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['20070315'], ['Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium'], ['Interventional'], ['November 16, 2009'], ['August 21, 2013'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['1801'], ['9-ING-41 in Patients With Advanced Cancers'], ['Interventional'], ['January 4, 2019'], ['November 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['63646'], ['Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer'], ['Interventional'], ['June 24, 2022'], ['October 15, 2026'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['21 Years'], []][['NCI-2009-00339'], ['Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy'], ['Interventional'], ['June 2008'], ['July 2011'], ['Completed'], ['Sponsor'], ['All'], [], [], ['21 Years']][['831-IO-101'], ['Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors'], ['Interventional'], ['March 31, 2022'], ['December 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DB-1303-O-1001'], ['A Study of DB-1303 in Advanced/Metastatic Solid Tumors'], ['Interventional'], ['January 31, 2022'], ['October 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PMV-586-101'], ['The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)'], ['Interventional'], ['October 29, 2020'], ['July 14, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['12 Years'], []][['S1201'], ['S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer'], ['Interventional'], ['February 2012'], ['September 19, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']][['ACI/2015'], ['Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)'], ['Interventional'], ['July 26, 2011'], ['December 31, 2023'], ['Recruiting'], ['Principal Investigator'], ['All'], [], ['1 Year'], ['75 Years']][['INCB 54828-101'], ['Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)'], ['Interventional'], ['February 27, 2015'], ['December 17, 2021'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['RAIN-3202'], ['Milademetan in Advanced/Metastatic Solid Tumors'], ['Interventional'], ['November 1, 2021'], ['August 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CR100845'], ['A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma'], ['Interventional'], ['June 15, 2012'], ['July 5, 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GWCA0701'], ['A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.'], ['Interventional'], ['November 2007'], ['January 2010'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MS201923_0001'], ['M6620 First in Human Study'], ['Interventional'], ['December 10, 2012'], ['March 11, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['TDM4529g'], ['A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies'], ['Interventional'], ['October 16, 2008'], ['September 20, 2029'], ['Recruiting'], ['Sponsor'], ['All'], [], [], []][['CV-MMAIT-3-001'], ['Vaccine Therapy for Patients With Stage III Melanoma'], ['Interventional'], [], [], ['Unknown status'], [], ['All'], [], ['18 Years'], ['80 Years']][['CV-MMAIT-4-001'], ['Vaccine Therapy for Patients With Stage IV Melanoma'], ['Interventional'], [], [], ['Unknown status'], [], ['All'], [], ['18 Years'], ['80 Years']][['CDR0000067196'], ['Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia'], ['Interventional'], ['July 1998'], ['August 2011'], ['Completed'], [], ['All'], [], ['18 Years'], []][['CDR0000069467'], ['Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer'], ['Interventional'], ['August 2002'], ['June 15, 2007'], ['Completed'], [], ['All'], [], ['18 Years'], ['120 Years']][['1992110-1'], ['Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education'], ['Observational'], ['March 7, 2023'], ['March 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['80 Years']][['18594'], ['First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas'], ['Interventional'], ['July 6, 2017'], ['April 19, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ARRAY-162-311'], [\"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer\"], ['Interventional'], ['June 27, 2013'], ['August 23, 2022'], ['Completed'], ['Sponsor'], ['Female'], ['Yes'], ['18 Years'], []][['C4221015'], ['A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer'], ['Interventional'], ['December 21, 2020'], ['November 15, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['16 Years'], []][['NO16968'], ['A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer'], ['Interventional'], ['April 18, 2003'], ['April 21, 2011'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GO42144'], ['A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation'], ['Interventional'], ['July 29, 2020'], ['November 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CD-ON-MEDI4736-1108'], ['A Phase 1/2 Study to Evaluate MEDI4736'], ['Interventional'], ['September 5, 2012'], ['February 28, 2020'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['ML28897'], ['My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors'], ['Interventional'], ['April 14, 2014'], ['May 12, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI 03-04'], ['Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer'], ['Interventional'], ['March 2004'], ['July 2007'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['9090-14'], ['A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC'], ['Interventional'], ['April 2013'], ['December 2015'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ONO-4059-09'], ['Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)'], ['Interventional'], ['December 29, 2021'], ['July 1, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['JTX-8064-101'], ['Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors'], ['Interventional'], ['January 12, 2021'], ['January 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['DB-1305-O-1001'], ['First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors'], ['Interventional'], ['July 19, 2022'], ['June 30, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BBI-20201001'], ['A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors'], ['Interventional'], ['February 24, 2020'], ['October 31, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ZWI-ZW49-101'], ['A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers'], ['Interventional'], ['April 15, 2019'], ['August 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['HSC-SPH-15-0443'], ['Stem Cell Injection in Cancer Survivors'], ['Interventional'], ['August 2016'], ['April 20, 2020'], ['Completed'], ['Principal Investigator'], ['All'], [], ['18 Years'], ['79 Years']][['AV-951-15-303'], ['A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC'], ['Interventional'], ['April 2016'], ['June 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['IDE397-001'], ['Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion'], ['Interventional'], ['April 14, 2021'], ['June 30, 2024'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['EORTC-08971'], ['Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer'], ['Interventional'], ['March 1998'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['CDR0000271174'], ['Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer'], ['Interventional'], ['August 2003'], ['May 1, 2009'], ['Completed'], [], ['All'], [], ['18 Years'], ['120 Years']][['213346'], ['Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors'], ['Interventional'], ['March 7, 2016'], ['October 27, 2027'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2009-00258'], ['Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer'], ['Interventional'], ['September 2007'], [], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['Pathway Gennomics 004'], ['Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease'], ['Observational'], ['November 2015'], ['August 2017'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['217228'], ['First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors'], ['Interventional'], ['March 22, 2022'], ['December 29, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['UCI 04-08'], ['Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer'], ['Interventional'], ['April 2005'], ['October 2011'], ['Terminated'], ['Sponsor-Investigator'], ['All'], [], ['18 Years'], []][['M15-891'], ['A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors'], ['Interventional'], ['December 14, 2016'], ['March 29, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['ARRAY-818-202'], ['An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer'], ['Interventional'], ['June 4, 2019'], ['June 30, 2024'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['YO39609'], ['A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)'], ['Interventional'], ['October 13, 2017'], ['February 8, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['3P-03-2'], ['Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.'], ['Interventional'], ['February 2005'], ['July 2006'], ['Terminated'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCAGN 1949-201'], ['A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies'], ['Interventional'], ['October 9, 2017'], ['September 17, 2019'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['5GYN-02-2'], ['Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma'], ['Interventional'], ['November 2002'], ['May 2010'], ['Completed'], ['Sponsor'], ['Female'], [], ['18 Years'], []][['213351'], ['Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042'], ['Interventional'], ['October 12, 2017'], ['April 20, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['INCAGN 1876-201'], ['Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies'], ['Interventional'], ['April 25, 2017'], ['November 9, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['GOG-0215'], ['Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries'], ['Interventional'], ['November 28, 2005'], [], ['Completed'], ['Sponsor'], ['Female'], [], [], []][['4830-001'], ['Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)'], ['Interventional'], ['July 11, 2018'], ['November 4, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D081SC00001'], ['Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer'], ['Interventional'], ['October 31, 2018'], ['October 30, 2022'], ['Active, not recruiting'], ['Sponsor'], ['Male'], [], ['18 Years'], ['99 Years']][['1363'], ['Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis'], ['Interventional'], ['November 1994'], ['September 1999'], ['Completed'], [], ['Female'], [], [], ['80 Years']][['CAMH2_1001'], ['A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer'], ['Interventional'], ['September 14, 2021'], ['January 17, 2025'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['17-568'], ['BRCA Founder OutReach (BFOR) Study'], ['Observational'], ['November 10, 2017'], ['May 10, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['25 Years'], []][['AG0315OG/CTC0140'], ['RegoNivo vs Standard of Care Chemotherapy in AGOC'], ['Interventional'], ['June 1, 2021'], ['June 1, 2026'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['PBTC-042'], ['Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors'], ['Interventional'], ['December 8, 2014'], ['February 25, 2019'], ['Terminated'], ['Sponsor'], ['All'], [], ['4 Years'], ['21 Years']][['2018-01B'], ['Stool Collection Sub-Study of Exact Sciences Protocol 2018-01'], ['Observational'], ['July 21, 2020'], ['May 25, 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['19741'], ['Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug'], ['Interventional'], ['September 30, 2019'], ['April 11, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO21223'], [\"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)\"], ['Interventional'], ['July 6, 2011'], ['July 30, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['BO29337'], [\"A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)\"], ['Interventional'], ['December 1, 2014'], ['March 16, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NRG-HN010'], ['Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer'], ['Interventional'], ['September 30, 2022'], ['July 31, 2028'], ['Recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['MS-700'], ['MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ'], ['Interventional'], ['August 2003'], ['April 2011'], ['Completed'], ['Sponsor'], ['Female'], [], ['45 Years'], []][['D5760C00001'], ['A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.'], ['Interventional'], ['September 23, 2015'], ['May 23, 2018'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], ['99 Years']][['20172841'], ['The PREDICT Registry for DCIS Patients With DCISionRT Testing'], ['Observational'], ['February 27, 2018'], ['November 2035'], ['Suspended'], ['Sponsor'], ['Female'], [], ['25 Years'], []][['NCI-2009-00534'], ['Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery'], ['Interventional'], ['April 24, 2006'], ['September 1, 2021'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2016-01041'], ['Nivolumab and Ipilimumab in Treating Patients With Rare Tumors'], ['Interventional'], ['January 13, 2017'], ['October 31, 2023'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-00723'], ['Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery'], ['Interventional'], ['August 8, 2012'], ['July 19, 2027'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['S1614'], ['Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors'], ['Interventional'], ['February 21, 2019'], ['February 28, 2027'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NSABP MPR-1'], ['NSABP Patient Registry and Biospecimen Profiling Repository'], ['Observational'], ['February 2013'], ['March 2022'], ['Completed'], ['Sponsor'], ['All'], [], ['18 Years'], []][['NCI-2012-00107'], ['Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer'], ['Interventional'], ['February 22, 2012'], ['August 1, 2021'], ['Unknown status'], ['Sponsor'], ['All'], [], ['18 Years'], []][['302'], ['177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)'], ['Interventional'], ['August 31, 2022'], ['December 31, 2024'], ['Withdrawn'], ['Sponsor'], ['All'], [], ['18 Years'], []][['D967MC00001'], ['A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations'], ['Interventional'], ['December 30, 2020'], ['January 17, 2028'], ['Active, not recruiting'], ['Sponsor'], ['All'], [], ['18 Years'], ['120 Years']]"
     ]
    }
   ],
   "source": [
    "for new_list in values_list:\n",
    "    print(new_list,end='')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "9a1aad07",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\"CCT1043\"], [\"Breast Cancer Trials Education Program\"], [\"Interventional\"], [\"May 2007\"], [\"December 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], []], [[\"150B-0158\"], [\"Breast Cancer Risk Reduction: A Patient Doctor Intervention\"], [\"Interventional\"], [\"June 2011\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"40 Years\"], [\"74 Years\"]], [[\"CHUM-CRYOABLATION\"], [\"Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers\"], [\"Interventional\"], [\"April 2013\"], [\"October 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20107812\"], [\"Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging\"], [\"Observational\"], [\"December 2010\"], [\"October 2013\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"234870\"], [\"Blood Glycan Biomarkers in Women With Stage IV Breast Cancer\"], [\"Observational\"], [\"September 2006\"], [\"January 12, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"FWA00010885\"], [\"Breast Cancer Survivorship & Work-Related Cognitive Limitation\"], [\"Observational\"], [\"September 2014\"], [\"February 2015\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"69 Years\"]], [[\"CC077515\"], [\"Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer\"], [\"Interventional\"], [\"January 2011\"], [\"March 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20022306\"], [\"Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy\"], [\"Interventional\"], [\"June 2002\"], [\"January 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"75 Years\"]], [[\"STUDY00001641\"], [\"Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women\"], [\"Interventional\"], [\"July 16, 2022\"], [\"December 1, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"45 Years\"], [\"80 Years\"]], [[\"00080\"], [\"Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease\"], [\"Observational\"], [\"July 2001\"], [\"September 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"IRB-14623 part 1\"], [\"Intellectual Impairment in Women With Breast Cancer\"], [\"Interventional\"], [\"January 12, 2009\"], [\"June 2013\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"40 Years\"], [\"65 Years\"]], [[\"IIT2015-11-Giuliano-SNBO\"], [\"Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy\"], [\"Interventional\"], [\"December 2015\"], [\"April 2020\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"13278\"], [\"Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)\"], [\"Observational\"], [\"September 30, 2013\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"200715040\"], [\"Molecular Imaging of Breast Cancer With Breast PET/CT\"], [\"Interventional\"], [\"April 2007\"], [\"July 2011\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SU-10042011-8529\"], [\"National Breast Cancer and Lymphedema Registry\"], [\"Observational\"], [\"September 12, 2011\"], [\"March 2, 2018\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-10748\"], [\"Magnetic Resonance Imaging of Breast Cancer\"], [\"Interventional\"], [\"April 1, 1995\"], [\"May 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"21 Years\"], []], [[\"IRB-12226\"], [\"Development of Vitamin D as a Therapy for Breast Cancer - Phase 2\"], [\"Interventional\"], [\"April 2008\"], [\"December 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"5110026\"], [\"Partial Breast Proton Therapy for Early Stage Breast Cancer\"], [\"Interventional\"], [\"May 4, 2011\"], [\"May 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"80 Years\"]], [[\"08063\"], [\"Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"December 2, 2008\"], [\"June 26, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"182-20-CA\"], [\"18F-fluoroestradiol (FES) PET/CT for Breast Cancer\"], [\"Interventional\"], [\"January 15, 2021\"], [\"December 15, 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"01-BR-003\"], [\"Guardant360\\\\u00ae Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer\"], [\"Observational\"], [\"July 2, 2020\"], [\"March 17, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"037519\"], [\"Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer\"], [\"Interventional\"], [\"November 3, 2004\"], [\"December 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08103\"], [\"Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"November 2008\"], [\"April 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"19-001004\"], [\"Brain Health in Breast Cancer Survivors\"], [\"Observational\"], [\"March 11, 2020\"], [\"March 15, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"35 Years\"], [\"65 Years\"]], [[\"14-001744\"], [\"Project Connect Online: An Internet-based Intervention for Women With Breast Cancer\"], [\"Interventional\"], [\"June 4, 2015\"], [\"June 17, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000257580\"], [\"Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"May 2002\"], [\"April 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"99002\"], [\"Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 18, 1999\"], [\"June 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"59 Years\"]], [[\"12175\"], [\"Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors\"], [\"Interventional\"], [\"August 2012\"], [\"July 2013\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"UCLA-9810046\"], [\"Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer\"], [\"Interventional\"], [\"January 1999\"], [\"October 2004\"], [\"Completed\"], [], [\"Female\"], [], [], []], [[\"1B-15-3\"], [\"Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy\"], [\"Observational\"], [\"August 10, 2015\"], [\"November 26, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRSNSTU0009\"], [\"Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2\"], [\"Observational\"], [\"July 2005\"], [\"April 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCSF-077518\"], [\"Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2\"], [\"Interventional\"], [\"August 2007\"], [\"December 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"07006\"], [\"Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy\"], [\"Observational\"], [\"October 2007\"], [\"January 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"10038\"], [\"Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)\"], [\"Interventional\"], [\"January 15, 2020\"], [\"January 15, 2035\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2015-06-Chung-SNBO\"], [\"Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65\"], [\"Interventional\"], [\"January 22, 2016\"], [\"June 2025\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"65 Years\"], []], [[\"SPI-POZ-101\"], [\"A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"July 13, 2018\"], [\"April 17, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"90 Years\"]], [[\"07213\"], [\"White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors\"], [\"Interventional\"], [\"June 2008\"], [\"December 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"09147\"], [\"MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer\"], [\"Observational\"], [\"November 2009\"], [\"May 20, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-34959\"], [\"Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer\"], [\"Observational\"], [\"August 2016\"], [\"July 8, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000430701\"], [\"Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer\"], [\"Interventional\"], [\"April 2005\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"11-003446\"], [\"Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors\"], [\"Interventional\"], [\"April 2012\"], [\"September 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], [\"65 Years\"]], [[\"03178\"], [\"IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer\"], [\"Interventional\"], [\"January 2005\"], [\"October 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"75 Years\"]], [[\"SC0001\"], [\"Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons\"], [\"Interventional\"], [\"January 2003\"], [\"January 2010\"], [\"Unknown status\"], [], [\"Female\"], [], [\"35 Years\"], [\"90 Years\"]], [[\"BRSADJ0003\"], [\"Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer\"], [\"Interventional\"], [\"January 2005\"], [\"August 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"USI2011001\"], [\"CRRS-4 Pivotal Somo\\\\u2022v\\\\u2122 ABUS ROC Reader Observer Study\"], [\"Observational\"], [\"July 2011\"], [\"September 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"IRB-48150\"], [\"68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer\"], [\"Interventional\"], [\"March 19, 2019\"], [\"June 18, 2024\"], [\"Suspended\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000442877\"], [\"Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 2005\"], [\"November 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT2017-07-HO-PembroRT\"], [\"Breast Cancer Study of Preoperative Pembrolizumab + Radiation\"], [\"Interventional\"], [\"December 22, 2017\"], [\"April 21, 2023\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A5481155\"], [\"Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy\"], [\"Observational\"], [\"June 30, 2020\"], [\"December 31, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2015-18-Mita-MK3475\"], [\"Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer\"], [\"Interventional\"], [\"September 10, 2017\"], [\"November 8, 2024\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000067909\"], [\"Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 1999\"], [\"April 2004\"], [\"Completed\"], [], [\"All\"], [], [], []], [[\"BMS-CA163-031\"], [\"BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2002\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CDR0000599060\"], [\"Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2008\"], [], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000515534\"], [\"ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 2006\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI 05-38\"], [\"Neoadjuvant Treatment of Breast Cancer\"], [\"Interventional\"], [\"October 2005\"], [\"September 4, 2013\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-12-6\"], [\"Light-Scattering Spectroscopy for Detection of Breast Cancer\"], [\"Interventional\"], [\"November 21, 2012\"], [\"November 19, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"037517\"], [\"Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 2004\"], [\"January 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], [\"120 Years\"]], [[\"IRB-13807\"], [\"Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer\"], [\"Interventional\"], [\"September 2002\"], [\"March 2029\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"IRB-31913\"], [\"Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\"], [\"Interventional\"], [\"August 2015\"], [\"December 2022\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"01-06-020\"], [\"Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression\"], [\"Interventional\"], [\"August 2001\"], [\"December 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"05015\"], [\"Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer\"], [\"Interventional\"], [\"September 27, 2005\"], [\"June 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"07170\"], [\"Study of Support Groups for African-American Breast Cancer Survivors\"], [\"Interventional\"], [\"January 2008\"], [\"September 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"09101\"], [\"Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"March 16, 2011\"], [\"December 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-13-2\"], [\"Core Biopsies for Establishing a Breast Tumor Tissue Repository\"], [\"Observational\"], [\"November 14, 2013\"], [\"November 14, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCD-986545\"], [\"Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 1996\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"IRB-57723\"], [\"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\"], [\"Interventional\"], [\"February 3, 2021\"], [\"February 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BNIT-BR-002\"], [\"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 2007\"], [\"September 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"960-CSP-USA_MIRA_USS2\"], [\"Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer\"], [\"Interventional\"], [\"May 2016\"], [\"October 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"30 Years\"], [\"70 Years\"]], [[\"STUDY2019000317\"], [\"Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer\"], [\"Observational\"], [\"October 3, 2018\"], [\"October 3, 2028\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000271533\"], [\"CP-724,714 in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2003\"], [\"May 2005\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"12-028 MWA - Breast Tumors\"], [\"Microwave Ablation of Breast Tumors\"], [\"Observational\"], [\"September 2012\"], [\"December 2012\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"IRB-21034\"], [\"Vitamin D and Breast Cancer: Does Weight Make a Difference?\"], [\"Interventional\"], [\"November 2011\"], [\"October 2015\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-21030\"], [\"Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer\"], [\"Interventional\"], [\"July 2012\"], [\"March 17, 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"F31AT003021\"], [\"Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors\"], [\"Interventional\"], [\"October 2005\"], [\"September 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"057519\"], [\"Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 1, 2006\"], [\"December 1, 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"1R01CA140481\"], [\"Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors\"], [\"Interventional\"], [\"August 2012\"], [\"July 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"B27IB3856\"], [\"UCLA Breast Cancer Survivor Health Promotion Research Study\"], [\"Interventional\"], [\"April 1, 2022\"], [\"June 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"50 Years\"], [\"75 Years\"]], [[\"U01AT003682\"], [\"A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue\"], [\"Interventional\"], [\"June 2008\"], [\"December 2010\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"40 Years\"], [\"65 Years\"]], [[\"53294\"], [\"Proton Therapy for Early Stage Breast Cancer\"], [\"Interventional\"], [\"February 2004\"], [\"May 12, 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"96139\"], [\"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer\"], [\"Interventional\"], [\"May 30, 1997\"], [\"December 30, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"60 Years\"]], [[\"08242\"], [\"Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life\"], [\"Observational\"], [\"June 11, 2009\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"08128\"], [\"Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer\"], [\"Observational\"], [\"September 4, 2008\"], [\"June 20, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"GENBASIX-00127\"], [\"Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters\"], [\"Observational\"], [\"January 2001\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CC# 087515\"], [\"Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer\"], [\"Interventional\"], [\"December 10, 2008\"], [\"July 29, 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"06102\"], [\"Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors\"], [\"Interventional\"], [\"October 2006\"], [\"June 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"587842\"], [\"Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer\"], [\"Observational\"], [\"April 2014\"], [\"April 7, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"UCI 03-70\"], [\"Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [\"July 2012\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000505536\"], [\"Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ\"], [\"Interventional\"], [\"October 2001\"], [\"May 2007\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"1B-03-1\"], [\"Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2003\"], [\"December 2006\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IORT\"], [\"Intraoperative Radiotherapy for Early Stage Breast Cancer\"], [\"Interventional\"], [\"June 2010\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"48 Years\"], []], [[\"10-001799\"], [\"A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors\"], [\"Interventional\"], [\"April 2011\"], [\"November 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"50 Years\"]], [[\"UCI-HS-2000-1141\"], [\"Angiogenesis in Early Breast Cancer for Prognosis Prediction\"], [\"Interventional\"], [\"November 2000\"], [\"July 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"160178\"], [\"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer\"], [\"Interventional\"], [\"August 15, 2018\"], [\"January 13, 2023\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"BRSMTS0002\"], [\"Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study\"], [\"Observational\"], [\"November 2000\"], [\"August 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"IRB-03518\"], [\"Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer\"], [\"Interventional\"], [\"October 2006\"], [\"March 2011\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"08092\"], [\"Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer\"], [\"Interventional\"], [\"November 2008\"], [\"May 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"50 Years\"], []], [[\"25IB-0023\"], [\"Exercise Study for Breast Cancer Survivors\"], [\"Interventional\"], [\"November 25, 2019\"], [\"December 2020\"], [\"Unknown status\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [], []], [[\"IRB# 06-05-104\"], [\"Delayed Adjuvant Herceptin\\\\u00ae Treatment in Patients With HER-2 Positive Breast Cancer\"], [\"Interventional\"], [\"January 2007\"], [\"October 2007\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CBCRP 11IB-0034\"], [\"Effect of Increased Light Exposure on Fatigue in Breast Cancer\"], [\"Interventional\"], [\"November 2005\"], [\"November 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000465214\"], [\"Radiation Therapy in Treating Women With Invasive Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [\"May 2004\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-13429\"], [\"Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women\"], [\"Interventional\"], [\"October 2000\"], [\"June 2013\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"SU-11052007-799\"], [\"Molecular Analysis of Breast Cancer\"], [\"Observational\"], [\"May 1996\"], [\"May 2050\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000316264\"], [\"Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy\"], [\"Interventional\"], [\"May 2003\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"GSM\"], [\"GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors\"], [\"Interventional\"], [\"November 18, 2016\"], [\"July 23, 2018\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [], []], [[\"UCSD-020815\"], [\"Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2003\"], [\"March 2008\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"60 Years\"]], [[\"BNIT-BR-003\"], [\"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy\"], [\"Interventional\"], [\"June 2010\"], [\"September 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT2018-17-McArthur-TCDRT\"], [\"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer\"], [\"Interventional\"], [\"July 2022\"], [\"July 2027\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1B-05-5\"], [\"Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI\"], [\"Interventional\"], [\"November 20, 2005\"], [\"November 20, 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"07102022_SR\"], [\"Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer\"], [\"Interventional\"], [\"September 1, 2022\"], [\"June 1, 2023\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"07100\"], [\"Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer\"], [\"Observational\"], [\"July 6, 2010\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"12383\"], [\"Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors\"], [\"Interventional\"], [\"July 15, 2013\"], [\"June 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"KCT 005\"], [\"A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery\"], [\"Interventional\"], [\"June 1, 2021\"], [\"December 31, 2021\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"05751\"], [\"Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases\"], [\"Interventional\"], [\"February 2005\"], [\"January 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"11115\"], [\"Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors\"], [\"Interventional\"], [\"June 1, 2012\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-08-7\"], [\"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer\"], [\"Interventional\"], [\"February 2009\"], [\"February 2011\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"07157\"], [\"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 11, 2008\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"UCSD#100231\"], [\"Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer\"], [\"Interventional\"], [\"June 2010\"], [\"October 2015\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI-HS-2006-5162\"], [\"Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis\"], [\"Interventional\"], [\"October 1, 2006\"], [\"October 30, 2017\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"90 Years\"]], [[\"AVF3359s\"], [\"Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study\"], [\"Interventional\"], [\"June 2006\"], [\"October 2008\"], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-07696\"], [\"Healing Touch During Chemotherapy Infusions for Women With Breast Cancer\"], [\"Interventional\"], [\"April 2007\"], [\"August 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"09-09-058\"], [\"Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients\"], [\"Observational\"], [\"May 2010\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-08051\"], [\"Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer\"], [\"Interventional\"], [\"January 2008\"], [\"December 2009\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRSADJ0013\"], [\"Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival\"], [\"Observational\"], [\"September 2006\"], [\"August 31, 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"45 Years\"], [\"75 Years\"]], [[\"IRB-13732\"], [\"Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention\"], [\"Interventional\"], [\"November 2005\"], [\"December 2010\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"05042\"], [\"Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer\"], [\"Interventional\"], [\"July 2005\"], [\"October 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], [\"65 Years\"]], [[\"08166\"], [\"Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 17, 2010\"], [\"September 27, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SPI-GCF-301-PK\"], [\"Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy\"], [\"Interventional\"], [\"May 11, 2017\"], [\"May 18, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BRSNSTU0002\"], [\"Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer\"], [\"Observational\"], [\"November 2001\"], [\"June 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"25 Years\"], [\"65 Years\"]], [[\"06136\"], [\"Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers\"], [\"Interventional\"], [\"August 2006\"], [\"November 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-59141\"], [\"Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer\"], [\"Interventional\"], [\"February 23, 2023\"], [\"March 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"5140020\"], [\"Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer\"], [\"Interventional\"], [\"February 12, 2014\"], [\"December 2023\"], [\"Suspended\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"BRSADJ0009\"], [\"A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer\"], [\"Observational\"], [\"January 2009\"], [\"September 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-14-7\"], [\"Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer\"], [\"Observational\"], [\"March 5, 2015\"], [\"February 7, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRSMTS0012\"], [\"Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers\"], [\"Interventional\"], [\"July 2010\"], [\"December 2014\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1B-08-1\"], [\"Green Tea in Breast Cancer Patients\"], [\"Interventional\"], [\"May 7, 2008\"], [\"June 6, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"TRIO 017\"], [\"Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2009\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"057514\"], [\"Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 20, 2007\"], [\"March 24, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"117513\"], [\"Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib\"], [\"Interventional\"], [\"April 27, 2012\"], [\"October 2, 2019\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000378088\"], [\"Study of Ductal Lavage in Women at High Risk for Breast Cancer\"], [\"Observational\"], [\"August 2002\"], [\"June 2004\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1098987\"], [\"Use of the Contura\\\\u2122 Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients\"], [\"Interventional\"], [\"October 2007\"], [\"December 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"TRIO 016\"], [\"Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2009\"], [\"March 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"173-18-CA\"], [\"Perioperative Mindfulness Proposal\"], [\"Interventional\"], [\"July 31, 2019\"], [\"December 31, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"157512\"], [\"Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer\"], [\"Observational\"], [\"August 2, 2016\"], [\"December 31, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16758\"], [\"Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer\"], [\"Interventional\"], [\"December 28, 2016\"], [\"February 28, 2022\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"11996\"], [\"Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies\"], [\"Interventional\"], [\"March 27, 2012\"], [\"December 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"VEG108843\"], [\"Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"April 2008\"], [\"November 2012\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-13-8\"], [\"Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery\"], [\"Interventional\"], [\"December 19, 2013\"], [\"September 25, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000069154\"], [\"Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer\"], [\"Interventional\"], [\"February 2001\"], [\"February 2005\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"QUILT-3.067\"], [\"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.\"], [\"Interventional\"], [\"March 16, 2018\"], [\"January 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"197520\"], [\"Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"March 11, 2021\"], [\"March 1, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI HS# 2015-1866\"], [\"Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System\"], [\"Observational\"], [\"May 2015\"], [\"January 25, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"CDR0000068369\"], [\"Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 2001\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"117527\"], [\"Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer\"], [\"Interventional\"], [\"November 1, 2012\"], [\"June 9, 2016\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"150860\"], [\"Tracking Physical Activity Throughout Chemotherapy for Breast Cancer\"], [\"Observational\"], [\"June 1, 2015\"], [\"February 8, 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"85 Years\"]], [[\"QUILT-3.058\"], [\"A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies\"], [\"Interventional\"], [\"September 27, 2021\"], [\"January 4, 2023\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2022-07-YUAN-IB-TNBC\"], [\"Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"April 2023\"], [\"October 2026\"], [\"Not yet recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"221183\"], [\"Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis\"], [\"Interventional\"], [\"November 2010\"], [\"March 4, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"CDR0000657044\"], [\"Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants\"], [\"Interventional\"], [\"January 2016\"], [], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2015-12-Goodman-STOP\"], [\"STOP Heart Disease in Breast Cancer Survivors Trial\"], [\"Interventional\"], [\"May 5, 2016\"], [\"May 25, 2018\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2012-02827\"], [\"GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 2003\"], [\"March 2010\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-02836\"], [\"Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer\"], [\"Interventional\"], [\"June 2005\"], [\"January 2008\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15BB-1300\"], [\"Nuevo Amanecer: Promoting the Psychosocial Health of Latinas\"], [\"Interventional\"], [\"February 2011\"], [\"May 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"017513\"], [\"Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ\"], [\"Interventional\"], [\"February 19, 2002\"], [\"June 30, 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"1B-12-10\"], [\"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 29, 2013\"], [\"March 2, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRS0001\"], [\"Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT\"], [\"Interventional\"], [\"February 2008\"], [\"December 2012\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"22239\"], [\"Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors\"], [\"Interventional\"], [\"March 15, 2023\"], [\"May 15, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"ITL-014-TACT-MBC\"], [\"Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"March 2014\"], [\"March 2014\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"20171\"], [\"Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer\"], [\"Interventional\"], [\"July 27, 2021\"], [\"December 12, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"IRB-52869\"], [\"Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"March 20, 2023\"], [\"December 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1B-21-6\"], [\"Breast Cancer Survivorship Biorepository\"], [\"Observational\"], [\"April 11, 2022\"], [\"April 11, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-63041\"], [\"Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer\"], [\"Interventional\"], [\"August 16, 2022\"], [\"August 2026\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"U54 CA155435-01 Project 3\"], [\"Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors\"], [\"Interventional\"], [\"August 2011\"], [\"December 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [], []], [[\"GC-627-05\"], [\"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy\"], [\"Interventional\"], [\"April 12, 2018\"], [\"March 5, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000367118\"], [\"GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu\"], [\"Interventional\"], [\"March 2004\"], [\"February 2005\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI 19-145 [HS# 1459]\"], [\"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 31, 2022\"], [\"December 31, 2028\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"20923\"], [\"Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand\"], [\"Observational\"], [\"May 18, 2020\"], [\"May 24, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [], [\"70 Years\"]], [[\"18496\"], [\"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"March 4, 2019\"], [\"December 21, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"21094\"], [\"CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"October 18, 2021\"], [\"December 1, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MMP-001\"], [\"Mindful Movement for Breast Cancer Survivors\"], [\"Interventional\"], [\"November 2015\"], [\"June 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"1B-16-3\"], [\"Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer\"], [\"Interventional\"], [\"April 21, 2017\"], [\"July 8, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"QUILT-3.057\"], [\"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine\"], [\"Interventional\"], [\"September 2018\"], [\"December 2021\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"21050\"], [\"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis\"], [\"Interventional\"], [\"December 21, 2022\"], [\"February 25, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"10192\"], [\"Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid\"], [\"Interventional\"], [\"September 14, 2012\"], [\"February 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"PILOT 171548\"], [\"RISE - Reduce Sitting Time Among Breast Cancer Survivors\"], [\"Interventional\"], [\"March 29, 2022\"], [\"February 7, 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"50 Years\"], []], [[\"1B-12-1\"], [\"Exercise Program for Early Breast Cancer Survivors\"], [\"Interventional\"], [\"May 21, 2012\"], [\"October 1, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"16-1856\"], [\"Integrative Approaches for Cancer Survivorship 2: Project 2\"], [\"Interventional\"], [\"September 2016\"], [\"June 4, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-53650\"], [\"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer\"], [\"Interventional\"], [\"October 13, 2020\"], [\"October 22, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SLNPain01\"], [\"Sentinel Lymph Node Mapping Post-Injection Site Pain\"], [\"Observational\"], [\"March 2014\"], [\"February 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"16-18567\"], [\"Integrative Approaches For Cancer Survivorship 2: Project 1\"], [\"Interventional\"], [\"September 2016\"], [\"September 21, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20107789\"], [\"Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging\"], [\"Observational\"], [\"December 2010\"], [\"December 2018\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"75 Years\"]], [[\"4 BB-2901\"], [\"Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?\"], [\"Interventional\"], [], [], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-12273\"], [\"Stress, Diurnal Cortisol, and Breast Cancer Survival\"], [\"Observational\"], [\"September 8, 2002\"], [\"December 2005\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"19-001881\"], [\"Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors\"], [\"Interventional\"], [\"September 29, 2021\"], [\"November 1, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"74 Years\"]], [[\"IRB-57111\"], [\"Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients\"], [\"Interventional\"], [\"March 15, 2021\"], [\"October 31, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16-185671\"], [\"Integrative Approaches to Cancer Survivorship: Project 3\"], [\"Interventional\"], [\"April 17, 2018\"], [\"January 30, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-58571\"], [\"Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer\"], [\"Interventional\"], [\"January 20, 2021\"], [\"October 12, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20141505\"], [\"Breast Tumor Oxygenation During Exercise\"], [\"Observational\"], [\"April 2015\"], [\"January 2018\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"70 Years\"]], [[\"IRB-13761\"], [\"Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2006\"], [\"November 2012\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"19206\"], [\"Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.\"], [\"Interventional\"], [\"March 25, 2020\"], [\"December 15, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"70 Years\"], []], [[\"17-000560\"], [\"Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors\"], [\"Interventional\"], [\"July 11, 2017\"], [\"December 3, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"19 Years\"], []], [[\"18549\"], [\"Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema\"], [\"Interventional\"], [\"April 19, 2019\"], [\"March 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"5R03CA144751-02\"], [\"Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer\"], [\"Interventional\"], [\"January 2010\"], [\"September 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [], []], [[\"UCSD POISE\"], [\"Predictors of Ovarian Insufficiency in Young Breast Cancer Patients\"], [\"Observational\"], [\"September 24, 2008\"], [\"July 18, 2019\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"45 Years\"]], [[\"BRS0027\"], [\"Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer\"], [\"Interventional\"], [\"July 2013\"], [\"July 2015\"], [\"Terminated\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"16-001271\"], [\"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer\"], [\"Interventional\"], [\"August 2, 2017\"], [\"March 31, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"19 Years\"], []], [[\"OMS-I140\"], [\"Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC\"], [\"Interventional\"], [\"September 2015\"], [\"July 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SIMR_onc19_IIS_D\\'Andre_Ashwaga\"], [\"Ashwagandha for Cognitive Dysfunction\"], [\"Interventional\"], [\"January 1, 2020\"], [\"November 1, 2022\"], [\"Unknown status\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"04125\"], [\"Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease\"], [\"Observational\"], [\"August 2005\"], [\"June 6, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"20 Years\"], []], [[\"1B-16-11\"], [\"Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer\"], [\"Interventional\"], [\"July 29, 2019\"], [\"July 29, 2025\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-11-5\"], [\"Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy\"], [\"Interventional\"], [\"September 4, 2012\"], [\"September 30, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"21152\"], [\"Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer\"], [\"Interventional\"], [\"June 21, 2022\"], [\"September 7, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"11174\"], [\"Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer\"], [\"Interventional\"], [\"February 15, 2012\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"19 Years\"], []], [[\"14135\"], [\"Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors\"], [\"Interventional\"], [\"September 7, 2014\"], [\"June 3, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"56 Years\"], []], [[\"TRIO-US B09\"], [\"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis\"], [\"Interventional\"], [\"June 26, 2013\"], [\"May 10, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20091527\"], [\"The Health of Women Study\"], [\"Observational\"], [\"August 2009\"], [\"July 18, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"08061\"], [\"Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors\"], [\"Interventional\"], [\"August 2008\"], [\"April 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"CDR0000428460\"], [\"Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer\"], [\"Interventional\"], [\"February 2005\"], [\"November 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], [\"65 Years\"]], [[\"02164\"], [\"Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease\"], [\"Interventional\"], [\"March 11, 2004\"], [\"June 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], [\"48 Years\"]], [[\"RSGPB-04-258-01-CPPB\"], [\"Weight Reduction Intervention for Breast Cancer Survivors\"], [\"Interventional\"], [\"January 2005\"], [\"December 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-14-5\"], [\"High-Intensity Interval Training for Stage I-III Breast Cancer Patients\"], [\"Interventional\"], [\"September 29, 2015\"], [\"July 15, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCLA-9908076\"], [\"Cryosurgery in Treating Women With Breast Lesions\"], [\"Interventional\"], [\"May 2001\"], [\"July 2004\"], [\"Completed\"], [], [\"Female\"], [], [], []], [[\"1B-09-14\"], [\"Endoscopic Breast Surgery in Treating Patients With Breast Cancer\"], [\"Interventional\"], [\"September 2010\"], [\"October 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"15 Years\"], []], [[\"1B-12-4\"], [\"Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer\"], [\"Interventional\"], [\"October 1, 2012\"], [\"October 21, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"7BB-2400\"], [\"Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?\"], [\"Observational\"], [\"July 1, 2000\"], [\"November 30, 2006\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"20 Years\"], [\"85 Years\"]], [[\"1R03CA168450-01\"], [\"Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)\"], [\"Interventional\"], [\"April 2013\"], [\"October 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"SNP-17-001\"], [\"Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer\"], [\"Observational\"], [\"September 21, 2018\"], [\"November 11, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"16294\"], [\"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer\"], [\"Interventional\"], [\"March 22, 2017\"], [\"November 22, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"SAIRB-15-0060\"], [\"A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.\"], [\"Observational\"], [\"December 2015\"], [], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"P0518095\"], [\"Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device\"], [\"Interventional\"], [\"October 31, 2017\"], [\"January 31, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"120108\"], [\"Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy\"], [\"Interventional\"], [\"March 2012\"], [\"December 2012\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"IRB-30982\"], [\"Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 2015\"], [\"July 2019\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"14253\"], [\"Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer\"], [\"Interventional\"], [\"January 7, 2016\"], [\"December 19, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"S07-002\"], [\"Use of the Contura\\\\u2122 Catheter to Deliver Accelerated Partial Breast Irradiation to \\\\\"Low-risk\\\\\" Breast Cancer Patients\"], [\"Interventional\"], [\"May 2008\"], [\"July 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"17753\"], [\"T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer\"], [\"Interventional\"], [\"February 5, 2020\"], [\"April 30, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"167514\"], [\"Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib\"], [\"Interventional\"], [\"October 9, 2018\"], [\"October 31, 2022\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"R01 CA119 159\"], [\"Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms\"], [\"Interventional\"], [\"March 2008\"], [\"July 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"30 Years\"], [\"70 Years\"]], [[\"IIT2019-21-Basho-TOPAZ\"], [\"TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases\"], [\"Interventional\"], [\"June 1, 2022\"], [\"June 1, 2024\"], [\"Withdrawn\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-01671\"], [\"Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status\"], [\"Interventional\"], [\"May 2005\"], [\"September 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"18-000427\"], [\"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted\"], [\"Interventional\"], [\"July 10, 2019\"], [\"July 1, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CL- Gedatolisib-001\"], [\"Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer\"], [\"Interventional\"], [\"January 2016\"], [\"March 15, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"VINJ007\"], [\"Acupuncture for CIPN in Breast Cancer Patients\"], [\"Interventional\"], [\"October 2015\"], [\"December 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"21-001819\"], [\"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"April 7, 2022\"], [\"April 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AVB620-C-001\"], [\"Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery\"], [\"Interventional\"], [\"April 2015\"], [\"January 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-37299\"], [\"4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"October 30, 2017\"], [\"February 14, 2022\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"BRSMTS0010\"], [\"Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast\"], [\"Interventional\"], [\"August 2007\"], [\"December 2011\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"RJ-101-RCT-001\"], [\"Study to Investigate the Effect of AB-101 in Breast Cancer Survivors\"], [\"Interventional\"], [\"July 9, 2018\"], [\"October 12, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"70 Years\"]], [[\"09109\"], [\"Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel\"], [\"Interventional\"], [\"January 2010\"], [\"May 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"13-001676\"], [\"Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus\"], [\"Interventional\"], [\"October 8, 2014\"], [\"November 30, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PA18-0280\"], [\"A Culturally Sensitive Social Support Intervention\"], [\"Interventional\"], [\"January 2015\"], [\"August 2021\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"06-08-010\"], [\"Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors\"], [\"Interventional\"], [\"March 2008\"], [\"October 2009\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"MRSGT-10-011-01-CPPB\"], [\"Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors\"], [\"Interventional\"], [\"June 2012\"], [\"March 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"14955\"], [\"Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 23, 2015\"], [\"January 8, 2019\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"5354-CL-1201\"], [\"A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery\"], [\"Interventional\"], [\"August 10, 2022\"], [\"September 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [\"Yes\"], [\"18 Years\"], []], [[\"14099\"], [\"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"January 7, 2015\"], [\"December 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000393552\"], [\"Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers\"], [\"Interventional\"], [\"November 2004\"], [], [\"Terminated\"], [], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"BMT86\"], [\"CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant\"], [\"Interventional\"], [\"September 1996\"], [\"June 2005\"], [\"Completed\"], [], [\"All\"], [], [\"19 Years\"], [\"70 Years\"]], [[\"BRSNSTU0024\"], [\"Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI\"], [\"Observational\"], [\"April 2008\"], [\"December 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"CDR0000069155\"], [\"Herbal Therapy in Treating Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 2001\"], [\"April 2006\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCDCC#237\"], [\"Oxaliplatin in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 2015\"], [\"December 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"KCT003\"], [\"A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema\"], [\"Interventional\"], [\"June 1, 2021\"], [\"December 31, 2021\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NU 98B3\"], [\"Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer\"], [\"Interventional\"], [\"October 1999\"], [\"April 2000\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000439421\"], [\"Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"April 2005\"], [\"December 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IM-T-hMN14-04\"], [\"Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer\"], [\"Interventional\"], [\"February 2000\"], [\"June 2003\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"16421\"], [\"Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention\"], [\"Interventional\"], [\"August 9, 2017\"], [\"December 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT 2014-01\"], [\"Emerging From the Haze\\\\u2122- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment\"], [\"Interventional\"], [\"July 6, 2015\"], [\"May 23, 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"140863\"], [\"Reproductive Health Survivorship Care Plan\"], [\"Interventional\"], [\"March 25, 2015\"], [\"January 24, 2019\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"45 Years\"]], [[\"Breast Pain\"], [\"Symptom Management After Breast Cancer Surgery\"], [\"Interventional\"], [\"September 2003\"], [\"December 2007\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CRICC-BB-IND-7186\"], [\"Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 1997\"], [\"October 2004\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"20080325\"], [\"A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"October 21, 2008\"], [\"February 7, 2018\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"14-071\"], [\"Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History\"], [\"Observational\"], [\"April 8, 2014\"], [\"April 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"60 Years\"], []], [[\"98096\"], [\"Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer\"], [\"Interventional\"], [\"May 1999\"], [\"December 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], [\"60 Years\"]], [[\"C07-104\"], [\"Safety and Efficacy Study Using Rexin-G for Breast Cancer\"], [\"Interventional\"], [\"July 2007\"], [\"June 2011\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"10-01831\"], [\"Fear of Recurrence Pilot Intervention for Women With Breast Cancer\"], [\"Interventional\"], [\"March 2011\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-11-9\"], [\"PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer\"], [\"Interventional\"], [\"November 22, 2013\"], [\"November 22, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI 18-79 [HS# 2020-5660]\"], [\"Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer\"], [\"Interventional\"], [\"July 23, 2020\"], [\"February 16, 2022\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-29691\"], [\"Molecular and Cellular Analysis of Breast Cancer\"], [\"Observational\"], [\"September 2014\"], [\"September 2024\"], [\"Suspended\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Minutes\"], []], [[\"CDR0000616135\"], [\"The Impact of Lymphedema on Breast Cancer Survivors\"], [\"Observational\"], [\"February 2007\"], [\"February 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"CDR0000465198\"], [\"Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery\"], [\"Interventional\"], [\"August 2004\"], [\"May 24, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"246600\"], [\"Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer\"], [\"Observational\"], [\"October 2008\"], [\"January 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"5BB-1801\"], [\"Alternative Support for Rural and Isolated Women in an HMO\"], [\"Interventional\"], [\"September 2000\"], [\"May 2002\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-15-6\"], [\"Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors\"], [\"Interventional\"], [\"March 8, 2019\"], [\"July 31, 2019\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCSF-067519\"], [\"Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients\"], [\"Interventional\"], [\"March 2007\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"16-001\"], [\"Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer\"], [\"Interventional\"], [\"February 23, 2016\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI 14-67 [HS# 2015-1888]\"], [\"Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab\"], [\"Interventional\"], [\"April 2015\"], [\"December 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"182113\"], [\"Improving Cognition After Cancer\"], [\"Interventional\"], [\"September 9, 2019\"], [\"February 1, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"40 Years\"], []], [[\"BRS0037\"], [\"Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors\"], [\"Interventional\"], [\"January 2014\"], [], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"CDR0000674337\"], [\"Monitoring and Predicting Chemotherapy Response Using DOSI\"], [\"Interventional\"], [\"June 2011\"], [\"October 6, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SU-03012010-5082\"], [\"Expanding Rural Access: Distance Delivery of Support Groups (Main Study)\"], [\"Interventional\"], [\"May 2008\"], [\"July 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"21 Years\"], []], [[\"IRB-17323\"], [\"Management of Insomnia in Breast Cancer Patients\"], [\"Interventional\"], [\"January 2011\"], [\"July 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"21 Years\"], []], [[\"HMH2015.002\"], [\"Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)\"], [\"Interventional\"], [\"August 2013\"], [\"December 30, 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PPHM 1401\"], [\"Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 2015\"], [\"June 2018\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BRS0039\"], [\"Dakin\\'s Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy\"], [\"Interventional\"], [\"July 2014\"], [\"July 7, 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CA025\"], [\"A Phase I/II Study of ABI-007 (Abraxane\\\\u00ae, Nab\\\\u00ae-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer\"], [\"Interventional\"], [\"August 2005\"], [\"February 2008\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16079\"], [\"Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer\"], [\"Interventional\"], [\"July 15, 2016\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08029\"], [\"Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer\"], [\"Interventional\"], [\"August 2008\"], [\"December 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"VI-ISRP-026\"], [\"A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes\"], [\"Interventional\"], [\"August 1, 2018\"], [\"March 1, 2020\"], [\"Suspended\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20-30638\"], [\"Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)\"], [\"Interventional\"], [\"February 1, 2022\"], [\"September 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"64 Years\"]], [[\"TCD11487\"], [\"A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer\"], [\"Interventional\"], [\"December 2008\"], [\"October 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI-HS-2007-5519\"], [\"Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)\"], [\"Interventional\"], [\"May 2007\"], [\"June 2008\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"85 Years\"]], [[\"JWCI OBCS WITH IORT\"], [\"Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.\"], [\"Interventional\"], [\"December 16, 2021\"], [\"February 2026\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"50 Years\"], []], [[\"BRS0031\"], [\"Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer\"], [\"Observational\"], [\"April 2015\"], [\"August 18, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"STOP-BC Trial\"], [\"Sulindac and Breast Density in Women at Risk of Developing Breast Cancer\"], [\"Interventional\"], [\"November 20, 2020\"], [\"February 2027\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"35 Years\"], [\"70 Years\"]], [[\"09021-02\"], [\"Health Benefits of Expressive Writing: Study One\"], [\"Interventional\"], [\"July 2009\"], [\"October 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"16-18737\"], [\"Nuevo Amanecer II: Translating a Stress Management Program for Latinas\"], [\"Interventional\"], [\"September 2016\"], [\"February 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000430705\"], [\"Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast\"], [\"Interventional\"], [\"November 2004\"], [], [\"Unknown status\"], [], [\"Female\"], [], [], []], [[\"147523\"], [\"Reversing Therapy Resistance With Epigenetic-Immune Modification\"], [\"Interventional\"], [\"May 4, 2015\"], [\"June 8, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000076422\"], [\"High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma\"], [\"Interventional\"], [\"December 1987\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2013-02225\"], [\"Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer\"], [\"Interventional\"], [\"December 2002\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCDCC#185\"], [\"Abraxane and Alimta in Advanced Solid Tumors\"], [\"Interventional\"], [\"April 2007\"], [\"October 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"P2100-SUR-S11\"], [\"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer\"], [\"Interventional\"], [\"September 10, 2021\"], [\"June 1, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"IRB-15005\"], [\"Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption\"], [\"Interventional\"], [\"April 2009\"], [\"April 2011\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"14036\"], [\"Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 1, 2014\"], [\"March 3, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-44367\"], [\"Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy\"], [\"Interventional\"], [\"August 1, 2018\"], [\"December 2022\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI 07-61 [HS# 2007-6084]\"], [\"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting\"], [\"Interventional\"], [\"February 2008\"], [\"July 2021\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], [\"90 Years\"]], [[\"GYNOVA0033\"], [\"Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer\"], [\"Interventional\"], [\"August 2016\"], [\"October 11, 2017\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SCP-1\"], [\"Reproductive Health Survivorship Care Plan Pilot\"], [\"Interventional\"], [\"March 20, 2014\"], [\"December 31, 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"45 Years\"]], [[\"LSB-12345\"], [\"Intraoperative Use of ClearEdge Device in Breast Conserving Surgery\"], [\"Interventional\"], [\"October 10, 2022\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000065692 (1B-97-2)\"], [\"Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer\"], [\"Interventional\"], [\"April 1997\"], [\"March 2000\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"12147\"], [\"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"July 17, 2013\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"19 Years\"], []], [[\"12-001 Single Fraction IORT\"], [\"Single Fraction Intraoperative Radiotherapy\"], [\"Interventional\"], [\"February 2012\"], [\"February 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"41 Years\"], [\"90 Years\"]], [[\"S11-00533\"], [\"Fresolimumab and Radiotherapy in Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2011\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NMCSD.2014.0053\"], [\"A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms\"], [\"Observational\"], [\"May 2015\"], [\"January 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"60 Years\"]], [[\"216529\"], [\"Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms\"], [\"Interventional\"], [\"March 2010\"], [\"March 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"10AB-2801\"], [\"Expanding Rural Access: Distance Delivery of Support\"], [\"Interventional\"], [\"November 2004\"], [\"June 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"21 Years\"], []], [[\"CP-18 100\"], [\"Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects\"], [\"Interventional\"], [\"May 2011\"], [\"April 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], [\"75 Years\"]], [[\"BRSADJ0020\"], [\"Acupuncture for Sleep Disruption in Cancer Survivors\"], [\"Interventional\"], [\"February 2011\"], [\"August 2012\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"1B-10-6\"], [\"Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer\"], [\"Interventional\"], [\"July 1, 2010\"], [\"December 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"30 Years\"], [\"75 Years\"]], [[\"Pro00043233\"], [\"A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 2016\"], [\"March 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"214750\"], [\"Evaluation of Breast CT\"], [\"Interventional\"], [\"November 22, 2004\"], [\"March 5, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"LAJ 08-8001\"], [\"Scripps Polster Breast Care Center Investigational GeneBank\"], [\"Observational\"], [\"July 2008\"], [\"June 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"30 Years\"], []], [[\"11130\"], [\"Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer\"], [\"Interventional\"], [\"June 2009\"], [\"May 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"CDR0000065828\"], [\"Diet and Estrogen Metabolism in Postmenopausal Women\"], [\"Interventional\"], [\"August 1997\"], [\"June 2004\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], [\"69 Years\"]], [[\"LUM-BC-1.0\"], [\"A Multicenter Breast Cancer Biospecimen Registry\"], [\"Observational\"], [\"February 2016\"], [], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"A112313\"], [\"Integrative Approaches for Cancer Survivorship\"], [\"Interventional\"], [\"January 2012\"], [\"October 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000616972\"], [\"Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)\"], [\"Observational\"], [\"October 1, 2008\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"L-503\"], [\"The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage\"], [\"Observational\"], [\"July 2011\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"025950\"], [\"Investigating the Impact of Tamoxifen Therapy on Ovarian Aging\"], [\"Observational\"], [\"June 2011\"], [\"March 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], []], [[\"BCA-003\"], [\"Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning\"], [\"Observational\"], [\"April 2008\"], [\"April 2011\"], [\"Unknown status\"], [], [\"Female\"], [], [\"21 Years\"], [\"50 Years\"]], [[\"18-001926\"], [\"Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors\"], [\"Interventional\"], [\"October 7, 2019\"], [\"June 1, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"800646\"], [\"Intervening on Women\\'s Health for Rural Young Breast Cancer Survivors\"], [\"Interventional\"], [\"October 15, 2021\"], [\"April 30, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"50 Years\"]], [[\"IIT2021-10-Giuliano-OmitRT\"], [\"Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response\"], [\"Interventional\"], [\"May 2022\"], [\"May 2028\"], [\"Not yet recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"40 Years\"], []], [[\"17-001864\"], [\"SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer\"], [\"Interventional\"], [\"April 7, 2019\"], [\"December 6, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20429001\"], [\"Central Obesity and Cancer Prevention for Chinese American Women\"], [\"Interventional\"], [\"October 16, 2019\"], [\"December 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"R01AT000486\"], [\"Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health\"], [\"Interventional\"], [\"May 2000\"], [\"January 2005\"], [\"Completed\"], [], [\"All\"], [], [], []], [[\"04140\"], [\"Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer\"], [\"Interventional\"], [\"June 2005\"], [\"August 2010\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000613050\"], [\"Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer\"], [\"Observational\"], [\"May 2007\"], [\"June 6, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], [\"80 Years\"]], [[\"CBCRP 23AB-1400\"], [\"Reducing Breast Cancer Risk in Korean American Women\"], [\"Interventional\"], [\"March 16, 2019\"], [\"December 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [\"Yes\"], [\"18 Years\"], []], [[\"Pro00009633\"], [\"Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment\"], [\"Observational\"], [\"September 2014\"], [\"September 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1B-14-6\"], [\"Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer\"], [\"Observational\"], [\"December 16, 2014\"], [\"August 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP101\"], [\"Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer\"], [\"Interventional\"], [], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"QUILT-3.013\"], [\"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer\"], [\"Interventional\"], [\"December 2016\"], [\"December 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-CTL\"], [\"Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors\"], [\"Interventional\"], [\"November 2010\"], [\"June 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"30 Years\"], [\"45 Years\"]], [[\"BMT42\"], [\"High Dose Chemotherapy and Autologous Transplant for Breast Cancer\"], [\"Interventional\"], [], [\"March 2005\"], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"CDR0000065380\"], [\"Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 1996\"], [\"November 2005\"], [\"Completed\"], [], [\"All\"], [], [], []], [[\"IRB-19595\"], [\"High Resolution 3D Diffusion-weighted Breast MRI\"], [\"Observational\"], [\"March 2011\"], [\"February 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-37161\"], [\"Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema\"], [\"Interventional\"], [\"July 20, 2016\"], [\"October 29, 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"P276-00/52/10\"], [\"A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin\"], [\"Interventional\"], [\"August 2011\"], [\"March 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRSADJ0023\"], [\"Phase I: At-Home Support for Rural Women Using Group Video Calling\"], [\"Interventional\"], [\"October 2012\"], [\"June 2014\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], []], [[\"STUDY00001356\"], [\"IIT2020-20-SHIRAZIP-WALK: Nature Walks\"], [\"Interventional\"], [\"June 21, 2021\"], [\"December 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"10005\"], [\"Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer\"], [\"Observational\"], [\"November 2010\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"99-11-084\"], [\"Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"July 2003\"], [\"November 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"11F.438\"], [\"Quantitative Subharmonic Breast Imaging\"], [\"Interventional\"], [\"November 2011\"], [\"April 5, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"18432\"], [\"Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease\"], [\"Interventional\"], [\"March 4, 2019\"], [\"July 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"PARW-OVCONS-0307\"], [\"Examining the Long-Term Risks of Oophorectomy\"], [\"Observational\"], [\"January 1980\"], [\"June 2004\"], [\"Completed\"], [], [\"Female\"], [], [\"30 Years\"], [\"55 Years\"]], [[\"IIT2018-01-McArthur-IPI\"], [\"Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer\"], [\"Interventional\"], [\"November 12, 2019\"], [\"June 2026\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CD07_TNBC\"], [\"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC\"], [\"Interventional\"], [\"April 22, 2019\"], [\"September 16, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"12751\"], [\"Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 12, 2012\"], [\"July 5, 2019\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"M10-265\"], [\"Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2008\"], [\"December 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT2019-14-SHIRAZIP-SWEAT\"], [\"Streaming Web-based Exercise At Home: A Pilot Study\"], [\"Interventional\"], [\"July 7, 2020\"], [\"March 30, 2023\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000617655\"], [\"Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast\"], [\"Interventional\"], [\"July 2009\"], [\"August 11, 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CDR0000594671\"], [\"Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery\"], [\"Interventional\"], [\"February 2008\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"TALES Trial\"], [\"Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial\"], [\"Interventional\"], [\"July 21, 2016\"], [\"January 31, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"50 Years\"]], [[\"NBI-3001-ST-0101\"], [\"Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer\"], [\"Interventional\"], [\"January 2002\"], [\"July 2008\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"HMH2015.001\"], [\"Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe\"], [\"Interventional\"], [\"March 2015\"], [\"September 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [], []], [[\"15754\"], [\"Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial\"], [\"Interventional\"], [\"March 13, 2017\"], [\"December 20, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"89 Years\"]], [[\"ROCHE-NP17787\"], [\"Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 2004\"], [\"December 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ACU-JOINT001\"], [\"Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain\"], [\"Interventional\"], [\"June 2015\"], [\"June 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"H 15430\"], [\"Neoadjuvant GW572016 to Treat Breast Cancer\"], [\"Interventional\"], [\"August 2004\"], [\"February 2012\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB-55153\"], [\"Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts\"], [\"Interventional\"], [\"April 28, 2021\"], [\"April 15, 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"EXPLLN21-01\"], [\"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG\"], [\"Interventional\"], [\"May 1, 2023\"], [\"March 1, 2025\"], [\"Not yet recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20152355\"], [\"Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI\"], [\"Interventional\"], [\"December 2015\"], [\"December 2019\"], [\"Withdrawn\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"80 Years\"]], [[\"228012\"], [\"Impact of Topical Tranexamic Acid in Breast Reconstruction\"], [\"Interventional\"], [\"March 30, 2023\"], [\"September 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCI 03-16 [HS# 2004-3681]\"], [\"Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women\"], [\"Interventional\"], [\"September 21, 2004\"], [\"December 12, 2018\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"48134\"], [\"Plant-based Diets and Risk of Cancer in the Adventist Health Study-2\"], [\"Observational\"], [\"February 1, 2002\"], [\"December 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"30 Years\"], []], [[\"DZ2019HE001\"], [\"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"September 21, 2020\"], [\"May 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-53132\"], [\"LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy\"], [\"Interventional\"], [\"September 10, 2021\"], [\"June 1, 2030\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"5160378\"], [\"Effect of Resveratrol on Serum IGF2 Among African American Women\"], [\"Interventional\"], [\"April 24, 2019\"], [\"June 30, 2024\"], [\"Suspended\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CBCRP 12BB-3900\"], [\"Telephone-Based Decision Support for Rural Patients\"], [\"Interventional\"], [\"October 2007\"], [\"June 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"KCT001\"], [\"Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study\"], [\"Interventional\"], [\"August 5, 2020\"], [\"May 28, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"11139\"], [\"Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 19, 2012\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"65 Years\"], []], [[\"1B-03-7\"], [\"A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)\"], [\"Interventional\"], [\"August 2006\"], [\"June 2008\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"16-000817\"], [\"Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)\"], [\"Interventional\"], [\"February 20, 2017\"], [\"February 1, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [], [\"49 Years\"]], [[\"EGF103892\"], [\"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.\"], [\"Interventional\"], [\"December 7, 2006\"], [\"September 12, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DCA Breast NSCLC\"], [\"Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)\"], [\"Interventional\"], [\"December 2009\"], [\"November 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-30470\"], [\"Brief Behavioral Intervention for Insomnia During Chemotherapy\"], [\"Interventional\"], [\"January 2015\"], [\"June 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"21 Years\"], []], [[\"BIOC-046\"], [\"A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide\"], [\"Observational\"], [\"September 7, 2022\"], [\"January 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"eFT508-0008\"], [\"A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC\"], [\"Interventional\"], [\"November 21, 2017\"], [\"January 22, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"090314\"], [\"Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade\"], [\"Observational\"], [\"July 2009\"], [\"November 2010\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [], []], [[\"IRB-06037\"], [\"Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy\"], [\"Interventional\"], [\"June 2008\"], [\"July 26, 2012\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-46373\"], [\"Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma\"], [\"Interventional\"], [\"March 22, 2019\"], [\"July 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"190311\"], [\"Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction\"], [\"Interventional\"], [\"October 20, 2022\"], [\"March 31, 2025\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"22 Years\"], [\"75 Years\"]], [[\"CDR0000522934\"], [\"Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer\"], [\"Interventional\"], [\"July 2006\"], [\"June 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"1K07CA181323-01A1\"], [\"Physical Activity and Neuropsychological Outcomes in a Cancer Population\"], [\"Interventional\"], [\"August 2014\"], [\"July 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], [\"85 Years\"]], [[\"DCIS Cryo\"], [\"Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ\"], [\"Interventional\"], [\"November 1, 2021\"], [\"November 1, 2026\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-06-9\"], [\"Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast\"], [\"Interventional\"], [\"October 2007\"], [\"November 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"18R5-002\"], [\"A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2013\"], [\"December 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"Pro00052823\"], [\"Tissue Expansion in Breast Reconstruction Without Drains\"], [\"Observational\"], [\"February 25, 2019\"], [\"October 2, 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"21 Years\"], []], [[\"2450-US-002\"], [\"Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 2010\"], [\"December 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"5170197\"], [\"Chemotherapy Induced Peripheral Neuropathy (CIPN)\"], [\"Interventional\"], [\"September 28, 2017\"], [\"September 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"OSU-15222\"], [\"Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer\"], [\"Interventional\"], [\"October 12, 2016\"], [\"December 11, 2021\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1B-09-12\"], [\"Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.\"], [\"Interventional\"], [\"December 2010\"], [\"October 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"MR2016-03\"], [\"A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer\"], [\"Observational\"], [\"March 1, 2017\"], [\"August 30, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"181367\"], [\"Physical Activity Intervention for Young Cancer Survivors\"], [\"Interventional\"], [\"September 1, 2019\"], [\"September 30, 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"OB0012018\"], [\"Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer\"], [\"Observational\"], [\"October 1, 2017\"], [\"May 1, 2022\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"NU 98B1\"], [\"Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer\"], [\"Interventional\"], [\"November 1998\"], [\"June 2005\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PEAK VP-00078\"], [\"PEAK PlasmaBlade\\\\u2122 4.0 Versus Traditional Electrosurgery in Lumpectomy\"], [\"Interventional\"], [\"July 2009\"], [\"February 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"2010-185\"], [\"Breast Health in Chinese American Women\"], [\"Interventional\"], [\"July 2010\"], [\"December 21, 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"42 Years\"], []], [[\"CH001\"], [\"Circadian Thermal Sensing to Detect Breast Disease\"], [\"Interventional\"], [\"June 2015\"], [\"February 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"DAMD17-03-1-067\"], [\"Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women\"], [\"Interventional\"], [\"September 2003\"], [\"September 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"SPI-POZ-203\"], [\"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies\"], [\"Interventional\"], [\"December 23, 2019\"], [\"March 29, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"HS-16-00483\"], [\"Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)\"], [\"Observational\"], [\"August 16, 2016\"], [\"April 29, 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"AD-13-5635\"], [\"Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers\"], [\"Interventional\"], [\"May 2013\"], [\"December 2017\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [], [\"85 Years\"]], [[\"KPSC IRB 11103\"], [\"Implementing Systematic Distress Screening in Breast Cancer\"], [\"Observational\"], [\"October 2, 2017\"], [\"November 30, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-50877\"], [\"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution\"], [\"Interventional\"], [\"January 2023\"], [\"December 2023\"], [\"Not yet recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2011-01-LEV\"], [\"An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging\"], [\"Interventional\"], [\"June 2011\"], [\"June 2012\"], [\"Unknown status\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"21051\"], [\"Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults\"], [\"Interventional\"], [\"August 24, 2021\"], [\"June 30, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"70 Years\"], []], [[\"2001-2192\"], [\"Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics\"], [\"Observational\"], [\"May 24, 2002\"], [\"December 19, 2013\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT2018-25-MITA-NEOBREADS\"], [\"NEOBREADS: Neoadjuvant Breast Diet Study\"], [\"Interventional\"], [\"March 21, 2019\"], [\"August 17, 2021\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"2000-1383\"], [\"Following the Use of Gel Prosethetics in Breast Reconstruction\"], [\"Observational\"], [\"February 1, 2001\"], [\"September 23, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"BRS0005\"], [\"SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants\"], [\"Observational\"], [\"June 2011\"], [\"September 23, 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08803\"], [\"Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy\"], [\"Interventional\"], [\"October 2008\"], [\"December 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2018-21-AMERSI-BREADS\"], [\"BREADS: Breast Adjuvant Diet Study\"], [\"Interventional\"], [\"February 4, 2020\"], [\"January 2024\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"GME Study\"], [\"Gene Expression, Meditative Movement, and Emotional Distress (GME)\"], [\"Interventional\"], [\"July 17, 2017\"], [\"February 15, 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"45 Years\"], []], [[\"17009\"], [\"Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients\"], [\"Interventional\"], [\"October 13, 2017\"], [\"October 1, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"0S-20-6\"], [\"Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy\"], [\"Observational\"], [\"December 18, 2020\"], [\"June 18, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"31801/1\"], [\"Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction\"], [\"Interventional\"], [\"September 2016\"], [\"March 2019\"], [\"Unknown status\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"LSB-01\"], [\"In Vitro Detection of Tissue Abnormality\"], [\"Interventional\"], [\"October 15, 2010\"], [\"January 9, 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"25 Years\"], [\"80 Years\"]], [[\"1B-22-2\"], [\"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors\"], [\"Interventional\"], [\"January 9, 2023\"], [\"January 9, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PROT002 - Test Plan 01 Rev A\"], [\"Blue Note Therapeutics Product BNT 103 Usability and User Engagement\"], [\"Interventional\"], [\"September 1, 2021\"], [\"December 31, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"35 Years\"], [\"55 Years\"]], [[\"MAP3BSS\"], [\"Effects of Exemestane on Bone Strength\"], [\"Observational\"], [\"April 2007\"], [\"June 2019\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"2008-0067\"], [\"Lynne Cohen Consortium Project: Multi-Center Database/Registry\"], [\"Observational\"], [\"July 2008\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UCSF-GC3-2021\"], [\"Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients\"], [\"Interventional\"], [\"April 18, 2017\"], [\"December 16, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"CA148791-01\"], [\"Reducing Breast Cancer Recurrence With Weight Loss\"], [\"Interventional\"], [\"May 2010\"], [\"February 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], []], [[\"ANG1005-EAP-01, EAP-02, EAP-03\"], [\"Expanded Access to ANG1005 for Individual Patients\"], [\"Expanded Access\"], [], [], [\"No longer available\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"STUDY00146320\"], [\"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens\"], [\"Interventional\"], [\"December 14, 2021\"], [\"January 31, 2026\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"45 Years\"], [\"60 Years\"]], [[\"NCI-2019-06461\"], [\"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"December 6, 2019\"], [\"June 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"217510\"], [\"Microbiome and Association With Implant Infections\"], [\"Interventional\"], [\"September 28, 2021\"], [\"December 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UPCC 25920\"], [\"Pilot Study of an NTproBNP Guided Strategy of Cardioprotection\"], [\"Interventional\"], [\"March 18, 2021\"], [\"June 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"03049\"], [\"Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2004\"], [\"August 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"HS-10-00455\"], [\"Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation\"], [\"Interventional\"], [\"January 2011\"], [\"December 2016\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"35 Years\"]], [[\"ANG-002\"], [\"Harvest of CTCs From MBC Patients Using the Parsortix\\\\u2122 PC1 System\"], [\"Observational\"], [\"March 29, 2018\"], [\"December 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"22 Years\"], []], [[\"17-000668\"], [\"Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery\"], [\"Interventional\"], [\"August 3, 2017\"], [\"February 1, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"19 Years\"], []], [[\"US-001\"], [\"SentiMag\\\\u00ae Intraoperative Comparison in Breast Cancer\"], [\"Interventional\"], [\"January 2015\"], [\"December 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GCO 15-1783\"], [\"Systematic Light Exposure for Fatigue in Breast Cancer Patients\"], [\"Interventional\"], [\"January 25, 2018\"], [\"April 30, 2022\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"MM-121-04-01-04\"], [\"A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers\"], [\"Interventional\"], [\"October 2010\"], [\"July 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DIG-001\"], [\"Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia\"], [\"Interventional\"], [\"July 2013\"], [\"December 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"TMENEO-100\"], [\"TME Neoadjuvant Breast Registry\"], [\"Observational\"], [\"July 2015\"], [\"July 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"15295\"], [\"Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 28, 2016\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"18112\"], [\"64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy\"], [\"Interventional\"], [\"November 3, 2021\"], [\"December 1, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IBCSG 25-02 / BIG 3-02\"], [\"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer\"], [\"Interventional\"], [\"November 3, 2003\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"DS8201-A-U302\"], [\"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]\"], [\"Interventional\"], [\"August 9, 2018\"], [\"April 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACOSOG-Z1071\"], [\"Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer\"], [\"Interventional\"], [\"July 2009\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20-275\"], [\"Testing a New Imaging Agent to Identify Cancer\"], [\"Interventional\"], [\"November 30, 2020\"], [\"November 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2018-05-ASHER-IMPROV2\"], [\"LOL: It\\'s All Improv After Cancer!\\\\u2122\"], [\"Interventional\"], [\"August 2, 2019\"], [\"July 2025\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP P-2\"], [\"Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women\"], [\"Interventional\"], [\"May 1999\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"IRB-11872\"], [\"Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples\"], [\"Observational\"], [\"August 2001\"], [\"January 2099\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"5150012\"], [\"Liposomal Bupivacaine in Implant Based Breast Reconstruction\"], [\"Interventional\"], [\"July 2015\"], [\"July 2017\"], [\"Terminated\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"0S-10-3\"], [\"Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer\"], [\"Interventional\"], [\"January 29, 2013\"], [\"January 29, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"19 Years\"], []], [[\"TORI B-03\"], [\"Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)\"], [\"Interventional\"], [\"June 2003\"], [\"January 2012\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"OUT-113-2005; 06140-01\"], [\"Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment\"], [\"Interventional\"], [\"October 2006\"], [\"June 2008\"], [\"Completed\"], [], [\"All\"], [], [\"21 Years\"], []], [[\"SDX-0103\"], [\"Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer\"], [\"Interventional\"], [\"August 26, 2022\"], [\"September 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACOSOG-Z11102\"], [\"Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer\"], [\"Interventional\"], [\"July 2012\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"PEM-06-01\"], [\"Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer\"], [\"Interventional\"], [\"September 2006\"], [\"March 2009\"], [\"Unknown status\"], [], [\"Female\"], [], [\"25 Years\"], []], [[\"ML18530\"], [\"XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer\"], [\"Interventional\"], [\"August 2005\"], [\"July 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"TRIO030\"], [\"A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide\"], [\"Interventional\"], [\"September 5, 2017\"], [\"March 13, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000069225\"], [\"S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer\"], [\"Interventional\"], [\"July 1998\"], [\"November 2003\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CALGB-70806\"], [\"Vitamin D and Breast Cancer Biomarkers in Female Patients\"], [\"Interventional\"], [\"October 2010\"], [\"December 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"55 Years\"]], [[\"MA32\"], [\"A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer\"], [\"Interventional\"], [\"June 25, 2010\"], [\"July 31, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"74 Years\"]], [[\"A011202\"], [\"Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy\"], [\"Interventional\"], [\"February 7, 2014\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"120BC201\"], [\"Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding\"], [\"Interventional\"], [\"November 2009\"], [\"October 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BrUOG-BR-211B\"], [\"Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer\"], [\"Interventional\"], [\"February 2008\"], [\"December 2015\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"19-188\"], [\"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial\"], [\"Interventional\"], [\"November 18, 2021\"], [\"July 31, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-31\"], [\"Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2\"], [\"Interventional\"], [\"February 2000\"], [\"November 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCCTG-N0434\"], [\"Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole\"], [\"Observational\"], [\"April 2006\"], [\"February 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A5481003\"], [\"Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"September 15, 2008\"], [\"December 20, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"dtectDx-Breast-001\"], [\"Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification\"], [\"Observational\"], [\"March 2013\"], [\"August 2014\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], [\"49 Years\"]], [[\"CELC-G-301\"], [\"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)\"], [\"Interventional\"], [\"September 30, 2022\"], [\"September 30, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALGB-40101\"], [\"Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer\"], [\"Interventional\"], [\"May 2002\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"DS8201-A-U201\"], [\"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)\"], [\"Interventional\"], [\"August 25, 2017\"], [\"September 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MAP3\"], [\"Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer\"], [\"Interventional\"], [\"February 11, 2004\"], [\"January 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"NSABP B-32\"], [\"Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"May 1999\"], [\"February 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"E7389-G000-399\"], [\"Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies\"], [\"Interventional\"], [\"August 2010\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BO25126\"], [\"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer\"], [\"Interventional\"], [\"November 8, 2011\"], [\"November 30, 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALGB-40105\"], [\"Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer\"], [\"Interventional\"], [\"February 2003\"], [\"January 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"NSABP B-30\"], [\"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes\"], [\"Interventional\"], [\"March 1999\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-39/RTOG 0413\"], [\"Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer\"], [\"Interventional\"], [\"March 2005\"], [\"August 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A6181068\"], [\"Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"August 2007\"], [\"June 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ACE-Breast-03\"], [\"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)\"], [\"Interventional\"], [\"April 5, 2021\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO28407\"], [\"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer\"], [\"Interventional\"], [\"January 31, 2014\"], [\"June 4, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP B-40\"], [\"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery\"], [\"Interventional\"], [\"November 2006\"], [\"March 2018\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"16338\"], [\"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer\"], [\"Interventional\"], [\"August 22, 2017\"], [\"June 24, 2029\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP B-42\"], [\"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer\"], [\"Interventional\"], [\"August 2006\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"DS8201-A-U305\"], [\"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)\"], [\"Interventional\"], [\"December 4, 2020\"], [\"December 31, 2030\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CCTG MA.39\"], [\"Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer\"], [\"Interventional\"], [\"May 30, 2018\"], [\"December 30, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"35 Years\"], []], [[\"CDR0000504319\"], [\"S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo\"], [\"Interventional\"], [\"October 2006\"], [\"July 11, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"E2108\"], [\"Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer\"], [\"Interventional\"], [\"February 8, 2011\"], [\"December 21, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CDR0000066135\"], [\"Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 1997\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"3144A2-3004 / B1891004\"], [\"Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer\"], [\"Interventional\"], [\"July 9, 2009\"], [\"October 4, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"V2011201\"], [\"Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 15, 2023\"], [\"May 26, 2024\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"C3441020\"], [\"Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer\"], [\"Interventional\"], [\"August 27, 2018\"], [\"September 23, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000063537\"], [\"Nutrition Intervention in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"April 1994\"], [\"December 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"48 Years\"], [\"78 Years\"]], [[\"CDR0000636131\"], [\"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"April 2010\"], [\"December 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A011502\"], [\"Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy\"], [\"Interventional\"], [\"December 8, 2016\"], [\"February 15, 2023\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"69 Years\"]], [[\"INCB 18424-268\"], [\"A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer\"], [\"Interventional\"], [\"May 2014\"], [\"January 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EGF105485\"], [\"Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer\"], [\"Interventional\"], [\"August 2006\"], [\"July 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CRAD001J2101\"], [\"Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2007\"], [\"March 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"DS8201-A-U301\"], [\"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]\"], [\"Interventional\"], [\"August 1, 2018\"], [\"September 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"06090\"], [\"TAC Versus TC for Adjuvant Breast Cancer\"], [\"Interventional\"], [\"May 29, 2007\"], [\"March 30, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"UCSD-980919\"], [\"Women\\'s Healthy Eating and Living Study\"], [\"Observational\"], [\"March 1995\"], [\"December 31, 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"IBCSG 24-02 / BIG 2-02\"], [\"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer\"], [\"Interventional\"], [\"December 17, 2003\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"CDR0000423180\"], [\"S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"August 2005\"], [\"August 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BO27938\"], [\"A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)\"], [\"Interventional\"], [\"April 3, 2013\"], [\"April 3, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"291\"], [\"BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)\"], [\"Interventional\"], [\"July 24, 2014\"], [\"November 30, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"CDR0000349337\"], [\"S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [\"October 1, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EGF30008\"], [\"Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 9, 2003\"], [\"March 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000069440\"], [\"S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"September 2002\"], [\"January 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011O12301C\"], [\"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer\"], [\"Interventional\"], [\"December 7, 2018\"], [\"May 29, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP-B-49\"], [\"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"April 2012\"], [\"November 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CTKI258A2202\"], [\"Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"July 2009\"], [\"March 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-33\"], [\"Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen\"], [\"Interventional\"], [\"May 2001\"], [\"February 2011\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000343619\"], [\"Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer\"], [\"Interventional\"], [\"July 2002\"], [\"August 22, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"NSABP B-36\"], [\"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"May 2004\"], [\"May 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"LIGAND-L1069-34\"], [\"Bexarotene in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 1998\"], [\"March 2003\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"PUMA-NER-6201\"], [\"An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide\"], [\"Interventional\"], [\"February 2015\"], [\"April 22, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IBCSG 48-14 / BIG 8-13\"], [\"Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer\"], [\"Interventional\"], [\"December 4, 2014\"], [\"December 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"42 Years\"]], [[\"WO42133\"], [\"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)\"], [\"Interventional\"], [\"September 4, 2020\"], [\"November 24, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"13892\"], [\"Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer\"], [\"Interventional\"], [\"August 6, 2008\"], [\"November 19, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000065813\"], [\"S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer\"], [\"Observational\"], [\"November 1997\"], [\"February 2001\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"EFC6089\"], [\"Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [\"September 2006\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000066563\"], [\"Combination Chemotherapy in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"August 1998\"], [], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CDR0000616008\"], [\"Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery\"], [\"Interventional\"], [\"April 2009\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"WO42633\"], [\"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy\"], [\"Interventional\"], [\"May 4, 2021\"], [\"October 26, 2034\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000068575\"], [\"S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 2001\"], [\"November 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCCTG-N093B\"], [\"Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2010\"], [\"September 3, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EFC11486\"], [\"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2009\"], [\"February 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"E3108\"], [\"Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer\"], [\"Interventional\"], [\"September 21, 2010\"], [\"May 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-302-02-01-01\"], [\"Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"March 2011\"], [\"January 2017\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SPI-POZ-201\"], [\"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 22, 2016\"], [\"March 11, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"A4061010\"], [\"AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2004\"], [\"November 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP-MGAH22-02\"], [\"Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer\"], [\"Interventional\"], [\"March 2013\"], [\"April 14, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ISB 1302-103\"], [\"Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 8, 2020\"], [\"July 24, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"E7389-A001-201\"], [\"A Study of E7389 in Advanced/Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"September 2004\"], [\"November 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-27\"], [\"Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed\"], [\"Interventional\"], [\"December 1995\"], [\"February 2010\"], [\"Completed\"], [], [\"Female\"], [], [], []], [[\"IIT2018-04-MCARTHUR-NEOHP\"], [\"Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab\"], [\"Interventional\"], [\"January 25, 2019\"], [\"July 2025\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO20289\"], [\"BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer\"], [\"Interventional\"], [\"December 2007\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACOSOG-Z0011\"], [\"Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer\"], [\"Interventional\"], [\"April 1999\"], [\"February 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CALGB-150007\"], [\"Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery\"], [\"Observational\"], [\"February 2002\"], [\"May 1, 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP BP-58\"], [\"Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer\"], [\"Interventional\"], [\"June 1998\"], [\"December 2002\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D081CC00006\"], [\"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer\"], [\"Interventional\"], [\"April 22, 2014\"], [\"May 28, 2029\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"ACOSOG-Z0010\"], [\"Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer\"], [\"Interventional\"], [\"April 1999\"], [\"July 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000065472\"], [\"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"May 1997\"], [\"March 2006\"], [\"Completed\"], [], [\"Female\"], [], [], []], [[\"TOC4129g\"], [\"A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 12, 2008\"], [\"November 23, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP FB-13\"], [\"Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer\"], [\"Interventional\"], [\"October 22, 2018\"], [\"January 30, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PVB Catheter Study\"], [\"Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks\"], [\"Interventional\"], [\"October 2010\"], [\"March 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A231701CD\"], [\"Increasing Patients\\' Engagement in Breast Cancer Surgery Decision-Making\"], [\"Interventional\"], [\"March 1, 2019\"], [\"December 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D967UC00001\"], [\"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)\"], [\"Interventional\"], [\"April 26, 2021\"], [\"December 30, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"D8480C00007\"], [\"AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.\"], [\"Interventional\"], [\"March 2007\"], [\"April 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"GO42784\"], [\"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician\\'s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)\"], [\"Interventional\"], [\"August 27, 2021\"], [\"November 21, 2033\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BTX-BCI-016-PRT\"], [\"Breast Cancer Index (BCI) Registry\"], [\"Observational\"], [\"April 14, 2021\"], [\"December 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"11-PIR-11\"], [\"The BEACON Study (Breast Cancer Outcomes With NKTR-102)\"], [\"Interventional\"], [\"December 2011\"], [\"June 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CALGB-49806\"], [\"Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer\"], [\"Interventional\"], [\"December 1999\"], [\"February 2002\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ORIN1001-001\"], [\"ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 25, 2019\"], [\"March 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP B-35\"], [\"Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy\"], [\"Interventional\"], [\"January 2003\"], [\"May 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"A5481008\"], [\"A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\"], [\"Interventional\"], [\"February 22, 2013\"], [\"August 26, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"3475-756\"], [\"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)\"], [\"Interventional\"], [\"December 27, 2018\"], [\"January 24, 2031\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20110148\"], [\"Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim\"], [\"Interventional\"], [\"January 17, 2013\"], [\"December 15, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"TDM4997g\"], [\"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician\\'s Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy\"], [\"Interventional\"], [\"September 2011\"], [\"August 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"06BR01\"], [\"Phase II Study in Patients With Operable Breast Cancer\"], [\"Interventional\"], [\"October 2006\"], [\"September 2009\"], [\"Unknown status\"], [], [\"Female\"], [], [\"21 Years\"], []], [[\"CZOL446E2352\"], [\"Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer\"], [\"Interventional\"], [\"February 2006\"], [\"July 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000068992\"], [\"Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2001\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"AFT-05\"], [\"PALbociclib CoLlaborative Adjuvant Study\"], [\"Interventional\"], [\"August 2015\"], [\"September 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000067353\"], [\"Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes\"], [\"Interventional\"], [\"October 1999\"], [], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CO-3810-025\"], [\"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 9, 2014\"], [\"January 18, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"9238IL/0048\"], [\"The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"August 2003\"], [\"September 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"32 Years\"], [\"91 Years\"]], [[\"CO40016\"], [\"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"January 6, 2018\"], [\"January 4, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TDM4652g\"], [\"A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 2009\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GE-280-401\"], [\"Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients\"], [\"Observational\"], [\"January 5, 2023\"], [\"October 2, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"99 Years\"]], [[\"A011401\"], [\"Breast Cancer WEight Loss Study (BWEL Study)\"], [\"Interventional\"], [\"August 2016\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"0001\"], [\"SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer\"], [\"Interventional\"], [\"May 5, 2017\"], [\"November 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"3144A1-202 / B1891013\"], [\"A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer\"], [\"Interventional\"], [\"April 4, 2007\"], [\"March 2, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"10663\"], [\"A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer\"], [\"Interventional\"], [\"May 2006\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLCL161A2201\"], [\"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer\"], [\"Interventional\"], [\"August 2012\"], [\"September 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000380937\"], [\"Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer\"], [\"Observational\"], [\"December 2004\"], [\"January 30, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"120 Years\"]], [[\"RTOG-1005\"], [\"Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery\"], [\"Interventional\"], [\"May 2011\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-44-I\"], [\"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab\"], [\"Interventional\"], [\"April 2008\"], [\"July 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NRG-BR007\"], [\"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)\"], [\"Interventional\"], [\"June 7, 2021\"], [\"July 2041\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"50 Years\"], [\"70 Years\"]], [[\"WO39391\"], [\"A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"August 2, 2018\"], [\"August 24, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALGB-49907\"], [\"Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer\"], [\"Interventional\"], [\"September 2001\"], [\"November 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"7962-012\"], [\"Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 1, 2009\"], [\"November 18, 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00504\"], [\"Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU\"], [\"Interventional\"], [\"November 2007\"], [\"October 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"OAM4861g\"], [\"Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer\"], [\"Interventional\"], [\"March 2011\"], [\"March 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000723653\"], [\"S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer\"], [\"Interventional\"], [\"May 2012\"], [\"February 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"NU 07B1\"], [\"Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"June 2007\"], [\"December 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"V3002401\"], [\"Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 12, 2021\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"CR004120\"], [\"A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"September 2004\"], [\"December 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20060359\"], [\"Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)\"], [\"Interventional\"], [\"June 2, 2010\"], [\"March 26, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"DS8201-A-U303\"], [\"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator\\'s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]\"], [\"Interventional\"], [\"December 27, 2018\"], [\"March 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP B-41\"], [\"A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer\"], [\"Interventional\"], [\"July 2007\"], [\"March 2017\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"673-201\"], [\"A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)\"], [\"Interventional\"], [\"December 13, 2013\"], [\"October 31, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO28509\"], [\"A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 6, 2013\"], [\"December 10, 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"E7389-G000-209\"], [\"A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer\"], [\"Interventional\"], [\"March 31, 2009\"], [\"April 30, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011G2301\"], [\"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer\"], [\"Interventional\"], [\"June 20, 2017\"], [\"March 9, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"S1207\"], [\"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer\"], [\"Interventional\"], [\"April 2013\"], [\"January 2030\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CRAD001J2301\"], [\"Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 10, 2009\"], [\"October 23, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A8641020\"], [\"A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations\"], [\"Interventional\"], [\"February 3, 2015\"], [\"January 14, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"Pro00045372\"], [\"LOL: It\\'s All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer\"], [\"Interventional\"], [\"November 30, 2016\"], [\"December 20, 2017\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000068630\"], [\"S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"May 2001\"], [\"February 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A8641016\"], [\"A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"November 4, 2013\"], [\"December 24, 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CALGB-79809\"], [\"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer\"], [\"Interventional\"], [\"December 2001\"], [\"February 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"RAD1901-308\"], [\"Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer\"], [\"Interventional\"], [\"May 10, 2019\"], [\"August 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SON-8184-1075\"], [\"Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2005\"], [\"September 2007\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000069030\"], [\"Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2001\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"BO22589\"], [\"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)\"], [\"Interventional\"], [\"July 31, 2010\"], [\"September 16, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D9268C00001\"], [\"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator\\'s Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)\"], [\"Interventional\"], [\"October 18, 2021\"], [\"August 15, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CRAD001Y2301\"], [\"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole\"], [\"Interventional\"], [\"June 3, 2009\"], [\"December 4, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A6181077\"], [\"Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer\"], [\"Interventional\"], [\"January 2006\"], [\"June 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"OPT-822-001\"], [\"Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects\"], [\"Interventional\"], [\"December 2011\"], [\"August 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"CDR0000334899\"], [\"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer\"], [\"Interventional\"], [\"November 2003\"], [\"January 2027\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15804\"], [\"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 23, 2016\"], [\"September 20, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SNDX-275-0602\"], [\"Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In\"], [\"Interventional\"], [\"May 2016\"], [\"March 10, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1033-011\"], [\"A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer\"], [\"Interventional\"], [\"December 2002\"], [\"May 2005\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"D3615C00001\"], [\"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer\"], [\"Interventional\"], [\"April 16, 2020\"], [\"June 7, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"3066A1-303\"], [\"Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer\"], [\"Interventional\"], [\"May 2004\"], [\"October 2006\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"EA1183\"], [\"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study\"], [\"Interventional\"], [\"April 2, 2020\"], [\"August 31, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"3144A2-3003 / B1891003\"], [\"Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"February 4, 2009\"], [\"June 3, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"3144A1-203 / B1891014\"], [\"A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer\"], [\"Interventional\"], [\"September 11, 2007\"], [\"February 7, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO21977\"], [\"A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2009\"], [\"September 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"05-055\"], [\"Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer\"], [\"Interventional\"], [\"June 2005\"], [\"May 2011\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"16058\"], [\"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"September 30, 2016\"], [\"September 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S1200\"], [\"S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer\"], [\"Interventional\"], [\"May 16, 2012\"], [\"July 1, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP14B014\"], [\"Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2010\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-121-02-02-10\"], [\"Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 15, 2017\"], [\"November 30, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"M12-914\"], [\"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer\"], [\"Interventional\"], [\"July 17, 2014\"], [\"January 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15342\"], [\"Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"December 2, 2016\"], [\"September 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"60 Years\"], []], [[\"BO41843\"], [\"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)\"], [\"Interventional\"], [\"October 9, 2020\"], [\"March 18, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000520348\"], [\"S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone\"], [\"Interventional\"], [\"March 2007\"], [\"January 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBKM120F2302\"], [\"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor\"], [\"Interventional\"], [\"August 7, 2012\"], [\"April 19, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A5481023\"], [\"Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)\"], [\"Interventional\"], [\"September 26, 2013\"], [\"September 28, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CBYL719X2402\"], [\"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments\"], [\"Interventional\"], [\"August 14, 2017\"], [\"July 17, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDX011-03\"], [\"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer\"], [\"Interventional\"], [\"July 2010\"], [\"November 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-302-02-02-03\"], [\"MM-302 Plus Trastuzumab vs. Chemotherapy of Physician\\'s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"July 2014\"], [\"June 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GDC4950g\"], [\"Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy\"], [\"Interventional\"], [\"October 2011\"], [\"April 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ACORN AC01B07\"], [\"1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy\"], [\"Interventional\"], [\"June 2007\"], [\"November 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EFC15935\"], [\"Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer\"], [\"Interventional\"], [\"October 14, 2020\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C015\"], [\"CPG 7909 Plus Herceptin\\\\u00ae In Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2002\"], [\"October 2003\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ML28257\"], [\"An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)\"], [\"Observational\"], [\"June 5, 2012\"], [\"November 16, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15417\"], [\"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer\"], [\"Interventional\"], [\"November 6, 2014\"], [\"September 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP B-46-I\"], [\"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"May 2009\"], [\"February 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"NCI-2009-00477\"], [\"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 15, 2008\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"17096\"], [\"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 4, 2015\"], [\"October 28, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"9238IL/0025\"], [\"A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"November 1998\"], [\"January 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"C4891001\"], [\"A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.\"], [\"Interventional\"], [\"March 3, 2023\"], [\"May 15, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBYL719C2301\"], [\"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.\"], [\"Interventional\"], [\"July 23, 2015\"], [\"June 8, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GS-US-586-6144\"], [\"Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"December 14, 2021\"], [\"January 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17395\"], [\"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer\"], [\"Interventional\"], [\"September 16, 2019\"], [\"March 23, 2023\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2017\"], [\"Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"July 2000\"], [\"October 2005\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"108919\"], [\"Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 7, 2008\"], [\"July 27, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"20060362\"], [\"QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 2008\"], [\"August 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CRAD001JUS226\"], [\"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"May 2014\"], [\"March 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"MM-121-02-02-07 (ARD11918)\"], [\"A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer\"], [\"Interventional\"], [\"August 2011\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"G1T28-213\"], [\"Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer\"], [\"Interventional\"], [\"November 22, 2021\"], [\"July 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-121-02-02-03 (ARD11588)\"], [\"Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer\"], [\"Interventional\"], [\"June 2010\"], [\"September 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"POL6326-009\"], [\"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 14, 2019\"], [\"March 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A6181094\"], [\"A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"November 2006\"], [\"August 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IMMU-132-05\"], [\"Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)\"], [\"Interventional\"], [\"November 7, 2017\"], [\"December 8, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"WO29522\"], [\"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)\"], [\"Interventional\"], [\"June 23, 2015\"], [\"August 31, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTMX-2009-002\"], [\"Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer\"], [\"Interventional\"], [\"December 29, 2020\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2008002\"], [\"A Clinical Study to Evaluate Somo\\\\u2022v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.\"], [\"Observational\"], [\"March 2009\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], []], [[\"TRIO 020\"], [\"Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone\"], [\"Interventional\"], [\"July 2014\"], [\"November 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1200.67\"], [\"Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases\"], [\"Interventional\"], [\"October 2011\"], [\"August 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EGF108916\"], [\"Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer\"], [\"Interventional\"], [\"November 2007\"], [\"March 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ARV-471-mBC-101\"], [\"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE\\\\u00ae) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 5, 2019\"], [\"February 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP B-59/GBG 96-GeparDouze\"], [\"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo\"], [\"Interventional\"], [\"December 19, 2017\"], [\"June 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000285698\"], [\"Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer\"], [\"Interventional\"], [\"February 2003\"], [\"August 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"BO28408\"], [\"A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer\"], [\"Interventional\"], [\"June 25, 2014\"], [\"May 29, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NeuVax\\\\u2122 PH3-01, BB-IND 009187\"], [\"Efficacy and Safety Study of NeuVax\\\\u2122 (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence\"], [\"Interventional\"], [\"November 2011\"], [\"September 21, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D931CC00001\"], [\"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer\"], [\"Interventional\"], [\"November 7, 2022\"], [\"December 7, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"SPI-GCF-302\"], [\"SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide\"], [\"Interventional\"], [\"May 10, 2017\"], [\"May 6, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EA1131\"], [\"Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy\"], [\"Interventional\"], [\"April 29, 2015\"], [\"March 29, 2031\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CR004645\"], [\"To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older\"], [\"Interventional\"], [\"April 2004\"], [\"December 2005\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"60 Years\"], []], [[\"D926XC00001\"], [\"A Study of Dato-DXd With or Without Durvalumab Versus Investigator\\'s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)\"], [\"Interventional\"], [\"November 28, 2022\"], [\"March 27, 2030\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"NCI-2011-02572\"], [\"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer\"], [\"Interventional\"], [\"January 6, 2011\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D9670C00001\"], [\"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator\\'s Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 24, 2020\"], [\"June 19, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"105 Years\"]], [[\"CDR0000065314\"], [\"S9630, Medroxyprogesterone in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"March 1997\"], [\"December 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CBKM120F2303\"], [\"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi\"], [\"Interventional\"], [\"October 3, 2012\"], [\"September 21, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SPI-GCF-301\"], [\"SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)\"], [\"Interventional\"], [\"January 19, 2016\"], [\"October 31, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDX011-04\"], [\"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer\"], [\"Interventional\"], [\"November 2013\"], [\"August 7, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA209-7FL\"], [\"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer\"], [\"Interventional\"], [\"November 20, 2019\"], [\"January 15, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IMMU-132-09\"], [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician\\'s Choice in Participants With HR+/HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 8, 2019\"], [\"October 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"G1T28-212\"], [\"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer\"], [\"Interventional\"], [\"November 19, 2021\"], [\"March 13, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CO42867\"], [\"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer\"], [\"Interventional\"], [\"June 20, 2021\"], [\"October 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D967RC00001\"], [\"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer\"], [\"Interventional\"], [\"October 25, 2021\"], [\"June 26, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"213831\"], [\"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease\"], [\"Interventional\"], [\"June 28, 2021\"], [\"August 28, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M12-895\"], [\"Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 23, 2012\"], [\"September 2, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NEO3-05\"], [\"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma\"], [\"Interventional\"], [\"April 2008\"], [\"July 2009\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGNTUC-016\"], [\"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer\"], [\"Interventional\"], [\"October 2, 2019\"], [\"April 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBYL719G12301\"], [\"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation\"], [\"Interventional\"], [\"July 16, 2020\"], [\"April 2, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO25632\"], [\"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 27, 2012\"], [\"November 21, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CO41101\"], [\"A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.\"], [\"Interventional\"], [\"November 25, 2019\"], [\"February 28, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"E7389-G000-301\"], [\"E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes\"], [\"Interventional\"], [\"September 20, 2006\"], [\"December 11, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ONT-380-206\"], [\"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer\"], [\"Interventional\"], [\"January 28, 2016\"], [\"August 11, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000064156\"], [\"Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer\"], [\"Interventional\"], [\"October 1995\"], [], [\"Completed\"], [], [\"Female\"], [], [], []], [[\"15805\"], [\"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"August 2015\"], [\"February 12, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"7339-009\"], [\"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)\"], [\"Interventional\"], [\"December 19, 2019\"], [\"January 26, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ANG1005-CLN-04\"], [\"ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases\"], [\"Interventional\"], [\"April 2014\"], [\"September 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2013-02228\"], [\"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"January 15, 2014\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S0812\"], [\"S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer\"], [\"Interventional\"], [\"November 1, 2011\"], [\"September 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"50 Years\"]], [[\"RTOG-9517\"], [\"Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer\"], [\"Interventional\"], [\"May 1997\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"CTKI258A2210\"], [\"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer\"], [\"Interventional\"], [\"April 2012\"], [\"April 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"17320\"], [\"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 14, 2019\"], [\"August 11, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SNDX-275-0301\"], [\"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"June 13, 2008\"], [\"November 26, 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A6191007\"], [\"Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 2006\"], [\"July 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"PCS-1402-10749\"], [\"Women Informed to Screen Depending on Measures of Risk (Wisdom Study)\"], [\"Interventional\"], [\"August 31, 2016\"], [\"March 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"74 Years\"]], [[\"SGNTUC-025\"], [\"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer\"], [\"Interventional\"], [\"December 1, 2020\"], [\"October 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1839US/0713\"], [\"Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2004\"], [\"May 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"AVENTIS-56976-TAX-311\"], [\"Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"August 1994\"], [\"June 2004\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ML18527\"], [\"A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 2005\"], [\"December 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"673-301\"], [\"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)\"], [\"Interventional\"], [\"October 14, 2013\"], [\"March 5, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"3160A2-201\"], [\"Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer\"], [\"Interventional\"], [\"May 2006\"], [\"February 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRE09-146\"], [\"PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations\"], [\"Interventional\"], [\"February 2010\"], [\"December 15, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EGF30001\"], [\"Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2004\"], [\"March 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"17384\"], [\"A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer\"], [\"Interventional\"], [\"May 10, 2021\"], [\"February 9, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1200.75\"], [\"LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment\"], [\"Interventional\"], [\"June 22, 2010\"], [\"July 6, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NRG-BR003\"], [\"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"July 2015\"], [\"November 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IPI-549-03\"], [\"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)\"], [\"Interventional\"], [\"December 17, 2019\"], [\"August 1, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ML43171\"], [\"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician\\'s Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)\"], [\"Interventional\"], [\"August 3, 2022\"], [\"March 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15450\"], [\"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain\"], [\"Interventional\"], [\"April 20, 2015\"], [\"November 8, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO29227\"], [\"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors\"], [\"Interventional\"], [\"August 19, 2014\"], [\"August 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP-00-0011\"], [\"Cryoablation of Small Breast Tumors in Early Stage Breast Cancer\"], [\"Interventional\"], [\"November 2013\"], [\"June 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"B2151009\"], [\"A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 14, 2016\"], [\"January 19, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"C31001\"], [\"Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 13, 2014\"], [\"June 29, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CALGB-369901\"], [\"Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer\"], [\"Observational\"], [\"August 2003\"], [\"December 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"CZOL446EUS32\"], [\"Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy\"], [\"Interventional\"], [\"September 2002\"], [\"January 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"CA163-115\"], [\"A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer\"], [\"Interventional\"], [\"March 2007\"], [\"November 2009\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D926PC00001\"], [\"A Study of Dato-DXd Versus Investigator\\'s Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)\"], [\"Interventional\"], [\"May 16, 2022\"], [\"December 3, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"V2000701\"], [\"Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 11, 2022\"], [\"January 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"CLEE011XUS29\"], [\"Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.\"], [\"Interventional\"], [\"June 14, 2016\"], [\"February 25, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP FB-5\"], [\"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer\"], [\"Interventional\"], [\"May 2007\"], [\"May 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"941466\"], [\"Assessing Breast Density\\'s Value in Imaging - A Comparative Effectiveness Study\"], [\"Observational\"], [\"September 2016\"], [\"February 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"89 Years\"]], [[\"CAL-03\"], [\"An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa\\\\u00ae) in Patients With Breast Cancer\"], [\"Interventional\"], [], [], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CO39611\"], [\"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer\"], [\"Interventional\"], [\"December 26, 2017\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A211801\"], [\"Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation\"], [\"Interventional\"], [\"February 23, 2022\"], [\"December 2033\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], [\"55 Years\"]], [[\"2014-0443\"], [\"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients\"], [\"Interventional\"], [\"October 2014\"], [\"December 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A4021004\"], [\"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"February 2007\"], [\"June 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"GS-US-592-6173\"], [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician\\'s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"July 25, 2022\"], [\"February 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GS-US-592-6238\"], [\"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician\\'s Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"July 20, 2022\"], [\"May 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2014-00746\"], [\"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic\"], [\"Interventional\"], [\"March 29, 2014\"], [\"October 28, 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LCMH-001\"], [\"Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer\"], [\"Interventional\"], [\"September 2008\"], [\"October 4, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], []], [[\"SMX 18001\"], [\"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation\"], [\"Interventional\"], [\"September 20, 2019\"], [\"February 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"NSABP MA.32.F\"], [\"Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32\"], [\"Observational\"], [\"July 2011\"], [\"September 2016\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"74 Years\"]], [[\"17471\"], [\"Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 14, 2018\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"70 Years\"], []], [[\"18459\"], [\"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer\"], [\"Interventional\"], [\"October 4, 2022\"], [\"March 15, 2032\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CR018286\"], [\"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy\"], [\"Interventional\"], [\"August 24, 2011\"], [\"August 8, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011F2301\"], [\"Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.\"], [\"Interventional\"], [\"June 9, 2015\"], [\"January 11, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGNLVA-002\"], [\"Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"February 27, 2018\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M14-011\"], [\"A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer\"], [\"Interventional\"], [\"April 2, 2014\"], [\"November 12, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"110264\"], [\"Treatment With Pazopanib for Neoadjuvant Breast Cancer\"], [\"Interventional\"], [\"July 2009\"], [\"April 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000068583\"], [\"Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2001\"], [\"March 2002\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"AL42478\"], [\"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic\"], [\"Expanded Access\"], [], [], [\"Approved for marketing\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RT-016\"], [\"Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer\"], [\"Interventional\"], [\"February 2004\"], [\"June 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"20060341\"], [\"Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients\"], [\"Interventional\"], [\"July 2007\"], [\"May 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A171601\"], [\"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 15, 2018\"], [\"August 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"70 Years\"], []], [[\"E7389-G000-305\"], [\"E7389 Versus Treatment of Physician\\'s Choice in Patients With Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2006\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A6181002\"], [\"A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.\"], [\"Interventional\"], [\"March 2004\"], [\"November 2005\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CRX100-001\"], [\"Study of CRX100 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"January 8, 2021\"], [\"March 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DARE\"], [\"DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"February 9, 2021\"], [\"December 15, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"TP2001-202\"], [\"APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)\"], [\"Interventional\"], [\"April 2008\"], [\"September 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CO40115\"], [\"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"April 2, 2018\"], [\"May 3, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000442919\"], [\"S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2005\"], [\"January 2007\"], [\"Withdrawn\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"EGF 20002\"], [\"Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.\"], [\"Interventional\"], [\"October 2002\"], [\"June 2005\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2012-02305\"], [\"Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2\"], [\"Interventional\"], [\"August 1999\"], [\"March 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S1202\"], [\"S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy\"], [\"Interventional\"], [\"May 15, 2013\"], [\"December 20, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"120 Years\"]], [[\"CZOL446EUS147\"], [\"Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"June 2010\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP-MGAH22-04\"], [\"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 24, 2015\"], [\"June 14, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2016-01595\"], [\"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer\"], [\"Interventional\"], [\"November 15, 2016\"], [\"May 31, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"G1T28-04\"], [\"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)\"], [\"Interventional\"], [\"February 2, 2017\"], [\"February 28, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000069347\"], [\"Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer\"], [\"Interventional\"], [\"August 2001\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"LCCC 9727\"], [\"High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 1997\"], [\"January 2003\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"65 Years\"]], [[\"CA180-261\"], [\"Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer\"], [\"Interventional\"], [\"February 2009\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Biomed 777-CLP-30\"], [\"The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer\"], [\"Interventional\"], [\"December 2004\"], [\"August 2006\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2018-01519\"], [\"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer\"], [\"Interventional\"], [\"September 12, 2018\"], [\"June 1, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"14392\"], [\"A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer\"], [\"Interventional\"], [\"November 2011\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-01073\"], [\"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery\"], [\"Interventional\"], [\"December 1, 2008\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2009-01172\"], [\"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery\"], [\"Interventional\"], [\"May 15, 2009\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALGB-70301\"], [\"Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer\"], [\"Observational\"], [\"October 2005\"], [\"June 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PT-304\"], [\"Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer\"], [\"Observational\"], [\"November 2009\"], [\"October 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08-PIR-05\"], [\"Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"October 2008\"], [\"January 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CRAD001C2222\"], [\"Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women\"], [\"Interventional\"], [\"March 2005\"], [\"April 2007\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00341\"], [\"Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery\"], [\"Interventional\"], [\"July 2007\"], [\"February 21, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"15362\"], [\"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"July 22, 2014\"], [\"January 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"9785-CL-1121\"], [\"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"August 28, 2014\"], [\"March 31, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00561\"], [\"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer\"], [\"Interventional\"], [\"November 2, 2007\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ABI-007-MBC-001\"], [\"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)\"], [\"Interventional\"], [\"September 26, 2013\"], [\"October 28, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"22339\"], [\"Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors\"], [\"Interventional\"], [\"June 6, 2023\"], [\"October 31, 2024\"], [\"Not yet recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A011801\"], [\"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial\"], [\"Interventional\"], [\"January 6, 2021\"], [\"May 2035\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D0819C00003\"], [\"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.\"], [\"Interventional\"], [\"March 27, 2014\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"16131\"], [\"Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"June 1, 2017\"], [\"January 28, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"12444\"], [\"Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"February 21, 2011\"], [\"October 20, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"STn-BR-105\"], [\"Safety and Immunological Response Rate Study of THERATOPE\\\\u00ae Vaccine in Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"August 2002\"], [\"August 2005\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"117515\"], [\"Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery\"], [\"Interventional\"], [\"May 18, 2012\"], [\"December 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], []], [[\"CDR0000068399\"], [\"Digital Mammography Screening Trial (ACRIN6652)\"], [\"Interventional\"], [\"October 2001\"], [\"June 30, 2005\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"120 Years\"]], [[\"18238\"], [\"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer\"], [\"Interventional\"], [\"March 11, 2022\"], [\"February 16, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"dtectDx-Breast-002\"], [\"Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol\"], [\"Observational\"], [\"March 2014\"], [], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], [\"75 Years\"]], [[\"16298\"], [\"Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 2, 2015\"], [\"August 13, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"AVF3694g\"], [\"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)\"], [\"Interventional\"], [\"December 2005\"], [\"December 2013\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000065011\"], [\"Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 1997\"], [], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"91466\"], [\"Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer\"], [\"Interventional\"], [\"April 2006\"], [\"November 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A011104\"], [\"MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer\"], [\"Interventional\"], [\"February 2014\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"11649\"], [\"Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 2008\"], [\"January 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CFEM345DUS59\"], [\"Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer\"], [\"Interventional\"], [\"March 2008\"], [\"June 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"CDR0000067956\"], [\"Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer\"], [\"Interventional\"], [\"July 2000\"], [\"August 2002\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CALGB-70305\"], [\"Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection\"], [\"Interventional\"], [\"June 2006\"], [\"June 15, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00665\"], [\"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer\"], [\"Interventional\"], [\"July 30, 2008\"], [\"October 15, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"09-009\"], [\"Evaluation of the Cook Biodesign\\\\u00ae Nipple Reconstruction Cylinder (NRC)\"], [\"Interventional\"], [\"September 2011\"], [\"April 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011A2301\"], [\"Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)\"], [\"Interventional\"], [\"December 17, 2013\"], [\"March 26, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"3475-522\"], [\"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)\"], [\"Interventional\"], [\"March 7, 2017\"], [\"September 30, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A6181099\"], [\"A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer\"], [\"Interventional\"], [\"February 2007\"], [\"June 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA163-046\"], [\"Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"September 2003\"], [\"March 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00475\"], [\"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive\"], [\"Interventional\"], [\"September 15, 2006\"], [\"July 2, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"155-CL-036\"], [\"A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 2009\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"10-008061\"], [\"Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction\"], [\"Interventional\"], [\"May 2011\"], [\"November 2013\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"3144A2-3005 / B1891005\"], [\"Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"August 21, 2009\"], [\"June 28, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"20-001275\"], [\"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"October 9, 2020\"], [\"September 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GS-US-595-6184\"], [\"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician\\'s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy\"], [\"Interventional\"], [\"December 12, 2022\"], [\"January 2031\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EGF104900\"], [\"Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2005\"], [\"October 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SGNLVA-001\"], [\"A Safety Study of SGN-LIV1A in Breast Cancer Patients\"], [\"Interventional\"], [\"October 22, 2013\"], [\"February 4, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2014-02409\"], [\"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"March 6, 2015\"], [\"May 25, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ARV-471-mBC-102\"], [\"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer\"], [\"Interventional\"], [\"September 8, 2022\"], [\"February 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"10112\"], [\"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 20, 2011\"], [\"February 22, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"60 Years\"], []], [[\"SMX 20-001\"], [\"Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation\"], [\"Interventional\"], [\"September 29, 2020\"], [\"February 10, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"0S-17-7\"], [\"Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer\"], [\"Interventional\"], [\"November 8, 2017\"], [\"December 31, 2018\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"VEG20007\"], [\"Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2006\"], [\"March 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"C31006\"], [\"Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy\"], [\"Interventional\"], [\"July 28, 2016\"], [\"November 25, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"NCI-2011-02623\"], [\"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer\"], [\"Interventional\"], [\"January 15, 2011\"], [\"March 7, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ONC-010\"], [\"EndoPredict\\\\u00ae Extended Endocrine Trial (EXET)\"], [\"Observational\"], [\"July 2, 2019\"], [\"March 31, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CRAD001Y2201\"], [\"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.\"], [\"Interventional\"], [\"February 26, 2013\"], [\"July 30, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2016-01130\"], [\"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer\"], [\"Interventional\"], [\"November 15, 2016\"], [\"August 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"WO40181\"], [\"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy\"], [\"Interventional\"], [\"September 6, 2018\"], [\"May 6, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"107CS-6\"], [\"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 25, 2018\"], [\"April 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI 2013-01-03\"], [\"Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy\"], [\"Interventional\"], [\"October 2015\"], [\"May 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PUMA-NER-1301\"], [\"A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting\"], [\"Interventional\"], [\"March 29, 2013\"], [\"December 9, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP-B-51\"], [\"Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery\"], [\"Interventional\"], [\"August 2013\"], [\"August 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011A2404\"], [\"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC\"], [\"Interventional\"], [\"November 30, 2016\"], [\"December 3, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AVI-014-P02\"], [\"Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia\"], [\"Interventional\"], [\"August 2007\"], [\"July 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00476\"], [\"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer\"], [\"Interventional\"], [\"October 13, 2008\"], [\"June 15, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17502\"], [\"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer\"], [\"Interventional\"], [\"December 10, 2019\"], [\"December 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011E2301\"], [\"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer\"], [\"Interventional\"], [\"November 20, 2014\"], [\"March 27, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"59 Years\"]], [[\"4703\"], [\"A Phase III Trial For Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2002\"], [\"November 2008\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"PMD-026-1-001\"], [\"Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"November 14, 2019\"], [\"March 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C4391002\"], [\"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors\"], [\"Interventional\"], [\"March 14, 2022\"], [\"December 30, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-01849\"], [\"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer\"], [\"Interventional\"], [\"May 19, 2000\"], [\"January 27, 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SGNTUC-028\"], [\"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer\"], [\"Interventional\"], [\"March 7, 2022\"], [\"June 30, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011X2107\"], [\"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer\"], [\"Interventional\"], [\"October 22, 2013\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NSABP FB-7\"], [\"Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer\"], [\"Interventional\"], [\"October 2010\"], [\"November 25, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000339812\"], [\"Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [], [\"Completed\"], [], [\"Female\"], [], [\"25 Years\"], []], [[\"09-040\"], [\"Study of Radiation Exposure and Bilateral Breast Cancer\"], [\"Observational\"], [\"May 2009\"], [\"May 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"54 Years\"]], [[\"S1703\"], [\"S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 16, 2018\"], [\"January 1, 2038\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-BR002\"], [\"Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival\"], [\"Interventional\"], [\"December 24, 2014\"], [\"December 20, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCCTG-N9431\"], [\"Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer\"], [\"Observational\"], [\"June 1996\"], [\"October 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"D8532C00001\"], [\"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease\"], [\"Interventional\"], [\"January 28, 2021\"], [\"February 1, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"15-102-14\"], [\"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician\\'s Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine\"], [\"Interventional\"], [\"November 2016\"], [\"July 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"3144A1-2206 / B1891017\"], [\"Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer\"], [\"Interventional\"], [\"December 9, 2008\"], [\"June 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VAR0033\"], [\"Immunobiology of Cancer\"], [\"Observational\"], [\"October 2008\"], [\"October 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2011-02585\"], [\"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"April 21, 2011\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACT16105\"], [\"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician\\'s Choice in Locally Advanced or Metastatic ER-positive Breast Cancer\"], [\"Interventional\"], [\"October 22, 2019\"], [\"September 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-01977\"], [\"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"July 26, 2012\"], [\"May 20, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA023\"], [\"Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 1, 2006\"], [\"March 1, 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"090214\"], [\"A Multi-Histology Phase II Study of 5-Fluoro-2\\'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)\"], [\"Interventional\"], [\"August 20, 2009\"], [\"April 11, 2019\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"S1501\"], [\"S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer\"], [\"Interventional\"], [\"September 15, 2017\"], [\"January 1, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20170770\"], [\"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer\"], [\"Interventional\"], [\"February 26, 2020\"], [\"January 14, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"91743\"], [\"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI\"], [\"Interventional\"], [\"February 2010\"], [\"January 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EGF103659\"], [\"EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer\"], [\"Expanded Access\"], [\"July 2006\"], [\"March 2015\"], [\"Approved for marketing\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"S2007\"], [\"Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases\"], [\"Interventional\"], [\"December 15, 2020\"], [\"December 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"213551\"], [\"A Phase III Trial of Niraparib Versus Physician\\'s Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients\"], [\"Interventional\"], [\"February 25, 2014\"], [\"October 26, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000617081\"], [\"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo\"], [\"Interventional\"], [\"September 2009\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"TDM4884g\"], [\"A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer\"], [\"Expanded Access\"], [\"May 2010\"], [], [\"No longer available\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"368255\"], [\"Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax\"], [\"Interventional\"], [\"May 21, 2013\"], [\"September 28, 2018\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"18175\"], [\"A Study of Imlunestrant, Investigator\\'s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\"], [\"Interventional\"], [\"October 4, 2021\"], [\"August 31, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20110147\"], [\"NOLAN: Naproxen or Loratadine and Neulasta\"], [\"Interventional\"], [\"November 1, 2012\"], [\"March 18, 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"NCI-2011-01379\"], [\"Veliparib With or Without Carboplatin in Treating Patients With Stage IV Breast Cancer\"], [\"Interventional\"], [\"June 30, 2010\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"111438\"], [\"Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 14, 2009\"], [\"March 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000065237\"], [\"SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial\"], [\"Observational\"], [\"February 1997\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"NCCTG-N00C9\"], [\"EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer\"], [\"Interventional\"], [\"December 2002\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2015-00383\"], [\"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy\"], [\"Interventional\"], [\"February 2, 2016\"], [\"April 4, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"999915030\"], [\"Self-Affirmation, Emotion, and Alcohol Consumption\"], [\"Observational\"], [\"November 19, 2014\"], [\"September 29, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"201209135\"], [\"Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer\"], [\"Interventional\"], [\"December 11, 2012\"], [\"March 11, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A011106\"], [\"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery\"], [\"Interventional\"], [\"December 13, 2013\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2015-01912\"], [\"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases\"], [\"Interventional\"], [\"July 7, 2016\"], [\"October 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SCUSF 0806\"], [\"Lisinopril or Coreg CR\\\\u00ae in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab\"], [\"Interventional\"], [\"March 2010\"], [\"November 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB 6110\"], [\"The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels\"], [\"Interventional\"], [\"January 2006\"], [\"March 2007\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"21 Years\"], []], [[\"CRAD001Y24135\"], [\"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"March 7, 2013\"], [\"January 13, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D8180C00034\"], [\"Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease\"], [\"Interventional\"], [\"February 2008\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D3614C00001\"], [\"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC\"], [\"Interventional\"], [\"June 25, 2019\"], [\"October 6, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"CDR0000069346\"], [\"Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer\"], [\"Interventional\"], [\"August 2001\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CD-ON-MEDI-573-1030\"], [\"Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 13, 2011\"], [\"June 28, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"CDR0000065241\"], [\"Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function\"], [\"Interventional\"], [\"December 1996\"], [], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"SPI-GCF-104\"], [\"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer\"], [\"Interventional\"], [\"March 11, 2020\"], [\"June 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"NUV-422-03\"], [\"Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC\"], [\"Interventional\"], [\"September 2022\"], [\"September 2026\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"WO29217\"], [\"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer\"], [\"Interventional\"], [\"July 14, 2014\"], [\"August 25, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-03778\"], [\"Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases\"], [\"Interventional\"], [\"January 2006\"], [\"March 14, 2019\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2019-06088\"], [\"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones\"], [\"Interventional\"], [\"December 27, 2019\"], [\"June 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SCO-120-19-22\"], [\"A Study in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"May 20, 2022\"], [\"January 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO16216\"], [\"A Study to Evaluate the Efficacy and Safety of Herceptin\\\\u00ae (Trastuzumab) in Combination With Arimidex\\\\u00ae (Anastrozole) an Aromatase Inhibitor Compared to Arimidex\\\\u00ae Alone in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2001\"], [\"October 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"GEN-602-CT-101\"], [\"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"March 1, 2019\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15419\"], [\"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread\"], [\"Interventional\"], [\"June 10, 2014\"], [\"October 22, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2017-01119\"], [\"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 12, 2019\"], [\"April 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NO16853\"], [\"A Study to Assess Capecitabine (Xeloda\\\\u00ae) in Patients With Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2003\"], [\"March 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CALGB-70604\"], [\"Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement\"], [\"Interventional\"], [\"March 2009\"], [\"January 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A5481082\"], [\"Palbociclib in Real World Practice\"], [\"Observational\"], [\"January 4, 2017\"], [\"October 1, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBYL719A2201\"], [\"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women\"], [\"Interventional\"], [\"March 11, 2014\"], [\"July 8, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2009-00284\"], [\"Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 31, 2008\"], [\"February 14, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI 06-46\"], [\"LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis\"], [\"Interventional\"], [\"March 2007\"], [\"August 2008\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"1200.11\"], [\"Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy\"], [\"Interventional\"], [\"September 2006\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"105-08-201\"], [\"Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall\"], [\"Interventional\"], [\"February 2013\"], [\"June 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SLN-USA-1\"], [\"Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes\"], [\"Interventional\"], [\"July 2015\"], [\"March 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"CDR0000449959\"], [\"T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors\"], [\"Interventional\"], [\"August 2005\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"NCI-2018-01581\"], [\"Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer\"], [\"Interventional\"], [\"December 14, 2018\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA163-048\"], [\"Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"November 2003\"], [\"March 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"EA1151\"], [\"Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer\"], [\"Interventional\"], [\"July 6, 2017\"], [\"December 31, 2030\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], [\"74 Years\"]], [[\"UCI 05-46\"], [\"Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab\"], [\"Interventional\"], [\"March 2006\"], [\"June 2010\"], [\"Terminated\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"WO43571\"], [\"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)\"], [\"Interventional\"], [\"July 4, 2022\"], [\"September 30, 2032\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CAAA504A12101\"], [\"Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress \\\\u03b1v\\\\u03b23 and \\\\u03b1v\\\\u03b25 Integrins.\"], [\"Interventional\"], [\"October 14, 2021\"], [\"November 10, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB-16617\"], [\"Stanford Accelerated Recovery Trial (START)\"], [\"Interventional\"], [\"May 2010\"], [\"July 2016\"], [\"Terminated\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"P0339 NBRST Registry\"], [\"NBRST: Prospective Neo-adjuvant REGISTRY Trial\"], [\"Observational\"], [\"July 2011\"], [\"January 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"3475-B49\"], [\"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)\"], [\"Interventional\"], [\"June 18, 2021\"], [\"July 21, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000066242\"], [\"MRI to Detect Breast Tumors in Women\"], [\"Interventional\"], [\"May 1998\"], [\"June 30, 2000\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"79 Years\"]], [[\"EGF106708\"], [\"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D\"], [\"Interventional\"], [\"May 16, 2007\"], [\"July 1, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTKI258A2128\"], [\"Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"December 2011\"], [\"July 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2009-00707\"], [\"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)\"], [\"Interventional\"], [\"April 7, 2006\"], [\"September 30, 2030\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"1839IL/0225\"], [\"Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study\"], [\"Interventional\"], [\"October 2003\"], [\"June 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"GYN0001\"], [\"Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program\"], [\"Observational\"], [\"January 2010\"], [\"July 2013\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ABI-007-ST-001\"], [\"Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 12, 2015\"], [\"September 12, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"OBI-822-011\"], [\"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC\"], [\"Interventional\"], [\"December 5, 2018\"], [\"December 30, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"H3B-6545-A001-101\"], [\"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"August 17, 2017\"], [\"October 1, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A221803\"], [\"Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy\"], [\"Interventional\"], [\"June 15, 2022\"], [\"December 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NEO3-09\"], [\"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes\"], [\"Interventional\"], [\"June 2010\"], [\"April 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011XUS10T\"], [\"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer\"], [\"Interventional\"], [\"February 2016\"], [\"April 2023\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"GLSI-21-01\"], [\"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects\"], [\"Interventional\"], [\"August 11, 2022\"], [\"December 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"PrE0102\"], [\"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI\"], [\"Interventional\"], [\"May 31, 2013\"], [\"September 12, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000066165\"], [\"Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors\"], [\"Interventional\"], [\"February 1998\"], [\"January 2001\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"A221702\"], [\"Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection\"], [\"Interventional\"], [\"May 31, 2019\"], [\"January 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S1222\"], [\"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 2014\"], [\"December 31, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CA048-001\"], [\"A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread\"], [\"Interventional\"], [\"September 22, 2020\"], [\"August 15, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"213363\"], [\"Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer\"], [\"Interventional\"], [\"April 15, 2016\"], [\"September 17, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"0S-17-5\"], [\"Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors\"], [\"Interventional\"], [\"August 17, 2017\"], [\"July 15, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1280-0022\"], [\"The XENERA\\\\u2122 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread\"], [\"Interventional\"], [\"November 28, 2018\"], [\"May 11, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"MC1835-ACCRU-BR-1701\"], [\"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery\"], [\"Interventional\"], [\"February 20, 2020\"], [\"January 15, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000069104\"], [\"Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 2001\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ODO-TE-B301\"], [\"Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC\"], [\"Interventional\"], [\"December 21, 2017\"], [\"June 28, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LPT109096\"], [\"Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.\"], [\"Interventional\"], [\"August 2007\"], [\"August 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"17237\"], [\"HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases\"], [\"Interventional\"], [\"August 31, 2018\"], [\"August 31, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"209514\"], [\"Pilot Study of Pancreatic Cancer Screening\"], [\"Observational\"], [\"January 20, 2022\"], [\"January 31, 2032\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"E7389-M001-218\"], [\"Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)\"], [\"Interventional\"], [\"August 28, 2015\"], [\"April 6, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTPR-0009\"], [\"Safety and Efficacy Study of the Xoft\\\\u00ae Axxent\\\\u00ae eBx\\\\u00ae IORT System\\\\u00ae\"], [\"Interventional\"], [\"May 8, 2012\"], [\"December 2029\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], []], [[\"18-27025\"], [\"SCOPE-Chinese Women Study\"], [\"Interventional\"], [\"July 20, 2020\"], [\"December 30, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SPI-GCF-12-201\"], [\"Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer\"], [\"Interventional\"], [\"March 25, 2013\"], [\"August 12, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16244\"], [\"Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer\"], [\"Expanded Access\"], [], [], [\"Approved for marketing\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-13-001\"], [\"MarginProbe 2.0 Data Collection Protocol\"], [\"Observational\"], [\"December 15, 2021\"], [\"December 31, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EGF105084\"], [\"Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer\"], [\"Interventional\"], [\"December 2, 2005\"], [\"March 15, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A211601\"], [\"Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502\"], [\"Observational\"], [\"August 1, 2018\"], [\"July 18, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"DAN-22220205\"], [\"A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2, 2022\"], [\"April 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLP0008\"], [\"Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients\"], [\"Interventional\"], [\"September 1, 2020\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SCRI BRE 145\"], [\"A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer\"], [\"Interventional\"], [\"December 2008\"], [\"November 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S0927\"], [\"S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec\\'v Hormone Thpy\"], [\"Interventional\"], [\"February 2012\"], [\"March 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"NCI-2019-02752\"], [\"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 21, 2019\"], [\"November 1, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16-304\"], [\"Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma\"], [\"Interventional\"], [\"April 1, 2018\"], [\"April 1, 2030\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"C3621001\"], [\"Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC\"], [\"Interventional\"], [\"November 27, 2018\"], [\"September 27, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ML29366\"], [\"A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy\"], [\"Interventional\"], [\"December 16, 2015\"], [\"December 29, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EZN-2208-03\"], [\"A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2009\"], [\"December 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"VEG108838\"], [\"Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer\"], [\"Interventional\"], [\"December 2007\"], [\"December 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"RTOG-9804\"], [\"Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ\"], [\"Interventional\"], [\"December 1999\"], [\"May 20, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"26 Years\"], [\"120 Years\"]], [[\"EA1181\"], [\"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy\"], [\"Interventional\"], [\"February 11, 2020\"], [\"December 31, 2038\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"960-CSP-USA_DenseBreasts_USS1\"], [\"A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts\"], [\"Interventional\"], [\"April 15, 2018\"], [\"April 30, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"70 Years\"]], [[\"NEPA-17-05\"], [\"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer\"], [\"Interventional\"], [\"March 16, 2018\"], [\"September 19, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"378-ONC-0030-184\"], [\"Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer\"], [\"Interventional\"], [\"November 2000\"], [\"August 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"A191901\"], [\"Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy\"], [\"Interventional\"], [\"February 15, 2021\"], [\"October 2025\"], [\"Suspended\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2015-00741\"], [\"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"November 6, 2015\"], [\"February 22, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"G1T48-01\"], [\"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer\"], [\"Interventional\"], [\"May 9, 2018\"], [\"September 29, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"CALGB-40903\"], [\"Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ\"], [\"Interventional\"], [\"February 2012\"], [\"January 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ML17771\"], [\"A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2004\"], [\"October 2004\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"S1904\"], [\"Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)\"], [\"Interventional\"], [\"September 1, 2020\"], [\"June 1, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"MM-111-01-100\"], [\"A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers\"], [\"Interventional\"], [\"June 2009\"], [\"March 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GS-US-350-1937\"], [\"GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer\"], [\"Interventional\"], [\"January 10, 2017\"], [\"July 19, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011AUS42\"], [\"A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\"], [\"Interventional\"], [\"June 7, 2017\"], [\"March 8, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TORI B-02\"], [\"Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)\"], [\"Interventional\"], [\"May 2005\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"15160\"], [\"Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities\"], [\"Interventional\"], [\"April 6, 2016\"], [\"October 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"OSNA-BC-001\"], [\"Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer\"], [\"Observational\"], [\"February 2007\"], [\"December 2008\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"RTOG 0517\"], [\"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer\"], [\"Interventional\"], [\"July 11, 2006\"], [\"February 27, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"114299\"], [\"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 5, 2011\"], [\"June 6, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ONCB-006-19F\"], [\"Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer\"], [\"Interventional\"], [\"April 19, 2023\"], [\"April 1, 2027\"], [\"Not yet recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"1505016201\"], [\"Trial to Compare Radiation Fibrosis With Five Versus Three Fractions\"], [\"Interventional\"], [\"July 2015\"], [\"July 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], [\"90 Years\"]], [[\"1407426\"], [\"Family History Study on Cancer Risk\"], [\"Interventional\"], [\"July 1, 2020\"], [\"August 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"25 Years\"], [\"75 Years\"]], [[\"PMT4979g\"], [\"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin\\'s Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer\"], [\"Interventional\"], [\"March 16, 2011\"], [\"June 25, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SVMC-ONC-222\"], [\"Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer\"], [\"Interventional\"], [\"April 1991\"], [\"June 2009\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"104603\"], [\"Excision Followed by Radiofrequency Ablation for Breast Cancer\"], [\"Interventional\"], [\"June 2010\"], [\"December 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], [\"100 Years\"]], [[\"NCI-2017-01921\"], [\"Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery\"], [\"Interventional\"], [\"October 31, 2018\"], [\"February 22, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"99000287\"], [\"Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs\"], [\"Observational\"], [\"July 2008\"], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"UCSD IIT 150729\"], [\"Histology-Independent Study of Palbociclib in Patients With Advanced Cancer\"], [\"Interventional\"], [\"July 1, 2018\"], [\"February 1, 2024\"], [\"Withdrawn\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"V0407\"], [\"Statins and Breast Cancer Biomarkers\"], [\"Interventional\"], [\"January 2005\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"35 Years\"], [\"55 Years\"]], [[\"BioDyn-15-003\"], [\"TR(ACE) Assay Clinical Specimen Study\"], [\"Observational\"], [\"September 2016\"], [\"April 2018\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"07-199\"], [\"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer\"], [\"Interventional\"], [\"October 2007\"], [\"August 30, 2022\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ICMBC-02\"], [\"Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial\"], [\"Interventional\"], [\"October 2014\"], [\"December 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"KD019-204\"], [\"Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 2014\"], [\"September 13, 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"LPT111111\"], [\"Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC\"], [\"Interventional\"], [\"July 2, 2008\"], [\"January 3, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRI-ROL-001\"], [\"Combination Study of SV-BR-1-GM With Retifanlimab\"], [\"Interventional\"], [\"March 16, 2018\"], [\"June 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"FLEX Registry\"], [\"MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles\"], [\"Observational\"], [\"April 28, 2017\"], [\"December 2037\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D0816R00012\"], [\"International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study\"], [\"Observational\"], [\"March 13, 2017\"], [\"May 20, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"229510\"], [\"Combination Therapy in Cancers With Mutations in DNA Repair Genes\"], [\"Interventional\"], [\"April 1, 2023\"], [\"December 31, 2027\"], [\"Not yet recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"LYT-100-2020-01\"], [\"LYT-100 in Healthy Volunteers and BCRL\"], [\"Interventional\"], [\"March 1, 2020\"], [\"September 9, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"NU 10C03\"], [\"Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer\"], [\"Interventional\"], [\"August 1, 2011\"], [\"January 20, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"18-124\"], [\"ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"August 22, 2018\"], [\"August 30, 2029\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"60 Years\"], []], [[\"PRO37771\"], [\"Benefits of Exercise Training in Women With Ischemic Syndrome\"], [\"Interventional\"], [\"January 2016\"], [\"October 2016\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"60 Years\"]], [[\"CBYL719H12301\"], [\"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss\"], [\"Interventional\"], [\"June 8, 2020\"], [\"June 19, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Biomed 777-CLP-29\"], [\"Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer\"], [\"Interventional\"], [\"June 2002\"], [\"January 2006\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CDR0000729174\"], [\"DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy\"], [\"Interventional\"], [\"August 27, 2012\"], [\"January 14, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EAZ171\"], [\"Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer\"], [\"Interventional\"], [\"June 27, 2019\"], [\"June 1, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"Wellderly Immune Antibodies\"], [\"Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort\"], [\"Observational\"], [\"June 2012\"], [\"May 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"90 Years\"], []], [[\"12-000493\"], [\"Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme\"], [\"Interventional\"], [\"December 7, 2012\"], [\"June 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A4581001\"], [\"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.\"], [\"Interventional\"], [\"February 2004\"], [\"July 2013\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011A2112C\"], [\"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.\"], [\"Interventional\"], [\"June 27, 2014\"], [\"October 26, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"07-022\"], [\"Bicalutamide in Treating Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 23, 2007\"], [\"June 24, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"112515\"], [\"Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone\"], [\"Interventional\"], [\"January 20, 2010\"], [\"March 30, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"A211102\"], [\"Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer\"], [\"Interventional\"], [\"February 1, 2015\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], [\"55 Years\"]], [[\"0C-07-3\"], [\"Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib\"], [\"Interventional\"], [\"March 2008\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IRB00041707\"], [\"Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil\"], [\"Interventional\"], [\"May 30, 2017\"], [\"July 29, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"NCI-2011-01472\"], [\"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy\"], [\"Interventional\"], [\"April 20, 2009\"], [\"May 19, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"19 Years\"], []], [[\"116911\"], [\"Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans\"], [\"Interventional\"], [\"May 2014\"], [\"February 2015\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"85 Years\"]], [[\"1808019498\"], [\"Converting HR+ Breast Cancer Into an Individualized Vaccine\"], [\"Interventional\"], [\"March 17, 2020\"], [\"December 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"90 Years\"]], [[\"19-031\"], [\"\\'ADVANCE\\' (A Pilot Trial)\"], [\"Interventional\"], [\"March 21, 2019\"], [\"March 21, 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"70 Years\"], []], [[\"OMS-I141 (KEYNOTE-890)\"], [\"Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC\"], [\"Interventional\"], [\"October 11, 2018\"], [\"August 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000066851\"], [\"MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer\"], [\"Interventional\"], [\"June 1999\"], [\"June 2002\"], [\"Completed\"], [], [\"Female\"], [], [\"25 Years\"], [\"120 Years\"]], [[\"NCI-2009-00702\"], [\"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy\"], [\"Interventional\"], [\"November 10, 2008\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D361DC00001\"], [\"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)\"], [\"Interventional\"], [\"May 10, 2021\"], [\"January 5, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"CDR0000538232\"], [\"Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children\"], [\"Observational\"], [\"September 2006\"], [\"October 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"097517\"], [\"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\"], [\"Interventional\"], [\"March 1, 2010\"], [\"December 2031\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"39855\"], [\"Microsurgical Breast Reconstruction & VTE\"], [\"Observational\"], [\"January 30, 2017\"], [\"December 15, 2017\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"90 Years\"]], [[\"SSC-311\"], [\"Adjunctive Efficacy Study Of The SoftScan\\\\u00ae Optical Breast Imaging System\"], [\"Observational\"], [\"November 2005\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"20 Years\"], [\"80 Years\"]], [[\"OIC-1UO-C001\"], [\"Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome\"], [\"Interventional\"], [\"April 2010\"], [\"September 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D9673C00007\"], [\"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"June 22, 2021\"], [\"February 9, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"2015-013-00US1\"], [\"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer\"], [\"Interventional\"], [\"November 10, 2017\"], [\"March 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"E4112\"], [\"MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ\"], [\"Interventional\"], [\"January 7, 2015\"], [\"November 2027\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRE007-12\"], [\"Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer\"], [\"Interventional\"], [\"February 2013\"], [\"January 2033\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"17-455\"], [\"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer\"], [\"Interventional\"], [\"June 21, 2018\"], [\"May 31, 2025\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"20-002000\"], [\"Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer\"], [\"Interventional\"], [\"April 8, 2021\"], [\"December 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA016\"], [\"Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"June 1, 2004\"], [\"October 1, 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB 4260\"], [\"Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women\"], [\"Observational\"], [\"January 1995\"], [\"December 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"40 Years\"], [\"60 Years\"]], [[\"CA163-100\"], [\"Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer\"], [\"Interventional\"], [\"October 2007\"], [\"December 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"TARGIT Boost\"], [\"A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.\"], [\"Interventional\"], [\"June 2013\"], [\"April 2022\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"HSC 07-4789\"], [\"The Healthy Elderly Longevity Cohort\"], [\"Observational\"], [\"August 2007\"], [\"January 2030\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"80 Years\"], []], [[\"SU-09112008-1298\"], [\"Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer\"], [\"Interventional\"], [], [], [\"Withdrawn\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"ARV-471-BC-201\"], [\"A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery\"], [\"Interventional\"], [\"February 15, 2023\"], [\"June 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"MA21\"], [\"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer\"], [\"Interventional\"], [\"December 4, 2000\"], [\"March 17, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"60 Years\"]], [[\"SO-BCA-003\"], [\"Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer\"], [\"Interventional\"], [\"March 9, 2017\"], [\"June 30, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D6997C00002\"], [\"Comparison of Fulvestrant (FASLODEX\\\\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.\"], [\"Interventional\"], [\"February 13, 2005\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], [\"130 Years\"]], [[\"13-559\"], [\"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer\"], [\"Interventional\"], [\"January 2014\"], [\"May 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"LCCC 0403\"], [\"Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 2005\"], [\"August 12, 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"ISI dV SP - NSM-01\"], [\"Robotic vs. Open NSM for Early Stage Breast Cancer\"], [\"Interventional\"], [\"April 2023\"], [\"December 2026\"], [\"Not yet recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"09-056\"], [\"Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer\"], [\"Observational\"], [\"July 2009\"], [\"July 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IPI-504-07\"], [\"Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer\"], [\"Interventional\"], [\"March 2009\"], [\"May 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000377698\"], [\"S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women\"], [\"Interventional\"], [\"November 2004\"], [\"July 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"147522\"], [\"A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 19, 2015\"], [\"January 31, 2021\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"13944\"], [\"Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients\"], [\"Interventional\"], [\"March 2011\"], [\"July 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PN-301-21\"], [\"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer\"], [\"Interventional\"], [\"February 28, 2022\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000069496\"], [\"Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer\"], [\"Interventional\"], [\"May 2002\"], [\"March 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EORTC-10085\"], [\"Male Breast Cancer: Understanding the Biology for Improved Patient Care\"], [\"Observational\"], [\"December 2010\"], [\"March 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"SCRI BRE 126\"], [\"Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2010\"], [\"September 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1040-000-002\"], [\"A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer\"], [\"Interventional\"], [\"January 2002\"], [\"May 2003\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CA180-059\"], [\"A Study of Dasatinib (BMS-354825) in Patients With Advanced \\'Triple-negative\\' Breast Cancer\"], [\"Interventional\"], [\"December 2006\"], [\"September 2008\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"F061229006\"], [\"Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer\"], [\"Interventional\"], [\"October 8, 2007\"], [\"March 31, 2022\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"19 Years\"], []], [[\"3144A1-2204 / B1891015\"], [\"Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 29, 2008\"], [\"June 7, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NOX66-005\"], [\"A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors\"], [\"Interventional\"], [\"October 25, 2021\"], [\"February 28, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CC#157521+167513\"], [\"Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease\"], [\"Interventional\"], [\"September 2, 2017\"], [\"September 30, 2023\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"AFT-38\"], [\"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 21, 2017\"], [\"March 31, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA180-088\"], [\"Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer\"], [\"Interventional\"], [\"December 2006\"], [\"May 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"D967JC00001\"], [\"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 28, 2020\"], [\"December 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AVB620-C-002\"], [\"Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery\"], [\"Interventional\"], [\"July 5, 2017\"], [\"November 18, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"A5481034\"], [\"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate\"], [\"Expanded Access\"], [], [], [\"No longer available\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"ARD11439\"], [\"Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen\"], [\"Interventional\"], [\"February 2010\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08218\"], [\"Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors\"], [\"Interventional\"], [\"September 2010\"], [\"December 11, 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"25 Years\"], []], [[\"0607-18 IUCRO-0154\"], [\"Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2007\"], [\"December 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MAP3B\"], [\"Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3\"], [\"Observational\"], [\"January 23, 2008\"], [\"January 10, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"35 Years\"], []], [[\"ARD11437\"], [\"Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer\"], [\"Interventional\"], [\"June 2010\"], [\"April 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PM1183-B-003-11\"], [\"A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer\"], [\"Interventional\"], [\"June 13, 2012\"], [\"October 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"STM01-102\"], [\"Trial of Myocet in Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2006\"], [], [\"Unknown status\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"11-344\"], [\"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases\"], [\"Interventional\"], [\"February 2012\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO28888\"], [\"A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)\"], [\"Interventional\"], [\"November 12, 2014\"], [\"March 13, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NRG-BR001\"], [\"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer\"], [\"Interventional\"], [\"August 2014\"], [\"May 20, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IMPACt\"], [\"Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry\"], [\"Observational\"], [\"November 2015\"], [\"August 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"REP0114\"], [\"A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"July 29, 2015\"], [\"March 23, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"21-159\"], [\"ATEMPT 2.0: Adjuvant T-DM1 vs TH\"], [\"Interventional\"], [\"June 16, 2021\"], [\"May 1, 2028\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"A231901CD\"], [\"Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions\"], [\"Interventional\"], [\"January 15, 2021\"], [\"January 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"ACOSOG-Z1072\"], [\"Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer\"], [\"Interventional\"], [\"September 2008\"], [], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A6181064\"], [\"Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"February 2007\"], [\"July 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NRG-BR005\"], [\"Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery\"], [\"Interventional\"], [\"April 13, 2017\"], [\"November 30, 2023\"], [\"Suspended\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RTOG 1014\"], [\"Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery\"], [\"Interventional\"], [\"June 2010\"], [\"May 20, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"SCRI BRE 154\"], [\"Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"July 2009\"], [\"July 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"09-03\"], [\"Multicenter Hologic Tomosynthesis Study\"], [\"Interventional\"], [\"September 2009\"], [\"January 2013\"], [\"Unknown status\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CAUY922A2101\"], [\"Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients\"], [\"Interventional\"], [\"July 2007\"], [\"April 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCSF CC#05591\"], [\"Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"February 2006\"], [\"December 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLBH589C2204\"], [\"A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab\"], [\"Interventional\"], [\"April 2008\"], [\"May 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"3160A6-2207\"], [\"Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer\"], [\"Interventional\"], [\"July 30, 2009\"], [\"May 31, 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"20140299\"], [\"Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases\"], [\"Interventional\"], [\"March 19, 2018\"], [\"December 3, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"10-005\"], [\"Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer\"], [\"Interventional\"], [\"April 2010\"], [\"July 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D5392C00050\"], [\"Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer\"], [\"Interventional\"], [\"April 2004\"], [\"October 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"55 Years\"], []], [[\"HALO Dx 001\"], [\"Phase I Human Analytics (HALO) Study\"], [\"Observational\"], [\"March 16, 2022\"], [\"March 2037\"], [\"Recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"45 Years\"], [\"90 Years\"]], [[\"NK-101\"], [\"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"January 18, 2018\"], [\"December 15, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA209-7A8\"], [\"A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer\"], [\"Interventional\"], [\"October 18, 2019\"], [\"July 27, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"OCOG-2007-LISA\"], [\"Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer\"], [\"Interventional\"], [\"August 2007\"], [\"June 2018\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"D699BC00001\"], [\"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.\"], [\"Interventional\"], [\"October 17, 2012\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"BRE 354\"], [\"A Study of U3-1402 in Subjects With Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 3, 2021\"], [\"November 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP FB-12\"], [\"Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling\"], [\"Interventional\"], [\"May 14, 2018\"], [\"October 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"B3271004\"], [\"A Study Of PF-05280014 Or Trastuzumab Plus Taxotere\\\\u00ae And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)\"], [\"Interventional\"], [\"September 23, 2014\"], [\"March 9, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"1602017205\"], [\"Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients\"], [\"Interventional\"], [\"July 2016\"], [\"April 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CA180-004\"], [\"Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer\"], [\"Interventional\"], [\"June 2007\"], [\"October 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"WO39392\"], [\"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer\"], [\"Interventional\"], [\"July 24, 2017\"], [\"September 26, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BGBC007\"], [\"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC\"], [\"Interventional\"], [\"July 26, 2017\"], [\"August 20, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LAE205INT3101\"], [\"Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer\"], [\"Interventional\"], [\"February 18, 2022\"], [\"December 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IBIO-301\"], [\"A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"March 18, 2018\"], [\"September 22, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CP-03-001\"], [\"MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery\"], [\"Interventional\"], [\"October 2008\"], [\"June 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"LOXO-PIK-21001\"], [\"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors\"], [\"Interventional\"], [\"May 11, 2022\"], [\"May 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UPCC 19115\"], [\"Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial\"], [\"Interventional\"], [\"February 2016\"], [\"November 2036\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"06-412\"], [\"Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response\"], [\"Interventional\"], [\"June 2007\"], [\"June 2017\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO29505\"], [\"A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer\"], [\"Interventional\"], [\"February 17, 2015\"], [\"August 2, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"17249\"], [\"A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body\"], [\"Interventional\"], [\"August 2, 2019\"], [\"May 14, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"KU36-44\"], [\"Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer\"], [\"Interventional\"], [\"June 15, 2007\"], [\"December 21, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"C0541001\"], [\"PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors\"], [\"Interventional\"], [\"November 1, 2017\"], [\"August 31, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D2270C00020\"], [\"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer\"], [\"Interventional\"], [\"December 7, 2015\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"130 Years\"]], [[\"MO27782\"], [\"A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer\"], [\"Interventional\"], [\"April 2012\"], [\"October 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16177\"], [\"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer\"], [\"Interventional\"], [\"November 14, 2016\"], [\"September 20, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 7839-204\"], [\"Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer\"], [\"Interventional\"], [\"October 2010\"], [\"October 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CR005143\"], [\"A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy\"], [\"Interventional\"], [\"March 2, 2006\"], [\"January 31, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"CRAD001W2301\"], [\"Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"October 2009\"], [\"June 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"REBACCCWFU-97202\"], [\"Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer\"], [\"Interventional\"], [\"August 27, 2004\"], [\"August 31, 2009\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"BRSNSTU0011\"], [\"Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample\"], [\"Observational\"], [\"October 2000\"], [\"April 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ZN-c5-001\"], [\"A Study of ZN-c5 in Subjects With Breast Cancer\"], [\"Interventional\"], [\"December 8, 2018\"], [\"December 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CO40151\"], [\"A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"February 13, 2018\"], [\"March 15, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"13-164 (ILC)\"], [\"Endocrine Response in Women With Invasive Lobular Breast Cancer\"], [\"Interventional\"], [\"September 30, 2015\"], [\"March 2023\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [], []], [[\"B2151002\"], [\"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)\"], [\"Interventional\"], [\"September 10, 2013\"], [\"January 8, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MCLA-128-CL02\"], [\"MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer\"], [\"Interventional\"], [\"January 15, 2018\"], [\"February 15, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"VAR0047\"], [\"Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2\"], [\"Observational\"], [\"October 2010\"], [\"December 2015\"], [\"Suspended\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBKM120F2202\"], [\"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation\"], [\"Interventional\"], [\"August 2012\"], [\"June 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"WO41554\"], [\"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 29, 2020\"], [\"September 19, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000374991\"], [\"Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer\"], [\"Interventional\"], [\"July 2004\"], [\"May 2008\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [], [\"44 Years\"]], [[\"E7389-M000-219\"], [\"Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)\"], [\"Interventional\"], [\"July 13, 2016\"], [\"August 16, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CL0006\"], [\"Intraoperative Detection of Residual Cancer in Breast Cancer\"], [\"Interventional\"], [\"February 6, 2018\"], [\"April 10, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"12228\"], [\"Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung\"], [\"Interventional\"], [\"July 2014\"], [], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TOL2506A\"], [\"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer\"], [\"Interventional\"], [\"July 1, 2021\"], [\"April 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"49 Years\"]], [[\"CDR0000594003\"], [\"Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02\"], [\"Interventional\"], [\"December 2007\"], [\"April 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"120 Years\"]], [[\"D8530C00002\"], [\"A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer\"], [\"Interventional\"], [\"April 22, 2020\"], [\"May 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"130 Years\"]], [[\"17-428\"], [\"Olaparib In Metastatic Breast Cancer\"], [\"Interventional\"], [\"April 1, 2018\"], [\"December 30, 2022\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"08007\"], [\"Ixabepilone + Carboplatin Metastatic Breast Cancer\"], [\"Interventional\"], [\"January 2010\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP FB-11\"], [\"A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer\"], [\"Interventional\"], [\"January 2015\"], [\"March 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CA191-011\"], [\"Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors\"], [\"Interventional\"], [\"December 31, 2010\"], [\"November 30, 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"E7389-G000-211\"], [\"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine\"], [\"Interventional\"], [\"October 2005\"], [\"September 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"849679\"], [\"RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)\"], [\"Interventional\"], [\"April 14, 2022\"], [\"February 1, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"11127\"], [\"The Hurria Older PatiEnts (HOPE) With Breast Cancer Study\"], [\"Observational\"], [\"September 9, 2011\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"65 Years\"], []], [[\"12345\"], [\"Primary Care Clinical Excellence Incentive Study\"], [\"Interventional\"], [\"November 1, 2019\"], [\"January 1, 2021\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000628769\"], [\"Optical Coherence Tomography in Tissue Samples From Women Undergoing Mastectomy for the Treatment or Prevention of Breast Ductal Intraepithelial Neoplasia\"], [\"Interventional\"], [\"November 2006\"], [\"March 2009\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"GO29642\"], [\"A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer\"], [\"Interventional\"], [\"December 29, 2014\"], [\"March 13, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"Biomed 777-CLP-32\"], [\"Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer\"], [\"Interventional\"], [\"November 2005\"], [\"June 2006\"], [\"Terminated\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"FOENIX-MBC2 TAS-120-201\"], [\"A Study of TAS-120 in Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 30, 2019\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1200.89\"], [\"Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer\"], [\"Interventional\"], [\"August 2011\"], [\"November 2014\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"Pro00019830\"], [\"The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function\"], [\"Observational\"], [\"September 2009\"], [\"January 2012\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA163-081\"], [\"Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)\"], [\"Interventional\"], [\"February 2004\"], [\"December 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"IIT2015-07-SHIAO-HIFIDELI\"], [\"Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis\"], [\"Observational\"], [\"August 21, 2016\"], [\"December 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBEZ235A2101\"], [\"A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer\"], [\"Interventional\"], [\"December 21, 2006\"], [\"January 8, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA163-132\"], [\"Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer\"], [\"Interventional\"], [\"May 2008\"], [\"August 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"15252\"], [\"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread\"], [\"Interventional\"], [\"March 10, 2014\"], [\"September 20, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"C3661001\"], [\"A Study of PF-06873600 in People With Cancer\"], [\"Interventional\"], [\"March 7, 2018\"], [\"November 28, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MCC-14662\"], [\"Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer\"], [\"Interventional\"], [\"February 2006\"], [\"August 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VICC BRE 1287\"], [\"GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer\"], [\"Interventional\"], [\"September 2013\"], [\"April 2015\"], [\"Terminated\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"201610\"], [\"Predicting Chronic Pain Following Breast Surgery\"], [\"Observational\"], [\"July 19, 2021\"], [\"December 31, 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"MC1831\"], [\"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"August 28, 2019\"], [\"April 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"MO27775\"], [\"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer\"], [\"Interventional\"], [\"February 17, 2012\"], [\"November 14, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"AURORA US\"], [\"Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer\"], [\"Observational\"], [\"September 16, 2019\"], [\"November 15, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"13-048\"], [\"T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)\"], [\"Interventional\"], [\"May 2013\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA163-131\"], [\"Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2008\"], [\"March 2010\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PREDAPT\"], [\"A Multicenter Cancer Biospecimen Collection Study\"], [\"Observational\"], [\"February 5, 2020\"], [\"February 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011A2207\"], [\"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer\"], [\"Interventional\"], [\"June 11, 2019\"], [\"December 30, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CZOL446EUS16\"], [\"Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions\"], [\"Interventional\"], [\"October 2001\"], [\"November 2002\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000460234\"], [\"Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance\"], [\"Observational\"], [\"October 2005\"], [\"March 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"78 Years\"]], [[\"NCI-2019-00048\"], [\"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer\"], [\"Interventional\"], [\"February 13, 2019\"], [\"February 19, 2022\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"29747\"], [\"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer\"], [\"Interventional\"], [\"December 6, 2018\"], [\"December 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"9061\"], [\"A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy\"], [\"Interventional\"], [\"June 2003\"], [\"December 2005\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"TCD11608\"], [\"A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis\"], [\"Interventional\"], [\"July 2010\"], [\"July 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"IRB-16-6815\"], [\"Quell Opioid Reduction and Pain Relief in Patients With Cancer\"], [\"Interventional\"], [\"July 2016\"], [\"October 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D8534C00001\"], [\"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)\"], [\"Interventional\"], [\"June 30, 2021\"], [\"November 26, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"NCI-2009-00266\"], [\"Phase II Study of Fluorine-18 3\\'-Deoxy-3\\'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer\"], [\"Interventional\"], [\"December 2008\"], [\"October 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MDX010-12\"], [\"Study of MDX-010 in Stage IV Breast Cancer\"], [\"Interventional\"], [\"May 2003\"], [\"February 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"CL0007\"], [\"Investigation of Novel Surgical Imaging for Tumor Excision\"], [\"Interventional\"], [\"November 4, 2019\"], [\"May 4, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CLEE011A2201\"], [\"A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)\"], [\"Interventional\"], [\"October 2013\"], [\"September 2014\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"AL-TNBC-01\"], [\"A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer\"], [\"Interventional\"], [\"August 14, 2020\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GRAIL-002\"], [\"The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types\"], [\"Observational\"], [\"February 28, 2017\"], [\"May 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"R01CA249419\"], [\"The Engaging Primary Care in Cancer Survivorship (EPICS) Study\"], [\"Interventional\"], [\"September 21, 2021\"], [\"May 31, 2025\"], [\"Enrolling by invitation\"], [\"Principal Investigator\"], [\"All\"], [], [\"21 Years\"], []], [[\"WO30085\"], [\"A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy\"], [\"Interventional\"], [\"September 26, 2016\"], [\"February 6, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MO42319\"], [\"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)\"], [\"Interventional\"], [\"June 7, 2021\"], [\"December 31, 2029\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACT16106\"], [\"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer\"], [\"Interventional\"], [\"February 4, 2020\"], [\"May 28, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1280.18\"], [\"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.\"], [\"Interventional\"], [\"May 4, 2017\"], [\"August 24, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"G1T28-208\"], [\"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)\"], [\"Interventional\"], [\"April 15, 2021\"], [\"October 25, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MO39196\"], [\"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)\"], [\"Interventional\"], [\"August 25, 2017\"], [\"January 17, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"91782\"], [\"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)\"], [\"Interventional\"], [\"May 2010\"], [\"January 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CZOL446E2105\"], [\"Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year\"], [\"Interventional\"], [\"November 2006\"], [\"November 2009\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"NCI-2012-02727\"], [\"Decitabine in Treating Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"December 2001\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ELA-0121\"], [\"Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer\"], [\"Interventional\"], [\"August 31, 2022\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TPR-0186\"], [\"Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer\"], [\"Interventional\"], [\"May 2008\"], [\"January 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"R21AT000348-01\"], [\"Massage Therapy for Cancer-Related Fatigue\"], [\"Interventional\"], [\"March 2001\"], [\"March 2004\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"16-032\"], [\"Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients\"], [\"Interventional\"], [\"June 3, 2016\"], [\"October 12, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"SYD985.002\"], [\"SYD985 vs. Physician\\'s Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"November 30, 2017\"], [\"December 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"NCI-2012-02938\"], [\"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"March 25, 2010\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"EGF103890\"], [\"Lapatinib and Bevacizumab for Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 27, 2007\"], [\"June 19, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"187519\"], [\"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer\"], [\"Interventional\"], [\"July 8, 2019\"], [\"July 30, 2023\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"ODO-TE-B201\"], [\"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC\"], [\"Interventional\"], [\"February 5, 2019\"], [\"June 11, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A221505\"], [\"Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer\"], [\"Interventional\"], [\"February 1, 2018\"], [\"August 2035\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"K5-101\"], [\"Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug\"], [\"Interventional\"], [\"September 2009\"], [\"May 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BT-CL-PGG-MEL/BCA-1621/MK3475\"], [\"Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer\"], [\"Interventional\"], [\"February 22, 2017\"], [\"December 31, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LPT111110\"], [\"Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects\"], [\"Interventional\"], [\"June 2008\"], [\"May 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"B7501001\"], [\"A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"June 2014\"], [\"July 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2019-05187\"], [\"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer\"], [\"Interventional\"], [\"November 20, 2019\"], [\"November 20, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"6133\"], [\"A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease\"], [\"Interventional\"], [\"March 2002\"], [\"July 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], []], [[\"ZWI-ZW25-202\"], [\"A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer\"], [\"Interventional\"], [\"June 10, 2020\"], [\"June 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RU011501I\"], [\"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer\"], [\"Interventional\"], [\"March 31, 2017\"], [\"July 31, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"URCC12048\"], [\"Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy\"], [\"Interventional\"], [\"February 3, 2014\"], [\"December 16, 2016\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"21 Years\"], []], [[\"99-037\"], [\"Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer\"], [\"Interventional\"], [\"July 1999\"], [\"March 2005\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"201973\"], [\"Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer\"], [\"Interventional\"], [\"February 2, 2017\"], [\"July 19, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"PCYC-1135-CA\"], [\"A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors\"], [\"Interventional\"], [\"March 2015\"], [\"August 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ARC-2 (AB928CSP0002)\"], [\"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies\"], [\"Interventional\"], [\"October 15, 2018\"], [\"July 2, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"3068A1-400\"], [\"Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density\"], [\"Observational\"], [\"October 2006\"], [\"April 2010\"], [\"Completed\"], [], [\"Female\"], [], [\"18 Years\"], [\"63 Years\"]], [[\"NCI-2016-01301\"], [\"Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer\"], [\"Interventional\"], [\"May 17, 2017\"], [\"July 1, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"2016-0142\"], [\"Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer\"], [\"Interventional\"], [\"February 23, 2017\"], [\"February 28, 2031\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"UAB 1794\"], [\"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD\"], [\"Interventional\"], [\"February 20, 2019\"], [\"July 22, 2024\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGNTUC-019\"], [\"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations\"], [\"Interventional\"], [\"January 11, 2021\"], [\"May 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GeneSearch BLN Assay PPC Study\"], [\"GeneSearch\\\\u2122 Breast Lymph Node (BLN) Assay Post Approval Study\"], [\"Observational\"], [\"December 2007\"], [\"December 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LA-EP06-302\"], [\"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim\"], [\"Interventional\"], [\"March 2012\"], [\"December 2013\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"08237\"], [\"Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer\"], [\"Interventional\"], [\"September 3, 2010\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"PB-2020-01\"], [\"ARGONAUT: Stool and Blood Sample Bank for Cancer Patients\"], [\"Observational\"], [\"July 1, 2022\"], [\"December 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D0816C00010\"], [\"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments\"], [\"Interventional\"], [\"February 6, 2015\"], [\"July 19, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"IRB-25970\"], [\"18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy\"], [\"Interventional\"], [\"March 4, 2013\"], [\"April 2019\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"0C-09-6\"], [\"Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors\"], [\"Interventional\"], [\"June 2010\"], [\"May 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SHRUS 1001\"], [\"Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors\"], [\"Interventional\"], [\"June 2015\"], [\"June 2021\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ACORN AEJSINS0601\"], [\"Treating Chronic Insomnia in Breast Cancer Patients\"], [\"Interventional\"], [\"August 2006\"], [\"January 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], [\"60 Years\"]], [[\"TAK-676-1003\"], [\"A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers\"], [\"Interventional\"], [\"September 9, 2021\"], [\"February 18, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1995563\"], [\"Measurements of Breast Tissue Optical Properties\"], [\"Observational\"], [\"December 1995\"], [\"July 2018\"], [\"Withdrawn\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"CADEX-0001\"], [\"Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer\"], [\"Observational\"], [\"March 1, 2019\"], [\"October 1, 2023\"], [\"Suspended\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"B9991025\"], [\"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors\"], [\"Interventional\"], [\"October 19, 2017\"], [\"January 4, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"14988\"], [\"PreView: The Preventive Video Education in Waiting Rooms Program\"], [\"Interventional\"], [\"July 2013\"], [\"March 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"50 Years\"], [\"70 Years\"]], [[\"CA209-9GW\"], [\"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread\"], [\"Interventional\"], [\"June 15, 2017\"], [\"July 6, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DMT-2015.001 ARM 1\"], [\"Delphinus SoftVue Prospective Case Collection - ARM 1\"], [\"Observational\"], [\"July 31, 2017\"], [\"July 31, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"DMT-2015.001 ARM 2\"], [\"Delphinus SoftVue Prospective Case Collection - ARM 2\"], [\"Observational\"], [\"December 6, 2016\"], [\"July 31, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"1-04\"], [\"Post Market Study Using the Xoft Axxent System\"], [\"Interventional\"], [\"March 26, 2007\"], [\"May 7, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"Pro20150001297\"], [\"Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery\"], [\"Interventional\"], [\"June 2015\"], [\"December 31, 2022\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"Female\"], [], [\"45 Years\"], []], [[\"1033IL/0039\"], [\"PROACT - Pre-Operative Arimidex Compared To Tamoxifen\"], [\"Interventional\"], [\"August 2000\"], [\"December 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"60 Years\"], []], [[\"IRB-31855\"], [\"18F-FSPG PET/CT for Cancer Patients on Therapy\"], [\"Interventional\"], [\"July 2015\"], [\"December 14, 2016\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"RU221408I\"], [\"Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel\"], [\"Interventional\"], [\"November 2014\"], [\"July 8, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SAN-BB-01\"], [\"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions\"], [\"Observational\"], [\"July 2013\"], [\"December 2040\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"110080\"], [\"Phase II ABT-888 With Cyclophosphamide\"], [\"Interventional\"], [\"January 12, 2011\"], [\"December 15, 2016\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBYL719X2101\"], [\"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene\"], [\"Interventional\"], [\"October 5, 2010\"], [\"April 16, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UMCC 2014.111\"], [\"The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)\"], [\"Interventional\"], [\"March 2015\"], [\"March 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], [\"69 Years\"]], [[\"20-028\"], [\"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)\"], [\"Interventional\"], [\"July 2, 2020\"], [\"December 30, 2025\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CUDC-907-102\"], [\"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors\"], [\"Interventional\"], [\"November 2014\"], [\"May 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"16 Years\"], []], [[\"CancerDyads\"], [\"Improving Survivorship Among Minority Cancer Dyads\"], [\"Interventional\"], [\"July 1, 2021\"], [\"December 31, 2024\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"09187\"], [\"Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload\"], [\"Interventional\"], [\"July 2010\"], [\"August 9, 2011\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VAR0053\"], [\"FNA Tumor Sampling for CD137 Modulation: A Pilot Study\"], [\"Observational\"], [\"March 2010\"], [\"January 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"CTP-0003 AirXpanders\"], [\"Patient Controlled Tissue Expansion for Breast Reconstruction\"], [\"Interventional\"], [\"October 2011\"], [\"August 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"BT5528-100\"], [\"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression\"], [\"Interventional\"], [\"November 7, 2019\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"6B-20-1\"], [\"18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases\"], [\"Interventional\"], [\"February 15, 2021\"], [\"February 15, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GeneSearch BLN Timing Study\"], [\"GeneSearch Breast Lymph Node (BLN) Assay Timing Study\"], [\"Observational\"], [\"December 2007\"], [\"December 2009\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"02-MX-003\"], [\"ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation\"], [\"Observational\"], [\"September 7, 2021\"], [\"February 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A2181002\"], [\"Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)\"], [\"Interventional\"], [\"November 2001\"], [\"December 2007\"], [\"Completed\"], [], [\"Female\"], [], [\"60 Years\"], [\"80 Years\"]], [[\"IRB00038639\"], [\"Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)\"], [\"Interventional\"], [\"February 1, 2014\"], [\"September 24, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], [\"100 Years\"]], [[\"D6900C00001\"], [\"First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies\"], [\"Interventional\"], [\"October 18, 2021\"], [\"June 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DS8201-A-U106\"], [\"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer\"], [\"Interventional\"], [\"February 10, 2020\"], [\"March 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DS8201-A-U105\"], [\"Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer\"], [\"Interventional\"], [\"June 20, 2018\"], [\"July 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PROT001\"], [\"Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment\"], [\"Interventional\"], [\"May 15, 2021\"], [\"September 1, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"GS-US-296-0101\"], [\"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 29, 2013\"], [\"April 23, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SY-5609-101\"], [\"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors\"], [\"Interventional\"], [\"January 23, 2020\"], [\"July 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"278100\"], [\"Tamoxifen-MRI Study\"], [\"Interventional\"], [\"September 2000\"], [\"July 2006\"], [\"Completed\"], [], [\"Female\"], [], [\"25 Years\"], [\"45 Years\"]], [[\"20430\"], [\"HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics\"], [\"Interventional\"], [\"December 30, 2021\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VAR0134\"], [\"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer\"], [\"Interventional\"], [\"August 8, 2017\"], [\"August 30, 2022\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"CMP-001-009\"], [\"A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer\"], [\"Interventional\"], [\"November 30, 2021\"], [\"March 7, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"14169\"], [\"Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening\"], [\"Interventional\"], [\"December 8, 2014\"], [\"September 6, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"55 Years\"], []], [[\"CTP-0005 AirXpanders\"], [\"AirXpanders AeroForm Tissue Expander System for Breast Reconstruction\"], [\"Interventional\"], [\"November 12, 2015\"], [\"September 26, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"7902-005\"], [\"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)\"], [\"Interventional\"], [\"February 12, 2019\"], [\"December 22, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLDE225X2114\"], [\"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"July 2012\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"0S-17-4\"], [\"Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer\"], [\"Observational\"], [\"August 30, 2018\"], [\"September 24, 2020\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO28289\"], [\"An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)\"], [\"Observational\"], [\"March 2012\"], [\"November 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2015-01097\"], [\"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors\"], [\"Interventional\"], [\"April 26, 2016\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PUMA-NER-5201\"], [\"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations\"], [\"Interventional\"], [\"September 30, 2013\"], [\"January 2, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000067052\"], [\"Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone\"], [\"Interventional\"], [\"August 1998\"], [\"January 2001\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EDO-S101-1002\"], [\"Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"October 6, 2017\"], [\"May 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO40933\"], [\"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.\"], [\"Interventional\"], [\"June 11, 2019\"], [\"January 4, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VAR0044\"], [\"Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors\"], [\"Interventional\"], [\"July 2009\"], [\"December 2011\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"19 Years\"], []], [[\"CYP003\"], [\"A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers\"], [\"Interventional\"], [\"February 2023\"], [\"February 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RTOG-9714\"], [\"Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer\"], [\"Interventional\"], [\"February 1998\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CR108208\"], [\"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies\"], [\"Interventional\"], [\"August 31, 2016\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"MM-121-05-01-05 (TCD11696)\"], [\"A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers\"], [\"Interventional\"], [\"October 2011\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M16-573\"], [\"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors\"], [\"Interventional\"], [\"July 13, 2018\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EMR 100070-001\"], [\"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)\"], [\"Interventional\"], [\"January 31, 2013\"], [\"December 16, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15025\"], [\"PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers\"], [\"Interventional\"], [\"July 7, 2015\"], [\"December 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"21 Years\"], []], [[\"XL184-021\"], [\"Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"September 5, 2017\"], [\"August 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SPI-POZ-501\"], [\"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib\"], [\"Interventional\"], [\"October 5, 2018\"], [\"April 5, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D4884C00001\"], [\"Study of Tremelimumab in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"November 2, 2015\"], [\"December 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"150 Years\"]], [[\"IMX-110-001\"], [\"IMX-110 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"February 15, 2018\"], [\"July 15, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"07-266\"], [\"The Active After Cancer Trial (AACT)\"], [\"Interventional\"], [\"October 2007\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"94098\"], [\"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer\"], [\"Interventional\"], [\"December 1994\"], [\"August 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"55 Years\"]], [[\"M16-074\"], [\"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"March 21, 2017\"], [\"April 13, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AREVAMED01\"], [\"Safety Study of \\\\u00b2\\\\u00b9\\\\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy\"], [\"Interventional\"], [\"July 2011\"], [\"July 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"19 Years\"], []], [[\"PROMIS\"], [\"PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score\"], [\"Observational\"], [\"May 2012\"], [\"December 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"90 Years\"]], [[\"CLEE011A2412B\"], [\"Roll-over Study to Allow Continued Access to Ribociclib\"], [\"Interventional\"], [\"July 7, 2022\"], [\"February 16, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DS1062-A-J101\"], [\"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)\"], [\"Interventional\"], [\"January 31, 2018\"], [\"January 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2020-013-00US3\"], [\"A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors\"], [\"Interventional\"], [\"August 9, 2021\"], [\"March 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"970652\"], [\"First-in-Human Positron Emission Tomography Study Using the 18F-\\\\u03b1v\\\\u03b26-Binding-Peptide\"], [\"Interventional\"], [\"November 2016\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"EA1141\"], [\"Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts\"], [\"Interventional\"], [\"December 27, 2016\"], [\"June 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"75 Years\"]], [[\"C4431001\"], [\"A Study of PF-07260437 in Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"October 7, 2021\"], [\"September 25, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1623168\"], [\"Healthy Moms: Prenatal Counseling for Postpartum Health\"], [\"Interventional\"], [\"February 1, 2021\"], [\"June 15, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"40 Years\"]], [[\"CDR0000355116\"], [\"Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation\"], [\"Interventional\"], [\"November 2003\"], [], [\"Completed\"], [], [\"All\"], [], [\"12 Years\"], [\"120 Years\"]], [[\"mRNA-2752-P101\"], [\"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies\"], [\"Interventional\"], [\"November 27, 2018\"], [\"April 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TRV-003\"], [\"Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance\"], [\"Observational\"], [\"July 15, 2022\"], [\"July 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"11-003 Mobetron\"], [\"Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)\"], [\"Interventional\"], [\"January 2011\"], [\"December 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"40 Years\"], []], [[\"19-000756\"], [\"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues\"], [\"Interventional\"], [\"November 5, 2019\"], [\"October 17, 2031\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000066283\"], [\"Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer\"], [\"Observational\"], [\"January 1998\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"N0574\"], [\"Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases\"], [\"Interventional\"], [\"July 2006\"], [\"December 15, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MTC-DOX-003\"], [\"Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver\"], [\"Interventional\"], [\"July 2001\"], [\"April 2003\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"0485-CL-0001\"], [\"Assessment and Tracking of Long-term Alefacept Safety\"], [\"Observational\"], [\"June 2003\"], [\"February 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CX-839-001\"], [\"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors\"], [\"Interventional\"], [\"February 2014\"], [\"March 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A221102\"], [\"Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment\"], [\"Interventional\"], [\"August 2013\"], [\"September 1, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"ARX788-1711\"], [\"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)\"], [\"Interventional\"], [\"March 20, 2018\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RTX-224-01\"], [\"RTX-224 Monotherapy in Patients With Solid Tumors\"], [\"Interventional\"], [\"January 12, 2022\"], [\"November 30, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"42674\"], [\"Effectiveness of Lay Navigators in Meeting Cancer Patients\\' Non-Clinical Needs: A Pilot Study\"], [\"Interventional\"], [\"February 15, 2017\"], [\"December 31, 2018\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"2005-0328\"], [\"Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer\"], [\"Interventional\"], [\"February 2006\"], [\"October 2008\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Cancer Pain Management\"], [\"Improving Cancer Pain Management Through Self-Care\"], [\"Interventional\"], [\"December 2007\"], [\"June 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"14238\"], [\"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer\"], [\"Interventional\"], [\"November 11, 2015\"], [\"September 11, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALGB-9871\"], [\"Docetaxel in Treating Patients With Solid Tumors\"], [\"Interventional\"], [\"September 1998\"], [\"January 2008\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PIONEER-01\"], [\"The PIONEER-01 Study of the Imagio Breast Imaging System\"], [\"Interventional\"], [\"December 21, 2012\"], [\"September 9, 2015\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"QUILT-2.025\"], [\"QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.\"], [\"Interventional\"], [\"August 10, 2018\"], [\"December 30, 2020\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TO-TAS0728-101\"], [\"A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities\"], [\"Interventional\"], [\"April 6, 2018\"], [\"June 9, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DCC-2036-01-004\"], [\"A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"January 2, 2019\"], [\"November 1, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"B7401001\"], [\"A Study Of PF-06664178 In Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"August 2014\"], [\"June 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TH1902-CTR-0001\"], [\"TH1902 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 4, 2021\"], [\"March 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2020-24-SHIRAZIP-BURN\"], [\"The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors\"], [\"Interventional\"], [\"January 10, 2022\"], [\"March 9, 2024\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"39 Years\"]], [[\"213409\"], [\"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study\"], [\"Interventional\"], [\"April 16, 2021\"], [\"November 13, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A00152-53\"], [\"Ultrasound Elastography of Breast Lesions\"], [\"Observational\"], [\"July 2008\"], [\"June 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"21 Years\"], []], [[\"IIT2020-13-GRESHAM-ELLY\"], [\"Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients\"], [\"Interventional\"], [\"December 2, 2020\"], [\"July 8, 2022\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"20-378\"], [\"Researching the Effect of Exercise on Cancer\"], [\"Interventional\"], [\"October 2, 2020\"], [\"October 2, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CRYO for Mastectomy (DoD)\"], [\"Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy\"], [\"Interventional\"], [\"September 15, 2022\"], [\"May 14, 2026\"], [\"Enrolling by invitation\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"15002\"], [\"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy\"], [\"Interventional\"], [\"June 14, 2016\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SY-1365-101\"], [\"A Study of SY-1365 in Adult Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"May 12, 2017\"], [\"June 24, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BA3021-001\"], [\"CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)\"], [\"Interventional\"], [\"June 27, 2018\"], [\"June 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"U01AT001653\"], [\"Women\\'s Isoflavone Soy Health (WISH) Trial\"], [\"Interventional\"], [\"March 2004\"], [\"March 2009\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"30 Years\"], []], [[\"D8488C00001\"], [\"Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer\"], [\"Interventional\"], [\"January 17, 2017\"], [\"March 16, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"CPDR001X2102\"], [\"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat\"], [\"Interventional\"], [\"October 14, 2016\"], [\"February 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MAPinitial\"], [\"UCLA Health Patient Health Maintenance Outreach Text Message\"], [\"Interventional\"], [\"March 9, 2023\"], [\"June 30, 2024\"], [\"Enrolling by invitation\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"PEDSVAR0038\"], [\"B-Receptor Signaling in Cardiomyopathy\"], [\"Observational\"], [\"November 2008\"], [\"October 2010\"], [\"Completed\"], [\"Sponsor-Investigator\"], [\"All\"], [], [], [\"40 Years\"]], [[\"213353\"], [\"Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer\"], [\"Interventional\"], [\"October 3, 2019\"], [\"January 12, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"IRB#13-6255\"], [\"Nonmyeloablative Allogeneic Transplant\"], [\"Interventional\"], [\"October 2001\"], [\"October 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"72 Years\"]], [[\"TPU-TAS-120-101\"], [\"A Study of TAS-120 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"July 2014\"], [\"June 30, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GS-US-382-1587\"], [\"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels\"], [\"Interventional\"], [\"August 19, 2022\"], [\"November 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GOG-8199\"], [\"Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer\"], [\"Observational\"], [\"June 7, 2010\"], [\"April 10, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"30 Years\"], []], [[\"KL264-01\"], [\"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies\"], [\"Interventional\"], [\"February 28, 2020\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"75 Years\"]], [[\"SLS17-201/MK3475-770\"], [\"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers\"], [\"Interventional\"], [\"June 28, 2019\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"K01CA190659\"], [\"Culturally Appropriate Nutrition Communication for Mexican American Women\"], [\"Interventional\"], [\"March 25, 2019\"], [\"December 25, 2022\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [\"Yes\"], [\"18 Years\"], [\"29 Years\"]], [[\"SGN228-001\"], [\"A Study of SGN-CD228A in Advanced Solid Tumors\"], [\"Interventional\"], [\"September 3, 2019\"], [\"March 9, 2023\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-398-01-01-02\"], [\"MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment\"], [\"Interventional\"], [\"November 2012\"], [\"October 2, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AMI-2008-01\"], [\"F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets\"], [\"Interventional\"], [\"January 2009\"], [\"June 2013\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TOS-358-001\"], [\"A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors\"], [\"Interventional\"], [\"February 15, 2023\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"S1008\"], [\"S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors\"], [\"Interventional\"], [\"March 2012\"], [\"January 2017\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], [\"120 Years\"]], [[\"PROT004\"], [\"Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer\"], [\"Interventional\"], [\"March 10, 2022\"], [\"December 15, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ITL-002-CRYO\"], [\"In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation\"], [\"Interventional\"], [\"August 2009\"], [\"May 2011\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"11-006682\"], [\"Assessing the Patient Experience in Cancer Care\"], [\"Observational\"], [\"May 2012\"], [\"September 2015\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"213356\"], [\"A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer\"], [\"Interventional\"], [\"June 21, 2013\"], [\"December 26, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"999912039\"], [\"Cancer Symptom Data From Multiple Treatment Centers\"], [\"Observational\"], [\"February 10, 2012\"], [\"May 23, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"AC480IV-001\"], [\"Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors\"], [\"Interventional\"], [\"November 2010\"], [\"June 2013\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IIT2021-07-Atkins-CARMA\"], [\"Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial\"], [\"Interventional\"], [\"October 7, 2022\"], [\"August 31, 2024\"], [\"Active, not recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"PRO1184-001\"], [\"PRO1184 for Advanced Solid Tumors\"], [\"Interventional\"], [\"December 7, 2022\"], [\"September 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ONC-392-001\"], [\"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC\"], [\"Interventional\"], [\"September 16, 2020\"], [\"December 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTL0211\"], [\"Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease\"], [\"Interventional\"], [\"July 2012\"], [\"March 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PRS-343-PCS_08_18\"], [\"PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors\"], [\"Interventional\"], [\"August 21, 2018\"], [\"July 1, 2021\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CT7001_001\"], [\"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies\"], [\"Interventional\"], [\"November 14, 2017\"], [\"December 15, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"R7075-ONC-2009\"], [\"REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"December 21, 2020\"], [\"April 1, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D8410C00001\"], [\"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies\"], [\"Interventional\"], [\"June 24, 2022\"], [\"December 8, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"CART-TnMUC1-01\"], [\"A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers\"], [\"Interventional\"], [\"October 10, 2019\"], [\"October 31, 2036\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA033\"], [\"A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma\"], [\"Interventional\"], [\"April 23, 2009\"], [\"February 12, 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C4551001\"], [\"Study of PF-07248144 in Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"November 16, 2020\"], [\"November 8, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"18232\"], [\"Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)\"], [\"Observational\"], [\"July 3, 2019\"], [\"March 31, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"S0702\"], [\"S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases\"], [\"Observational\"], [\"December 2008\"], [\"June 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], [\"120 Years\"]], [[\"MT-5111_001\"], [\"Study of MT-5111 in HER2-positive Solid Tumors\"], [\"Interventional\"], [\"November 12, 2019\"], [\"May 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BB-1701-101\"], [\"A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors\"], [\"Interventional\"], [\"July 28, 2020\"], [\"December 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"0S-13-1\"], [\"Cancer Genetics Hereditary Cancer Panel Testing\"], [\"Observational\"], [\"June 12, 2014\"], [\"January 5, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"D9720C00001\"], [\"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies\"], [\"Interventional\"], [\"November 12, 2020\"], [\"January 15, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"FPX-01-01\"], [\"A Phase 1/2 Study of [225Ac]-FPI-1434 Injection\"], [\"Interventional\"], [\"January 17, 2019\"], [\"June 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16-214-02\"], [\"A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors\"], [\"Interventional\"], [\"December 19, 2016\"], [\"April 28, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1454-001\"], [\"Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)\"], [\"Interventional\"], [\"February 3, 2017\"], [\"April 21, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2009-00042\"], [\"Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer\"], [\"Interventional\"], [\"April 2003\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2693-CL-0304\"], [\"A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause\"], [\"Interventional\"], [\"July 10, 2019\"], [\"January 4, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"65 Years\"]], [[\"ONCX-NAV-G201\"], [\"A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors\"], [\"Interventional\"], [\"August 5, 2022\"], [\"December 15, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"FT500-101\"], [\"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"February 15, 2019\"], [\"November 15, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2693-CL-0302\"], [\"A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2\"], [\"Interventional\"], [\"July 10, 2019\"], [\"April 23, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"65 Years\"]], [[\"CUDC-101-102\"], [\"A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors\"], [\"Interventional\"], [\"July 2010\"], [\"October 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Pro00046105\"], [\"Emerging From the Haze for Gynecologic Cancer Survivors\"], [\"Interventional\"], [\"January 10, 2017\"], [\"November 2017\"], [\"Completed\"], [\"Principal Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"DF1001-001\"], [\"Study of DF1001 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"November 11, 2019\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2693-CL-0301\"], [\"A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause\"], [\"Interventional\"], [\"July 11, 2019\"], [\"August 11, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"65 Years\"]], [[\"BPX603-201A\"], [\"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors\"], [\"Interventional\"], [\"December 7, 2020\"], [\"January 2, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"XL092-001\"], [\"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors\"], [\"Interventional\"], [\"March 20, 2019\"], [\"November 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 123667-101\"], [\"Study of INCB123667 in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"July 5, 2022\"], [\"July 30, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"ADCT-502-101\"], [\"Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression\"], [\"Interventional\"], [\"May 18, 2017\"], [\"April 5, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ZN-A-1041-101-US\"], [\"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors\"], [\"Interventional\"], [\"October 15, 2020\"], [\"November 30, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NEO3-06\"], [\"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma\"], [\"Interventional\"], [\"May 2009\"], [\"August 2013\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TAEK-VAC-HerBy-001\"], [\"TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer\"], [\"Interventional\"], [\"August 10, 2020\"], [\"June 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IPI-549-01\"], [\"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549\"], [\"Interventional\"], [\"December 2015\"], [\"December 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MORAb-202-G000-201\"], [\"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FR\\\\u03b1)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types\"], [\"Interventional\"], [\"August 6, 2020\"], [\"March 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"13517\"], [\"A Study of LY3023414 in Participants With Advanced Cancer\"], [\"Interventional\"], [\"July 31, 2012\"], [\"February 2, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M19-037\"], [\"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"May 21, 2019\"], [\"November 12, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17350\"], [\"Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel\"], [\"Interventional\"], [\"February 27, 2015\"], [\"April 18, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MER-XMT-2056-1\"], [\"A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2\"], [\"Interventional\"], [\"January 24, 2023\"], [\"November 2025\"], [\"Suspended\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"XmAb22841-01\"], [\"A Study of XmAb\\\\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors\"], [\"Interventional\"], [\"May 29, 2019\"], [\"February 16, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20190131\"], [\"Study of AMG 650 in Adult Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 11, 2020\"], [\"February 15, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"NUV-868-01\"], [\"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 29, 2022\"], [\"February 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MM-310-01-01-01\"], [\"A Study Evaluating MM-310 in Patients With Solid Tumors\"], [\"Interventional\"], [\"February 22, 2017\"], [\"December 2018\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16897\"], [\"Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)\"], [\"Interventional\"], [\"March 24, 2015\"], [\"July 27, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDX1127-06\"], [\"A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer\"], [\"Interventional\"], [\"October 2015\"], [\"May 22, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"FPA150-001\"], [\"FPA150 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 27, 2018\"], [\"May 10, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"3068A1-301\"], [\"Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women\"], [\"Interventional\"], [\"December 2001\"], [\"September 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"55 Years\"], [\"80 Years\"]], [[\"CBKM120B2101\"], [\"A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients\"], [\"Interventional\"], [\"April 2010\"], [\"November 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PY314-1-01\"], [\"A Study of PY314 in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"October 29, 2020\"], [\"October 28, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CALAA-01-ST-001\"], [\"Safety Study of CALAA-01 to Treat Solid Tumor Cancers\"], [\"Interventional\"], [\"May 2008\"], [\"September 2012\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"B7661001\"], [\"A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"October 17, 2014\"], [\"November 5, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CPI-006-001\"], [\"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers\"], [\"Interventional\"], [\"April 25, 2018\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCAGN 2385-101\"], [\"A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies\"], [\"Interventional\"], [\"June 18, 2018\"], [\"October 7, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCAGN 2390-101\"], [\"A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies\"], [\"Interventional\"], [\"September 24, 2018\"], [\"August 18, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"KB-0742-1001\"], [\"A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma\"], [\"Interventional\"], [\"February 8, 2021\"], [\"December 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"12 Years\"], []], [[\"D8532C00004\"], [\"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers\"], [\"Interventional\"], [\"June 13, 2022\"], [\"December 13, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"50 Years\"], [\"70 Years\"]], [[\"C34003\"], [\"A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"August 12, 2016\"], [\"November 30, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NP-G2-044-P1-01\"], [\"Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies\"], [\"Interventional\"], [\"December 21, 2017\"], [\"May 7, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"HMBD-002-V4C26-01\"], [\"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab\"], [\"Interventional\"], [\"January 1, 2022\"], [\"January 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M15-916\"], [\"A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)\"], [\"Interventional\"], [\"July 3, 2017\"], [\"November 27, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BPI-2358-105 Phase 2\"], [\"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2\"], [\"Interventional\"], [\"April 5, 2017\"], [\"April 20, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO39733\"], [\"A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors\"], [\"Interventional\"], [\"December 21, 2017\"], [\"September 29, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BP29842\"], [\"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)\"], [\"Interventional\"], [\"December 7, 2015\"], [\"November 10, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-CC004\"], [\"Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer\"], [\"Interventional\"], [\"May 31, 2017\"], [\"February 22, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"CR-TSC-001\"], [\"NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)\"], [\"Interventional\"], [\"September 2005\"], [\"December 12, 2007\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IA0132\"], [\"Cognition in the Study of Tamoxifen and Raloxifene\"], [\"Interventional\"], [\"October 2001\"], [\"March 2008\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"65 Years\"], []], [[\"S1714\"], [\"Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer\"], [\"Observational\"], [\"March 1, 2019\"], [\"February 28, 2026\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCAGN 1876-202\"], [\"INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies\"], [\"Interventional\"], [\"November 21, 2017\"], [\"July 1, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA-170-101\"], [\"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas\"], [\"Interventional\"], [\"May 2016\"], [\"May 7, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RXDX-101-02\"], [\"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\"], [\"Interventional\"], [\"November 19, 2015\"], [\"April 1, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BPI-2358-105 phase 3\"], [\"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3\"], [\"Interventional\"], [\"May 29, 2018\"], [\"February 8, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"XmAb20717-01\"], [\"A Study of XmAb\\\\u00ae20717 in Subjects With Selected Advanced Solid Tumors\"], [\"Interventional\"], [\"July 10, 2018\"], [\"September 6, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ARRAY-818-103\"], [\"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors\"], [\"Interventional\"], [\"January 2, 2018\"], [\"April 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AFT-25\"], [\"Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS\"], [\"Interventional\"], [\"February 22, 2017\"], [\"July 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"Female\"], [], [\"40 Years\"], [\"99 Years\"]], [[\"PRS-343-PCS_04_16\"], [\"PRS-343 in HER2-Positive Solid Tumors\"], [\"Interventional\"], [\"September 28, 2017\"], [\"October 7, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"A212102\"], [\"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection\"], [\"Observational\"], [\"August 1, 2022\"], [\"February 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"40 Years\"], [\"75 Years\"]], [[\"CRLX-001\"], [\"Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors\"], [\"Interventional\"], [\"May 2006\"], [\"April 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C016\"], [\"PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)\"], [\"Interventional\"], [\"September 2002\"], [\"June 2007\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"827486\"], [\"Pulmonary Hypertension and Anastrozole Trial\"], [\"Interventional\"], [\"December 7, 2017\"], [\"July 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2020-13883\"], [\"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\"], [\"Interventional\"], [\"March 5, 2021\"], [\"March 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 18424-270\"], [\"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib\"], [\"Interventional\"], [\"November 30, 2016\"], [\"December 31, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EMR 200066-006\"], [\"Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"May 2011\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"82 Years\"]], [[\"FT536-101\"], [\"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors\"], [\"Interventional\"], [\"May 31, 2022\"], [\"April 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TMPS-101\"], [\"Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors\"], [\"Interventional\"], [\"March 15, 2022\"], [\"July 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"06-103\"], [\"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma\"], [\"Interventional\"], [\"October 23, 2006\"], [\"October 26, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20140318\"], [\"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611\"], [\"Interventional\"], [\"February 5, 2016\"], [\"July 26, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16447\"], [\"Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients\"], [\"Interventional\"], [\"September 2013\"], [\"December 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CX-5461-04\"], [\"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation\"], [\"Interventional\"], [\"September 8, 2021\"], [\"June 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-BN009\"], [\"Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery\"], [\"Interventional\"], [\"December 15, 2020\"], [\"January 31, 2030\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"J0867\"], [\"Concentration and Activity of Lapatinib in Vestibular Schwannomas\"], [\"Interventional\"], [\"June 2009\"], [\"August 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"HBS701\"], [\"Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash\"], [\"Interventional\"], [\"April 3, 2008\"], [\"December 30, 2009\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D0816R00006\"], [\"Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer\"], [\"Observational\"], [\"April 21, 2015\"], [\"September 30, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"A9001502\"], [\"Treatment Resistance Following Anti-cancer Therapies\"], [\"Interventional\"], [\"February 13, 2019\"], [\"December 14, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"2018-01\"], [\"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors\"], [\"Observational\"], [\"August 23, 2018\"], [\"March 31, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-MGC018-01\"], [\"MGC018 With or Without MGA012 in Advanced Solid Tumors\"], [\"Interventional\"], [\"November 21, 2018\"], [\"June 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ORM-5029-01-001\"], [\"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors\"], [\"Interventional\"], [\"October 3, 2022\"], [\"October 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MER-XMT-1660-1\"], [\"A Study of XMT-1660 in Participants With Solid Tumors\"], [\"Interventional\"], [\"August 15, 2022\"], [\"January 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Minnelide 101\"], [\"A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide\\\\u2122 Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"October 10, 2017\"], [\"December 1, 2022\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 24360-202/ ECHO-202\"], [\"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers\"], [\"Interventional\"], [\"July 17, 2014\"], [\"November 6, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CA052-002\"], [\"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"May 27, 2021\"], [\"September 15, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"M15-394\"], [\"ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"September 18, 2015\"], [\"March 25, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DS8201-A-J101\"], [\"Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors\"], [\"Interventional\"], [\"September 2015\"], [\"September 30, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CYT-0851-01\"], [\"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors\"], [\"Interventional\"], [\"October 9, 2019\"], [\"December 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-01040\"], [\"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction\"], [\"Interventional\"], [\"June 12, 2012\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTAP101-CL-1017\"], [\"Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid\"], [\"Interventional\"], [\"December 2014\"], [\"March 17, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DCL-10-001\"], [\"Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned\"], [\"Interventional\"], [\"December 2011\"], [\"January 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TTX-080-001\"], [\"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers\"], [\"Interventional\"], [\"July 14, 2020\"], [\"June 1, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGNSTNV-001\"], [\"A Study of SGN-STNV in Advanced Solid Tumors\"], [\"Interventional\"], [\"January 18, 2021\"], [\"March 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ATRC-101-A01\"], [\"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies\"], [\"Interventional\"], [\"February 11, 2020\"], [\"March 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D5330C00004\"], [\"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents\"], [\"Interventional\"], [\"October 31, 2014\"], [\"November 26, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"CLGK974X2101\"], [\"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands\"], [\"Interventional\"], [\"December 1, 2011\"], [\"November 23, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AGS-22M6E-11-1\"], [\"A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4\"], [\"Interventional\"], [\"June 2011\"], [\"April 2015\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TT420X1103\"], [\"Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"July 14, 2021\"], [\"December 1, 2022\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"AMC-078\"], [\"Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection\"], [\"Interventional\"], [\"November 2013\"], [\"December 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-MGA271-01\"], [\"Safety Study of MGA271 in Refractory Cancer\"], [\"Interventional\"], [\"July 2011\"], [\"April 18, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGNTGT-001\"], [\"A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer\"], [\"Interventional\"], [\"May 29, 2020\"], [\"April 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-MGD013-01\"], [\"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms\"], [\"Interventional\"], [\"August 18, 2017\"], [\"February 8, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"FPI-1966-101\"], [\"A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours\"], [\"Interventional\"], [\"April 20, 2022\"], [\"December 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SM08502-ONC-01\"], [\"A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"November 6, 2017\"], [\"December 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2015-00054\"], [\"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\"], [\"Interventional\"], [\"August 12, 2015\"], [\"December 31, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TESTW007\"], [\"Safety and Efficacy of LibiGel\\\\u00ae for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women\"], [\"Interventional\"], [\"January 2008\"], [\"December 2012\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"50 Years\"], []], [[\"CALGB-70501\"], [\"Collection of Patient-Reported Symptoms and Performance Status Via the Internet\"], [\"Interventional\"], [\"December 2006\"], [\"June 1, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BM010\"], [\"ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain\"], [\"Interventional\"], [\"September 2009\"], [\"November 14, 2016\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EAQ202\"], [\"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials\"], [\"Interventional\"], [\"October 28, 2021\"], [\"January 25, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"39 Years\"]], [[\"TJ004309STM103\"], [\"A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ\\\\u00ae) in Patients With Ovarian Cancer and Selected Solid Tumors\"], [\"Interventional\"], [\"November 2, 2021\"], [\"June 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1603.00\"], [\"Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation\"], [\"Interventional\"], [\"April 2002\"], [\"October 2004\"], [\"Completed\"], [], [\"All\"], [], [\"12 Years\"], []], [[\"7465-CL-202\"], [\"A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)\"], [\"Interventional\"], [\"March 9, 2020\"], [\"July 31, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17477\"], [\"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)\"], [\"Interventional\"], [\"May 2, 2017\"], [\"September 1, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"12 Years\"], []], [[\"S1415CD\"], [\"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)\"], [\"Interventional\"], [\"October 7, 2016\"], [\"August 12, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"FT-003\"], [\"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy\"], [\"Observational\"], [\"June 11, 2019\"], [\"December 2037\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"101\"], [\"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors\"], [\"Interventional\"], [\"February 2, 2021\"], [\"December 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PACT-0101\"], [\"A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors\"], [\"Interventional\"], [\"July 3, 2019\"], [\"August 12, 2022\"], [\"Suspended\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15441\"], [\"A Study of LY3022855 In Participants With Breast or Prostate Cancer\"], [\"Interventional\"], [\"May 2015\"], [\"October 4, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C3881001\"], [\"PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"October 4, 2018\"], [\"March 30, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CPG-01-001\"], [\"COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.\"], [\"Interventional\"], [\"September 6, 2018\"], [\"December 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 106385-102\"], [\"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors\"], [\"Interventional\"], [\"February 3, 2021\"], [\"December 29, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"111767\"], [\"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents\"], [\"Interventional\"], [\"October 2008\"], [\"August 19, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"KY1044-CT01\"], [\"Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer\"], [\"Interventional\"], [\"January 28, 2019\"], [\"November 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PRP-001\"], [\"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors\"], [\"Interventional\"], [\"January 3, 2011\"], [\"January 30, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CNIR178X2201\"], [\"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma\"], [\"Interventional\"], [\"August 28, 2017\"], [\"February 14, 2023\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CPO-100-US-101\"], [\"Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 24, 2021\"], [\"March 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"213360\"], [\"A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens\"], [\"Interventional\"], [\"March 23, 2015\"], [\"August 23, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"D3610C00001\"], [\"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules\"], [\"Interventional\"], [\"December 1, 2010\"], [\"December 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"130 Years\"]], [[\"ST101-101\"], [\"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"July 1, 2020\"], [\"January 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ATLAS-101\"], [\"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies\"], [\"Interventional\"], [\"August 12, 2020\"], [\"January 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"200-04\"], [\"A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.\"], [\"Observational\"], [\"February 26, 2021\"], [\"December 23, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16704\"], [\"Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)\"], [\"Interventional\"], [\"December 12, 2016\"], [\"March 31, 2024\"], [\"Recruiting\"], [\"Sponsor-Investigator\"], [\"Female\"], [], [\"18 Years\"], []], [[\"P-MUC1C-ALLO1-001\"], [\"P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"February 15, 2022\"], [\"April 2039\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ONCR-177-101\"], [\"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors\"], [\"Interventional\"], [\"May 20, 2020\"], [\"July 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000415581\"], [\"RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma\"], [\"Interventional\"], [\"December 2004\"], [\"May 2008\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CORT125134-550\"], [\"Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors\"], [\"Interventional\"], [\"May 23, 2016\"], [\"September 12, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"7339-002\"], [\"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)\"], [\"Interventional\"], [\"December 12, 2018\"], [\"December 1, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2011-02500\"], [\"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction\"], [\"Interventional\"], [\"June 20, 2011\"], [], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"JZP712-201\"], [\"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"March 3, 2022\"], [\"June 23, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17493\"], [\"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors\"], [\"Interventional\"], [\"June 13, 2019\"], [\"March 26, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"6 Months\"], [\"21 Years\"]], [[\"XmAb23104-01\"], [\"A Study of XmAb\\\\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)\"], [\"Interventional\"], [\"May 1, 2019\"], [\"September 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CTMX-M-2009-001\"], [\"PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors\"], [\"Interventional\"], [\"June 1, 2017\"], [\"September 10, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1697.00\"], [\"Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)\"], [\"Interventional\"], [\"May 2004\"], [\"September 2008\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"4 Years\"], []], [[\"ADCT-301-103\"], [\"Study of ADCT-301 in Patients With Selected Advanced Solid Tumors\"], [\"Interventional\"], [\"November 9, 2018\"], [\"December 8, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TPST-1120-001\"], [\"TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers\"], [\"Interventional\"], [\"March 20, 2019\"], [\"June 23, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17-262-01\"], [\"REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies\"], [\"Interventional\"], [\"March 15, 2018\"], [\"May 9, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2020-05428\"], [\"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer\"], [\"Interventional\"], [\"February 1, 2021\"], [\"December 31, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C3651010\"], [\"Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia\"], [\"Interventional\"], [\"May 11, 2021\"], [\"August 9, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IT-01\"], [\"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6\"], [\"Interventional\"], [\"February 9, 2017\"], [\"February 22, 2023\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17494\"], [\"Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation\"], [\"Expanded Access\"], [], [], [\"Available\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"C3441037\"], [\"A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"December 21, 2020\"], [\"July 22, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"70 Years\"]], [[\"EMR100018-001\"], [\"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies\"], [\"Interventional\"], [\"December 13, 2013\"], [\"August 9, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PY159-2-01\"], [\"A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors\"], [\"Interventional\"], [\"November 10, 2020\"], [\"April 7, 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ELVCAP-001-01\"], [\"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors\"], [\"Interventional\"], [\"September 29, 2020\"], [\"June 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PV-10-LC-01\"], [\"A Study to Assess PV-10 Chemoablation of Cancer of the Liver\"], [\"Interventional\"], [\"October 2009\"], [\"February 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CP-MGD009-01\"], [\"Safety Study of MGD009 in B7-H3-expressing Tumors\"], [\"Interventional\"], [\"September 2015\"], [\"November 25, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"707-IO-101\"], [\"Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies\"], [\"Interventional\"], [\"June 9, 2021\"], [\"July 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MDNA11-01\"], [\"A Beta-only IL-2 ImmunoTherapY (ABILITY) Study\"], [\"Interventional\"], [\"August 27, 2021\"], [\"December 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [\"Yes\"], [\"18 Years\"], []], [[\"GB1275-1101 (KEYNOTE-A36)\"], [\"GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma\"], [\"Interventional\"], [\"August 13, 2019\"], [\"April 11, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCB 57643-101\"], [\"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies\"], [\"Interventional\"], [\"May 18, 2016\"], [\"February 13, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"7684A-005\"], [\"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)\"], [\"Interventional\"], [\"September 16, 2021\"], [\"February 22, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RTOG-1008\"], [\"Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery\"], [\"Interventional\"], [\"January 2011\"], [\"October 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RTOG-0924\"], [\"Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer\"], [\"Interventional\"], [\"July 2011\"], [\"July 2031\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"M14-546\"], [\"A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer\"], [\"Interventional\"], [\"April 14, 2015\"], [\"July 5, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"15834\"], [\"Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors\"], [\"Interventional\"], [\"May 26, 2017\"], [\"July 26, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TAK-500-1001\"], [\"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"April 26, 2022\"], [\"March 20, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ARC-5 (AB928CSP0005)\"], [\"A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies\"], [\"Interventional\"], [\"July 24, 2018\"], [\"September 3, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO41929\"], [\"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors\"], [\"Interventional\"], [\"May 24, 2021\"], [\"May 16, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"39110-107\"], [\"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors\"], [\"Interventional\"], [\"January 25, 2016\"], [\"November 20, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17159\"], [\"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"November 15, 2013\"], [\"November 17, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BIND-014-001\"], [\"A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer\"], [\"Interventional\"], [\"January 2011\"], [\"February 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PAL-E602-001\"], [\"Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)\"], [\"Interventional\"], [\"February 11, 2022\"], [\"June 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D6015C00001\"], [\"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours\"], [\"Interventional\"], [\"July 1, 2015\"], [\"August 22, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"CC-223-ST-001\"], [\"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma\"], [\"Interventional\"], [\"July 20, 2010\"], [\"December 9, 2016\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"9161\"], [\"Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors\"], [\"Interventional\"], [\"August 3, 2015\"], [\"December 31, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"39 Years\"]], [[\"XL184-203\"], [\"Study of Cabozantinib (XL184) in Adults With Advanced Malignancies\"], [\"Interventional\"], [\"August 2009\"], [\"June 2014\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"VICCGI1523\"], [\"Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study\"], [\"Observational\"], [\"July 2015\"], [\"August 31, 2021\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-GU006\"], [\"BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER\"], [\"Interventional\"], [\"April 27, 2018\"], [\"October 31, 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"NRG-LU002\"], [\"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer\"], [\"Interventional\"], [\"April 7, 2017\"], [\"October 2031\"], [\"Suspended\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-GU009\"], [\"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial\"], [\"Interventional\"], [\"December 15, 2020\"], [\"December 31, 2033\"], [\"Recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"AFT-28\"], [\"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer\"], [\"Interventional\"], [\"December 2016\"], [\"January 12, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-GU005\"], [\"Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer\"], [\"Interventional\"], [\"November 16, 2017\"], [\"December 2030\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], []], [[\"CLIN-17-008\"], [\"Study of the Safety and Effectiveness of Motiva Implants\\\\u00ae\"], [\"Interventional\"], [\"April 6, 2018\"], [\"February 28, 2033\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], [\"70 Years\"]], [[\"Adela-EDMRD-001\"], [\"cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease\"], [\"Observational\"], [\"May 3, 2022\"], [\"December 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"40 Years\"], []], [[\"NC318-01\"], [\"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"September 28, 2018\"], [\"April 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"16804\"], [\"Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel\"], [\"Interventional\"], [\"May 9, 2014\"], [\"October 2, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1430.00\"], [\"Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer\"], [\"Interventional\"], [\"August 1998\"], [], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"16712\"], [\"A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer\"], [\"Interventional\"], [\"April 10, 2018\"], [\"October 3, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"RXDX-101-03\"], [\"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\"], [\"Interventional\"], [\"May 3, 2016\"], [\"June 15, 2025\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"0 Years\"], [\"18 Years\"]], [[\"IMC-F106C-101\"], [\"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors\"], [\"Interventional\"], [\"February 25, 2020\"], [\"February 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"B9991004\"], [\"A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)\"], [\"Interventional\"], [\"November 9, 2015\"], [\"February 28, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20289\"], [\"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\"], [\"Interventional\"], [\"September 30, 2015\"], [\"October 31, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"LOXO-IDH-20002\"], [\"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations\"], [\"Interventional\"], [\"October 16, 2020\"], [\"May 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20210104\"], [\"A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression\"], [\"Interventional\"], [\"September 23, 2022\"], [\"July 28, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"0701\"], [\"Cardiac Safety Assessment Study of Picoplatin in Solid Tumors\"], [\"Interventional\"], [\"June 2008\"], [\"July 2009\"], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"FLX475-02\"], [\"Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab\"], [\"Interventional\"], [\"September 25, 2018\"], [\"December 2023\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CO-338-100\"], [\"A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes\"], [\"Interventional\"], [\"November 21, 2019\"], [\"July 15, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"G200502\"], [\"Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.\"], [\"Interventional\"], [\"May 2007\"], [\"September 2008\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"BM004\"], [\"ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain\"], [\"Interventional\"], [\"March 2008\"], [\"September 2012\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"100 Years\"]], [[\"INCB 54329-101\"], [\"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies\"], [\"Interventional\"], [\"April 14, 2015\"], [\"January 31, 2018\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ZWI-ZW25-101\"], [\"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers\"], [\"Interventional\"], [\"September 2016\"], [\"August 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BDTX-189-01\"], [\"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.\"], [\"Interventional\"], [\"December 19, 2019\"], [\"September 16, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CBYL719X2105J\"], [\"A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors\"], [\"Interventional\"], [\"November 27, 2012\"], [\"June 1, 2017\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TTI-621-02\"], [\"Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides\"], [\"Interventional\"], [\"September 2016\"], [\"March 31, 2020\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CLEE011XUS03\"], [\"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\"], [\"Interventional\"], [\"August 25, 2014\"], [\"January 17, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BR005\"], [\"Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging\"], [\"Observational\"], [\"April 18, 2017\"], [\"January 1, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"B1271002\"], [\"Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer\"], [\"Interventional\"], [\"October 2011\"], [\"December 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"SGN2FF-001\"], [\"A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors\"], [\"Interventional\"], [\"February 23, 2017\"], [\"June 24, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TP-CA-001\"], [\"Tempus Priority Study: A Pan-tumor Observational Study\"], [\"Observational\"], [\"October 19, 2020\"], [\"October 19, 2030\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"CB103-C-101\"], [\"Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies\"], [\"Interventional\"], [\"December 5, 2017\"], [\"November 11, 2022\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"20070315\"], [\"Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium\"], [\"Interventional\"], [\"November 16, 2009\"], [\"August 21, 2013\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"1801\"], [\"9-ING-41 in Patients With Advanced Cancers\"], [\"Interventional\"], [\"January 4, 2019\"], [\"November 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"63646\"], [\"Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer\"], [\"Interventional\"], [\"June 24, 2022\"], [\"October 15, 2026\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"21 Years\"], []], [[\"NCI-2009-00339\"], [\"Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy\"], [\"Interventional\"], [\"June 2008\"], [\"July 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [], [\"21 Years\"]], [[\"831-IO-101\"], [\"Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors\"], [\"Interventional\"], [\"March 31, 2022\"], [\"December 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DB-1303-O-1001\"], [\"A Study of DB-1303 in Advanced/Metastatic Solid Tumors\"], [\"Interventional\"], [\"January 31, 2022\"], [\"October 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PMV-586-101\"], [\"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)\"], [\"Interventional\"], [\"October 29, 2020\"], [\"July 14, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"12 Years\"], []], [[\"S1201\"], [\"S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer\"], [\"Interventional\"], [\"February 2012\"], [\"September 19, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"ACI/2015\"], [\"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)\"], [\"Interventional\"], [\"July 26, 2011\"], [\"December 31, 2023\"], [\"Recruiting\"], [\"Principal Investigator\"], [\"All\"], [], [\"1 Year\"], [\"75 Years\"]], [[\"INCB 54828-101\"], [\"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)\"], [\"Interventional\"], [\"February 27, 2015\"], [\"December 17, 2021\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"RAIN-3202\"], [\"Milademetan in Advanced/Metastatic Solid Tumors\"], [\"Interventional\"], [\"November 1, 2021\"], [\"August 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CR100845\"], [\"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma\"], [\"Interventional\"], [\"June 15, 2012\"], [\"July 5, 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GWCA0701\"], [\"A Study of Sativex\\\\u00ae for Pain Relief in Patients With Advanced Malignancy.\"], [\"Interventional\"], [\"November 2007\"], [\"January 2010\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MS201923_0001\"], [\"M6620 First in Human Study\"], [\"Interventional\"], [\"December 10, 2012\"], [\"March 11, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"TDM4529g\"], [\"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies\"], [\"Interventional\"], [\"October 16, 2008\"], [\"September 20, 2029\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [], []], [[\"CV-MMAIT-3-001\"], [\"Vaccine Therapy for Patients With Stage III Melanoma\"], [\"Interventional\"], [], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"CV-MMAIT-4-001\"], [\"Vaccine Therapy for Patients With Stage IV Melanoma\"], [\"Interventional\"], [], [], [\"Unknown status\"], [], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"CDR0000067196\"], [\"Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia\"], [\"Interventional\"], [\"July 1998\"], [\"August 2011\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000069467\"], [\"Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer\"], [\"Interventional\"], [\"August 2002\"], [\"June 15, 2007\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"1992110-1\"], [\"Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education\"], [\"Observational\"], [\"March 7, 2023\"], [\"March 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"80 Years\"]], [[\"18594\"], [\"First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas\"], [\"Interventional\"], [\"July 6, 2017\"], [\"April 19, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ARRAY-162-311\"], [\"A Study of MEK162 vs. Physician\\'s Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer\"], [\"Interventional\"], [\"June 27, 2013\"], [\"August 23, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [\"Yes\"], [\"18 Years\"], []], [[\"C4221015\"], [\"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer\"], [\"Interventional\"], [\"December 21, 2020\"], [\"November 15, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"16 Years\"], []], [[\"NO16968\"], [\"A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer\"], [\"Interventional\"], [\"April 18, 2003\"], [\"April 21, 2011\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GO42144\"], [\"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation\"], [\"Interventional\"], [\"July 29, 2020\"], [\"November 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CD-ON-MEDI4736-1108\"], [\"A Phase 1/2 Study to Evaluate MEDI4736\"], [\"Interventional\"], [\"September 5, 2012\"], [\"February 28, 2020\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"ML28897\"], [\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"April 14, 2014\"], [\"May 12, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI 03-04\"], [\"Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer\"], [\"Interventional\"], [\"March 2004\"], [\"July 2007\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"9090-14\"], [\"A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC\"], [\"Interventional\"], [\"April 2013\"], [\"December 2015\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ONO-4059-09\"], [\"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)\"], [\"Interventional\"], [\"December 29, 2021\"], [\"July 1, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"JTX-8064-101\"], [\"Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors\"], [\"Interventional\"], [\"January 12, 2021\"], [\"January 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"DB-1305-O-1001\"], [\"First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors\"], [\"Interventional\"], [\"July 19, 2022\"], [\"June 30, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BBI-20201001\"], [\"A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors\"], [\"Interventional\"], [\"February 24, 2020\"], [\"October 31, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ZWI-ZW49-101\"], [\"A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers\"], [\"Interventional\"], [\"April 15, 2019\"], [\"August 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"HSC-SPH-15-0443\"], [\"Stem Cell Injection in Cancer Survivors\"], [\"Interventional\"], [\"August 2016\"], [\"April 20, 2020\"], [\"Completed\"], [\"Principal Investigator\"], [\"All\"], [], [\"18 Years\"], [\"79 Years\"]], [[\"AV-951-15-303\"], [\"A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC\"], [\"Interventional\"], [\"April 2016\"], [\"June 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"IDE397-001\"], [\"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion\"], [\"Interventional\"], [\"April 14, 2021\"], [\"June 30, 2024\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"EORTC-08971\"], [\"Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer\"], [\"Interventional\"], [\"March 1998\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"CDR0000271174\"], [\"Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer\"], [\"Interventional\"], [\"August 2003\"], [\"May 1, 2009\"], [\"Completed\"], [], [\"All\"], [], [\"18 Years\"], [\"120 Years\"]], [[\"213346\"], [\"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 7, 2016\"], [\"October 27, 2027\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2009-00258\"], [\"Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer\"], [\"Interventional\"], [\"September 2007\"], [], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"Pathway Gennomics 004\"], [\"Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease\"], [\"Observational\"], [\"November 2015\"], [\"August 2017\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"217228\"], [\"First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"March 22, 2022\"], [\"December 29, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"UCI 04-08\"], [\"Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer\"], [\"Interventional\"], [\"April 2005\"], [\"October 2011\"], [\"Terminated\"], [\"Sponsor-Investigator\"], [\"All\"], [], [\"18 Years\"], []], [[\"M15-891\"], [\"A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors\"], [\"Interventional\"], [\"December 14, 2016\"], [\"March 29, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"ARRAY-818-202\"], [\"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer\"], [\"Interventional\"], [\"June 4, 2019\"], [\"June 30, 2024\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"YO39609\"], [\"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)\"], [\"Interventional\"], [\"October 13, 2017\"], [\"February 8, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"3P-03-2\"], [\"Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.\"], [\"Interventional\"], [\"February 2005\"], [\"July 2006\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCAGN 1949-201\"], [\"A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies\"], [\"Interventional\"], [\"October 9, 2017\"], [\"September 17, 2019\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"5GYN-02-2\"], [\"Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma\"], [\"Interventional\"], [\"November 2002\"], [\"May 2010\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"18 Years\"], []], [[\"213351\"], [\"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042\"], [\"Interventional\"], [\"October 12, 2017\"], [\"April 20, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"INCAGN 1876-201\"], [\"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies\"], [\"Interventional\"], [\"April 25, 2017\"], [\"November 9, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"GOG-0215\"], [\"Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries\"], [\"Interventional\"], [\"November 28, 2005\"], [], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [], []], [[\"4830-001\"], [\"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)\"], [\"Interventional\"], [\"July 11, 2018\"], [\"November 4, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D081SC00001\"], [\"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer\"], [\"Interventional\"], [\"October 31, 2018\"], [\"October 30, 2022\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"Male\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"1363\"], [\"Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis\"], [\"Interventional\"], [\"November 1994\"], [\"September 1999\"], [\"Completed\"], [], [\"Female\"], [], [], [\"80 Years\"]], [[\"CAMH2_1001\"], [\"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer\"], [\"Interventional\"], [\"September 14, 2021\"], [\"January 17, 2025\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"17-568\"], [\"BRCA Founder OutReach (BFOR) Study\"], [\"Observational\"], [\"November 10, 2017\"], [\"May 10, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"25 Years\"], []], [[\"AG0315OG/CTC0140\"], [\"RegoNivo vs Standard of Care Chemotherapy in AGOC\"], [\"Interventional\"], [\"June 1, 2021\"], [\"June 1, 2026\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"PBTC-042\"], [\"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors\"], [\"Interventional\"], [\"December 8, 2014\"], [\"February 25, 2019\"], [\"Terminated\"], [\"Sponsor\"], [\"All\"], [], [\"4 Years\"], [\"21 Years\"]], [[\"2018-01B\"], [\"Stool Collection Sub-Study of Exact Sciences Protocol 2018-01\"], [\"Observational\"], [\"July 21, 2020\"], [\"May 25, 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"19741\"], [\"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug\"], [\"Interventional\"], [\"September 30, 2019\"], [\"April 11, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO21223\"], [\"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin\\'s Lymphoma (GALLIUM)\"], [\"Interventional\"], [\"July 6, 2011\"], [\"July 30, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"BO29337\"], [\"A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin\\'s Lymphoma (fNHL)\"], [\"Interventional\"], [\"December 1, 2014\"], [\"March 16, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NRG-HN010\"], [\"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer\"], [\"Interventional\"], [\"September 30, 2022\"], [\"July 31, 2028\"], [\"Recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"MS-700\"], [\"MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ\"], [\"Interventional\"], [\"August 2003\"], [\"April 2011\"], [\"Completed\"], [\"Sponsor\"], [\"Female\"], [], [\"45 Years\"], []], [[\"D5760C00001\"], [\"A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.\"], [\"Interventional\"], [\"September 23, 2015\"], [\"May 23, 2018\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"99 Years\"]], [[\"20172841\"], [\"The PREDICT Registry for DCIS Patients With DCISionRT Testing\"], [\"Observational\"], [\"February 27, 2018\"], [\"November 2035\"], [\"Suspended\"], [\"Sponsor\"], [\"Female\"], [], [\"25 Years\"], []], [[\"NCI-2009-00534\"], [\"Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery\"], [\"Interventional\"], [\"April 24, 2006\"], [\"September 1, 2021\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2016-01041\"], [\"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors\"], [\"Interventional\"], [\"January 13, 2017\"], [\"October 31, 2023\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-00723\"], [\"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery\"], [\"Interventional\"], [\"August 8, 2012\"], [\"July 19, 2027\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"S1614\"], [\"Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors\"], [\"Interventional\"], [\"February 21, 2019\"], [\"February 28, 2027\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NSABP MPR-1\"], [\"NSABP Patient Registry and Biospecimen Profiling Repository\"], [\"Observational\"], [\"February 2013\"], [\"March 2022\"], [\"Completed\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"NCI-2012-00107\"], [\"Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer\"], [\"Interventional\"], [\"February 22, 2012\"], [\"August 1, 2021\"], [\"Unknown status\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"302\"], [\"177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)\"], [\"Interventional\"], [\"August 31, 2022\"], [\"December 31, 2024\"], [\"Withdrawn\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], []], [[\"D967MC00001\"], [\"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations\"], [\"Interventional\"], [\"December 30, 2020\"], [\"January 17, 2028\"], [\"Active, not recruiting\"], [\"Sponsor\"], [\"All\"], [], [\"18 Years\"], [\"120 Years\"'"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "json.dumps(values_list).strip('[]')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "8ccf3c47",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a dataframe from the dictionaries\n",
    "df = pd.DataFrame(sourced_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "3d9aad2b",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>OrgStudyId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>ResponsiblePartyType</th>\n",
       "      <th>Gender</th>\n",
       "      <th>GenderBased</th>\n",
       "      <th>MinimumAge</th>\n",
       "      <th>MaximumAge</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Rank</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>[CCT1043]</td>\n",
       "      <td>[Breast Cancer Trials Education Program]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[May 2007]</td>\n",
       "      <td>[December 2015]</td>\n",
       "      <td>[Completed]</td>\n",
       "      <td>[Principal Investigator]</td>\n",
       "      <td>[Female]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[21 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>[150B-0158]</td>\n",
       "      <td>[Breast Cancer Risk Reduction: A Patient Docto...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[June 2011]</td>\n",
       "      <td>[December 2012]</td>\n",
       "      <td>[Completed]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[40 Years]</td>\n",
       "      <td>[74 Years]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>[CHUM-CRYOABLATION]</td>\n",
       "      <td>[Anti-Tumor Immunity Induced by Cryoablation o...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[April 2013]</td>\n",
       "      <td>[October 2014]</td>\n",
       "      <td>[Terminated]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>[20107812]</td>\n",
       "      <td>[Monitoring and Predicting Breast Cancer Neoad...</td>\n",
       "      <td>[Observational]</td>\n",
       "      <td>[December 2010]</td>\n",
       "      <td>[October 2013]</td>\n",
       "      <td>[Withdrawn]</td>\n",
       "      <td>[Principal Investigator]</td>\n",
       "      <td>[Female]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>[234870]</td>\n",
       "      <td>[Blood Glycan Biomarkers in Women With Stage I...</td>\n",
       "      <td>[Observational]</td>\n",
       "      <td>[September 2006]</td>\n",
       "      <td>[January 12, 2016]</td>\n",
       "      <td>[Completed]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[Female]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1681</th>\n",
       "      <td>[S1614]</td>\n",
       "      <td>[Prophylactic Antiviral Therapy in Patients Wi...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[February 21, 2019]</td>\n",
       "      <td>[February 28, 2027]</td>\n",
       "      <td>[Active, not recruiting]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1682</th>\n",
       "      <td>[NSABP MPR-1]</td>\n",
       "      <td>[NSABP Patient Registry and Biospecimen Profil...</td>\n",
       "      <td>[Observational]</td>\n",
       "      <td>[February 2013]</td>\n",
       "      <td>[March 2022]</td>\n",
       "      <td>[Completed]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1683</th>\n",
       "      <td>[NCI-2012-00107]</td>\n",
       "      <td>[Study of Positron Emission Tomography and Com...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[February 22, 2012]</td>\n",
       "      <td>[August 1, 2021]</td>\n",
       "      <td>[Unknown status]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1684</th>\n",
       "      <td>[302]</td>\n",
       "      <td>[177Lu-DTPA-Omburtamab Radioimmunotherapy for ...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[August 31, 2022]</td>\n",
       "      <td>[December 31, 2024]</td>\n",
       "      <td>[Withdrawn]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1685</th>\n",
       "      <td>[D967MC00001]</td>\n",
       "      <td>[A Study of T-DXd for the Treatment of Solid T...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[December 30, 2020]</td>\n",
       "      <td>[January 17, 2028]</td>\n",
       "      <td>[Active, not recruiting]</td>\n",
       "      <td>[Sponsor]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[18 Years]</td>\n",
       "      <td>[120 Years]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1685 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "               OrgStudyId                                         BriefTitle  \\\n",
       "Rank                                                                           \n",
       "1               [CCT1043]           [Breast Cancer Trials Education Program]   \n",
       "2             [150B-0158]  [Breast Cancer Risk Reduction: A Patient Docto...   \n",
       "3     [CHUM-CRYOABLATION]  [Anti-Tumor Immunity Induced by Cryoablation o...   \n",
       "4              [20107812]  [Monitoring and Predicting Breast Cancer Neoad...   \n",
       "5                [234870]  [Blood Glycan Biomarkers in Women With Stage I...   \n",
       "...                   ...                                                ...   \n",
       "1681              [S1614]  [Prophylactic Antiviral Therapy in Patients Wi...   \n",
       "1682        [NSABP MPR-1]  [NSABP Patient Registry and Biospecimen Profil...   \n",
       "1683     [NCI-2012-00107]  [Study of Positron Emission Tomography and Com...   \n",
       "1684                [302]  [177Lu-DTPA-Omburtamab Radioimmunotherapy for ...   \n",
       "1685        [D967MC00001]  [A Study of T-DXd for the Treatment of Solid T...   \n",
       "\n",
       "             StudyType            StartDate       CompletionDate  \\\n",
       "Rank                                                               \n",
       "1     [Interventional]           [May 2007]      [December 2015]   \n",
       "2     [Interventional]          [June 2011]      [December 2012]   \n",
       "3     [Interventional]         [April 2013]       [October 2014]   \n",
       "4      [Observational]      [December 2010]       [October 2013]   \n",
       "5      [Observational]     [September 2006]   [January 12, 2016]   \n",
       "...                ...                  ...                  ...   \n",
       "1681  [Interventional]  [February 21, 2019]  [February 28, 2027]   \n",
       "1682   [Observational]      [February 2013]         [March 2022]   \n",
       "1683  [Interventional]  [February 22, 2012]     [August 1, 2021]   \n",
       "1684  [Interventional]    [August 31, 2022]  [December 31, 2024]   \n",
       "1685  [Interventional]  [December 30, 2020]   [January 17, 2028]   \n",
       "\n",
       "                 OverallStatus      ResponsiblePartyType    Gender  \\\n",
       "Rank                                                                 \n",
       "1                  [Completed]  [Principal Investigator]  [Female]   \n",
       "2                  [Completed]                 [Sponsor]     [All]   \n",
       "3                 [Terminated]                 [Sponsor]     [All]   \n",
       "4                  [Withdrawn]  [Principal Investigator]  [Female]   \n",
       "5                  [Completed]                 [Sponsor]  [Female]   \n",
       "...                        ...                       ...       ...   \n",
       "1681  [Active, not recruiting]                 [Sponsor]     [All]   \n",
       "1682               [Completed]                 [Sponsor]     [All]   \n",
       "1683          [Unknown status]                 [Sponsor]     [All]   \n",
       "1684               [Withdrawn]                 [Sponsor]     [All]   \n",
       "1685  [Active, not recruiting]                 [Sponsor]     [All]   \n",
       "\n",
       "     GenderBased  MinimumAge   MaximumAge  \n",
       "Rank                                       \n",
       "1             []  [21 Years]           []  \n",
       "2             []  [40 Years]   [74 Years]  \n",
       "3             []  [18 Years]           []  \n",
       "4             []  [18 Years]           []  \n",
       "5             []  [18 Years]           []  \n",
       "...          ...         ...          ...  \n",
       "1681          []  [18 Years]           []  \n",
       "1682          []  [18 Years]           []  \n",
       "1683          []  [18 Years]           []  \n",
       "1684          []  [18 Years]           []  \n",
       "1685          []  [18 Years]  [120 Years]  \n",
       "\n",
       "[1685 rows x 11 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Set the rank as the index\n",
    "df.set_index('Rank', inplace = True)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bf94e677",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "069265e5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank\n",
      "1                 [CCT1043]\n",
      "2               [150B-0158]\n",
      "3       [CHUM-CRYOABLATION]\n",
      "4                [20107812]\n",
      "5                  [234870]\n",
      "               ...         \n",
      "1681                [S1614]\n",
      "1682          [NSABP MPR-1]\n",
      "1683       [NCI-2012-00107]\n",
      "1684                  [302]\n",
      "1685          [D967MC00001]\n",
      "Name: OrgStudyId, Length: 1685, dtype: object\n"
     ]
    }
   ],
   "source": [
    "df['OrgStudyId'] = df['OrgStudyId'].values.tolist()\n",
    "print(df['OrgStudyId'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "687fe0d0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank\n",
      "1                 CCT1043\n",
      "2               150B-0158\n",
      "3       CHUM-CRYOABLATION\n",
      "4                20107812\n",
      "5                  234870\n",
      "               ...         \n",
      "1681                S1614\n",
      "1682          NSABP MPR-1\n",
      "1683       NCI-2012-00107\n",
      "1684                  302\n",
      "1685          D967MC00001\n",
      "Name: OrgStudyId, Length: 1685, dtype: object\n"
     ]
    }
   ],
   "source": [
    "OrgStudyId = str(df['OrgStudyId']).replace('[', '').replace(']','')\n",
    "print(OrgStudyId)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "574a0aa4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank\n",
      "1                [Breast Cancer Trials Education Program]\n",
      "2       [Breast Cancer Risk Reduction: A Patient Docto...\n",
      "3       [Anti-Tumor Immunity Induced by Cryoablation o...\n",
      "4       [Monitoring and Predicting Breast Cancer Neoad...\n",
      "5       [Blood Glycan Biomarkers in Women With Stage I...\n",
      "                              ...                        \n",
      "1681    [Prophylactic Antiviral Therapy in Patients Wi...\n",
      "1682    [NSABP Patient Registry and Biospecimen Profil...\n",
      "1683    [Study of Positron Emission Tomography and Com...\n",
      "1684    [177Lu-DTPA-Omburtamab Radioimmunotherapy for ...\n",
      "1685    [A Study of T-DXd for the Treatment of Solid T...\n",
      "Name: BriefTitle, Length: 1685, dtype: object\n"
     ]
    }
   ],
   "source": [
    "df['BriefTitle'] = df['BriefTitle'].values.tolist()\n",
    "print(df['BriefTitle'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "764a07e1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank\n",
      "1                Breast Cancer Trials Education Program\n",
      "2       Breast Cancer Risk Reduction: A Patient Docto...\n",
      "3       Anti-Tumor Immunity Induced by Cryoablation o...\n",
      "4       Monitoring and Predicting Breast Cancer Neoad...\n",
      "5       Blood Glycan Biomarkers in Women With Stage I...\n",
      "                              ...                        \n",
      "1681    Prophylactic Antiviral Therapy in Patients Wi...\n",
      "1682    NSABP Patient Registry and Biospecimen Profil...\n",
      "1683    Study of Positron Emission Tomography and Com...\n",
      "1684    177Lu-DTPA-Omburtamab Radioimmunotherapy for ...\n",
      "1685    A Study of T-DXd for the Treatment of Solid T...\n",
      "Name: BriefTitle, Length: 1685, dtype: object\n"
     ]
    }
   ],
   "source": [
    "BriefTitle = str(df['BriefTitle']).replace('[', '').replace(']','')\n",
    "print(BriefTitle)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "304b49db",
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax (1921817964.py, line 2)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;36m  Input \u001b[1;32mIn [50]\u001b[1;36m\u001b[0m\n\u001b[1;33m    for x in df['StudyType']\u001b[0m\n\u001b[1;37m                             ^\u001b[0m\n\u001b[1;31mSyntaxError\u001b[0m\u001b[1;31m:\u001b[0m invalid syntax\n"
     ]
    }
   ],
   "source": [
    "df['StudyType'] = x[0] \n",
    "for x in df['StudyType'] \n",
    "    if len(x)<2 \n",
    "    else "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ba3fe47c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "PythonData",
   "language": "python",
   "name": "pythondata"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
